<SEC-DOCUMENT>0001493152-24-017297.txt : 20240430
<SEC-HEADER>0001493152-24-017297.hdr.sgml : 20240430
<ACCEPTANCE-DATETIME>20240430172608
ACCESSION NUMBER:		0001493152-24-017297
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		91
CONFORMED PERIOD OF REPORT:	20240131
FILED AS OF DATE:		20240430
DATE AS OF CHANGE:		20240430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STREAMLINE HEALTH SOLUTIONS INC.
		CENTRAL INDEX KEY:			0001008586
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373]
		ORGANIZATION NAME:           	06 Technology
		IRS NUMBER:				311455414
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0131

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-28132
		FILM NUMBER:		24898711

	BUSINESS ADDRESS:	
		STREET 1:		2400 OLD MILTON PARKWAY
		STREET 2:		BOX 1353
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30009
		BUSINESS PHONE:		888-997-8732

	MAIL ADDRESS:	
		STREET 1:		2400 OLD MILTON PARKWAY
		STREET 2:		BOX 1353
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STREEAMLINE HEALTH SOLUTIONS INC.
		DATE OF NAME CHANGE:	20060809

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LANVISION SYSTEMS INC
		DATE OF NAME CHANGE:	19960220
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:STRM="http://streamlinehealth.net/20240131">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_037_STRM_streamlinehealth.net_20240131 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230201_20240131 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001008586 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_064_Integer_5_Integer -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000004" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000006" name="dei:EntityCentralIndexKey">0001008586</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-01-31" id="xdx2ixbrl0086" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-01-31" id="xdx2ixbrl0131" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LongTermLineOfCredit" contextRef="AsOf2023-01-31" id="xdx2ixbrl0147" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2024-01-31" id="xdx2ixbrl0152" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-01-31" id="xdx2ixbrl0161" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-02-012023-01-31" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2022-02-012023-01-31" id="xdx2ixbrl0235" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-02-012023-01-31" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="From2022-02-012023-01-31" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="STRM:StockIssuedDuringPeriodValueSurrenderOfShares" contextRef="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-02-012024-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-02-01to2024-01-31" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="From2023-02-012024-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="From2023-02-01to2024-01-31" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="STRM:StockIssuedDuringPeriodValueSurrenderOfShares" contextRef="From2023-02-012024-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityOther" contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityOther" contextRef="From2023-02-012024-01-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-02-012024-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-02-012024-01-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-02-012023-01-31" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2022-02-012023-01-31" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-02-01to2024-01-31" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" contextRef="From2023-02-01to2024-01-31" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-02-01to2024-01-31" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2022-02-012023-01-31" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2023-02-01to2024-01-31" id="xdx2ixbrl0530" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="STRM:DeferredFinancingCosts" contextRef="From2022-02-012023-01-31" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="From2023-02-01to2024-01-31" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"/>
  <ix:nonNumeric contextRef="AsOf2024-01-31_us-gaap_LeaseholdImprovementsMember" id="xdx2ixbrl0599" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric>
  <ix:nonFraction name="STRM:AcquisitionEarnoutLiabilityFairValue" contextRef="AsOf2024-01-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0647" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="STRM:AcquisitionEarnoutLiabilityFairValue" contextRef="AsOf2024-01-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0649" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="STRM:AcquisitionEarnoutLiabilityFairValue" contextRef="AsOf2023-01-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0655" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="STRM:AcquisitionEarnoutLiabilityFairValue" contextRef="AsOf2023-01-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0657" unitRef="USD" xs:nil="true"/>
  <ix:nonNumeric contextRef="AsOf2024-01-31_srt_MinimumMember" id="xdx2ixbrl0732" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">P1Y</ix:nonNumeric>
  <ix:nonFraction name="STRM:EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks" contextRef="From2023-02-01to2024-01-31" id="xdx2ixbrl0782" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="STRM:EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks" contextRef="From2022-02-012023-01-31" id="xdx2ixbrl0783" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-01-31_us-gaap_CostOfSalesMember" id="xdx2ixbrl0821" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-01-31_us-gaap_CostOfSalesMember" id="xdx2ixbrl0827" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember" id="xdx2ixbrl0833" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-01-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="xdx2ixbrl0845" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-01-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="xdx2ixbrl0851" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-01-31_custom_SeveranceExpensesMember" id="xdx2ixbrl0857" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-01-31_custom_ProfessionalFeesMember" id="xdx2ixbrl0869" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-01-31_custom_ProfessionalFeesMember" id="xdx2ixbrl0875" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-01-31_custom_AccruedExpensesMember" id="xdx2ixbrl0881" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-02-01to2024-01-31" id="xdx2ixbrl1167" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2022-02-012023-01-31" id="xdx2ixbrl1168" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" contextRef="AsOf2024-01-31" id="xdx2ixbrl1262" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2024-01-31" id="xdx2ixbrl1268" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="From2023-02-01to2024-01-31" id="xdx2ixbrl1301" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" contextRef="From2022-02-012023-01-31" id="xdx2ixbrl1305" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-02-01to2024-01-31" id="xdx2ixbrl1381" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-02-01to2024-01-31" id="xdx2ixbrl1383" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-02-01to2024-01-31" id="xdx2ixbrl1385" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-02-01to2024-01-31" id="xdx2ixbrl1387" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-01-31" id="xdx2ixbrl1403" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-01-31" id="xdx2ixbrl1411" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2024-01-31" id="xdx2ixbrl1419" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="From2023-02-01to2024-01-31" id="xdx2ixbrl1579" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" contextRef="From2022-02-012023-01-31" id="xdx2ixbrl1583" unitRef="USD" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="strm-20240131.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-02-01to2024-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_SoftwareasAsAServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">STRM:SoftwareasAsAServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_SoftwareasAsAServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">STRM:SoftwareasAsAServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_MaintenanceAndSupportMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">STRM:MaintenanceAndSupportMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_MaintenanceAndSupportMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">STRM:MaintenanceAndSupportMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_ProfessionalFeesAndLicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">STRM:ProfessionalFeesAndLicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_ProfessionalFeesAndLicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">STRM:ProfessionalFeesAndLicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_custom_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_InternalUseSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:InternalUseSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_custom_InternalUseSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:InternalUseSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_SecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_SecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_SecondAmendedAndRestatedLoanAndSecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecondAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_DebtAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:DebtAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_custom_DebtAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:DebtAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_DebtAgreementMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:DebtAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_us-gaap_OtherNoncurrentAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_OtherNoncurrentAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_EquityAwardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:EquityAwardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_EquityAwardMember_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:EquityAwardMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_EquityAwardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:EquityAwardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_EquityAwardMember_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:EquityAwardMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_OfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">STRM:OfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_OfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">STRM:OfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-162023-10-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-16</xbrli:startDate>
        <xbrli:endDate>2023-10-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_ComputerEquipmentAndSoftwareMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_ComputerEquipmentAndSoftwareMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_OfficeFurnitureAndFixturesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:OfficeFurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_OfficeFurnitureAndFixturesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:OfficeFurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_CostOfSoftwareAsASeviceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:CostOfSoftwareAsASeviceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_CostOfSoftwareAsASeviceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:CostOfSoftwareAsASeviceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_CostOfProfessionalFeesAndLicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:CostOfProfessionalFeesAndLicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_CostOfProfessionalFeesAndLicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:CostOfProfessionalFeesAndLicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_us-gaap_TransferredOverTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_us-gaap_TransferredOverTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_us-gaap_TransferredAtPointInTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_us-gaap_TransferredAtPointInTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_UnvestedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">STRM:UnvestedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_UnvestedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">STRM:UnvestedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_UnvestedRestrictedSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">STRM:UnvestedRestrictedSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_custom_SeveranceExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:SeveranceExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_SeveranceExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:SeveranceExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_SeveranceExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:SeveranceExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_custom_ProfessionalFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:ProfessionalFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_ProfessionalFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:ProfessionalFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_ProfessionalFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:ProfessionalFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_custom_AccruedExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:AccruedExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_AccruedExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:AccruedExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_AccruedExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:AccruedExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-14</xbrli:startDate>
        <xbrli:endDate>2021-08-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-16_custom_AveleadConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_AcquisitionRestrictedCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:AcquisitionRestrictedCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-14</xbrli:startDate>
        <xbrli:endDate>2021-08-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-16_custom_AveleadConsultingLLCMember_custom_AcquisitionRestrictedCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:AcquisitionRestrictedCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:UnitPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-14</xbrli:startDate>
        <xbrli:endDate>2021-08-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-16_custom_AveleadConsultingLLCMember_custom_AcquisitionRestrictedCommonStockMember_custom_UnitPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:AcquisitionRestrictedCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:UnitPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:UnitPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_AveleadConsultingLLCMember_custom_FirstYearEarnoutMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:UnitPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">STRM:FirstYearEarnoutMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-20</xbrli:startDate>
        <xbrli:endDate>2022-11-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-21_custom_UnitPurchaseAgreementMember_custom_FirstYearEarnoutMember_custom_AveleadConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:UnitPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">STRM:FirstYearEarnoutMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_RenewalContingentConsiderationMember_custom_FirstYearEarnoutMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:UnitPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">STRM:RenewalContingentConsiderationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">STRM:FirstYearEarnoutMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-20</xbrli:startDate>
        <xbrli:endDate>2022-11-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_RenewalContingentConsiderationMember_custom_AveleadConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:UnitPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">STRM:RenewalContingentConsiderationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-20</xbrli:startDate>
        <xbrli:endDate>2022-11-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_SecondYearEarnoutMember_custom_AveleadConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">STRM:SecondYearEarnoutMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_SecondYearEarnoutMember_custom_AveleadConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">STRM:SecondYearEarnoutMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-262024-03-27_custom_SecondYearEarnoutMember_us-gaap_SubsequentEventMember_custom_AveleadConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">STRM:SecondYearEarnoutMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-26</xbrli:startDate>
        <xbrli:endDate>2024-03-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-012023-09-01_custom_AveleadConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-01</xbrli:startDate>
        <xbrli:endDate>2023-09-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_AlpharettaOfficeLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:AlpharettaOfficeLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_AlpharettaOfficeLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:AlpharettaOfficeLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-292021-10-02_custom_SubleaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SubleaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-29</xbrli:startDate>
        <xbrli:endDate>2021-10-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_SubleaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SubleaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-142021-08-16_custom_SuwaneeOfficeLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SuwaneeOfficeLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-14</xbrli:startDate>
        <xbrli:endDate>2021-08-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_SuwaneeOfficeLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SuwaneeOfficeLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-28_custom_SuwaneeOfficeLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SuwaneeOfficeLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-26_custom_LoanAgreementMember_custom_WesternAllianceBankMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">STRM:WesternAllianceBankMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-26_us-gaap_PrimeRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-26_us-gaap_BaseRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-26_custom_SecurityAgreementMember_custom_BridgeBankMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">STRM:BridgeBankMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-26_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-252021-08-26_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-25</xbrli:startDate>
        <xbrli:endDate>2021-08-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-29_custom_SecondModificationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecondModificationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-282022-11-29_custom_SecondModificationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecondModificationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-28</xbrli:startDate>
        <xbrli:endDate>2022-11-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-29_us-gaap_PrimeRateMember_custom_SecondModificationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecondModificationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-29_us-gaap_BaseRateMember_custom_SecondModificationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecondModificationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_SecondAmendedAndRestatedLoanAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecondAmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_SecondAmendedAndRestatedLoanAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecondAmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-282022-11-29_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-28</xbrli:startDate>
        <xbrli:endDate>2022-11-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandAndTwentyTwoMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandAndTwentyTwoMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_JanuaryThirtyOneTwoThousandTwentyThreeMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandTwentyThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_JanuaryThirtyOneTwoThousandTwentyThreeMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandTwentyThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyThreeMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandTwentyThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyThreeMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandTwentyThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_JulyThirtyOneTwoThousandTwentyThreeMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandTwentyThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_JulyThirtyOneTwoThousandTwentyThreeMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandTwentyThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandTwentyThreeMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandTwentyThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandTwentyThreeMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandTwentyThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_JanuaryThirtyOneTwoThousandTwentyFourMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandTwentyFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_JanuaryThirtyOneTwoThousandTwentyFourMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandTwentyFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyFourMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandTwentyFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyFourMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandTwentyFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandTwentyFourAndThereafterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandTwentyFourAndThereafterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_ClientRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">STRM:ClientRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_InternallyDevelopedSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">STRM:InternallyDevelopedSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_us-gaap_TrademarksAndTradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_custom_ClientRelationshipsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">STRM:ClientRelationshipsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_custom_ClientRelationshipsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">STRM:ClientRelationshipsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_custom_ClientRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">STRM:ClientRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_custom_InternallyDevelopedSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">STRM:InternallyDevelopedSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_TrademarksAndTradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_ThroughFiscalTwoThousandThirtyEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">STRM:ThroughFiscalTwoThousandThirtyEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_TaxCutsAndJobsActMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">STRM:TaxCutsAndJobsActMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_StateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">STRM:StateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_FederalRDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">STRM:FederalRDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_GeorgiaRDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">STRM:GeorgiaRDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-232022-10-24_custom_PurchaseAgreementMember_custom_TwoThousandTwentyTwoOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">STRM:TwoThousandTwentyTwoOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-23</xbrli:startDate>
        <xbrli:endDate>2022-10-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-24_custom_PurchaseAgreementMember_custom_TwoThousandTwentyTwoOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">STRM:TwoThousandTwentyTwoOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-22_custom_OneHundredEightyConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-28_custom_OneHundredEightyConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">STRM:ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-07_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">STRM:ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">STRM:ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-152023-06-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-15</xbrli:startDate>
        <xbrli:endDate>2023-06-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-15_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">STRM:ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-15_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">STRM:ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_OneCustomerMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:OneCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-012022-01-31_custom_TwoCustomerMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:TwoCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-012022-01-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneCustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:OneCustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_CustomerOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:CustomerOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_CustomerTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:CustomerTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_CustomerThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:CustomerThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_CustomerFourMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:CustomerFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_CustomerOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:CustomerOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_CustomerTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:CustomerTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_CustomerThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:CustomerThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_CustomerFourMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:CustomerFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-012022-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-012022-11-01_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-202022-05-20_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-20</xbrli:startDate>
        <xbrli:endDate>2022-05-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-04-01_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember_custom_MrGreenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">STRM:MrGreenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-04-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-04-01_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember_custom_MrStilwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">STRM:MrStilwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-04-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-012022-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:MasterServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:MasterServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-10-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:MasterServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:MasterServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:MasterServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:MasterServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012024-01-31_custom_SOWMember_custom_OneHundredEightyConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SOWMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012023-01-31_custom_SOWMember_custom_OneHundredEightyConsultingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SOWMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-01_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-01_custom_NotesMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">STRM:NotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-012024-02-01_us-gaap_SubsequentEventMember_custom_NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">STRM:NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-01</xbrli:startDate>
        <xbrli:endDate>2024-02-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_us-gaap_SubsequentEventMember_custom_ExceptDirectorsAndOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">STRM:ExceptDirectorsAndOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-062024-02-06_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-06</xbrli:startDate>
        <xbrli:endDate>2024-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-06_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_ThirdModificationLoanAgreementMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:ThirdModificationLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_ThirdModificationLoanAgreementMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:ThirdModificationLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_AprilThirtyTwoThousandAndTwentyFourMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_AprilThirtyTwoThousandAndTwentyFourMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandAndTwentyFourMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandAndTwentyFourMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandAndTwentyFourMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandAndTwentyFourMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFiveMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_AprilThirtyTwoThousandTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandTwentyFiveMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_AprilThirtyTwoThousandTwentyFiveMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandTwentyFiveMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandTwentyFiveMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandTwentyFiveMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandTwentyFiveMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandTwentyFiveMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandTwentyFiveMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandTwentyFiveMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_AprilThirtyTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFiveMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001008586</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>STRM:Integer</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000645" toRefs="Footnote000660"/>
  <ix:relationship fromRefs="xdx2ixbrl0647" toRefs="Footnote000660"/>
  <ix:relationship fromRefs="xdx2ixbrl0649" toRefs="Footnote000660"/>
  <ix:relationship fromRefs="Fact000651" toRefs="Footnote000660"/>
  <ix:relationship fromRefs="Fact000653" toRefs="Footnote000660"/>
  <ix:relationship fromRefs="xdx2ixbrl0655" toRefs="Footnote000660"/>
  <ix:relationship fromRefs="xdx2ixbrl0657" toRefs="Footnote000660"/>
  <ix:relationship fromRefs="Fact000659" toRefs="Footnote000660"/>
  <ix:relationship fromRefs="Fact000779" toRefs="Footnote000794"/>
  <ix:relationship fromRefs="Fact000780" toRefs="Footnote000794"/>
  <ix:relationship fromRefs="xdx2ixbrl0782" toRefs="Footnote000799"/>
  <ix:relationship fromRefs="xdx2ixbrl0783" toRefs="Footnote000799"/>
  <ix:relationship fromRefs="Fact001578" toRefs="Footnote001586"/>
  <ix:relationship fromRefs="xdx2ixbrl1583" toRefs="Footnote001586"/>
  <ix:relationship fromRefs="xdx2ixbrl1579" toRefs="Footnote001587"/>
  <ix:relationship fromRefs="Fact001584" toRefs="Footnote001587"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90E_edei--DocumentType_c20230201__20240131_zpep035GX674"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000013" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--DocumentAnnualReport_c20230201__20240131_zCuMzLnynsF7"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended <span id="xdx_90E_edei--DocumentPeriodEndDate_c20230201__20240131_zDKeCxRCvvFh"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" format="ixt:datemonthdayyearen" id="Fact000015" name="dei:DocumentPeriodEndDate"><span id="xdx_907_edei--CurrentFiscalYearEndDate_c20230201__20240131_zccFlRK2AQsf"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" format="ixt:datemonthdayen" id="Fact000016" name="dei:CurrentFiscalYearEndDate">January 31</ix:nonNumeric></span>, <span id="xdx_901_edei--DocumentFiscalYearFocus_c20230201__20240131_zZM2SYE5GjI7"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000017" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--DocumentTransitionReport_c20230201__20240131_zgK9JSNwjls5"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" format="ixt:booleanfalse" id="Fact000018" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from ___________to___________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number: <span id="xdx_902_edei--EntityFileNumber_c20230201__20240131_zDLA2dDrDCF3"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000019" name="dei:EntityFileNumber">000-28132</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_902_edei--EntityRegistrantName_c20230201__20240131_zrFBhX3BcA2h"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000020" name="dei:EntityRegistrantName">STREAMLINE
HEALTH SOLUTIONS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Exact
name of registrant as specified in its charter)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20230201__20240131_zVq8gJ8ggRT9"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" format="ixt-sec:stateprovnameen" id="Fact000021" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20230201__20240131_zr6vwoXRpz93"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000022" name="dei:EntityTaxIdentificationNumber">31-1455414</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(State
    or other jurisdiction of</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(I.R.S.
    Employer</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>incorporation
    or organization)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identification
    No.)</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20230201__20240131_zr2zOhhK5329"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000023" name="dei:EntityAddressAddressLine1">2400
Old Milton Pkwy.</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressAddressLine2_c20230201__20240131_zJGyY2upGr9e"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000024" name="dei:EntityAddressAddressLine2">Box 1353</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressCityOrTown_c20230201__20240131_z1J5iERVjHe6"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000025" name="dei:EntityAddressCityOrTown">Alpharetta</ix:nonNumeric></span>,
<span id="xdx_909_edei--EntityAddressStateOrProvince_c20230201__20240131_zXHRcafn6OE9"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000026" name="dei:EntityAddressStateOrProvince">GA</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressPostalZipCode_c20230201__20240131_zcZod8pY5ag4"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000027" name="dei:EntityAddressPostalZipCode">30009</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Address
of principal executive offices) (Zip Code)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--CityAreaCode_c20230201__20240131_zjNioeYWZ0P5"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000028" name="dei:CityAreaCode">(888)</ix:nonNumeric></span>
<span id="xdx_90D_edei--LocalPhoneNumber_c20230201__20240131_zfjETQf0WRi1"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000029" name="dei:LocalPhoneNumber">997-8732</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Registrant&#8217;s
telephone number, including area code)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--Security12bTitle_c20230201__20240131_zWioxBpGtMdh"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000030" name="dei:Security12bTitle">Common
    Stock, $0.01 par value per share</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--TradingSymbol_c20230201__20240131_zG9hLaryRTNj"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000031" name="dei:TradingSymbol">STRM</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--SecurityExchangeName_c20230201__20240131_zYcxTUK1sGie"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" format="ixt-sec:exchnameen" id="Fact000032" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(g) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_901_edei--EntityWellKnownSeasonedIssuer_c20230201__20240131_zaxfHvHAFBLh"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000033" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_90E_edei--EntityVoluntaryFilers_c20230201__20240131_zXgXDrfmGVT3"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000034" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_903_edei--EntityCurrentReportingStatus_c20230201__20240131_zw9I93UfOsPh"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000035" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
<span id="xdx_906_edei--EntityInteractiveDataCurrent_c20230201__20240131_zDb1E4o094F3"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000036" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;,
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntityFilerCategory_c20230201__20240131_zUNRjFD19Rt3"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" format="ixt-sec:entityfilercategoryen" id="Fact000037" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_903_edei--EntitySmallBusiness_c20230201__20240131_zyUEoV5Mi4q8"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" format="ixt:booleantrue" id="Fact000038" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20230201__20240131_zqzQWzHX1Ex5"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" format="ixt:booleanfalse" id="Fact000039" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_906_edei--IcfrAuditorAttestationFlag_c20230201__20240131_zGBRHZDcefK3"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" format="ixt:booleanfalse" id="Fact000040" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_90E_edei--DocumentFinStmtErrorCorrectionFlag_c20230201__20240131_zFtEesLMdKNa" title="Document Financial Statement Error Correction"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" format="ixt:booleanfalse" id="Fact000042" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <span id="xdx_90B_edei--EntityShellCompany_dbF_c20230201__20240131_ztkQMBTULvq6"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" format="ixt:booleanfalse" id="Fact000043" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant, computed using the closing
price as reported by The NASDAQ Stock Market, Inc. for the Registrant&#8217;s Common Stock on July 31, 2023, the last business day of
the Registrant&#8217;s most recently completed second fiscal quarter, was $<span id="xdx_90B_edei--EntityPublicFloat_iI_c20230731_zHK9dMOzERO6"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2023-07-31" id="Fact000044" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,165,443</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares outstanding of the Registrant&#8217;s Common Stock, $0.01 par value per share, as of April 26, 2024 was <span id="xdx_904_edei--EntityCommonStockSharesOutstanding_iI_c20240426_z9rGrFmLlFb3"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-04-26" id="Fact000045" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,362,533</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Documents
incorporated by reference:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--DocumentsIncorporatedByReferenceTextBlock_c20230201__20240131_znNEetgG7pIj" title="Documents incorporated by reference"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000047" name="dei:DocumentsIncorporatedByReferenceTextBlock">Information
required by Part III is incorporated by reference from the Registrant&#8217;s Proxy Statement for its 2024 annual meeting of stockholders
or an amendment to this Annual Report on Form 10-K, which will be filed with the Securities and Exchange Commission within 120 days after
the end of its fiscal year ended January 31, 2024</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORWARD-LOOKING
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make forward-looking statements in this Annual Report on Form 10-K (the &#8220;Report&#8221;) and in other materials we file with the
Securities and Exchange Commission (&#8220;SEC&#8221;) or otherwise make public. These statements about future events and expectations
are &#8220;forward-looking&#8221; within the meaning of Sections 27A of the Securities Act of 1933, as amended, and 21E of the Securities
Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). In this Report, both Part I, Item 1, &#8220;Business,&#8221; and Part
II, Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contain forward-looking
statements. In addition, our senior management makes forward-looking statements to analysts, investors, the media, and others. Statements
with respect to expected revenue, income, receivables, backlog, client attrition, acquisitions and other growth opportunities, sources
of funding operations and acquisitions, the integration of our solutions, the performance of our channel partner relationships, the sufficiency
of available liquidity, research and development, and other statements of our plans, beliefs or expectations are forward-looking statements.
These and other statements using words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221;
&#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;may,&#8221;
&#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions also are forward-looking statements. Each forward-looking
statement speaks only as of the date of the particular statement. The forward-looking statements we make are not guarantees of future
performance, and we have based these statements on our assumptions and analyses in light of our experience and perception of historical
trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances. Forward-looking
statements by their nature involve substantial risks and uncertainties that could significantly affect expected results, and actual future
results could differ materially from those described in such statements. Management cautions against putting undue reliance on forward-looking
statements or projecting any future results based on such statements or present or historical earnings levels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
the factors that could cause actual future results to differ materially from our expectations are the risks and uncertainties described
in Part I, Item 1A, &#8220;Risk Factors&#8221; herein, and the other cautionary statements in other documents we file with the SEC, including
the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitive
    products and pricing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    demand and market acceptance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">entry
    into new markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possibility that any of the anticipated benefits of the acquisition of Avelead Consulting, LLC (&#8220;Avelead&#8221;) will not be
    realized or will not be realized within the expected time period, the businesses of the Company and the Avelead segment may not be
    integrated successfully or such integration may be more difficult, time-consuming or costly than expected, customers may terminate
    and/or decrease the use of our products and services, or revenues following the Avelead acquisition may be lower than expected;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
    product and services development and commercialization;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">key
    strategic alliances with vendors and channel partners that resell our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainty
    in continued relationships with clients due to termination rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to control costs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability,
    quality and security of products produced and services provided by third-party vendors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    healthcare regulatory environment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    changes in legislation, regulation and government funding affecting the healthcare industry;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">healthcare
    information systems budgets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of our relationships with channel partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
    in operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    future cash needs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    consummation of resources in researching acquisitions, business opportunities or financings and capital market transactions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure to adequately integrate past and future acquisitions into our business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">critical
    accounting policies and judgments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other standard-setting organizations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in economic, business and market conditions impacting the healthcare industry and the markets in which we operate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to maintain compliance with the terms of our credit facilities; and</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
    extent to which health epidemics and other outbreaks of communicable diseases could disrupt our operations and/or materiality and
    adversely affect our business and financial conditions;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain compliance with the continued listing standards of the Nasdaq Capital Market (&#8220;Nasdaq&#8221;).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
of these factors are beyond our ability to predict or control. Any of these factors, or a combination of these factors, could materially
affect our future financial condition or results of operations and the ultimate accuracy of our forward-looking statements. There also
are other factors that we may not describe (generally because we currently do not perceive them to be material) that could cause actual
results to differ materially from our expectations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1. <i>Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
in 1989, Streamline Health Solutions, Inc. is a provider of solutions and services in the middle of the revenue cycle for healthcare
providers throughout the United States and Canada. Streamline Health&#8217;s technology helps hospitals improve their financial performance
by optimizing data and coding for every patient encounter prior to bill submission. By performing these activities before billing, providers
can drive net revenue through reduced revenue leakage, overbilling, and days in accounts receivable. This enables providers to achieve
more predictable revenue streams using technology rather than manual intervention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides software solutions, professional consulting, and auditing services, which capture, aggregate,
and translate structured and unstructured data to deliver intelligently organized, easily-accessible predictive insights to its clients.
Hospitals and certain hospital-owned-and operated physician groups use the knowledge generated by Streamline Health to help them improve
their financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s software solutions are delivered to clients either by access to the Company&#8217;s hosted web applications in the cloud through a secure
connection, commonly referred to as a software as a service (&#8220;SaaS&#8221;) delivery method, or by a fixed-term or perpetual license, where such software
is installed locally in the client&#8217;s data center.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates exclusively in one segment as a provider of health information technology solutions and associated services that improve
healthcare processes and information flows within a healthcare facility. The Company sells its solutions and services in North America
to hospitals and health systems through its direct sales force and its reseller partnerships.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context requires otherwise, references to &#8220;Streamline Health,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221;
and &#8220;our&#8221; in this Report are intended to mean Streamline Health Solutions, Inc. and its wholly-owned subsidiaries. All references
to a fiscal year refer to the fiscal year commencing February 1 in that calendar year and ending on January 31 of the following calendar
year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Solutions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company offers solutions and services to assist its clients in revenue cycle management including its two flagship technologies
RevID<sup>TM </sup>and eValuator<sup>TM</sup>. RevID offers automated, daily reconciliation of clinical event activity to patient
billing charge items prior to billing. eValuator provides 100% automated coding analysis prior to billing. In addition, the Company
offers an array of professional services, including system implementation. The Company&#8217;s solutions and services are designed
to improve the flow of critical revenue cycle information throughout the enterprise. The solutions and services help to transform the
structure of information between disparate information technology systems into actionable data, giving the end user comprehensive
access to clinical and business intelligence to enhance billing accuracy and decision-making. Solutions can be accessed securely
through SaaS or delivered either by a perpetual license or by a fixed-term license installed locally.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>RevID
Automated Revenue Reconciliation &#8211; </i></b>RevID is a cloud-based SaaS solution that delivers automated, daily charge
reconciliation. RevID identifies discrepancies between a provider&#8217;s clinical and billing departments and ensures that
every medical service is tracked, accounted for, and ultimately accurately billed, thereby reducing revenue leakage. RevID functions
on a pre-bill basis, allowing providers to catch mistakes and discrepancies prior to billing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>eValuator
Coding Analysis Platform &#8211;</i></b> This technology is a cloud-based SaaS solution that delivers the capability of fully automated
analysis on 100% of billing codes entered by a healthcare provider&#8217;s coding team. This is done on a pre-bill basis, enabling providers
to identify and address their highest-impact cases prior to billing. Rule sets are enabled for inpatient, outpatient and pro-fee cases.
With eValuator, providers can add an audit function on a pre-bill basis to all cases, allowing the provider to better optimize reimbursements
and mitigate risk on its billing practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Data
Comparison Engine (&#8220;DCE&#8221; or &#8220;Compare&#8221;) &#8211; </i></b>Compare is a cloud-based SaaS system synchronization module
that reconciles data in different software used by hospitals within their operations. Compare operates continuously and automates the
reconciliation of these systems to identify discrepancies or errors occurring between systems. Additionally, the Compare module can be
utilized as a maintenance check when a hospital adds additional disparate software systems or converts to a new software system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Coding
&amp; CDI Solutions &#8211; CDI</i></b> provides an integrated on-premise or cloud-based software suite that enhances the productivity
of CDI and Coding staff and enables the seamless sharing of patient data. This suite of solutions includes workflows such as CDI, Abstracting
and Physician Query.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
Management Solutions (FMBA)</i></b> &#8211; FMBA has been sunset by the Company. FMBA solutions enable financial staff across the healthcare
enterprise to drill down quickly into actionable and real-time financial data and key performance indicators to improve revenue realization.
This suite of solutions includes individual workflows such as accounts receivable management, denials management, claims processing,
spend management and audit management.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Professional
Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
and Coding Services &#8212;</i></b> The Company provides technology-enabled audit and coding services to help clients review and optimize
their internal clinical documentation and coding functions across the applicable segment of the client&#8217;s enterprise. The Company offers its Audit and Coding services to primarily support eValuator
clients by expanding audit capacity to drive net revenue retention rates. The Company
provides these services using experienced coders and auditors through use of its eValuator proprietary software to improve the targeting
of records with the highest likelihood of requiring an audit. The audit services are provided for inpatient diagnostic-related group
(DRG) code auditing, outpatient ambulatory payment classification (APC) auditing, hierarchical condition categories (HCC) auditing and
Physician/Pro-Fee services coding and auditing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Software
Services &#8211; </i></b>Software services relates to implementation of our core software modules, including data collection, configuration
of the software based on the clients&#8217; needs, training and support. Support services include non-specified upgrades to the software.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Professional
Services &#8211; </i></b>The Company&#8217;s professional services are typically associated with hospital revenue cycle assistance and
include troubleshooting, staff augmentation and &#8220;ad hoc&#8221; services. Services may include, but are not limited to, review of
workflow processes, development and optimization of new workflows, optimization of interfaces, performance of audits and reconciliations,
interim resources and project management of system implementations or conversions. The Company has replaced its emphasis on professional
services with technology solutions. The Company&#8217;s premise is that technology on the front end of the revenue cycle process will
reduce waste and errors in the coding and the backend.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clients
and Strategic Partners</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides transformational, data-driven solutions to some of the most well-respected healthcare enterprises
in the United States and Canada. The Company provides these solutions
through a combination of direct sales and relationships with strategic channel partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2023, one individual client accounted for 10% or more of our revenue and represented approximately $5.1 million of total
revenue. During fiscal 2022, two individual clients accounted for 10% or more of our revenue and represented approximately $7.9
million of total revenue. A SaaS client who accounted for approximately $4.4 million, or 19%, and $4.2 million, or 17%, of our
revenues for fiscal 2023 and fiscal 2022, respectively, did not renew a contract with the Company, effective December 31, 2023. Four
clients represented 14%, 12%, 12% and 11% respectively, of accounts receivable as of January 31, 2024, and four clients represented
13%, 12%, 12% and 10%, respectively, of accounts receivable as of January 31, 2023. Many of our clients are invoiced on an annual
basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information regarding our major clients, please see &#8220;Risks Relating to Our Business - Our sales have been concentrated in
a small number of clients&#8221; in Part 1, Item 1A, &#8220;Risk Factors&#8221; herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisitions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company regularly evaluates opportunities for acquisitions for portions of the Company that may not align with current
growth strategies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acquired all of the equity interests of Avelead as part of the Company&#8217;s strategic expansion into the revenue cycle management,
acute-care healthcare space. The acquisition was completed on August 16, 2021. The aggregate consideration for the purchase of Avelead
was approximately $29.7 million (at fair value) consisting of (i) $12.5 million in cash, net of cash acquired, (ii) $6.5 million in common
stock, and (iii) approximately $10.7 million in contingent consideration. The Company issued 5,021,972 shares of its restricted common
stock to Avelead equity holders in connection with the acquisition. See Note 3 - Business Combination to our consolidated
financial statements included in Part II Item 8, &#8220;Financial Statements and Supplementary Data&#8221; for additional information
regarding the acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Segments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has determined it has only one operating segment
based on the guidance of <i>ASC 280-10-50 </i>paragraphs 1 through 8, The Company has a sole chief operating decision
maker who reviews a single set of financials, information, has accountability for the performance of the organization, and allocates resources
to drive success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal 2022, the Company had two reporting units for evaluation of goodwill: Streamline Solutions and Avelead Solutions. The Company
determined that, effective January 1, 2023, it has one reporting unit for purposes of evaluation of goodwill, which was used for evaluation of goodwill for fiscal 2023. At the end of fiscal 2022,
the Company consolidated and combined its operations for Streamline Solutions and Avelead Solutions. For total assets at January 31,
2024 and 2023 and total revenue and net loss for the fiscal years ended January 31, 2024 and 2023, see our consolidated financial statements
included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contracts,
License and Services Fees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company enters into agreements with its clients that specify the scope of the system to be installed and/or services to be provided by
the Company, as well as the agreed-upon pricing, applicable term duration and the timetable for the associated licenses and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
clients purchasing software to be installed locally or provided on a SaaS model, there are multiple performance obligations that include
either a perpetual or term license and right to access the applicable software functionality (whether installed locally at the client
site or the right to use the Company&#8217;s solutions as a part of SaaS services), terms regarding maintenance and support services,
and professional services for implementation, integration, process engineering, optimization and training, as well as fees and payment
terms for each of the foregoing. If the client purchases solutions on a perpetual license model, the client is billed the license fee
up front. Maintenance and support is provided on a term basis for separate fees, with an initial term typically from one to five years
in length. The maintenance and support fee is charged annually, in advance, commencing either upon contract execution or deployment of
the solution in live production. If the client purchases solutions on a term-based model, the client is billed periodically a combined
access fee for a specified term, typically from one to seven years in length. The access fee includes the access rights along with all
maintenance and support services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also generally provides software and SaaS clients professional services for implementation, integration, process
engineering, optimization and training. These services and the associated fees are separate from the license, maintenance and access
fees. Professional services are provided on either a fixed-fee or hourly arrangements billable to clients based on agreed-to payment
milestones (fixed fee) or monthly payment structure on hours incurred (hourly). These services can either be included at the time
the related locally installed software or SaaS solution is licensed as part of the initial purchase agreement or added as an
addendum to the existing agreement for services required after the initial implementation. The Company recognizes revenue for
implementation for certain of its eValuator SaaS solution over the contract term, as it has been determined that those
implementation services are not a distinct performance obligation, whereas for other SaaS and Software solutions such as Coding
&amp; CDI, RevID and Compare, it has been determined that its implementation services are a distinct performance obligation and,
accordingly, are recognized separately as professional services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
and Coding services are provided through a stand-alone services agreement or services addendum to an existing master
services agreement with the client. These review services are available as either a one-time service or recurring monthly, quarterly
or annual review structure. These services are typically provided on a per reviewed account/chart basis. Monthly minimums are
required where material discounts have been offered. Revenue is generally recognized when the chart is reviewed (i.e, service is
completed).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commencement of revenue recognition on software solutions varies depending on the size and complexity of the system and/or services involved,
the implementation or performance schedule requested by the client and usage by clients of SaaS for software-based components. The Company&#8217;s
agreements are generally non-cancellable but provide that the client may terminate its agreement upon a material breach by the Company
and/or may delay certain aspects of the installation or associated payments in such events. The Company does allow for termination for
convenience in certain situations. Therefore, it is difficult for the Company to accurately predict the revenue it expects to achieve
in any particular period, and a termination or installation delay of one or more phases of an agreement, or the failure of the Company
to procure additional agreements, could have a material adverse effect on the Company&#8217;s business, financial condition, and results
of operations, as further discussed in Part 1, Item 1A, &#8220;Risk Factors&#8221; herein. In the third quarter of fiscal 2023, the Company
received a notice from a significant SaaS client who accounted for approximately 19% and 17% of our  revenue for
fiscal 2023 and fiscal 2022, respectively, of its intent not to renew its contract following the expiration of the current term on December
31, 2023. With the exception of the foregoing, the Company has not historically experienced a material amount of contract cancellations;
however, the Company sometimes experiences delays in the course of contract performance and the Company accounts for them accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Third-Party
License Fees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incorporates software licensed from various third-party vendors into its proprietary software. The Company licenses these software
products and pays the required license fees when such software is delivered to clients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Associates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 31, 2024, the Company had 77 employees, a net decrease of 35 employees during fiscal 2023. All employees
are full-time employees. The Company utilizes independent contractors to supplement its staff, as needed. None of the Company&#8217;s
associates are represented by a labor union or subject to a collective bargaining agreement. The Company has never experienced a work
stoppage and believes that its employee relations are good. The Company&#8217;s success depends, to a significant degree, on its management,
sales and technical personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information on contracts, backlog, acquisitions and research and development, see also Part II, Item 7, &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RevID product has competition in charge reconciliation, generally. The Company believes RevID&#8217;s automated charge reconciliation
technique is unique in the industry as it interacts with disparate clinical systems identifying unbilled services. There
are products that purport to provide similar services, including FinThrive&#8217;s Charge Capture Audit Tool and CloudMed Tool set. The Company anticipates that additional competition may develop as pre-bill, daily charge reconciliation becomes a standard
within the industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
eValuator product has numerous competitors in the auditing software industry. The Company believes eValuator is unique in that it is
designed and has the requisite workflow to perform audits on a pre-bill basis. The Company believes it is an industry leader in pre-bill
auditing technology. We have seen competition on similar products that are being utilized by clients as a pre-bill auditing tool, such
as PwC Smart and 3M, however, these similar products are intended to be utilized for post-bill auditing which is a different workflow
than what is necessary for pre-bill auditing. We expect to have competition in the pre-bill technology industry. Client processes dictate
that correcting errors prior to billing is more efficient and effective than having an audit after billing. There will be larger and
more sophisticated competitors than our Company. Accordingly, using the time we have to gain market share prior to direct competition
is critical to the Company&#8217;s success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compare product has little direct competition outside of manual reconciliations. The Company believes few systems exist that can
accurately compare the various software systems used by hospitals. Examples of potential competitors include Vitalware, Craneware
and FinThrive&#8217;s Chargemaster toolkit. The Company believes Compare is unique because it can be easily fine-tuned to work with
a wide array of hospital systems to create a bespoke offering for specific clients, easing transitions to new platforms or acting as
an ongoing maintenance check tool.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
our Coding and CDI Solutions and eValuator Coding Analysis Platform, several companies historically have dominated the clinical information
system software market. The industry is undergoing consolidation and realignment as companies position themselves to compete more effectively.
Strategic alliances between vendors of other healthcare systems are increasing. Barriers to entry to this market include technological
and application sophistication, the ability to offer a proven product, creating and utilizing a well-established client base and distribution
channels, brand recognition, the ability to operate on a variety of operating systems and hardware platforms, the ability to integrate
with pre-existing systems and capital for sustained development and marketing activities. The Company has many competitors including
clinical information system vendors that are larger, more established and have substantially more resources than the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
our Audit and Coding Services, there are numerous companies and independent consultants who offer these services. Barriers to entry
to this market include creating and utilizing a well-established client base and distribution channels, brand recognition,
establishing differentiators for our services and capital for sustained development and marketing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes that these obstacles taken together represent a moderate to high-level barrier to entry. The Company believes that the
principal competitive factors in its market are client recommendations and references, company reputation, system reliability, system
features and functionality (including ease of use), technological advancements, client service and support, breadth and quality of the
systems, the potential for enhancements and future compatible products, the effectiveness of marketing and sales efforts, price, and
the size and perceived financial stability of the vendor. In addition, the Company believes that the speed with which companies in its
market can anticipate the evolving healthcare industry structure and identify unmet needs are important competitive factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional
Intellectual Property Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the software licenses described in other sections of this Item 1, &#8220;Business&#8221;, the Company also holds registered
trademarks for its Streamline Health&#174; and other key trademarks used in selling its products. These marks are currently active, with
registrations being valid for a period of three years each. The Company actively renews these marks at the end of each registration period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clients derive a substantial portion of their revenue from third-party private and governmental payors, including through Medicare, Medicaid
and other government-sponsored programs. Our clients also have express handling and retention obligations under information-based laws
such as the Health Insurance Portability and Accountability Act of 1996. There are no material regulatory proposals of which the Company
is aware that we believe currently have a high likelihood of passage that we anticipate would have a material impact on the operation
or demand of the Company&#8217;s products and services. However, the Company acknowledges there is currently great uncertainty in the
U.S. healthcare market, generally, from a regulatory perspective. In addition, there is regulatory uncertainty in the data and technology
sectors as it relates to information security regulations. Material changes could have unanticipated impact on demand or usability of
the Company&#8217;s solutions, require the Company to incur additional development and/or operating costs (on a one-time or recurring
basis) or cause clients to terminate their agreements or otherwise be unable to pay amounts owed to the Company, as further discussed
in Part 1, Item 1A, &#8220;Risk Factors&#8221; herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Environmental
Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe we are compliant in all material aspects with all applicable environmental laws. We do not anticipate that such compliance will
have a material effect on capital expenditures, earnings or the competitive position of our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Business Conduct and Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a Code of Business Conduct and Ethics that guides and binds each of our employees, officers and directors which is available on
the &#8220;Investor Relations&#8221; page of our website, www.streamlinehealth.net, under the &#8220;Corporate Governance&#8221; tab.
We use an anonymous compliance hotline for employees and outside parties to report potential instances of noncompliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copies
of documents filed by the Company with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports
on Form 8-K, proxy statements and all amendments to those reports and statements, if any, can be found at the website http://investor.streamlinehealth.net
as soon as practicable after such material is electronically filed with, or furnished to, the SEC. The information contained on the Company&#8217;s
website is not part of, or incorporated by reference into, this Report. Copies can be downloaded free of charge from the Company&#8217;s
website or directly from the SEC website, https://www.sec.gov. Also, copies of the Company&#8217;s annual report on Form 10-K will be
made available, free of charge, upon written request to the Company, attention: Corporate Secretary, 2400 Old Milton Pkwy, Box 1353,
Alpharetta, GA 30009.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1A. <i>Risk Factors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investment in our common stock or other securities involves a number of risks. You should carefully consider each of the risks described
below before deciding to invest in our common stock or other securities. If any of the following risks develops into actual events, our
business, financial condition or results of operations could be negatively affected, the market price of our common stock or other securities
could decline, and you may lose all or part of your investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
sales have been concentrated in a small number of clients.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
revenues have been concentrated in a relatively small number of large clients, and we have historically derived a substantial percentage
of our total  revenue from a few clients. For the fiscal years ended January 31, 2024 and 2023, our five largest
clients accounted for 38% and 46%, respectively, of our total  revenue. A client who accounted for approximately
$4.4 million, or 19%, of our revenue for fiscal 2023, and $4.2 million, or 17%, of our revenue
for fiscal 2022, terminated its contract with the Company, effective December 31, 2023. If one or more clients terminate all or any portion
of a master agreement, delay installations or if we fail to procure additional agreements, there could be a material adverse effect on
our business, financial condition and results of operations. See Note 9 - Major Clients to our consolidated financial statements included
in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221;, herein for further information regarding representation
of the Company&#8217;s largest individual major clients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Over
the last several years, we have completed acquisitions, and may undertake additional acquisitions in the future. Any failure to adequately
integrate past and future acquisitions into our business could have a material adverse effect on us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisitions
will require that we integrate into our existing operations separate companies that historically operated independently or as part of
another, larger organization, and had different systems, processes and cultures. Acquisitions may require integration of finance and
administrative organizations and involve exposure to different legal and regulatory regimes in jurisdictions in which we have not previously
operated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the last several years, we have completed acquisitions of businesses through asset and stock purchases. We expect that we will make additional
acquisitions in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisitions
involve a number of risks, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential failure to achieve the expected benefits of the acquisition, including the inability to generate sufficient revenue to
    offset acquisition costs, or the inability to achieve expected synergies or cost savings;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    expenses related to acquired businesses or technologies and their integration into our existing businesses or technology;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    diversion of financial, managerial and other resources from existing operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risks of entering into new markets in which we have little or no experience or where competitors may have stronger positions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    write-offs or amortization of acquired assets or investments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential loss of key employees, clients or partners of an acquired business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in client purchases due to uncertainty related to any acquisition;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    unknown liabilities associated with an acquisition; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    tax effects of any such acquisitions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to successfully integrate acquired businesses or fail to implement our business strategies with respect to acquisitions, we may
not be able to achieve projected results or support the amount of consideration paid for such acquired businesses, which could have an
adverse effect on our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finally,
if we finance acquisitions by issuing equity or convertible or other debt securities, our existing stockholders may be diluted, or we
could face constraints related to the terms of and repayment obligations related to the incurrence of indebtedness. This could adversely
affect the market price of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
could consume resources in researching acquisitions, business opportunities or financings and capital market transactions that are not
ultimately consummated, which could materially adversely affect our financial condition and subsequent attempts to locate and acquire
or invest in another business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that the investigation of each specific acquisition or business opportunity and the negotiation, drafting, and execution of
relevant agreements, disclosure documents, and other instruments with respect to such transaction will require substantial management
time and attention and substantial costs for financial advisors, accountants, attorneys and other advisors. If a decision is made not
to consummate a specific acquisition, business opportunity or financing and capital market transaction, the costs incurred up to that
point for the proposed transaction likely would not be recoverable. Furthermore, even if an agreement is reached relating to a specific
acquisition, investment target or financing, we may fail to consummate the investment or acquisition for any number of reasons, including
those beyond our control. Any such event could consume significant management time and result in a loss to us of the related costs incurred,
which could adversely affect our financial position and our ability to consummate other acquisitions and investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
significant increase in new SaaS contracts could require a significant cash outlay, which could adversely affect near term cash flow.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
new or existing clients purchase significant amounts of our SaaS services, we may have to expend a significant amount of initial setup
costs and time before those new clients are able to begin using such services, and we cannot begin to recognize revenues from those SaaS
agreements until the commencement of such services. Accordingly, we anticipate that our near-term cash flow may be adversely affected
by significant incremental setup costs from new SaaS clients that would not be offset by revenue until new SaaS clients go into production.
While we anticipate long-term growth in profitability through increases in recurring SaaS subscription fees and significantly improved
profit visibility, any inability to adequately finance setup costs for new SaaS solutions could result in the failure to put new SaaS
solutions into production and could have a material adverse effect on our liquidity, financial position and results of operations. In
addition, this near-term cash flow demand could adversely impact our financial flexibility and cause us to forego otherwise attractive
business opportunities or investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not see the anticipated market interest or growth in our software solutions. In addition, coding audit services and associated software
and technologies represent a new market for the Company, and we may not see the anticipated market interest or growth due to being a
new player in the industry.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is currently investing in the eValuator platform as well as new software-based technologies relating to high automation and machine-based
analytics regarding a client&#8217;s coding audit process. The return on this investment requires that the product developments continue
to be defined and completed in a timely and cost-effective manner, there remains general interest in the marketplace (for both existing
and future clients) for this technology, the demand for the product generates sufficient revenue in light of the development costs and
that the Company is able to execute a successful product launch for these technologies. If the Company is unable to meet these requirements
when launching these technologies, or if there is a delay in the launch process, the Company may not see an increase in revenue to offset
the current development costs or otherwise translate to added growth and revenue for the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clients
may exercise termination rights within their contracts, which may cause uncertainty in anticipated and future revenue streams.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generally does not allow for termination of a client&#8217;s agreement except at the end of the agreed upon term or for cause.
However, certain of the Company&#8217;s client contracts provide that the client may terminate the contract without cause prior to the
end of the term of the agreement by providing written notice, sometimes with relatively short notice periods. In the third quarter of
fiscal 2023, a client who accounted for approximately $4.4 million, or 19%, of our revenue for fiscal 2023, and
$4.2 million, or 17%, of our revenue for fiscal 2022, terminated its contract with the Company, effective December
31, 2023. The Company also provides trial or evaluation periods for certain clients, especially for new products and services. Furthermore,
there can be no assurance that a client will not cancel all or any portion of an agreement, even without an express early termination
right, and the Company may face additional costs or hardships collecting on amounts owed if a client terminates an agreement without
such a right. Whether resulting from termination for cause or the limited termination for convenience rights discussed above, the existence
of contractual relationships with these clients is not an assurance that we will continue to provide services for our clients through
the entire term of their respective agreements. If clients representing a significant portion of our revenue terminated their agreements
unexpectedly, we may not, in the short-term, be able to replace the revenue and income from such contracts and this would have a material
adverse effect on the Company&#8217;s business, financial condition, results of operations and cash flows. In addition, client contract
terminations could harm our reputation within the industry, especially any termination for cause, which could negatively impact our ability
to obtain new clients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in healthcare regulations impacting coding, payers and other aspects of the healthcare regulatory cycle could have substantial impact
on our financial performance, growth and operating costs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
sales and profitability depend, in part, on the extent to which coverage of and reimbursement for medical care provided is available
from governmental health programs, private health insurers, managed care plans and other third-party payors. Unanticipated regulatory
changes could materially impact the need for and/or value of our solutions. For example, if governmental or other third-party payors
materially reduce reimbursement rates or fail to reimburse our clients adequately, our clients may suffer adverse financial consequences.
Changes in regulations affecting the healthcare industry, such as any increased regulation by governmental agencies of the purchase and
sale of medical products, or restrictions on permissible discounts and other financial arrangements, could also directly impact the capabilities
our solutions and services provide and the pricing arrangements we are required to offer to be competitive in the market. Similarly,
the U.S. Congress may adopt legislation that may change, override, conflict with or pre-empt the currently existing regulations and which
could restrict the ability of clients to obtain, use or disseminate patient health information and/or impact the value of the functionality
our products and services provide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
situations would, in turn, reduce the demand for our solutions or services and/or the ability for a client to purchase our solutions
or services. This could have a material impact on our financial performance. In addition, the speed with which the Company can respond
to and address any such changes when compared with the response of other companies in the same market (especially companies who may accurately
anticipate the evolving healthcare industry structure and identify unmet needs) are important competitive factors. If the Company is
not able to address the modifications in a timely manner compared with our competition, that may further reduce demand for our solutions
and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
potential impact on us of new or changes in existing federal, state and local regulations governing healthcare information could be substantial.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
regulations issued to date have not had a material adverse effect on our business. However, we cannot predict the potential impact of
new or revised regulations that have not yet been released or made final, or any other regulations that might be adopted. The U.S. Congress
may adopt legislation that may change, override, conflict with or pre-empt the currently existing regulations and which could restrict
the ability of clients to obtain, use or disseminate patient health information. Although the features and architecture of our existing
solutions can be modified, it may be difficult to address the changing regulation of healthcare information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
healthcare industry is highly regulated. Any material changes in the political, economic or regulatory healthcare environment that affect
the group purchasing business or the purchasing practices and operations of healthcare organizations, or that lead to consolidation in
the healthcare industry, could require us to modify our services or reduce the funds available to providers to purchase our solutions
and services.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business, financial condition and results of operations depend upon conditions affecting the healthcare industry generally and hospitals
and health systems particularly. Our ability to grow will depend upon the economic environment of the healthcare industry, as well as
our ability to increase the number of solutions that we sell to our clients. The healthcare industry is highly regulated and is subject
to changing political, economic and regulatory influences. Factors such as changes in reimbursement policies for healthcare expenses,
consolidation in the healthcare industry, regulation, litigation and general economic conditions affect the purchasing practices, operation
and, ultimately, the operating funds of healthcare organizations. In particular, changes in regulations affecting the healthcare industry,
such as any increased regulation by governmental agencies of the purchase and sale of medical products, or restrictions on permissible
discounts and other financial arrangements, could require us to make unplanned modifications to our solutions and services, or result
in delays or cancellations of orders or reduce funds and demand for our solutions and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clients derive a substantial portion of their revenue from third-party private and governmental payors, including through Medicare, Medicaid
and other government-sponsored programs. Our sales and profitability depend, in part, on the extent to which coverage of and reimbursement
for medical care provided is available from governmental health programs, private health insurers, managed care plans and other third-party
payors. If governmental or other third-party payors materially reduce reimbursement rates or fail to reimburse our clients adequately,
our clients may suffer adverse financial consequences, which in turn, may reduce the demand for and ability to purchase our solutions
or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face significant competition, including from companies with significantly greater resources.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently compete with many other companies for the licensing of similar software solutions and related services. Several companies
historically have dominated the clinical information systems software market and several of these companies have either acquired,
developed, or are developing their own analytics and coding/clinical documentation improvement solutions, as well as the resultant
workflow technologies. The industry is undergoing consolidation and realignment as companies position themselves to compete more
effectively. Many of these companies are larger than us and have significantly more resources to invest in their business. In
addition, information and document management companies serving other industries may enter the market. Suppliers and companies with
whom we may establish strategic alliances also may compete with us. Such companies and vendors may either individually, or by
forming alliances excluding us, place bids for large agreements in competition with us. A decision on the part of any of these
competitors to focus additional resources in any of our solution focuses (charge reconciliation, coding audit solutions, analytics
and coding/clinical documentation improvement), workflow technologies and other markets addressed by us could have a material
adverse effect on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
healthcare industry is evolving rapidly, which may make it more difficult for us to be competitive in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. healthcare system is under intense pressure to improve in many areas, including modernization, universal access and controlling
skyrocketing costs of care. We believe that the principal competitive factors in our market are client recommendations and references,
company reputation, system reliability, system features and functionality (including ease of use), technological advancements, client
service and support, breadth and quality of the systems, the potential for enhancements and future compatible solutions, the effectiveness
of marketing and sales efforts, price and the size and perceived financial stability of the vendor. In addition, we believe that the
speed with which companies in our market can anticipate the evolving healthcare industry structure and identify unmet needs is an important
competitive factor. If we are unable to keep pace with changing conditions and new developments, we will not be able to compete successfully
in the future against existing or potential competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rapid
technology changes and short product life cycles could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for our solutions and services is characterized by rapidly changing technologies, regulatory requirements, evolving industry standards
and new product introductions and enhancements that may render existing solutions obsolete or less competitive. As a result, our position
in the healthcare information technology market could change rapidly due to unforeseen changes in the features and functions of competing
products, as well as the pricing models for such products. Our future success will depend, in part, upon our ability to enhance our existing
solutions and services and to develop and introduce new solutions and services to meet changing requirements. Moreover, competitors may
develop competitive products that could adversely affect our operating results. We need to maintain an ongoing research and development
program to continue to develop new solutions and apply new technologies to our existing solutions but may not have sufficient funds with
which to undertake such required research and development. If we are not able to foresee changes or to react in a timely manner to such
developments, we may experience a material, adverse impact on our business, operating results and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
intellectual property rights are valuable, and any inability to protect them could reduce the value of our solutions and services.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property, which represents an important asset to us, has some protection against infringement through copyright and trademark
law. We generally have little patent protection on our software. We rely upon license agreements, employment agreements, confidentiality
agreements, nondisclosure agreements and similar agreements to maintain the confidentiality of our proprietary information and trade
secrets. Notwithstanding these precautions, others may copy, reverse engineer or independently design technology similar to our solutions.
If we fail to protect adequately our intellectual property through trademarks and copyrights, license agreements, employment agreements,
confidentiality agreements, nondisclosure agreements or similar agreements, our intellectual property rights may be misappropriated by
others, invalidated or challenged, and our competitors could duplicate our technology or may otherwise limit any competitive technology
advantage we may have. It may be necessary to litigate to enforce or defend our proprietary technology or to determine the validity of
the intellectual property rights of others. Any litigation, successful or unsuccessful, may result in substantial cost and require significant
attention by management and technical personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the rapid pace of technological change, we believe our future success is likely to depend upon continued innovation, technical expertise,
marketing skills and client support and services rather than on legal protection of our intellectual property rights. However, we have
aggressively asserted our intellectual property rights when necessary and intend to do so in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
could be subjected to claims of intellectual property infringement that could be expensive to defend.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we do not believe that our solutions and services infringe upon the intellectual property rights of third parties, the potential for
intellectual property infringement claims continually increases as the number of software patents and copyrighted and trademarked materials
continues to rapidly expand. Any claim for intellectual property right infringement, even if not meritorious, could be expensive to defend.
If we were held liable for infringing third party intellectual property rights, we could incur substantial damage awards, and potentially
be required to cease using the technology, produce non-infringing technology or obtain a license to use such technology. Such potential
liabilities or increased costs could be material to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to maintain effective internal control over financial reporting, we may fail to prevent or detect material misstatements
in our financial statements, in which case investors may lose confidence in the accuracy and completeness of our financial statements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the preparation of the consolidated financial statements for each of our fiscal years, our management conducts a review
of our internal control over financial reporting. We are also required to maintain effective disclosure controls and procedures. Any
failure to maintain adequate controls or to adequately implement required new or improved controls could harm operating results, or cause
failure to meet reporting obligations in a timely and accurate manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third
party products are essential to our software.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
software incorporates software licensed from various vendors into our proprietary software. In addition, third-party, stand-alone software
is required to operate some of our proprietary software modules. The loss of the ability to use these third-party products, or ability
to obtain substitute third-party software at comparable prices, could have a material adverse effect on our ability to license our software.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
solutions may not be error-free and could result in claims of breach of contract and liabilities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
solutions are very complex and may not be error-free, especially when first released. Although we perform extensive testing, failure
of any solution to operate in accordance with its specifications and documentation could constitute a breach of the license agreement
and require us to correct the deficiency. If such deficiency is not corrected within the agreed-upon contractual limitations on liability
and cannot be corrected in a timely manner, it could constitute a material breach of a contract allowing the termination thereof and
possibly subjecting us to liability. Also, we sometimes indemnify our clients against third-party infringement claims. If such claims
are made, even if they are without merit, they could be expensive to defend. Our license and SaaS agreements generally limit our liability
arising from these types of claims, but such limits may not be enforceable in some jurisdictions or under some circumstances. A significant
uninsured or under-insured judgment against us could have a material adverse impact on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
could be liable to third parties from the use of our solutions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
solutions provide access to patient information used by physicians and other medical personnel in providing medical care. The medical
care provided by physicians and other medical personnel are subject to numerous medical malpractice and other claims. We attempt to limit
any potential liability of ours to clients by limiting the warranties on our solutions in our agreements with our clients (i.e., healthcare
providers). However, such agreements do not protect us from third-party claims by patients who may seek damages from any or all persons
or entities connected to the process of delivering patient care. We maintain insurance, which provides limited protection from such claims,
if such claims result in liability to us. Although no such claims have been brought against us to date regarding injuries related to
the use of our solutions, such claims may be made in the future. A significant uninsured or under-insured judgment against us could have
a material adverse impact on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
SaaS and support services could experience interruptions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
provide SaaS for many clients, including the storage of critical patient, financial and administrative data. In addition, we provide
support services to clients through our client support organization. We have redundancies, such as backup generators, redundant telecommunications
lines and backup facilities built into our operations to prevent disruptions. However, complete failure of all generators, impairment
of all telecommunications lines or severe casualty damage to the primary building or equipment inside the primary building housing our
hosting center or client support facilities could cause a temporary disruption in operations and adversely affect clients who depend
on the application hosting services. Any interruption in operations at our data center or client support facility could cause us to lose
existing clients, impede our ability to obtain new clients, result in revenue loss, cause potential liability to our clients, and increase
our operating costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business and operations would suffer in the event of computer system failures, cyber-attacks or a deficiency in our cybersecurity. Our
SaaS solutions are provided over an internet connection and any breach of security or confidentiality of protected health information
could expose us to significant expense and harm our reputation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to
damage from a variety of causes, including computer viruses, malware, intentional or accidental mistakes or errors by users with authorized
access to our computer systems, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions
over the Internet, or attachments to emails. The risk of a security breach or disruption, particularly through cyber-attacks or cyber
intrusions, including by computer hackers, non-U.S. governments, extra-state actors and cyber terrorists, has generally increased as
the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
provide remote SaaS solutions for clients, including the storage of critical patient, financial and administrative data. We have security
measures in place to prevent or detect misappropriation of protected health information. We must maintain facility and systems security
measures to preserve the confidentiality of data belonging to clients, as well as their patients, that resides on computer equipment
in our data center, which we handle via application hosting services, or that is otherwise in our possession. Notwithstanding efforts
undertaken to protect data, it can be vulnerable to infiltration as well as unintentional lapse. If any disruption or security breach
was to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information,
we could face claims for contract breach, penalties and other liabilities for violation of applicable laws or regulations, significant
costs for remediation and re-engineering to prevent future occurrences and serious harm to our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the current environment, there are numerous and evolving risks to cybersecurity and privacy, including criminal hackers, hacktivists,
state-sponsored intrusions, industrial espionage, employee malfeasance and human or technological error. High-profile security breaches
at other companies and in government agencies have increased in recent years, and security industry experts and government officials
have warned about the risks of hackers and cyber-attacks targeting businesses such as ours. Computer hackers and others routinely attempt
to breach the security of technology products, services and systems, and to fraudulently induce employees, clients, or others to disclose
information or unwittingly provide access to systems or data. We can provide no assurance that our current IT systems, software, or third-party
services, or any updates or upgrades thereto will be fully protected against third-party intrusions, viruses, hacker attacks, information
or data theft or other similar threats.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legislative
or regulatory action in these areas is also evolving, and we may be unable to adapt our IT systems to accommodate these changes. We have
experienced and expect to continue to experience sophisticated attempted cyber-attacks of our IT networks. Although none of these attempted
cyber-attacks has had a material adverse impact on our operations or financial condition, we cannot guarantee that any such incidents
will not have such an impact in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
loss of key personnel could adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends, to a significant degree, on our management, sales force and technical personnel. We must recruit, motivate and retain
highly skilled managers, sales, consulting and technical personnel, including solution programmers, database specialists, consultants
and system architects who have the requisite expertise in the technical environments in which our solutions operate. Competition for
such technical expertise is intense. Our failure to attract and retain qualified personnel could have a material adverse effect on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future success depends upon our ability to grow, and if we are unable to manage our growth effectively, we may incur unexpected expenses
and be unable to meet our clients&#8217; requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to expand our operations if we successfully achieve greater demand for our products and services. We cannot be certain that
our systems, procedures, controls and human resources will be adequate to support expansion of our operations. Our future operating results
will depend on the ability of our officers and employees to manage changing business conditions and to implement and improve our technical,
administrative, financial control and reporting systems. We may not be able to expand and upgrade our systems and infrastructure to accommodate
these increases. Difficulties in managing any future growth, including as a result of integrating any prior or future acquisition with
our existing businesses, could cause us to incur unexpected expenses or render us unable to meet our clients&#8217; requirements, and
consequently have a significant negative impact on our business, financial condition and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not have access to sufficient or cost-efficient capital to support our growth, execute our business plans and remain competitive
in our markets.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our operations grow and as we implement our business strategies, we expect to use both internal and external sources of capital. In addition
to cash flow from normal operations, we may need additional capital in the form of debt or equity to operate and support our growth,
execute our business plans and remain competitive in our markets. We may have no or limited availability to such external capital, in
which case our future prospects may be materially impaired. Furthermore, we may not be able to access external sources of capital on
reasonable or favorable terms. Our business operations could be subject to both financial and operational covenants that may limit the
activities we may undertake, even if we believe they would benefit the Company. While we believe our existing sources of liquidity will
provide sufficient resources to meet our current working capital and cash requirements, if we require an increase in capital to meet
our future business needs or if we are unable to comply with covenants under our credit facilities, such capital may not be available
to us on terms acceptable to us, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unstable
market and economic conditions and potential disruptions in the credit markets may adversely affect our business, including the availability
and cost of short-term funds for liquidity requirements and our ability to meet long-term commitments, which could adversely affect our
results of operations, cash flows and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
internally generated funds are not available from operations, we may be required to rely on the banking and credit markets to meet our
financial commitments and short-term liquidity needs. Our access to funds under our revolving credit facility or pursuant to arrangements
with other financial institutions is dependent on the financial institution&#8217;s ability to meet funding commitments. Financial institutions
may not be able to meet their funding commitments if they experience shortages of capital and liquidity or if they experience high volumes
of borrowing requests from other borrowers within a short period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
credit and financial markets have recently, and may continue to, experience extreme volatility and disruptions, including severely diminished
liquidity and credit availability, declines in consumer confidence, declines in economic growth, inflationary pressure and interest rate
changes and uncertainty about economic stability. There can be no assurance that future credit and financial market instability and a
deterioration in confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such
economic downturn, liquidity shortages, volatile business environment or continued unpredictable and unstable market conditions. If the
equity and credit markets deteriorate, or if adverse developments are experienced by financial institutions, it may cause short-term
liquidity risk and also make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure
any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial
performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one
or more of our current service providers, financial institutions, manufacturers and other partners may be adversely affected by the foregoing
risks, which could directly affect our ability to attain our operating goals on schedule and on budget.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
must maintain compliance with the terms of our existing credit facilities or receive a waiver for any non-compliance. The failure to
maintain compliance could have a material adverse effect on our ability to finance our ongoing operations and we may not be able to find
an alternative lending source if a default occurs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a credit facility with Western Alliance Bank (&#8220;WAB&#8221;) pursuant that certain Second Amended and Restated Loan and Security
Agreement (as amended and modified, the &#8220;Loan Agreement&#8221;). The Loan Agreement includes (i) a term loan facility with an initial
maximum principal amount of $10,000,000 and (ii) a $2,000,000 revolving line of credit. The Loan Agreement is secured by substantially
all of the assets of the Company, its subsidiaries, and certain of our affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement has a five-year term, and the maximum principal amount was advanced in a single-cash advance on or about the closing date.
Interest accrued under the Loan Agreement is due monthly, and the Company is required to make monthly interest-only payments through
the one-year anniversary of the closing date. From the first anniversary of the closing date through the maturity date, the Company is
required to make monthly payments of principal and interest that increase over the term of the agreement. The Loan Agreement requires
principal repayments of $500,000 in the second year, $1,000,000 in the third year, $2,000,000 in the fourth year, and $3,000,000 in the
fifth year, respectively, with the remaining outstanding principal balance and all accrued but unpaid interest due in full on the maturity
date. The Loan Agreement may also require early repayments if certain conditions are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement also includes negative covenants, subject to exceptions, which limit transfers, capital expenditures, indebtedness, certain
liens, investments, acquisitions, dispositions of assets, restricted payments and the business activities of the Company, as well as
customary representations and warranties, affirmative covenants and events of default, including cross defaults and a change of control
default. Specifically, the Loan Agreement requires us to satisfy a Maximum ARR Net Leverage Ratio, Maximum Debt to Adjusted EBITDA Ratio,
and Fixed Charge Coverage Ratio (as such terms are defined in the Loan Agreement) and maintain minimum Adjusted EBITDA on an ongoing
basis, measured at the end of each fiscal quarter. For the period ended January 31, 2024, the Company was not in compliance with certain
financial covenants under the Loan Agreement; however, on February 7, 2024, the Company received a waiver from WAB pursuant to that certain
Third Modification and Waiver (the &#8220;Third Modification&#8221;) to the Loan Agreement (see Refer to Note 14 &#8211; Subsequent Events
to our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; for additional
information regarding the Third Modification.).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.23in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not maintain compliance with all of the continuing covenants and other terms and conditions of our existing credit facilities or
secure a waiver for any non-compliance, we could be required to repay outstanding borrowings on an accelerated basis, which could subject
us to decreased liquidity and other negative impacts on our business, results of operations and financial condition. Furthermore, if
we needed to do so, it may be difficult for us to find an alternative lending source. In addition, because our assets are pledged as
a security under our credit facilities, if we are not able to cure any default or repay outstanding borrowings, our assets are subject
to the risk of foreclosure by our lenders. Without a sufficient credit facility, we would be adversely affected by a lack of access to
liquidity needed to operate our business. Any disruption in access to credit could force us to take measures to conserve cash, such as
deferring important research and development expenses, which measures could have a material adverse effect on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Economic
conditions in the U.S. and globally may have significant effects on our clients and suppliers that could result in material adverse effects
on our business, operating results and stock price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Economic
conditions in the U.S. and globally could deteriorate and cause the worldwide economy to enter into a stagnant period that could materially
adversely affect our clients&#8217; access to capital or willingness to spend capital on our solutions and services or their levels of
cash liquidity with which to pay for solutions that they will order or have already ordered from us. In addition, the ongoing conflict
between Russia and Ukraine could lead to disruption, instability and volatility in global markets and industries that could negatively
impact our operations. The U.S. government, and other governments in jurisdictions in which we operate, have imposed severe sanctions
and export controls against Russia and Russian interests and threatened additional sanctions and controls. The impact of these measures,
as well as potential responses to them by Russia, is currently unknown and they could adversely affect our business, partners or clients.
Challenging economic conditions also would likely negatively impact our business, which could result in: (1) reduced demand for our solutions
and services; (2) increased price competition for our solutions and services; (3) increased risk of collectability of cash from our clients;
(4) increased risk in potential reserves for doubtful accounts and write-offs of accounts receivable; (5) reduced revenues; and (6) higher
operating costs as a percentage of revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the foregoing potential consequences of a deterioration of economic conditions are difficult to forecast and mitigate. As a consequence,
our operating results for a particular period are difficult to predict, and, therefore, prior results are not necessarily indicative
of future results. Any of the foregoing effects could have a material adverse effect on our business, results of operations, and financial
condition and could adversely affect the market price of our common stock and other securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
variability of our quarterly operating results can be significant.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating results have fluctuated from quarter-to-quarter in the past, and we may experience continued fluctuations in the future. Future
revenues and operating results may vary significantly from quarter-to-quarter as a result of a number of factors, many of which are outside
of our control. These factors include: the relatively large size of client agreements; unpredictability in the number and timing of software
licenses and sales of application hosting services; length of the sales cycle; delays in installations; changes in clients&#8217; financial
conditions or budgets; increased competition; the development and introduction of new products and services; the loss of significant
clients or remarketing partners; changes in government regulations, particularly as they relate to the healthcare industry; the size
and growth of the overall healthcare information technology markets; any liability and other claims that may be asserted against us;
our ability to attract and retain qualified personnel; national and local general economic and market conditions; and other factors discussed
in this Report and our other filings with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business, results of operations and financial condition has been, and may continue to be, materially adversely affected by the COVID-19
pandemic</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic, and its attendant economic damage, has had an adverse impact on our revenue and may continue to adversely affect our
business, results of operations and financial condition. These and other potential impacts of COVID-19 may continue to materially and
adversely affect our business, results of operations and financial condition. We may experience adverse impacts to our business as a
result of any economic recession or depression that has occurred or may occur in the future as a result of the COVID-19 pandemic. For
instance, changes in the behavior of customers, businesses and their employees as a result of the COVID-19 pandemic, including social
distancing practices, even after formal restrictions have been lifted, are unknown. Furthermore, the financial condition of our customers
and vendors may be adversely impacted, which may result in a decrease in the demand for our products, the inability and our franchisees&#8217;
ability to operate store locations or a disruption to our supply chain. Any of these events may, in turn, have a material adverse impact
our business, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
preparation of our financial statements requires the use of estimates that may vary from actual results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management
to make significant estimates that affect the financial statements. One of our most critical estimates is the capitalization of software
development costs. Due to the inherent nature of these estimates, we may be required to significantly increase or decrease such estimates
upon determination of the actual results. Any required adjustments could have a material adverse effect on us and our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to improve and maintain the quality of internal control over financial reporting and disclosure controls and procedures or other lapses
in compliance could materially and adversely affect our ability to provide timely and accurate financial information about us or subject
us to potential liability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the preparation of the consolidated financial statements for each of our fiscal years, our management conducts a review
of our internal control over financial reporting. We are also required to maintain effective disclosure controls and procedures. Any
failure to maintain adequate controls or to adequately implement required new or improved controls could harm operating results, or cause
failure to meet reporting obligations in a timely and accurate manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our common stock is likely to be highly volatile as the stock market in general can be highly volatile.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public trading of our common stock is based on many factors that could cause fluctuation in the price of our common stock. These factors
may include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    economic and market conditions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actual
    or anticipated variations in annual or quarterly operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of or negative research coverage by securities analysts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions
    or trends in the healthcare information technology industry;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in the market valuations of other companies in our industry;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Announcements
    by us or our competitors of significant acquisitions, strategic partnerships, divestitures, joint ventures or other strategic initiatives;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Announced
    or anticipated capital commitments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ability
    to maintain listing of our common stock on Nasdaq;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additions
    or departures of key personnel; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
    and repurchases of our common stock by us, our officers and directors or our significant stockholders, if any.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
of these factors are beyond our control. Further, as a result of our relatively small public float, our common stock may be less liquid,
and the trading price for our common stock may be more affected by relatively small volumes of trading than is the case for the common
stock of companies with a broader public ownership. These factors may cause the market price of our common stock to decline, regardless
of our operating performance or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
equity research analysts do not publish research reports about our business or if they issue unfavorable commentary or downgrade our
common stock, the price of our common stock could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock may rely in part on the research and reports that equity research analysts publish about our business
and us. We do not control the opinions of these analysts. The price of our stock could decline if one or more equity analysts downgrade
our stock or if those analysts issue other unfavorable commentary or cease publishing reports about our business or us. Furthermore,
if no equity research analysts conduct research or publish reports about our business and us, the market price of our common stock could
decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>All
of our debt obligations and any preferred stock that we may issue in the future will have priority over our common stock with respect
to payment in the event of a bankruptcy, liquidation, dissolution or winding up.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any bankruptcy, liquidation, dissolution or winding up of the Company, our shares of common stock would rank in right of payment or distribution
below all debt claims against us and all of our outstanding shares of preferred stock, if any. As a result, holders of our shares of
common stock will not be entitled to receive any payment or other distribution of assets in the event of a bankruptcy or upon a liquidation
or dissolution until after all of our obligations to our debt holders and holders of preferred stock have been satisfied. Accordingly,
holders of our common stock may lose their entire investment in the event of a bankruptcy, liquidation, dissolution or winding up of
the Company. Similarly, holders of our preferred stock would rank junior to our debt holders and creditors in the event of a bankruptcy,
liquidation, dissolution or winding up of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
may be future sales or other dilution of our equity, which may adversely affect the market price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 31, 2024, we had outstanding options and warrants to purchase 67,500 and no shares of the Company&#8217;s common
stock, respectively. The exercise of such options and warrants and conversion of convertible securities would dilute the ownership percentages
of our existing stockholders, and any sales in the public market of common stock underlying such securities could adversely affect prevailing
market prices for our common stock. We are generally not restricted from issuing in public or private offerings additional shares of
common stock or preferred stock, and other securities that are convertible into or exchangeable for, or that represent a right to receive,
common stock or preferred stock or any substantially similar securities. Such offerings represent the potential for a significant increase
in the number of outstanding shares of our common stock. The market price of our common stock could decline as a result of sales of common
stock, preferred stock or similar securities in the market made after an offering or the perception that such sales could occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
issuance of preferred stock could adversely affect holders of shares of our common stock, which may negatively impact your investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors is authorized to issue classes or series of preferred stock without any action on the part of the stockholders. The
Board of Directors also has the power, without stockholder approval, to set the terms of any such classes or series of preferred stock
that may be issued, including rights and preferences over the shares of common stock with respect to dividends or upon our dissolution,
winding-up or liquidation, and other terms. If we issue preferred stock in the future that has a preference over the shares of our common
stock with respect to the payment of dividends or upon our dissolution, winding up or liquidation, or if we issue preferred stock with
voting rights that dilute the voting power of the shares of our common stock, the rights of the holders of shares of our common stock
or the market price of our common stock could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 31, 2024, we had no shares of preferred stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not currently intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will
depend solely on appreciation in the price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our common stock and do not currently intend to do so for the foreseeable future. We
currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on
your common stock for the foreseeable future and the success of an investment in shares of our common stock will depend upon any future
appreciation in its value. The trading price of our common stock could decline and you could lose all or part of your investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sales
of shares of our common stock or securities convertible into our common stock in the public market may cause the market price of our
common stock to fall.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of shares of our common stock or securities convertible into our common stock in an offering from time to time could have the
effect of depressing the market price for shares of our common stock. In addition, because our common stock is thinly traded, resales
of shares of our common stock by our largest stockholders or insiders could have the effect of depressing market prices for our common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to maintain compliance with Nasdaq listing requirements, our stock could be delisted, and the trading price, volume and
marketability of our stock could be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market. To maintain listing on The Nasdaq Capital Market, we must satisfy minimum financial
and other continued listing requirements and standards, including the Minimum Bid Price Requirement (as discussed below) and those regarding
director independence and independent committee requirements, minimum stockholders&#8217; equity, and certain corporate governance requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to maintain a minimum bid price of $1.00 per share. On October 24, 2023, we received a letter from the Listing Qualifications
Department (the &#8220;Staff&#8221;) of the Nasdaq Stock Market indicating that the closing bid price of our common stock had been below
the minimum bid price of $1.00 per share for the previous 30 consecutive business days, which is required for continued listing on The
Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Price Requirement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq has provided the Company with 180 calendar days, or until April 22, 2024, to
regain compliance with the Minimum Bid Price Requirement. During this period, our common stock will continue to trade uninterrupted on
The Nasdaq Capital Market under the symbol &#8220;STRM.&#8221; To regain compliance, the closing bid price of our common stock must be
at least $1.00 for a minimum of 10 consecutive business days at any time before April 22, 2024. If by April 22, 2024, the Company cannot
demonstrate compliance with the Minimum Bid Price Requirement, it may be eligible for additional time, subject to meeting the continued
listing requirements for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement. If the Company meets these
requirements, we will have an additional 180 calendar days to comply with the Minimum Bid Price Requirement to maintain the listing of
our common stock on The Nasdaq Capital Market. If we are not eligible for the second compliance period, the Staff will provide notice
that our common stock will be subject to delisting, which determination may be appealed to the Nasdaq Hearings Panel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement, even if we maintain compliance
with the other listing requirements. In the event that our common stock is delisted from The Nasdaq Capital Market and is not eligible
for quotation or listing on another market or exchange, trading of our common stock could be conducted only in the over-the-counter market
or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event,
it could become more difficult to dispose of, or obtain accurate price quotations for, our common stock, and there would likely also
be a reduction in our coverage by securities analysts and the news media, which could cause the price of our common stock to decline
further. Also, it may be difficult for us to raise additional capital if we are not listed on a major exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
a delisting would also likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase
our common stock when you wish to do so. In the event of a delisting, we may take actions to restore our compliance with The Nasdaq Stock
Market&#8217;s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to
become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping
below the Minimum Bid Price Requirement or prevent future non-compliance with The Nasdaq Stock Market&#8217;s listing requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
Regarding Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk factors presented above are all of the ones that we currently consider material. However, they are not the only ones facing the
Company. Additional risks not presently known to us, or which we currently consider immaterial, may also adversely affect us. There may
be risks that a particular investor views differently from us, and our analysis might be wrong. If any of the risks that we face actually
occur, our business, financial condition and operating results could be materially adversely affected and could differ materially from
any possible results suggested by any forward-looking statements that we have made or might make. In such case, the market price of our
common stock or other securities could decline and you could lose all or part of your investment. <b>We expressly disclaim any obligation
to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required
by law.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1B. <i>Unresolved Staff Comments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1C. <i>Cybersecurity</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Management and Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize the critical importance of developing, implementing, and maintaining robust cybersecurity measures to maintain the security,
confidentiality, integrity, and availability of our business systems and confidential information, including personal information and
intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cybersecurity program includes systems and processes for assessing, identifying and managing material risks from cybersecurity
threats and include maintenance and monitoring of information security policies aligned with information technology controls; user
and employee awareness of cybersecurity policies and practices; information systems configuration management; and infrastructure
security systems. Management makes concerted efforts to select third-party software providers with a demonstrated track-record of
effectively addressing cybersecurity concerns. In event of a cybersecurity incident, we would rely upon these providers. We have
developed and implemented cybersecurity and data privacy processes and procedures that are informed by recognized cybersecurity
frameworks and standards, including Microsoft Azure CSPM and SOC 2. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use this framework, together with information collected from periodic manual assessments and automated testing, to tailor aspects of
our cybersecurity practices given the nature of our assets, operations and business.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of our information technology team actively monitor threats to the information technology environment and work with our
third-party service providers to monitory cybersecurity threats. In light of the Company&#8217;s current size and limited personnel, management believes relying on experienced third-party providers is the most prudent and cost-effective
course.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, there have been no cybersecurity threats that have materially affected or are reasonably likely to
materially affect our business, operations, or financial condition. For more information on how cybersecurity risk could materially affect
our company&#8217;s business strategy, results of operations, or financial condition, please refer to the &#8220;Risk Factors&#8221;
section of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity
is an important part of our risk management processes and an area of focus for our Board of Directors and management. Our Board of Directors
is responsible for general cybersecurity risk oversight and stays informed on data privacy and information security issues and vulnerabilities
that may be applicable to the Company. Our Board of Directors reviews and evaluates management&#8217;s evaluation and mitigation of cybersecurity
risks as part of its oversight of the Company&#8217;s risk management program. Management periodically reviews cybersecurity risks and
risk mitigation plans and activities with the Board of Directors. We outsource most aspects of our information technology management
and these third-party providers are available to address any cybersecurity issues that may arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
2. <i>Properties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the Company moved its principal offices to a subleased office space at 11800 Amber Park Drive, Suite 125, Alpharetta, Georgia
30009. The office space totals 7,409 square feet and the sublease expired on March 31, 2023. In October 2021, we subleased this space
to a third party for the remaining lease period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 16, 2021, contemporaneous with the acquisition of Avelead, the Company assumed a lease of office space at 1172 Satellite Boulevard
NW, Office Suite 100, Suwannee, Georgia 30024. The lease expired on February 28, 2022. The lease was renewed in February 2022 for one
year on substantially the same terms. The tenant of the lease is an entity controlled by the former owner of Avelead and former Chief
Strategy Officer of the Company. The lease expired on February 28, 2023 and was not renewed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to occupying the subleased office space located in Alpharetta, Georgia, the Company occupied shared office space under a membership agreement
which provides for membership fees based on the number of contracted seats.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has moved to a virtual office model and does not have a physical office space. Membership agreements and daily space rentals
are leveraged by the Company when groups need to meet in person. Our mailing address is 2400 Old Milton Pkwy, Box 1353, Alpharetta, GA
30009. We believe the virtual environment is adequate for the Company&#8217;s current and planned future operations. Suitable alternative
space is available to accommodate expansion of the Company&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3. <i>Legal Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are, from time to time, a party to various legal proceedings and claims, which arise in the ordinary course of business. We are not aware
of any legal matters that could have a material adverse effect on our consolidated results of operations, financial position or cash
flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
4. <i>Mine Safety Disclosures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5. <i>Market For Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock trades on the NASDAQ Capital Market under the symbol STRM.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Company&#8217;s stock transfer agent&#8217;s records, the Company had 215 stockholders of record as of April 29, 2024.
Because brokers and other institutions on behalf of stockholders hold many of such shares, the Company is unable to determine with complete
accuracy the current total number of stockholders represented by these record holders. The Company estimates that it has approximately
2,728 stockholders, based on information provided by Broadridge Financial Solutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has never declared or paid any cash dividends on its common stock and does not currently intend to do so for the foreseeable
future. The Company currently intends to invest its future earnings, if any, to fund its growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended January 31, 2024, we issued an aggregate of 459,117 shares of common stock to 180 Consulting (as defined below)
as compensation for services provided pursuant to the Master Services Agreement, effective March 19, 2020, by and between the Company
and 180 Consulting and related statements of work. The shares were issued in reliance on the exemption
from registration available under Section 4(a)(2) of the Securities Act and the certificates
representing such shares have a legend imprinted on them stating that the shares have not been registered under the Securities Act and
cannot be transferred until properly registered under the Securities Act or pursuant to an exemption from such registration.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">180
Consulting has earned, cumulatively, through the Master Services Agreement, 1,479,911 shares of common stock through January 31, 2024.
206,517 shares of common stock were earned but not issued as of the end of our fiscal year ended January 31, 2024. In June 2023, the
Company filed a Registration Statement on Form S-3 to register 394,127 shares of common stock that were previously issued to 180 Consulting
pursuant to Rule 416 of the Securities Act of 1933. See Note 12 &#8211; Commitments and Contingencies to our consolidated financial
statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information with respect to our repurchases of common stock during the three months ended January 31,
2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Number of Shares Purchased (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average Price Paid per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maximum Number of Shares that May Yet Be Purchased under the Plans or Programs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">November 1 - November 30</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">14,529</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">0.43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>December 1 - December 31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">January 1 - January 31</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,529</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.43</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
    represents shares surrendered by employees to satisfy tax withholding obligations resulting from restricted stock that vested during
    the three months ended January 31, 2024.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
6. [Reserved]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
7. <i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has identified its primary role as aiding healthcare providers to enhance their revenue cycle management by concentrating on
the intermediary stages of the revenue cycle, specifically from initial charge capture to bill drop. This strategic focus remains consistent
as the Company continues to prioritize initiatives within this segment. Our clients predominantly consist of acute-care hospital systems and
their affiliated clinics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commitment to this segment is underscored by our two flagship software solutions: RevID and eValuator. The Company is dedicated to
spearheading an industry-wide effort aimed at improving the financial performance of healthcare providers by shifting billing
interventions upstream to enhance coding accuracy. As a result of our solutions, clients have reduced revenue leakage, mitigated
risks of under-billing and over-billing, and reduced both denials and accounts receivable turnover.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
focusing on the intermediary stages of the revenue cycle, we believe we offer a distinctive and compelling value proposition that
can help us attract more clients. Through innovation and strategic acquisitions, we have broadened our target markets beyond
inpatient facilities to encompass outpatient centers, clinics, and physician practices. Our suite of revenue cycle solutions,
including eValuator and RevID, is highly competitive, enabling us to secure five significant new clients and our first
enterprise client (using multiple products) in fiscal 2023. These clients represent some of the most renowned names in healthcare,
reflecting our salesforce&#8217;s emphasis on industry-leading organizations whose processes often serve as benchmarks for smaller
facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 16, 2023, the Company announced it was executing a strategic restructuring designed to reduce expenses while maintaining the
Company&#8217;s ability to expand its SaaS business (the &#8220;Strategic Restructuring&#8221;). The Strategic Restructuring initiatives
included a reduction in force, resulting in the termination of 26 employees, or approximately 24% of the Company&#8217;s workforce. To
execute the Strategic Restructuring, the Company recognized one-time restructuring costs associated with the workforce reduction of $759,000,
which consisted of approximately $731,000 in severance and other employee termination-related expenses and approximately $28,000 in incurred
legal fees, in fiscal 2023. The Company expects to realize approximately $5,800,000 in annualized cost savings as a result of the Strategic
Restructuring. Approximately 60% of the expected savings related to the reduction in force were realized during the fourth
quarter of fiscal 2023. The remaining expected cost savings are vendor-related expenses which are expected to be recognized beginning
in the first quarter of fiscal 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Acquisitions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 16, 2021, the Company completed an acquisition of Avelead, a recognized leader in providing solutions and services to improve
revenue integrity for healthcare providers nationwide. The Company believes Avelead&#8217;s solutions will complement and extend the
value the Company can deliver to its clients. Refer to Note 3 &#8211; Business Combination in our consolidated financial
statements included in Part I, Item I, &#8220;Financial Statements&#8221; for further information on the Avelead acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Macro-Economic
Conditions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regardless
of the state of the Affordable Care Act, the healthcare industry continues to face sweeping changes and new standards of care that are
putting greater pressure on healthcare providers to be more efficient in every aspect of their operations. We believe these changes represent
ongoing opportunities for our Company to work with our direct clients and various resellers to provide information technology solutions
to help providers meet these new requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic, and its attendant economic damage, had an adverse impact on our revenue. Our healthcare clients were
significantly impacted by the pandemic, and continue to struggle with high turnover rates and a challenging labor market in clinical
and administrative departments resulting in a backlog of IT projects. As a result, our market has become highly unpredictable,
diminishing our ability to accurately forecast the timing of sales and implementations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Operations for the fiscal years ended January 31, 2024 and 2023 (in thousands):</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Software as a Service</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">14,075</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">12,326</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,749</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">14</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Maintenance and Support</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,483</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(165</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Professional fees and licenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,080</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,877</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(48</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,596</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,889</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,293</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cost of sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,053</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,342</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling, general and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,710</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,283</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,573</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,704</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,042</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(338</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Impairment of goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impairment of long-lived assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">963</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">963</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,243</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,523</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,647</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,831</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,816</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other (expense) income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">904</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(477</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(290</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax benefit (expense)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(71</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">117</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(165</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,697</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,379</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(7,318</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(64</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Adjusted EBITDA(1)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,386</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,757</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,371</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">63</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP
    measure meaning net earnings (loss) before net interest expense, tax (expense) benefit, depreciation, amortization, stock-based compensation
    expense, transactional and other expenses that do not relate to our core operations. See &#8220;Use of Non-GAAP Financial Measures&#8221;
    below for additional information and reconciliation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, for each fiscal year indicated, certain operating data as percentages of total revenues:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Operations (1)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Software as a service</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">62.3</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">49.5</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Maintenance and support</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Professional fees and licenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18.6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32.5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cost of sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling, general and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65.4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24.3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Impairment of goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Impairment of long-lived assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">186.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">143.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(86.9</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43.5</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other (expense) income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.9</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax benefit (expense)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(82.7</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(45.7</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cost of Sales to Revenues ratio, by revenue stream:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Software as a service</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">46.7</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">51.6</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Maintenance and support</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">7.3</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">9.5</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Professional fees and licenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">99.1</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">81.8</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
    a significant percentage of the operating costs are incurred at levels that are not necessarily correlated with revenue levels, a
    variation in the timing of software licenses and installations and the resulting revenue recognition can cause significant variations
    in operating results. As a result, period-to-period comparisons may not be meaningful with respect to the past results nor are they
    necessarily indicative of the future results of the Company in the near or long-term. The data in the table is presented solely for
    the purpose of reflecting the relationship of various operating elements to revenues for the periods indicated.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of Fiscal 2023 with Fiscal 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenues</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 to 2022 Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands):</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Software as a service</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">14,075</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">12,326</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,749</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">14</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Maintenance and support</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,483</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(165</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Professional fees and licenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,080</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,877</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(48</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total Revenues</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,596</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,889</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,293</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Software
as a service (SaaS)</span></i> &#8212; Revenues from SaaS are primarily comprised of the Company&#8217;s flagship products; eValuator
and RevID. Revenues from SaaS in fiscal 2023 were $14,075,000, as compared to $12,326,000 in fiscal 2022. The $1,749,000 increase in
SaaS revenue was primarily attributable to new client wins, incremental sales to existing clients and recognition of a full year of
revenue from certain clients that implemented our solutions during fiscal 2022, partially offset by client non-renewals. In fiscal 2023, the
Company received notice from a significant SaaS client of its intent not to renew its contract following the expiration of the
current term on December 31, 2023. Fiscal 2023 SaaS revenue reflects losing one month of revenue related to that client. The Company
expects minimal growth in its SaaS business year-over-year but expects sequential growth in each quarter of fiscal 2024 as the
Company replenishes the lost revenue related to the non-renewal of the client contract. At January 31, 2024, the Company had
approximately $3,900,000 in SaaS annual contract value for contracts that has not been implemented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<br/></span></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Maintenance
and support</span></i> &#8212; Revenues from maintenance and support are derived from our legacy CDI and Abstracting products. In
fiscal 2023, these revenues were slightly lower as compared to fiscal 2022. $381,000 of the revenue decline was the result of site
terminations and reductions, which was offset by $137,000 of new sales acquired through our channel partner and $78,000 of new
revenue from existing clients related to CPI adjustments. As the Company maintains its focus on SaaS products the Company expects
maintenance and support revenue will continue to decrease in fiscal 2024 as a result of pricing pressure, anticipated non-renewal of contracts and minimal new sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Professional
fees and licenses</span></i> &#8212; Revenues from professional fees and licenses include proprietary software, term license, professional
services and audit and coding services revenues. Total professional fees and licenses revenues in fiscal 2023 were $4,203,000, a decline of $3,877,000 as compared
to $8,080,000 in fiscal 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no perpetual software license revenues recognized in fiscal 2023, as compared to $663,000 in fiscal 2022. The Company has
primarily shifted its business from perpetual software licenses to a SaaS model. Software license sales come primarily from channel partners who were nonproductive in fiscal 2023. As a result of these channel partner relationships the Company has limited
ability to influence sales of these products. Term license revenue for fiscal 2023 decreased $318,000 from fiscal 2022 to a total of
$238,000 due to a term license non-renewal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
services revenues in fiscal 2023 were $1,764,000 as compared to $4,319,000 in fiscal 2022. The decrease in professional services
revenue was attributable to the Company and certain clients choosing at the end of fiscal 2022 to not renew consulting contracts
which accounted for approximately $3,100,000 of professional services revenue in fiscal 2022. The consulting services contracts had
low margins compared to our SaaS solutions and the Company does not intend to pursue such professional services contracts in the
future. The decrease in professional services revenue was partially offset by $700,000 of revenue from new and ongoing
implementation services for  the Company&#8217;s RevID solution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from audit and coding services in fiscal 2023 were $2,201,000, as compared to $2,542,000 in fiscal 2022. Certain revenue-generating
clients from fiscal 2022 did not require audit services in fiscal 2023 resulting in a decrease of $985,000 in revenue for fiscal
2023 compared to fiscal 2022. Existing clients had various shifts in their demand for audit services that resulted in $554,000 of
incremental revenue for fiscal 2023 compared to fiscal 2022. The Company
believes demand for its onshore, technically proficient coders and auditors in the marketplace is strong and that it has a
competitive edge in providing audit and coding services as an offering with the eValuator solution as a technology-enabled service.
The Company anticipates the audit and coding services business to remain relatively flat in fiscal 2024 to support shifting demand
among clients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cost
of Revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 to 2022 Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands):</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Cost of software as a service</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">6,573</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">6,358</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">215</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">3</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cost of maintenance and support</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">315</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(112</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of professional fees and licenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,165</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,610</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,445</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total cost of sales</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,053</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,395</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,342</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Cost
of software as a service (SaaS)</span></i> &#8212; The Cost of SaaS consists of expenses associated with (i) amortization of
capitalized software, (ii) royalties payable to third-parties for use of their coding related content, and (iii) personnel and
network infrastructure required to deploy and support applications for each client. Expenses related to SaaS increased by
$215,000 in fiscal 2023 compared to fiscal 2022, driven by an increase of $161,000 for fiscal 2023 compared to fiscal 2022 for
amortization of capitalized software features that were put into service during the fiscal year. The Company expects amortization of
capitalized software costs to stay relatively consistent in fiscal 2024 as compared to fiscal 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
expenses included in our cost of SaaS are tied to volumes. These expenses include coding tools supporting eValuator and a third-party system
that translates data from the hospital system to the Company&#8217;s systems. In fiscal 2023 and 2022, cost of SaaS included non-cash
amortization of capitalized software amounts of $2,229,000 and $2,068,000, respectively. The non-cash amounts impacted fiscal 2023 and 2022 margins by 16% and 17%, respectively. The company expects SaaS
margins will expand as it implements new clients. Certain expenses included in cost of SaaS, such as labor and third-party content providers, negatively impact
gross margin before a client is fully implemented and revenue is recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Cost
of maintenance and support</span></i> &#8211; The cost of maintenance and support includes compensation and benefits for client support
personnel required to provide product support for clients on our CDI and Abstracting software licenses. This cost decreased by
approximately $62,000 related to staff augmentation for client support personnel in fiscal 2023 compared
to fiscal 2022. The Company continuously analyzes the allocation of its support resources and adjusts their alignment accordingly as
the Company shifts away from license-based software to its flagship SaaS products. The cost of maintenance and support
decreased by $77,000 in fiscal 2023 compared to fiscal 2022 as a result of reduced royalties related to third party components of
our CDI and Abstracting software. As clients move to other solutions, we expect these costs to continue to decline. The Company
expects the overall cost of maintenance and support to remain relatively flat in fiscal 2024 compared to fiscal 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Cost
of professional fees and licenses</span></i> &#8211; The cost of professional fees and licenses includes the cost of software licenses,
the cost of professional services and the cost of audit and coding services. The aggregate cost of professional fees and licenses
was $4,165,000 and $6,610,000 for fiscal 2023 and fiscal 2022 respectively. The decrease in cost of professional fees and licenses
was attributable to a reduction of personnel, contractors, and expenses related to a significant consulting-based client contract
that was terminated in the fourth quarter of fiscal 2022 which led to a decrease of $2,461,000 in employee, staff augmentation and
related expenses for fiscal 2023 as compared to fiscal 2022. In fiscal 2023, slight increases related to the cost of providing audit services with
compensation and benefits for internal audit services personnel, and related expenses resulted in total increased costs of $163,000,
while outside contracting decreased by $57,000 as compared to fiscal 2022. This cost shift reflects a move from contract labor to
employee labor to provide better service to our audit services clients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software license costs decreased $121,000
from fiscal 2022 to fiscal 2023 as a result of lower amortization of development costs associated with the Company&#8217;s Coding and
CDI product. The Company expects the remaining capitalized Coding and CDI software license costs to be fully amortized by the end of
fiscal 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The gross margin on professional fees and licenses revenue decreased in fiscal 2023 as compared to fiscal 2022 primarily
due to the 48% decrease in related revenue including the high margin software license revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Selling,
General and Administrative Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 to 2022 Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands):</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">General and administrative expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">9,841</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">10,718</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(877</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(8</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Sales and marketing expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,869</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,565</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(696</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total selling, general, and administrative expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,710</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,283</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,573</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(10</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses comprise various costs including compensation and associated benefits, reimbursable travel and
entertainment expenses related to our executive and administrative staff, general corporate expenditures, amortization of intangible
assets, and occupancy costs. For fiscal 2023, the decrease of $877,000 as compared to fiscal 2022 was primarily attributable to a
reduction of $222,000 in employee compensation and related benefits, a $211,000 decrease in amortization costs, a $199,000 decrease
in rent expense, and a $189,000 decrease in bad debt expenses as compared to fiscal 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
alignment with the Company&#8217;s strategic plan to streamline operations, these expenses are strategically managed to support sustainable
growth, enhanced profitability, and improved cash flows. Additionally, recent adjustments in response to the loss of a major customer
underscore our commitment to adaptability and resilience in challenging market conditions. This comprehensive approach reflects our commitment
to simplifying our business operations while pursuing our overarching objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
and marketing expenses primarily encompass compensation, associated benefits, travel and entertainment costs for our sales and
marketing personnel. Additionally, sales and marketing expenses include costs from third parties related to advertising, marketing
and trade show attendance. In fiscal 2023, sales and marketing expenses decreased by $696,000 compared to fiscal 2022. The decline
in sales and marketing expense was comprised of a reduction in overall staff augmentation and other related expenses of
approximately $472,000 and a reduction of $182,000 related to trade shows and various other marketing services in fiscal 2023 as
compared to fiscal 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For fiscal 2024, the Company expects increased expenses related to trade show participation and travel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 to 2022 Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands):</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Research and development expense</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,704</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">6,042</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(338</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(6</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Capitalized research and development cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(322</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16</td><td style="text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of employee compensation and related benefits, the use of independent contractors for specific
near-term development projects and an allocated portion of general overhead costs, including occupancy costs, if material. Total research
and development expense and capitalized research and development expense for fiscal 2023 were $5,704,000 and $1,697,000, respectively.
The $338,000 decrease in research and development expense was driven by decreases of $529,000 for employee compensation and related benefits
and a decrease of $150,000 in independent contractor expense for fiscal 2023 compared to fiscal 2022. The decrease in employee and independent
contractor expenses drove a reduction of capitalized research and development cost of $322,000 in fiscal 2023 as compared to fiscal 2022.
The Company continues to focus research and development activities on eValuator and RevID, its flagship SaaS solutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal 2023 and fiscal 2022, as a percentage of revenue, total research and development costs were approximately 23% and 25%, respectively. In
fiscal 2023, the Company was awarded $61,000 from the State of Georgia for its annual research and development tax credit. At the
end of fiscal 2023, the cumulative balance of unused research and development credits was $149,000. These research and development
tax credits can be applied to current Georgia payroll taxes due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of Goodwill</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the third quarter of fiscal 2023, the Company tested the reporting unit&#8217;s goodwill for possible impairment as of October 31, 2023.
Refer to Note 6 &#8211; Goodwill and Intangible Assets to our consolidated financial statements included in Part II, Item 8, &#8220;Financial
Statements and Supplementary Data&#8221; for more information on the goodwill impairment testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<!-- Field: Split-Segment; Name: split_001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company concluded that goodwill was impaired based on the weighted combination of the discounted debt-free net cash flow and the market
capitalization method value estimates which resulted in a calculated fair value lower than its carrying value. The Company recorded an
impairment of goodwill in the amount of $9,813,000 for fiscal 2023, with no goodwill impairments reported in fiscal 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of long-lived assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated Useful Life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finite-lived assets:</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 32%; text-align: left; padding-left: 10pt">Client relationships</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: right">10 years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">8,370,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,058,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">6,312,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Internally developed software</td><td>&#160;</td>
    <td style="text-align: right">9 years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,380,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,742,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,638,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Trademarks and tradenames</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt">15 years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,340,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">219,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,121,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,090,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,019,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,071,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
mentioned above, in the third quarter of fiscal 2023, the Company tested long-lived assets, including intangible assets, for
recoverability that, if failed, would indicate impairment as of October 31, 2023. The Company, in reviewing long-lived assets to
define asset group(s), identified an abandoned asset. A separate long-lived asset for &#8220;client relationships&#8221; related to
the Avelead acquisition was no longer going to be used following the Company&#8217;s determination that these services were not part
of its core offerings going forward and was classified as abandoned (the &#8220;Abandoned Asset&#8221;). The Company adjusted the
Abandoned Asset&#8217;s carrying value to its salvage value which would be zero given no future cash flows. In fiscal 2023, the Company recorded $963,000 for the impairment of the Abandoned Asset with no other long-lived
impairments reported in fiscal 2022. The Company wrote-off the Abandoned Asset during fiscal 2023 with a gross asset value of $1,330,000.
There was no impact to the consolidated statements of operations as this eliminated the asset and accumulated amortization of the fully
amortized intangible assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer
to Note 6 &#8211; Goodwill and Intangible Assets to our consolidated financial statements included in Part II, Item 8, &#8220;Financial
Statements and Supplementary Data&#8221; for more information on the long-lived asset impairment testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
(Expense) income</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 to 2022 Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands):</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Interest expense</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(1,071</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(749</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(322</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">43</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Acquisition earnout valuation adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,944</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,873</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2638</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">201</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(170</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(85</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total other (expense) income</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">904</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(477</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,381</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(290</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense consists of interest associated with the term loan and the revolving line of credit, deferred financing costs, less interest
related to capitalization of software. Interest expense increased in fiscal 2023 from the prior year period primarily due to the
$10,000,000 term loan with Western Alliance Bank (Refer to Note 5 &#8211; Debt to our consolidated financial statements included in
Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; for additional information) and higher interest rates.
Further, interest rates increased at an accelerated pace in fiscal 2023. The Board of Governors of the Federal Reserve (the
&#8220;Federal Reserve&#8221;) has been reacting to inflation through interest rate increases. Recent interest rate increases are
expected to continue at a slower pace than that experienced in fiscal 2023. Until such time as the Federal Reserve begins to
decrease interest rates, the Company expects increased interest expense (year-over-year) for fiscal 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition
earnout valuation adjustments for fiscal 2023 include a valuation adjustment of $1,944,000 compared to an adjustment of $71,000 for fiscal
2022. The valuation adjustment is related to the acquisition earnout liabilities associated with the Avelead acquisition (Refer to Note
3 &#8211; Business Combination of the consolidated financial statements included in Part II, Item 8, &#8220;Financial
Statements and Supplementary Data&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income for fiscal 2023 and fiscal 2022 primarily includes income related to the sublease of the Alpharetta location (Refer to Note 4
&#8211; Operating Leases).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provision
for Income Taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For fiscal 2023 and fiscal 2022, we recorded income tax benefit of $46,000 and tax expense of $71,000, respectively,
which is comprised of estimated federal, state, and local income tax provisions. The Company has a substantial amount of net operating
losses for federal and state income tax purposes. The Company recorded an increase to the federal income tax valuation allowance in each
of fiscal 2023 and fiscal 2022 of approximately $4.0 and $2.0 million, respectively, which offset related tax benefits for operating
losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Non-GAAP Financial Measures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to provide investors with greater insight and allow for a more comprehensive understanding of the information used by management
and the Board of Directors in its financial and operational decision-making, the Company has supplemented the Consolidated Financial
Statements presented on a GAAP basis in this Report with the following non-GAAP financial measures: EBITDA, Adjusted EBITDA, and Adjusted
EBITDA Margin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis
of Company results as reported under GAAP. The Company compensates for such limitations by relying primarily on our GAAP results and
using non-GAAP financial measures only as supplemental data. We also provide a reconciliation of non-GAAP to GAAP measures used. Investors
are encouraged to carefully review this reconciliation. In addition, because these non-GAAP measures are not measures of financial performance
under GAAP and are susceptible to varying calculations, these measures, as defined us, may differ from and may not be comparable to similarly
titled measures used by other companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EBITDA,
Adjusted EBITDA, and Adjusted EBITDA Margin</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
define: (i) EBITDA as net earnings (loss) before net interest expense, income tax expense (benefit), depreciation and amortization; (ii)
Adjusted EBITDA as net earnings (loss) before net interest expense, income tax expense (benefit), depreciation, amortization, share-based
compensation expense, transaction related expenses, and other expenses or benefits that do not relate to our core operations such as
severance and impairment charges and debt forgiveness; and (iii) Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of GAAP net
revenue. EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin are used to facilitate a comparison of our operating performance on a consistent
basis from period to period and provide for a more complete understanding of factors and trends affecting our business than GAAP measures
alone. These measures assist management and the Board and may be useful to investors in comparing our operating performance consistently
over time as they remove the impact of our capital structure (primarily interest charges), asset base (primarily depreciation and amortization),
items outside the control of the management team (taxes) and expenses that do not relate to our core operations including: transaction-related
expenses (such as professional and advisory services), corporate restructuring expenses (such as severances) and other operating costs
that are expected to be non-recurring in nature. Adjusted EBITDA removes the impact of share-based compensation expense, which is another
non-cash item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors and management also use these measures (i) as one of the primary methods for planning and forecasting overall expectations
and for evaluating, on at least a quarterly and annual basis, actual results against such expectations; and (ii) as a performance evaluation
metric in determining achievement of certain executive and associate incentive compensation programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lender uses a measurement that is similar to the Adjusted EBITDA measurement described herein to assess our operating performance. The
lender under our Loan Agreement requires delivery of compliance reports certifying compliance with financial covenants, certain of which
are based on a measurement that is similar to the Adjusted EBITDA measurement reviewed by our management and Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EBITDA,
Adjusted EBITDA and Adjusted EBITDA Margin are not measures of liquidity under GAAP or otherwise and are not alternatives to cash flow
from continuing operating activities, despite the advantages regarding the use and analysis of these measures as mentioned above. EBITDA,
Adjusted EBITDA, and Adjusted EBITDA Margin, as disclosed in this Report have limitations as analytical tools, and you should not consider
these measures in isolation or as a substitute for analysis of our results as reported under GAAP; nor are these measures intended to
be measures of liquidity or free cash flow for our discretionary use. Some of the limitations of EBITDA and its variations are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EBITDA
    does not reflect our cash expenditures or future requirements for capital expenditures or contractual commitments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EBITDA
    does not reflect changes in, or cash requirements for, our working capital needs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EBITDA
    does not reflect the interest expense, or the cash requirements to service interest or principal payments under our Loan Agreement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EBITDA
    does not reflect income tax payments that we may be required to make; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
    depreciation and amortization are non-cash charges, the assets being depreciated and amortized often will have to be replaced in
    the future, and EBITDA does not reflect any cash requirements for such replacements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjusted
EBITDA has all the inherent limitations of EBITDA. To properly and prudently evaluate our business, the Company encourages readers to
review the GAAP financial statements included elsewhere in this Report, and not rely on any single financial measure to evaluate our
business. We also strongly urge readers to review the reconciliation of these non-GAAP financial measures to the most comparable GAAP
measure in this section, along with the consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and
Supplementary Data&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table reconciles EBITDA and Adjusted EBITDA to net loss  for the fiscal years ended January 31, 2024
and 2023 (amounts in thousands). All of the items included in the reconciliation from EBITDA and Adjusted EBITDA to net loss  are either recurring non-cash items, or items that management does not consider in assessing our on-going operating performance.
In the case of the non-cash items, management believes that investors may find it useful to assess the Company&#8217;s comparative operating
performance because the measures without such items are less susceptible to variances in actual performance resulting from depreciation,
amortization and other expenses that do not relate to our core operations and are more reflective of other factors that affect operating
performance. In the case of items that do not relate to our core operations, management believes that investors may find it useful to
assess our operating performance if the measures are presented without these items because their financial impact does not reflect ongoing
operating performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Adjusted EBITDA Reconciliation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net loss</p></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(18,697</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(11,379</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,071</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">749</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Income tax expense (benefit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(46</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Depreciation and amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,229</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,233</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">EBITDA</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,443</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,326</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Share-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,680</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Impairment of goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Impairment of long-lived assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">963</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Non-cash valuation adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,944</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(71</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Acquisition-related costs, severance, and transaction-related bonuses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">397</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,149</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Other non-recurring expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(33</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(189</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Restructuring charges</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">759</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Adjusted EBITDA</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,386</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,757</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Adjusted EBITDA margin (1)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjusted
    EBITDA as a percentage of GAAP net revenues.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
of Critical Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&#8217;s most critical accounting policies. Refer to Note 2 &#8211; Significant Accounting Policies
to our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; for a
complete discussion of the significant accounting policies and methods used in the preparation of our consolidated financial statements.</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company derives revenue from the sale of internally developed software, either by licensing for local installation or by a SaaS delivery
model, through our direct sales force or through third-party resellers. Licensed, locally installed clients on a perpetual model utilize
our support and maintenance services for a separate fee, whereas term-based locally installed license fees and SaaS fees include support
and maintenance. The Company also derives revenue from professional services that support the implementation, configuration, training
and optimization of the applications, as well as audit and consulting services The Company recognizes revenue to depict the transfer
of promised goods or services to clients in an amount that reflects the consideration to which the entity expects to be entitled in exchange
for those goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
obligations are the unit of accounting for revenue recognition and generally represent the distinct goods or services that are promised
to the client. If we determine that we have not satisfied a performance obligation, we will defer recognition of the revenue until the
performance obligation is deemed to be satisfied. Maintenance and support and SaaS agreements are generally non-cancellable or contain
significant penalties for early cancellation, although clients typically have the right to terminate their contracts for cause if we
fail to perform material obligations. However, if non-standard acceptance periods, non-standard performance criteria, or cancellation
or right of refund terms are required, revenue is recognized upon the satisfaction of such criteria. Certain contracts may include aspects
of variable consideration as it relates to performance guarantees and service level agreements. Significant judgment is required to determine
the standalone selling price (&#8220;SSP&#8221;) for each performance obligation, impact of variable consideration on total contract
price, the amount allocated to each performance obligation and whether it depicts the amount that the Company expects to receive in exchange
for the related product and/or service. The Company recognizes revenue for implementation for certain of its eValuator SaaS solution
over the contract term, as it has been determined that those implementation services are not a distinct performance obligation. Services
for other SaaS and Software solutions such as CDI, RevID and Compare, have been determined as a distinct performance obligation. For
these agreements, the Company estimates SSP of its software licenses using the residual approach when the software license is sold with
other services and observable SSPs exist for the other services. The Company estimates the SSP for maintenance, professional services,
software as a service and audit services based on observable standalone sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer
to Note 2 &#8211; Significant Accounting Policies to our consolidated financial statements included in Part II, Item 8, &#8220;Financial
Statements and Supplementary Data&#8221; for additional information regarding our revenue recognition policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Capitalized
Software Development Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software
development costs for software to be sold, leased, or marketed are accounted for in accordance with Accounting Standards Codification
(&#8220;ASC&#8221;) 985-20, <i>Software &#8212; Costs of Software to be Sold, Leased or Marketed</i>. Costs associated with the planning
and design phase of software development are classified as research and development costs and are expensed as incurred. Once technological
feasibility has been established, a portion of the costs incurred in development, including coding, testing and quality assurance, are
capitalized until available for general release to clients, and subsequently reported at the lower of unamortized cost or net realizable
value. Amortization is calculated on a solution-by-solution basis and is included in cost of professional fees and licenses on the consolidated
statements of operations. Annual amortization is measured at the greater of a) the ratio of the software product&#8217;s current gross
revenues to the total of current and expected gross revenues or b) straight-line over the remaining economic life of the software (typically
two years). Unamortized capitalized costs determined to be in excess of the net realizable value of a solution are expensed at the date
of such determination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal-use
software development costs are accounted for in accordance with ASC 350-40, <i>Internal-Use Software</i>. The costs incurred in the preliminary
stages of development are expensed as research and development costs as incurred. Once an application has reached the development stage,
internal and external costs incurred to develop internal-use software are capitalized and amortized on a straight-line basis over the
estimated useful life of the software (typically three to four years). Maintenance and enhancement costs, including those costs in the
post-implementation stages, are typically expensed as incurred, unless such costs relate to substantial upgrades and enhancements to
the software that result in added functionality, in which case the costs are capitalized and amortized on a straight-line basis over
the estimated useful life of the software. The Company reviews the carrying value for impairment whenever facts and circumstances exist
that would suggest that assets might be impaired or that the useful lives should be modified. Amortization expense related to capitalized
internal-use software development costs is included in Cost of software as a service on the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Goodwill
and Intangible Assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
and other intangible assets were recognized in conjunction with the acquisitions of Interpoint Partners, LLC (&#8220;Interpoint&#8221;),
Meta Health Technology, Inc. (&#8220;Meta&#8221;), Clinical Looking Glass&#174; (&#8220;CLG&#8221;), Opportune IT, Unibased Systems Architecture,
Inc. (&#8220;Unibased&#8221;), and Avelead. Identifiable intangible assets include purchased intangible assets with finite lives, which
primarily consist of internally-developed software, client relationships, non-compete agreements and license agreements. Finite-lived
purchased intangible assets are amortized over their expected period of benefit, which generally ranges from one month to 15 years, using
the straight-line method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
assess the useful lives and possible impairment of existing recognized goodwill on at least an annual basis, and goodwill and intangible
assets when an event occurs that may trigger such a review. Factors considered important which could trigger a review include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    under-performance relative to historical or projected future operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    changes in the manner of use of the acquired assets or the strategy for the overall business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification
    of other impaired assets within a reporting unit;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disposition
    of a significant portion of an operating segment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    negative industry or economic trends;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    decline in the Company&#8217;s stock price for a sustained period; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decline in the market capitalization relative to the net book value.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company completed its annual goodwill assessment for fiscal 2023 as of October 31, 2023. We used a weighted sum of income and market
approaches to determine the fair value of the Company&#8217;s goodwill. Under the income approach, the fair value was based on the present
value of the estimated debt-free, discounted cash flows that the reporting unit is expected to generate. Cash flow projections were based
on management&#8217;s estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions.
The discount rate was based on the weighted average cost of capital appropriate for the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the third quarter of fiscal 2023, the Company received a notice from a significant SaaS client of its intent not to renew its contract
following the expiration of the current term on December 31, 2023. The Company also announced it was accelerating the Strategic Restructuring
to reduce costs while continuing the Company&#8217;s focus on expanding its SaaS operations. These announcements triggered a significant
decrease in the Company&#8217;s share price. Based on these factors, we determined there were indicators that the goodwill may be impaired,
and accordingly, performed an interim goodwill impairment test as of October 31, 2023. The results of the impairment test showed the
fair value of the reporting unit was lower than the carrying value, resulting in a $9.8 million goodwill impairment charge. As of January
31, 2024, no further impairment was required for goodwill. The remaining goodwill balance of the Company after recording the goodwill
impairment charge is $13.3 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
during the third quarter of fiscal 2023, due to the factors discussed above, we assessed whether the carrying amounts of the Company&#8217;s
long-lived assets may not be recoverable and, therefore, impaired. Our assessment resulted in an impairment charge of $1.0 million, primarily
attributable to client relationships related to a subset of consulting related services the Company expects will not be a core part of
its business going forward. The impairment charge was calculated using the asset&#8217;s salvage value as it was considered no longer
held for use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of our reporting unit and intangible assets is subjective in nature and involves the use of significant estimates and assumptions,
particularly related to future operating results and cash flows. These estimates and assumptions include, but are not limited to, revenue
growth rates and operating margins used to calculate projected future cash flows, risk-adjusted discount rates, and future economic and
market conditions. If we do not achieve our forecasts or the Company&#8217;s share price declines further, it is possible the goodwill
of the Company could be deemed to be impaired again in a future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risks and potential impacts on the fair value of our goodwill and long-lived assets are included in our risk factor disclosures referenced
under &#8220;Item 1A. Risk Factors&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and for tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net
deferred tax assets, we consider whether it is more likely than not that some or all of the deferred tax assets will not be realized.
We establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.
Refer to Note 7 &#8211; Income Taxes to our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements
and Supplementary Data&#8221; for further details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s liquidity is dependent upon numerous factors including: (i) the timing and amount of revenues and collection of contractual
amounts from clients, (ii) amounts invested in research and development and capital expenditures, and (iii) the level of operating expenses,
all of which can vary significantly from quarter-to-quarter. The Company&#8217;s primary cash requirements include regular payment of
payroll and other business expenses, principal and interest payments on debt and minor amounts of capital expenditures. Capital expenditures
generally include computer hardware and computer software to support internal development efforts or SaaS data center infrastructure.
Operations are funded with cash generated by operations and borrowings under the bank credit facilities. The Company believes that cash
flows from operations and available credit facilities are adequate to fund current obligations for twelve months from the date of issuance
of the audit report on the Company&#8217;s consolidated financial statements. Cash and cash equivalent balances at January 31, 2024 and
2023 were $3,190,000 and $6,598,000, respectively. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Capital
Raise</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Registered
Direct Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 24, 2022, the Company entered into purchase agreements with certain investors pursuant to which the Company agreed to issue and
sell in a registered direct offering (the &#8220;2022 Offering&#8221;) an aggregate of 6,299,989 shares of common stock, par value $0.01
per share, at a purchase price of $1.32 per share. The gross proceeds to the Company from the 2022 Offering were approximately $8,316,000.
The Company intends to use the proceeds of the 2022 Offering for general corporate purposes. The 2022 Offering closed on October 26,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Debt
Private Placement</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 1, 2024, the Company entered into a securities purchase agreement with certain accredited investors, including certain directors
and officers of the Company, pursuant to which the Company agreed to sell to the investors unsecured subordinated promissory notes in
the aggregate principal amount of $4.4 million and warrants to purchase up to an aggregate of 4,052,631 shares of the Company&#8217;s
common stock in a private placement (the &#8220;Debt Private Placement&#8221;). The closing of the Debt Private Placement occurred on
February 7, 2024. Refer to Note 14 &#8211; Subsequent Events to our consolidated financial statements included in Part II, Item 8, &#8220;Financial
Statements and Supplementary Data&#8221; for additional information regarding the Debt Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Common
Stock Private Placement</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2024, the Company completed the sale of 263,158 shares of the Company&#8217;s common stock to an accredited investor at a
purchase price of $0.38 per share for an aggregate purchase price of $100,000 (the &#8220;Common Stock Private Placement&#8221;). Refer
to Note 14 &#8211; Subsequent Events to our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements
and Supplementary Data&#8221; for additional information regarding the Common Stock Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Authorized
Shares Amendment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the 2022 Annual Meeting of Stockholders (the &#8220;2022 Annual Meeting&#8221;) held on June 7, 2022, the Company&#8217;s stockholders
approved an amendment to the Streamline Health Solutions, Inc. Third Amended and Restated 2013 Plan (the &#8220;2013 Plan&#8221;) to
increase the number of shares of the Company&#8217;s common stock authorized for issuance thereunder by 2,000,000 shares, from 8,223,246
shares to 10,223,246 shares. The Company&#8217;s stockholders also approved an amendment to the Company&#8217;s Certificate of Incorporation,
as amended, to increase the total number of authorized shares of the Company&#8217;s common stock from 65,000,000 shares to 85,000,000
shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the 2023 Annual Meeting of Stockholders (the &#8220;2023 Annual Meeting&#8221;) held on June 15, 2023, the Company&#8217;s stockholders
approved an amendment to the 2013 Plan to increase the number of shares of the Company&#8217;s common stock authorized for issuance thereunder
by 1,000,000 shares, from 10,223,246 shares to 11,223,246 shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Credit
Facility</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has liquidity through the Loan Agreement with Western Alliance Bank (&#8220;WAB&#8221;). On November 29, 2022, the Company executed
the Second Modification (the &#8220;Second Modification&#8221;) to the Loan Agreement which expanded the Company&#8217;s total borrowing
to include a $2,000,000 revolving line of credit. The revolving line of credit is co-terminus with the term loan portion of the Loan
Agreement and matures on August 26, 2026. There are no requirements to draw on the line of credit. Amounts outstanding under the line
of credit portion of the Loan Agreement bear interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal)
plus 1.5%, with a Prime &#8220;floor&#8221; rate of 3.25%. The Second Modification also amended certain financial covenants under the
Loan Agreement. Refer to Note 5 &#8211; Debt to our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements
and Supplementary Data&#8221; for additional information regarding the Loan Agreement and the Second Modification. At January 31, 2024,
there was a $1,500,000 outstanding balance on the revolving line of credit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Loan Agreement, the Company has a term loan facility with an initial, maximum, principal amount of $10,000,000. Amounts outstanding
under the Loan Agreement bear interest at a per annum rate equal to the Prime Rate (as published in The Wall Street
Journal) plus 1.5%, with a Prime &#8220;floor&#8221; rate of 3.25%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Second Modification includes customary financial covenants as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Minimum
    Cash. </b>Borrowers shall, at all times, maintain unrestricted cash in an amount not less than Two Million Dollars ($2,000,000).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
    Debt to ARR Ratio. </b>Borrowers&#8217; Maximum Debt to ARR Ratio, measured on a quarterly basis as of the last day of each fiscal
    quarter, shall not be greater than the amount set forth under the heading &#8220;Maximum Debt to ARR Ratio&#8221; as of, and for
    each of the dates appearing adjacent to such &#8220;Maximum Debt to ARR Ratio&#8221;.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quarter
    Ending</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
                                            Debt to</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARR
    Ratio</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    31, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.80
    to 1.00</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    31, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.70
    to 1.00</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    30, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.65
    to 1.00</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    31, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.60
    to 1.00</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    31, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.55
    to 1.00</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    31, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.55
    to 1.00</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
    Debt to Adjusted EBITDA Ratio. </b>Commencing with the quarter ending April 30, 2024, Borrowers&#8217; Maximum Debt to Adjusted EBITDA
    Ratio, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4) quarter period then ended,
    shall not be greater than the amount set forth under the heading &#8220;Maximum Debt to Adjusted EBITDA Ratio&#8221; as of, and for
    each of the dates appearing adjacent to such &#8220;Maximum Debt to Adjusted EBITDA Ratio&#8221;.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quarter
    Ending</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
    Debt to Adjusted EBITDA Ratio</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    30, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.50
    to 1.00</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    31, 2024, and on the last day of each quarter, thereafter</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00
    to 1.00</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed
    Charge Coverage Ratio</b>. Commencing with the quarter ending April 30, 2024, Borrowers shall maintain a Fixed Charge Coverage Ratio
    of not less than 1.20 to 1.00, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4)
    quarter period then ended.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement includes customary negative covenants, subject to exceptions, which limit transfers, capital expenditures,
indebtedness, certain liens, investments, acquisitions, dispositions of assets, restricted payments, and the business activities of
the Company, as well as customary representations and warranties, affirmative covenants and events of default, including cross
defaults and a change of control default. The line of credit is also subject to customary prepayment requirements. For the period
ended January 31, 2024, the Company was not in compliance with the Maximum Debt to ARR Ratio covenant under the Loan Agreement; however, on February 7, 2024, the Company received a waiver from WAB in connection with the execution of the Third
Modification (as defined below). Refer to Note 5 &#8211; Debt to our consolidated financial statements included in Part II, Item 8,
&#8220;Financial Statements and Supplementary Data&#8221; for more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 7, 2024, the Company executed the Third Modification and Waiver (the &#8220;Third Modification&#8221;) to the Loan Agreement.
Refer to Note 14 &#8211; Subsequent Events to our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements
and Supplementary Data&#8221; for additional information regarding the Third Modification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant
cash obligations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of January, 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify; padding-bottom: 2.5pt">Term loan (1)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">9,066</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">9,714</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term loan balance is reported net of unamortized deferred financing costs
of $69,000 and $105,000 plus accrued financing costs payable of $135,000 and $69,000 each as of January 31, 2024 and 2023, respectively.
Refer to Note 5 &#8211; Debt to our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary
Data&#8221; for additional information. The term loan balance as of January 31, 2024 and January 31, 2023 was bank term debt.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
cash flow activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(18,697</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(11,379</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Non-cash adjustments to net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,120</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cash impact of changes in assets and liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,331</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,884</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt">Net cash used in operating activities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,215</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(7,143</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had a higher net loss from operations and higher non-cash adjustments to net loss primarily due to higher rates of amortization
and goodwill and intangible impairments than fiscal 2023. &#160;The Company&#8217;s accounts receivable was significantly lower in fiscal
2023 as compared to fiscal 2022 primarily due to the timing of collection on certain annual invoices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investing
cash flow activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Purchases of property and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(54</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(10</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Capitalized software development costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,567</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,924</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net cash used in investing activities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,621</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,934</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cash used in investing activities for fiscal 2023 and fiscal 2022 includes capitalized software development costs. The Company expects
continued capitalizable projects associated with the Company&#8217;s flagship products; however, the rate of capitalization may temporarily
remain constant or decrease as a result of the 2023 Restructuring.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financing
cash flow activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Proceeds from issuance of common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,316</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from line of credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Payments of acquisition earnout liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,012</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Payments for costs directly attributable to the issuance of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(52</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Repayment of bank term loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(750</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(250</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from term loan payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Payments related to settlement of employee shared-based awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(280</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(197</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Payment of deferred financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net cash provided by financing activities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">428</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,791</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cash provided by financing activities for fiscal 2023 was primarily attributable to draws on the line of credit offset by the principal
payments on the term loan. Refer to Note 5 &#8211; Debt to our consolidated financial statements included in Part II, Item 8, &#8220;Financial
Statements and Supplementary Data&#8221; for more information. The $44,000 of deferred financing costs payments are related to the debt private financing as further described in
Note 14 &#8211; Subsequent to our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary
Data.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cash provided by financing activities for fiscal 2022 was primarily
attributable to the 2022 Offering of the Company&#8217;s common stock, which closed on October 26, 2022, offset by earnout payments related
to the Avelead acquisition. Refer to Note 8 &#8211; Equity to our consolidated financial statements included in Part II, Item 8, &#8220;Financial
Statements and Supplementary Data&#8221; for additional information on the 2022 Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
7A. <i>Quantitative and Qualitative Disclosures About Market Risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a &#8220;smaller reporting company,&#8221; as defined by Item 10 of Regulation S-K, we are not required to provide this information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8. <i>Financial Statements and Supplementary Data</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS AND SCHEDULE COVERED BY REPORTS OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ch_001">Report of Independent Registered Public Accounting Firm</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ch_002">Consolidated Balance Sheets at January 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ch_003">Consolidated Statements of Operations for the two years ended January 31, 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ch_004">Consolidated Statements of Changes in Stockholders&#8217; Equity for the two years ended January 31, 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ch_005">Consolidated Statements of Cash Flows for the two years ended January 31, 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ak_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">52<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ak_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule II &#8212; Valuation and Qualifying Accounts</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">80<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other financial statement schedules are omitted because they are not applicable or the required information is included in the consolidated
financial statements or notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ch_001"></span>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
and Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Streamline
Health Solutions, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Opinion
on the Consolidated Financial Statements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Streamline Health Solutions, Inc. and its subsidiaries (the &#8220;Company&#8221;)
as of January 31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders&#8217; equity, and cash flows
for each of the years in the two-year period ended January 31, 2024, and the related notes and financial statement schedule II (collectively
referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of the Company as of January 31, 2024 and 2023, and the results of their operations and
their cash flows for each of the years in the two-year period ended January 31, 2024, in conformity with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
for Opinion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and
are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules
and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures include examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Critical
Audit Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated
or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Critical
Audit Matter &#8211; Capitalized Software Development Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 2 to the financial statements, the Company develops internal-use software within the scope of ASC 350-40, <i>Internal-Use
Software (&#8220;Topic 350&#8221;)</i>. Costs associated with the preliminary stages of development are classified as research and development
costs and expensed as incurred. Costs associated with the application development stage are capitalized. Maintenance and enhancement
costs, including costs in the post-implementation stages, are typically expensed as incurred, unless such costs relate to substantial
upgrades and enhancements that result in added functionality, in which case the costs are capitalized. Capitalized amounts are amortized
on a straight-line basis over the estimated useful life of the software.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
identified capitalized internal-use software development costs as a critical audit matter. Our principal considerations for this determination
were the high degree of auditor judgment and subjectivity required in evaluating management&#8217;s determination of the activities and
costs that qualify for capitalization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary procedures we performed to address this critical audit matter included:</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtained an
    understanding of the Company&#8217;s process for determining the activities and costs that qualify for capitalization.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tested the mathematical
    accuracy of the roll forward of capitalized software and related amortization expense. We also tested the completeness and accuracy
    of applicable system-generated reports, including reconcilements of details to associated sub-ledgers.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For a sample of capitalized
    costs, we evaluated the relevance of the software development guidance applied, by performing the following:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assessed the eligibility of costs
    for capitalization, in accordance with applicable guidance, and whether such costs were incurred during the application development
    stage.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recalculated the capitalized amount based on hours
    incurred for direct payroll related costs or associated vendor contracts and invoices for work performed by third parties.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the software implementation timelines supporting
    the capitalization periods for implementation and development as well as the dates software was placed in service.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inquired of product managers and software engineers
    for significant projects to assess the nature of the costs and the time devoted to capitalizable activities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><b><i>&#160;</i></b></p>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Critical
Audit Matter &#8211; Goodwill Impairment Assessment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Notes 2 and 6 to the financial statements, based on triggering events, the Company identified indicators of possible impairment
and initiated testing using a valuation date of October 31, 2023. The testing for impairment was performed under the guidance of ASC
350, <i>Intangibles &#8211; Goodwill and Other (&#8220;Topic 350&#8221;)</i>. The Company recorded an impairment of goodwill in the amount
of $9,813,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
analyzing goodwill for potential impairment in the quantitative impairment test, the Company uses a combination of the income and market
approaches to estimate the fair value of the Company&#8217;s equity. Under the income approach, the Company calculates the fair value
based on discounted estimated future cash flows. Under the market approach, the Company estimates the fair value based on the total number
of shares outstanding and the current market price of the shares as of the valuation date with a control premium applied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
identified the quantitative impairment test of goodwill as a critical audit matter. Our principal considerations for that determination
included the judgment involved in assessing management&#8217;s impairment test of goodwill due to the measurement uncertainty involved
in determining the fair value of equity of the reporting unit. In particular, the fair value estimate under the income approach is sensitive
to changes in assumptions such as discount rates and expected future cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary procedures we performed to address this critical audit matter included:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtained an understanding of management&#8217;s
    process for assessing goodwill impairment and performing the quantitative goodwill impairment test, including management&#8217;s
    process for developing assumptions used in the income and market approaches to estimate the fair value of equity.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated management&#8217;s revenue growth rates,
    margins, and cash flows against current industry and economic trends, while also considering the current and future business, customer
    base, and product mix.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assessed revenue growth and margins by comparing past
    projections to actual performance.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With the assistance of our valuation professionals
    with specialized skills and knowledge, we evaluated the (1) valuation methodology, (2) discount rate, and (3) long-term revenue growth
    rate used in the income approach to estimate the fair value.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tested management&#8217;s reconciliation of the fair
    value of equity to the market capitalization of the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    developments in the Company&#8217;s business from the third quarter of fiscal 2023, the period in which the impairment charge was
    recorded, through January 31, 2024 to determine if events or circumstances have occurred that would more likely than not further
    reduce the fair value of the business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>/s/
<span id="xdx_907_edei--AuditorName_c20230201__20240131_zAtdG5JIp0Q8"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000048" name="dei:AuditorName">FORVIS, LLP</ix:nonNumeric></span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--AuditorLocation_c20230201__20240131_z378e6jbewhe"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000049" name="dei:AuditorLocation">Atlanta,
Georgia</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April
30, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ch_002"></span>STREAMLINE
HEALTH SOLUTIONS, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(rounded
to the nearest thousand dollars, except share and per share information)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_111_zOPL5Jx7KKOd" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240131_zU0USsVHaNNi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230131_zAscvEuxsS4f" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsAbstract_iB_zXer2KEcSTH" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrentAbstract_i01B_zCWFPvBVv9V3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzs9C_z0gzpvBwXLG7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-01-31" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,190,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-01-31" id="Fact000058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,598,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzs9C_zkjEhvp68752" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accounts receivable, net of allowance for credit losses of $<span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_c20240131_zpmZFmRD7OY7" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2024-01-31" id="Fact000063" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">86,000</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_c20230131_zz8DT0twSyO2" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2023-01-31" id="Fact000065" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">132,000</ix:nonFraction></span>, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-01-31" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,237,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-01-31" id="Fact000061" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,719,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ContractWithCustomerAssetNetCurrent_i02I_maCzs9C_zzMT6BeW3zqh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Contract receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="AsOf2024-01-31" id="Fact000067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">780,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="AsOf2023-01-31" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">960,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzs9C_zcGVS7ctc19j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-01-31" id="Fact000070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">629,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-01-31" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">710,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsCurrent_i02TI_mtCzs9C_maCzHPh_zoZ3sLKkcI32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-01-31" id="Fact000073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,836,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-01-31" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,987,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsNoncurrentAbstract_i01B_zKoQw56bGHu8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_i02I_pp0p0_maCzCvE_zBaItpcf73a1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Property and equipment, net of accumulated amortization of $<span id="xdx_90F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pp0p0_c20240131_z18CNJd2hWN4" title="Accumulated amortization, property and equipment"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-01-31" id="Fact000082" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">291,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pp0p0_c20230131_zpTbC4N4eA2j" title="Accumulated amortization, property and equipment"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-01-31" id="Fact000084" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">246,000</ix:nonFraction></span> respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-01-31" id="Fact000079" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">88,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-01-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">79,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzCvE_zq2MRYEMs5El" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Right-of use asset for operating lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0086">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-01-31" id="Fact000087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CapitalizedComputerSoftwareNet_i02I_maCzCvE_zqw1N5nnSNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Capitalized software development costs, net of accumulated amortization of $<span id="xdx_905_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20240131_zTOVnJDyR5e4"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization" contextRef="AsOf2024-01-31" id="Fact000091" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,960,000</ix:nonFraction></span>
and $<span id="xdx_906_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20230131_zExIdF37b5B7"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization" contextRef="AsOf2023-01-31" id="Fact000092" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,224,000</ix:nonFraction></span>,
respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareNet" contextRef="AsOf2024-01-31" id="Fact000089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,798,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareNet" contextRef="AsOf2023-01-31" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,846,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maCzCvE_zQLRMVxvq0a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Intangible assets, net of accumulated amortization of $<span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20240131_zo0OpXRpiq4a" title="Accumulated amortization, intangible assets"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-01-31" id="Fact000097" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,019,000</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20230131_zC0xV6uRnPWg" title="Accumulated amortization, intangible assets"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-01-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,627,000</ix:nonFraction></span>, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-01-31" id="Fact000094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,071,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-01-31" id="Fact000095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,793,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Goodwill_i02I_maCzCvE_ztbdK0cB6aGc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2024-01-31" id="Fact000101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,276,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2023-01-31" id="Fact000102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,089,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherAssetsNoncurrent_i02I_maCzCvE_zoklxBjIXjLg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-01-31" id="Fact000104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,666,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-01-31" id="Fact000105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,695,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsNoncurrent_i02TI_mtCzCvE_maCzHPh_zpUu4vz2Lo2h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-01-31" id="Fact000107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,899,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2023-01-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,534,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Assets_i01TI_mtCzHPh_zO57zEi38yx" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-01-31" id="Fact000110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,735,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-01-31" id="Fact000111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,521,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_zIObIoFAZPA4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_i02I_maLCzDSV_zilnUBwZCbU6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 10pt">Accounts payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-01-31" id="Fact000119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,253,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-01-31" id="Fact000120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">626,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCzDSV_zRgAW2mQmwqf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-01-31" id="Fact000122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,023,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-01-31" id="Fact000123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,265,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebtCurrent_i02I_pp0p0_maLCzDSV_zG43hd3GIsj2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Current portion of term loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2024-01-31" id="Fact000125" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2023-01-31" id="Fact000126" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">750,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredRevenueCurrent_i02I_pp0p0_maLCzDSV_zzS9BjbqyA79" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Deferred revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2024-01-31" id="Fact000128" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,112,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2023-01-31" id="Fact000129" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,361,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzDSV_zoG9Tenm5jV2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Operating lease obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0131">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-01-31" id="Fact000132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetAcquisitionContingentConsiderationLiabilityCurrent_i02I_pp0p0_maLCzDSV_zB2ONUZabWxc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Acquisition earnout liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" contextRef="AsOf2024-01-31" id="Fact000134" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,794,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" contextRef="AsOf2023-01-31" id="Fact000135" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,738,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrent_i02TI_maCzxYt_mtLCzDSV_zcFRYVGiARc1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-01-31" id="Fact000137" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,682,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-01-31" id="Fact000138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,775,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zYyCz6aoI4f8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LongTermLoansPayable_i02I_pp0p0_maLNzBu6_zNPIGauESu9h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Term loan, net of deferred financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermLoansPayable" contextRef="AsOf2024-01-31" id="Fact000143" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,566,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermLoansPayable" contextRef="AsOf2023-01-31" id="Fact000144" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,964,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LongTermLineOfCredit_i02I_pp0p0_maLNzBu6_ziC5BoAuABwi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Line of credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermLineOfCredit" contextRef="AsOf2024-01-31" id="Fact000146" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0147">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredRevenueNoncurrent_i02I_pp0p0_maLNzBu6_zTaeQBIAoN93" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Deferred revenues, less current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="AsOf2024-01-31" id="Fact000149" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">173,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="AsOf2023-01-31" id="Fact000150" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">167,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherLiabilitiesNoncurrent_i02I_maLNzBu6_zlVml54CrTL5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0152">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2023-01-31" id="Fact000153" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesNoncurrent_i02TI_maCzxYt_mtLNzBu6_zIWSrT5hCrOg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2024-01-31" id="Fact000155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,239,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2023-01-31" id="Fact000156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,235,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Liabilities_i01TI_mtCzxYt_maLASEzCbx_zDvcSuizSuih" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-01-31" id="Fact000158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,921,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-01-31" id="Fact000159" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,010,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CommitmentsAndContingencies_i01I_zgpq31pgaYCb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Commitments and contingencies &#8211; Note 12</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0161">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CommonStockValue_i02I_maSEzMEd_zkgGHWo9uAT9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Common stock, $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240131_zNYvFE6Tz2f9" title="Common stock, par value"><span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230131_zG0xeUcV8XQh" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-01-31" id="Fact000170" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-01-31" id="Fact000172" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value per share, <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20240131_ztoXxbQNUa0c" title="Common stock, shares authorized"><span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20230131_zJrNOj8NQGzk" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-01-31" id="Fact000174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-01-31" id="Fact000176" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">85,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20240131_zus0CZDmyGZ" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20240131_z4mW0blNSD8j" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-01-31" id="Fact000178" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-01-31" id="Fact000180" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,945,498</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20230131_zfUhqav9mdd6" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20230131_zl0dlyY4WoC2" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-01-31" id="Fact000182" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-01-31" id="Fact000184" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,567,210</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-01-31" id="Fact000167" format="ixt:numdotdecimal" decimals="0" unitRef="USD">590,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-01-31" id="Fact000168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">576,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maSEzMEd_zezMi1zbsLU4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2024-01-31" id="Fact000186" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,923,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2023-01-31" id="Fact000187" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,973,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzMEd_zArUfUrydKpg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-01-31" id="Fact000189" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">115,699,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-01-31" id="Fact000190" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">97,038,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzMEd_maLASEzCbx_zmC3EyAKXuza" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-01-31" id="Fact000192" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,814,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-01-31" id="Fact000193" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,511,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzCbx_zpXj0qX85wKg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-01-31" id="Fact000195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,735,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-01-31" id="Fact000196" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,521,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ch_003"></span>STREAMLINE
HEALTH SOLUTIONS, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(rounded
to the nearest thousand dollars, except share and per share information)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_113_zQxY64pUX3Oj" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230201__20240131_zyEQYHGBcplh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220201__20230131_zuIrltRwUuR8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--RevenuesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Revenues:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_pp0p0_hsrt--ProductOrServiceAxis__custom--SoftwareasAsAServiceMember_z7o6c0Y4zti1" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left; padding-left: 10pt">Software as a service</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-02-012024-01-31_custom_SoftwareasAsAServiceMember" id="Fact000201" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,075,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-02-012023-01-31_custom_SoftwareasAsAServiceMember" id="Fact000202" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,326,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_pp0p0_hsrt--ProductOrServiceAxis__custom--MaintenanceAndSupportMember_z5qJ1XJpA8ok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Maintenance and support</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-02-012024-01-31_custom_MaintenanceAndSupportMember" id="Fact000204" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,318,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-02-012023-01-31_custom_MaintenanceAndSupportMember" id="Fact000205" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,483,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_pp0p0_hsrt--ProductOrServiceAxis__custom--ProfessionalFeesAndLicensesMember_zi514AHbq6E8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Professional fees and licenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-02-012024-01-31_custom_ProfessionalFeesAndLicensesMember" id="Fact000207" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,203,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-02-012023-01-31_custom_ProfessionalFeesAndLicensesMember" id="Fact000208" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,080,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_pp0p0_maOILzkSE_zdSPeAf6RP42" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-02-01to2024-01-31" id="Fact000210" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,596,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-02-012023-01-31" id="Fact000211" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,889,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingExpensesAbstract_iB_z4IqkVwwakza" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CostOfSoftwareAsService_i01_maCAEz7Ba_zUk8xJGGaaLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Cost of software as a service</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:CostOfSoftwareAsService" contextRef="From2023-02-01to2024-01-31" id="Fact000216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,573,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:CostOfSoftwareAsService" contextRef="From2022-02-012023-01-31" id="Fact000217" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,358,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CostOfMaintenanceAndSupport_i01_maCAEz7Ba_zjxCR7alCAAg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Cost of maintenance and support</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:CostOfMaintenanceAndSupport" contextRef="From2023-02-01to2024-01-31" id="Fact000219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">315,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:CostOfMaintenanceAndSupport" contextRef="From2022-02-012023-01-31" id="Fact000220" format="ixt:numdotdecimal" decimals="0" unitRef="USD">427,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--CostOfProfessionalFeesAndLicenses_i01_maCAEz7Ba_zb4skYPpbh36" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Cost of professional fees and licenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:CostOfProfessionalFeesAndLicenses" contextRef="From2023-02-01to2024-01-31" id="Fact000222" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,165,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:CostOfProfessionalFeesAndLicenses" contextRef="From2022-02-012023-01-31" id="Fact000223" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,610,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maCAEz7Ba_zthMJmLFtyK8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Selling, general and administrative expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-02-01to2024-01-31" id="Fact000225" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,710,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-02-012023-01-31" id="Fact000226" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,283,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_i01_maCAEz7Ba_zJSiJHdKFXN4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-02-01to2024-01-31" id="Fact000228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,704,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-02-012023-01-31" id="Fact000229" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,042,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--GoodwillImpairmentLoss_i01_maCAEz7Ba_zBiyRHF2tX04" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Impairment of goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-02-01to2024-01-31" id="Fact000231" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,813,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0232">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_i01_maCAEz7Ba_zUBZDINORLZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 10pt">Impairment of long-lived assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2023-02-01to2024-01-31" id="Fact000234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">963,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0235">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CostsAndExpenses_i01T_mtCAEz7Ba_msOILzkSE_zFElOywRNodb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2023-02-01to2024-01-31" id="Fact000237" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,243,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2022-02-012023-01-31" id="Fact000238" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,720,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingIncomeLoss_iT_mtOILzkSE_maILFCOzFoB_zy0jxDNt5AYl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-02-01to2024-01-31" id="Fact000240" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,647,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-02-012023-01-31" id="Fact000241" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,831,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InterestExpense_i01N_di_msILFCOzFoB_zj3A2UamM68l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-02-01to2024-01-31" id="Fact000246" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,071,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-02-012023-01-31" id="Fact000247" format="ixt:numdotdecimal" decimals="0" unitRef="USD">749,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--AcquisitionEarnoutValuationAdjustments_i01_pp0p0_maILFCOzFoB_zA2Jngrl3MXl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Acquisition earnout valuation adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:AcquisitionEarnoutValuationAdjustments" contextRef="From2023-02-01to2024-01-31" id="Fact000249" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,944,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:AcquisitionEarnoutValuationAdjustments" contextRef="From2022-02-012023-01-31" id="Fact000250" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherNonoperatingIncomeExpense_i01_maILFCOzFoB_znXYXWYC7oC9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-02-01to2024-01-31" id="Fact000252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-02-012023-01-31" id="Fact000253" format="ixt:numdotdecimal" decimals="0" unitRef="USD">201,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzFoB_maNILzsLN_zZBzRTorJTbf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-02-01to2024-01-31" id="Fact000255" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,743,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-02-012023-01-31" id="Fact000256" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,308,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iN_pp0p0_di_msNILzsLN_zRBVjAgjwrHl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Income tax benefit (expense)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-02-01to2024-01-31" id="Fact000258" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">46,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-02-012023-01-31" id="Fact000259" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_iT_pp0p0_mtNILzsLN_zIs3DlilfNfi" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-02-01to2024-01-31" id="Fact000261" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">18,697,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-02-012023-01-31" id="Fact000262" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">11,379,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and Diluted Earnings Per Share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_i01_c20230201__20240131_zDJxVH7PHVvh" title="Basic Earnings Per Share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_i01_pid_c20230201__20240131_z6BfDSo2haR" title="Diluted Earnings Per Share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-02-01to2024-01-31" id="Fact000264" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-02-01to2024-01-31" id="Fact000266" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.33</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_i01_pid_c20220201__20230131_zjtSmASJEKB4" title="Basic Earnings Per Share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_i01_pid_c20220201__20230131_zF8U7uVE0zmj" title="Diluted Earnings Per Share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-02-012023-01-31" id="Fact000268" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-02-012023-01-31" id="Fact000270" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.23</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average number of common shares &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_c20230201__20240131_z5E38LHttsSk" title="Weighted average number of common shares - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pid_c20230201__20240131_z8I7uIXlxZu6" title="Weighted average number of common shares - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-02-01to2024-01-31" id="Fact000272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-02-01to2024-01-31" id="Fact000274" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,510,419</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_c20220201__20230131_z8Mxz6eeVUx1" title="Weighted average number of common shares - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pid_c20220201__20230131_zpVtigDSXCme" title="Weighted average number of common shares - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-02-012023-01-31" id="Fact000276" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-02-012023-01-31" id="Fact000278" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,324,858</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ch_004"></span>STREAMLINE
HEALTH SOLUTIONS, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(rounded
to the nearest thousand dollars, except share information)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_114_zhCR8E2p7Sq8" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>stock</b></span></p></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zJUjPeazvwE4" style="font-weight: bold; text-align: center">Common</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zRQ8LgRHEmPg" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>paid in</b></span></p></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z96Pi93qBpd" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B7_zocNBjzku3Fi" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>stockholders&#8217;</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43D_c20220201__20230131_eus-gaap--StockholdersEquity_iS_zBPC755RZnCg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%">Balance at January 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20220201__20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmq8TajN3st9" title="Balance, shares" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-01-31_us-gaap_CommonStockMember" id="Fact000285" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47,840,950</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-01-31_us-gaap_CommonStockMember" id="Fact000280" format="ixt:numdotdecimal" decimals="0" unitRef="USD">478,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000281" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,225,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-01-31_us-gaap_RetainedEarningsMember" id="Fact000282" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">85,659,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-01-31" id="Fact000283" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,044,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_z38kfZN59vLf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220201__20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHa8Qvd6Ojmc" title="Exercise of Stock Options, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember" id="Fact000292" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-02-012023-01-31" id="Fact000290" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zGLNPY4oFxP7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Restricted stock issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20220201__20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0TuXJNtwvFg" title="Restricted stock issued, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember" id="Fact000299" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,876,962</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember" id="Fact000294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000295" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zDYHxAlTkRk6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Issuance of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoRtNItAWPXc" title="Issuance of Common Stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember" id="Fact000306" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,171,027</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember" id="Fact000301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,246,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-02-012023-01-31" id="Fact000304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,328,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zaSl7VMSY9Db" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Offering expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000309" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">52,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-02-012023-01-31" id="Fact000311" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">52,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_iN_pp0p0_di_zt1NK9WMhyr1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Restricted stock forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_iN_pid_di_c20220201__20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk6Tonom3Zx2" title="Restricted stock forfeited, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember" id="Fact000318" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">199,300</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember" id="Fact000313" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000314" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueSurrenderOfShares_zg5jDjO7wf5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Surrender of stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesSurrenderOfShares_iN_pid_di_c20220201__20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zco4ljfUctK7" title="Surrender of stock, shares" style="text-align: right">(<ix:nonFraction name="STRM:StockIssuedDuringPeriodSharesSurrenderOfShares" contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember" id="Fact000325" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,429</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="STRM:StockIssuedDuringPeriodValueSurrenderOfShares" contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember" id="Fact000320" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="STRM:StockIssuedDuringPeriodValueSurrenderOfShares" contextRef="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000321" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">196,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="STRM:StockIssuedDuringPeriodValueSurrenderOfShares" contextRef="From2022-02-012023-01-31" id="Fact000323" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">197,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zx6wAhKIW0wc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Share-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,761,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-02-012023-01-31" id="Fact000330" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,761,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zJUAf0BD89zl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember" id="Fact000334" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,379,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-02-012023-01-31" id="Fact000335" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,379,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_439_c20230201__20240131_eus-gaap--StockholdersEquity_iS_zUdjmm5WnrA5" style="vertical-align: bottom; background-color: White">
    <td>Balance at January 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20230201__20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH5xPtsumKJi" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-01-31_us-gaap_CommonStockMember" id="Fact000342" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,567,210</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-01-31_us-gaap_CommonStockMember" id="Fact000337" format="ixt:numdotdecimal" decimals="0" unitRef="USD">576,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,973,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-01-31_us-gaap_RetainedEarningsMember" id="Fact000339" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">97,038,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-01-31" id="Fact000340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,511,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_430_c20230201__20240131_eus-gaap--StockholdersEquity_iS_zY0HW1TfsgE3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20230201__20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEzd57jRY3Og" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-01-31_us-gaap_CommonStockMember" id="Fact000349" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,567,210</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-01-31_us-gaap_CommonStockMember" id="Fact000344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">576,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000345" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,973,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-01-31_us-gaap_RetainedEarningsMember" id="Fact000346" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">97,038,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-01-31" id="Fact000347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,511,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zHjyBLRVv50l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Restricted stock issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20230201__20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSzoTCLOgIo1" title="Restricted stock issued, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember" id="Fact000356" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,947,738</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember" id="Fact000351" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-02-012024-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000352" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_iN_pp0p0_di_zX70g8fKP5gj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Restricted stock forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_iN_pid_di_c20230201__20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsA0LrP8ndMg" title="Restricted stock forfeited, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember" id="Fact000363" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">378,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember" id="Fact000358" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="From2023-02-012024-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000359" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueSurrenderOfShares_zTm9h3vkyg0a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Surrender of stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--StockIssuedDuringPeriodSharesSurrenderOfShares_iN_pid_di_c20230201__20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqOs3GQAs5X4" title="Surrender of stock, shares" style="text-align: right">(<ix:nonFraction name="STRM:StockIssuedDuringPeriodSharesSurrenderOfShares" contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember" id="Fact000370" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">190,950</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="STRM:StockIssuedDuringPeriodValueSurrenderOfShares" contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember" id="Fact000365" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="STRM:StockIssuedDuringPeriodValueSurrenderOfShares" contextRef="From2023-02-012024-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000366" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">278,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="STRM:StockIssuedDuringPeriodValueSurrenderOfShares" contextRef="From2023-02-01to2024-01-31" id="Fact000368" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">280,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityOther_zjWi4ZnU6HE6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Adoption of ASU 2016-13</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityOther" contextRef="From2023-02-012024-01-31_us-gaap_RetainedEarningsMember" id="Fact000374" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityOther" contextRef="From2023-02-01to2024-01-31" id="Fact000375" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zRlW4Y3V2aM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Share-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-02-012024-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,244,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-02-01to2024-01-31" id="Fact000380" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,244,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zTZd0SBcmF03" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-02-012024-01-31_us-gaap_RetainedEarningsMember" id="Fact000384" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,697,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-02-01to2024-01-31" id="Fact000385" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,697,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr id="xdx_438_c20230201__20240131_eus-gaap--StockholdersEquity_iE_zE2zO4dT4d0j" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at January 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20230201__20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuzTJFneUG2i" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-01-31_us-gaap_CommonStockMember" id="Fact000392" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,945,498</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-01-31_us-gaap_CommonStockMember" id="Fact000387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">590,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,923,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-01-31_us-gaap_RetainedEarningsMember" id="Fact000389" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">115,699,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-01-31" id="Fact000390" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,814,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20230201__20240131_eus-gaap--StockholdersEquity_iE_zDkhomi1gfWc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20230201__20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMfVTGZBI5ih" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-01-31_us-gaap_CommonStockMember" id="Fact000399" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,945,498</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-01-31_us-gaap_CommonStockMember" id="Fact000394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">590,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,923,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-01-31_us-gaap_RetainedEarningsMember" id="Fact000396" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">115,699,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-01-31" id="Fact000397" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,814,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ch_005"></span>STREAMLINE
HEALTH SOLUTIONS, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(rounded
to the nearest thousand dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_112_zUwWzjn0u57g" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230201__20240131_zzINplzfwta4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220201__20230131_zMcgtn4r20N1" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>2022</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>2022</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zHOMJwHSyGSf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 64%">Cash flows from operating activities:</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 14%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 14%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_maNCPBUzvZU_z8C3sCA6oqOj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 10pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-02-01to2024-01-31" id="Fact000404" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,697,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-02-012023-01-31" id="Fact000405" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,379,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zy8gZGbVbBw2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DepreciationAndAmortization_i01_maNCPBUzvZU_zCxauhfqU59" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-02-01to2024-01-31" id="Fact000410" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,331,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-02-012023-01-31" id="Fact000411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,313,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AcquisitionEarnoutValuationAdjustments_i01N_di_msNCPBUzvZU_zTUUayyMYyc4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Acquisition earnout valuation adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="STRM:AcquisitionEarnoutValuationAdjustments" contextRef="From2023-02-01to2024-01-31" id="Fact000413" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,944,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="STRM:AcquisitionEarnoutValuationAdjustments" contextRef="From2022-02-012023-01-31" id="Fact000414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--ProvisionForDeferredIncomeTaxes_i02_maNCPBUzvZU_zoKZrSJr9TMh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Provision for deferred income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="STRM:ProvisionForDeferredIncomeTaxes" contextRef="From2023-02-01to2024-01-31" id="Fact000416" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">104,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:ProvisionForDeferredIncomeTaxes" contextRef="From2022-02-012023-01-31" id="Fact000417" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_i02_maNCPBUzvZU_zIJUlIQ9bW41" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Share-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-02-01to2024-01-31" id="Fact000419" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,102,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-02-012023-01-31" id="Fact000420" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,680,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--GoodwillImpairmentLoss_i01_maNCPBUzvZU_zFXE5eqNDnU4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Impairment of goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-02-01to2024-01-31" id="Fact000422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,813,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_i01_maNCPBUzvZU_zFSytWv2Vu8d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Impairment of long-lived assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2023-02-01to2024-01-31" id="Fact000425" format="ixt:numdotdecimal" decimals="0" unitRef="USD">963,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0426">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProvisionForDoubtfulAccounts_i02_maNCPBUzvZU_zRGknBvDeq8b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Provision for credit losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2023-02-01to2024-01-31" id="Fact000428" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2022-02-012023-01-31" id="Fact000429" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zx2xW29BHra6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Changes in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccountsAndOtherReceivables_i03N_di_msNCPBUzvZU_zX8Rjbv8KMmj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Accounts and contract receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2023-02-01to2024-01-31" id="Fact000434" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,708,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2022-02-012023-01-31" id="Fact000435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,202,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i03N_di_msNCPBUzvZU_zXsql7tELcH4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2023-02-01to2024-01-31" id="Fact000437" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2022-02-012023-01-31" id="Fact000438" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,197,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzvZU_z3GrcdmiC6X7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-02-01to2024-01-31" id="Fact000440" format="ixt:numdotdecimal" decimals="0" unitRef="USD">544,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-02-012023-01-31" id="Fact000441" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">152,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_maNCPBUzvZU_zAARRzOVnwej" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Accrued expenses and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-02-01to2024-01-31" id="Fact000443" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,277,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-02-012023-01-31" id="Fact000444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,069,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInDeferredRevenue_i03_maNCPBUzvZU_z8hl7GQW1na9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Deferred revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2023-02-01to2024-01-31" id="Fact000446" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,243,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2022-02-012023-01-31" id="Fact000447" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,598,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_maCCERCz6OU_mtNCPBUzvZU_z0ogNDW9IxW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-02-01to2024-01-31" id="Fact000449" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,215,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-02-012023-01-31" id="Fact000450" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,143,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zfk0C7JqPDWg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzA5s_zRpKAhDjq7Mj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-02-01to2024-01-31" id="Fact000455" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-02-012023-01-31" id="Fact000456" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PaymentsToDevelopSoftware_i01N_di_msNCPBUzA5s_z2SmF7gBltu9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Capitalization of software development costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToDevelopSoftware" contextRef="From2023-02-01to2024-01-31" id="Fact000458" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,567,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToDevelopSoftware" contextRef="From2022-02-012023-01-31" id="Fact000459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,925,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzA5s_maCCERCz6OU_z9lx0e5HPIki" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-02-01to2024-01-31" id="Fact000461" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,621,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-02-012023-01-31" id="Fact000462" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,935,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zmqYk6ebioy" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUz0I8_z6CVBCXToGhg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Proceeds from issuance of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-02-012023-01-31" id="Fact000468" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,316,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PaymentsOfMergerRelatedCostsFinancingActivities_i01N_di_msNCPBUz0I8_zNutmdJJdE8g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Payment of acquisition earnout liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" contextRef="From2022-02-012023-01-31" id="Fact000471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,012,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--PaymentsOfStockIssuanceCosts_i01N_di_msNCPBUz0I8_zbuH8ho2G8C7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Payments for costs directly attributable to the issuance of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0473">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-02-012023-01-31" id="Fact000474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--RepaymentsOfLongTermDebt_i01N_di_msNCPBUz0I8_zAIrv5V3EI7f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Repayment of bank term loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="From2023-02-01to2024-01-31" id="Fact000476" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="From2022-02-012023-01-31" id="Fact000477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromLinesOfCredit_i01_maNCPBUz0I8_ze4MFb4tnKce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Proceeds from line of credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2023-02-01to2024-01-31" id="Fact000479" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0480">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_i01N_di_msNCPBUz0I8_zGtJZVKfgj34" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Payments related to settlement of employee shared-based awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2023-02-01to2024-01-31" id="Fact000482" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2022-02-012023-01-31" id="Fact000483" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsOfFinancingCosts_i01N_di_msNCPBUz0I8_zwg98QXmvg2h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Payment of deferred financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2023-02-01to2024-01-31" id="Fact000485" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2022-02-012023-01-31" id="Fact000486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromPaymentsForOtherFinancingActivities_i01_maNCPBUz0I8_zD4IEDLnxel8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="From2023-02-01to2024-01-31" id="Fact000488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="From2022-02-012023-01-31" id="Fact000489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUz0I8_maCCERCz6OU_zTPayQt1Du6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-02-01to2024-01-31" id="Fact000491" format="ixt:numdotdecimal" decimals="0" unitRef="USD">428,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-02-012023-01-31" id="Fact000492" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,791,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCz6OU_zVi2TDbl14P4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net decrease in cash and cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-02-01to2024-01-31" id="Fact000494" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,408,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-02-012023-01-31" id="Fact000495" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,287,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_znAOOoRADsm9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-01-31" id="Fact000497" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,598,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-01-31" id="Fact000498" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,885,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zvoEAd0p4Mcc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-01-31" id="Fact000500" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,190,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-01-31" id="Fact000501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,598,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zazH6EKNH6yk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Supplemental cash flow disclosures:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestPaidNet_i01_ztBA40ObPK49" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Interest paid, net of amounts capitalized</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-02-01to2024-01-31" id="Fact000506" format="ixt:numdotdecimal" decimals="0" unitRef="USD">989,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"/><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-02-012023-01-31" id="Fact000507" format="ixt:numdotdecimal" decimals="0" unitRef="USD">651,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxesPaidNet_i01_zUa8YnL5HLcf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Income taxes paid</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-02-01to2024-01-31" id="Fact000509" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"/><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-02-012023-01-31" id="Fact000510" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STREAMLINE
HEALTH SOLUTIONS, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ak_002"></span><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January
31, 2024 and 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000512" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"><p id="xdx_80A_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zA2UWp7zlpaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
1 &#8212; <span id="xdx_828_zms7fanVITki">ORGANIZATION AND DESCRIPTION OF BUSINESS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Streamline
Health Solutions, Inc. and each of its wholly-owned subsidiaries, Streamline Health, LLC, Avelead Consulting, LLC, Streamline
Consulting Solutions, LLC and Streamline Pay &amp; Benefits, LLC, (collectively, unless the context requires otherwise, &#8220;we&#8221;,
&#8220;us&#8221;, &#8220;our&#8221;, &#8220;Streamline&#8221;, or the &#8220;Company&#8221;) operates in one segment as a provider
of healthcare information technology solutions and associated services. The Company provides these capabilities through the
licensing of its Coding &amp; CDI, eValuator coding analysis platform, RevID, and other workflow software applications and the use
of such applications by software as a service (&#8220;SaaS&#8221;). The Company also provides audit services to help clients
optimize their internal clinical documentation and coding functions, as well as implementation and consulting services to complement
its software solutions. The Company&#8217;s software and services enable hospitals and integrated healthcare delivery systems in the
United States and Canada to capture, store, manage, route, retrieve and process patient clinical, financial and other healthcare
provider information related to the patient revenue cycle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fiscal
Year</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references to a fiscal year refer to the fiscal year commencing February 1 in that calendar year and ending on January 31 of the following
calendar year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000514" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zuoJOMT1riek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
2 &#8212; <span id="xdx_82D_zKMZYRenVXTh">SIGNIFICANT ACCOUNTING POLICIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000516" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zBSu67ZrIzqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zMxyAnKWevrd">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of Streamline Health Solutions, Inc. and its wholly-owned subsidiaries, Streamline
Health, LLC, Avelead Consulting, LLC, Streamline Consulting Solutions, LLC and Streamline Pay &amp; Benefits, LLC. All significant intercompany
transactions and balances are eliminated in consolidation. All amounts in the consolidated financial statements, notes and tables have
been rounded to the nearest thousand dollars, except share and per share amounts, unless otherwise indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has determined it has only one operating segment based on the guidance of <i>ASC 280-10-50 </i>paragraphs 1 through 8, The Company
has a sole chief operating decision maker who reviews a single set of financials, information, has accountability for the performance
of the organization, and allocates resources to drive success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal 2022, the Company had two reporting units for evaluation of goodwill: Streamline Solutions and Avelead Solutions. The Company
determined that, effective January 1, 2023, it has one reporting unit for purposes of evaluation of goodwill, which was used for evaluation
of goodwill for fiscal 2023. At the end of fiscal 2022, the Company consolidated and combined its operations for Streamline Solutions
and Avelead Solutions. For total assets at January 31, 2024 and 2023 and total revenue and net loss for the fiscal years ended January
31, 2024 and 2023, see our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary
Data&#8221; herein.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000518" name="STRM:GoingConcernPolicyTextBlock"><p id="xdx_842_ecustom--GoingConcernPolicyTextBlock_z04TyckKPcLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zcBCCKzLHlv8">Going
Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of obligations in the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the Company&#8217;s Quarterly Report on Form 10-Q for the period ended October 31, 2023, the Company raised substantial doubt about
its ability to continue as a going concern. It cited the &#8220;ability to achieve cash from operations and raise additional debt or
equity capital to fund its ongoing operations&#8221; as requirements to mitigate the substantial doubt. As of this filing, the
Company has been able to successfully implement a cost reduction plan, obtain additional capital, and restructure the covenants for
its existing credit facility. Collectively, these initiatives alleviated the substantial doubt about the Company&#8217;s ability to continue as a going concern. Refer to the
&#8220;Restructuring&#8221; subtopic of this Note 1 (Organization and Description of Business) and Note 14 &#8211; Subsequent Events
to our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; for
additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000520" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zT18YACMCUE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zLdYdGtUBpJ7">Reclassification</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
amounts for fiscal 2022 were reclassified to conform to the current period classification. The Company incurred certain acquisition-related
costs related to the acquisition of Avelead totaling $<span id="xdx_90C_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20230201__20240131_zLSxskQwCZpi" title="Acquisition related costs"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2023-02-01to2024-01-31" id="Fact000522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,000</ix:nonFraction></span> consisting primarily of professional service fees. The aforementioned acquisition-related
costs for fiscal 2022 were previously presented in a separate, single caption and are now included in selling, general, and administrative
expense in the accompanying condensed consolidated statements of operations, which is consistent with the presentation for the current
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000524" name="us-gaap:UseOfEstimates"><p id="xdx_841_eus-gaap--UseOfEstimates_zYRzg40CSL39" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_z7lvcZppkJTa">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management
to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing
basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, stock-based compensation,
capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration and income
taxes. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000526" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQN5GPYeb917" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zpKSz8Ifca33">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash demand deposits. Cash deposits
are placed in Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured financial institutions. Cash deposits may exceed FDIC
insured levels from time to time. For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company
considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Non-Cash
Items</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000528" name="STRM:ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock"><p id="xdx_89F_ecustom--ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock_z1maRBLwUz69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following items that were non-cash items related to the consolidated statements of cash flows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zNqLG3nkHJTj" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230201__20240131_zurqW0nQ9sbh" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220201__20230131_zEEvneV5twwa" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Fiscal Year</b></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr id="xdx_40A_eus-gaap--RestrictedStockExpense_zog1qLL5VDyc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Payment of acquisition earnout liabilities in restricted common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2022-02-012023-01-31" id="Fact000531" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,012,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--CapitalizedSoftwarePurchasedWithStock_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized software purchased with stock (<i>See Note 12</i>)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:CapitalizedSoftwarePurchasedWithStock" contextRef="From2023-02-01to2024-01-31" id="Fact000533" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:CapitalizedSoftwarePurchasedWithStock" contextRef="From2022-02-012023-01-31" id="Fact000534" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DeferredFinancingCosts_z5B0BQA42Im8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:DeferredFinancingCosts" contextRef="From2023-02-01to2024-01-31" id="Fact000536" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zY1Afzd2Ab5g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000539" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_84B_eus-gaap--TradeAndOtherAccountsReceivablePolicy_ztpdyWecksi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zFjauAPTw4g3">Receivables</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
and contract receivables are comprised of amounts owed to the Company for licensed software, professional services, including coding
audit services, consulting services, maintenance services, and software as a service and are presented net of the allowance for credit losses. The timing of revenue recognition may not coincide with the billing terms of the client contract, resulting in unbilled receivables
or deferred revenues; therefore, certain contract receivables represent revenues recognized prior to client billings. Individual contract
terms with clients or resellers determine when receivables are due. Accounts receivable represent amounts that the entity has an unconditional
right to consideration. For billings where the criteria for revenue recognition have not been met, deferred revenue is recorded until
the Company satisfies the respective performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000541" name="STRM:AllowanceForCreditLossesPolicyTextBlock"><p id="xdx_841_ecustom--AllowanceForCreditLossesPolicyTextBlock_ze7ToCazvDBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zZjdgKK0Ieh1">Allowance
for Credit Losses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adjusts accounts receivable down to net realizable value. Effective February 1, 2023, the Company implemented ASC 326-10,
Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;CECL&#8221;).
CECL provides the framework for the Company to evaluate its allowance for credit losses. In determining the
allowance for credit losses, the Company established a historical credit loss rate adjusted for a premium, addressing any
prospective changes to the risk of credit loss, that is applied against current sales. The Company evaluates individual receivables
based upon the most recent information available and the status of any open or unresolved issues with the client preventing the
payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables.
During these periodic reviews, significant judgement is required for the Company to determine the appropriate allowances for
doubtful accounts for estimated losses resulting from the unwillingness of its clients or resellers to make required payments. The
Company believes its reserve is adequate, however, results may differ in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the changes to the allowance account with the adoption of CECL:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000543" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfRestructuringReserveByTypeOfCostTextBlock_zfqA1D3oTMu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zu0obzYOwHKb" style="display: none">SCHEDULE
OF RESERVE RESULTS IN FUTURE PERIODS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CECL Adoption</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="text-align: center">&#160;</td><td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Provision adjustments</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Write-offs &amp; Recoveries</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 39%; text-align: left; padding-bottom: 1.5pt">Allowance for credit losses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20230201__20240131_z5AgnJ7s7tPl" title="Allowance for credit losses, Balance" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2023-01-31" id="Fact000545" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--AllowanceForDoubtfulAccountsReceivableCECLAdoption_c20230201__20240131_zeIXWjucoLQ4" title="Allowance for credit losses, CECL Adoption" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction name="STRM:AllowanceForDoubtfulAccountsReceivableCECLAdoption" contextRef="From2023-02-01to2024-01-31" id="Fact000547" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">36,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="width: 1%">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 1%">$</td>
    <td id="xdx_987_eus-gaap--ProvisionForDoubtfulAccounts_c20230201__20240131_zUzIajVrro0k" title="Allowance for credit losses, Provision adjustments" style="border-bottom: Black 1.5pt solid; text-align: right; width: 9%; vertical-align: bottom">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2023-02-01to2024-01-31" id="Fact000549" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,000</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; width: 1%">)&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 2%; text-align: left">$</td><td id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20230201__20240131_zZhmkzIUbMp2" title="Allowance for credit losses, Write-offs &amp; Recoveries" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20230201__20240131_zZ33ZyhBjhP5" title="Allowance for credit losses, Balance" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2024-01-31" id="Fact000553" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zkt8sf5GfK1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000555" name="STRM:AccruedExpensesPolicyTextBlock"><p id="xdx_843_ecustom--AccruedExpensesPolicyTextBlock_zAS3WcLE6cMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zEPilTYadTI9">Accrued
Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000557" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zssA1ZOPLkr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zjVvaM2jJJZh" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF ACCRUED EXPENSES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49F_20240131_zudJCphoE676" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_491_20230131_zZ3PQl6Hw3c3" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">January 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="text-align: center">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedSalariesCurrent_iI_zqBBCbxfpXD5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Employee benefits and related compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"> <ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2024-01-31" id="Fact000559" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,071,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2023-01-31" id="Fact000560" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,079,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedExchangeFeeRebateCurrentAndNoncurrent_iI_zw3eVdmgVRr7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Professional fees and services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedExchangeFeeRebateCurrentAndNoncurrent" contextRef="AsOf2024-01-31" id="Fact000562" format="ixt:numdotdecimal" decimals="0" unitRef="USD">389,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedExchangeFeeRebateCurrentAndNoncurrent" contextRef="AsOf2023-01-31" id="Fact000563" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ThirdPartylicense_iI_zLPCmN1DR3Ol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Third party licenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:ThirdPartylicense" contextRef="AsOf2024-01-31" id="Fact000565" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:ThirdPartylicense" contextRef="AsOf2023-01-31" id="Fact000566" format="ixt:numdotdecimal" decimals="0" unitRef="USD">285,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ConcessionAccrualAmount_iI_zg0nP7105bSd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Customer concessions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:ConcessionAccrualAmount" contextRef="AsOf2024-01-31" id="Fact000568" format="ixt:numdotdecimal" decimals="0" unitRef="USD">233,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:ConcessionAccrualAmount" contextRef="AsOf2023-01-31" id="Fact000569" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_zvCIgbXYJ7Ra" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">State income and sales taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="AsOf2024-01-31" id="Fact000571" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="AsOf2023-01-31" id="Fact000572" format="ixt:numdotdecimal" decimals="0" unitRef="USD">331,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestPayableCurrent_iI_z4i3QH3r3wQ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Interest, primarily on term loan</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2024-01-31" id="Fact000574" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-01-31" id="Fact000575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_iTI_zNtAGpNP6L76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Total accrued expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"> <ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-01-31" id="Fact000577" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,023,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-01-31" id="Fact000578" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,265,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_ziQEqkTWZ7Nk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000580" name="STRM:ConcessionsAccrualPolicyTextBlock"><p id="xdx_844_ecustom--ConcessionsAccrualPolicyTextBlock_zVUnlXdpFBWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zlO4ItNiqHx7">Concessions
Accrual</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company offers certain service level agreements within its client contracts such as uptime, support hours, and levels of support. Our
contracts may include, and we may offer, credits to clients when these service line agreements are not met. The service level agreements
are accounted for as variable consideration using a portfolio approach. As a result, we record an estimate of these concessions against
our recorded revenue. In determining the concessions accrual, the Company evaluates historical concessions granted relative to revenue
as well as future potential risk that these service level agreements will not be met. The Company records a provision, reducing revenue,
for the estimated amount of concessions incurred on the revenue recorded. The Company evaluates the amount of the concession accrual
each period for adequacy. Historically, concessions have not been significant. The concession accrual included in accrued expenses on
the Company&#8217;s consolidated balance sheet was $<span id="xdx_90F_ecustom--ConcessionAccrualAmount_iI_c20240131_zAOFCrXEIub6" title="Concession accrual amount"><ix:nonFraction name="STRM:ConcessionAccrualAmount" contextRef="AsOf2024-01-31" id="Fact000582" format="ixt:numdotdecimal" decimals="0" unitRef="USD">233,000</ix:nonFraction></span> and $<span id="xdx_905_ecustom--ConcessionAccrualAmount_iI_c20230131_zWGrpYfO73Rl" title="Concession accrual amount"><ix:nonFraction name="STRM:ConcessionAccrualAmount" contextRef="AsOf2023-01-31" id="Fact000584" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,000</ix:nonFraction></span> as of January 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000586" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zutAhpeflC7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zd2A8EaYq0yl">Property
and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000588" name="STRM:PropertyPlantAndEquipmentTableTextBlock"><p id="xdx_891_ecustom--PropertyPlantAndEquipmentTableTextBlock_zC7KvXeAvWKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related
assets. Estimated useful lives are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z81ryXv2b0Dk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    equipment and software</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember__srt--RangeAxis__srt--MinimumMember_z0N5TyjreMg1" title="Property and equipment, useful lives"><ix:nonNumeric contextRef="AsOf2024-01-31_custom_ComputerEquipmentAndSoftwareMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000590" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember__srt--RangeAxis__srt--MaximumMember_z7GCMwRYZIdk" title="Property and equipment, useful lives"><ix:nonNumeric contextRef="AsOf2024-01-31_custom_ComputerEquipmentAndSoftwareMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000592" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">4</ix:nonNumeric></span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDDJAkGpKx3" title="Property and equipment, useful lives"><ix:nonNumeric contextRef="AsOf2024-01-31_us-gaap_OfficeEquipmentMember" format="ixt-sec:duryear" id="Fact000594" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    furniture and fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zNnHLxZxDsNd" title="Property and equipment, useful lives"><ix:nonNumeric contextRef="AsOf2024-01-31_custom_OfficeFurnitureAndFixturesMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000596" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>-<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z8hTCuXJU7Ic" title="Property and equipment, useful lives"><ix:nonNumeric contextRef="AsOf2024-01-31_custom_OfficeFurnitureAndFixturesMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000598" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zH8BRKAElZcc" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0599">Term
    of lease or estimated useful life, whichever is shorter</span></span></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_zyNmEEv8K9y2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for property and equipment in fiscal 2023 and 2022 was $<span id="xdx_90D_eus-gaap--Depreciation_pp0p0_c20230201__20240131_zQ9oaRDYoXqc" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-02-01to2024-01-31" id="Fact000601" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--Depreciation_pp0p0_c20220201__20230131_zq7fFQ6ABi41" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-02-012023-01-31" id="Fact000603" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Normal
repairs and maintenance are expensed as incurred. Replacements are capitalized and the property and equipment accounts are relieved of
the items being replaced or disposed of, if no longer of value. The related cost and accumulated depreciation of the disposed assets
are eliminated and any gain or loss on disposition is included in the results of operations in the year of disposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<ix:exclude><!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000605" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zaelwKPvQTk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zAB09QPfEXra">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine whether an arrangement is a lease at inception. Right-of-use assets represent our right to use an underlying asset for the
lease term, and lease liabilities represent our obligation to make lease payments arising from the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected
lease term. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our
obligation to make lease payments arising from the lease. Since our lease arrangements do not provide an implicit rate, we use our estimated
incremental borrowing rate for the expected remaining lease term at commencement date in determining the present value of future lease
payments. We recognize operating lease cost on a straight-line basis by aggregating any rent abatement with the total expected rental
payments and amortizing the expense ratably over the term of the lease. Sublease income is recognized as other income over the period
of the lease, as the sublease is outside of the Company&#8217;s normal business operations. See Note 4 &#8211; Operating Leases for further
details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000607" name="us-gaap:CostsIncurredPolicy"><p id="xdx_844_eus-gaap--CostsIncurredPolicy_zkpabqXMLj52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zbj0NRIwpPY4">Debt
Issuance Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
related to the Second Amended and Restated Loan and Security Agreement (as amended and modified, the &#8220;Loan Agreement&#8221;)
with Western Alliance Bank (&#8220;WAB&#8221;) was capitalized and amortized to interest expense on a straight-line basis, which is not materially different
from the effective interest method, over the term of the related debt, and presented on the Company&#8217;s consolidated balance sheets
as a direct deduction from the carrying amount of the non-current portion of our term loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000609" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zX8DXegzCyW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zs8Gtbk0U2t3">Impairment
of Long-Lived Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews the carrying value of long-lived assets for impairment whenever facts and circumstances exist that would suggest that
assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation
are changes in market position and profitability. If facts and circumstances are present which may indicate that the carrying amount
of the assets may not be recoverable, the Company will prepare a projection of the undiscounted cash flows of the specific asset or asset
group and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment
will be made to reduce the carrying amount of these assets to their fair values. For fiscal 2023, an impairment of long-lived assets
in the amount of $963,000 was recorded. Refer to Note 6 &#8211; Goodwill and Intangible Assets to our consolidated financial statements
included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000611" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"><p id="xdx_845_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_zF7a44pacboh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zwXJ9NUbrFKi">Capitalized
Software Development Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software
development costs for software to be sold, leased, or marketed are accounted for in accordance with ASC 985-20, <i>Software &#8212; Costs
of Software to be Sold, Leased or Marketed</i>. Costs associated with the planning and design phase of software development are classified
as research and development costs and are expensed as incurred. Once technological feasibility has been established, a portion of the
costs incurred in development, including coding, testing and quality assurance, are capitalized until available for general release to
clients, and subsequently reported at the lower of unamortized cost or net realizable value. Amortization is calculated on a solution-by-solution
basis and is included in cost of professional fees and licenses on the consolidated statements of operations. Annual amortization is
measured at the greater of (i) the ratio of the software product&#8217;s current gross revenues to the total of current and expected
gross revenues or (ii) straight-line over the remaining economic life of the software (typically two years). Unamortized capitalized
costs determined to be in excess of the net realizable value of a solution are expensed at the date of such determination. Capitalized
software development costs for software to be sold, leased, or marketed, net of accumulated amortization, totaled $<span id="xdx_902_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SoftwareMember_z8hB6KTQk9M5" title="Capitalized software development costs, net of accumulated amortization"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization" contextRef="AsOf2024-01-31_custom_SoftwareMember" id="Fact000613" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">287,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20230131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SoftwareMember_zAXpZNJbSf9l" title="Capitalized software development costs, net of accumulated amortization"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization" contextRef="AsOf2023-01-31_custom_SoftwareMember" id="Fact000615" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">522,000</ix:nonFraction></span>
as of January 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal-use
software development costs are accounted for in accordance with ASC 350-40, <i>Internal-Use Software</i>. The costs incurred in the preliminary
stages of development are expensed as research and development costs as incurred. Once an application has reached the development stage,
internal and external costs incurred to develop internal-use software are capitalized and amortized on a straight-line basis over the
estimated useful life of the software (typically three to four years). Maintenance and enhancement costs, including those costs in the
post-implementation stages, are typically expensed as incurred, unless such costs relate to substantial upgrades and enhancements to
the software that result in added functionality, in which case the costs are capitalized and amortized on a straight-line basis over
the estimated useful life of the software. The Company reviews the carrying value for impairment whenever facts and circumstances exist
that would suggest that assets might be impaired or that the useful lives should be modified. Amortization expense related to capitalized
internal-use software development costs is included in Cost of software as a service on the consolidated statements of operations. Capitalized
software development costs for internal-use software, net of accumulated amortization, totaled $<span id="xdx_90E_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zOXhpu5ZLb8l" title="Capitalized software development costs, net of accumulated amortization"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization" contextRef="AsOf2024-01-31_custom_InternalUseSoftwareMember" id="Fact000617" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,511,000</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20230131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zH2TNWGlNF9d" title="Capitalized software development costs, net of accumulated amortization"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization" contextRef="AsOf2023-01-31_custom_InternalUseSoftwareMember" id="Fact000619" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,324,000</ix:nonFraction></span> as of January
31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated useful lives of software (including software to be sold and internal-use software) are reviewed frequently and adjusted as
appropriate to reflect upcoming development activities that may include significant upgrades and/or enhancements to the existing functionality.
The Company reviews, on an on-going basis, the carrying value of its capitalized software development expenditures, net of accumulated
amortization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense on all capitalized software development was $<span id="xdx_900_eus-gaap--CapitalizedComputerSoftwareAmortization1_pp0p0_c20230201__20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zc4Hyffjbrol"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAmortization1" contextRef="From2023-02-012024-01-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" id="Fact000620" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,463,000</ix:nonFraction></span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_905_eus-gaap--CapitalizedComputerSoftwareAmortization1_pp0p0_c20220201__20230131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zOk89cFM1Ls9"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAmortization1" contextRef="From2022-02-012023-01-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" id="Fact000621" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,423,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
fiscal 2023 and 2022, respectively. Further, the Company recognized an impairment of approximately $<span id="xdx_907_eus-gaap--AssetImpairmentCharges_pp0p0_c20230201__20240131_zslU6fQnpVz9"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2023-02-01to2024-01-31" id="Fact000622" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_90E_eus-gaap--AssetImpairmentCharges_pp0p0_c20220201__20230131_zw3eAPJdspS2"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2022-02-012023-01-31" id="Fact000623" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
fiscal 2023 and fiscal 2022, respectively, related to cancelled or abandoned enhancement projects during fiscal 2023 and fiscal 2022
that have been recognized within amortization expense. Additionally, in fiscal 2023, entries of approximately $<span id="xdx_906_ecustom--AmortizedAndAbandonedAssets_pp0p0_c20230201__20240131_zfwYJdf0m7B7"><ix:nonFraction name="STRM:AmortizedAndAbandonedAssets" contextRef="From2023-02-01to2024-01-31" id="Fact000624" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
fully amortized and abandoned assets were offset from their corresponding capitalization and
accumulated amortization balance sheet accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the &#8220;carry-over&#8221; method for amortizing capitalized software development costs. Under the &#8220;carry-over&#8221;
method, the costs of the enhancements are added to the unamortized costs of the previous version of the product and the combined amount
is amortized over the remaining useful life of the product. Including unamortized cost of the original product with the cost of the enhancement
for purposes of applying the net realizable value test and amortization provisions is consistent with accounting guidance for software
companies that improve their software and discontinue selling or marketing the older versions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"></p><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000626" name="STRM:ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock"><p id="xdx_898_ecustom--ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock_zyTJHWMBeMT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zhrv1Qznrut">SCHEDULE
OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230201__20240131_zQfxTl39hMgl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220201__20230131_zz7OEADW8UZj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Amortization expense on internally-developed software included in:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CapitalizedComputerSoftwareAmortization1_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfSoftwareAsASeviceMember_zcyQJUA5T4Pa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: justify">Cost of software as a service</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAmortization1" contextRef="From2023-02-012024-01-31_custom_CostOfSoftwareAsASeviceMember" id="Fact000628" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,229,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAmortization1" contextRef="From2022-02-012023-01-31_custom_CostOfSoftwareAsASeviceMember" id="Fact000629" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,068,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareAmortization1_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfSoftwareAsASeviceMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfProfessionalFeesAndLicensesMember_zQTBEgFtBCWl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Cost of professional fees and licenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAmortization1" contextRef="From2023-02-012024-01-31_custom_CostOfProfessionalFeesAndLicensesMember" id="Fact000631" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAmortization1" contextRef="From2022-02-012023-01-31_custom_CostOfProfessionalFeesAndLicensesMember" id="Fact000632" format="ixt:numdotdecimal" decimals="0" unitRef="USD">355,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CapitalizedComputerSoftwareAmortization1_zRiRX6M6htrb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total amortization expense on internally-developed software</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAmortization1" contextRef="From2023-02-01to2024-01-31" id="Fact000634" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,463,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAmortization1" contextRef="From2022-02-012023-01-31" id="Fact000635" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,423,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zzFc3kastks3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interest capitalized to software development cost reduces the Company&#8217;s interest expense recognized in the consolidated statements
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expense was $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230201__20240131_zssQTQhnUnt1" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-02-01to2024-01-31" id="Fact000637" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,704,000</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220201__20230131_z9G8p4mA0aH9" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-02-012023-01-31" id="Fact000639" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,042,000</ix:nonFraction></span> in fiscal 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000641" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z7tG6fNFobLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zbQxjSCMpnXj">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB&#8217;s authoritative guidance on fair value measurements establishes a framework for measuring fair value and expands
disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to
develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine
fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the
following three categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Quoted market prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs that are not corroborated by market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based
on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. For fiscal 2023 and 2022,
there were no transfers of assets or liabilities between Levels 1, 2, or 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000643" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zxOrPn2IPCe5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below provides information on our liabilities that are measured at fair value on a recurring basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zTMLbE3nRxHe" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total Fair</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quoted Prices in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Active Markets</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Observable Inputs</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unobservable Inputs</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>At January 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F46_zvAP6QeUHmKf" style="padding-left: 10pt; width: 36%; text-align: left">Acquisition earnout liability (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131_fKDEp_z6YHvUHgJQGh" title="Acquisition earnout liability, Fair Value" style="width: 12%; text-align: right"><ix:nonFraction name="STRM:AcquisitionEarnoutLiabilityFairValue" contextRef="AsOf2024-01-31" id="Fact000645" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,794,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zqleoxHBOC68" title="Acquisition earnout liability fair value" style="width: 12%; text-align: right">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0647">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEp_zYR5RNQPDAd6" title="Acquisition earn out liability" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fKDEp_zj6kL5TBNcA9" title="Acquisition earn out liability fair value, observable inputs" style="width: 12%; text-align: right"><ix:nonFraction name="STRM:AcquisitionEarnoutLiabilityFairValue" contextRef="AsOf2024-01-31_us-gaap_FairValueInputsLevel3Member" id="Fact000651" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,794,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>At January 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F4F_z7qG32tUQ7Ui" style="padding-left: 10pt; text-align: left">Acquisition earnout liability (1)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131_fKDEp_z7lGordx0Joa" title="Acquisition earnout liability, Fair Value" style="text-align: right"><ix:nonFraction name="STRM:AcquisitionEarnoutLiabilityFairValue" contextRef="AsOf2023-01-31" id="Fact000653" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,738,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zlmP8WJ3vUs4" title="Acquisition earnout liability fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEp_zcRF96jDYkij" title="Acquisition earn out liability" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0657">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fKDEp_zKFbiSF0PWr6" title="Acquisition earn out liability fair value, observable inputs" style="text-align: right"><ix:nonFraction name="STRM:AcquisitionEarnoutLiabilityFairValue" contextRef="AsOf2023-01-31_us-gaap_FairValueInputsLevel3Member" id="Fact000659" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,738,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td id="xdx_F0D_zJGjjfpxLUhd" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zzAhJ0nNsIgj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000660" xml:lang="en-US">The
    fair value of the acquisition earnout liability is based upon a probability-weighted discounted cash flow that was completed at the
    date of acquisition and updated as of January 31, 2024. The change in the fair value of the acquisition earnout liability decreased
    $<span id="xdx_90F_ecustom--AcquisitionEarnoutLiabilityChangeInValuation_c20230201__20240131_z0jICDkaYQXh" title="Acquisition earnout liability, change in valuation" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUgQVNTRVRTIEFORCBMSUFCSUxJVElFUyBNRUFTVVJFRCBPTiBSRUNVUlJJTkcgQkFTSVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="STRM:AcquisitionEarnoutLiabilityChangeInValuation" contextRef="From2023-02-01to2024-01-31" id="Fact000662" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,944,000</ix:nonFraction></span> for the year ended January 31, 2024, which is entirely recognized in &#8220;Acquisition earnout valuation adjustments&#8221;
    in the accompanying consolidated statement of operations.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    probability-weighted discounted cash flow is calculated using a Monte Carlo valuation method. The valuation model provides numerous
    outcomes. The outcomes are averaged and discounted to present value, which provides the current value point estimate. The significant
    inputs include our forecast of Avelead SaaS revenue, the probabilities associated with each of (i) a change in control or (ii) a
    certain client termination, as well as other normal and customary inputs to financial models, including but not limited to, risk
    factors and interest rates.</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_zApULSgz9ali" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s term loan under its Loan Agreement was determined through an analysis of the interest rate spread from
the date of closing the loan (August 2021) to the date of the most recent balance sheets, January 31, 2024 and January 31, 2023. The
term loan bears interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zAsaxSKShrR2" title="Prime interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-01-31_custom_SecurityAgreementMember" id="Fact000664" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.5</ix:nonFraction></span>%, with a Prime
&#8220;floor&#8221; rate of <span id="xdx_90D_ecustom--PrimeInterestRatePercentage_pid_dp_uPure_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_z5xOTtlqE5H3" title="Prime interest rate percentage"><ix:nonFraction name="STRM:PrimeInterestRatePercentage" contextRef="From2023-02-012024-01-31_custom_SecurityAgreementMember" id="Fact000666" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.25</ix:nonFraction></span>%. The prime rate is variable and, thus accommodates changes in the market interest rate. However, the
interest rate spread (the <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131_zwxH5JQDtpE"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-01-31" id="Fact000667" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.5</ix:nonFraction></span>% added to the Prime Rate) is fixed. We estimated the impact of the changes in the interest rate spread
by analogizing the effect of the change in the Corporate bond rates, reduced for any changes in the market interest rate. This provided
us with an estimated change to the interest rate spread of approximately <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--TypeOfArrangementAxis__custom--SecondAmendedAndRestatedLoanAndSecurityAgreementMember_zizgfI88JDdc" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-01-31_custom_SecondAmendedAndRestatedLoanAndSecurityAgreementMember" id="Fact000669" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.5</ix:nonFraction></span>% from the date we entered the debt agreement to January
31, 2024 and January 31, 2023. The fair value of the debt as of January 31, 2024 and January 31, 2023 was estimated to be $<span id="xdx_90F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_zGvO65KA1klc" title="Debt instrument carrying amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-01-31_custom_DebtAgreementMember" id="Fact000671" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,807,000</ix:nonFraction></span>
and $<span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_zFSdnLsbmjmb" title="Debt instrument carrying amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-01-31_custom_DebtAgreementMember" id="Fact000673" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,550,000</ix:nonFraction></span>, respectively, or a discount to book value of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_z4wysqInh0nb" title="Term loan"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-01-31_custom_DebtAgreementMember" id="Fact000675" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">193,000</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_zPpmQzcVJBDd" title="Term loan"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-01-31_custom_DebtAgreementMember" id="Fact000677" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></span>, respectively. The fair value of the line of credit
as of January 31, 2024 was estimated to be $<span id="xdx_90B_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFjJDCqM5xMa" title="Debt instrument carrying amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-01-31_custom_DebtAgreementMember_us-gaap_FairValueInputsLevel2Member" id="Fact000679" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,463,000</ix:nonFraction></span>, or a discount to book value of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z5ECMMfpfUK6" title="Term loan"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-01-31_custom_DebtAgreementMember_us-gaap_FairValueInputsLevel2Member" id="Fact000681" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,000</ix:nonFraction></span>. The fair value of long-term debt was estimated using Level 2 inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000683" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z0La9yYYwfQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zwV0UXDf5CDf">Revenue
Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
derive revenue from the sale of internally-developed software, either by licensing for local installation or by a SaaS delivery model,
through our direct sales force or through third-party resellers. Licensed, locally-installed clients on a perpetual model utilize our
support and maintenance services for a separate fee, whereas term-based locally installed license fees and SaaS fees include support
and maintenance. We also derive revenue from professional services that support the implementation, configuration, training and optimization
of the applications, as well as audit services and consulting services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize revenue in accordance with Accounting Standards Codification (ASC) 606, <i>Revenue from Contracts with Clients</i> (&#8220;ASC
606&#8221;), under the core principle of recognizing revenue to depict the transfer of promised goods or services to clients in an amount
that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
commence revenue recognition (Step 5 below) in accordance with that core principle after applying the following steps:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    1: Identify the contract(s) with a client</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    2: Identify the performance obligations in the contract</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    3: Determine the transaction price</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    4: Allocate the transaction price to the performance obligations in the contract</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    5: Recognize revenue when (or as) the entity satisfies a performance obligation</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Often
contracts contain more than one performance obligation. Performance obligations are the unit of accounting for revenue recognition and
generally represent the distinct goods or services that are promised to the client. Revenue is recognized net of any taxes collected
from clients and subsequently remitted to governmental authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we determine that we have not satisfied a performance obligation, we defer recognition of the revenue until the performance obligation
is satisfied. Maintenance and support and SaaS agreements are generally non-cancellable or contain significant penalties for early cancellation,
although clients typically have the right to terminate their contracts for cause if we fail to perform material obligations. However,
if non-standard acceptance periods, non-standard performance criteria, or cancellation or right of refund terms are required, revenue
is recognized upon the satisfaction of such criteria.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price is determined by summing all the consideration the Company expects to receive from the client under the contract. At
times, a contract may have variable attributes (i.e., performance guarantees, service level agreements, optional terms) that the Company
must consider when establishing the transaction price to mitigate significant revenue reversals for the contract. The determined transaction
price is allocated based on the standalone selling price (&#8220;SSP&#8221;) of the performance obligations in contract. Significant
judgment is required to determine the SSP for each performance obligation, inclusion of variable consideration, the amount allocated
to each performance obligation and whether it depicts the amount that the Company expects to receive in exchange for the related product
and/or service. The Company recognizes revenue for implementation of its eValuator SaaS solution over the contract term, as it has been
determined that those implementation services are not a distinct performance obligation. Services for other SaaS and Software solutions
such as CDI, RevID and Compare, have been determined as a distinct performance obligation. For these agreements, the Company estimates
SSP of its software licenses using the residual approach when the software license is sold with other services and observable SSPs exist
for the other services. The Company estimates the SSP for maintenance, professional services, software as a service and audit services
based on observable standalone sales.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract
Combination</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may execute more than one contract or agreement with a single client. The Company evaluates whether the agreements were negotiated
as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance
of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions
reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related
to those arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has utilized the portfolio approach as the practical expedient. We have applied the revenue model to a portfolio of contracts
with similar characteristics where we expected that the financial statements would not differ materially from applying it to the individual
contracts within that portfolio.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Software
Licenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s software license arrangements provide the client with the right to use functional intellectual property. Implementation,
support, and other services are typically considered distinct performance obligations when sold with a software license unless these
services are determined to significantly modify the software. Revenue is recognized at a point in time. Typically, this is upon shipment
of components or electronic download of software.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Maintenance
and Support Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
maintenance and support obligations include multiple discrete performance obligations, with the two largest being unspecified product
upgrades or enhancements, and technical support, which can be offered at various points during a contract period. We believe that the
multiple discrete performance obligations within our overall maintenance and support obligations can be viewed as a single performance
obligation since both the unspecified upgrades and technical support are activities to fulfill the maintenance performance obligation
and are rendered concurrently. Maintenance and support agreements entitle clients to technology support, version upgrades, bug fixes
and service packs. We recognize maintenance and support revenue over the contract term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Software-Based
Solution Professional Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides various professional services to clients with software licenses. These include project management, software implementation
and software modification services. Revenues from arrangements to provide professional services are generally distinct from the other
promises in the contract and are recognized as the related services are performed. Consideration payable under these arrangements is
either fixed fee or on a time-and-materials basis and is recognized over time as the services are performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Software
as a Service</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SaaS-based
contracts include a right to use of the Company&#8217;s platform and support which represent a single promise to provide continuous access
to its software solutions. Implementation services for the Company&#8217;s eValuator product are included as part of the single promise
for its respective contracts. The Company recognizes revenue for implementation of the eValuator product over the contract term as it
is determined that the implementation on eValuator is not a distinct performance obligation. Implementation services for other SaaS products
are deemed to be separate performance obligations that are recognized over time as the services are performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides technology-enabled coding audit services to help clients review and optimize their internal clinical documentation and
coding functions across the applicable segment of the client&#8217;s enterprise. Audit services are a separate performance obligation.
We recognize revenue over time as the services are performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disaggregation
of Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000685" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_z0jY4a01NTw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information about disaggregated revenue by type and nature of revenue stream:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zlMowoknXAu9" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF DISAGGREGATON OF REVENUE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230201__20240131_zXglfbiAOxt4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220201__20230131_zjOgp3IivuTh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zQhbKUjvP4Ig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Over time revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-02-012024-01-31_us-gaap_TransferredOverTimeMember" id="Fact000687" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,358,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-02-012023-01-31_us-gaap_TransferredOverTimeMember" id="Fact000688" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,670,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zYqnLNCuvL5i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Point in time revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-02-012024-01-31_us-gaap_TransferredAtPointInTimeMember" id="Fact000690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">238,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-02-012023-01-31_us-gaap_TransferredAtPointInTimeMember" id="Fact000691" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,219,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zNl6JRI2goeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-02-01to2024-01-31" id="Fact000693" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,596,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-02-012023-01-31" id="Fact000694" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,889,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z571tbGvK3ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company includes revenue categories of (i) over time and (ii) point in time revenue. The Company includes revenue categories of (i) SaaS,
(ii) maintenance and support, (iii) professional services, and (iv) audit services as over time revenue. For point in time revenue, the
performance obligation is recognized as the point in time when the obligation is fully satisfied. The Company includes software licenses
as point in time revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract
Assets and Deferred Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company receives payments from clients based upon contractual billing schedules. Contract receivables include amounts related to the
Company&#8217;s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenues include
payments received in advance of performance under the contract. Our contract receivables and deferred revenue are reported on an individual
contract basis at the end of each reporting period. Contract receivables are classified as current or noncurrent based on the timing
of when we expect to bill the client. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to
recognize revenue. In the year ended January 31, 2024, we recognized approximately $<span id="xdx_904_eus-gaap--DeferredRevenue_iI_pp0p0_c20230131_zjvxR3hWRfE3" title="Deferred revenue"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2023-01-31" id="Fact000696" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,642,000</ix:nonFraction></span> in revenue from deferred revenues outstanding
as of January 31, 2023. Revenue allocated to remaining performance obligations was $<span id="xdx_903_eus-gaap--RevenueRemainingPerformanceObligation_iI_pp0p0_c20240131_zzJQFtl5lLgi" title="Revenue remaining performance obligation"><ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="AsOf2024-01-31" id="Fact000698" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,414,000</ix:nonFraction></span> &#160;&#160;as of January 31, 2024, of
which <span id="xdx_90E_eus-gaap--RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_c20230201__20240131_zMKGqlhUohX1" title="Revenue, remaining performance obligation, expected timing of satisfaction, explanation"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact000700" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation">the Company expects to recognize approximately 46% over the next 12 months and the remainder thereafter.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deferred
costs (costs to fulfill a contract and contract acquisition costs)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
defer the direct costs, which include salaries and benefits, for professional services related to SaaS contracts as a cost to fulfill
a contract. These deferred costs will be amortized on a straight-line basis over the contractual term. As of January 31, 2024, and 2023,
we had deferred costs of $<span id="xdx_907_eus-gaap--DeferredCostsCurrentAndNoncurrent_iI_pp0p0_c20240131_zVdxuFx5yI48" title="Deferred costs, net"><ix:nonFraction name="us-gaap:DeferredCostsCurrentAndNoncurrent" contextRef="AsOf2024-01-31" id="Fact000702" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">77,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--DeferredCostsCurrentAndNoncurrent_iI_pp0p0_c20230131_zfIOvjbI3BN" title="Deferred costs, net"><ix:nonFraction name="us-gaap:DeferredCostsCurrentAndNoncurrent" contextRef="AsOf2023-01-31" id="Fact000704" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">94,000</ix:nonFraction></span>, respectively, net of accumulated amortization of $<span id="xdx_905_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_pp0p0_c20240131_zXk7UyCFT7qd" title="Accumulated amortization of deferred costs"><ix:nonFraction name="us-gaap:AccumulatedAmortizationOfOtherDeferredCosts" contextRef="AsOf2024-01-31" id="Fact000706" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">102,000</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_pp0p0_c20230131_zfuai8uwzf78" title="Accumulated amortization of deferred costs"><ix:nonFraction name="us-gaap:AccumulatedAmortizationOfOtherDeferredCosts" contextRef="AsOf2023-01-31" id="Fact000708" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">176,000</ix:nonFraction></span>, respectively. Amortization
expense of these costs was $<span id="xdx_90A_ecustom--DeferredCostsAmortizationExpenses_pp0p0_c20230201__20240131_z8JxABz7wmd9" title="Deferred costs, amortization expense"><ix:nonFraction name="STRM:DeferredCostsAmortizationExpenses" contextRef="From2023-02-01to2024-01-31" id="Fact000710" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">82,000</ix:nonFraction></span> and $<span id="xdx_901_ecustom--DeferredCostsAmortizationExpenses_pp0p0_c20220201__20230131_zM3D3eB7wswd" title="Deferred costs, amortization expense"><ix:nonFraction name="STRM:DeferredCostsAmortizationExpenses" contextRef="From2022-02-012023-01-31" id="Fact000712" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">83,000</ix:nonFraction></span> in fiscal 2023 and 2022, respectively. There were no impairment losses for these capitalized
costs for the fiscal 2023 and 2022. Additionally, in fiscal 2023, approximately $<span id="xdx_905_eus-gaap--OtherAmortizationOfDeferredCharges_pp0p0_c20230201__20240131_z0ccSphI8kFj" title="Amortized contracts"><ix:nonFraction name="us-gaap:OtherAmortizationOfDeferredCharges" contextRef="From2023-02-01to2024-01-31" id="Fact000714" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">155,000</ix:nonFraction></span> of fully amortized contracts were cleared
from their corresponding capitalization and accumulated amortization balance sheet accounts, while no such adjustments were made in fiscal
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
acquisition costs, which consist of sales commissions paid or payable, is considered incremental and recoverable costs of obtaining a
contract with a client. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis
over the contract term. As a practical expedient, we expense sales commissions as incurred when the amortization period of related deferred
commission costs would have been one year or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
commissions costs paid and payable, which are included on the consolidated balance sheets within other non-current assets totaled $<span id="xdx_90E_ecustom--DeferredCommissionsCostsPaidAndPayable_iI_pp0p0_c20240131__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherNoncurrentAssetsMember_z6mG0uzfKR5b" title="Deferred commissions costs paid and payable"><ix:nonFraction name="STRM:DeferredCommissionsCostsPaidAndPayable" contextRef="AsOf2024-01-31_us-gaap_OtherNoncurrentAssetsMember" id="Fact000716" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,461,000</ix:nonFraction></span>
and $<span id="xdx_907_ecustom--DeferredCommissionsCostsPaidAndPayable_iI_pp0p0_c20230131__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherNoncurrentAssetsMember_zp6gUZHH6ZN2" title="Deferred commissions costs paid and payable"><ix:nonFraction name="STRM:DeferredCommissionsCostsPaidAndPayable" contextRef="AsOf2023-01-31_us-gaap_OtherNoncurrentAssetsMember" id="Fact000718" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,534,000</ix:nonFraction></span>, respectively, as of January 31, 2024 and 2023. In fiscal 2023 and 2022, amortization expense associated with deferred
sales commissions was $<span id="xdx_905_eus-gaap--AmortizationOfDeferredSalesCommissions_pp0p0_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zgWVS2cRmPA3" title="Amortization expense with deferred sales commissions"><ix:nonFraction name="us-gaap:AmortizationOfDeferredSalesCommissions" contextRef="From2023-02-012024-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember" id="Fact000720" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">588,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--AmortizationOfDeferredSalesCommissions_pp0p0_c20220201__20230131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zC5wRguPWwcf" title="Amortization expense with deferred sales commissions"><ix:nonFraction name="us-gaap:AmortizationOfDeferredSalesCommissions" contextRef="From2022-02-012023-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember" id="Fact000722" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">411,000</ix:nonFraction></span>, respectively, and was included in selling, general and administrative expenses on the consolidated
statements of operations. There were $<span id="xdx_909_eus-gaap--CapitalizedContractCostImpairmentLoss_pp0p0_c20230201__20240131_zq6Lz5yN6ife" title="Impairment loss"><ix:nonFraction name="us-gaap:CapitalizedContractCostImpairmentLoss" contextRef="From2023-02-01to2024-01-31" id="Fact000724" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,000</ix:nonFraction></span> and <span id="xdx_901_eus-gaap--CapitalizedContractCostImpairmentLoss_pp0p0_do_c20220201__20230131_zbNQzc4gtAk9" title="Impairment loss"><ix:nonFraction name="us-gaap:CapitalizedContractCostImpairmentLoss" contextRef="From2022-02-012023-01-31" id="Fact000726" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span> impairment losses for these capitalized costs that was included with the amortization
expense for fiscal 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000728" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zL8F4xbnR08b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zXy7zlnS4U5c">Concentrations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments, which potentially expose the Company to concentrations of credit risk, consist primarily of accounts receivable. The Company&#8217;s
accounts receivables are concentrated in the healthcare industry. However, the Company&#8217;s clients typically are well-established
hospitals, medical facilities or major health information systems companies with good credit histories that resell the Company&#8217;s
solutions. Payments from clients have been received within normal time frames for the industry. However, some hospitals and medical facilities
have experienced significant operating losses as a result of limits on third-party reimbursements from insurance companies and governmental
entities and extended payment of receivables from these entities is not uncommon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has relied on a limited number of clients and remarketing partners for a substantial portion of its total revenues.
The Company expects that a significant portion of its future revenues will continue to be generated by a limited number of clients and
its remarketing partners.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000730" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zeAj1BAjGsyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zR3ftPEEQhza">Goodwill
and Intangible Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
and other intangible assets were recognized in conjunction with the Avelead acquisition, and certain other acquisitions from fiscal
2013 and prior (prior to divestiture of such assets). Identifiable intangible assets include purchased intangible assets with finite
lives, which primarily consist of internally-developed software and client relationships. Finite-lived purchased intangible assets
are amortized over their expected period of benefit, which generally ranges from <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dxL_c20240131__srt--RangeAxis__srt--MinimumMember_zA4bGYLesFfg" title="Finite-lived intangible assets amortized period::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl0732">one</span></span>
to <span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20240131__srt--RangeAxis__srt--MaximumMember_zBVML3cJc0Db" title="Finite-lived intangible assets amortized period"><ix:nonNumeric contextRef="AsOf2024-01-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000734" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">15</ix:nonNumeric></span>
years, using the straight-line method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses the useful lives and possible impairment of intangible assets when an event occurs that may trigger such a review. Factors
considered important which could trigger a review include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    underperformance relative to historical or projected future operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    changes in the manner of use of the acquired assets or the strategy for the overall business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification
    of other impaired assets within a reporting unit;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disposition
    of a significant portion of an operating segment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    negative industry or economic trends;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    decline in the Company&#8217;s stock price for a sustained period; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decline in the market capitalization relative to the net book value.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining
whether a triggering event has occurred involves significant judgment by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses goodwill annually (as of November 1), or more frequently when events and circumstances, such as the ones mentioned above,
occur indicating that the recorded goodwill may be impaired. In assessing qualitative factors to determine whether it is more likely
than not that the fair value of a reporting unit is less than its carrying amount, the Company assesses relevant events and circumstances
that may impact the fair value and the carrying amount of a reporting unit. The identification of relevant events and circumstances and
how these may impact a reporting unit&#8217;s fair value or carrying amount involve significant judgments by management. These judgments
include the consideration of macroeconomic conditions, industry and market considerations, cost factors, overall financial performance,
events which are specific to the Company and trends in the market price of the Company&#8217;s common stock. Each factor is assessed
to determine whether it impacts the impairment test positively or negatively, and the magnitude of any such impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended January 31, 2023, the Company did not note any of the above qualitative factors, which would be considered a triggering
event for goodwill impairment. During the year ended January 31, 2024, the Company identified one or more factors that triggered goodwill
impairment as of October 31, 2023, as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the third quarter of fiscal 2023, the Company received a notice from a significant SaaS client of its intent not to renew its contract
following the expiration of the current term on December 31, 2023. At that time, the Company elected to accelerate the execution of the
2023 Restructuring that was designed to reduce costs while maintaining the Company&#8217;s ability to expand its SaaS business. Both
the client termination and the execution of the Strategic Restructuring were announced on October 16, 2023. Following these announcements,
the Company&#8217;s share price declined significantly. Based on these events (collectively, the &#8220;Triggering Events&#8221;), the
Company identified indicators of possible impairment and initiated testing using a valuation date of October 31, 2023. The impairment
tests were conducted under guidance of ASC Topic 360, Impairment and Disposal of Long-Lived Assets (&#8220;ASC 360&#8221;) for certain
long-lived assets, including capitalized contract costs, developed technology, client relationships and trade names, and in accordance
with ASC Topic 350, Intangibles &#8211; Goodwill and Other (&#8220;ASC 350&#8221;) with respect to the reporting unit&#8217;s goodwill.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reporting
units are determined based on the organizational structure the entity has in place at the date of the impairment test. A reporting unit
is an operating segment or component business unit with the following characteristics: (a) it has discrete financial information, (b)
segment management regularly reviews its operating results (generally an operating segment has a segment manager who is directly accountable
to and maintains regular contact with the chief operating decision maker to discuss operating activities, financial results, forecasts
or plans for the segment), and (c) its economic characteristics are dissimilar from other units (this contemplates the nature of the
products and services, the nature of the production process, the type or class of client for the products and services and the methods
used to distribute the products and services). The Company determined that for fiscal 2023 it has one operating segment and one reporting
unit, while for fiscal 2022 it had one operating segment and two reporting units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of its reporting unit using a combination of the market approach and income approach, via
discounted cash flow valuation models which include, but are not limited to, assumptions such as a &#8220;risk-free&#8221; rate of
return on an investment, the weighted average cost of capital of a market participant and future revenue, operating margin, working
capital and capital expenditure trends. Determining the fair value of reporting units and goodwill includes significant judgment by
management, and different judgments could yield different results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performed its annual goodwill assessment for fiscal 2023 as of October 31, 2023 using the approaches described above. The
assessment identified a goodwill impairment of $9,813,000 that was recorded. Based on the analysis performed for fiscal 2022, the fair
value of the reporting units exceeded the carrying amount of the reporting unit, including goodwill, and, therefore, a goodwill impairment
loss was not recognized. &#160; Refer to Note 6 &#8211; Goodwill and Intangible Assets to our consolidated financial statements included
in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000736" name="STRM:EquityAwardPolicyTextBlock"><p id="xdx_84C_ecustom--EquityAwardPolicyTextBlock_zKl6DDIRUcyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_za30GXIH31Ah">Equity
Awards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as
expense over the requisite service period. For awards to non-employees, the Company recognizes compensation expense in the same
manner as if the entity had paid cash for the goods or services. The Company incurred total annual compensation expense related to
stock-based awards of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230201__20240131__us-gaap--AwardTypeAxis__custom--EquityAwardMember_zH1uJNztuAL8" title="Compensation expense related to stock-based award"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-02-012024-01-31_custom_EquityAwardMember" id="Fact000738" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,102,000</ix:nonFraction></span>
in fiscal 2023, net of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20230201__20240131__us-gaap--AwardTypeAxis__custom--EquityAwardMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zw4aTB8Ufp58" title="Compensation expense related to stock-based award"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-02-012024-01-31_custom_EquityAwardMember_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact000740" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,000</ix:nonFraction></span>
of capitalized non-employee stock compensation, and $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20220201__20230131__us-gaap--AwardTypeAxis__custom--EquityAwardMember_z74WRKZ8A4ye" title="Compensation expense related to stock-based award"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-02-012023-01-31_custom_EquityAwardMember" id="Fact000742" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,680,000</ix:nonFraction></span>
net of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20220201__20230131__us-gaap--AwardTypeAxis__custom--EquityAwardMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMZp75ifhVhj" title="Compensation expense related to stock-based award"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-02-012023-01-31_custom_EquityAwardMember_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact000744" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,000</ix:nonFraction></span> of capitalized non-employee stock compensation, in fiscal 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the stock options granted are estimated at the date of grant using a Black-Scholes option pricing model. Option pricing
model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. The Company
recognizes forfeitures as they occur. These assumptions are subjective and are generally derived from external (such as, risk-free rate
of interest) and historical data (such as, volatility factor, expected term and forfeiture rates). Future grants of equity awards accounted
for as stock-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period
of future awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market
close price per share on the grant date. The Company expenses the compensation cost of these awards as the restriction period
lapses, which is typically a one- to four-year service period to the Company. In fiscal 2023 and 2022, <span id="xdx_903_ecustom--SurrenderOfStockSharesDuringPeriod_c20230201__20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztKBLwWQQkS" title="Surrender of stock, shares"><ix:nonFraction name="STRM:SurrenderOfStockSharesDuringPeriod" contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember" id="Fact000746" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">190,950</ix:nonFraction></span>
and <span id="xdx_90E_ecustom--SurrenderOfStockSharesDuringPeriod_c20220201__20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCzvG3cob019" title="Surrender of stock, shares"><ix:nonFraction name="STRM:SurrenderOfStockSharesDuringPeriod" contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember" id="Fact000748" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,429</ix:nonFraction></span>
shares of common stock were surrendered to the Company to satisfy tax withholding obligations totaling $<span id="xdx_901_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z9vP8EYbfCl1" title="Cost of shares for tax withholding"><ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2023-02-012024-01-31_us-gaap_RestrictedStockMember" id="Fact000750" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,000</ix:nonFraction></span>
and $<span id="xdx_908_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHWOF4tLnhYd" title="Cost of shares for tax withholding"><ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember" id="Fact000752" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,000</ix:nonFraction></span>,
respectively, in connection with the vesting of restricted stock awards. Shares surrendered by the restricted stock award recipients
in accordance with the applicable plan are deemed cancelled, and therefore are not available to be reissued. The Company awarded <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230201__20240131__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zn293hzastO8" title="Number shares of restricted stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-02-012024-01-31_custom_OfficersAndDirectorsMember" id="Fact000754" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,203,621</ix:nonFraction></span>
and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220201__20230131__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zz1WS8q7RpXb" title="Number shares of restricted stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-02-012023-01-31_custom_OfficersAndDirectorsMember" id="Fact000756" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">890,731</ix:nonFraction></span>
shares of restricted stock to its executive officers and directors of the Company in fiscal 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000758" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_z2Bp32guHuX7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zuOU4Xaz3zHi">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net
deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be
realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets
will not be realized. Refer to Note 7 &#8211; Income Taxes to our consolidated financial statements included in Part II, Item 8, &#8220;Financial
Statements and Supplementary Data&#8221; for further details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether
certain tax positions are more likely than not to be sustained upon examination by tax authorities. At January 31, 2024, the Company
believes it has appropriately accounted for any uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000760" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zdkEWKyw49A8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zOl7MFqG7GD1">Net
Earnings (Loss) Per Common Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company presents basic and diluted earnings per share (&#8220;EPS&#8221;) data for our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
unvested restricted stock awards are considered non-participating securities because holders are not entitled to non-forfeitable rights
to dividends or dividend equivalents during the vesting term. In accordance with ASC 260, securities are deemed not to be participating
in losses if there is no obligation to fund such losses. Diluted EPS for our common stock is computed using the treasury stock method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000762" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zSKoGeFheh9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is the calculation of the basic and diluted net loss per share of common stock:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zm55lTHK41lc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230201__20240131_zT16hi7c2tZe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220201__20230131_zYEzhQSz4uQ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Basic earnings (loss) per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperations_i01_zBDKZfLAlsh" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Loss, net of tax</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="From2023-02-01to2024-01-31" id="Fact000764" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,697,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="From2022-02-012023-01-31" id="Fact000765" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,379,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_i01_zcADVlyaHmAd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic net loss per share of common stock </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2023-02-01to2024-01-31" id="Fact000767" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.33</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2022-02-012023-01-31" id="Fact000768" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.23</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Diluted earnings (loss) per share (1):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_i01_zrjqeeC06QW2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss available to common stockholders </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" contextRef="From2023-02-01to2024-01-31" id="Fact000770" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,697,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" contextRef="From2022-02-012023-01-31" id="Fact000771" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,379,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_i01_zHSqEJzPzmPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Diluted net loss per share of common stock </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="From2023-02-01to2024-01-31" id="Fact000773" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.33</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="From2022-02-012023-01-31" id="Fact000774" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.23</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_zcStVat5IQg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-02-01to2024-01-31" id="Fact000776" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,697,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-02-012023-01-31" id="Fact000777" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,379,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zGLtOkhm5wdg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average shares outstanding &#8211; Basic (1)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F45_zYg8GXeSOw63" style="display: none">(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-02-01to2024-01-31" id="Fact000779" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,510,419</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-02-012023-01-31" id="Fact000780" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,324,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks_pid_z9VIeZG2nNmb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of dilutive securities - Stock options and Restricted stock (2)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F4E_z505HyUzBWob" style="display: none">(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0783">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zDqQ2pJbNI0e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average shares outstanding &#8211; Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-02-01to2024-01-31" id="Fact000785" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,510,419</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-02-012023-01-31" id="Fact000786" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,324,858</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareBasic_pid_zMA0HSp97Zkj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net loss per share of common stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zUrF65h71AU9"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zomVu3fzr7o6">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-02-01to2024-01-31" id="Fact000788" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000790" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000791" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.33</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zaQNiVQiGZue"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zRmiwnEX7gW2">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-02-012023-01-31" id="Fact000789" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" id="Fact000792" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" id="Fact000793" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.23</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_F0E_zl3tpEFjuksg" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_zbOLVzSiI5j4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000794" xml:lang="en-US">Excludes
    the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of January 31, 2024
    and 2023, there were <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zOkiNJqczEvk" title="Diluted earnings per share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-02-012024-01-31_custom_UnvestedRestrictedStockMember" id="Fact000796" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,970,521</ix:nonFraction></span> and <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z2lI0oNs2rt9" title="Diluted earnings per share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-02-012023-01-31_custom_UnvestedRestrictedStockMember" id="Fact000798" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,848,031</ix:nonFraction></span> unvested restricted shares of common stock, respectively.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_F01_zJ3XaglWt9Ta" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zqD6zjckRZpk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000799" xml:lang="en-US">Diluted
    net loss per share excludes the effect of shares that are anti-dilutive. As of January 31, 2024, there were <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6ObtBNkGuq3" title="Diluted earnings per share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-02-012024-01-31_us-gaap_EmployeeStockOptionMember" id="Fact000801" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,500</ix:nonFraction></span> outstanding stock
    options and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedSharesMember_z7x8lmNjloWl" title="Diluted earnings per share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-02-012024-01-31_custom_UnvestedRestrictedSharesMember" id="Fact000803" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,970,521</ix:nonFraction></span> unvested restricted shares of common stock. As of January 31, 2023, there were <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zg2cyB4sQ6Wk" title="Diluted earnings per share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-02-012023-01-31_us-gaap_EmployeeStockOptionMember" id="Fact000805" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">628,598</ix:nonFraction></span> outstanding stock options
    and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zKuhWu16S4uk" title="Diluted earnings per share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-02-012023-01-31_custom_UnvestedRestrictedStockMember" id="Fact000807" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,848,031</ix:nonFraction></span> unvested restricted shares of common stock.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_z8jXXPKpkPg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<ix:exclude><!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000809" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock"><p id="xdx_846_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zvZi28wtxQN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zumJhOzXsvw9">Loss
Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the possibility of various loss contingencies arising in the normal course of business. We consider the likelihood of
the loss or impairment of an asset or the incurrence of a liability as well as our ability to reasonably estimate the amount of loss
in determining loss contingencies. An estimated loss contingency is accrued when it is probable that a liability has been incurred or
an asset has been impaired, and the amount of loss can be reasonably estimated. We regularly evaluate current information available to
us to determine whether to accrue for a loss contingency and adjust any previous accrual.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000811" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"><p id="xdx_84A_eus-gaap--CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_zQ0wKmvymZw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zugotMys2zFf">Restructuring</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 16, 2023, the Company announced it was executing a Strategic Restructuring designed to reduce expenses while maintaining the
Company&#8217;s ability to expand its SaaS business. The Strategic Restructuring initiatives included a reduction in force, resulting
in the termination of <span id="xdx_908_ecustom--NumberOfEmployeesTerminated_iI_uInteger_c20231016_ztRLXFZsGe6k" title="Number of employees terminated"><ix:nonFraction name="STRM:NumberOfEmployeesTerminated" contextRef="AsOf2023-10-16" id="Fact000813" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">26</ix:nonFraction></span> employees, or approximately <span id="xdx_90C_ecustom--PercentageOfWorkforceTerminated_iI_dp_uPure_c20231016_zCIaWNVmFlOl" title="Percentage of workforce terminated"><ix:nonFraction name="STRM:PercentageOfWorkforceTerminated" contextRef="AsOf2023-10-16" id="Fact000815" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24</ix:nonFraction></span>% of the Company&#8217;s workforce. To execute the Strategic Restructuring, the
Company incurred one-time restructuring costs associated with the workforce reduction of approximately $<span id="xdx_905_eus-gaap--RestructuringCosts_c20231016__20231016_zOntCOm1uCwk" title="Restructuring costs"><ix:nonFraction name="us-gaap:RestructuringCosts" contextRef="From2023-10-162023-10-16" id="Fact000817" format="ixt:numdotdecimal" decimals="0" unitRef="USD">759,000</ix:nonFraction></span>, and the Company has
recognized all expenses associated with the Strategic Restructuring as of the end of fiscal 2023. The costs pertain to severance and
other employee termination-related costs and various professional fees the Company required to assist with execution of the Strategic
Restructuring. The following is a reconciliation of the Strategic Restructuring liability reflected on the Company&#8217;s condensed
consolidated balance sheet under &#8220;Accrued expenses&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000819" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_zcPd5Sclhq91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_zVUN80vYpDjh" style="display: none">SCHEDULE OF RECONCILIATION OF THE
RESTRUCTURING LIABILITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="22" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Accrued</b></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Accrued</b></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of January 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance as of January 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 Expenses to Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 Cash Payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance as of January 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Costs Incurred to Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Expected Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Severance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 34%">Cost of sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zK31whEsQUl" title="Accrued Balance as of January 31, 2023" style="width: 8%; text-align: right">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0821">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zsRfRkAAqw71" title="2023 Expenses to Date" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-02-012024-01-31_us-gaap_CostOfSalesMember" id="Fact000823" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">154</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zcnAbrwMJzQa" title="2023 Cash Payments" style="width: 8%; text-align: right"><ix:nonFraction name="STRM:AccruedCashPayments" contextRef="From2023-02-012024-01-31_us-gaap_CostOfSalesMember" id="Fact000825" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">154</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z1XWbK9im3gh" title="Accrued Balance as of October 31, 2023" style="width: 8%; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zb2xjwlXrNb4" title="Total Costs Incurred to Date" style="width: 8%; text-align: right"><ix:nonFraction name="STRM:AccruedCostsIncurred" contextRef="AsOf2024-01-31_us-gaap_CostOfSalesMember" id="Fact000829" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">154</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zFGeb8oZh734" title="Total Expected Costs" style="width: 8%; text-align: right"><ix:nonFraction name="STRM:AccruedExpectedCosts" contextRef="From2023-02-012024-01-31_us-gaap_CostOfSalesMember" id="Fact000831" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">154</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling, general, and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zgF3AlYQNYUi" title="Accrued Balance as of January 31, 2023" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0833">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zFKeiNiACPD5" title="2023 Expenses to Date" style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-02-012024-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember" id="Fact000835" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">350</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zlGv358wxWZ9" title="2023 Cash Payments" style="text-align: right"><ix:nonFraction name="STRM:AccruedCashPayments" contextRef="From2023-02-012024-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember" id="Fact000837" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">276</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zwjns1Y39W3j" title="Accrued Balance as of October 31, 2023" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember" id="Fact000839" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zqiRzO1j4id2" title="Total Costs Incurred to Date" style="text-align: right"><ix:nonFraction name="STRM:AccruedCostsIncurred" contextRef="AsOf2024-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember" id="Fact000841" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">350</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zm3HYOaSlDqi" title="Total Expected Costs" style="text-align: right"><ix:nonFraction name="STRM:AccruedExpectedCosts" contextRef="From2023-02-012024-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember" id="Fact000843" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">350</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zy3QuKboUiOk" title="Accrued Balance as of January 31, 2023" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0845">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUNiTrqAejec" title="2023 Expenses to Date" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-02-012024-01-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000847" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4NPCwihCzLj" title="2023 Cash Payments" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="STRM:AccruedCashPayments" contextRef="From2023-02-012024-01-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000849" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zuMRQ6AL6PJf" title="Accrued Balance as of October 31, 2023" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgrKQdtRzK87" title="Total Costs Incurred to Date" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="STRM:AccruedCostsIncurred" contextRef="AsOf2024-01-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000853" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z7In9BvhxtD8" title="Total Expected Costs" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="STRM:AccruedExpectedCosts" contextRef="From2023-02-012024-01-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000855" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total severance expense</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zcGYDLCzhqB2" title="Accrued Balance as of January 31, 2023" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zFdNqBp0GSDf" title="2023 Expenses to Date" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-02-012024-01-31_custom_SeveranceExpensesMember" id="Fact000859" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">731</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zbwd77jepsYj" title="2023 Cash Payments" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="STRM:AccruedCashPayments" contextRef="From2023-02-012024-01-31_custom_SeveranceExpensesMember" id="Fact000861" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">657</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zwEck8mknhDi" title="Accrued Balance as of October 31, 2023" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-01-31_custom_SeveranceExpensesMember" id="Fact000863" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_980_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zFr7ZMv4ErYc" title="Total Costs Incurred to Date" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="STRM:AccruedCostsIncurred" contextRef="AsOf2024-01-31_custom_SeveranceExpensesMember" id="Fact000865" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">731</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zqrWNVOuH3bk" title="Total Expected Costs" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="STRM:AccruedExpectedCosts" contextRef="From2023-02-012024-01-31_custom_SeveranceExpensesMember" id="Fact000867" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">731</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Professional fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zdCAEngK0Gh6" title="Accrued Balance as of January 31, 2023" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0869">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zSWcGLNkZwgd" title="2023 Expenses to Date" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-02-012024-01-31_custom_ProfessionalFeesMember" id="Fact000871" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zUTCupmUPFGg" title="2023 Cash Payments" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="STRM:AccruedCashPayments" contextRef="From2023-02-012024-01-31_custom_ProfessionalFeesMember" id="Fact000873" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zbnlHH6m9rwd" title="Accrued Balance as of October 31, 2023" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0875">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zsWSpXRo7Mkg" title="Total Costs Incurred to Date" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="STRM:AccruedCostsIncurred" contextRef="AsOf2024-01-31_custom_ProfessionalFeesMember" id="Fact000877" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zlKYj9LQchU5" title="Total Expected Costs" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="STRM:AccruedExpectedCosts" contextRef="From2023-02-012024-01-31_custom_ProfessionalFeesMember" id="Fact000879" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_z5PZIGP8Azf2" title="Accrued Balance as of January 31, 2023" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0881">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zyRdI1Qbma37" title="2023 Expenses to Date" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-02-012024-01-31_custom_AccruedExpensesMember" id="Fact000883" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">759</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98A_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zMmuGj9t21Bk" title="2023 Cash Payments" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="STRM:AccruedCashPayments" contextRef="From2023-02-012024-01-31_custom_AccruedExpensesMember" id="Fact000885" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">685</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zhqpQ87SlXH6" title="Accrued Balance as of October 31, 2023" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-01-31_custom_AccruedExpensesMember" id="Fact000887" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zeQHXKBypUL1" title="Total Costs Incurred to Date" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="STRM:AccruedCostsIncurred" contextRef="AsOf2024-01-31_custom_AccruedExpensesMember" id="Fact000889" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">759</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zKbmG4cP32U4" title="Total Expected Costs" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="STRM:AccruedExpectedCosts" contextRef="From2023-02-012024-01-31_custom_AccruedExpensesMember" id="Fact000891" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">759</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zRFfSpqmEYml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000893" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z1THQ0hFrhN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zikcQEMVG2X">Accounting
Pronouncements Recently Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2019, the FASB issued ASU 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which improves guidance around accounting for financial losses on accounts receivable. For smaller reporting entities, ASU
2016-13 is effective for annual periods beginning after December 15, 2022, including interim periods within those fiscal years. The Company&#8217;s
adoption of ASU 2016-13 was effective February 1, 2023. An analysis of contract receivables, including credit losses, was conducted during
the first quarter of fiscal 2024. The adoption of this ASU did not have a material impact on our consolidated financial statements
or disclosures.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000895" name="STRM:RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock"><p id="xdx_84B_ecustom--RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zbwSureRh1pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zZlBtIO4H9M6">Recent
Accounting Pronouncements Not Yet Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves
guidance around the disclosures about a public entity&#8217;s reportable segments and additional details about a reportable segment&#8217;s
expenses. ASU 2023-07 is effective for all public entities for annual periods beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. The Company&#8217;s adoption of ASU 2023-07 will be effective in the annual report
for the fiscal year ending January 31, 2025. The adoption of this ASU is not expected to have a material impact on our consolidated financial
statements or disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhance the transparency
and decision usefulness of income tax disclosures. For public entities, ASU 2023-09 is effective for annual periods beginning after December
15, 2024. The adoption of this ASU is not expected to have a material impact on our consolidated financial statements or disclosures.</span></p>

</ix:nonNumeric><p id="xdx_859_zOFzDldd3uXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000897" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p id="xdx_808_eus-gaap--BusinessCombinationDisclosureTextBlock_z0GiYrjXb3kk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
3 &#8212; <span id="xdx_821_zTDtu1VIstu2">BUSINESS COMBINATION </span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Avelead
Acquisition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acquired all of the equity interests of Avelead as part of the Company&#8217;s strategic expansion into the revenue cycle management,
acute-care healthcare space (the &#8220;Transaction&#8221;). The Transaction was completed on August 16, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate consideration for the purchase of Avelead was approximately $<span id="xdx_903_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zljhiLyQsGWi"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember" id="Fact000898" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">29.7</ix:nonFraction></span> million (at fair value) consisting of (i) $<span id="xdx_90D_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn5n6_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zFrLiyTqrCN3"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember" id="Fact000899" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.5</ix:nonFraction></span> million in
cash, net of cash acquired, (ii) $<span id="xdx_907_eus-gaap--BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_iI_pn5n6_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zBuvZghmG4Pl"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" contextRef="AsOf2021-08-16_custom_AveleadConsultingLLCMember" id="Fact000900" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.5</ix:nonFraction></span> million in common stock, and (iii) approximately $<span id="xdx_90A_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn5n6_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_z9jKYmQFYSdc"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2021-08-16_custom_AveleadConsultingLLCMember" id="Fact000901" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.7</ix:nonFraction></span> million in contingent consideration (see
below). The Company issued <span id="xdx_90D_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardTypeAxis__custom--AcquisitionRestrictedCommonStockMember_zJlIzxzGJ0si"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_AcquisitionRestrictedCommonStockMember" id="Fact000902" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,021,972</ix:nonFraction></span> shares of its restricted common stock (the &#8220;Acquisition Restricted Common Stock&#8221;). The
Acquisition Restricted Common Stock had a fair value as of the closing date of the acquisition of $<span id="xdx_90A_ecustom--BusinessAcquisitionEquityInterestIssuedFairValue_iI_pn5n6_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardTypeAxis__custom--AcquisitionRestrictedCommonStockMember_zDCi3oV8pN2c"><ix:nonFraction name="STRM:BusinessAcquisitionEquityInterestIssuedFairValue" contextRef="AsOf2021-08-16_custom_AveleadConsultingLLCMember_custom_AcquisitionRestrictedCommonStockMember" id="Fact000903" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.5</ix:nonFraction></span> million. <span id="xdx_908_eus-gaap--BusinessCombinationContingentConsiderationArrangementsDescription_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardTypeAxis__custom--AcquisitionRestrictedCommonStockMember_ztVzzWeVUgTj" title="Business combination description"><ix:nonNumeric contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_AcquisitionRestrictedCommonStockMember" id="Fact000905" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription">Additionally, the Transaction
included two types of contingent consideration; the first is referred to herein as &#8220;SaaS Contingent Consideration&#8221; and the
second is referred to herein as &#8220;Renewal Contingent Consideration.&#8221; The SaaS Contingent Consideration and Renewal Contingent
Consideration had an aggregate value of approximately $10.7 million as of the date of closing.</ix:nonNumeric></span> The owners of Avelead are also referred
to herein as &#8220;Sellers&#8221; and are enumerated in the UPA (as defined below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Unit Purchase Agreement (hereafter referred to as the &#8220;UPA&#8221;), stated that the purchase price for Avelead at closing included
a cash payment of $<span id="xdx_905_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn5n6_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zuopL5akMCN6"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember" id="Fact000906" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">11.9</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. Additionally, the Company paid $<span id="xdx_90D_ecustom--PaymentsToAcquireBusinessesSellerExpenses_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zmRCUNKv4She"><ix:nonFraction name="STRM:PaymentsToAcquireBusinessesSellerExpenses" contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember" id="Fact000907" format="ixt:numdotdecimal" decimals="0" unitRef="USD">285,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the Sellers&#8217; closing costs, $<span id="xdx_90F_ecustom--PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_z6dF7hfxdaDi"><ix:nonFraction name="STRM:PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment" contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember" id="Fact000908" format="ixt:numdotdecimal" decimals="0" unitRef="USD">285,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">related to the working capital adjustment as
defined in the UPA. Finally, at closing, the Company issued the Acquisition Restricted Common Stock with a fair value of approximately
$<span id="xdx_90A_ecustom--BusinessAcquisitionEquityInterestIssuedFairValue_iI_pn5n6_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardTypeAxis__custom--AcquisitionRestrictedCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zbQyiyN8LFj1"><ix:nonFraction name="STRM:BusinessAcquisitionEquityInterestIssuedFairValue" contextRef="AsOf2021-08-16_custom_AveleadConsultingLLCMember_custom_AcquisitionRestrictedCommonStockMember_custom_UnitPurchaseAgreementMember" id="Fact000909" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.5</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, based on a 30-day average of the closing
price of the Company&#8217;s common stock prior to the closing date. The SaaS Contingent Consideration and the Renewal Contingent Consideration
described in more detail below were included in the UPA as potential future consideration for the Transaction. These are reflected on
the Company&#8217;s consolidated balance sheet as &#8220;Acquisition earnout liability.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
contingent consideration is comprised of &#8220;SaaS Contingent Consideration&#8221; and &#8220;Renewal Contingent Consideration&#8221;
which are described in more detail as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    SaaS Contingent Consideration is calculated based upon Avelead&#8217;s recurring SaaS revenue recognized during the first and second
    year following the closing of the Transaction. The Company will pay the SaaS Contingent Consideration as follows: (i) <span id="xdx_90A_ecustom--PaymentOfSaasContingentConsiderationInCashPercentage_iI_pid_dp_uPure_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zMOz2yXFDH6k" title="Payment of SaaS contingent consideration in cash, percentage"><ix:nonFraction name="STRM:PaymentOfSaasContingentConsiderationInCashPercentage" contextRef="AsOf2021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember" id="Fact000911" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% in cash
    and (ii) <span id="xdx_90C_ecustom--PaymentOfSaasContingentConsiderationInSharesPercentage_iI_pid_dp_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_z3Wg896PKv6h" title="Payment of SaaS contingent consideration in cash, percentage"><ix:nonFraction name="STRM:PaymentOfSaasContingentConsiderationInSharesPercentage" contextRef="AsOf2021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember" id="Fact000913" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% in shares of Company common stock valued at the time the earnout is paid subject to a collar, as described below.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 74.2pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--FirstYearPaymentOfSaasContingentConsiderationDescription_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_z3WMjwobknx" title="First year payment of SaaS contingent consideration, description"><ix:nonNumeric contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember" id="Fact000915" name="STRM:FirstYearPaymentOfSaasContingentConsiderationDescription">The
    first year SaaS Contingent Consideration was calculated as 75% of Avelead&#8217;s recognized SaaS revenue from September 1, 2021
    to August 31, 2022. The first-year payment was subject to a deduction of $665,000 spread equally between the cash and common stock
    portion of the earnout consideration. Assuming that Avelead was within 80% of its forecasted SaaS revenue in the first year earnout,
    the Company agreed to a floor and ceiling on the value of the Company&#8217;s restricted common stock issued as consideration for
    the earnout. That collar had a floor of $3.50 per share and a ceiling of $5.50 per share for the first year earnout. The first year
    SaaS Contingent Consideration was paid on November 21, 2022, as discussed in more detail below.</ix:nonNumeric></span> </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--SecondYearPaymentOfSaasContingentConsiderationDescription_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zYuX1Amlmfv3" title="Second year payment of SaaS contingent consideration, description"><ix:nonNumeric contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember" id="Fact000917" name="STRM:SecondYearPaymentOfSaasContingentConsiderationDescription">The
    second year SaaS Contingent Consideration was calculated as 40% of Avelead&#8217;s recognized SaaS revenue from September 1, 2022
    to August 31, 2023. Assuming that Avelead was within 80% of its forecasted SaaS revenue in the second year earnout, the Company agreed
    to a floor and ceiling on the Company&#8217;s restricted common stock issued as consideration for the earnout. That collar had a
    floor of $4.50 per share and a ceiling of $6.50 per share for the second year earnout. The second year SaaS Contingent Consideration
    remained outstanding as of January 31, 2024, as the Company and the Sellers work towards a resolution regarding the payment of the
    second year SaaS Contingent Consideration.</ix:nonNumeric> </span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_90A_ecustom--ForecastedRevenueDescription_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zPpBj5hYLXzf" title="Forecasted revenue description"><ix:nonNumeric contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember" id="Fact000919" name="STRM:ForecastedRevenueDescription">If
    Avelead does not achieve 80% of its forecasted revenue, the price per share will revert back to the Company&#8217;s market price
    based upon a 30-day average.</ix:nonNumeric></span></i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 74.2pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
    &#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--RenewalContingentConsiderationDescription_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_z9OYtmiVY2qe" title="Renewal contingent consideration, description"><ix:nonNumeric contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember" id="Fact000921" name="STRM:RenewalContingentConsiderationDescription">The
    Renewal Contingent Consideration was tied directly to a successful renewal of a specific client of Avelead. To meet the definition
    of a renewal, Avelead was required to achieve a minimum threshold of contracted revenue in an updated, annual, renewed contract with
    the specified client. The renewal occurred on or about June 1, 2022 and June 1, 2023. The Renewal Contingent Consideration was payable
    in shares of Company restricted common stock valued as of the date of closing. The Renewal Contingent Consideration is either earned
    or not earned based upon the renewal of the specified client at the minimum amount of contracted revenue. There is no pro-ration
    of the underlying Renewal Contingent Consideration. On November 21, 2022, the Company issued 627,746 shares of restricted common
    stock to the Sellers in connection with the first year Renewal Contingent Consideration. The second year Renewal Contingent Consideration
    remained outstanding as of January 31, 2024, as the Company and the Sellers work towards a resolution regarding the payment of the
    second year Renewal Contingent Consideration.</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2022, the Company made the first year earnout payments and issued shares of restricted common stock to the Sellers in accordance
with the UPA. In connection with the first year earnout payment, the Company made an aggregate cash payment of $<span id="xdx_909_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_c20221120__20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardDateAxis__custom--FirstYearEarnoutMember_z49niAWMqlBg" title="Business combination, cash payments"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_AveleadConsultingLLCMember_custom_FirstYearEarnoutMember" id="Fact000923" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,012,000</ix:nonFraction></span> and issued
<span id="xdx_908_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20221120__20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardDateAxis__custom--FirstYearEarnoutMember_zzRDn1IGFC2f" title="Business acquisition, equity interest issued or issuable, number of shares"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_AveleadConsultingLLCMember_custom_FirstYearEarnoutMember" id="Fact000925" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,243,292</ix:nonFraction></span> unregistered securities in the form of restricted common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--AwardDateAxis__custom--FirstYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_z1a40Gt4ZmPi" title="Common stock par or stated value per share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-11-21_custom_UnitPurchaseAgreementMember_custom_FirstYearEarnoutMember_custom_AveleadConsultingLLCMember" id="Fact000927" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share (&#8220;restricted common stock&#8221;),
for the SaaS Contingent Consideration and issued <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20221120__20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--RenewalContingentConsiderationMember__us-gaap--AwardDateAxis__custom--FirstYearEarnoutMember_zNYU9YI7nPt7" title="Sale of stock number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_RenewalContingentConsiderationMember_custom_FirstYearEarnoutMember" id="Fact000929" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">627,746</ix:nonFraction></span> shares of restricted common stock for the Renewal Contingent Consideration.
The estimated aggregate value of the first year earnout payment was $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20221120__20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--AwardDateAxis__custom--FirstYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zn6xY44bmVrg" title="Sale of stock consideration"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_AveleadConsultingLLCMember_custom_FirstYearEarnoutMember" id="Fact000931" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000,000</ix:nonFraction></span> with respect to the SaaS Contingent Consideration and
$<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20221120__20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--RenewalContingentConsiderationMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zRvUhSxrupE5" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_RenewalContingentConsiderationMember_custom_AveleadConsultingLLCMember" id="Fact000933" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> with respect to the Renewal Contingent Consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 31, 2024, the Company has not made the second year earnout payments to the Sellers or issued shares of common stock in connection
therewith. In connection with the second year earnout payment, the Company has estimated cash payments of $<span id="xdx_901_eus-gaap--PaymentsToAcquireBusinessesGross_c20230201__20240131__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zrG109Fkx30a"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="From2023-02-012024-01-31_custom_SecondYearEarnoutMember_custom_AveleadConsultingLLCMember" id="Fact000934" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,214,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and will issue <span id="xdx_90B_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20230201__20240131__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_z1Xaz1O44iii"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2023-02-012024-01-31_custom_SecondYearEarnoutMember_custom_AveleadConsultingLLCMember" id="Fact000935" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">961,640</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of restricted common stock for the SaaS
Contingent Consideration and <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230201__20240131__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zP9G4OCg78r9"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-02-012024-01-31_custom_SecondYearEarnoutMember_custom_AveleadConsultingLLCMember" id="Fact000936" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">627,746</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of restricted common stock for the Renewal
Contingent Consideration. The estimated aggregate value of the second year earnout payment is $<span id="xdx_907_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_c20240131__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_za2lbhNYsX3g"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2024-01-31_custom_SecondYearEarnoutMember_custom_AveleadConsultingLLCMember" id="Fact000937" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,550,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the SaaS Contingent Consideration and $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230201__20240131__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember_zs5shzbs4PK8"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-02-012024-01-31_custom_SecondYearEarnoutMember_custom_AveleadConsultingLLCMember" id="Fact000938" format="ixt:numdotdecimal" decimals="0" unitRef="USD">244,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the Renewal Contingent Consideration. The
Company and the Sellers reached an agreement to defer the cash portion of the SaaS Contingent Consideration and Renewal Contingent Consideration
payments over time through October 31, 2024. On March 27, 2024, the Company issued <span id="xdx_900_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240326__20240327__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zOJJ8hYvl6qa"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2024-03-262024-03-27_custom_SecondYearEarnoutMember_us-gaap_SubsequentEventMember_custom_AveleadConsultingLLCMember" id="Fact000939" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">961,640</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of restricted common stock to the Sellers
for the SaaS Contingent Consideration and <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240326__20240327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zzXxlfFPzjM3"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-03-262024-03-27_custom_SecondYearEarnoutMember_us-gaap_SubsequentEventMember_custom_AveleadConsultingLLCMember" id="Fact000940" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">627,746</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of restricted common stock for the Renewal
Contingent Consideration. These liabilities are reflected at the fair value of the future commitment on the Company&#8217;s consolidated
balance sheet, as Acquisition Earnout Liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement and a separation agreement with each of the two Sellers. Acquisition-related costs
include the cost of a two-year separation agreement with one of the Sellers. The separation agreement was expensed at the closing of
the transaction as there were no material future obligations of the Seller to the Company within acquisition-related costs. The
employment agreement with the other Seller had a two-year term and entitled the Seller to six-months separation pay in the event of
termination without cause. The expense for the employment agreement is recognized ratably over the service period customary with
other employment agreements within selling, general, and administrative expense. On September 1, 2023, the Company terminated
the employment agreement. In exchange for a general release from the Seller, the Company agreed to accelerate the vesting of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230901__20230901__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zTzrifl80XDi"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-09-012023-09-01_custom_AveleadConsultingLLCMember" id="Fact000941" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">outstanding
and unvested shares of restricted common stock of the Company previously granted to the Seller, subject to such Seller&#8217;s
non-revocation of a general release of claims against the Company.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000943" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_801_eus-gaap--LesseeOperatingLeasesTextBlock_zZ6L7M7dB6D5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
4 &#8212; <span id="xdx_829_zORiPJxz1Ht5">OPERATING LEASES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine whether an arrangement is a lease at inception. Right-of-use assets represent our right to use an underlying asset for the
lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use
assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term.
Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate for the expected remaining lease
term at commencement date for new and existing leases in determining the present value of future lease payments. Operating lease expense
is recognized on a straight-line basis over the lease term. The Company has moved to a virtual office model and does not have a physical
office space. Membership agreements and daily space rentals are leveraged by the Company when groups need to meet in person with the
costs expensed as incurred. As of January 31, 2024, the Company recorded $<span id="xdx_90D_eus-gaap--RentalProperties_iI_c20240131_z2mmkkD3VD8g" title="Related to space rental"><ix:nonFraction name="us-gaap:RentalProperties" contextRef="AsOf2024-01-31" id="Fact000945" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span> related to such space
rentals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Alpharetta
Office Lease</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The Company entered into a lease
for office space in Alpharetta, Georgia, on March 1, 2020. The lease expired on March 31, 2023. At inception, the Company recorded a right-of
use asset of $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20211031_zuP0bsIHz5Kc"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-10-31" id="Fact000946" format="ixt:numdotdecimal" decimals="0" unitRef="USD">540,000</ix:nonFraction></span>, and related current and long-term operating lease obligation in the accompanying consolidated balance sheet. As
of January 31, 2023, operating lease right-of use assets totaled $<span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20230131_zMQCNrdm2jBk"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-01-31" id="Fact000947" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,000</ix:nonFraction></span>, and the associated lease liability of $<span id="xdx_903_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20230131_z1GAL0ABNyY8"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-01-31" id="Fact000948" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></span> is included in
current liabilities. The Company used a discount rate of <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20230131_zeDFLRWvNKX6"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2023-01-31" id="Fact000949" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.5</ix:nonFraction></span>% to determine the lease liability. As of January 31, 2024 and 2023, the Company
had lease operating costs of approximately $<span id="xdx_90C_eus-gaap--OperatingLeaseCost_c20230201__20240131_zXRatNaUCtw2"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-02-01to2024-01-31" id="Fact000950" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,000</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--OperatingLeaseCost_c20220201__20230131_zLKYqNB83osg"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-02-012023-01-31" id="Fact000951" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,000</ix:nonFraction></span>, respectively. The Company paid cash of approximately $<span id="xdx_908_eus-gaap--OperatingLeasePayments_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--AlpharettaOfficeLeaseMember_zQK5b0xMCyhk"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-02-012024-01-31_custom_AlpharettaOfficeLeaseMember" id="Fact000952" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,000</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--OperatingLeasePayments_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--AlpharettaOfficeLeaseMember_z6126frP7vGg"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-02-012023-01-31_custom_AlpharettaOfficeLeaseMember" id="Fact000953" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,000</ix:nonFraction></span>
for the lease in fiscal 2023 and fiscal 2022, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2021, the Company entered into an agreement with a third-party to sublease its office space in Alpharetta, Georgia, (the
&#8220;Sublease Agreement&#8221;). The sublease term is for <span id="xdx_901_ecustom--SubleaseTerm_dtM_c20210929__20211002__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember_z3Hdl6GBoTVc" title="Sublease, term"><ix:nonNumeric contextRef="From2021-09-292021-10-02_custom_SubleaseAgreementMember" format="ixt-sec:durmonth" id="Fact000955" name="STRM:SubleaseTerm">18</ix:nonNumeric></span>
months which coincides with the Company&#8217;s underlying lease (see below). The Company received $<span id="xdx_90E_eus-gaap--SubleaseIncome_c20210929__20211002__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember_zp86tu3avmI2" title="Sublease income"><ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="From2021-09-292021-10-02_custom_SubleaseAgreementMember" id="Fact000957" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,000</ix:nonFraction></span>
from the sublessee over the term of the sublease. The sublease did not relieve the Company of its original obligation under the
lease, and therefore the Company did not adjust the operating lease right-of-use asset and related liability. The Company incurred
an amount of fees and expenses to enter into the Sublease Agreement that were recorded as &#8220;acquisition-related costs&#8221;
for fiscal 2021. As of January 31, 2024, the Company recorded $<span id="xdx_90D_eus-gaap--OtherIncome_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember_z2p1ft3suaAh" title="Other income related to sublease"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2023-02-012024-01-31_custom_SubleaseAgreementMember" id="Fact000959" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,000</ix:nonFraction></span>
as other income related to the sublease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Suwanee
Office Lease</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
acquiring Avelead on August 16, 2021 (refer to Note 3 &#8211; Business Combination), the Company assumed an operating
lease agreement for the corporate office space of Avelead. The 36-month term lease commenced March 1, 2019, and initially expired on
<span id="xdx_905_eus-gaap--LeaseExpirationDate1_dd_c20210814__20210816__us-gaap--TypeOfArrangementAxis__custom--SuwaneeOfficeLeaseMember_zHbO3yR6pZM3" title="Lease expiration date"><ix:nonNumeric contextRef="From2021-08-142021-08-16_custom_SuwaneeOfficeLeaseMember" format="ixt:datemonthdayyearen" id="Fact000961" name="us-gaap:LeaseExpirationDate1">February 28, 2022</ix:nonNumeric></span>. As of January 31, 2024, the Company recorded $<span id="xdx_90B_eus-gaap--PaymentsForRent_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SuwaneeOfficeLeaseMember_z71DgwKydOKh" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-02-012024-01-31_custom_SuwaneeOfficeLeaseMember" id="Fact000963" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span> in rent expense. The lessor is an entity controlled by one of
the Sellers that was employed by the Company until August 2023. In February 2022, the Company renewed the lease for twelve months. The
Company made monthly lease payments of $<span id="xdx_90D_eus-gaap--OperatingLeasePayments_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SuwaneeOfficeLeaseMember_zhqUe2Q07mXj" title="Operating lease, payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-02-012024-01-31_custom_SuwaneeOfficeLeaseMember" id="Fact000965" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,999</ix:nonFraction></span> for a total of $<span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_c20230228__us-gaap--TypeOfArrangementAxis__custom--SuwaneeOfficeLeaseMember_zXDQKxe118l" title="Operating lease"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-02-28_custom_SuwaneeOfficeLeaseMember" id="Fact000967" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,984</ix:nonFraction></span> over the term of the lease. The lease expired on February 28, 2023,
and was not renewed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000969" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zsxCJkOLdqxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
5 &#8212; <span id="xdx_829_zYHz7clzYlC3">DEBT</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact000971" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfDebtTableTextBlock_zZTqivM7mC6l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
principal balances on debt consisted of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zIytIO7PNH0l" style="display: none">SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240131_zacxl86TTnN4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230131_zRpV9I2nBiVh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzuRq_zw3eOnhiWl2h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Term loan</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-01-31" id="Fact000973" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-01-31" id="Fact000974" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,750,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinancingCostPayable_iI_maLTDzuRq_z5rOfXEcrXl2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><p style="margin: 0">Financing cost payable</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="STRM:FinancingCostPayable" contextRef="AsOf2024-01-31" id="Fact000976" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,000</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:FinancingCostPayable" contextRef="AsOf2023-01-31" id="Fact000977" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredFinancingCost_iNI_di_msLTDzuRq_zd3Zcy02MIQ6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Deferred financing cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="STRM:DeferredFinancingCost" contextRef="AsOf2024-01-31" id="Fact000979" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="STRM:DeferredFinancingCost" contextRef="AsOf2023-01-31" id="Fact000980" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--LongTermDebt_iTI_mtLTDzuRq_z56OAhOzgq42" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2024-01-31" id="Fact000982" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,066,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2023-01-31" id="Fact000983" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,714,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LongTermDebtCurrent_iNI_di_zWlNIc4uEZT1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: Current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2024-01-31" id="Fact000985" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2023-01-31" id="Fact000986" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iTI_zvHBV6E31KO2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Non-current portion of debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2024-01-31" id="Fact000988" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,566,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2023-01-31" id="Fact000989" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,964,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zlautnZKsq8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Term
Loan Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 26, 2021, the Company and its subsidiaries entered into the Loan Agreement with WAB. Pursuant
to the Loan Agreement, WAB agreed to provide the Company and its subsidiaries with a term loan facility in the maximum principal amount
of $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--WesternAllianceBankMember_zolzc6KMxtG3" title="Line of credit facility, maximum borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2021-08-26_custom_LoanAgreementMember_custom_WesternAllianceBankMember" id="Fact000991" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000,000</ix:nonFraction></span>. Amounts outstanding under the term loan portion of the Loan Agreement bear interest at a per annum rate equal to the
Prime Rate (as published in The Wall Street Journal) plus <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20210826__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zvnjpTPQ0A9e" title="Debt instrument, interest rate, effective percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2021-08-26_us-gaap_PrimeRateMember" id="Fact000993" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.5</ix:nonFraction></span>%, with a Prime &#8220;floor&#8221; rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210826__us-gaap--VariableRateAxis__us-gaap--BaseRateMember_zmoy6yfsNuyj" title="Debt instrument, interest rate, stated percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-08-26_us-gaap_BaseRateMember" id="Fact000995" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.25</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement has a five-year term, and the maximum principal amount was advanced in a single-cash advance on or about the closing date.
Interest accrued under the Loan Agreement is due monthly, and the Company is required to make monthly interest-only payments through
the one-year anniversary of the closing date. From the first anniversary of the closing date through the maturity date, the Company is
required to make monthly payments of principal and interest that increase over the term of the agreement. The Loan Agreement requires
principal repayments on the anniversary date of the closing of the debt agreement of $<span id="xdx_906_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--WesternAllianceBankMember_zMv6ZNbCxWF2" title="Long term debt, maturity, year two"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="AsOf2021-08-26_custom_LoanAgreementMember_custom_WesternAllianceBankMember" id="Fact000997" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> in the second year, $<span id="xdx_902_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--WesternAllianceBankMember_zWlDZJVGh1af" title="Long term debt, maturity, year three"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="AsOf2021-08-26_custom_LoanAgreementMember_custom_WesternAllianceBankMember" id="Fact000999" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> in the third
year, $<span id="xdx_90D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--WesternAllianceBankMember_zG9kAWnzotu2" title="Long term debt, maturity, year four"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="AsOf2021-08-26_custom_LoanAgreementMember_custom_WesternAllianceBankMember" id="Fact001001" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span> in the fourth year, and $<span id="xdx_90A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--BridgeBankMember_zQPu2yxZHzmh" title="Long term debt, maturity, year five"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextRef="AsOf2021-08-26_custom_SecurityAgreementMember_custom_BridgeBankMember" id="Fact001003" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span> in the fifth year, respectively, with the remaining outstanding principal balance
and all accrued but unpaid interest due in full on the maturity date. The Loan Agreement may also require early repayments if certain
conditions are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded $<span id="xdx_908_eus-gaap--DeferredOfferingCosts_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zfFHRTnmpuu" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2021-08-26_custom_LoanAgreementMember" id="Fact001005" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,000</ix:nonFraction></span> in deferred financing costs related to the Loan Agreement. These deferred financing costs are being amortized
over the term of the loan. The Company will also incur $<span id="xdx_90A_eus-gaap--AmortizationOfFinancingCosts_c20210825__20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zVZ9UOeEzA46" title="Amortization of debt issuance costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2021-08-252021-08-26_custom_LoanAgreementMember" id="Fact001007" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span> in financing costs at the earlier of the term date of the loan, or pre-payment.
These costs are being accreted, through interest expense, to the full value of the $<span id="xdx_902_eus-gaap--AccretionExpense_c20210825__20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z8xJYZF8FsI5" title="Accretion expense"><ix:nonFraction name="us-gaap:AccretionExpense" contextRef="From2021-08-252021-08-26_custom_LoanAgreementMember" id="Fact001009" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span> over the term of the loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Debt
Modification and Revolving Line of Credit</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 29, 2022, the Company executed the Second Modification (the &#8220;Second Modification&#8221;) to the Second Amended and Restated
Loan and Security Agreement (as amended and modified, the &#8220;Loan Agreement&#8221;). The Second Modification expanded the Company&#8217;s
total borrowing to include a $<span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zbZxdumpgfDb" title="Line of credit facility, maximum borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2022-11-29_custom_SecondModificationAgreementMember" id="Fact001011" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span> revolving line of credit. The revolving line of credit is co-terminus with the term loan and
matures on <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zzY8SicthUyk" title="Line of credit facility, matures"><ix:nonNumeric contextRef="From2022-11-282022-11-29_custom_SecondModificationAgreementMember" format="ixt:datemonthdayyearen" id="Fact001013" name="us-gaap:DebtInstrumentMaturityDate">August 26, 2026</ix:nonNumeric></span>. There are no requirements to draw on the line of credit. Amounts outstanding under the line of credit portion
of the Loan Agreement bear interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20221129__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_z1sKUFS2jD6h" title="Debt instrument, interest rate, effective percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2022-11-29_us-gaap_PrimeRateMember_custom_SecondModificationAgreementMember" id="Fact001015" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.5</ix:nonFraction></span>%,
with a Prime &#8220;floor&#8221; rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20221129__us-gaap--VariableRateAxis__us-gaap--BaseRateMember__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zTdGrQuN08lk" title="Debt instrument, interest rate, effective percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2022-11-29_us-gaap_BaseRateMember_custom_SecondModificationAgreementMember" id="Fact001017" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.25</ix:nonFraction></span>%. The Second Modification also amended the covenants of the Company under the Loan Agreement.
At January 31, 2024, there was a $<span id="xdx_90C_eus-gaap--LongTermLineOfCredit_iI_c20240131_zVOo7cyBolKa" title="Line of credit"><ix:nonFraction name="us-gaap:LongTermLineOfCredit" contextRef="AsOf2024-01-31" id="Fact001019" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,000</ix:nonFraction></span> balance outstanding on the revolving line of credit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Second Modification includes customary financial covenants as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Minimum
    Cash. </b><span id="xdx_902_eus-gaap--DebtInstrumentCovenantDescription_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zAi2y4nfay61" title="Debt financial covenants, description"><ix:nonNumeric contextRef="From2022-11-282022-11-29_custom_SecondModificationAgreementMember" id="Fact001021" name="us-gaap:DebtInstrumentCovenantDescription">Borrowers shall, at all times, maintain unrestricted cash in an amount not less than Two Million Dollars ($2,000,000).</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
    Debt to ARR Ratio. </b>Borrowers&#8217; Maximum Debt to ARR Ratio, measured on a quarterly basis as of the last day of each fiscal
    quarter, shall not be greater than the amount set forth under the heading &#8220;Maximum Debt to ARR Ratio&#8221; as of, and for
    each of the dates appearing adjacent to such &#8220;Maximum Debt to ARR Ratio&#8221;.</span></td></tr>
  </table>
<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001023" name="STRM:ScheduleOfMaximumDebtToARRRatioTableTextBlock"><p id="xdx_89C_ecustom--ScheduleOfMaximumDebtToARRRatioTableTextBlock_zFsyON9BqLI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z3IDq1bf3Ssi" style="display: none">SCHEDULE OF MAXIMUM DEBT TO ARR RATIO</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 82%; font-weight: bold">Quarter Ending</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum Debt to</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARR Ratio</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>October 31, 2022</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyTwoMember__srt--RangeAxis__srt--MinimumMember_zkYZyp1qcArk" title="Maximum Debt to ARR Ratio"><ix:nonFraction name="STRM:MaximumDebtToArrRatio" contextRef="AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandAndTwentyTwoMember_srt_MinimumMember" id="Fact001025" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.80</ix:nonFraction></span> to <span id="xdx_90A_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyTwoMember__srt--RangeAxis__srt--MaximumMember_zS6lLRAspk34" title="Maximum Debt to ARR Ratio"><ix:nonFraction name="STRM:MaximumDebtToArrRatio" contextRef="AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandAndTwentyTwoMember_srt_MaximumMember" id="Fact001027" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>January 31, 2023</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_z0nfek6Cs6Mk" title="Maximum Debt to ARR Ratio"><ix:nonFraction name="STRM:MaximumDebtToArrRatio" contextRef="AsOf2024-01-31_custom_JanuaryThirtyOneTwoThousandTwentyThreeMember_srt_MinimumMember" id="Fact001029" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.70</ix:nonFraction></span> to <span id="xdx_90B_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_zGxFFbwbwcJf" title="Maximum Debt to ARR Ratio"><ix:nonFraction name="STRM:MaximumDebtToArrRatio" contextRef="AsOf2024-01-31_custom_JanuaryThirtyOneTwoThousandTwentyThreeMember_srt_MaximumMember" id="Fact001031" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>April 30, 2023</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_zjdTm3Km4f02" title="Maximum Debt to ARR Ratio"><ix:nonFraction name="STRM:MaximumDebtToArrRatio" contextRef="AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyThreeMember_srt_MinimumMember" id="Fact001033" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.65</ix:nonFraction></span> to <span id="xdx_90B_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_z5yhyJiREnbi" title="Maximum Debt to ARR Ratio"><ix:nonFraction name="STRM:MaximumDebtToArrRatio" contextRef="AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyThreeMember_srt_MaximumMember" id="Fact001035" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>July 31, 2023</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_zlDVmHjdrCC9" title="Maximum Debt to ARR Ratio"><ix:nonFraction name="STRM:MaximumDebtToArrRatio" contextRef="AsOf2024-01-31_custom_JulyThirtyOneTwoThousandTwentyThreeMember_srt_MinimumMember" id="Fact001037" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.60</ix:nonFraction></span> to <span id="xdx_908_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_zIU2Q1CZLso3" title="Maximum Debt to ARR Ratio"><ix:nonFraction name="STRM:MaximumDebtToArrRatio" contextRef="AsOf2024-01-31_custom_JulyThirtyOneTwoThousandTwentyThreeMember_srt_MaximumMember" id="Fact001039" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>October 31, 2023</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_z2V2Wox2jlPh" title="Maximum Debt to ARR Ratio"><ix:nonFraction name="STRM:MaximumDebtToArrRatio" contextRef="AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandTwentyThreeMember_srt_MinimumMember" id="Fact001041" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.55</ix:nonFraction></span> to <span id="xdx_90B_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_zjZmiRMW8Ztd" title="Maximum Debt to ARR Ratio"><ix:nonFraction name="STRM:MaximumDebtToArrRatio" contextRef="AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandTwentyThreeMember_srt_MaximumMember" id="Fact001043" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>January 31, 2024</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyFourMember__srt--RangeAxis__srt--MinimumMember_zBWwJwWdAdPd" title="Maximum Debt to ARR Ratio"><ix:nonFraction name="STRM:MaximumDebtToArrRatio" contextRef="AsOf2024-01-31_custom_JanuaryThirtyOneTwoThousandTwentyFourMember_srt_MinimumMember" id="Fact001045" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.50</ix:nonFraction></span> to <span id="xdx_90A_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyFourMember__srt--RangeAxis__srt--MaximumMember_zMtLsRQmtJC4" title="Maximum Debt to ARR Ratio"><ix:nonFraction name="STRM:MaximumDebtToArrRatio" contextRef="AsOf2024-01-31_custom_JanuaryThirtyOneTwoThousandTwentyFourMember_srt_MaximumMember" id="Fact001047" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zHzogOIpf796" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
    Debt to Adjusted EBITDA Ratio. </b>Commencing with the quarter ending April 30, 2024, Borrowers&#8217; Maximum Debt to Adjusted EBITDA
    Ratio, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4) quarter period then ended,
    shall not be greater than the amount set forth under the heading &#8220;Maximum Debt to Adjusted EBITDA Ratio&#8221; as of, and for
    each of the dates appearing adjacent to such &#8220;Maximum Debt to Adjusted EBITDA Ratio&#8221;.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001049" name="STRM:ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock"><p id="xdx_897_ecustom--ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock_z2gxz2BthnRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z751i3gbxyBb" style="display: none">SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 82%; font-weight: bold">Quarter Ending</td><td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center">Maximum Debt to <br/> Adjusted EBITDA <br/> Ratio</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>April 30, 2024</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFourMember__srt--RangeAxis__srt--MaximumMember_zkR455tskqui" title="Maximum Debt to Adjusted EBITDA Ratio"><ix:nonFraction name="STRM:MaximumDebtToAdjustedEbitdaRatio" contextRef="AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyFourMember_srt_MaximumMember" id="Fact001051" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.50</ix:nonFraction></span> to <span id="xdx_906_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFourMember__srt--RangeAxis__srt--MinimumMember_zoRTWmnmgy78" title="Maximum Debt to Adjusted EBITDA Ratio"><ix:nonFraction name="STRM:MaximumDebtToAdjustedEbitdaRatio" contextRef="AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyFourMember_srt_MinimumMember" id="Fact001053" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">July 31, 2024 and on the last day of each quarter, thereafter</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFourAndThereafterMember__srt--RangeAxis__srt--MaximumMember_zNn7v3KAhd88" title="Maximum Debt to Adjusted EBITDA Ratio"><ix:nonFraction name="STRM:MaximumDebtToAdjustedEbitdaRatio" contextRef="AsOf2024-01-31_custom_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember_srt_MaximumMember" id="Fact001055" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.00</ix:nonFraction></span> to <span id="xdx_908_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFourAndThereafterMember__srt--RangeAxis__srt--MinimumMember_zVr7Scg6blh1" title="Maximum Debt to Adjusted EBITDA Ratio"><ix:nonFraction name="STRM:MaximumDebtToAdjustedEbitdaRatio" contextRef="AsOf2024-01-31_custom_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember_srt_MinimumMember" id="Fact001057" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_ziSMZYVA39b1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed
    Charge Coverage Ratio</b>. Commencing with the quarter ending April 30, 2024, Borrowers shall maintain a Fixed Charge Coverage Ratio
    of not less than <span id="xdx_90E_ecustom--FixedChargeCoverageRatio_iI_pid_dp_uPure_c20240131__us-gaap--TypeOfArrangementAxis__custom--SecondAmendedAndRestatedLoanAgreementMember__srt--RangeAxis__srt--MaximumMember_zstQE2rV7Vya" title="Fixed charge coverage ratio"><ix:nonFraction name="STRM:FixedChargeCoverageRatio" contextRef="AsOf2024-01-31_custom_SecondAmendedAndRestatedLoanAgreementMember_srt_MaximumMember" id="Fact001059" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.20</ix:nonFraction></span> to <span id="xdx_90B_ecustom--FixedChargeCoverageRatio_iI_pid_dp_uPure_c20240131__us-gaap--TypeOfArrangementAxis__custom--SecondAmendedAndRestatedLoanAgreementMember__srt--RangeAxis__srt--MinimumMember_ze42ulTljAX2" title="Fixed charge coverage ratio"><ix:nonFraction name="STRM:FixedChargeCoverageRatio" contextRef="AsOf2024-01-31_custom_SecondAmendedAndRestatedLoanAgreementMember_srt_MinimumMember" id="Fact001061" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span>, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4)
    quarter period then ended.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement also includes customary negative covenants, subject to exceptions, which limit transfers, capital expenditures, indebtedness,
certain liens, investments, acquisitions, dispositions of assets, restricted payments, and the business activities of the Company, as
well as customary representations and warranties, affirmative covenants and events of default, including cross defaults and a change
of control default. The line of credit also is subject to customary prepayment requirements. For the period ended January 31, 2024, the
Company was not in compliance with the Maximum Debt to ARR Ratio covenant pursuant to the Second Modification; however, on February 7,
2024, the Company was provided a waiver exception for being non-compliant. (Refer to Note 14 &#8211; Subsequent to our consolidated financial
statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; for additional information.). Substantially
all the assets of the Company are collateralized by the Loan Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded $<span id="xdx_903_eus-gaap--DeferredOfferingCosts_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_ztfOiIrVBthh" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2022-11-29_custom_SecondModificationAgreementMember" id="Fact001063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></span> in deferred financing costs related to the Second Modification. These deferred financing costs are being amortized
over the remaining term of the loan. The Company also incurred $<span id="xdx_90F_eus-gaap--AmortizationOfFinancingCosts_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zdXe0A0VdW5k" title="Amortization of debt issuance costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2022-11-282022-11-29_custom_SecondModificationAgreementMember" id="Fact001065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> in financing costs at the earlier of the term date of the loan,
or pre-payment. These costs are being accreted, through interest expense, to the full value of the $<span id="xdx_902_eus-gaap--AccretionExpense_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zYaSLtehLtff" title="Accretion expense"><ix:nonFraction name="us-gaap:AccretionExpense" contextRef="From2022-11-282022-11-29_custom_SecondModificationAgreementMember" id="Fact001067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> over the remaining term of
the loan. The full value of $<span id="xdx_903_eus-gaap--AccretionExpense_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zeeRIhZKuXXh" title="Accretion expense"><ix:nonFraction name="us-gaap:AccretionExpense" contextRef="From2022-11-282022-11-29_custom_LoanAgreementMember" id="Fact001069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> includes the $<span id="xdx_906_eus-gaap--AmortizationOfFinancingCosts_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zvowiqlzqXJ4" title="Amortization of debt issuance costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2022-11-282022-11-29_custom_LoanAgreementMember" id="Fact001071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span> costs incurred in connection with the Loan Agreement (see below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 7, 2024, the Company executed the Third Modification and Waiver (the &#8220;Third Modification&#8221;) to the Loan Agreement.
Refer to Note 14 &#8211; Subsequent Events to our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements
and Supplementary Data&#8221; for additional information regarding the Third Modification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001073" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><p id="xdx_803_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zwOGYfPl1Qci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
6 &#8212; <span id="xdx_82D_zUp5YMYXKat6">GOODWILL AND INTANGIBLE ASSETS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Goodwill</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001075" name="us-gaap:ScheduleOfGoodwillTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zZardVLaIU58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
changes in the carrying amount of goodwill were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zxZmo1Gj5IRe" style="display: none">SCHEDULE OF CARRYING AMOUNT OF GOODWILL</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; font-weight: bold">Balance as of January 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Goodwill_iS_c20230201__20240131_zlxNipDbwq9l" title="Beginning Balance" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2023-01-31" id="Fact001077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,089,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--GoodwillImpairmentLoss_iN_di_c20230201__20240131_zyFcjkFtMFB7" title="Impairment" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-02-01to2024-01-31" id="Fact001079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,813,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance as of January 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--Goodwill_iE_c20230201__20240131_zsZz6nlQnf98" title="Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2024-01-31" id="Fact001081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,276,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z27e2JlM9LW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, the Company was notified by a legacy client of its intent to not renew its contract as of its expiration on December 31,
2023. At that time, the Company elected to accelerate the execution of a planned strategic restructuring that was designed to reduce
costs while maintaining the Company&#8217;s ability to expand its SaaS business. Both the client termination and the execution of the
strategic restructuring were announced on October 16, 2023. Following these announcements, the Company&#8217;s share price declined significantly.
Based on these events (collectively, the &#8220;Triggering Events&#8221;), the Company identified indicators of possible impairment and
initiated testing using a valuation date of October 31, 2023. The impairment tests were conducted under guidance of ASC Topic 360, Impairment
and Disposal of Long-Lived Assets (&#8220;ASC 360&#8221;) for certain long-lived assets, including capitalized contract costs, developed
technology, client relationships and trade names, and in accordance with ASC Topic 350, Intangibles &#8211; Goodwill and Other (&#8220;ASC
350&#8221;) with respect to the reporting unit&#8217;s goodwill.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that, effective January 31, 2023, it had one reporting unit for purposes of evaluation of goodwill. Based on the Triggering
Events and in conjunction with the preparation of the Company&#8217;s financial statements for the three and nine months ended October
31, 2023, the Company tested the reporting unit&#8217;s goodwill for possible impairment as of October 31, 2023. The testing for impairment
was performed under the guidance of ASC 350. The testing utilized a discounted debt-free net cash flow (&#8220;DCF&#8221;) method under
the income approach and the market capitalization method (&#8220;MCM&#8221;) under the market approach. The sum of the weighted values
of each method was used to derive the fair value of the Company&#8217;s equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MCM calculates the aggregate market value of the Company based on the total number of shares outstanding and the current market price
of the shares as of the valuation date. Data on similar mergers and acquisitions within the healthcare technology sector are observed
to determine control premium that represents a stock premium percentage offered by an acquirer to a public company. The control premium
applied to the aggregate market value represents MCM calculated fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DCF incorporates the use of projected financial information and a discount rate using a weighted average cost of capital with cost of
equity estimated based on the capital asset pricing model. The cash-flow projections are based on financial forecasts developed by management
that include forecasts of future operating results based on internal budgets and strategic plans to invest in working capital to support
anticipated revenue growth. External factors and business conditions are considered by management when setting the long-term growth rates.
The selected discount rate considers the risk and nature of the reporting unit&#8217;s cash flows and the rates of return market participants
would require to invest their capital in the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company concluded that its goodwill was impaired based on the weighted combination of the DCF and MCM value estimates which resulted
in a calculated fair value lower than the equity carrying value. The Company recorded an impairment of goodwill in the amount of $<span id="xdx_902_eus-gaap--GoodwillImpairmentLoss_c20230201__20240131_zr3YIcIRhfe6" title="Iimpairment of goodwill"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-02-01to2024-01-31" id="Fact001083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,813,000</ix:nonFraction></span>
reported as &#8220;Goodwill Impairment&#8221; on its condensed consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001085" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z0tKhaXfP2ba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zCWJo3lKiO31" style="display: none">SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Estimated</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Useful Life</p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gross</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Assets</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Accumulated</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Amortization</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finite-lived assets:</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 32%; text-align: left">Client relationships</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zrAtJp1Pwu99"><ix:nonNumeric contextRef="AsOf2024-01-31_custom_ClientRelationshipsMember" format="ixt-sec:duryear" id="Fact001086" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">10</ix:nonNumeric>
</span>years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zPJhIoUfjtKd" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-01-31_custom_ClientRelationshipsMember" id="Fact001087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,370,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zw0aySaIuQo2" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-01-31_custom_ClientRelationshipsMember" id="Fact001088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,058,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zbvzIg2SW02k" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-01-31_custom_ClientRelationshipsMember" id="Fact001089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,312,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Internally developed software</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zj9hTXL9sRC9" title="Estimated Useful Life"><ix:nonNumeric contextRef="AsOf2024-01-31_custom_InternallyDevelopedSoftwareMember" format="ixt-sec:duryear" id="Fact001091" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">9</ix:nonNumeric></span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zuZLW7E0x7p1" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-01-31_custom_InternallyDevelopedSoftwareMember" id="Fact001092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,380,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zWvK68GGiqZ1" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-01-31_custom_InternallyDevelopedSoftwareMember" id="Fact001093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,742,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zbgqaPz0jdNk" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-01-31_custom_InternallyDevelopedSoftwareMember" id="Fact001094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,638,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Trademarks and tradenames</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zolfD7Xprw4j" title="Estimated Useful Life"><ix:nonNumeric contextRef="AsOf2024-01-31_us-gaap_TrademarksAndTradeNamesMember" format="ixt-sec:duryear" id="Fact001096" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">15</ix:nonNumeric></span> years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zhhRANoQzo49" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-01-31_us-gaap_TrademarksAndTradeNamesMember" id="Fact001097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,340,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zgxDtPUtCJSj" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-01-31_us-gaap_TrademarksAndTradeNamesMember" id="Fact001098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">219,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zMOvLqsAVzh5" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-01-31_us-gaap_TrademarksAndTradeNamesMember" id="Fact001099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,121,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131_z1OkRfogUgF1" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-01-31" id="Fact001100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,090,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131_zLFdb3M5fFda" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-01-31" id="Fact001101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,019,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131_zcTyDDCzHyGg" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-01-31" id="Fact001102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,071,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2023</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Estimated</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Gross</b></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finite-lived assets:</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 42%; text-align: left">Client relationships</td><td style="width: 2%">&#160;</td>
    <td style="width: 11%; text-align: right"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zV1i0JE3VEpk" title="Estimated Useful Life"><ix:nonNumeric contextRef="AsOf2023-01-31_custom_ClientRelationshipsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001104" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">8</ix:nonNumeric></span>-<span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember__srt--RangeAxis__srt--MaximumMember_z8hVTU3RojKg" title="Estimated Useful Life"><ix:nonNumeric contextRef="AsOf2023-01-31_custom_ClientRelationshipsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001106" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">10</ix:nonNumeric></span> years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zzoDVtEV274l" title="Gross Assets" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-01-31_custom_ClientRelationshipsMember" id="Fact001108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,700,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zCK2Hn9NRNKd" title="Accumulated Amortization" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-01-31_custom_ClientRelationshipsMember" id="Fact001110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,463,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zBouebbLJZMb" title="Net Assets" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-01-31_custom_ClientRelationshipsMember" id="Fact001112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,237,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Internally Developed Software</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zeeptGzkGeei" title="Estimated Useful Life"><ix:nonNumeric contextRef="AsOf2023-01-31_custom_InternallyDevelopedSoftwareMember" format="ixt-sec:duryear" id="Fact001114" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">9</ix:nonNumeric></span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_z0VNmctoNHRb" title="Gross Assets" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-01-31_custom_InternallyDevelopedSoftwareMember" id="Fact001116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,380,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zQoRviMMpna8" title="Accumulated Amortization" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-01-31_custom_InternallyDevelopedSoftwareMember" id="Fact001118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,034,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zFptHsuDx831" title="Net Assets" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-01-31_custom_InternallyDevelopedSoftwareMember" id="Fact001120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,346,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Trademarks and Tradenames</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zXxhFr1tiWyg" title="Estimated Useful Life"><ix:nonNumeric contextRef="AsOf2023-01-31_us-gaap_TrademarksAndTradeNamesMember" format="ixt-sec:duryear" id="Fact001122" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">15</ix:nonNumeric></span> years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zeu2D5Iz8Rm1" title="Gross Assets" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-01-31_us-gaap_TrademarksAndTradeNamesMember" id="Fact001124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,340,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zJTw8PcWAA04" title="Accumulated Amortization" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-01-31_us-gaap_TrademarksAndTradeNamesMember" id="Fact001126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zXmjGzLczgw6" title="Net Assets" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-01-31_us-gaap_TrademarksAndTradeNamesMember" id="Fact001128" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,210,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131_zYwcI85UHPe2" title="Gross Assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-01-31" id="Fact001130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,420,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131_z1I7dKke1HEa" title="Accumulated Amortization" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-01-31" id="Fact001132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,627,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131_zKr0y3GhpsI3" title="Net Assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-01-31" id="Fact001134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,793,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zRgg54n2w0Ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
360 defines a multi-step process to test long-lived assets, including intangible assets, for recoverability that if failed would indicate
impairment. First, the Company must consider whether indicators of impairment of long-lived assets are present, which the Company determined
the Triggering Events provided such indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Next,
the Company must review the long-lived assets to define asset group(s) that would reflect the lowest level of assets to which discrete
cash flows are identifiable. In performing this review, the Company identified that the long-lived asset &#8220;client relationships&#8221;
related to Avelead should be classified as abandoned (the &#8220;Abandoned Asset&#8221;) with the Company determining that it no longer
has plans to provide the corresponding consulting service. The Abandoned Asset&#8217;s carrying value would need to be set to its salvage
value which would be zero given no future cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined the lowest level of discrete cash flows is at the reporting unit level, and all remaining long-lived assets (excluding
the Abandoned Asset) and goodwill would represent its only asset group. Recoverability is assessed by comparing that the sum of the discrete
undiscounted cash flows exceeds the carrying value of the asset group. The undiscounted cash flow projections are based on 8-year (representing
the useful life of the primary asset in the asset group) financial forecasts developed by management that include forecasts of future
operating results based on internal budgets and strategic plans to investment in working capital to support anticipated revenue growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undiscounted cash flows for the long-lived assets were above the carrying amounts indicating that the long-lived asset group is recoverable
and no further impairment to long-lived assets exists as of October 31, 2023. In fiscal 2023, the Company recorded $<span id="xdx_900_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_c20230201__20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z4d3XJczvN0k" title="Impairment of intangible assets"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2023-02-012024-01-31_us-gaap_CustomerRelationshipsMember" id="Fact001136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">963,000</ix:nonFraction></span> as &#8220;Impairment
of long-lived assets&#8221; on its condensed consolidated statement of operations to adjust the Abandoned Asset to its salvage value
of zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized amortization expense on intangible assets of $<span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230201__20240131_zeHV6Fia2Wl1" title="Amortization expense on intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-02-01to2024-01-31" id="Fact001138" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,760,000</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220201__20230131_z6qmN26wFBeb" title="Amortization expense on intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-02-012023-01-31" id="Fact001140" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,971,000</ix:nonFraction></span> for fiscal 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001142" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z3WsMyjAmgHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
over the next five fiscal years for intangible assets is estimated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zheQPGRews7k" style="display: none">SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20240131_z3oLC4PSdK9f" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Annual</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Amortization Expense</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_pp0p0_maFLIANzAN0_zTk48zW7E1g2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 24%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" contextRef="AsOf2024-01-31" id="Fact001144" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,635,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_maFLIANzAN0_zzQpMrORtxil" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2024-01-31" id="Fact001146" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,635,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_maFLIANzAN0_zwCQrZv3s3Y5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2024-01-31" id="Fact001148" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,635,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_maFLIANzAN0_zaXNcPo0IcJ" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2024-01-31" id="Fact001150" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,635,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_maFLIANzAN0_zDyuNEpyY9lj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2024-01-31" id="Fact001152" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,635,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_maFLIANzAN0_zveLcOWCT879" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="AsOf2024-01-31" id="Fact001154" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,896,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzAN0_zi4Bbf2nuCsl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-01-31" id="Fact001156" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,071,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8A3_zdySMZfatYue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company wrote-off the Abandoned Asset during fiscal 2023 with a gross asset value of $<span id="xdx_902_ecustom--AbandonedAssetWroteOff_c20230201__20240131_zn6JKjcl5iYd" title="Abandoned asset wrote off"><ix:nonFraction name="STRM:AbandonedAssetWroteOff" contextRef="From2023-02-01to2024-01-31" id="Fact001158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,330,000</ix:nonFraction></span>.
There was no impact to the consolidated statements of operations as this eliminated the asset and accumulated amortization of the
fully amortized intangible assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001160" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_z0QsTAEQDhKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
7 &#8212; <span id="xdx_825_zUoyWeLKFENi">INCOME TAXES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001162" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z1Qrk4Y3zRCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal 2023 and 2022, income taxes  consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zA0vPqReRg71" style="display: none">SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230201__20240131_zK9Z94Chs8Aj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220201__20230131_ztYIg4MFNvs7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zHdWE5OHgBu4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current tax expense:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pp0p0_maCITEBzxs7_maCITEBzyfy_zln98wYUgcac" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1167">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1168">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_maCITEBzxs7_maCITEBzyfy_z0HCcPDp7gu5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 68%; padding-bottom: 1.5pt">State</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-02-01to2024-01-31" id="Fact001170" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">58,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2022-02-012023-01-31" id="Fact001171" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">62,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_mtCITEBzyfy_maITEBzkRn_zI44rvTIDQjh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total current tax benefit (expense)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-02-01to2024-01-31" id="Fact001173" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">58,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-02-012023-01-31" id="Fact001174" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">62,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_pp0p0_zVVcGihGw8gi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax expense:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_pp0p0_maDITEBzEci_zX46sTZiTwB9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2023-02-01to2024-01-31" id="Fact001179" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">86,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2022-02-012023-01-31" id="Fact001180" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_pp0p0_maDITEBzEci_z0sLtM9QTvO5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2023-02-01to2024-01-31" id="Fact001182" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2022-02-012023-01-31" id="Fact001183" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_mtDITEBzEci_maITEBzkRn_zEsztPFY84Xi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total deferred tax benefit (expense)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2023-02-01to2024-01-31" id="Fact001185" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">104,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-02-012023-01-31" id="Fact001186" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">9,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iNT_pp0p0_di_zAQDDkMGpnl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Income tax benefit (expense)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-02-01to2024-01-31" id="Fact001188" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">46,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-02-012023-01-31" id="Fact001189" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zGMnPHHgPuia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax expense differs from the amount computed using the federal statutory income tax rate of <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230201__20240131_zwyrMnXeSjJf" title="Federal statutory income tax rates"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220201__20230131_zyESb8BACKog" title="Federal statutory income tax rates"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-02-01to2024-01-31" id="Fact001191" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-02-012023-01-31" id="Fact001193" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></ix:nonFraction></span></span>% for fiscal 2023 and 2022 as follows:</span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001195" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zMHzVXyBtkoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zpGmPnL31wr4" style="display: none">SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230201__20240131_zdRPrvbxm4N2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220201__20230131_znHyhoj5jHN1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzHX9_zYnfgoYxevDb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Federal tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-02-01to2024-01-31" id="Fact001197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,887,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2022-02-012023-01-31" id="Fact001198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,348,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzHX9_zZ04t8iYdAol" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State and local tax expense, net of federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-02-01to2024-01-31" id="Fact001200" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">28,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-02-012023-01-31" id="Fact001201" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">52,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--IncreaseInValuationAllowance_maITEBzHX9_z7as09OTZl36" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Increase in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="STRM:IncreaseInValuationAllowance" contextRef="From2023-02-01to2024-01-31" id="Fact001203" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,994,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="STRM:IncreaseInValuationAllowance" contextRef="From2022-02-012023-01-31" id="Fact001204" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,128,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Permanent items:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzHX9_zrEiOYLMxBih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2023-02-01to2024-01-31" id="Fact001206" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">36,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2022-02-012023-01-31" id="Fact001207" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationTaxContingencies_maITEBzHX9_ztJDKeJbtkIi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reserve for uncertain tax position</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxContingencies" contextRef="From2023-02-01to2024-01-31" id="Fact001209" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxContingencies" contextRef="From2022-02-012023-01-31" id="Fact001210" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzHX9_zFpDOgFQVLdj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Federal research and development (R&amp;D) tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2023-02-01to2024-01-31" id="Fact001212" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2022-02-012023-01-31" id="Fact001213" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">91,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maITEBzHX9_zpOrSEBP7lQc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="From2023-02-01to2024-01-31" id="Fact001215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="From2022-02-012023-01-31" id="Fact001216" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">289,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzHX9_zEbhWzWLmjt" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2023-02-01to2024-01-31" id="Fact001218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2022-02-012023-01-31" id="Fact001219" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_iN_pp0p0_di_mtITEBzHX9_zQgu6mmP2ozl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax benefit (expense)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-02-01to2024-01-31" id="Fact001221" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">46,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-02-012023-01-31" id="Fact001222" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zgdgYCRdCv9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001224" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zv36hcAdw4Jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides deferred income taxes for temporary differences between assets and liabilities recognized for financial reporting and
income tax purposes. The income tax effects of these temporary differences and credits are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zfItXsqgt5ii" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240131_zXO8HXMTiuV8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230131_z8vd3bHHaNpi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_pp0p0_maDTAGz9oc_zRIO7O8FElF" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: left">Allowance for credit losses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" contextRef="AsOf2024-01-31" id="Fact001226" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" contextRef="AsOf2023-01-31" id="Fact001227" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pp0p0_maDTAGz9oc_zd6lF5OZoxfc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="AsOf2024-01-31" id="Fact001229" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">209,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="AsOf2023-01-31" id="Fact001230" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">122,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent_iI_pp0p0_maDTAGz9oc_zeOTs4iteHP8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent" contextRef="AsOf2024-01-31" id="Fact001232" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">67,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="STRM:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent" contextRef="AsOf2023-01-31" id="Fact001233" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">232,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGz9oc_zMLinn0EzTNg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net operating loss carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-01-31" id="Fact001235" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,748,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-01-31" id="Fact001236" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,242,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGz9oc_zCWnxE8BKypi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-01-31" id="Fact001238" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">427,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-01-31" id="Fact001239" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">342,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0_maDTAGz9oc_z85X9citugQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Finite-lived intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2024-01-31" id="Fact001241" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,739,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2023-01-31" id="Fact001242" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,344,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGz9oc_zBnPnRI21A1d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">R&amp;D tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-01-31" id="Fact001244" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,434,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-01-31" id="Fact001245" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,407,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGz9oc_zIclNQdpMsZi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-01-31" id="Fact001247" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-01-31" id="Fact001248" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz9oc_maDTANzJA3_zkAnyFA288R1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-01-31" id="Fact001250" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,651,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-01-31" id="Fact001251" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,730,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzJA3_zDkBBx59OVWl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-01-31" id="Fact001253" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,646,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-01-31" id="Fact001254" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,347,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzJA3_msDTLz2p6_zZJc9wZIqx7b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Net deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-01-31" id="Fact001256" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-01-31" id="Fact001257" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">383,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iNI_di_msDITLz6FT_z0DOkUahtVz9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2024-01-31" id="Fact001259" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2023-01-31" id="Fact001260" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_iNI_pp0p0_di_maDITLz6FT_zZM8b7iXr1I7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Finite-lived intangible liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1262">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" contextRef="AsOf2023-01-31" id="Fact001263" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">482,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pp0p0_di_mtDITLz6FT_maDTLz2p6_zcoJWLgTWOc2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2024-01-31" id="Fact001265" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2023-01-31" id="Fact001266" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">487,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxLiabilities_iNTI_pp0p0_di_mtDTLz2p6_zQ7nVN5dLW39" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1268">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2023-01-31" id="Fact001269" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">104,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_z6lYHOtDhRmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
January 31, 2024, the Company had U.S. federal net operating loss carry forwards of $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_c20240131_zGGtBbLB9te8" title="Operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-01-31" id="Fact001271" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,107,000</ix:nonFraction></span> and
$<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_c20240131__us-gaap--AwardDateAxis__custom--ThroughFiscalTwoThousandThirtyEightMember_z0ISIW5wxln1" title="Operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-01-31_custom_ThroughFiscalTwoThousandThirtyEightMember" id="Fact001273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,083,000</ix:nonFraction></span>
of these net operating losses expire at various dates through fiscal 2038. The remaining $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240131__us-gaap--IncomeTaxAuthorityAxis__custom--TaxCutsAndJobsActMember_zCo0WH0jSV71" title="Operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-01-31_custom_TaxCutsAndJobsActMember" id="Fact001275" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,024,000</ix:nonFraction></span>
of these net operating losses can be carried forward indefinitely under the provisions of the Tax Cuts and Jobs Act (TCJA). The TCJA
also eliminated the ability to carry back net operating losses. The Company also had state net operating loss carry forwards of
$<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240131__us-gaap--IncomeTaxAuthorityAxis__custom--StateMember_zuICpj29hBA7" title="Operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-01-31_custom_StateMember" id="Fact001277" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,650,000</ix:nonFraction></span>
and Federal R&amp;D credit carry forwards of $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240131__us-gaap--IncomeTaxAuthorityAxis__custom--FederalRDMember_zhseEcqZgeGe" title="Operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-01-31_custom_FederalRDMember" id="Fact001279" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,699,000</ix:nonFraction></span>
and Georgia R&amp;D credit carry forwards of $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240131__us-gaap--IncomeTaxAuthorityAxis__custom--GeorgiaRDMember_zqlleKFDmiul" title="Operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-01-31_custom_GeorgiaRDMember" id="Fact001281" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">94,000</ix:nonFraction></span>,
all of which expire at various dates through fiscal 2042.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that all or some portion
of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of
future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal
of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The Company established
a valuation allowance of $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20240131_zMVGNVAkXOc7" title="Valuation allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-01-31" id="Fact001283" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,646,000</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20230131_zusbfdb8iKXi" title="Valuation allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-01-31" id="Fact001285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,347,000</ix:nonFraction></span> at January 31, 2024 and 2023, respectively. The increase in the valuation allowance
of $<span id="xdx_90B_ecustom--IncreaseInValuationAllowance_iN_di_c20230201__20240131_zd3t7kwtsuQ4" title="Increase in the valuation allowance"><ix:nonFraction name="STRM:IncreaseInValuationAllowance" contextRef="From2023-02-01to2024-01-31" id="Fact001287" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,994,000</ix:nonFraction></span> was driven primarily by the Company&#8217;s federal net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and its subsidiaries are subject to U.S. federal income tax as well as income taxes in multiple state and local jurisdictions.
The Company has concluded all U.S. federal tax matters for years through January 31, 2020. All material state and local income tax matters
have been concluded for years through January 31, 2019. The Company is no longer subject to IRS examination for periods prior to the
tax year ended January 31, 2020; however, carry forward losses that were generated prior to the tax year ended January 31, 2020 may still
be adjusted by the IRS if they are used in a future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has recorded a reserve, including interest and penalties, for uncertain tax positions of $<span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefits_iI_c20240131_zuyb7xilvXH1" title="Uncertain tax positions"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2024-01-31" id="Fact001289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_c20230131_zeHJDZeMPYP" title="Uncertain tax positions"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2023-01-31" id="Fact001291" format="ixt:numdotdecimal" decimals="0" unitRef="USD">333,000</ix:nonFraction></span> as of January
31, 2024 and 2023, respectively. As of January 31, 2024 and 2023, the Company had no accrued interest and penalties associated with unrecognized
tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001293" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zBBYb2k1Qaif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the beginning and ending amounts of gross unrecognized tax benefits (excluding interest and penalties) is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zco6YfUw1Us3" style="display: none">SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230201__20240131_zAFXu7xAOzG5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220201__20230131_zrpjmT2kHiN6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--UnrecognizedTaxBenefits_iS_pp0p0_zcGhxziP7LK6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Beginning of fiscal year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2023-01-31" id="Fact001295" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">333,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2022-01-31" id="Fact001296" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">315,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zHnr6XOaNOl4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additions for tax positions for the current year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="From2023-02-01to2024-01-31" id="Fact001298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="From2022-02-012023-01-31" id="Fact001299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_znxu2MOPPXM7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additions for tax positions of prior years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1301">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="From2022-02-012023-01-31" id="Fact001302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_iN_pp0p0_di_zxYg9zzSSCdb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Subtractions for tax positions of prior years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" contextRef="From2023-02-01to2024-01-31" id="Fact001304" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1305">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--UnrecognizedTaxBenefits_iE_pp0p0_zlVG4La0zBuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">End of fiscal year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2024-01-31" id="Fact001307" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">340,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2023-01-31" id="Fact001308" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">333,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zQr5qCZdR7kg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001310" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1lTSQwNPUv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
8 &#8212; <span id="xdx_826_zKMNKL0mM8ve">EQUITY</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital
Raise</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 24, 2022, the Company entered into purchase agreements with certain investors pursuant to which the Company agreed to issue and
sell in a registered direct offering (the &#8220;2022 Offering&#8221;) an aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221023__20221024__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoOfferingMember_zFQ3m2idyT17" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-10-232022-10-24_custom_PurchaseAgreementMember_custom_TwoThousandTwentyTwoOfferingMember" id="Fact001312" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,299,989</ix:nonFraction></span> shares of common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221024__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoOfferingMember_zmlwlvaOToyl" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-10-24_custom_PurchaseAgreementMember_custom_TwoThousandTwentyTwoOfferingMember" id="Fact001314" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span>
per share, at a purchase price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20221024__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoOfferingMember_zrsaMwwpvWtc" title="Purchase price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-10-24_custom_PurchaseAgreementMember_custom_TwoThousandTwentyTwoOfferingMember" id="Fact001316" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span> per share. The gross proceeds to the Company from the 2022 Offering were approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20221023__20221024__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoOfferingMember_zeTT1OhRoaZ3" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-10-232022-10-24_custom_PurchaseAgreementMember_custom_TwoThousandTwentyTwoOfferingMember" id="Fact001318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,316,000</ix:nonFraction></span>.
The Company used the proceeds of the 2022 Offering for general corporate purposes. The 2022 Offering closed on October 26, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
of Shares Issued to 180 Consulting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2022, the Company filed a Registration Statement on Form S-3 (Registration No. 333-265773) for purposes of registering for resale
<span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220622__us-gaap--RelatedPartyTransactionAxis__custom--OneHundredEightyConsultingLLCMember_zmDdCUaDdny2" title="Common stock issued for resale"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-06-22_custom_OneHundredEightyConsultingLLCMember" id="Fact001320" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">272,653</ix:nonFraction></span> shares of common stock issued to 180 Consulting, LLC (&#8220;180 Consulting&#8221;). The Registration Statement was declared
effective by the SEC on July 1, 2022.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 28, 2023, the Company filed a Registration Statement on Form S-3 (Registration No. 333-272993) for purposes of registering for resale
<span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230628__us-gaap--RelatedPartyTransactionAxis__custom--OneHundredEightyConsultingLLCMember_ztJBweR0Qf8k" title="Common stock issued for resale"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-06-28_custom_OneHundredEightyConsultingLLCMember" id="Fact001322" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">394,127</ix:nonFraction></span> shares of common stock issued to 180 Consulting, LLC (&#8220;180 Consulting&#8221;). The Registration Statement was declared
effective by the SEC on July 10, 2023.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Authorized
Shares Increase</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the 2022 Annual Meeting, the Company&#8217;s stockholders approved an amendment to the Streamline Health Solutions, Inc. Third Amended
and Restated 2013 Stock Incentive Plan to increase the number of shares of the Company&#8217;s common stock authorized for issuance thereunder
by <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20230201__20240131__us-gaap--PlanNameAxis__custom--ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_z744qi2KtRz4" title="Number of additional shares authorized to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2023-02-012024-01-31_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" id="Fact001324" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> shares, from <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20220607__us-gaap--PlanNameAxis__custom--ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_zRljjQxsHmD3" title="Number of shares authorized to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2022-06-07_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" id="Fact001326" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,223,246</ix:nonFraction></span> shares to <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240131__us-gaap--PlanNameAxis__custom--ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zWmSjofC3ge8" title="Number of shares authorized to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2024-01-31_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_srt_MaximumMember" id="Fact001328" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,223,246</ix:nonFraction></span> shares. The Company&#8217;s stockholders also approved an amendment to the Company&#8217;s
Certificate of Incorporation, as amended, to increase the total number of authorized shares of the Company&#8217;s common stock from
<span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20220607_zRzLxq4Ong2j" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-06-07" id="Fact001330" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,000,000</ix:nonFraction></span> shares to <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20240131_zr5QccP3x4X8" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-01-31" id="Fact001332" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">85,000,000</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the 2023 Annual Meeting, the Company&#8217;s stockholders approved an amendment to the 2013 Plan to increase the number of shares of
the Company&#8217;s common stock authorized for issuance thereunder by <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20230615__20230615_zdP2IZQMXGy5" title="Number of additional shares authorized to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2023-06-152023-06-15" id="Fact001334" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares, from <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20230615__us-gaap--PlanNameAxis__custom--ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_zXWE8hGqA3J3" title="Number of shares authorized to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2023-06-15_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" id="Fact001336" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,223,246</ix:nonFraction></span> shares to <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20230615__us-gaap--PlanNameAxis__custom--ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zYG2EzryR264" title="Number of shares authorized to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2023-06-15_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_srt_MaximumMember" id="Fact001338" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,223,246</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001340" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_800_eus-gaap--ConcentrationRiskDisclosureTextBlock_z5eB8SJFvElg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
9 &#8212; <span id="xdx_827_zGD4nTjGCSM1">MAJOR CLIENTS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2023, <span id="xdx_907_eus-gaap--ConcentrationRiskCustomer_c20230201__20240131_zUPwj5WXHLgd"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact001341" name="us-gaap:ConcentrationRiskCustomer">one individual client accounted
for 10% or more of our revenue.</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This client accounted
for <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20240131__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zLypvvdd55o7"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-02-012024-01-31_custom_OneCustomerMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember" id="Fact001342" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of total revenue for fiscal 2023. In the third quarter of fiscal 2023, the Company received a notice from this client of its intent not
to renew its contract following the expiration of the current term on December 31, 2023. During fiscal 2022, <span id="xdx_90F_eus-gaap--ConcentrationRiskCustomer_c20220201__20230131_z6P4n6yuGhge"><ix:nonNumeric contextRef="From2022-02-012023-01-31" id="Fact001343" name="us-gaap:ConcentrationRiskCustomer">two
individual clients accounted for 10% or more of our revenue.</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
clients accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210201__20220131__srt--MajorCustomersAxis__custom--TwoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z9X1KOGudy7e"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-02-012022-01-31_custom_TwoCustomerMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember" id="Fact001344" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210201__20220131__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_z5LRkXkjM4rd"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-02-012022-01-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneCustomerMember" id="Fact001345" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
respectively, of total revenue for fiscal 2022. Four clients represented <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20240131__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z5mnHrJyy0J7"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-02-012024-01-31_custom_CustomerOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember" id="Fact001346" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></span>%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20240131__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z7xKXSAr6sSj"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-02-012024-01-31_custom_CustomerTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember" id="Fact001347" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20240131__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zEGnqlVuaWo4"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-02-012024-01-31_custom_CustomerThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember" id="Fact001348" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20240131__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zk7bqkzdfSsd"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-02-012024-01-31_custom_CustomerFourMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember" id="Fact001349" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
respectively, of accounts receivable as of January 31, 2024, and four clients represented <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20230131__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zBhFm1wOAXP1"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-02-012023-01-31_custom_CustomerOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember" id="Fact001350" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
<span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20230131__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zf18hvwHMAeb"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-02-012023-01-31_custom_CustomerTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember" id="Fact001351" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
<span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20230131__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zARBzlAETThi"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-02-012023-01-31_custom_CustomerThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember" id="Fact001352" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20230131__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zLM9PZDHfogb"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-02-012023-01-31_custom_CustomerFourMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember" id="Fact001353" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
respectively, of accounts receivable as of January 31, 2023. Many of our clients are invoiced on an annual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001355" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock"><p id="xdx_805_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_z5c6rMuNfTui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
10 &#8212; <span id="xdx_826_zNNifCgVyW4b">EMPLOYEE RETIREMENT PLAN</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has established a 401(k) retirement plan that covers all associates. Company contributions to the plan may be made at the discretion
of the board of directors. The Company&#8217;s matched amount is 50% up to the first 4% of compensation deferred by each associate. The
total compensation expense for this matching contribution was $<span id="xdx_901_eus-gaap--DefinedContributionPlanCostRecognized_pp0p0_c20230201__20240131_zPm2id33qf5" title="Defined contribution plan, cost recognized"><ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="From2023-02-01to2024-01-31" id="Fact001357" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">242,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--DefinedContributionPlanCostRecognized_pp0p0_c20220201__20230131_z7D0klclvwO9" title="Defined contribution plan, cost recognized"><ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="From2022-02-012023-01-31" id="Fact001359" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">258,000</ix:nonFraction></span> in fiscal 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001361" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zR3mSH78pWti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
11 &#8212; <span id="xdx_822_zix3myPlcav8">STOCK-BASED COMPENSATION</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Option Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2013 Plan replaced the Company&#8217;s 2005 Incentive Compensation Plan (the &#8220;2005 Plan&#8221;). The 2005 Plan expired based upon
its terms. Accordingly, all the outstanding awards and any unallocated pool of un-issued options under the 2005 Plan were re-characterized
to the 2013 Plan. <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zRjmMTacv4Z2" title="Stock options plan, description"><ix:nonNumeric contextRef="From2023-02-012024-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember" id="Fact001363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">Under these plans, the Company is authorized to issue equity awards (stock options, stock appreciation rights or &#8220;SARs&#8221;,
and restricted stock) to directors and associates of the Company. Under the 2013 Plan, as amended, the Company is authorized to issue
a number of shares not to exceed <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zYk0QCKfDYrl" title="Number of shares authorized to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2024-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember" id="Fact001365" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,223,246</ix:nonFraction></span>. The options granted under the 2013 Plan have terms of ten years or less, and typically vest
and become fully exercisable ratably over three years of continuous service to the Company from the date of grant</ix:nonNumeric></span>. At January 31, 2024
and 2023, options to purchase <span id="xdx_905_ecustom--NumberOfOptionsToPurchaseCommonStock_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z6GtEpRtsUqj" title="Number of options to purchase common stock"><ix:nonFraction name="STRM:NumberOfOptionsToPurchaseCommonStock" contextRef="From2023-02-012024-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember" id="Fact001367" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,500</ix:nonFraction></span> and <span id="xdx_903_ecustom--NumberOfOptionsToPurchaseCommonStock_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zI5rslcRw3n3" title="Number of options to purchase common stock"><ix:nonFraction name="STRM:NumberOfOptionsToPurchaseCommonStock" contextRef="From2022-02-012023-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember" id="Fact001369" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">628,958</ix:nonFraction></span> shares of the Company&#8217;s common stock, respectively, had been granted and were
outstanding under these plans. At January 31, 2024, there were no SARs outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001371" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXNWPfNbByXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity in fiscal 2023 follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_z6AWhgsLlTTl" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life in <br/> Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">intrinsic <br/> value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding as of January 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230201__20240131_z9rzQnSYOxv8" title="Number of options, Outstanding" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-01-31" id="Fact001373" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">628,958</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230201__20240131_zBV5DS90SPtf" title="Weighted average exercise price, Outstanding" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-01-31" id="Fact001375" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.95</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220201__20230131_zQn7bX5YnDDd" title="Remaining Life in Years, Outstanding"><ix:nonNumeric contextRef="From2022-02-012023-01-31" format="ixt-sec:duryear" id="Fact001377" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.31</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230201__20240131_zE19UeU1K4mc" title="Aggregate intrinsic value, Outstanding" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-01-31" id="Fact001379" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">360,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230201__20240131_zWn0MkN626K1" title="Number of options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1381">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230201__20240131_zz3I3PGuVxR1" title="Weighted average exercise price, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1383">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230201__20240131_z7EX6ISFLaa4" title="Number of options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1385">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230201__20240131_zkqgh9ok7CU7" title="Weighted average exercise price, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1387">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230201__20240131_zZWVO32mGON7" title="Number of options, Expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-02-01to2024-01-31" id="Fact001389" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230201__20240131_zZju4jJge4L1" title="Weighted average exercise price, Expired" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-02-01to2024-01-31" id="Fact001391" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230201__20240131_zSPzPuqKmLs" title="Number of options, Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-02-01to2024-01-31" id="Fact001393" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">522,208</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230201__20240131_z6OxGZcLNs3a" title="Weighted average exercise price, Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-02-01to2024-01-31" id="Fact001395" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.55</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding as of January 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230201__20240131_zXz717fImZ23" title="Number of options, Outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-01-31" id="Fact001397" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230201__20240131_zAtr4ouxiGWg" title="Weighted average exercise price, Outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-01-31" id="Fact001399" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.73</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230201__20240131_zkDfaZVnkpE" title="Remaining Life in Years, Outstanding"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" format="ixt-sec:duryear" id="Fact001401" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.37</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230201__20240131_zSuSirRD9zde" title="Aggregate intrinsic value, Outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1403">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable as of January 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240131_zA224pL4KPVd" title="Number of options, Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-01-31" id="Fact001405" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240131_zC5bpjYI2ujg" title="Weighted average exercise price, Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-01-31" id="Fact001407" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.73</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230201__20240131_zb27FH3wNuqc" title="Remaining Life in Years, Exercisable"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" format="ixt-sec:duryear" id="Fact001409" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">2.37</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20240131_zxHUGEW6m4E6" title="Aggregate intrinsic value, Exercisable" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1411">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested as of January 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20240131_zBrksG5tDsii" title="Number of options, Vested or expected to vest" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2024-01-31" id="Fact001413" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20240131_zKlTMvZVX3ej" title="Weighted average exercise price, Vested or expected to vest" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-01-31" id="Fact001415" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.73</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230201__20240131_zwo7CT2xA9lj" title="Remaining Life in Years, Vested or expected to vest"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" format="ixt-sec:duryear" id="Fact001417" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">2.37</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pp0p0_c20240131_zYrdbEi8mAVe" title="Aggregate intrinsic value, Vested or expected to vest" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1419">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zNvMECiwJla5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
options were granted in fiscal 2023 or fiscal 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
January 31, 2024, there was <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_do_c20240131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zHd45qitU1De" title="Unrecognized Compensation cost, stock options"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2024-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember" id="Fact001421" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span>  unrecognized compensation cost related to non-vested stock-option awards.  The expense associated with stock option awards was $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zzGzYQpHhbQ4" title="Stock option expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-02-012023-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember" id="Fact001423" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210201__20220131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zpZCOisOlCMk" title="Stock option expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-02-012022-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember" id="Fact001425" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">132,000</ix:nonFraction></span>,
respectively, for fiscal 2023 and 2022. No options were exercised during fiscal 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2013 Plan contains change in control provisions whereby any outstanding equity awards under the plans subject to vesting, which have
not fully vested as of the date of the change in control, shall automatically vest and become immediately exercisable. One of the change
in control provisions is deemed to occur if there is a change in beneficial ownership, or authority to vote, directly or indirectly,
of securities representing <span id="xdx_908_ecustom--InvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240131_zksPPAwG4dsb" title="Ownership Percentage"><ix:nonFraction name="STRM:InvestmentOwnershipPercentage" contextRef="AsOf2024-01-31" id="Fact001427" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% or more of the total of all of the Company&#8217;s then-outstanding voting securities, unless through
a transaction arranged by or consummated with the prior approval of the Board of Directors. Other change in control provisions relate
to mergers and acquisitions or a determination of change in control by the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to grant restricted stock awards to associates and directors under the 2013 Plan. The Company has also issued restricted
stock as inducement grants to certain new employees. The restrictions on the shares granted generally lapse over a one- to four-year
term of continuous employment from the date of grant. On November 1, 2022, our then-serving CEO, Wyche T. Green, III, was awarded <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20221101__20221101__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFXwcPEJqNWd" title="Number of restricted stocks awarded, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-11-012022-11-01_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember" id="Fact001429" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span>
shares of restricted common stock that will vest in three substantially equal annual installments commencing on the first anniversary
of the date of grant. On May 20, 2022, Mr. Green was awarded <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220520__20220520__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxLQszwr6Ht9" title="Number of restricted stocks awarded, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-05-202022-05-20_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember" id="Fact001431" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span> shares of restricted common stock that will vest in three substantially
equal annual installments commencing on the first anniversary of the date of grant. On April 1, 2023, Mr. Green was awarded <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230401__20230401__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--MrGreenMember_z37kHInn2VAe" title="Number of restricted stocks awarded, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-04-012023-04-01_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember_custom_MrGreenMember" id="Fact001433" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> shares
of restricted common stock that will vest in three substantially equal annual installments commencing on the first anniversary of the
date of grant. Prior to his appointment as CEO of the Company, Mr. Stilwill was awarded <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230401__20230401__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--MrStilwillMember_z2X04kcHRQv4" title="Number of restricted stocks awarded, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-04-012023-04-01_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember_custom_MrStilwillMember" id="Fact001435" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">170,000</ix:nonFraction></span> shares of restricted common stock on
April 1, 2023, that will vest in three substantially equal annual installments commencing on the first anniversary of the date of grant.
The grant date fair value per share of restricted stock, which is based on the closing price of our common stock on the grant date, is
expensed on a straight-line basis as the restriction period lapses. The shares represented by restricted stock awards are
considered outstanding at the grant date, as the recipients are entitled to voting rights. A summary of restricted stock award activity
for fiscal 2023 and 2022 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001437" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zjM3yWYFsDA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zO7G2ebkJoQl" style="display: none">SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Weighted</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Non-vested</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Average</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Number of</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Grant Date</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair Value</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 64%">Non-vested balance at January 31, 2022</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220201__20230131_zYnFhfptDY6l" title="Number of RSUs, Non vested, Outstanding, Beginning balance" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-01-31" id="Fact001439" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,043,350</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220201__20230131_zEuLXWMANKh6" title="Weighted Average Grant Date Fair Value, Beginniing balance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-01-31" id="Fact001441" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.57</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zGP6dQdbY7b2" title="Number of RSUs, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember" id="Fact001443" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,505,731</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zmB5td5Fd6fl" title="Weighted Average Grant Date Fair Value, RSUs granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember" id="Fact001445" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.47</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2rQ1F0faCo8" title="Number of RSUs, vested" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember" id="Fact001447" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">501,750</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcM3KJZ27nH3" title="Weighted Average Grant Date Fair Value, RSUs vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember" id="Fact001449" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.63</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcWA3EZI1BR2" title="Number RSUs, forfeited" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember" id="Fact001451" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">199,300</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs36HOvacnKh" title="Weighted Average Grant Date Fair Value, RSUs forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember" id="Fact001453" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.49</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Non-vested balance at January 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230201__20240131_zBoj4mi8JkQf" title="Number of RSUs, Non vested, Outstanding, Beginning balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-01-31" id="Fact001455" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,848,031</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230201__20240131_zi6wkponXkb9" title="Weighted Average Grant Date Fair Value, Beginning balance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-01-31" id="Fact001457" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.48</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4cAqLD9qWHi" title="Number of RSUs, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-02-012024-01-31_us-gaap_RestrictedStockMember" id="Fact001459" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,488,621</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUoxAxyM8tqb" title="Weighted Average Grant Date Fair Value, RSUs granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-02-012024-01-31_us-gaap_RestrictedStockMember" id="Fact001461" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.57</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztks46YVO2pc" title="Number of RSUs, vested" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-02-012024-01-31_us-gaap_RestrictedStockMember" id="Fact001463" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">982,631</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs4ruRfP73dc" title="Weighted Average Grant Date Fair Value, RSUs vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-02-012024-01-31_us-gaap_RestrictedStockMember" id="Fact001465" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.48</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3kMfkbYn4Vd" title="Number RSUs, forfeited" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2023-02-012024-01-31_us-gaap_RestrictedStockMember" id="Fact001467" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">383,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcCEpa7518V" title="Weighted Average Grant Date Fair Value, RSUs forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2023-02-012024-01-31_us-gaap_RestrictedStockMember" id="Fact001469" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.67</ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Non-vested balance at January 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230201__20240131_zJ3GXytTKXPk" title="Number of RSUs, Non vested, Outstanding, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-01-31" id="Fact001471" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,970,521</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230201__20240131_zOW8QWyzHUNf" title="Weighted Average Grant Date Fair Value, Ending balance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-01-31" id="Fact001473" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.51</ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zX3Bw8CpyROg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
January 31, 2024, there was $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztSGfHKRWsE5" title="Unrecognized compensation cost related to restricted stock awards"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember" id="Fact001475" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,938,000</ix:nonFraction></span> of unrecognized compensation cost related to restricted stock awards. That cost is expected to be recognized
over a remaining period of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_pp0p0_dtY_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOUH2fFwVvP1" title="Cost expected remaining period"><ix:nonNumeric contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember" format="ixt-sec:duryear" id="Fact001477" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">1.80</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expense associated with restricted stock awards for associates and directors was $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zH9uUvSujJEk" title="Stock option expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-02-012023-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember" id="Fact001479" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,590,000</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210201__20220131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziMLtBvYwohf" title="Stock option expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-02-012022-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember" id="Fact001481" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">983,000</ix:nonFraction></span>,
for fiscal 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001483" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z3olXSo5JyKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
12&#8212; <span id="xdx_827_zxCT69eXbWf2">COMMITMENTS AND CONTINGENCIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consulting
Agreement with 180 Consulting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 19, 2020, the Company entered into a Master Services Agreement (the &#8220;MSA&#8221;) with 180 Consulting, pursuant to which 180
Consulting has provided and will continue to provide a variety of consulting services in support of eValuator products including product
management, operational consulting, staff augmentation, internal systems platform integration and software engineering services, among
others, through separate executed statements of work (&#8220;SOWs&#8221;). On September 20, 2021, the Company entered into a separate
MSA in support of Avelead products. As of December 2023, all outstanding SOWs under both MSAs were effectively replaced by two new SOWs.
As of the end of fiscal 2023, there were two active SOWs under the eValuator MSA, and no active SOWS under the Avelead MSA. One of the
active SOWs include the ability to earn stock at a conversion rate to be calculated 20 days after the execution of the related SOW. The
MSA includes a termination clause upon a 90-day written notice. While no related party has a direct or indirect material interest in
this MSA or the related SOWs, individuals providing services to us under the MSA, and the related SOWs may share workspace and administrative
costs with 121G Consulting LLC (&#8220;121G&#8221;). 180 Consulting earned <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zMhHLa2jZNJl"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-02-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember" id="Fact001484" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">564,707</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares for the year ended January 31, 2024 and
has earned an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zyunfUAmg8f1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember" id="Fact001485" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,479,911</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares through January 31, 2024. For services
rendered by 180 Consulting, the Company recorded total cash fees of $<span id="xdx_907_eus-gaap--ProfessionalFees_c20230801__20231031__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zPVjOGhQqUA3"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2023-08-012023-10-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember" id="Fact001486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,580,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and non-employee stock compensation of $<span id="xdx_908_eus-gaap--ProfessionalFees_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zs3LLvVHgHHe"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2022-02-012023-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember" id="Fact001487" format="ixt:numdotdecimal" decimals="0" unitRef="USD">582,000</ix:nonFraction>
</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for fiscal 2023 as compared to $<span id="xdx_905_ecustom--NonEmployeeStockCompensation_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zBwPgZmRAhM4"><ix:nonFraction name="STRM:NonEmployeeStockCompensation" contextRef="From2023-02-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember" id="Fact001488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,281,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_ecustom--NonEmployeeStockCompensation_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_z8Z6NjVupbI6"><ix:nonFraction name="STRM:NonEmployeeStockCompensation" contextRef="From2022-02-012023-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember" id="Fact001489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">640,000</ix:nonFraction></span>,
respectively, for fiscal 2022</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. In addition, as
of the date of this report, the Company has not issued to 180 Consulting an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231101__20240131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zRSAuzs7dQYa"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-11-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember" id="Fact001490" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">206,517</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares as compensation for services previously
rendered during the three-months ended January 31, 2024. Such <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231101__20240131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z2oPoPKfdYzd"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-11-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember_us-gaap_PrivatePlacementMember" id="Fact001491" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">564,707</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares will be issued in reliance on an exemption
from registration available under Section 4(a)(2) of the Securities Act. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inclusive
of the MSA executed with 180 Consulting are SOWs that provide for the Company to sublicense a software through 180 Consulting that is
owned by 121G. This is a services agreement for access to software that assists the Company in implementing and integrating with our
clients&#8217; technology. The license agreement is designed such that there is no material financial benefit that accrues to 121G. 180
Consulting licenses the software from 121G at cost. The Company paid approximately $<span id="xdx_90D_eus-gaap--ProfessionalFees_pp0p0_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SOWMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zCmpTNOKJGr8" title="Professional fees"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2023-02-012024-01-31_custom_SOWMember_custom_OneHundredEightyConsultingLLCMember" id="Fact001493" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">563,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--ProfessionalFees_pp0p0_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--SOWMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zXY6VpvP7sgk" title="Professional fees"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2022-02-012023-01-31_custom_SOWMember_custom_OneHundredEightyConsultingLLCMember" id="Fact001495" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">301,000</ix:nonFraction></span> for the SOWs that include the sublicense
agreement in each of the fiscal years ended January 31, 2024 and 2023, respectively, which are included in the aforementioned totals
above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are, from time to time, a party to various legal proceedings and claims, which arise in the ordinary course of business. We are not aware
of any legal matters that are reasonably possible to have a material adverse effect on the Company&#8217;s consolidated results of operations,
financial position or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001497" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zoIDIDdfg0Tb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
13 - <span id="xdx_821_zqhEKEEWAwX8">RELATED PARTY TRANSACTIONS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer
to Note 3 &#8211; Business Combination. The Company acquired Avelead on August 16, 2021. We assumed a lease for corporate
office space from one of the selling shareholders of Avelead who was employed by the Company through August 2023. This lease term ended
February 2022 but was renewed for a term of 12 months through February 2023. For the year ended January 31, 2024, the Company recorded
rent expense of $<span id="xdx_90F_eus-gaap--PaymentsForRent_c20230201__20240131_z5zPDi2dKoKd" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-02-01to2024-01-31" id="Fact001499" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span>. Refer to Note 4 &#8211; Operating Leases to our consolidated financial statements included in Part II, Item 8,
&#8220;Financial Statements and Supplementary Data&#8221; for more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001501" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zA3kgVqh9DU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
14 &#8212; <span id="xdx_824_zRs7xio7EOD4">SUBSEQUENT EVENTS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Debt
Private Placement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 1, 2024, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain
accredited investors, including certain directors and officers of the Company (collectively, the &#8220;Investors&#8221;), pursuant to
which the Company agreed to sell to the Investors unsecured subordinated promissory notes (the &#8220;Notes&#8221;) in the aggregate
principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHXgzuLiZOV4" title="Debt principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-02-01_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001503" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.4</ix:nonFraction></span> million and warrants (the &#8220;Warrants&#8221;) to purchase up to an aggregate of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z9Qs8HhWdpmg" title="Number of shares purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-01_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001505" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,052,631</ix:nonFraction></span> shares of the
Company&#8217;s common stock (the &#8220;Common Stock&#8221;) in a private placement (the &#8220;Debt Private Placement&#8221;). The
closing of the Debt Private Placement occurred on February 7, 2024 (the &#8220;Closing Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Debt Private Placement, the Investors and each of the Company&#8217;s directors and officers agreed, subject to certain
exceptions set forth in the lock-up agreements, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any
short sale or otherwise dispose of any shares of Common Stock, or any options or warrants to purchase any shares of Common Stock, or
any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock, for a period commencing
on the date of the lock-up agreement and ending 90 days from the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<ix:exclude><!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes bear interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20240201__us-gaap--ShortTermDebtTypeAxis__custom--NotesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLMRLP7iySJ8" title="Notes bear interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2024-02-01_custom_NotesMember_us-gaap_SubsequentEventMember" id="Fact001507" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% per annum and mature on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20240201__20240201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesMember_zAyPkBibryH8" title="Notes maturity date"><ix:nonNumeric contextRef="From2024-02-012024-02-01_us-gaap_SubsequentEventMember_custom_NotesMember" format="ixt:datemonthdayyearen" id="Fact001509" name="us-gaap:DebtInstrumentMaturityDate">August 7, 2026</ix:nonNumeric></span> (the &#8220;Maturity Date&#8221;). All accrued and unpaid
interest on the Notes will be capitalized and added to the outstanding principal balance of the Notes and will be payable in cash on
the Maturity Date. The Company may redeem the Notes, in whole or in part, prior to the Maturity Date without any premium or penalty.
In the event the Company prepays any portion of the then outstanding principal balance of the Notes on or before the twelve (12) month
anniversary of the Closing Date, in addition to such prepayment of the principal balance, the Company must pay to the Investors a prepayment
fee (in accordance with the each Investor&#8217;s pro-rata share of the Notes) in an amount equal to the amount of interest that would
have accrued but for the prepayment from the date of such prepayment through such twelve (12) month anniversary of the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights of each Investor to receive payments under the Notes are subordinate to the rights of Western Alliance Bank (&#8220;WAB&#8221;),
pursuant to a subordination agreement which the Investors entered into with WAB concurrently with the Debt Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrants have an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYZJaip5tMMc" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-04-30_us-gaap_SubsequentEventMember" id="Fact001511" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.38</ix:nonFraction></span> (except for Warrants issued to the Company&#8217;s directors and officers which have an exercise
price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ExceptDirectorsAndOfficersMember_zXhgZQCv4sW7" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-04-30_us-gaap_SubsequentEventMember_custom_ExceptDirectorsAndOfficersMember" id="Fact001513" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.39</ix:nonFraction></span>), are immediately exercisable, and will expire on the fourth anniversary of the Closing Date. The Warrants are subject
to customary adjustments for certain transactions affecting the Company&#8217;s capitalization. The terms of the Warrants preclude a
holder thereof from exercising such holder&#8217;s Warrants, and the Company from giving effect to such exercise, if after giving effect
to the issuance of Common Stock upon such exercise, the holder (together with the holder&#8217;s affiliates and any other persons acting
as a group together with the holder or any of the holder&#8217;s affiliates) would beneficially own in excess of <span id="xdx_902_ecustom--AffiliatesEffectivePercentage_iI_pid_dp_uPure_c20240430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQLorGwk9Su9" title="Affiliates effective percentage"><ix:nonFraction name="STRM:AffiliatesEffectivePercentage" contextRef="AsOf2024-04-30_us-gaap_SubsequentEventMember" id="Fact001515" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% of the number
of shares of Common Stock outstanding immediately after giving effect to the issuance of Common Stock upon such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes and the Warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended
(the &#8220;Securities Act&#8221;), and/or Regulation D promulgated thereunder and, along with the Common Stock underlying the Warrants,
have not been registered under the Securities Act or applicable state securities laws. Accordingly, the Notes, the Warrants and the Common
Stock underlying the Warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption
from such registration requirements and in accordance with applicable state securities laws. The securities were offered and sold to
&#8220;accredited investors&#8221; as that term is defined in Rule 501(a) under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Private Placement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2024, the Company completed the sale of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240206__20240206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z4ELvf7NvACc" title="Number of shares issued"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-02-062024-02-06_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember" id="Fact001517" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">263,158</ix:nonFraction></span> shares of the Company&#8217;s common stock to an accredited investor at a
purchase price of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_c20240206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zs7wf1kUsyB5" title="Purchase price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-02-06_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember" id="Fact001519" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.38</ix:nonFraction></span> per share for an aggregate purchase price of $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240206__20240206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zO2Q3YIN7py8" title="Aggregate purchase price"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-02-062024-02-06_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember" id="Fact001521" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> (the &#8220;Common Stock Private Placement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock described above was offered in a private placement under Section 4(a)(2) of the Securities Act and/or Regulation D promulgated
thereunder and has not been registered under the Securities Act or applicable state securities laws. Accordingly, such common stock may
not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements
and in accordance with applicable state securities laws. The Common Stock was offered and sold to an &#8220;accredited investor&#8221;
as that term is defined in Rule 501(a) under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loan
Modification</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 7, 2024, the Company and certain of its subsidiaries entered into a Third Modification and Waiver (the &#8220;Third Modification&#8221;)
to the Loan Agreement with Western Alliance Bank.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Third Modification waived the Company&#8217;s non-compliance with the Maximum Debt to ARR Ratio under the Loan Agreement and amended
certain financial covenants as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
    ARR Net Leverage Ratio. </b>Borrowers&#8217; ARR Net Leverage Ratio, measured on a quarterly basis as of the last day of each fiscal
    quarter, shall not be greater than the amount set forth under the heading &#8220;Maximum ARR Net Leverage Ratio&#8221; as of, and
    for each of the dates appearing adjacent to such &#8220;Maximum ARR Net Leverage Ratio.</span></td></tr>
  </table>
<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001523" name="STRM:ScheduleOfMaximumARRNetLeverageTableTextBlock"><p id="xdx_898_ecustom--ScheduleOfMaximumARRNetLeverageTableTextBlock_zn3DAkHvDuVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;<span id="xdx_8B2_zl5leknhgzJg" style="display: none">SCHEDULE
OF MAXIMUM ARR NET LEVERAGE RATIO</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 81%; font-weight: bold">Quarter Ending</td>
    <td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum ARR Net Leverage Ratio</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>April 30, 2024</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYL8dbOqU7dj" title="Maximum ARR net leverage ratio"><ix:nonFraction name="STRM:MaximumArrNetLeverageRatio" contextRef="AsOf2024-02-07_custom_AprilThirtyTwoThousandAndTwentyFourMember_srt_MinimumMember_us-gaap_SubsequentEventMember" id="Fact001525" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.50</ix:nonFraction></span> to <span id="xdx_903_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZGaBn88elT7" title="Maximum ARR net leverage ratio"><ix:nonFraction name="STRM:MaximumArrNetLeverageRatio" contextRef="AsOf2024-02-07_custom_AprilThirtyTwoThousandAndTwentyFourMember_srt_MaximumMember_us-gaap_SubsequentEventMember" id="Fact001527" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>July 31, 2024</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXDyg1rAAOu" title="Maximum ARR net leverage ratio"><ix:nonFraction name="STRM:MaximumArrNetLeverageRatio" contextRef="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandAndTwentyFourMember_srt_MinimumMember_us-gaap_SubsequentEventMember" id="Fact001529" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.45</ix:nonFraction></span> to <span id="xdx_901_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4bD19zzJLIi" title="Maximum ARR net leverage ratio"><ix:nonFraction name="STRM:MaximumArrNetLeverageRatio" contextRef="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandAndTwentyFourMember_srt_MaximumMember_us-gaap_SubsequentEventMember" id="Fact001531" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>October 31, 2024</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHNHYJNleNcf" title="Maximum ARR net leverage ratio"><ix:nonFraction name="STRM:MaximumArrNetLeverageRatio" contextRef="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandAndTwentyFourMember_srt_MinimumMember_us-gaap_SubsequentEventMember" id="Fact001533" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.40</ix:nonFraction></span> to <span id="xdx_90D_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdU4HUWEgNl7" title="Maximum ARR net leverage ratio"><ix:nonFraction name="STRM:MaximumArrNetLeverageRatio" contextRef="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandAndTwentyFourMember_srt_MaximumMember_us-gaap_SubsequentEventMember" id="Fact001535" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>January 31, 2025</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGXzjPhyYRBb" title="Maximum ARR net leverage ratio"><ix:nonFraction name="STRM:MaximumArrNetLeverageRatio" contextRef="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember" id="Fact001537" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.35</ix:nonFraction></span> to <span id="xdx_908_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zN794vr0cRh" title="Maximum ARR net leverage ratio"><ix:nonFraction name="STRM:MaximumArrNetLeverageRatio" contextRef="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFiveMember_srt_MaximumMember_us-gaap_SubsequentEventMember" id="Fact001539" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zp08xu0aVB09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
    Debt to Adjusted EBITDA Ratio. </b>Commencing with the quarter ending April 30, 2025, Borrowers&#8217; Maximum Debt to Adjusted EBITDA
    Ratio, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4) quarter period then ended,
    shall not be greater than the amount set forth under the heading &#8220;Maximum Debt to Adjusted EBITDA Ratio&#8221; as of, and for
    each of the dates appearing adjacent to such &#8220;Maximum Debt to Adjusted EBITDA Ratio&#8221;.</span></td></tr>
  </table>
<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001541" name="STRM:ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock"><p id="xdx_893_ecustom--ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock_zbRhfhXAR2T4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_z36XCCnXa4R3" style="display: none">SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 81%; font-weight: bold">Quarter Ending</td>
    <td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum Debt to Adjusted EBITDA Ratio</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>April 30, 2025</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z634W75TIPkd" title="Maximum Debt to Adjusted EBITDA Ratio"><ix:nonFraction name="STRM:MaximumDebtToAdjustedEbitdaRatio" contextRef="AsOf2024-02-07_custom_AprilThirtyTwoThousandTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember" id="Fact001543" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.50</ix:nonFraction></span> to <span id="xdx_906_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zW5HjjpfOLK6" title="Maximum Debt to Adjusted EBITDA Ratio"><ix:nonFraction name="STRM:MaximumDebtToAdjustedEbitdaRatio" contextRef="AsOf2024-02-07_custom_AprilThirtyTwoThousandTwentyFiveMember_srt_MaximumMember_us-gaap_SubsequentEventMember" id="Fact001545" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>July 31, 2025</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zndajFfrR7lb" title="Maximum Debt to Adjusted EBITDA Ratio"><ix:nonFraction name="STRM:MaximumDebtToAdjustedEbitdaRatio" contextRef="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember" id="Fact001547" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.00</ix:nonFraction></span> to <span id="xdx_902_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPNp0gh9xaMj" title="Maximum Debt to Adjusted EBITDA Ratio"><ix:nonFraction name="STRM:MaximumDebtToAdjustedEbitdaRatio" contextRef="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandTwentyFiveMember_srt_MaximumMember_us-gaap_SubsequentEventMember" id="Fact001549" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>October 31, 2025</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsNDLOgxTSE8" title="Maximum Debt to Adjusted EBITDA Ratio"><ix:nonFraction name="STRM:MaximumDebtToAdjustedEbitdaRatio" contextRef="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember" id="Fact001551" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.50</ix:nonFraction></span> to <span id="xdx_90B_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKF5mmPQictf" title="Maximum Debt to Adjusted EBITDA Ratio"><ix:nonFraction name="STRM:MaximumDebtToAdjustedEbitdaRatio" contextRef="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandTwentyFiveMember_srt_MaximumMember_us-gaap_SubsequentEventMember" id="Fact001553" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">January 31, 2026 and on the last day of each quarter thereafter</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQ1edTu7ZW4" title="Maximum Debt to Adjusted EBITDA Ratio"><ix:nonFraction name="STRM:MaximumDebtToAdjustedEbitdaRatio" contextRef="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember_srt_MinimumMember_us-gaap_SubsequentEventMember" id="Fact001555" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.00</ix:nonFraction></span> to <span id="xdx_90A_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zieXxiJi69ba" title="Maximum Debt to Adjusted EBITDA Ratio"><ix:nonFraction name="STRM:MaximumDebtToAdjustedEbitdaRatio" contextRef="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember_srt_MaximumMember_us-gaap_SubsequentEventMember" id="Fact001557" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zgAxWkKvE4b9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed
    Charge Coverage Ratio</b>. Commencing with the quarter ending April 30, 2025, Borrowers shall maintain a Fixed Charge Coverage Ratio
    of not less than <span id="xdx_909_ecustom--FixedChargeCoverageRatio_iI_pid_dp_uPure_c20240207__us-gaap--TypeOfArrangementAxis__custom--ThirdModificationLoanAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIv6ASSMMDf3" title="Fixed charge coverage ratio"><ix:nonFraction name="STRM:FixedChargeCoverageRatio" contextRef="AsOf2024-02-07_custom_ThirdModificationLoanAgreementMember_srt_MaximumMember_us-gaap_SubsequentEventMember" id="Fact001559" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.20</ix:nonFraction></span> to <span id="xdx_90E_ecustom--FixedChargeCoverageRatio_iI_pid_dp_uPure_c20240207__us-gaap--TypeOfArrangementAxis__custom--ThirdModificationLoanAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zM3nVmvbxsm4" title="Fixed charge coverage ratio"><ix:nonFraction name="STRM:FixedChargeCoverageRatio" contextRef="AsOf2024-02-07_custom_ThirdModificationLoanAgreementMember_srt_MinimumMember_us-gaap_SubsequentEventMember" id="Fact001561" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span>, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4)
    quarter period then ended.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>e.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Minimum
    Adjusted EBITDA. </b>Commencing with the quarter ending January 31, 2024, Borrowers shall maintain Adjusted EBITDA, measured on a
    quarterly basis as of the last day of each fiscal quarter, in an amount not less than the amounts (or, in the case of amounts set
    forth in parentheses, no worse than the amounts) set forth under the heading &#8220;Minimum Adjusted EBITDA&#8221; as of, and for
    each of the dates appearing adjacent to such &#8220;Minimum Adjusted EBITDA.</span></td></tr>
  </table>
<ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001563" name="STRM:ScheduleOfMinimumAdjustedEBITDATableTextBlock"><p id="xdx_89E_ecustom--ScheduleOfMinimumAdjustedEBITDATableTextBlock_zmyLnqyM4LPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;<span id="xdx_8BC_zGClJf5IisO8" style="display: none">SCHEDULE
OF MINIMUM ADJUSTED EBITDA</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Quarter Ending</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Minimum Adjusted EBITDA</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">January 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAHKv9XnP7Tf" title="Minimum Adjusted EBITDA" style="width: 16%; text-align: right">(<ix:nonFraction name="STRM:MinimumAdjustedEbitda" contextRef="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember" id="Fact001565" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,750,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>April 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztQimNPIzrJa" title="Minimum Adjusted EBITDA" style="text-align: right">(<ix:nonFraction name="STRM:MinimumAdjustedEbitda" contextRef="AsOf2024-02-07_custom_AprilThirtyTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember" id="Fact001567" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,560,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>July 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1LyXupcKxgg" title="Minimum Adjusted EBITDA" style="text-align: right">(<ix:nonFraction name="STRM:MinimumAdjustedEbitda" contextRef="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember" id="Fact001569" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,960,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>October 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0Xz7h4bcx13" title="Minimum Adjusted EBITDA" style="text-align: right">(<ix:nonFraction name="STRM:MinimumAdjustedEbitda" contextRef="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember" id="Fact001571" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,500,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>January 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFiveMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3VsY5uHAob2" title="Minimum Adjusted EBITDA" style="text-align: right"><ix:nonFraction name="STRM:MinimumAdjustedEbitda" contextRef="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFiveMember_us-gaap_SubsequentEventMember" id="Fact001573" format="ixt:numdotdecimal" decimals="0" unitRef="USD">430,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zsv2skD6YZbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" escape="true" id="Fact001575" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"><p id="xdx_804_esrt--ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_ziJUF1suz0d7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Schedule
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_003"></span><span id="xdx_825_zL7MiJcbFLjh">Valuation
and Qualifying Accounts and Reserves</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Streamline
Health Solutions, Inc and Subsidiaries.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the two years ended January 31, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(in
thousands of dollars)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at Beginning</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Period</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Charged to Costs and</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expenses</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b id="xdx_F5B_zV7DWB6suPWi">(1)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Deductions &#8211; Other Accounts</b></p>

</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F5B_zJuceKht5xe6">(2)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deductions</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>End of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Year ended January 31, 2024:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 32%; text-align: left">Allowance for doubtful accounts</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_pn3n3_c20230201__20240131_zZLImkf6vnmf" class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2023-01-31" id="Fact001576" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20230201__20240131_z1k2l5PaLfH3" class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" contextRef="From2023-02-01to2024-01-31" id="Fact001577" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_986_eus-gaap--ValuationAllowancesAndReservesChargedToOtherAccounts_pn3n3_c20230201__20240131_fKDEp_zh4bBYA0DPNh" class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" style="text-align: right; width: 10%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" contextRef="From2023-02-01to2024-01-31" id="Fact001578" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">36</ix:nonFraction></td>
    <td style="width: 1%">)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20230201__20240131_fKDIp_z0Npxkq8WqF7" class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1579">&#8212;</span></td><td style="width: 1%; text-align: left"/><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_pn3n3_c20230201__20240131_z9TIxgARzxGc" class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2024-01-31" id="Fact001580" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">86</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Year ended January 31, 2023:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Allowance for doubtful accounts</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_pn3n3_c20220201__20230131_zMH2HRz2Pj17" class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" style="text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2022-01-31" id="Fact001581" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20220201__20230131_zj53Qi6VeHek" class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" style="text-align: right"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" contextRef="From2022-02-012023-01-31" id="Fact001582" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">189</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><p id="xdx_98E_eus-gaap--ValuationAllowancesAndReservesChargedToOtherAccounts_pn3n3_c20220201__20230131_fKDEp_zLKF4y0XM5h1" class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1583">&#8212;</span></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20220201__20230131_fKDIp_zHOKrlLbtdXd" class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" style="text-align: right">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="From2022-02-012023-01-31" id="Fact001584" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">133</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_pn3n3_c20220201__20230131_z3ewtJR2qVoi" class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" style="text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2023-01-31" id="Fact001585" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F05_zp3FTL55sJff" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zARjFMaHTQD7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001586" xml:lang="en-US">Adjustments to retained earnings for adoption of ASC 326-10, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit
Losses on Financial Instruments (Refer to the subtopic of Accounting Pronouncements Recently Adopted in Note 2 &#8211; Significant Accounting
Policies to our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221;
for more information.)</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td id="xdx_F05_z4l7xymCPB99" style="font: 10pt Times New Roman, Times, Serif">(2)</td>
    <td id="xdx_F1A_zgnOhMXv45Y2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:footnote id="Footnote001587" xml:lang="en-US">Uncollectible accounts written off, net of recoveries.</ix:footnote></td></tr>
  </table>
<p id="xdx_8A5_zHg4tQmu83L8" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0">&#160;</p>

</ix:nonNumeric><p id="xdx_81D_zh0huRSW09U4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9. <i>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9A. <i>Controls and Procedures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Chief Executive Officer (who serves as our principal executive officer) and our Chief Financial Officer (who serves as our principal
financial officer) have evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(c))
as of the end of the period covered by this Report (January 31, 2024). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of January 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Report on Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined
in Rule 13a-15(f) of the Exchange Act. Our internal control over financial reporting is a process designed by, and under the supervision
of, our Chief Executive Officer and Chief Financial Officer and effected by our management and our Board of Directors to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with U.S. GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect
misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
internal control material weakness is a significant deficiency, or combination of significant deficiencies, that results in more than
a remote likelihood that a material misstatement of the consolidated financial statements will not be prevented or detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, including our principal executive officer and principal financial officer, conducted an evaluation of the effectiveness of
our internal control over financial reporting as of January 31, 2024, and concluded that our internal control over financial reporting
was effective as of January 31, 2024. In making the assessment of internal control over financial reporting, management used the criteria
established in Internal Control - Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act)
that occurred during the year ended January 31, 2024 that have materially affected, or are reasonably likely to materially affect, our
internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have performed additional analyses and other procedures to enable management to conclude that our consolidated financial statements included
in this report fairly, in all material respects, our financial condition and results of operations as of the year ended January 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9B. <i>Other Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9C. <i>Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
10. <i>Directors, Executive Officers and Corporate Governance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
regarding directors, executive officers and corporate governance will be set forth in the proxy statement for our 2024 Annual Meeting,
which will be filed with the SEC within 120 days after the end of the fiscal year covered by this Report and is incorporated herein by
reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
11. <i>Executive Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
regarding executive compensation will be set forth in the proxy statement for our 2024 Annual Meeting, which will be filed with the SEC
within 120 days after the end of the fiscal year covered by this Report and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
12. <i>Securities Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
regarding security ownership of certain beneficial owners and management and related stockholder matters will be set forth in the proxy
statement for our 2024 Annual Meeting, which will be filed with the SEC within 120 days after the end of the fiscal year covered by this
Report and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
13. <i>Certain Relationships and Related Transactions and Directors Independence</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
regarding certain relationships and related transactions and director independence will be set forth in the proxy statement for our 2024
Annual Meeting, which will be filed with the SEC within 120 days after the end of the fiscal year covered by this Report and is incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
14. <i>Principal Accountant Fees and Services</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Independent Registered Public Accounting Firm is FORVIS, LLP (PCAOB Firm ID No. <span id="xdx_905_edei--AuditorFirmId_c20230201__20240131_zbm5Pnjf6aAl" class="xdx_phnt_RG9jdW1lbnQgLSBDb3ZlcgA_"><ix:nonNumeric contextRef="From2023-02-01to2024-01-31" id="Fact001588" name="dei:AuditorFirmId">686</ix:nonNumeric></span>) located in Atlanta, Georgia. Information regarding
principal accountant fees and services will be set forth in the proxy statement for our 2024 Annual Meeting, which will be filed with
the SEC within 120 days after the end of the fiscal year covered by this Report and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    15. <i>Exhibits and Financial Statement Schedules</i></b>) See Index to Consolidated Financial Statements and Schedule Covered by
    Reports of Registered Public Accounting Firms included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data,&#8221;
    of this Report. See Index to Exhibits contained in this Report.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Index to Exhibits contained in this Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16. <i>Form 10-K Summary</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBITS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315221020544/ex2-1.htm" style="-sec-extract: exhibit">Unit Purchase Agreement, dated August 16, 2021, by and among Streamline Health Solutions, Inc., Avelead Consulting, LLC, Jawad Shaikh and Badar Shaikh (Incorporated by reference from Exhibit 2.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on August 18, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000100858614000008/strm20140731ex31.htm" style="-sec-extract: exhibit">Certificate of Incorporation of Streamline Health Solutions, Inc. f/k/a/ LanVision Systems, Inc., as amended through August 19, 2014 (Incorporated by reference from Exhibit 3.1 of the Company&#8217;s Quarterly Report on Form 10-Q, as filed with the SEC on September 15, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315221012713/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment of Certificate of Incorporation of Streamline Health Solutions, Inc. (Incorporated by reference from Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on May 24, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315222016177/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment of Certificate of Incorporation of Streamline Health Solutions, Inc. (Incorporated by reference from Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on June 8, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000110465914025620/a14-9976_1ex3d1.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws of Streamline Health Solutions, Inc., as amended and restated through March 28, 2014 (Incorporated by reference from Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on April 3, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen
    Common Stock Certificate of Streamline Health Solutions, Inc. (Incorporated by reference from the Company&#8217;s Registration Statement
    on Form S-1, File Number 333-01494, as filed with the SEC on April 15, 1996).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-2.htm">Description of Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">4.3</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315224005268/ex4-1.htm" style="-sec-extract: exhibit">Form <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of Warrant of Streamline Health Solutions, Inc. (Incorporated by reference from Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on February 7, 2024).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000110465913043879/a13-12987_2ex99.htm" style="-sec-extract: exhibit">Streamline Health Solutions, Inc. 1996 Associate Stock Purchase Plan, as amended and restated effective July 1, 2013 (Incorporated by reference from the Registration Statement on Form S-8, File Number 333-188763, as filed with the Commission on May 22, 2013).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000095015205004757/l14201aexv10w1.txt" style="-sec-extract: exhibit">2005 Incentive Compensation Plan of Streamline Health Solutions, Inc. (Incorporated by reference from Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on May 26, 2005).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2(a)#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000119312512472499/d439589dex43.htm" style="-sec-extract: exhibit">Amendment No. 2 to 2005 Incentive Compensation Plan of Streamline Health Solutions, Inc. (Incorporated by reference from Exhibit 4.3 of the Company&#8217;s Registration Statement on Form S-8, as filed with the SEC on November 15, 2012).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2(b)#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315220019673/ex10-2c.htm" style="-sec-extract: exhibit">Amendment No. 3 to 2005 Incentive Compensation Plan of Streamline Health Solutions, Inc. (Incorporated by reference from Exhibit 10.2(c) of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on October 20, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2(c)#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000110465919022886/a19-8623_1def14a.htm" style="-sec-extract: exhibit">Streamline Health Solutions, Inc. Third Amended and Restated 2013 Stock Incentive Plan (Incorporated by reference from Appendix A to the Company&#8217;s Definitive Proxy Statement on Schedule 14A, as filed with the SEC on April 22, 2019).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315221012713/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Streamline Health Solutions, Inc. Third Amended and Restated 2013 Stock Incentive Plan (Incorporated by reference from Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on May 24, 2021).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.3(a)#</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315222012527/formdef14a.htm" style="-sec-extract: exhibit">Amendment No. 2 to Streamline Health Solutions, Inc. Third Amended and Restated 2013 Stock Incentive Plan (Incorporated by reference from Appendix B to the Company&#8217;s Definitive Proxy Statement on Schedule 14A, as filed with the SEC on May 9, 2022).</a></p>
</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.3(b)#</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315223016225/formdef14a.htm" style="-sec-extract: exhibit">Amendment No. 3 to Streamline Health Solutions, Inc. Third Amended and Restated 2013 Stock Incentive Plan (Incorporated by reference from Appendix B to the Company&#8217;s Definitive Proxy Statement on Schedule 14A, as filed with the SEC on May 11, 2023).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3(c)#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000110465914062784/a14-19546_1ex10d2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Restricted Stock Award Agreement for Non-Employee Directors (Incorporated by reference from Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on August 25, 2014).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3(d)#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000110465914062784/a14-19546_1ex10d3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Restricted Stock Award Agreement for Executives (Incorporated by reference from Exhibit 10.3 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on August 25, 2014).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3(e)#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000110465914062784/a14-19546_1ex10d4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Stock Option Agreement for Executives (Incorporated by reference from Exhibit 10.4 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on August 25, 2014).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000110465919054950/a19-20492_1ex10d2.htm#Exhibit10_2_085415" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated October 17, 2019, by and between the Company and Wyche T. &#8220;Tee&#8221; Green, III (Incorporated by reference from Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on October 18, 2019).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.5#*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0"><a href="ex10-5.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated February 15, 2022, by and between the Company and Benjamin L. Stilwill.</span></a></p>


</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.6#</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315223044051/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement, dated December 4, 2023, by and between the Company and Bryant James Reeves (Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on December 7, 2023).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.7#*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0"><a href="ex10-7.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated February 4, 2021, by and between the Company and Wendy L. Lovvorn.</span></a></p>


</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.8#</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000155837018007448/strm-20180731ex1012e5310.htm" style="-sec-extract: exhibit">Employment Agreement dated September 10, 2018 by and between Streamline Health Solutions, Inc. and Thomas J. Gibson (Incorporated by reference from Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q, as filed with the SEC on September 12, 2018).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315221020544/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Stock Agreement by and between Streamline Health Solutions, Inc. and Jawad Shaikh, dated as of August 16, 2021 (Incorporated by reference from Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on August 18, 2021).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315221020544/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Stock Agreement by and between Streamline Health Solutions, Inc. and Badar Shaikh, dated as of August 16, 2021 (Incorporated by reference from Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on August 18, 2021).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000095015206004975/l20743aexv10w1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement for all directors and officers of Streamline Health Solutions, Inc. (Incorporated by reference from Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on June 7, 2006).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315221020544/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Stock Agreement by and between Streamline Health Solutions, Inc. and Badar Shaikh, dated as of August 16, 2021 (Incorporated by reference from Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on August 18, 2021).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000155837020000067/strm-20191031ex105dac1df.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan and Security Agreement dated as of December 11, 2019 by and among Bridge Bank, a division of Western Alliance Bank, Streamline Health Solutions, Inc. and Streamline Health, Inc. (Incorporated by reference from Exhibit 10.5 of the Company&#8217;s Quarterly Report on Form 10-Q, as filed with the SEC on January 7, 2020).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315221005219/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Loan and Security Agreement dated as of March 2, 2021 by and among Western Alliance Bank, Streamline Health Solutions, Inc. and Streamline Health, Inc. (Incorporated by reference from Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on March 2, 2021).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315221021559/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amended and Restated Loan and Security Agreement, dated August 26, 2021, by and among Streamline Health Solutions, Inc., Streamline Health, Inc., Streamline Pay &amp; Benefits, LLC, Streamline Consulting Solutions, LLC, Avelead Consulting, LLC and Western Alliance Bank (Incorporated by reference from Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on August 30, 2021.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315222025383/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waiver of Second Amended and Restated Loan and Security Agreement, dated August 26, 2022, by and among the Company, Streamline Health, LLC, Streamline Pay &amp; Benefits, LLC, Avelead Consulting, LLC, Streamline Consulting Solutions, LLC and Western Alliance Bank (Incorporated by reference from Exhibit 10.2 of the Quarterly Report on Form 10-Q, filed September 8, 2022).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315222034459/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Modification to Second Amended and Restated Loan and Security Agreement, dated November 29, 2022, by and between Streamline Health Solutions, Inc. and certain of its subsidiaries party thereto, and Western Alliance Bank (Incorporated by reference from Exhibit 10.1 of the Current Report on Form 8-K, filed December 5, 2022).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0">10.13(e)</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315224005268/ex10-3.htm" style="-sec-extract: exhibit">Third Modification to Second Amended and Restated Loan and Security Agreement, dated February 7, 2024, by and between Streamline Health Solutions, Inc. and certain of its subsidiaries party thereto, and Western Alliance Bank (Incorporated by reference from Exhibit 10.3 of the Current Report on Form 8-K, filed February 7, 2024).</a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000110465919053826/a19-19939_1ex10d1.htm#Exhibit10_1_083342" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, dated October 10, 2019, between the Company and each purchaser identified on the signature pages thereto (Incorporated by reference from Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on October 11, 2019).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000110465919053826/a19-19939_1ex10d2.htm#EXhibit10_2_084553" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Rights Agreement, dated October 10, 2019, between the Company and each of the several purchasers signatory thereto (Incorporated by reference from Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on October 11, 2019).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315222029722/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Agreement dated as of October 24, 2022, by and among Streamline Health Solutions, Inc. and the purchasers thereto (Incorporated by reference from Exhibit 10.1 of the Current Report on Form 8-K, filed October 27, 2022).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315220004658/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Master Services and Non-Disclosure Agreement, dated as of March 18, 2020, by and between Streamline Health Solutions, Inc. and 180 Consulting, LLC (Incorporated by reference from Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on March 25, 2020).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315220011010/ex10-6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sublease Agreement (Incorporated by reference from Exhibit 10.6 to the Company&#8217;s Quarterly Report on Form 10-Q, as filed with the SEC on June 11, 2020).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.19</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315224005268/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, by and among Streamline Health Solutions, Inc. and each purchaser identified on the signature pages thereto (Incorporated by reference from Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on February 7, 2024).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.20</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1008586/000149315224005268/ex10-2.htm" style="-sec-extract: exhibit">Form of Promissory Note of Streamline Health Solutions, Inc. (Incorporated by reference from Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on February 7, 2024).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex21-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries of Streamline Health Solutions, Inc.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex23-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Independent Registered Public Accounting Firm - FORVIS, LLP</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#P_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included in signature page)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification by Chief Executive Officer pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification by Chief Financial Officer pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following financial information from Streamline Health Solutions, Inc.&#8217;s Annual Report on Form 10-K for the fiscal year ended
    January 31, 2024 filed with the SEC on April 30, 2024, formatted in XBRL includes: (i) Consolidated Balance Sheets at January 31,
    2024 and 2023, (ii) Consolidated Statements of Operations for the two years ended January 31, 2024, (iii) Consolidated Statements
    of Changes in Stockholders&#8217; Equity for the two years ended January 31, 2024, (iv) Consolidated Statements of Cash Flows for
    the two years ended January 31, 2024, and (v) the Notes to Consolidated Financial Statements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
    Contracts and Compensatory Arrangements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    SEC file number reference for documents filed with the SEC pursuant to the Exchange Act, is 000-28132.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">STREAMLINE
    HEALTH SOLUTIONS, INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/S/
    BENJAMIN L. STILWILL</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benjamin
    L. Stilwill</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>President
    and Chief Executive Officer</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="P_001"></span>POWER
OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person whose signature appears below hereby constitutes and appoints Benjamin L. Stilwill and Bryant J. Reeves, III, and each of them,
his attorneys-in-fact, each with the power of substitution, for him and in his name, place and stead, in any and all capacities, to sign
this annual report on Form 10-K and any and all amendments to this annual report on Form 10-K, and to file the same, with all exhibits
thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and all intents and purposes as he might
or could do in person, hereby ratifying and confirming all that such attorneys-in-fact and agents or any of them or his or their substitute
or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATE:
April 30, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant in the capacities and on the date indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    WYCHE T. &#8220;TEE&#8221; GREEN, III</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Chairman and Chairman of the Board</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    30, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wyche
    T. &#8220;Tee&#8221; Green, III</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/S/
    BENJAMIN L. STILWILL</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    30, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benjamin
    L. Stilwill</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Principal
    Executive Officer)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 32%"><span style="font-size: 10pt"><i>/s/ BRYANT J. REEVES, III</i></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 50%"><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 14%"><span style="font-size: 10pt">April 30,2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Bryant J. Reeves, III</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><i>(Principal Financial Officer and</i></span></p>
                                   <p style="margin-top: 0; margin-bottom: 0"></p></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><i>Principal Accounting Officer)</i></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    JONATHAN R. PHILLIPS</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    30, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan
    R. Phillips</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    JUSTIN FERAYORNI</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    30, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Justin
    Ferayorni</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    JUDITH E. STARKEY</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    30, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judith
    E. Starkey</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    KENAN H. LUCAS</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    30, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenan
    H. Lucas</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/<i>s/
    MATTHEW ETHERIDGE</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    30, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew
    Etheridge</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 85; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>






























































<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p>




















































<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--  
       -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>ex4-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF THE REGISTRANT&rsquo;S SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTERED
PURSUANT TO SECTION 12 OF THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Streamline
Health Solutions, Inc. (the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; and &ldquo;us&rdquo;) has authority to issue
90,000,000 shares of all classes of stock, consisting of 85,000,000 shares of common stock, par value $0.01 per share (the &ldquo;Common
Stock&rdquo;), and 5,000,000 shares of preferred stock, par value $0.01 per share (the &ldquo;Preferred Stock&rdquo;). The following
summary describes the Common Stock of the Company, which is the only class of securities of the Company registered pursuant to Section
12 of the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to
(i) our Certificate of Incorporation, as amended through June 7, 2022 (as so amended, the &ldquo;Certificate of Incorporation&rdquo;),
and (ii) our Amended and Restated Bylaws, as amended and restated through March 28, 2014 (as so amended, the &ldquo;Bylaws&rdquo;), each
of which is incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.2 is a part. We encourage
you to read our Certificate of Incorporation, our Bylaws and the applicable provisions of the Delaware General Corporation Law (the &ldquo;DGCL&rdquo;),
for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting.
</I>Holders of Common Stock are entitled to one vote per share for the election of directors and on all other matters that require stockholder
approval, subject in all cases to the rights of any outstanding Preferred Stock, if any. Holders of our Common Stock do not have cumulative
voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Bylaws provide that the holders of a majority of all of the shares of our capital stock issued, outstanding and entitled to vote shall
constitute a quorum for the transaction of business. When a quorum is present, the affirmative vote of the majority of shares of our
capital stock present in person or represented by proxy at the meeting and entitled to vote on the subject matter shall be the act of
the stockholders, unless the question is one upon which by express provisions of an applicable law, our Certificate of Incorporation
or our Bylaws a different vote is required, in which case such express provision shall govern and control the decision of such question.
Our Bylaws provide that, when a quorum is present at a meeting of stockholders at which directors are to be elected, directors are elected
by a plurality of the votes of the shares of capital stock present in person or represented by proxy at the meeting and entitled to vote
on the election of directors. Our Certificate of Incorporation provides that the affirmative vote of the holders of not less than 66
2/3% of the outstanding shares of Common Stock entitled to vote upon the election of directors shall be required to effect: (1) an amendment
to the Certificate of Incorporation, (2) a merger or consolidation of the Company with or into another corporation, or the sale or transfer
of all or substantially all of the assets of the Company to another entity; or (3) the removal of a member of the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends
and Other Distributions.</I> Subject to the rights of holders of any then outstanding shares of our Preferred Stock, our holders of Common
Stock are entitled to receive such dividends as may be declared from time to time by our Board of Directors from funds legally available
therefor. We do not currently pay cash dividends on our Common Stock, and we currently intend to retain any future earnings for use in
our business. Any future determination as to the declaration of dividends on our Common Stock will be made at the discretion of the Board
of Directors and will depend on our earnings, operating and financial condition, capital requirements and other factors deemed relevant
by the Board of Directors, including the applicable requirements of the DGCL, which provides that dividends are payable only out of surplus
or net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. The payment of dividends on our
Common Stock may be restricted by the provisions of credit agreements or other financing documents that we may enter into or the terms
of securities that we may issue from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Merger,
Consolidation or Sale of Assets.</I> Subject to any preferential rights of any outstanding Preferred Stock, if any, holders of our Common
Stock shall be entitled to receive all cash, securities and other property received by us pro rata on the basis of the number of shares
of Common Stock held by each of them in any of the following situations: (1) our merger or consolidation with or into another corporation
in which we do not survive, (2) the sale or transfer of all or substantially all of our assets to another entity or (3) a merger or consolidation
in which we are the surviving entity but the Common Stock shall be exchanged for stock, securities or property of another entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Distribution
on Dissolution.</I> After payment or provision for all liabilities, and subject to any preferential rights of any outstanding Preferred
Stock, if any, in the event of our liquidation, dissolution or winding up, holders of our Common Stock are entitled to receive a portion
of the remaining funds to be distributed. Such funds shall be paid to the holders of our Common Stock pro rata on the basis of the number
of shares of Common Stock held by each of them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Rights.</I> The shares of our Common Stock are not subject to any redemption provisions and are not convertible. Holders of our Common
Stock do not have any preemptive rights enabling such holders to purchase, subscribe for or receive shares of any class of our Common
Stock or any other securities convertible into shares of any class of our Common Stock or any redemption rights. Holders of Common Stock
have no sinking fund rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
outstanding shares of our Common Stock are fully paid and non-assessable. All shares of Common Stock have equal rights and preferences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights, preferences and privileges of holders of our Common Stock are subject to, and may be adversely affected by, those of the holders
of Preferred Stock, and will be subject to those of the holders of any shares of our Preferred Stock that we may issue in the future.
As of April 30, 2024, we had no shares of Preferred Stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 30, 2024, we have warrants (the &ldquo;Warrants&rdquo;) outstanding to purchase up to an aggregate of 4,052,631 shares of Common
Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrants have an exercise price of $0.38 (except for Warrants issued to the Company&rsquo;s directors and officers which have an exercise
price of $0.39), and are exercisable any time on or after February 7, 2024, and prior to February 7, 2028. The Warrants are exercisable
for cash or on a cashless basis, at the holder&rsquo;s option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price and number of shares of Common Stock issuable upon exercise of the Warrants may be adjusted in certain circumstances,
including in the event of a stock split, stock dividend, recapitalization, or combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant holders do not have the rights or privileges of holders of shares of our Common Stock or any voting rights until they exercise
their Warrants and receive shares of our Common Stock. After the issuance of shares of Common Stock upon exercise of the Warrants, each
holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders of the Company. The Warrants
were issued in a private placement pursuant to an exemption under the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock is listed on the NASDAQ Capital Market under the symbol &ldquo;STRM.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our Common Stock is Computershare Inc., 250 Royall Street, Canton, Massachusetts 02021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware
Anti-Takeover Law and Provisions of our Certificate of Incorporation and Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Delaware
Anti-Takeover Law.</I> We are subject to Section 203 of the DGCL. Section 203 generally prohibits a public Delaware corporation from
engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three years after the date
of the transaction in which the person became an interested stockholder, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior
    to the date of such business combination, the board of directors of the corporation approved either the business combination or the
    transaction that resulted in the stockholder becoming an interested stockholder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder
    owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes
    of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers of the corporation
    and (b) shares issued under employee stock plans under which employee participants do not have the right to determine confidentially
    whether shares held subject to the plan will be tendered in a tender or exchange offer; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    or subsequent to the date of such business combination, the business combination is approved by the board of directors of the corporation
    and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66
    2/3% of the outstanding voting stock that is not owned by the interested stockholder.</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
203 defines a business combination to include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    merger or consolidation involving the corporation and the interested stockholder or any merger or consolidation involving the corporation
    and another entity that is caused by the interested stockholder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    sale, lease, exchange, mortgage, pledge, transfer or other disposition involving the interested stockholder of 10% or more of the
    assets of the corporation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the
    interested stockholder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    transaction involving the corporation that has the effect of increasing the proportionate share of its stock owned by the interested
    stockholder; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided
    by or through the corporation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting
stock of the corporation and any affiliate or associate of such entity or person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Our
Certificate of Incorporation and Bylaws.</I> Provisions of our Certificate of Incorporation and Bylaws may delay or discourage transactions
involving an actual or potential change in our control or change in our management, including transactions in which stockholders might
otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests.
Therefore, these provisions could adversely affect the price of our Common Stock. Among other things, our Certificate of Incorporation
and Bylaws:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">permit
    our Board of Directors to issue up to 5,000,000 shares of Preferred Stock, with such designations, powers, preferences and rights
    as our Board of Directors may authorize (including the right to approve an acquisition or other change in control);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that the authorized number of directors may be changed only by the Board of Directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative
    vote of a majority of directors then in office, even if less than a quorum; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">do
    not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of capital stock entitled to
    vote in any election of directors to elect all of the directors standing for election, if they should so choose).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amendment or repeal of any of these provisions of our Certificate of Incorporation would require approval of holders of not less than
66 2/3% of the outstanding shares of Common Stock entitled to vote upon the election of directors. Our Bylaws may be amended by an affirmative
vote of a majority of the entire Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>ex10-5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.5</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EMPLOYMENT
AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
<B>EMPLOYMENT AGREEMENT </B>(together with <U>Exhibit A</U> attached hereto, the &ldquo;<U>Agreement</U>&rdquo;) is entered as of February
15, 2022, by and between Streamline Health, LLC, a Delaware limited liability company with its headquarters in Alpharetta, Georgia (the
&ldquo;<U>Company</U>&rdquo;), and Ben Stilwill, a resident of the state of Pennsylvania (&ldquo;<U>Executive</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RECITALS<FONT STYLE="font-weight: normal">:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Company is a wholly owned subsidiary of Streamline Health Solutions, Inc. (&ldquo;STRM&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Company and Executive hereby agree that Executive will serve as an officer of the Company pursuant to the terms and conditions set
forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, in consideration of the premises and the agreements contained herein, and for other good and valuable consideration, the
receipt and adequacy of which the parties hereby acknowledge, the parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EMPLOYMENT</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company hereby agrees to employ Executive, and Executive, in consideration of such employment and other consideration set forth herein,
hereby accepts employment, upon the terms and conditions set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POSITION
                                            AND DUTIES</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the Term (as defined in Section 10 of this Agreement), Executive will be employed as CEO and President of the Company and may also serve
as an officer or director of affiliates of the Company for no additional compensation, as part of Executive&rsquo;s services to the Company
hereunder. While employed hereunder, Executive will do all things necessary, legal and incident to the above positions, and otherwise
will perform such executive- level functions, as the CEO of Streamline Health Solutions, Inc. (the &ldquo;<U>CEO</U>&rdquo;) or other
person as may be designated by the Company as are commensurate with Executive&rsquo;s position, to whom Executive will report, or other
person(s) the Board of Directors of STRM (the &ldquo;<U>Board</U>&rdquo;) may establish from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPENSATION
                                            AND BENEFITS</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to such modifications as may be contemplated by <U>Exhibit A</U> attached hereto and approved from time to time by the Board or the Compensation
Committee of the Board of Directors of STRM (the &ldquo;<U>Committee</U>&rdquo;), and unless otherwise consented to by Executive, during
the Term, Executive will receive the compensation and benefits listed on the attached <U>Exhibit A</U>, which is incorporated herein
and expressly made a part of this Agreement. Such compensation and benefits will be paid and provided by the Company in accordance with
the Company&rsquo;s regular payroll, compensation and benefits plans, programs and policies, as in effect from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXPENSES</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will pay or reimburse Executive for all travel and out-of-pocket expenses reasonably incurred or paid by Executive in connection
with the performance of Executive&rsquo;s duties as an employee of the Company upon compliance with the Company&rsquo;s procedures for
expense reimbursement, including the presentation of expense statements or receipts or such other supporting documentation as the Company
may reasonably require. All expenses eligible for reimbursement in connection with the Executive&rsquo;s employment with the Company
must be incurred by Executive during the term of employment and must be in accordance with the Company&rsquo;s expense reimbursement
policies. The amount of reimbursable expenses incurred in one taxable year will not affect the expenses eligible for reimbursement in
any other taxable year. Each category of reimbursement will be paid as soon as administratively practicable, but in no event will any
such reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. No right
to reimbursement is subject to liquidation or exchange for other benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BINDING
                                            AGREEMENT</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company warrants and represents to Executive that the Company, acting by the officer executing this Agreement on its behalf of the Company,
has the full right and authority to enter into this Agreement and to perform all of its obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OUTSIDE
                                            EMPLOYMENT</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
will devote Executive&rsquo;s full time and attention to the performance of the duties incident to Executive&rsquo;s position with the
Company, and will not have any other employment with any other enterprise or substantial responsibility for any enterprise which would
be inconsistent with Executive&rsquo;s duty to devote Executive&rsquo;s full time and attention to Company matters; <I>provided, however,
</I>that the foregoing will not prevent Executive from participation in any charitable or civic organization or, subject to President
consent, which consent will not be unreasonably withheld, from service in a non-executive capacity on the boards of directors of up to
two</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
other companies that does not interfere with Executive&rsquo;s performance of the duties and responsibilities to be performed by Executive
under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFIDENTIAL
                                            INFORMATION AND TRADE SECRETS</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is in the business of providing solutions, including comprehensive suites of health information management solutions relating
to enterprise content management, computer assisted coding, business analytics, clinical analytics, patient scheduling and integrated
workflow systems, that help hospitals, physician groups and other healthcare organizations improve efficiencies and business processes
across the enterprise to enhance and protect revenues, offering a flexible, customizable way to optimize the clinical and financial performance
of any healthcare organization (the &ldquo;<U>Business</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of this Agreement, &ldquo;<U>Confidential Information</U>&rdquo; will mean proprietary or confidential data, information,
documents, or materials (in oral, written, unwritten or electronic form) which belongs to or pertains to the Company&rsquo;s Business
and which was disclosed to Executive or which Executive became aware of as a consequence of Executive&rsquo;s relationship with the Company.
Confidential Information includes, without limitation, the Company&rsquo;s services, processes, patents, systems, equipment, creations,
designs, formats, programming, discoveries, inventions, improvements, computer programs, data kept on computers, engineering, research,
development, applications, financial information, information regarding services and products in development, market information, including
test marketing or localized marketing, other information regarding processes or plans in development, trade secrets, training manuals,
know-how of the Company, and the customers, clients, suppliers and others with whom the Company does or has in the past done, business
(including any information about the identity of the Company&rsquo;s customers or suppliers and written customer lists and customer prospect
lists), or information about customer requirements, transactions, work orders, pricing policies, plans or any other Confidential Information,
which the Company deems confidential and proprietary and which is generally not known to others outside the Company and which gives or
tends to give the Company a competitive advantage over persons who do not possess such information or the secrecy of which is otherwise
of value to the Company in the conduct of its business &mdash; regardless of when and by whom such information was developed or acquired,
and regardless of whether any of these are described in writing, reduced to practice, copyrightable or considered copyrightable, patentable
or considered patentable; <I>provided, however, </I>that &ldquo;<U>Confidential Information</U>&rdquo; will not include general industry
information or information which is publicly available or is otherwise in the public domain without breach of this Agreement, information
which Executive has lawfully acquired from a source other than through his employment with the Company, or information which is required
to be disclosed pursuant to any law, regulation or rule of any governmental body or authority or court order (in which event Executive
will immediately notify the Company of such requirement or order so as to give the Company an opportunity to seek a protective order
or other manner of protection prior to production or disclosure of the information). Executive acknowledges that Confidential Information
is novel and proprietary to and of considerable value to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
Information will also include confidential information of third parties, clients or prospective clients that has been provided to the
Company or to Executive in conjunction with Executive&rsquo;s employment, which information the Company is obligated to treat as confidential.
Confidential Information does not include information voluntarily disclosed to the public by the Company, except where such public disclosure
has been made by the Executive without authorization from the Company, or which has been independently developed and disclosed by others,
or which has otherwise entered the public domain through lawful means.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
acknowledges that all Confidential Information is the valuable, unique and special asset of the Company and that the Company owns the
sole and exclusive right, title and interest in and to this Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) To
the extent that the Confidential Information rises to the level of a trade secret under applicable law, then Executive will, during Executive&rsquo;s
employment and for as long thereafter as the Confidential Information remains a trade secret (or for the maximum period of time otherwise
allowed under applicable law) protect and maintain the confidentiality of these trade secrets and refrain from disclosing, copying or
using the trade secrets without the Company&rsquo;s prior written consent, except as necessary in Executive&rsquo;s performance of Executive&rsquo;s
duties while employed with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
To the extent that the Confidential Information defined above does not rise to the level of a trade secret under applicable law,
Executive will not, during Executive&rsquo;s employment and thereafter for a period of two </FONT>(2) years, disclose, or cause to
be disclosed in any way, Confidential Information, or any part thereof, to any person, firm, corporation, association or any other
operation or entity, or use the Confidential Information on Executive&rsquo;s own behalf, for any reason or purpose except as
necessary in the performance of his duties while employed with the Company. Executive further agrees that, during Executive&rsquo;s
employment and thereafter for a period of two (2) years, Executive will not distribute, or cause to be distributed, Confidential
Information to any third person or permit the reproduction of Confidential Information, except on behalf of the Company in
Executive&rsquo;s capacity as an employee of the Company. Executive will take all reasonable care to avoid unauthorized disclosure
or use of the Confidential Information. Executive agrees that all restrictions contained in this Section 7 are reasonable and valid
under the circumstances and hereby waives all defenses to the strict enforcement thereof by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, nothing in this Agreement is intended to or will be used in any way to prevent Executive from testifying truthfully under
oath in a judicial proceeding or to limit Executive&rsquo;s right to communicate with a government agency, as provided for, protected
under or warranted by applicable law. Further, Executive shall not be held criminally or civilly liable under any federal or state trade
secret law for the disclosure of a trade secret that (i) is made in confidence to a federal, state, or local government official, either
directly or indirectly, or to an attorney and solely for the purpose of reporting or investigating a suspected violation of law or (ii)
is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, if Executive
files a lawsuit for retaliation for reporting a suspected violation of law, Executive may disclose the trade secret to his attorney and
use the trade secret information in the court proceeding, as long as Executive files any document containing the trade secret under seal
and does not disclose the trade secret, except pursuant to court order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
agrees that, upon the request of the Company, or in any event immediately upon termination of his employment for whatever reason, Executive
will immediately deliver up to the Company or its designee all Confidential Information in Executive&rsquo;s possession or control, and
all notes, records, memoranda, correspondence, files and other papers, and all copies thereof, relating to or containing Confidential
Information. Executive does not have, nor can Executive acquire, any property or other rights in Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPERTY
                                            OF THE COMPANY</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
ideas, inventions, discoveries, proprietary information, know-how, processes and other developments and, more specifically, improvements
to existing inventions, conceived by Executive, alone or with others, during the term of Executive&rsquo;s employment with the Company,
whether or not during working hours and whether or not while working on a specific project, that are within the scope of the Company&rsquo;s
Business operations or that relate to any work or projects of the Company, shall be deemed to be a &ldquo;work made for hire&rdquo; (as
defined in the United States Copyright Act, 17 U.S.C.A. &sect;101 et seq., as amended) to the greatest extend possible and are and will
remain the exclusive property of the Company. Inventions, improvements and discoveries relating to the Business of the Company conceived
or made by Executive, either alone or with others, while employed with the Company are conclusively and irrefutably presumed to have
been made during the period of employment and are the sole property of the Company. The Executive will promptly disclose in writing any
such matters to the Company but to no other person without the consent of the Company. Executive hereby assigns and agrees to assign
all right, title and interest in and to such matters to the Company. Executive will, upon request of the Company, execute such assignments
or other instruments and assist the Company in the obtaining, at the Company&rsquo;s sole expense, of any patents, trademarks or similar
protection, if available, in the name of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROTECTIVE
                                            COVENANTS</B></FONT></TD>
    </TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Non-Solicitation
of Customers, Clients, or Vendors</U>. During Executive&rsquo;s employment and for a period of two (2) years following the date of any
voluntary or involuntary termination of Executive&rsquo;s employment for any reason, Executive agrees not to solicit, directly or indirectly
(including by assisting others), any business from any of the Company&rsquo;s customers, clients, or vendors (including actively sought
prospective customers, clients, or vendors) with whom Executive has had material contact during the most recent two (2) years prior to
the solicitation for the purpose of providing products or services that are competitive with those provided by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Non-Piracy
of Employees</U>. During Executive&rsquo;s employment and for a period of two (2) years following the date of any voluntary or
involuntary termination of Executive&rsquo;s employment for any reason, Executive covenants and agrees that Executive will not,
directly or indirectly, on Executive&rsquo;s own behalf or on behalf of any other person or entity (i) solicit, recruit or hire (or
attempt to solicit, recruit or hire) or otherwise assist anyone in soliciting, recruiting or hiring, any employee or independent
contractor of the Company who performed work for the Company and with whom Executive had material business contact within the last
year of Executive&rsquo;s employment with the Company to work for or provide services to any business that competes with the
Business, or (ii) otherwise encourage, solicit or support any such employee or independent contractor to leave his or her employment
or engagement with the Company or to violate the terms of any agreement or understanding between that individual and the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Non-Compete</U>.
During Executive&rsquo;s employment with the Company and for a period of two (2) years following the date of any voluntary, or one (1)
year following the date of any involuntary, termination of Executive&rsquo;s employment for any reason, Executive agrees not to, directly
or indirectly, either on Executive&rsquo;s own behalf or on behalf of any other person or entity, in the Territory, compete with the
Company by performing services for any person or entity competitor engaging in competition with the Business, that are the same as or
similar to the duties performed by Executive during the most recent two (2)-year period, provided that the foregoing will not prohibit
Executive from owning not more than five percent (5%) of the outstanding stock of a corporation subject to the reporting requirements
of the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;). The &ldquo;<U>Territory</U>&rdquo; will be
defined to be that geographic area comprised of the following states in the United States of America, the District of Columbia, and the
Canadian provinces of Quebec and Alberta:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alabama</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indiana</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nebraska</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">South
    Carolina</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alaska</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iowa</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">South
    Dakota</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arizona</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kansas</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    Hampshire</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tennessee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arkansas</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kentucky</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    Jersey</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Texas</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">California</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Louisiana</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    Mexico</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utah</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colorado</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maine</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vermont</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Connecticut</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maryland</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">North
    Carolina</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Virginia</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Florida</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Massachusetts</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">North
    Dakota</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Georgia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michigan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ohio</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">West
    Virginia</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hawaii</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minnesota</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oklahoma</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wisconsin</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Idaho</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mississippi</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oregon</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wyoming</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Illinois</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Missouri</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pennsylvania</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Montana</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rhode
    Island</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>;
provided, however, </I>that the Territory described herein is a good faith estimate of the geographic area that is now applicable as
the area in which the Company does business during the term of Executive&rsquo;s employment, and the Company and Executive agree that
this non-compete covenant will ultimately be construed to cover only so much of such Territory as relates to the geographic areas in
which the Executive does business for and on behalf of the Company within the most recent two (2)-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TERM</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
earlier terminated pursuant to Section 11 herein, the term of this Agreement will be for a period beginning on the effective date specified
in <U>Exhibit A</U> and ending on March 13, 2023 (the &ldquo;<U>Initial Term</U>&rdquo;). Upon expiration of the Initial Term, this Agreement
will automatically renew in successive twelve (12)-month periods (each a &ldquo;<U>Renewal Period</U>&rdquo;), unless Executive or the
Company notifies the other party at least sixty (60) days prior to the end of the Initial Term or the applicable Renewal Period that
this Agreement will not be renewed. The Initial Term, and, if this Agreement is renewed in accordance with this Section 10, each Renewal
Period, will be included in the definition of &ldquo;<U>Term</U>&rdquo; for purposes of this Agreement. Unless waived in writing by the
Company, the requirements of Section 7 (Confidential Information and Trade Secrets), Section 8 (Property of the Company) and Section
9 (Protective Covenants) will survive the expiration or termination of this Agreement or Executive&rsquo;s employment for any reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TERMINATION</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Death</U>.
This Agreement and Executive&rsquo;s employment hereunder will be terminated on the death of Executive, effective as of the date of Executive&rsquo;s
death. In such event, the Company will pay to the estate of Executive the sum of (i) accrued but unpaid Base Salary (as defined in Exhibit
A) earned prior to Executive&rsquo;s death (to be paid in accordance with normal practices of the Company or as otherwise required by
law) and (ii) expenses incurred by Executive prior to his death for which Executive is entitled to reimbursement under (and paid in accordance
with) Section 4 herein, and Executive will be entitled to no severance or other post-termination benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Continued
Disability</U>. This Agreement and Executive&rsquo;s employment hereunder may be terminated, at the option of the Company, upon a Continued
Disability (as defined herein) of Executive. For the purposes of this Agreement, and unless otherwise required under Section 409A of
the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;), &ldquo;<U>Continued Disability</U>&rdquo; will be defined
as the inability or incapacity (either mental or physical) of Executive to continue to perform Executive&rsquo;s duties hereunder for
a continuous period of one hundred twenty (120) working days, or if, during any calendar year of the Term hereof because of disability,
Executive was unable to perform Executive&rsquo;s duties hereunder for a total period of one hundred eighty (180) working days regardless
of whether or not such days are consecutive. The determination as to whether Executive is unable to perform the duties of Executive&rsquo;s
job will be made by the Board or the Committee in its reasonable discretion; <I>provided, however, </I>that if Executive is not satisfied
with the decision of the Board or the Committee, Executive will submit to examination by three (3) competent physicians who practice
in the metropolitan area in which the Company maintains its principal executive office, one of whom will be selected by the Company,
another of whom will be selected by Executive, with the third to be selected by the physicians so selected. The determination of a majority
of the physicians so selected will supersede the determination of the Board or the Committee and will be final and conclusive. In the
event of the termination of Executive&rsquo;s employment due to Continued Disability, the Company will provide to Executive (i) accrued
but unpaid Base Salary earned through the date of the Executive&rsquo;s termination of employment (paid in accordance with the normal
practices of the Company or as otherwise required by law), (ii) expenses incurred by Executive prior to his termination of employment
for which Executive is entitled to reimbursement under (and paid in accordance with) Section 4 herein, and (iii) any vested benefits
earned by the Executive under any employee benefit plan of the Company or its affiliates under which he was participating immediately
prior to the termination date, which such benefits to be provided in accordance with the terms of the applicable employee benefit plan
(the &ldquo;<U>Accrued Obligations</U>&rdquo;), and Executive will be entitled to no severance or other post-termination benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Termination
by the Company for Good Cause, by Executive Other Than for Good Reason, or upon Non-Renewal of the Term by Company or Executive</U>.
Notwithstanding any other provision of this Agreement, the Company may at any time terminate this Agreement and Executive&rsquo;s employment
hereunder for Good Cause, Executive may at any time terminate his employment other than for Good Reason (as defined in Section 11(d)
herein), Company may notify Executive that it will not renew the Term, or Executive may notify the Company that he will not renew the
Term. For this purpose, &ldquo;<U>Good Cause</U>&rdquo; will include the following: the current use of illegal drugs; conviction of any
crime which involves moral turpitude, fraud or misrepresentation; commission of any act which would constitute a felony or which adversely
impacts the business or reputation of the Company; fraud; misappropriation or embezzlement of Company funds or property; willful misconduct
or grossly negligent or reckless conduct which is materially injurious to the reputation, business or business relationships of the Company;
material violation or default on any of the provisions of this Agreement; or material and continuous failure to meet reasonable performance
criteria or reasonable standards of conduct as established from time to time by the Board, which failure continues for at least thirty
(30) days after written notice from the Company to Executive. Notice of a termination by the Company for Good Cause will be delivered
in writing to Executive stating the Good Cause for such action. If the employment of Executive is terminated by the Company for Good
Cause, if Executive terminates employment for any reason other than for Good Reason (including, but not limited to, resignation or retirement),
or if Executive notifies the Company he will not renew the Term, then, the Company will provide Executive (i) accrued but unpaid salary
through the termination date (paid in accordance with the normal practices of the Company or as otherwise required by law), (ii) expenses
incurred by Executive prior to his termination date for which Executive is entitled to reimbursement under (and paid in accordance with)
Section 4 herein and (iii) any vested benefits earned by the Executive under any employee benefit plan of the Company or its affiliates
under which he was participating immediately prior to the termination date, which such benefits to be provided in accordance with the
terms of the applicable employee benefit plan, and Executive will be entitled to no severance or other post- termination benefits. For
the sake of clarity, no election by the Company not to renew the Term will trigger any rights to severance or other benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>Termination
by the Company without Good Cause or by Executive for Good Reason</U>. The Company may terminate this Agreement and Executive&rsquo;s
employment at any time, including for reasons other than Good Cause (as &ldquo;<U>Good Cause</U>&rdquo; is defined in Section 11(c) above.
For the purposes herein, &ldquo;<U>Good Reason</U>&rdquo; will mean (i) a material diminution of Executive&rsquo;s base salary; (ii)
a material diminution in Executive&rsquo;s authority, duties, or responsibilities; or (iii) any other action or inaction that constitutes
a material breach of the terms of this Agreement; provided that Executive&rsquo;s termination will not be treated as for Good Reason
unless Executive provides the Company with notice of the existence of the condition claimed to constitute Good Reason within ninety (90)
days of the initial existence of such condition and the Company fails to remedy such condition within thirty (30) days following the
Company&rsquo;s receipt of such notice. In the event that (i) the Company terminates the employment of Executive during the Term for
reasons other than for Good Cause, death or Continued Disability or (ii) Executive terminates employment for Good Reason, then Executive
shall be entitled to the Accrued Obligations (as defined in Section 11(b)) and, subject to Executive&rsquo;s signing, delivering and
not revoking a complete general release of all claims against the Company in a form acceptable to the Company (the &ldquo;Release&rdquo;),
which Release must be signed, delivered and not revoked within the period set forth in the Release, and provided that Executive is not
in default of his obligations under Section 7, 8, or 9 herein, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) Payment
of an amount equal to six (6) months of Executive&rsquo;s base salary in effect at the time of termination, payable in accordance with
the regular pay periods of the Company (but no less frequently than monthly and in equal installments) beginning on the first payroll
date following the date of termination of employment provided, however, that all payments otherwise due during the first sixty (60) days
following termination of employment shall be accumulated and, if the Release requirements have been met, paid on the sixtieth (60<SUP>th</SUP>)
day following termination of employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) Payment
of an amount equal to the product of six (6) times the monthly rate of the Company&rsquo;s subsidy for coverage in its medical, dental
and vision plans for active employees (including any applicable coverage for spouses and dependents) in effect on the date of termination,
payable in a lump sum on the sixtieth (60th) day following termination of employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
payments set forth in Section 11(d)(i) and (ii) are collectively referred to as the &ldquo;<U>Severance Payments.</U>&rdquo; All other
rights the Executive may have, other than as set forth in this Section, shall terminate upon such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTIFICATION
                                            TO PROSPECTIVE EMPLOYERS</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Executive seeks or is offered employment by any other company, firm or person during his employment or during the post- termination restricted
periods, he will notify the prospective employer of the existence and terms of the Confidential Information and Trade Secrets provision
in Section 7 and the Protective Covenants provision in Section 9 of this Agreement. Executive may disclose the language of Sections 7
and 9 but may not disclose the remainder of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHANGE
                                            IN CONTROL</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            the event of a Change in Control (as defined herein) of the Company during the Term,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) If
Executive has remained continuously employed with the Company through the date of the Change in Control, all stock options, restricted
stock, and all other equity awards (if any) granted to Executive that are outstanding immediately prior to the Change in Control shall
immediately vest in full as of the date of the Change in Control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) If,
during the Term and within ninety (90) days prior to or twelve (12) months following a Change in Control, the Company terminates the
employment of Executive for reasons other than for Good Cause, death or Continued Disability, then, Executive shall receive the Accrued
Obligations (as defined in Section 6(a), and, subject to the Release requirements set forth in Section 11(d) and provided that Executive
is not in default of his obligations under Section 7, 8, or 9 herein, (A) Executive shall be entitled to the Severance Payments set forth
in and pursuant to Section 11(d) and (B) all stock options, restricted stock, and other equity awards (if any) granted to Executive that
are outstanding immediately prior to the date of termination shall immediately vest in full as of the date of termination and, with respect
to any outstanding options, will remain exercisable by Executive from such vesting date (i.e., the date of termination) until the earlier
of: (x) the end of the applicable option period or (y) one hundred and eighty (180) days from the date of Executive&rsquo;s termination
of employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            purposes of this Agreement, &ldquo;<U>Change in Control</U>&rdquo; means any of the following
                                            events:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) A
change in control of the direction and administration of the Company&rsquo;s business of a nature that would be required to be reported
in response to Item 6(e) of Schedule 14A of Regulation 14A promulgated under the Exchange Act, as in effect on the date hereof and any
successor provision of the regulations under the Exchange Act, whether or not the Company is then subject to such reporting requirements;
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) Any
&ldquo;<U>person</U>&rdquo; (as such term is used in Section 13(d) and Section 14(d)(2) of the Exchange Act but excluding any employee
benefit plan of the Company) is or becomes the &ldquo;<U>beneficial owner</U>&rdquo; (as defined in Rule 13d-3 under the Exchange Act),
directly or indirectly, of securities of the Company representing more than one half (1/2) of the combined voting power of the Company&rsquo;s
outstanding securities then entitled to vote for the election of directors; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company sells all or substantially all of the assets of the Company; or</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) The
consummation of a merger, reorganization, consolidation or similar business combination that constitutes a change in control as defined
in the Company&rsquo;s 2013 Second Amended and Restated Stock Incentive Plan or other successor stock plan or results in the occurrence
of any event described in Sections 13(b) (i), (ii) or (iii) above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, a Change in Control will not be deemed to have occurred unless such event would also be a Change in Control under Code
Section 409A or would otherwise be a permitted distribution event under Code Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) If
any payment or distribution by the Company to or for the benefit of Executive, whether paid or payable or distributed or distributable
pursuant to the terms of this Agreement or otherwise pursuant to or by reason of any other agreement, policy, plan, program or arrangement
or the lapse or termination of any restriction on or the vesting or exercisability of any payment or benefit (each a &ldquo;<U>Payment</U>&rdquo;),
would be subject to the excise tax imposed by Section 4999 of the Code (or any successor provision thereto) or to any similar tax imposed
by state or local law (such tax or taxes are hereafter collectively referred to as the &ldquo;<U>Excise Tax</U>&rdquo;), then the aggregate
amount of Payments payable to Executive shall be reduced to the aggregate amount of Payments that may be made to the Executive without
incurring an excise tax (the &ldquo;<U>Safe-Harbor Amount</U>&rdquo;) in accordance with the immediately following sentence. Any such
reduction shall be made in the following order: (i) first, any future cash payments (if any) shall be reduced (if necessary, to zero);
(ii) second, any current cash payments shall be reduced (if necessary, to zero); (iii) third, all non-cash payments (other than equity
or equity derivative related payments) shall be reduced (if necessary, to zero); and (iv) fourth, all equity or equity derivative payments
shall be reduced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACKNOWLEDGEMENTS</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and Executive each hereby acknowledge and agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The
covenants, restrictions, agreements and obligations set forth herein are founded upon valuable consideration, and, with respect to the
covenants, restrictions, agreements and obligations set forth in Sections 7 and 9 hereof, are reasonable in duration, the activities
proscribed, and geographic scope;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 30.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) In
the event of a breach or threatened breach by Executive of any of the covenants, restrictions, agreements and obligations set forth in
Sections 7 or 9 hereof, monetary damages or the other remedies at law that may be available to the Company for such breach or threatened
breach will be inadequate and, without prejudice to the Company&rsquo;s right to pursue any other remedies at law or in equity available
to it for such breach or threatened breach, including, without limitation, the recovery of damages from Executive, the Company will be
entitled to injunctive relief from a court of competent jurisdiction or the arbitrator; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The
time period, proscribed activities, and geographical area set forth in the Confidential Information and Trade Secrets provision in Section
7 or the Protective Covenants provision in Section 9 hereof are each divisible and separable, and, in the event that they are judicially
held invalid or unenforceable as to such time period, scope of activities, or geographical area, they will be valid and enforceable to
such extent and in such geographical area(s) and for such time period(s) which the court or arbitrator determines to be reasonable and
enforceable. Executive agrees that in the event any court of competent jurisdiction or arbitrator determines that the covenants in Sections
7 and 9 are invalid or unenforceable to join with the Company in requesting that court or arbitrator to construe the applicable provision
by limiting or reducing it so as to be enforceable to the extent compatible with the then applicable law. Furthermore, any period of
restriction or covenant herein stated will not include any period of violation or period of time required for litigation to enforce such
restriction or covenant and Executive agrees that the time periods for the covenants in Sections 7 and 9 of this Agreement shall be tolled
during any period in which Executive is in violation of either of those provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICES</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
notice or communication required or permitted hereunder will be given in writing and will be sufficiently given if delivered by email
or sent by overnight, nationally recognized courier to such party addressed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 30.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the case of the Company, if addressed to it as follows: </FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Streamline
Health Solutions, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2400
Old Milton Parkway Box #1353</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpharetta,
GA 30009</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
Thomas.gibson@streamlinehealth.net</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) In
the case of Executive, if addressed to Executive at the most recent address on file with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such notice delivered personally or sent via mail will be deemed to have been received on the date it is delivered. Any address for the
giving of notice hereunder may be changed by notice in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT,
                                            SUCCESSORS AND ASSIGNS</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement will inure to the benefit of and be binding upon the parties hereto and their respective legal representatives, successors
and assigns. The Company may assign or otherwise transfer its rights under this Agreement to any successor or affiliated business or
corporation (whether by sale of stock, merger, consolidation, sale of assets or otherwise), but this Agreement may not be assigned, nor
may her duties hereunder be delegated, by Executive. In the event that the Company assigns or otherwise transfers its rights under this
Agreement to any successor or affiliated business or corporation (whether by sale of stock, merger, consolidation, sale of assets or
otherwise), for all purposes of this Agreement, the &ldquo;<U>Company</U>&rdquo; will then be deemed to include the successor or affiliated
business or corporation to which the Company, assigned or otherwise transferred its rights hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MODIFICATION</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may not be released, discharged, abandoned, changed or modified by the parties in any manner, except by an instrument in writing
signed by each of the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SEVERABILITY
                                            AND WAIVER</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
invalidity or unenforceability of any particular provision of this Agreement will not affect any other provisions hereof, and the parties
will use their best efforts to substitute a valid, legal and enforceable provision, which, insofar as practical, implements the purpose
of this Agreement. If the parties are unable to reach such agreement, then the provisions will be modified as set forth in Section 14(c)
above. Any failure to enforce any provision of this Agreement will not constitute a waiver thereof or of any other provision hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COUNTERPARTS</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be signed in counterparts (and delivered via facsimile transmission or by digitally scanned signature delivered electronically),
and each of such counterparts will constitute an original document and such counterparts, taken together, will constitute one and the
same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 31.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENTIRE
                                            AGREEMENT</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
constitutes the entire agreement among the parties with respect to the subject matter of this Agreement and supersedes all prior and
contemporaneous agreements, understandings, and negotiations, whether written or oral, with respect to such subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DISPUTE
                                            RESOLUTION</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth in Section 14 above, and excluding ERISA health and disability plan claims, workers&rsquo; compensation claims, unemployment
compensation claims, claims related to sexual harassment or assault, claims to enforce the Confidential Information and Trade Secrets
provision in Section 7 or the Protective Covenants provision in Section 9 , or any other claims that cannot be required to be arbitrated
as a matter of law, any and all disputes arising out of or in connection with the execution, interpretation, performance or non-performance
of this Agreement or any agreement or other instrument between, involving or affecting the parties (including the validity, scope and
enforceability of this arbitration clause) (&ldquo;Covered Claims&rdquo;), will be submitted to and resolved by arbitration. The arbitration
will be conducted pursuant to the terms of the Federal Arbitration Act and the Employment Arbitration Rules and Mediation Procedures
of the American Arbitration Association effective at the time of filing, as supplemented by the terms of this Agreement. This Agreement
means that Streamline and Executive agree to use binding arbitration, instead of going to court, for any Covered Claims that arise between
Executive and Streamline or any of Streamline&rsquo;s employees or agents. Executive understands and agrees that arbitration is the only
forum for resolving Covered Claims and that both Streamline and he are waiving the right to a trial before a judge or a jury in federal
or state court in favor of arbitration for them. Streamline and Executive agree that Covered Claims will be arbitrated only on an individual
basis, and that both Streamline and Executive waive the right to participate in or receive money or any other relief from any class,
collective or representative proceeding of Covered Claims. No party may bring a claim on behalf of other individuals, and any arbitrator
hearing a Covered Claim may not: (i) combine more than one individual&rsquo;s claim or claims into a single case; (ii) participate in
or facilitate notification of others of potential claims; or (iii) arbitrate any form of a class, collective or representative proceeding.
Streamline will pay the arbitrator&rsquo;s fees and expenses, including but not limited to travel fees, per diem costs, and any administrative
fees. In the event that Executive initiates an arbitration proceeding under this Agreement, Executive shall be liable for the AAA-mandated
portion of the filing fee not to exceed $300.00; Streamline shall pay the remainder of any filing fee in excess of that amount as set
forth in the applicable AAA Employment/Workplace Fee Schedule. The arbitrator shall have the authority to award the same damages or other
relief that would have been available in court pursuant to applicable law. Streamline and Executive agree that the arbitrator shall have
the additional right to rule on motions to dismiss and/or motions for summary judgment, applying the standards governing such motions
under the Federal Rules of Civil Procedure. Executive understands that the ability of the parties to obtain documents, witness statements,
and other discovery is generally more limited in arbitration than in court proceedings. Executive also understands that arbitration awards
are generally final and binding, and a party&rsquo;s ability to have a court reverse or modify an arbitration award is very limited.
The arbitrator must issue an award in writing, setting forth the reasons for the arbitrator&rsquo;s determination. The arbitrator&rsquo;s
authority shall be limited to deciding the case submitted by the party bringing the arbitration and any counterclaims filed therein.
Therefore, no decision by any arbitrator under this Agreement shall serve as precedent in other arbitrations. If the arbitrator makes
an award, a judgment on the award may be entered in any court having jurisdiction. Either party may notify the other party at any time
of the existence of a controversy potentially requiring arbitration by certified mail, and the parties will attempt in good faith to
resolve their differences within fifteen (15) days after the receipt of such notice. If the dispute cannot be resolved within the fifteen-day
period, either party may file a written demand for arbitration with the American Arbitration Association. The place of arbitration will
be Atlanta, Georgia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 30.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    by Executive</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    by the Company</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GOVERNING
                                            LAW; FORUM SELECTION</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions of this Agreement will be governed by and interpreted in accordance with the internal laws of the State of Georgia and the
laws of the United States applicable therein. Executive acknowledges and agrees that Executive is subject to personal jurisdiction in
state and federal courts in Georgia, and waives any objection thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CODE
                                            SECTION 409A</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
any other provision in this Agreement to the contrary, if and to the extent that Code Section 409A is deemed to apply to any benefit
under this Agreement, it is the general intention of the Company that such benefits will, to the extent practicable, comply with, or
be exempt from, Code Section 409A, and this Agreement will, to the extent practicable, be construed in accordance therewith. To the maximum
extent permitted under Code Section 409A and its corresponding regulations, Severance Payments under this Agreement are intended to meet
the requirements of the short-term deferral exemption under Code Section 409A and the &ldquo;separation pay exception&rdquo; under Treas.
Reg. &sect;1.409A-1(b)(9)(iii). For purposes of the application of Treas. Reg. &sect; 1.409A-1(b)(4) (or any successor provision), each
payment in a series of payments to the Executive will be deemed a separate payment. Deferrals of benefits distributable pursuant to this
Agreement that are otherwise exempt from Code Section 409A in a manner that would cause Code Section 409A to apply will not be permitted
unless such deferrals follow Code Section 409A. In the event that the Company (or a successor thereto) has any stock which is publicly
traded on an established securities market or otherwise and Executive is determined to be a &ldquo;<U>specified employee</U>&rdquo; (as
defined under Code Section 409A), any payment that is deemed to be deferred compensation under Code Section 409A to be made to the Executive
upon a separation from service may not be made before the date that is six (6) months after Executive&rsquo;s separation from service
(or death, if earlier). To the extent that Executive becomes subject to the six (6)-month delay rule, all payments that would have been
made to Executive during the six (6) months following her separation from service that are not otherwise exempt from Code Section 409A,
if any, will be accumulated and paid to Executive during the seventh (7th) month following his separation from service, and any remaining
payments due will be made in their ordinary course as described in this Agreement. For the purposes herein, the phrase &ldquo;<U>termination
of employment</U>&rdquo; or similar phrases will be interpreted in accordance with the term &ldquo;<U>separation from service</U>&rdquo;
as defined under Code Section 409A if and to the extent required under Code Section 409A. Further, (i) in the event that Code Section
409A requires that any special terms, provisions or conditions be included in this Agreement, then such terms, provisions and conditions
will, to the extent practicable, be deemed to be made a part of this Agreement, and (ii) terms used in this Agreement will be construed
in accordance with Code Section 409A if and to the extent required. Further, in the event that this Agreement or any benefit thereunder
will be deemed not to comply with Code Section 409A, then neither the Company, the Board, STRM, the Committee nor its or their affiliates
designees or agents will be liable to any participant or other person for actions, decisions or determinations made in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>24.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WITHHOLDING.</B></FONT></TD>
    </TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may withhold from any amounts payable under this Agreement such federal, state, local or foreign taxes as will be required to
be withheld pursuant to any applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>25.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATTORNEYS&rsquo;
                                            FEES.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company successfully enforces any right under this Agreement through legal process of any kind, then the Company shall be entitled
to recover from Executive its costs of such enforcement, including reasonable attorneys&rsquo; fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
page follows.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, this Agreement has been executed by the parties hereto as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STREAMLINE
    HEALTH SOLUTIONS, INC.</B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    &amp; Chief Executive Officer</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/18/2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Wyche T. Green, III </I></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wyche
    T. &ldquo;Tee&rdquo; Green, III</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXECUTIVE</B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/17/2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Benjamin L. Stilwill </I></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benjamin
    L. Stilwill</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page to B. Stilwill - Employment Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
A TO EMPLOYMENT AGREEMENT (THE &ldquo;<U>AGREEMENT</U>&rdquo;) DATED AS OF FEBRUARY 15, 2022, BETWEEN STREAMLINE HEALTH LLC AND Benjamin
L. Stilwill &mdash; COMPENSATION AND BENEFITS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Effective
                                            Date</U>. This agreement is dated February 15, 2022, and is effective as of that date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Base
                                            Salary</U>. Base Salary will be paid at an annualized rate of $280,000, which will be subject
                                            to annual review and adjustment by the Committee but will not be reduced below $280,000 without
                                            the consent of Executive (&ldquo;<U>Base Salary</U>&rdquo;). Such amounts will be payable
                                            to Executive in accordance with the normal payroll practices of the Company, but not less
                                            frequently than monthly.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Annual
                                            Bonus</U>. During the term of employment, Executive will be eligible to participate in and
                                            earn an annual bonus of up to fifty percent (50%) of Executive&rsquo;s then current Base
                                            Salary, subject to attainment of annual performance goals determined by the Committee or
                                            Board and in accordance with the terms of the Company&rsquo;s or STRM&rsquo;s executive bonus
                                            plan, as may be amended from time to time. For the 2022 fiscal year, if Executive remains
                                            employed by the Company on March 15, 2023, Executive shall be entitled to a target annual
                                            bonus for the fiscal year ending January 31, 2023 equal to fifty percent (50%) of Executive&rsquo;s
                                            then current Base Salary. The annual bonus earned (if any) for a particular fiscal year will
                                            be paid pursuant to such conditions as are established by the Compensation Committee and,
                                            to the extent payable under a bonus plan, subject to such terms and conditions as may be
                                            set out in such plan. The annual bonus earned (if any) will, if payable, be paid in cash
                                            in a lump sum no later than March 15<SUP>th</SUP> of the fiscal year following the fiscal
                                            year during which Executive&rsquo;s right to the annual bonus vests. For the avoidance of
                                            doubt, by way of example, the annual bonus payable for the 2022 fiscal year ending on January
                                            31, 2023, will be paid no later than March 15, 2023.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Benefits</U>.
                                            Executive will be eligible to participate in the Company&rsquo;s or STRM&rsquo;s benefit
                                            plans generally made available by the Company or STRM to Company employees, subject to all
                                            terms and conditions of such plans as they may be amended from time to time. During the Term,
                                            Executive will accrue vacation days and personal days totaling an aggregate of twenty (20)
                                            days per annum, prorated for fiscal year ended January 31, 2023, in accordance with the Company&rsquo;s
                                            vacation policies, as in effect from time to time. The Company reserves the right to amend
                                            or cancel any employee benefit plans at any time in its sole discretion, subject to the terms
                                            of such employee benefit plan and applicable law.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Grant
                                            of Restricted Stock</U>. On or as soon as administratively feasible following the execution
                                            of this Agreement and subject to approval of the Committee, Executive will receive a grant
                                            of 100,000 shares of restricted stock. The vesting of such shares will occur in three (3)
                                            equal annual installments over the first three years of continuous employment under this
                                            Agreement. Such grant will be made pursuant to, and otherwise subject to, the terms and conditions
                                            of the Streamline Health Solutions, Inc. Third Amended and Restated 2013 Stock Incentive
                                            Plan and the related restricted stock grant agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -45.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>4
<FILENAME>ex10-7.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.7</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EMPLOYMENT
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
<B>EMPLOYMENT AGREEMENT </B>(together with Exhibit A, the &ldquo;Agreement&rdquo;) is entered as of February 4, 2021, by and between
Streamline Health Solutions, Inc., a Delaware corporation with its headquarters in Atlanta, Georgia (the &ldquo;Company&rdquo;), and
Wendy Lucio, a resident of the state of Georgia (&ldquo;Executive&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECITALS</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Company and Executive hereby agree that Executive will serve as an officer of the Company pursuant to the terms and conditions set
forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, in consideration of the premises and the agreements contained herein, and for other good and valuable consideration, the
receipt and adequacy of which the parties hereby acknowledge, the parties agree as follows:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EMPLOYMENT</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company hereby agrees to employ Executive, and Executive, in consideration of such employment and other consideration set forth herein,
hereby accepts employment, upon the terms and conditions set forth herein.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POSITION
    AND DUTIES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the Term (as defined in Section 10 of this Agreement), Executive will be employed as Chief People Officer of the Company and may also
serve as an officer or director of affiliates of the Company for no additional compensation, as part of Executive&rsquo;s services to
the Company hereunder. While employed hereunder, Executive will do all things necessary, legal and incident to the above positions, and
otherwise will perform such executive- level functions, as the Chief Executive Officer of the Company (the &ldquo;CEO&rdquo;), to whom
Executive will report, or the Board of Directors of the Company (the &ldquo;Board&rdquo;) may establish from time to time.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPENSATION
    AND BENEFITS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to such modifications as may be contemplated by Exhibit A and approved from time to time by the Board or the Compensation Committee of
the Board (the &ldquo;Committee&rdquo;), and unless otherwise consented to by Executive, Executive will receive the compensation and
benefits listed on the attached Exhibit A, which is incorporated herein and expressly made a part of this Agreement. Such compensation
and benefits will be paid and provided by the Company in accordance with the Company&rsquo;s regular payroll, compensation and benefits
policies.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXPENSES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will pay or reimburse Executive for all travel and out-of-pocket expenses reasonably incurred or paid by Executive in connection
with the performance of Executive&rsquo;s duties as an employee of the Company upon compliance with the Company&rsquo;s procedures for
expense reimbursement, including the presentation of expense statements or receipts or such other supporting documentation as the Company
may reasonably require. All expenses eligible for reimbursements in connection with the Executive&rsquo;s employment with the Company
must be incurred by Executive during the term of employment and must be in accordance with the Company&rsquo;s expense reimbursement
policies. The amount of reimbursable expenses incurred in one taxable year will not affect the expenses eligible for reimbursement in
any other taxable year. Each category of reimbursement will be paid as soon as administratively practicable, but in no event will any
such reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. No right
to reimbursement is subject to liquidation or exchange for other benefits.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: justify; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BINDING
    AGREEMENT</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company warrants and represents to Executive that the Company, acting by the officer executing this Agreement on its behalf of the Company,
has the full right and authority to enter into this Agreement and to perform all of its obligations hereunder.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OUTSIDE
    EMPLOYMENT</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
will devote their full time and attention to the performance of the duties incident to Executive&rsquo;s position with the Company, and
will not have any other employment with any other enterprise or substantial responsibility for any enterprise which would be inconsistent
with Executive&rsquo;s duty to devote Executive&rsquo;s full time and attention to Company matters; <I>provided, however, </I>that the
foregoing will not prevent Executive from participation in any charitable or civic organization or, subject to CEO consent, which consent
will not be unreasonably withheld, from service in a non-executive capacity on the boards of directors of up to two other companies that
does not interfere with Executive&rsquo;s performance of the duties and responsibilities to be performed by Executive under this Agreement.
Notwithstanding the foregoing, Executive may continue human resources consulting services (&ldquo;Consulting&rdquo;), so long as such
Consulting does not engage in competition with the Company or use or disclose Company Confidential Information in the performance of
such Consulting.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFIDENTIAL
    INFORMATION AND TRADE SECRETS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is in the business of providing solutions, including comprehensive suites of health information management solutions relating
to enterprise content management, computer assisted coding, business analytics, clinical analytics and integrated workflow systems, that
help hospitals, physician groups and other healthcare organizations improve efficiencies and business processes across the enterprise
to enhance and protect revenues, offering a flexible, customizable way to optimize the clinical and financial performance of any healthcare
organization (the &ldquo;Business&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of this Agreement, &ldquo;Confidential Information&rdquo; will mean any written or unwritten information which relates to
or is used in the Company&rsquo;s Business (including, without limitation, the Company&rsquo;s services, processes, patents, systems,
equipment, creations, designs, formats, programming, discoveries, inventions, improvements, computer programs, data kept on computers,
engineering, research, development, applications, financial information, information regarding services and products in development,
market information, including test marketing or localized marketing, other information regarding processes or plans in development, trade
secrets, training manuals, know-how of the Company, and the customers, clients, suppliers and others with whom the Company does or has
in the past done, business (including any information about the identity of the Company&rsquo;s customers or suppliers and written customer
lists and customer prospect lists), or information about customer requirements, transactions, work orders, pricing policies, plans or
any other Confidential Information, which the Company deems confidential and proprietary and which is generally not known to others outside
the Company and which gives or tends to give the Company a competitive advantage over persons who do not possess such information or
the secrecy of which is otherwise of value to the Company in the conduct of its business &mdash; regardless of when and by whom such
information was developed or acquired, and regardless of whether any of these are described in writing, reduced to practice, copyrightable
or considered copyrightable, patentable or considered patentable; <I>provided, however, </I>that &ldquo;Confidential Information&rdquo;
will not include general industry information or information which is publicly available or is otherwise in the public domain without
breach of this Agreement, information which Executive has lawfully acquired from a source other than through his employment with the
Company, or information which is required to be disclosed pursuant to any law, regulation or rule of any governmental body or authority
or court order (in which event Executive will immediately notify the Company of such requirement or order so as to give the Company an
opportunity to seek a protective order or other manner of protection prior to production or disclosure of the information). Executive
acknowledges that Confidential Information is novel and proprietary to and of considerable value to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: justify; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
Information will also include confidential information of third parties, clients or prospective clients that has been provided to the
Company or to Executive in conjunction with Executive&rsquo;s employment, which information the Company is obligated to treat as confidential.
Confidential Information does not include information voluntarily disclosed to the public by the Company, except where such public disclosure
has been made by the Executive without authorization from the Company, or which has been independently developed and disclosed by others,
or which has otherwise entered the public domain through lawful means.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything to the contrary set forth in this Agreement, pursuant to the Defend Trade Secrets Act of 2016 (18 U.S.C. &sect; 1833(b)(1)),
no individual shall be held criminally or civilly liable under federal or state law for the disclosure of a trade secret that: (1) is
made (x) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (y) solely
for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in
a lawsuit or other proceeding, if such filing is made under seal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
acknowledges that all Confidential Information is the valuable, unique and special asset of the Company and that the Company owns the
sole and exclusive right, title and interest in and to this Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
To the extent that the Confidential Information rises to the level of a trade secret under applicable law, then Executive will, during
Executive&rsquo;s employment and for as long thereafter as the Confidential Information remains a trade secret (or for the maximum period
of time otherwise allowed under applicable law) protect and maintain the confidentiality of these trade secrets and refrain from disclosing,
copying or using the trade secrets without the Company&rsquo;s prior written consent, except as necessary in Executive&rsquo;s performance
of Executive&rsquo;s duties while employed with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
To the extent that the Confidential Information defined above does not rise to the level of a trade secret under applicable law,
Executive will not, during Executive&rsquo;s employment and thereafter for a period of two </FONT>(2) years, disclose, or cause to
be disclosed in any way, Confidential Information, or any part thereof, to any person, firm, corporation, association or any other
operation or entity, or use the Confidential Information on Executive&rsquo;s own behalf, for any reason or purpose except as
necessary in the performance of his duties while employed with the Company. Executive further agrees that, during Executive&rsquo;s
employment and thereafter for a period of two (2) years, Executive will not distribute, or cause to be distributed, Confidential
Information to any third person or permit the reproduction of Confidential Information, except on behalf of the Company in
Executive&rsquo;s capacity as an employee of the Company. Executive will take all reasonable care to avoid unauthorized disclosure
or use of the Confidential Information. Executive agrees that all restrictions contained in this Section 7 are reasonable and valid
under the circumstances and hereby waives all defenses to the strict enforcement thereof by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
agrees that, upon the request of the Company, or in any event immediately upon termination of his employment for whatever reason, Executive
will immediately deliver up to the Company or its designee all Confidential Information in Executive&rsquo;s possession or control, and
all notes, records, memoranda, correspondence, files and other papers, and all copies thereof, relating to or containing Confidential
Information. Executive does not have, nor can Executive acquire, any property or other rights in Confidential Information.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: justify; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPERTY
    OF THE COMPANY</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
ideas, inventions, discoveries, proprietary information, know-how, processes and other developments and, more specifically, improvements
to existing inventions, conceived by Executive, alone or with others, during the term of Executive&rsquo;s employment with the Company,
whether or not during working hours and whether or not while working on a specific project, that are within the scope of the Company&rsquo;s
Business operations or that relate to any work or projects of the Company, are and will remain the exclusive property of the Company.
Inventions, improvements and discoveries relating to the Business of the Company conceived or made by Executive, either alone or with
others, while employed with the Company are conclusively and irrefutably presumed to have been made during the period of employment and
are the sole property of the Company. The Executive will promptly disclose in writing any such matters to the Company but to no other
person without the consent of the Company. Executive hereby assigns and agrees to assign all right, title and interest in and to such
matters to the Company. Executive will, upon request of the Company, execute such assignments or other instruments and assist the Company
in the obtaining, at the Company&rsquo;s sole expense, of any patents, trademarks or similar protection, if available, in the name of
the Company.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROTECTIVE
    COVENANTS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Non-Solicitation
of Customers or Clients</U>. During Executive&rsquo;s employment and for a period of two </FONT>(2) years following the date of any
voluntary or involuntary termination of Executive&rsquo;s employment for any reason, Executive agrees not to solicit, directly or
indirectly (including by assisting others), any business from any of the Company&rsquo;s customers or clients, including actively
sought prospective customers or clients, with whom Executive has had material contact during Executive&rsquo;s employment with the
Company, for the purpose of providing products or services that are competitive with those provided by the Company. As used in this
paragraph, &ldquo;material contact&rdquo; means the contact between Executive and each customer, client or vendor, or potential
customer, client or vendor (i) with whom or which Executive dealt on behalf of the Company, (ii) whose dealings with the Company
were coordinated or supervised by Executive, (iii) about whom Executive obtained confidential information in the ordinary course of
business as a result of Executive&rsquo;s association with the Company, or (iv) who receives products or services authorized by the
Company, the sale or provision of which products or services results or resulted in compensation, commissions or earnings for
Executive within two years prior to the date of the Executive&rsquo;s termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Non-Piracy of Employees</U>. During Executive&rsquo;s employment and for a period of two (2) years following the date of any voluntary
or involuntary termination of Executive&rsquo;s employment for any reason, Executive covenants and agrees that Executive will not, directly
or indirectly, within the Territory, as defined below: (i) solicit, recruit or hire (or attempt to solicit, recruit or hire) or otherwise
assist anyone in soliciting, recruiting or hiring, any employee or independent contractor of the Company who performed work for the Company
and worked with Executive within the last year of Executive&rsquo;s employment with the Company, or (ii) otherwise encourage, solicit
or support any such employee or independent contractor to leave his or her employment or engagement with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: justify; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Non-Compete</U>. During Executive&rsquo;s employment with the Company and (i) for a period of two (2) years following the date of
any termination of Executive&rsquo;s employment for any reason other than termination of Executive&rsquo;s employment by the Company
without Good Cause or by the Executive for Good Reason or (ii) for a period of one (1) year following the date of any termination of
Executive&rsquo;s employment with the Company by the Company without Good Cause or by the Executive for Good Reason; and provided in
each of (i) and (ii) that the Company is not in default of its obligations specified in Sections 11 and 13 hereof, Executive agrees not
to, directly or indirectly, compete with the Company, as an officer, director, member, principal, partner, shareholder, owner, manager,
supervisor, administrator, employee, consultant or independent contractor, by working for a competitor to, or engaging in competition
with, the Business, in the Territory, in a capacity in which Executive performs duties and responsibilities that are the same as or similar
to the duties performed by Executive while employed by the Company, provided that the foregoing will not prohibit Executive from owning
not more than 5% of the outstanding stock of a corporation subject to the reporting requirements of the Securities Exchange Act of 1934,
as amended (the &ldquo;Exchange Act&rdquo;). The &ldquo;Territory&rdquo; will be defined to be that geographic area comprised of the
following states in the United States of America, the District of Columbia, the Canadian provinces of Quebec and Alberta:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alabama</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indiana</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nebraska</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">South
    Carolina</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alaska</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iowa</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">South
    Dakota</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arizona</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kansas</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    Hampshire</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tennessee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arkansas</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kentucky</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    Jersey</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Texas</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">California</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Louisiana</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    Mexico</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utah</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colorado</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maine</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vermont</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Connecticut
    Delaware</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maryland</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">North
    Carolina</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Virginia</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Florida</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Massachusetts</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">North
    Dakota</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Georgia</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michigan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ohio</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">West
    Virginia</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hawaii</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minnesota</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oklahoma</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wisconsin</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Idaho</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mississippi</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oregon</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wyoming</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Illinois</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Missouri</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pennsylvania</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Montana</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rhode
    Island</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>;
provided, however, </I>that the Territory described herein is a good faith estimate of the geographic area that is now applicable as
the area in which the Company does or will do business during the term of Executive&rsquo;s employment, and the Company and Executive
agree that this non-compete covenant will ultimately be construed to cover only so much of such Territory as relates to the geographic
areas in which the Executive does business for and on behalf of the Company within the two-year period preceding termination of Executive&rsquo;s
employment.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TERM</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
earlier terminated pursuant to Section 11 herein, the term of this Agreement will be for a period beginning on the start date specified
in Exhibit A and ending on the date of the one year anniversary of the start date specified in Exhibit A (the &ldquo;Initial Term&rdquo;).
Upon expiration of the Initial Term, this Agreement will automatically renew in successive one-year periods (each a &ldquo;Renewal Period&rdquo;),
unless Executive or the Company notifies the other party at least 60 days prior to the end of the Initial Term or the applicable Renewal
Period that this Agreement will not be renewed. The Initial Term, and, if this Agreement is renewed in accordance with this Section 10,
each Renewal Period, will be included in the definition of &ldquo;Term&rdquo; for purposes of this Agreement. Unless waived in writing
by the Company, the requirements of Section 7 (Confidential Information and Trade Secrets), Section 8 (Property of the Company) and Section
9 (Protective Covenants) will survive the expiration or termination of this Agreement or Executive&rsquo;s employment for any reason.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TERMINATION</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Death</U>. This Agreement and Executive&rsquo;s employment hereunder will be terminated on the death of Executive, effective as of
the date of Executive&rsquo;s death. In such event, the Company will pay to the estate of Executive the sum of (i) accrued but unpaid
base salary earned prior to Executive&rsquo;s death (to be paid in accordance with normal practices of the Company) and (ii) expenses
incurred by Executive prior to his death for which Executive is entitled to reimbursement under (and paid in accordance with) Section
4 herein, and Executive will be entitled to no severance or other post-termination benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: justify; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Continued
Disability</U>. This Agreement and Executive&rsquo;s employment hereunder may be terminated, at the option of the Company, upon a
Continued Disability (as defined herein) of Executive. For the purposes of this Agreement, and unless otherwise required under
Section 409A of the Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;), &ldquo;Continued Disability&rdquo; will be
defined as the inability or incapacity (either mental or physical) of Executive to continue to perform Executive&rsquo;s duties
hereunder for a continuous period of one hundred twenty (120) working days, or if, during any calendar year of the Term hereof
because of disability, Executive will have been unable to perform Executive&rsquo;s duties hereunder for a total period of one
hundred eighty </FONT>(180) working days regardless of whether or not such days are consecutive. The determination as to whether
Executive is unable to perform the essential functions of Executive&rsquo;s job will be made by the Board or the Committee in its
reasonable discretion; <I>provided, however, </I>that if Executive is not satisfied with the decision of the Board or the Committee,
Executive will submit to examination by three competent physicians who practice in the metropolitan area in which the Company
maintains its principal executive office, one of whom will be selected by the Company, another of whom will be selected by
Executive, with the third to be selected by the physicians so selected. The determination of a majority of the physicians so
selected will supersede the determination of the Board or the Committee and will be final and conclusive. In the event of the
termination of Executive&rsquo;s employment due to Continued Disability, the Company will pay to Executive the sum of (i) accrued
but unpaid base salary earned prior to the date of the Executive&rsquo;s termination of employment due to Continued Disability (paid
in accordance with the normal practices of the Company), and (ii) expenses incurred by Executive prior to his termination of
employment for which Executive is entitled to reimbursement under (and paid in accordance with) Section 4 herein, and Executive will
be entitled to no severance or other post-termination benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Termination by the Company for Good Cause, by Executive Other Than for Good Reason, or upon Non-Renewal of the Term by Executive</U>.
Notwithstanding any other provision of this Agreement, the Company may at any time terminate this Agreement and Executive&rsquo;s employment
hereunder for Good Cause, Executive may at any time terminate his employment other than for Good Reason (as defined in Section 11(d)
herein), or Executive may notify the Company that he will not renew the Term. For this purpose, &ldquo;Good Cause&rdquo; will include
the following: the current use of illegal drugs; conviction of any crime which involves moral turpitude, fraud or misrepresentation;
commission of any act which would constitute a felony or which adversely impacts the business or reputation of the Company; fraud; misappropriation
or embezzlement of Company funds or property; willful misconduct or grossly negligent or reckless conduct which is materially injurious
to the reputation, business or business relationships of the Company; material violation or default on any of the provisions of this
Agreement; or material and continuous failure to meet reasonable performance criteria or reasonable standards of conduct as established
from time to time by the Board, which failure continues for at least 30 days after written notice from the Company to Executive. Notice
of a termination by the Company for Good Cause will be delivered in writing to Executive stating the Good Cause for such action. If the
employment of Executive is terminated by the Company for Good Cause, if Executive terminates employment for any reason other than for
Good Reason (including, but not limited to, resignation), or if Executive notifies the Company he will not renew the Term, then, the
Company will pay to Executive the sum of (i) accrued but unpaid salary through the termination date (paid in accordance with the normal
practices of the Company), and (ii) expenses incurred by Executive prior to his termination date for which Executive is entitled to reimbursement
under (and paid in accordance with) Section 4 herein, and Executive will be entitled to no severance or other post- termination benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: justify; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Termination by the Company without Good Cause or by Executive for Good Reason</U>. The Company may terminate this Agreement and Executive&rsquo;s
employment at any time, including for reasons other than Good Cause (as &ldquo;Good Cause&rdquo; is defined in Section 11(c) above),
Executive may terminate his employment at any time, including for Good Reason, or the Company may elect not to renew the Term. For the
purposes herein, &ldquo;Good Reason&rdquo; will mean (i) a material diminution of Executive&rsquo;s base salary; (ii) a material diminution
in Executive&rsquo;s authority, duties, or responsibilities; or (iii) any other action or inaction that constitutes a material breach
of the terms of this Agreement; provided that Executive&rsquo;s termination will not be treated as for Good Reason unless Executive provides
the Company with notice of the existence of the condition claimed to constitute Good Reason within 45 days of the initial existence of
such condition and the Company fails to remedy such condition within 30 days following the Company&rsquo;s receipt of such notice. In
the event that (i) the Company terminates the employment of Executive during the Term for reasons other than for Good Cause, death or
Continued Disability or (ii) Executive terminates employment for Good Reason, then the Company will pay Executive the sum of (A) accrued
but unpaid salary through the termination date, and payments of any bonuses and commission earned and payable for up to 90 days following
the termination date (as paid in accordance with the normal practices of the Company), (B) expenses incurred by Executive prior to his
termination date for which Executive is entitled to reimbursement under (and paid in accordance with) Section 4 herein, and (C) provided
that Executive is not in default of his obligations under Section 7, 8, or 9 herein, an amount equal to six months&rsquo; base salary
((A) through (C), being hereinafter referred to, collectively, as the &ldquo;Separation Benefits&rdquo;). In such event, the payments
described in (C) in the preceding sentence will be made following Executive&rsquo;s execution (and non-revocation) of a form of general
release of claims as is acceptable to the Board or the Committee if the general release form is provided to the Executive within one
month of the Executive&rsquo;s date of termination, in accordance with the normal payroll practices of the Company; provided that the
portion of the severance payment described in clause (C) above that exceeds the &ldquo;separation pay limit,&rdquo; if any, will be paid
to the Executive in a lump sum payment within thirty (30) days following the date of Executive&rsquo;s termination of employment (or
such earlier date following the date of Executive&rsquo;s termination of employment, if any, as may be required under applicable wage
payment laws), but in no event later than the fifteenth (15th) day of the third (3rd) month following the Executive&rsquo;s date of termination.
The &ldquo;separation pay limit&rdquo; will mean two (2) times the lesser of: (1) the sum of Executive&rsquo;s annualized compensation
based upon the annual rate of pay for services provided to the Company for the calendar year immediately preceding the calendar year
in which Executive&rsquo;s date of termination of employment occurs (adjusted for any increase during that calendar year that was expected
to continue indefinitely if Executive had not terminated employment); and (2) the maximum dollar amount of compensation that may be taken
into account under a tax-qualified retirement plan under Code Section 401(a)(17) for the year in which his termination of employment
occurs. The lump-sum payment to be made to Executive pursuant to this Section 11(d) is intended to be exempt from Code Section 409A under
the exemption found in Regulation Section 1.409A-1(b)(4) for short-term deferrals. The remaining portion of the severance payment described
in clause (C) above will be paid in periodic installments over the 15-month period commencing on the first post- termination payroll
date following expiration of the revocation period described above and will be paid in accordance with the normal payroll practices of
the Company. Notwithstanding the foregoing, in no event will such remaining portion of the severance payment described in clause (C)
above be paid to Executive later than December 31 of the second calendar year following the calendar year in which Executive&rsquo;s
date of termination of employment occurs. The payments to be made to Executive pursuant to the immediately preceding sentence are intended
to be exempt from Code Section 409A under the exemption found in Regulation Section 1.409A- 1(b)(9)(iii) for separation pay plans (<I>i.e.,
</I>the so-called &ldquo;two times&rdquo; pay exemption). For the sake of clarity, no election by the Company not to renew the Term will
trigger any rights to severance or other benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Payment of COBRA Premiums</U>. In the event that the Company terminates Executive&rsquo;s employment for any reason other than Good
Cause or Executive terminates his employment for Good Reason, then, provided that Executive timely elects to receive continued coverage
under the Company&rsquo;s group medical and dental insurance plans pursuant to the Consolidated Omnibus Budget Reconciliation Act of
1986, as amended (&ldquo;COBRA&rdquo;), for the period commencing on the date of Executive&rsquo;s termination and continuing until the
earlier of the end of the six-month period following his termination date or the first of the month immediately following the Company&rsquo;s
receipt of notice from Executive terminating such coverage, Executive (and any qualified dependents) will be entitled to coverage under
such plans (as may be amended during the period of coverage) in which Executive was participating immediately prior to the date of his
termination of employment (the &ldquo;COBRA Coverage&rdquo;). The cost of the premiums for such coverage will be borne by the Company,
except that Executive will reimburse the Company for premiums becoming due each month with respect to such coverage in an amount equal
to the difference between the amount of such premiums and the portion thereof currently being paid by Executive. Executive&rsquo;s portion
of such premiums will be payable by the first of each month commencing the first month following the month in which his termination of
employment occurs. The period during which Executive is being provided with health insurance under this Agreement at the Company&rsquo;s
expense will be credited against Executive&rsquo;s period of COBRA coverage, if any. Further, if at any time during the period Executive
is entitled to premium payments under this Section 11(e), Executive becomes entitled to receive health insurance from a subsequent employer,
the Company&rsquo;s obligation to continue premium payments to Executive shall terminate immediately.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: justify; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADVICE
    TO PROSPECTIVE EMPLOYERS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Executive seeks or is offered employment by any other company, firm or person during his employment or during the post- termination restricted
periods, he will notify the prospective employer of the existence and terms of the non-competition and confidentiality agreements set
forth in Sections 7 and 9 of this Agreement. Executive may disclose the language of Sections 7 and 9 but may not disclose the remainder
of this Agreement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHANGE
    IN CONTROL</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
In the event of a Change in Control (as defined herein) of the Company, (i) all stock options, restricted stock, and all other equity
awards granted to Executive prior to the Change in Control will immediately vest in full, (ii) if, within 90 days prior to a Change in
Control, the Company terminates the employment of Executive for reasons other than for Good Cause, death or Continued Disability, or
Executive terminates employment for Good Reason, then, the Company will (x) pay the Executive the sum of (A) accrued but unpaid salary
through the termination date (paid in accordance with the normal practices of the Company), (B) expenses incurred by Executive prior
to his termination date for which Executive is entitled to reimbursement under (and paid in accordance with) Section 4 herein, and (C)
provided that Executive is not in default of his obligations under Section 7, 8, or 9 herein, an amount equal to twelve months&rsquo;
base salary ((A) through (C), being hereinafter referred to, collectively, as the &ldquo;Change in Control Separation Benefits&rdquo;)
and (y) provide the COBRA Coverage, and all other stock options, restricted stock, and other equity awards granted to Executive will
immediately vest in full as of the date of termination and will remain exercisable until the earlier of the end of the applicable option
period or one hundred and eighty (180) days from the date of Executive&rsquo;s termination of employment, and (iii) if, within 12 months
following a Change in Control, the Company terminates the employment of Executive for reasons other than for Good Cause, death or Continued
Disability or Executive terminates employment for Good Reason, then (a) the Company will provide the Change in Control Separation Benefits
and the COBRA Coverage, and (b) all stock options, restricted stock, and other equity awards granted to Executive will immediately vest
in full as of the date of termination and will remain exercisable until the earlier of the end of the applicable option period or one
hundred and eighty (180) days from the date of Executive&rsquo;s termination of employment. In the event Executive seeks to terminate
his employment for Good Reason, such termination will not be treated for purposes of this Section 13 as a termination for Good Reason
unless Executive provides the Company with notice of the existence of the condition claimed to constitute Good Reason within 90 days
of the initial existence of such condition and the Company fails to remedy such condition within 30 days following the Company&rsquo;s
receipt of such notice.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
For purposes of this Agreement, &ldquo;Change in Control&rdquo; means any of the following events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
A change in control of the direction and administration of the Company&rsquo;s business of a nature that would be required to be reported
in response to Item 6(e) of Schedule 14A of Regulation 14A promulgated under the Exchange Act, as in effect on the date hereof and any
successor provision of the regulations under the Exchange Act, whether or not the Company is then subject to such reporting requirements;
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Any &ldquo;person&rdquo; (as such term is used in Section 13(d) and Section 14(d)(2) of the Exchange Act but excluding any employee benefit
plan of the Company) is or becomes the &ldquo;beneficial owner&rdquo; (as defined in Rule 13d-3 under the Exchange Act), directly or
indirectly, of securities of the Company representing more than one half of the combined voting power of the Company&rsquo;s outstanding
securities then entitled to vote for the election of directors; or</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Company sells all or substantially all of the assets of the Company; or</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: justify; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
The consummation of a merger, reorganization, consolidation or similar business combination that constitutes a change in control as defined
in the Company&rsquo;s 2013 Second Amended and Restated Stock Incentive Plan or other successor stock plan or results in the occurrence
of any event described in Sections 13(b) (i), (ii) or (iii) above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding anything to the contrary contained in this Agreement, in the event any amounts payable hereunder would be considered
to be excess parachute payments for purposes of the amount payable following the occurrence of a Change of Control that is treated as
a &ldquo;change in the ownership or effective control&rdquo; of the Company or &ldquo;in the ownership of a substantial portion of the
assets&rdquo; of the Company for purposes of Code Sections 280G and 4999, those payments that are treated for purposes of Code Section
280G as being contingent on a &ldquo;change in the ownership or effective control&rdquo; (as that phrase is used for purposes of Code
Section 280G) of the Company will be reduced, if and to the extent necessary, so that no payments under this Agreement are treated as
excess parachute payments.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACKNOWLEDGEMENTS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and Executive each hereby acknowledge and agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The covenants, restrictions, agreements and obligations set forth herein are founded upon valuable consideration, and, with respect to
the covenants, restrictions, agreements and obligations set forth in Sections 7, 8 and 9 hereof, are reasonable in duration, the activities
proscribed, and geographic scope;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In the event of a breach or threatened breach by Executive of any of the covenants, restrictions, agreements and obligations set forth
in Sections 7, 8 or 9 hereof, monetary damages or the other remedies at law that may be available to the Company for such breach or threatened
breach will be inadequate and, without prejudice to the Company&rsquo;s right to pursue any other remedies at law or in equity available
to it for such breach or threatened breach, including, without limitation, the recovery of damages from Executive, the Company will be
entitled to injunctive relief from a court of competent jurisdiction or the arbitrator; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The time period, proscribed activities, and geographical area set forth in Section 9 hereof are each divisible and separable, and, in
the event that the covenants not to compete contained therein are judicially held invalid or unenforceable as to such time period, scope
of activities, or geographical area, they will be valid and enforceable to such extent and in such geographical area(s) and for such
time period(s) which the court determines to be reasonable and enforceable. Executive agrees that in the event any court of competent
jurisdiction determines that the above covenants are invalid or unenforceable to join with the Company in requesting that court to construe
the applicable provision by limiting or reducing it so as to be enforceable to the extent compatible with the then applicable law. Furthermore,
any period of restriction or covenant herein stated will not include any period of violation or period of time required for litigation
to enforce such restriction or covenant.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
notice or communication required or permitted hereunder will be given in writing and will be sufficiently given if delivered personally
or sent by telecopy to such party addressed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
In the case of the Company, if addressed to it as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Streamline
Health Solutions, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10800 Amber Park Drive</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
125</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpharetta,
Georgia 30009</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: justify; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In the case of Executive, if addressed to Executive at the most recent address on file with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such notice delivered personally will be deemed to have been received on the date of such delivery. Any address for the giving of notice
hereunder may be changed by notice in writing.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NON-INTERFERENCE</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything to the contrary set forth in this Agreement or in any other agreement between Executive and the Company, nothing in this Agreement
or in any other agreement shall limit Executive&rsquo;s ability, or otherwise interfere with Executive&rsquo;s rights, to (a) file a
charge or complaint with the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and
Health Administration, the Securities and Exchange Commission, or any other federal, state, or local governmental agency or commission
(each a &ldquo;Government Agency&rdquo;), (b) communicate with any Government Agency or otherwise participate in any investigation or
proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the
Company, (c) receive an award for information provided to any Government Agency, or (d) engage in activity specifically protected by
Section 7 of the National Labor Relations Act, or any other federal or state statute or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT,
    SUCCESSORS AND ASSIGNS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement will inure to the benefit of and be binding upon the parties hereto and their respective legal representatives, successors
and assigns. The Company may assign or otherwise transfer its rights under this Agreement to any successor or affiliated business or
corporation (whether by sale of stock, merger, consolidation, sale of assets or otherwise), but this Agreement may not be assigned, nor
may his duties hereunder be delegated, by Executive. In the event that the Company assigns or otherwise transfers its rights under this
Agreement to any successor or affiliated business or corporation (whether by sale of stock, merger, consolidation, sale of assets or
otherwise), for all purposes of this Agreement, the &ldquo;Company&rdquo; will then be deemed to include the successor or affiliated
business or corporation to which the Company, assigned or otherwise transferred its rights hereunder.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MODIFICATION</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may not be released, discharged, abandoned, changed or modified in any manner, except by an instrument in writing signed by
each of the parties hereto.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SEVERABILITY</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
invalidity or unenforceability of any particular provision of this Agreement will not affect any other provisions hereof, and the parties
will use their best efforts to substitute a valid, legal and enforceable provision, which, insofar as practical, implements the purpose
of this Agreement. If the parties are unable to reach such agreement, then the provisions will be modified as set forth in Section 14(c)
above. Any failure to enforce any provision of this Agreement will not constitute a waiver thereof or of any other provision hereof.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: justify; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COUNTERPARTS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be signed in counterparts (and delivered via facsimile transmission or by digitally scanned signature delivered electronically),
and each of such counterparts will constitute an original document and such counterparts, taken together, will constitute one and the
same instrument.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENTIRE
    AGREEMENT</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
constitutes the entire agreement among the parties with respect to the subject matter of this Agreement and supersedes all prior and
contemporaneous agreements, understandings, and negotiations, whether written or oral, with respect to such subject matter.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DISPUTE
    RESOLUTION</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth in Section 14 above, any and all disputes arising out of or in connection with the execution, interpretation, performance
or non-performance of this Agreement or any agreement or other instrument between, involving or affecting the parties (including the
validity, scope and enforceability of this arbitration clause), will be submitted to and resolved by arbitration. The arbitration will
be conducted pursuant to the terms of the Federal Arbitration Act and the Employment Arbitration Rules and Mediation Procedures of the
American Arbitration Association. Either party may notify the other party at any time of the existence of a controversy potentially requiring
arbitration by certified mail, and the parties will attempt in good faith to resolve their differences within fifteen (15) days after
the receipt of such notice. If the dispute cannot be resolved within the fifteen-day period, either party may file a written demand for
arbitration with the American Arbitration Association. The place of arbitration will be mutually agreed by the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initialed
    by Executive</FONT></TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initialed
    by the Company</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GOVERNING
    LAW; FORUM SELECTION</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions of this Agreement will be governed by and interpreted in accordance with the internal laws of the State of Georgia and the
laws of the United States applicable therein. Executive acknowledges and agrees that Executive is subject to personal jurisdiction in
state and federal courts in Fulton County, Georgia, and waives any objection thereto.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>24.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CODE
    SECTION 409A</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
any other provision in this Agreement to the contrary, if and to the extent that Code Section 409A is deemed to apply to any benefit
under this Agreement, it is the general intention of the Company that such benefits will, to the extent practicable, comply with, or
be exempt from, Code Section 409A, and this Agreement will, to the extent practicable, be construed in accordance therewith. Deferrals
of benefits distributable pursuant to this Agreement that are otherwise exempt from Code Section 409A in a manner that would cause Code
Section 409A to apply will not be permitted unless such deferrals follow Code Section 409A. In the event that the Company (or a successor
thereto) has any stock which is publicly traded on an established securities market or otherwise and Executive is determined to be a
&ldquo;specified employee&rdquo; (as defined under Code Section 409A), any payment that is deemed to be deferred compensation under Code
Section 409A to be made to the Executive upon a separation from service may not be made before the date that is six months after Executive&rsquo;s
separation from service (or death, if earlier). To the extent that Executive becomes subject to the six-month delay rule, all payments
that would have been made to Executive during the six months following his separation from service that are not otherwise exempt from
Code Section 409A, if any, will be accumulated and paid to Executive during the seventh month following his separation from service,
and any remaining payments due will be made in their ordinary course as described in this Agreement. For the purposes herein, the phrase
&ldquo;termination of employment&rdquo; or similar phrases will be interpreted in accordance with the term &ldquo;separation from service&rdquo;
as defined under Code Section 409A if and to the extent required under Code Section 409A. Further, (i) in the event that Code Section
409A requires that any special terms, provisions or conditions be included in this Agreement, then such terms, provisions and conditions
will, to the extent practicable, be deemed to be made a part of this Agreement, and (ii) terms used in this Agreement will be construed
in accordance with Code Section 409A if and to the extent required. Further, in the event that this Agreement or any benefit thereunder
will be deemed not to comply with Code Section 409A, then neither the Company, the Board, the Committee nor its or their designees or
agents will be liable to any participant or other person for actions, decisions or determinations made in good faith.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>25.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WITHHOLDING</B>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may withhold from any amounts payable under this Agreement such federal, state, local or foreign taxes as will be required to
be withheld pursuant to any applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
page follows.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: justify; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, this Agreement has been executed by the parties hereto effective as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STREAMLINE
    HEALTH SOLUTIONS, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Wyche T. Green</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wyche
    &ldquo;Tee&rdquo; Green</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXECUTIVE</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Wendy Lucio</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wendy Lucio 217</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grove Court</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carrollton,
    GA 30117</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page to Wendy Lucio Employment Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: justify; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
A TO EMPLOYMENT AGREEMENT (&ldquo;AGREEMENT&rdquo;) DATED AS OF FEBRUARY 4, 2021, BETWEEN STREAMLINE HEALTH SOLUTIONS, INC. AND WENDY
LUCIO -- COMPENSATION AND BENEFITS</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Start
    Date</U>. Executive&rsquo;s start date will be March 1, 2021.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Base
    Salary</U>. Base Salary will be paid at an annualized rate of $170,000, which will be subject to annual review and adjustment by
    the Compensation Committee or the Board but will not be reduced below $170,000 without the consent of Executive. Such amounts will
    be payable to Executive in accordance with the normal payroll practices of the Company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Annual
    Bonus</U>. Target annual bonus and target goals will be set by the Compensation Committee annually and based on a combination of
    individual and Company performance. Target annual bonus (prorated for any partial period) will be 40% of Executive&rsquo;s Base Salary,
    as my be increased from time- to-time. The annual bonus will be paid pursuant to such conditions as are established by the Compensation
    Committee and, to the extent payable under a bonus plan, subject to such terms and conditions as may be set out in such plan. The
    annual bonus will, if payable, be paid in cash no later than March 14 of the fiscal year following the fiscal year during which Executive&rsquo;s
    right to the annual bonus vests.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Benefits</U>.
    Executive will be eligible to participate in the Company&rsquo;s benefit plans on the same terms and conditions as provided for other
    Company executives, subject to all terms and conditions of such plans as they may be amended from time to time and will accrue vacation
    days and personal days totaling an aggregate of 20 days per annum prorated for 2019.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Grant
    of Restricted Stock</U>. Executive will receive the following grants of equity incentives:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
    A grant of 75,000 restricted shares of common stock, par value $0.01 per share, upon your hire date referred to in paragraph 1 above.
    The vesting of such shares will be in three substantially equal annual installments over the first three years of employment. Such
    grant will be made pursuant to and otherwise subject to the terms and conditions of the Company&rsquo;s Second Amended and Restated
    2013 Stock Incentive Plan and the related restricted stock grant agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STREAMLINE
HEALTH SOLUTIONS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSIDIARIES
OF STREAMLINE HEALTH SOLUTIONS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Jurisdiction of<BR> Incorporation</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% Owned</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 64%">Streamline Health, LLC</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: center">Delaware</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">100</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Avelead Consulting, LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Delaware</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Streamline Consulting Solutions, LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Delaware</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Streamline Pay &amp; Benefits, LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Delaware</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We consent to the incorporation by reference in the Registration Statements on Form S 3 (Nos. 333 234567, 333 255723, 333 265773, 333
267187 and 333 272993) and Form S 8 (Nos. 333 188764, 333 208752, 333 220953, 333 233728, 333 258445, 333 265774 and 333 272995) of Streamline
Health Solutions, Inc. (the &ldquo;Company&rdquo;) of our reports dated April 30, 2024, with respect to the consolidated financial statements of the
Company, included in this Annual Report on Form 10 K for the year ended January 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
FORVIS, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Atlanta,
Georgia</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>April
30, 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STREAMLINE
HEALTH SOLUTIONS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Benjamin L. Stilwill, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this annual report on Form 10-K of Streamline Health Solutions, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25IN"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25IN"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are
    responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
    and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such disclosure control and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
    ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case on an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    30, 2024</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/S/
    BENJAMIN L. STILWILL</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STREAMLINE
HEALTH SOLUTIONS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Bryant J. Reeves, III, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this annual report on Form 10-K of Streamline Health Solutions, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are
    responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
    and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case on an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25IN"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25IN"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    30, 2024</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    BRYANT J. REEVES, III</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STREAMLINE
HEALTH SOLUTIONS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Benjamin L. Stilwill, President and Chief Executive Officer of Streamline Health Solutions, Inc. (the
&ldquo;Company&rdquo;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    annual report on Form 10-K of the Company for the annual period ended January 31, 2024 (the &ldquo;Report&rdquo;) fully complies
    with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/S/
    BENJAMIN L. STILWILL</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    30, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company
and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STREAMLINE
HEALTH SOLUTIONS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Bryant J. Reeves, III, Chief Financial Officer of Streamline Health Solutions, Inc. (the &ldquo;Company&rdquo;), certify, pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    annual report on Form 10-K of the Company for the annual period ended January 31, 2024 (the &ldquo;Report&rdquo;) fully complies
    with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    BRYANT J. REEVES, III</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Chief Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    30, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company
and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>













</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>strm-20240131.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWauNWbP9z5Z82ekhvWBybTlabycgDD8CWy6DxcwmYXEJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:STRM="http://streamlinehealth.net/20240131" elementFormDefault="qualified" targetNamespace="http://streamlinehealth.net/20240131">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://streamlinehealth.net/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/OrganizationAndDescriptionOfBusiness" id="OrganizationAndDescriptionOfBusiness">
          <link:definition>00000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
          <link:definition>00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/BusinessCombination" id="BusinessCombination">
          <link:definition>00000009 - Disclosure - BUSINESS COMBINATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/OperatingLeases" id="OperatingLeases">
          <link:definition>00000010 - Disclosure - OPERATING LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/Debt" id="Debt">
          <link:definition>00000011 - Disclosure - DEBT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/GoodwillAndIntangibleAssets" id="GoodwillAndIntangibleAssets">
          <link:definition>00000012 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000013 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/Equity" id="Equity">
          <link:definition>00000014 - Disclosure - EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/MajorClients" id="MajorClients">
          <link:definition>00000015 - Disclosure - MAJOR CLIENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/EmployeeRetirementPlan" id="EmployeeRetirementPlan">
          <link:definition>00000016 - Disclosure - EMPLOYEE RETIREMENT PLAN</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>00000017 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>00000019 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000020 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReserves" id="ValuationAndQualifyingAccountsAndReserves">
          <link:definition>00000021 - Disclosure - Valuation and Qualifying Accounts and Reserves</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
          <link:definition>00000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
          <link:definition>00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/DebtTables" id="DebtTables">
          <link:definition>00000024 - Disclosure - DEBT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsTables" id="GoodwillAndIntangibleAssetsTables">
          <link:definition>00000025 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>00000026 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>00000027 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/SubsequentEventsTables" id="SubsequentEventsTables">
          <link:definition>00000028 - Disclosure - SUBSEQUENT EVENTS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfNon-cashItemsRelatedToCondensedConsolidatedStatementsOfCashFlowsDetails" id="ScheduleOfNon-cashItemsRelatedToCondensedConsolidatedStatementsOfCashFlowsDetails">
          <link:definition>00000029 - Disclosure - SCHEDULE OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfReserveResultsInFuturePeriodsDetails" id="ScheduleOfReserveResultsInFuturePeriodsDetails">
          <link:definition>00000030 - Disclosure - SCHEDULE OF RESERVE RESULTS IN FUTURE PERIODS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfAccruedExpensesDetails" id="ScheduleOfAccruedExpensesDetails">
          <link:definition>00000031 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails" id="ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails">
          <link:definition>00000032 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails" id="ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails">
          <link:definition>00000033 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" id="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
          <link:definition>00000034 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical" id="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical">
          <link:definition>00000035 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfDisaggregatonOfRevenueDetails" id="ScheduleOfDisaggregatonOfRevenueDetails">
          <link:definition>00000036 - Disclosure - SCHEDULE OF DISAGGREGATON OF REVENUE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" id="ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails">
          <link:definition>00000037 - Disclosure - SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical" id="ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical">
          <link:definition>00000038 - Disclosure - SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails" id="ScheduleOfReconciliationOfRestructuringLiabilityDetails">
          <link:definition>00000039 - Disclosure - SCHEDULE OF RECONCILIATION OF THE RESTRUCTURING LIABILITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative" id="SignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000040 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative" id="BusinessCombinationDetailsNarrative">
          <link:definition>00000041 - Disclosure - BUSINESS COMBINATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative" id="OperatingLeasesDetailsNarrative">
          <link:definition>00000042 - Disclosure - OPERATING LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails" id="ScheduleOfOutstandingPrincipalBalancesDetails">
          <link:definition>00000043 - Disclosure - SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails" id="ScheduleOfMaximumDebtToArrRatioDetails">
          <link:definition>00000044 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ARR RATIO (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails" id="ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails">
          <link:definition>00000045 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
          <link:definition>00000046 - Disclosure - DEBT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfCarryingAmountOfGoodwillDetails" id="ScheduleOfCarryingAmountOfGoodwillDetails">
          <link:definition>00000047 - Disclosure - SCHEDULE OF CARRYING AMOUNT OF GOODWILL (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails" id="ScheduleOfFinite-livedIntangibleAssetsDetails">
          <link:definition>00000048 - Disclosure - SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" id="ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails">
          <link:definition>00000049 - Disclosure - SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative" id="GoodwillAndIntangibleAssetsDetailsNarrative">
          <link:definition>00000050 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails" id="ScheduleOfIncomeTaxesForContinuingOperationDetails">
          <link:definition>00000051 - Disclosure - SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="ScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
          <link:definition>00000052 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>00000053 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfGrossUnrecognizedTaxBenefitsDetails" id="ScheduleOfGrossUnrecognizedTaxBenefitsDetails">
          <link:definition>00000054 - Disclosure - SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>00000055 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/EquityDetailsNarrative" id="EquityDetailsNarrative">
          <link:definition>00000056 - Disclosure - EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/MajorClientsDetailsNarrative" id="MajorClientsDetailsNarrative">
          <link:definition>00000057 - Disclosure - MAJOR CLIENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/EmployeeRetirementPlanDetailsNarrative" id="EmployeeRetirementPlanDetailsNarrative">
          <link:definition>00000058 - Disclosure - EMPLOYEE RETIREMENT PLAN (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>00000059 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails" id="ScheduleOfRestrictedStockAwardActivityDetails">
          <link:definition>00000060 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>00000061 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>00000063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails" id="ScheduleOfMaximumArrNetLeverageRatioDetails">
          <link:definition>00000064 - Disclosure - SCHEDULE OF MAXIMUM ARR NET LEVERAGE RATIO (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails" id="ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails">
          <link:definition>00000065 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails" id="ScheduleOfMinimumAdjustedEbitdaDetails">
          <link:definition>00000066 - Disclosure - SCHEDULE OF MINIMUM ADJUSTED EBITDA (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000067 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReservesDetails" id="ValuationAndQualifyingAccountsAndReservesDetails">
          <link:definition>00000068 - Disclosure - Valuation and Qualifying Accounts and Reserves (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="strm-20240131_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="strm-20240131_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="strm-20240131_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="strm-20240131_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="STRM_SoftwareasAsAServiceMember" name="SoftwareasAsAServiceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_MaintenanceAndSupportMember" name="MaintenanceAndSupportMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ProfessionalFeesAndLicensesMember" name="ProfessionalFeesAndLicensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_SoftwareMember" name="SoftwareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_InternalUseSoftwareMember" name="InternalUseSoftwareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_SecurityAgreementMember" name="SecurityAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_SecondAmendedAndRestatedLoanAndSecurityAgreementMember" name="SecondAmendedAndRestatedLoanAndSecurityAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_DebtAgreementMember" name="DebtAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_EquityAwardMember" name="EquityAwardMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_OfficersAndDirectorsMember" name="OfficersAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_OfficeFurnitureAndFixturesMember" name="OfficeFurnitureAndFixturesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_CostOfSoftwareAsASeviceMember" name="CostOfSoftwareAsASeviceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_CostOfProfessionalFeesAndLicensesMember" name="CostOfProfessionalFeesAndLicensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_UnvestedRestrictedStockMember" name="UnvestedRestrictedStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_UnvestedRestrictedSharesMember" name="UnvestedRestrictedSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_SeveranceExpensesMember" name="SeveranceExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ProfessionalFeesMember" name="ProfessionalFeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AccruedExpensesMember" name="AccruedExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AveleadConsultingLLCMember" name="AveleadConsultingLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AcquisitionRestrictedCommonStockMember" name="AcquisitionRestrictedCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_UnitPurchaseAgreementMember" name="UnitPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_FirstYearEarnoutMember" name="FirstYearEarnoutMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_RenewalContingentConsiderationMember" name="RenewalContingentConsiderationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_SecondYearEarnoutMember" name="SecondYearEarnoutMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AlpharettaOfficeLeaseMember" name="AlpharettaOfficeLeaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_SubleaseAgreementMember" name="SubleaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_SuwaneeOfficeLeaseMember" name="SuwaneeOfficeLeaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_LoanAgreementMember" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_WesternAllianceBankMember" name="WesternAllianceBankMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_BridgeBankMember" name="BridgeBankMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_SecondModificationAgreementMember" name="SecondModificationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_SecondAmendedAndRestatedLoanAgreementMember" name="SecondAmendedAndRestatedLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_OctoberThirtyOneTwoThousandAndTwentyTwoMember" name="OctoberThirtyOneTwoThousandAndTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_JanuaryThirtyOneTwoThousandTwentyThreeMember" name="JanuaryThirtyOneTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AprilThirtyTwoThousandTwentyThreeMember" name="AprilThirtyTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_JulyThirtyOneTwoThousandTwentyThreeMember" name="JulyThirtyOneTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_OctoberThirtyOneTwoThousandTwentyThreeMember" name="OctoberThirtyOneTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_JanuaryThirtyOneTwoThousandTwentyFourMember" name="JanuaryThirtyOneTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AprilThirtyTwoThousandTwentyFourMember" name="AprilThirtyTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember" name="JulyThirtyOneTwoThousandTwentyFourAndThereafterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ClientRelationshipsMember" name="ClientRelationshipsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_InternallyDevelopedSoftwareMember" name="InternallyDevelopedSoftwareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ThroughFiscalTwoThousandThirtyEightMember" name="ThroughFiscalTwoThousandThirtyEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_TaxCutsAndJobsActMember" name="TaxCutsAndJobsActMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_StateMember" name="StateMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_FederalRDMember" name="FederalRDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_GeorgiaRDMember" name="GeorgiaRDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_TwoThousandTwentyTwoOfferingMember" name="TwoThousandTwentyTwoOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_OneHundredEightyConsultingLLCMember" name="OneHundredEightyConsultingLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" name="ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_OneCustomerMember" name="OneCustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_TwoCustomerMember" name="TwoCustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_CustomerOneMember" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_CustomerTwoMember" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_CustomerThreeMember" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_CustomerFourMember" name="CustomerFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_TwoThousandThirteenIncentiveCompensationPlanMember" name="TwoThousandThirteenIncentiveCompensationPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_StockOptionsMember" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_MrGreenMember" name="MrGreenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_MrStilwillMember" name="MrStilwillMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_MasterServicesAgreementMember" name="MasterServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_SOWMember" name="SOWMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_NotesMember" name="NotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ExceptDirectorsAndOfficersMember" name="ExceptDirectorsAndOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ThirdModificationLoanAgreementMember" name="ThirdModificationLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AprilThirtyTwoThousandAndTwentyFourMember" name="AprilThirtyTwoThousandAndTwentyFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_JulyThirtyOneTwoThousandAndTwentyFourMember" name="JulyThirtyOneTwoThousandAndTwentyFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember" name="OctoberThirtyOneTwoThousandAndTwentyFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember" name="JanuaryThirtyOneTwoThousandAndTwentyFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AprilThirtyTwoThousandTwentyFiveMember" name="AprilThirtyTwoThousandTwentyFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_JulyThirtyOneTwoThousandTwentyFiveMember" name="JulyThirtyOneTwoThousandTwentyFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_OctoberThirtyOneTwoThousandTwentyFiveMember" name="OctoberThirtyOneTwoThousandTwentyFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember" name="JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember" name="JanuaryThirtyOneTwoThousandAndTwentyFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_CostOfSoftwareAsService" name="CostOfSoftwareAsService" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_CostOfMaintenanceAndSupport" name="CostOfMaintenanceAndSupport" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_CostOfProfessionalFeesAndLicenses" name="CostOfProfessionalFeesAndLicenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AcquisitionEarnoutValuationAdjustments" name="AcquisitionEarnoutValuationAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_StockIssuedDuringPeriodValueSurrenderOfShares" name="StockIssuedDuringPeriodValueSurrenderOfShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_StockIssuedDuringPeriodSharesSurrenderOfShares" name="StockIssuedDuringPeriodSharesSurrenderOfShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ProvisionForDeferredIncomeTaxes" name="ProvisionForDeferredIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_DisclosureOperatingLeasesAbstract" name="DisclosureOperatingLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_DisclosureSubsequentEventsAbstract" name="DisclosureSubsequentEventsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_DisclosureValuationAndQualifyingAccountsAndReservesAbstract" name="DisclosureValuationAndQualifyingAccountsAndReservesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AllowanceForCreditLossesPolicyTextBlock" name="AllowanceForCreditLossesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AccruedExpensesPolicyTextBlock" name="AccruedExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ConcessionsAccrualPolicyTextBlock" name="ConcessionsAccrualPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_EquityAwardPolicyTextBlock" name="EquityAwardPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" name="RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock" name="ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_PropertyPlantAndEquipmentTableTextBlock" name="PropertyPlantAndEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock" name="ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ScheduleOfMaximumDebtToARRRatioTableTextBlock" name="ScheduleOfMaximumDebtToARRRatioTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock" name="ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ScheduleOfMaximumARRNetLeverageTableTextBlock" name="ScheduleOfMaximumARRNetLeverageTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock" name="ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ScheduleOfMinimumAdjustedEBITDATableTextBlock" name="ScheduleOfMinimumAdjustedEBITDATableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_CapitalizedSoftwarePurchasedWithStock" name="CapitalizedSoftwarePurchasedWithStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_DeferredFinancingCosts" name="DeferredFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AllowanceForDoubtfulAccountsReceivableCECLAdoption" name="AllowanceForDoubtfulAccountsReceivableCECLAdoption" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ThirdPartylicense" name="ThirdPartylicense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ConcessionAccrualAmount" name="ConcessionAccrualAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AcquisitionEarnoutLiabilityFairValue" name="AcquisitionEarnoutLiabilityFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AcquisitionEarnoutLiabilityChangeInValuation" name="AcquisitionEarnoutLiabilityChangeInValuation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks" name="EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AccruedCashPayments" name="AccruedCashPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AccruedCostsIncurred" name="AccruedCostsIncurred" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AccruedExpectedCosts" name="AccruedExpectedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AmortizedAndAbandonedAssets" name="AmortizedAndAbandonedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_PrimeInterestRatePercentage" name="PrimeInterestRatePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_DeferredCostsAmortizationExpenses" name="DeferredCostsAmortizationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_DeferredCommissionsCostsPaidAndPayable" name="DeferredCommissionsCostsPaidAndPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_SurrenderOfStockSharesDuringPeriod" name="SurrenderOfStockSharesDuringPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_NumberOfEmployeesTerminated" name="NumberOfEmployeesTerminated" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_PercentageOfWorkforceTerminated" name="PercentageOfWorkforceTerminated" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_BusinessAcquisitionEquityInterestIssuedFairValue" name="BusinessAcquisitionEquityInterestIssuedFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_PaymentsToAcquireBusinessesSellerExpenses" name="PaymentsToAcquireBusinessesSellerExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment" name="PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_PaymentOfSaasContingentConsiderationInCashPercentage" name="PaymentOfSaasContingentConsiderationInCashPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_PaymentOfSaasContingentConsiderationInSharesPercentage" name="PaymentOfSaasContingentConsiderationInSharesPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_FirstYearPaymentOfSaasContingentConsiderationDescription" name="FirstYearPaymentOfSaasContingentConsiderationDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_SecondYearPaymentOfSaasContingentConsiderationDescription" name="SecondYearPaymentOfSaasContingentConsiderationDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ForecastedRevenueDescription" name="ForecastedRevenueDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_RenewalContingentConsiderationDescription" name="RenewalContingentConsiderationDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_SubleaseTerm" name="SubleaseTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_FinancingCostPayable" name="FinancingCostPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_DeferredFinancingCost" name="DeferredFinancingCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_MaximumDebtToArrRatio" name="MaximumDebtToArrRatio" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_MaximumDebtToAdjustedEbitdaRatio" name="MaximumDebtToAdjustedEbitdaRatio" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_FixedChargeCoverageRatio" name="FixedChargeCoverageRatio" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AbandonedAssetWroteOff" name="AbandonedAssetWroteOff" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_IncreaseInValuationAllowance" name="IncreaseInValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_NumberOfOptionsToPurchaseCommonStock" name="NumberOfOptionsToPurchaseCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_InvestmentOwnershipPercentage" name="InvestmentOwnershipPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_NonEmployeeStockCompensation" name="NonEmployeeStockCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_MaximumArrNetLeverageRatio" name="MaximumArrNetLeverageRatio" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_MinimumAdjustedEbitda" name="MinimumAdjustedEbitda" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AffiliatesEffectivePercentage" name="AffiliatesEffectivePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_SurrenderOfStockDuringPeriodValue" name="SurrenderOfStockDuringPeriodValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensation" name="AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AllowanceForDoubtfulAccountsPolicyTextBlock" name="AllowanceForDoubtfulAccountsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AllowanceForDoubtfulAccountsReceivableProvisionadjustments" name="AllowanceForDoubtfulAccountsReceivableProvisionadjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AveleadMember" name="AveleadMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_BusinessCombinationEarnoutRestrictedShares" name="BusinessCombinationEarnoutRestrictedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedUnbilledRevenue" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedUnbilledRevenue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationshipsSaaS" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationshipsSaaS" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationshipsConsulting" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationshipsConsulting" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInternallyDevelopedSoftware" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInternallyDevelopedSoftware" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademarksAndTradenames" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademarksAndTradenames" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ScheduleOfIntangibleAssetsAndGoodwillEstimatedUsefulLivesTableTextBlock" name="ScheduleOfIntangibleAssetsAndGoodwillEstimatedUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLifeDescription" name="AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLifeDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_CustomerRelationshipsConsultingMember" name="CustomerRelationshipsConsultingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_FiniteLivedIntangibleAssetsAmortizationExpenseCurrentYear" name="FiniteLivedIntangibleAssetsAmortizationExpenseCurrentYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_AmortizationOfIntangibleAssetsWroteOffFully" name="AmortizationOfIntangibleAssetsWroteOffFully" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ThroughFiscal2038Member" name="ThroughFiscal2038Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_StockOptionsPlanDescription" name="StockOptionsPlanDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_VestInFourQuarterlyInstallmentsMember" name="VestInFourQuarterlyInstallmentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_SecondModificationDebtAgreementMember" name="SecondModificationDebtAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ThirdModificationDebtAgreementMember" name="ThirdModificationDebtAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_ImpairmentOfFinitelivedAssets" name="ImpairmentOfFinitelivedAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="STRM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" name="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>strm-20240131_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://streamlinehealth.net/role/Cover" xlink:href="strm-20240131.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/BalanceSheets" xlink:href="strm-20240131.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/BalanceSheetsParenthetical" xlink:href="strm-20240131.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/StatementsOfOperations" xlink:href="strm-20240131.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity" xlink:href="strm-20240131.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/StatementsOfCashFlows" xlink:href="strm-20240131.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/OrganizationAndDescriptionOfBusiness" xlink:href="strm-20240131.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SignificantAccountingPolicies" xlink:href="strm-20240131.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/BusinessCombination" xlink:href="strm-20240131.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/OperatingLeases" xlink:href="strm-20240131.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/Debt" xlink:href="strm-20240131.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/GoodwillAndIntangibleAssets" xlink:href="strm-20240131.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/IncomeTaxes" xlink:href="strm-20240131.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/Equity" xlink:href="strm-20240131.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/MajorClients" xlink:href="strm-20240131.xsd#MajorClients" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/EmployeeRetirementPlan" xlink:href="strm-20240131.xsd#EmployeeRetirementPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/Stock-basedCompensation" xlink:href="strm-20240131.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/CommitmentsAndContingencies" xlink:href="strm-20240131.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/RelatedPartyTransactions" xlink:href="strm-20240131.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SubsequentEvents" xlink:href="strm-20240131.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReserves" xlink:href="strm-20240131.xsd#ValuationAndQualifyingAccountsAndReserves" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies" xlink:href="strm-20240131.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SignificantAccountingPoliciesTables" xlink:href="strm-20240131.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/DebtTables" xlink:href="strm-20240131.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsTables" xlink:href="strm-20240131.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/IncomeTaxesTables" xlink:href="strm-20240131.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/Stock-basedCompensationTables" xlink:href="strm-20240131.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SubsequentEventsTables" xlink:href="strm-20240131.xsd#SubsequentEventsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfNon-cashItemsRelatedToCondensedConsolidatedStatementsOfCashFlowsDetails" xlink:href="strm-20240131.xsd#ScheduleOfNon-cashItemsRelatedToCondensedConsolidatedStatementsOfCashFlowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfReserveResultsInFuturePeriodsDetails" xlink:href="strm-20240131.xsd#ScheduleOfReserveResultsInFuturePeriodsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfAccruedExpensesDetails" xlink:href="strm-20240131.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails" xlink:href="strm-20240131.xsd#ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails" xlink:href="strm-20240131.xsd#ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="strm-20240131.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical" xlink:href="strm-20240131.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfDisaggregatonOfRevenueDetails" xlink:href="strm-20240131.xsd#ScheduleOfDisaggregatonOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:href="strm-20240131.xsd#ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical" xlink:href="strm-20240131.xsd#ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails" xlink:href="strm-20240131.xsd#ScheduleOfReconciliationOfRestructuringLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="strm-20240131.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative" xlink:href="strm-20240131.xsd#BusinessCombinationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative" xlink:href="strm-20240131.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails" xlink:href="strm-20240131.xsd#ScheduleOfOutstandingPrincipalBalancesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails" xlink:href="strm-20240131.xsd#ScheduleOfMaximumDebtToArrRatioDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails" xlink:href="strm-20240131.xsd#ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/DebtDetailsNarrative" xlink:href="strm-20240131.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfCarryingAmountOfGoodwillDetails" xlink:href="strm-20240131.xsd#ScheduleOfCarryingAmountOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails" xlink:href="strm-20240131.xsd#ScheduleOfFinite-livedIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:href="strm-20240131.xsd#ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative" xlink:href="strm-20240131.xsd#GoodwillAndIntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails" xlink:href="strm-20240131.xsd#ScheduleOfIncomeTaxesForContinuingOperationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="strm-20240131.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="strm-20240131.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfGrossUnrecognizedTaxBenefitsDetails" xlink:href="strm-20240131.xsd#ScheduleOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative" xlink:href="strm-20240131.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/EquityDetailsNarrative" xlink:href="strm-20240131.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/MajorClientsDetailsNarrative" xlink:href="strm-20240131.xsd#MajorClientsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/EmployeeRetirementPlanDetailsNarrative" xlink:href="strm-20240131.xsd#EmployeeRetirementPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails" xlink:href="strm-20240131.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails" xlink:href="strm-20240131.xsd#ScheduleOfRestrictedStockAwardActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative" xlink:href="strm-20240131.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="strm-20240131.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="strm-20240131.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails" xlink:href="strm-20240131.xsd#ScheduleOfMaximumArrNetLeverageRatioDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails" xlink:href="strm-20240131.xsd#ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails" xlink:href="strm-20240131.xsd#ScheduleOfMinimumAdjustedEbitdaDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative" xlink:href="strm-20240131.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReservesDetails" xlink:href="strm-20240131.xsd#ValuationAndQualifyingAccountsAndReservesDetails" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaapContractWithCustomerAssetNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapContractWithCustomerAssetNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaapCapitalizedComputerSoftwareNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapCapitalizedComputerSoftwareNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaapAssetAcquisitionContingentConsiderationLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLineOfCredit" xlink:label="loc_us-gaapLongTermLineOfCredit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapLongTermLineOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfSoftwareAsService" xlink:label="loc_STRMCostOfSoftwareAsService" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_STRMCostOfSoftwareAsService" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfMaintenanceAndSupport" xlink:label="loc_STRMCostOfMaintenanceAndSupport" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_STRMCostOfMaintenanceAndSupport" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfProfessionalFeesAndLicenses" xlink:label="loc_STRMCostOfProfessionalFeesAndLicenses" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_STRMCostOfProfessionalFeesAndLicenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AcquisitionEarnoutValuationAdjustments" xlink:label="loc_STRMAcquisitionEarnoutValuationAdjustments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_STRMAcquisitionEarnoutValuationAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AcquisitionEarnoutValuationAdjustments" xlink:label="loc_STRMAcquisitionEarnoutValuationAdjustments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_STRMAcquisitionEarnoutValuationAdjustments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ProvisionForDeferredIncomeTaxes" xlink:label="loc_STRMProvisionForDeferredIncomeTaxes" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_STRMProvisionForDeferredIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToDevelopSoftware" xlink:label="loc_us-gaapPaymentsToDevelopSoftware" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToDevelopSoftware" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="loc_us-gaapPaymentsOfMergerRelatedCostsFinancingActivities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfMergerRelatedCostsFinancingActivities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfLongTermDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLongTermDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaapProceedsFromPaymentsForOtherFinancingActivities" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/OrganizationAndDescriptionOfBusiness" xlink:title="00000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/BusinessCombination" xlink:title="00000009 - Disclosure - BUSINESS COMBINATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/OperatingLeases" xlink:title="00000010 - Disclosure - OPERATING LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Debt" xlink:title="00000011 - Disclosure - DEBT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/GoodwillAndIntangibleAssets" xlink:title="00000012 - Disclosure - GOODWILL AND INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/IncomeTaxes" xlink:title="00000013 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Equity" xlink:title="00000014 - Disclosure - EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/MajorClients" xlink:title="00000015 - Disclosure - MAJOR CLIENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/EmployeeRetirementPlan" xlink:title="00000016 - Disclosure - EMPLOYEE RETIREMENT PLAN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Stock-basedCompensation" xlink:title="00000017 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/RelatedPartyTransactions" xlink:title="00000019 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SubsequentEvents" xlink:title="00000020 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReserves" xlink:title="00000021 - Disclosure - Valuation and Qualifying Accounts and Reserves" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SignificantAccountingPoliciesTables" xlink:title="00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/DebtTables" xlink:title="00000024 - Disclosure - DEBT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsTables" xlink:title="00000025 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/IncomeTaxesTables" xlink:title="00000026 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Stock-basedCompensationTables" xlink:title="00000027 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SubsequentEventsTables" xlink:title="00000028 - Disclosure - SUBSEQUENT EVENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfNon-cashItemsRelatedToCondensedConsolidatedStatementsOfCashFlowsDetails" xlink:title="00000029 - Disclosure - SCHEDULE OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfReserveResultsInFuturePeriodsDetails" xlink:title="00000030 - Disclosure - SCHEDULE OF RESERVE RESULTS IN FUTURE PERIODS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical" xlink:title="00000035 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfDisaggregatonOfRevenueDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF DISAGGREGATON OF REVENUE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical" xlink:title="00000038 - Disclosure - SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF RECONCILIATION OF THE RESTRUCTURING LIABILITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000040 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative" xlink:title="00000041 - Disclosure - BUSINESS COMBINATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative" xlink:title="00000042 - Disclosure - OPERATING LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FinancingCostPayable" xlink:label="loc_STRMFinancingCostPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_STRMFinancingCostPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DeferredFinancingCost" xlink:label="loc_STRMDeferredFinancingCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_STRMDeferredFinancingCost" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ARR RATIO (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/DebtDetailsNarrative" xlink:title="00000046 - Disclosure - DEBT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfCarryingAmountOfGoodwillDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF CARRYING AMOUNT OF GOODWILL (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative" xlink:title="00000050 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_IncreaseInValuationAllowance" xlink:label="loc_STRMIncreaseInValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_STRMIncreaseInValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxContingencies" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxContingencies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000053 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaapDeferredTaxAssetsDeferredIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsDeferredIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent" xlink:label="loc_STRMDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_STRMDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" weight="-1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfGrossUnrecognizedTaxBenefitsDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative" xlink:title="00000055 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/EquityDetailsNarrative" xlink:title="00000056 - Disclosure - EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/MajorClientsDetailsNarrative" xlink:title="00000057 - Disclosure - MAJOR CLIENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/EmployeeRetirementPlanDetailsNarrative" xlink:title="00000058 - Disclosure - EMPLOYEE RETIREMENT PLAN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000061 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails" xlink:title="00000064 - Disclosure - SCHEDULE OF MAXIMUM ARR NET LEVERAGE RATIO (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails" xlink:title="00000065 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails" xlink:title="00000066 - Disclosure - SCHEDULE OF MINIMUM ADJUSTED EBITDA (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative" xlink:title="00000067 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReservesDetails" xlink:title="00000068 - Disclosure - Valuation and Qualifying Accounts and Reserves (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>strm-20240131_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://streamlinehealth.net/role/Cover" xlink:href="strm-20240131.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/BalanceSheets" xlink:href="strm-20240131.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/BalanceSheetsParenthetical" xlink:href="strm-20240131.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/StatementsOfOperations" xlink:href="strm-20240131.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity" xlink:href="strm-20240131.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/StatementsOfCashFlows" xlink:href="strm-20240131.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/OrganizationAndDescriptionOfBusiness" xlink:href="strm-20240131.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SignificantAccountingPolicies" xlink:href="strm-20240131.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/BusinessCombination" xlink:href="strm-20240131.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/OperatingLeases" xlink:href="strm-20240131.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/Debt" xlink:href="strm-20240131.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/GoodwillAndIntangibleAssets" xlink:href="strm-20240131.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/IncomeTaxes" xlink:href="strm-20240131.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/Equity" xlink:href="strm-20240131.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/MajorClients" xlink:href="strm-20240131.xsd#MajorClients" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/EmployeeRetirementPlan" xlink:href="strm-20240131.xsd#EmployeeRetirementPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/Stock-basedCompensation" xlink:href="strm-20240131.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/CommitmentsAndContingencies" xlink:href="strm-20240131.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/RelatedPartyTransactions" xlink:href="strm-20240131.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SubsequentEvents" xlink:href="strm-20240131.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReserves" xlink:href="strm-20240131.xsd#ValuationAndQualifyingAccountsAndReserves" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies" xlink:href="strm-20240131.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SignificantAccountingPoliciesTables" xlink:href="strm-20240131.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/DebtTables" xlink:href="strm-20240131.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsTables" xlink:href="strm-20240131.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/IncomeTaxesTables" xlink:href="strm-20240131.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/Stock-basedCompensationTables" xlink:href="strm-20240131.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SubsequentEventsTables" xlink:href="strm-20240131.xsd#SubsequentEventsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfNon-cashItemsRelatedToCondensedConsolidatedStatementsOfCashFlowsDetails" xlink:href="strm-20240131.xsd#ScheduleOfNon-cashItemsRelatedToCondensedConsolidatedStatementsOfCashFlowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfReserveResultsInFuturePeriodsDetails" xlink:href="strm-20240131.xsd#ScheduleOfReserveResultsInFuturePeriodsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfAccruedExpensesDetails" xlink:href="strm-20240131.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails" xlink:href="strm-20240131.xsd#ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails" xlink:href="strm-20240131.xsd#ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="strm-20240131.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical" xlink:href="strm-20240131.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfDisaggregatonOfRevenueDetails" xlink:href="strm-20240131.xsd#ScheduleOfDisaggregatonOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:href="strm-20240131.xsd#ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical" xlink:href="strm-20240131.xsd#ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails" xlink:href="strm-20240131.xsd#ScheduleOfReconciliationOfRestructuringLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="strm-20240131.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative" xlink:href="strm-20240131.xsd#BusinessCombinationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative" xlink:href="strm-20240131.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails" xlink:href="strm-20240131.xsd#ScheduleOfOutstandingPrincipalBalancesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails" xlink:href="strm-20240131.xsd#ScheduleOfMaximumDebtToArrRatioDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails" xlink:href="strm-20240131.xsd#ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/DebtDetailsNarrative" xlink:href="strm-20240131.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfCarryingAmountOfGoodwillDetails" xlink:href="strm-20240131.xsd#ScheduleOfCarryingAmountOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails" xlink:href="strm-20240131.xsd#ScheduleOfFinite-livedIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:href="strm-20240131.xsd#ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative" xlink:href="strm-20240131.xsd#GoodwillAndIntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails" xlink:href="strm-20240131.xsd#ScheduleOfIncomeTaxesForContinuingOperationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="strm-20240131.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="strm-20240131.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfGrossUnrecognizedTaxBenefitsDetails" xlink:href="strm-20240131.xsd#ScheduleOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative" xlink:href="strm-20240131.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/EquityDetailsNarrative" xlink:href="strm-20240131.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/MajorClientsDetailsNarrative" xlink:href="strm-20240131.xsd#MajorClientsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/EmployeeRetirementPlanDetailsNarrative" xlink:href="strm-20240131.xsd#EmployeeRetirementPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails" xlink:href="strm-20240131.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails" xlink:href="strm-20240131.xsd#ScheduleOfRestrictedStockAwardActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative" xlink:href="strm-20240131.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="strm-20240131.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="strm-20240131.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails" xlink:href="strm-20240131.xsd#ScheduleOfMaximumArrNetLeverageRatioDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails" xlink:href="strm-20240131.xsd#ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails" xlink:href="strm-20240131.xsd#ScheduleOfMinimumAdjustedEbitdaDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative" xlink:href="strm-20240131.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReservesDetails" xlink:href="strm-20240131.xsd#ValuationAndQualifyingAccountsAndReservesDetails" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SoftwareasAsAServiceMember" xlink:label="loc_STRMSoftwareasAsAServiceMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_STRMSoftwareasAsAServiceMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MaintenanceAndSupportMember" xlink:label="loc_STRMMaintenanceAndSupportMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_STRMMaintenanceAndSupportMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ProfessionalFeesAndLicensesMember" xlink:label="loc_STRMProfessionalFeesAndLicensesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_STRMProfessionalFeesAndLicensesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesAbstract_90" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfSoftwareAsService" xlink:label="loc_STRMCostOfSoftwareAsService_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_STRMCostOfSoftwareAsService_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfMaintenanceAndSupport" xlink:label="loc_STRMCostOfMaintenanceAndSupport_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_STRMCostOfMaintenanceAndSupport_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfProfessionalFeesAndLicenses" xlink:label="loc_STRMCostOfProfessionalFeesAndLicenses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_STRMCostOfProfessionalFeesAndLicenses_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapGoodwillImpairmentLoss_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapCostsAndExpenses_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_us-gaapInterestExpense_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AcquisitionEarnoutValuationAdjustments" xlink:label="loc_STRMAcquisitionEarnoutValuationAdjustments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_STRMAcquisitionEarnoutValuationAdjustments_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_90" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_90" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_90" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_90" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_90" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_90" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_90" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_StockIssuedDuringPeriodValueSurrenderOfShares" xlink:label="loc_STRMStockIssuedDuringPeriodValueSurrenderOfShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMStockIssuedDuringPeriodValueSurrenderOfShares_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_StockIssuedDuringPeriodSharesSurrenderOfShares" xlink:label="loc_STRMStockIssuedDuringPeriodSharesSurrenderOfShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMStockIssuedDuringPeriodSharesSurrenderOfShares_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaapStockholdersEquityOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityOther_50" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/OrganizationAndDescriptionOfBusiness" xlink:title="00000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/BusinessCombination" xlink:title="00000009 - Disclosure - BUSINESS COMBINATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/OperatingLeases" xlink:title="00000010 - Disclosure - OPERATING LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Debt" xlink:title="00000011 - Disclosure - DEBT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/GoodwillAndIntangibleAssets" xlink:title="00000012 - Disclosure - GOODWILL AND INTANGIBLE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/IncomeTaxes" xlink:title="00000013 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Equity" xlink:title="00000014 - Disclosure - EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/MajorClients" xlink:title="00000015 - Disclosure - MAJOR CLIENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/EmployeeRetirementPlan" xlink:title="00000016 - Disclosure - EMPLOYEE RETIREMENT PLAN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Stock-basedCompensation" xlink:title="00000017 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/RelatedPartyTransactions" xlink:title="00000019 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SubsequentEvents" xlink:title="00000020 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReserves" xlink:title="00000021 - Disclosure - Valuation and Qualifying Accounts and Reserves" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SignificantAccountingPoliciesTables" xlink:title="00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/DebtTables" xlink:title="00000024 - Disclosure - DEBT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsTables" xlink:title="00000025 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/IncomeTaxesTables" xlink:title="00000026 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Stock-basedCompensationTables" xlink:title="00000027 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SubsequentEventsTables" xlink:title="00000028 - Disclosure - SUBSEQUENT EVENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfNon-cashItemsRelatedToCondensedConsolidatedStatementsOfCashFlowsDetails" xlink:title="00000029 - Disclosure - SCHEDULE OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfReserveResultsInFuturePeriodsDetails" xlink:title="00000030 - Disclosure - SCHEDULE OF RESERVE RESULTS IN FUTURE PERIODS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ComputerEquipmentAndSoftwareMember" xlink:label="loc_STRMComputerEquipmentAndSoftwareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_STRMComputerEquipmentAndSoftwareMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OfficeFurnitureAndFixturesMember" xlink:label="loc_STRMOfficeFurnitureAndFixturesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_STRMOfficeFurnitureAndFixturesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfSoftwareAsASeviceMember" xlink:label="loc_STRMCostOfSoftwareAsASeviceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_STRMCostOfSoftwareAsASeviceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfProfessionalFeesAndLicensesMember" xlink:label="loc_STRMCostOfProfessionalFeesAndLicensesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_STRMCostOfProfessionalFeesAndLicensesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="loc_us-gaapCapitalizedComputerSoftwareAmortization1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCapitalizedComputerSoftwareAmortization1_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AcquisitionEarnoutLiabilityFairValue" xlink:label="loc_STRMAcquisitionEarnoutLiabilityFairValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_STRMAcquisitionEarnoutLiabilityFairValue_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical" xlink:title="00000035 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfDisaggregatonOfRevenueDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF DISAGGREGATON OF REVENUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaapTimingOfTransferOfGoodOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaapTimingOfTransferOfGoodOrServiceDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTimingOfTransferOfGoodOrServiceAxis" xlink:to="loc_us-gaapTimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaapTimingOfTransferOfGoodOrServiceDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTimingOfTransferOfGoodOrServiceAxis" xlink:to="loc_us-gaapTimingOfTransferOfGoodOrServiceDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaapTransferredOverTimeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTimingOfTransferOfGoodOrServiceDomain" xlink:to="loc_us-gaapTransferredOverTimeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredAtPointInTimeMember" xlink:label="loc_us-gaapTransferredAtPointInTimeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTimingOfTransferOfGoodOrServiceDomain" xlink:to="loc_us-gaapTransferredAtPointInTimeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical" xlink:title="00000038 - Disclosure - SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_UnvestedRestrictedStockMember" xlink:label="loc_STRMUnvestedRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_STRMUnvestedRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_UnvestedRestrictedSharesMember" xlink:label="loc_STRMUnvestedRestrictedSharesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_STRMUnvestedRestrictedSharesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_60" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF RECONCILIATION OF THE RESTRUCTURING LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SeveranceExpensesMember" xlink:label="loc_STRMSeveranceExpensesMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_STRMSeveranceExpensesMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ProfessionalFeesMember" xlink:label="loc_STRMProfessionalFeesMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_STRMProfessionalFeesMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AccruedExpensesMember" xlink:label="loc_STRMAccruedExpensesMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_STRMAccruedExpensesMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AccruedCashPayments" xlink:label="loc_STRMAccruedCashPayments_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMAccruedCashPayments_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AccruedCostsIncurred" xlink:label="loc_STRMAccruedCostsIncurred_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMAccruedCostsIncurred_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AccruedExpectedCosts" xlink:label="loc_STRMAccruedExpectedCosts_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMAccruedExpectedCosts_190" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000040 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SoftwareMember" xlink:label="loc_STRMSoftwareMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_STRMSoftwareMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_InternalUseSoftwareMember" xlink:label="loc_STRMInternalUseSoftwareMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_STRMInternalUseSoftwareMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecurityAgreementMember" xlink:label="loc_STRMSecurityAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSecurityAgreementMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecondAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="loc_STRMSecondAmendedAndRestatedLoanAndSecurityAgreementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSecondAmendedAndRestatedLoanAndSecurityAgreementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DebtAgreementMember" xlink:label="loc_STRMDebtAgreementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMDebtAgreementMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaapOtherNoncurrentAssetsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_us-gaapOtherNoncurrentAssetsMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_EquityAwardMember" xlink:label="loc_STRMEquityAwardMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_STRMEquityAwardMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapGranteeStatusAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OfficersAndDirectorsMember" xlink:label="loc_STRMOfficersAndDirectorsMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_STRMOfficersAndDirectorsMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts_350" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ConcessionAccrualAmount" xlink:label="loc_STRMConcessionAccrualAmount_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_STRMConcessionAccrualAmount_350" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciation_350" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:label="loc_us-gaapCapitalizedComputerSoftwareAccumulatedAmortization_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCapitalizedComputerSoftwareAccumulatedAmortization_350" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="loc_us-gaapCapitalizedComputerSoftwareAmortization1_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCapitalizedComputerSoftwareAmortization1_350" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_350" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AmortizedAndAbandonedAssets" xlink:label="loc_STRMAmortizedAndAbandonedAssets_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_STRMAmortizedAndAbandonedAssets_350" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_350" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_350" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PrimeInterestRatePercentage" xlink:label="loc_STRMPrimeInterestRatePercentage_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_STRMPrimeInterestRatePercentage_350" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_350" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_350" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredRevenue_350" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaapRevenueRemainingPerformanceObligation_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRevenueRemainingPerformanceObligation_350" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:label="loc_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_350" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="loc_us-gaapDeferredCostsCurrentAndNoncurrent_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredCostsCurrentAndNoncurrent_350" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedAmortizationOfOtherDeferredCosts" xlink:label="loc_us-gaapAccumulatedAmortizationOfOtherDeferredCosts_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedAmortizationOfOtherDeferredCosts_350" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DeferredCostsAmortizationExpenses" xlink:label="loc_STRMDeferredCostsAmortizationExpenses_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_STRMDeferredCostsAmortizationExpenses_350" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAmortizationOfDeferredCharges" xlink:label="loc_us-gaapOtherAmortizationOfDeferredCharges_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOtherAmortizationOfDeferredCharges_350" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DeferredCommissionsCostsPaidAndPayable" xlink:label="loc_STRMDeferredCommissionsCostsPaidAndPayable_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_STRMDeferredCommissionsCostsPaidAndPayable_350" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDeferredSalesCommissions" xlink:label="loc_us-gaapAmortizationOfDeferredSalesCommissions_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAmortizationOfDeferredSalesCommissions_350" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostImpairmentLoss" xlink:label="loc_us-gaapCapitalizedContractCostImpairmentLoss_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCapitalizedContractCostImpairmentLoss_350" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_350" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapShareBasedCompensation_350" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SurrenderOfStockSharesDuringPeriod" xlink:label="loc_STRMSurrenderOfStockSharesDuringPeriod_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_STRMSurrenderOfStockSharesDuringPeriod_350" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation_350" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_350" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_NumberOfEmployeesTerminated" xlink:label="loc_STRMNumberOfEmployeesTerminated_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_STRMNumberOfEmployeesTerminated_350" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PercentageOfWorkforceTerminated" xlink:label="loc_STRMPercentageOfWorkforceTerminated_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_STRMPercentageOfWorkforceTerminated_350" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaapRestructuringCosts_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRestructuringCosts_350" xlink:type="arc" order="29" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative" xlink:title="00000041 - Disclosure - BUSINESS COMBINATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AveleadConsultingLLCMember" xlink:label="loc_STRMAveleadConsultingLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_STRMAveleadConsultingLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AcquisitionRestrictedCommonStockMember" xlink:label="loc_STRMAcquisitionRestrictedCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_STRMAcquisitionRestrictedCommonStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_UnitPurchaseAgreementMember" xlink:label="loc_STRMUnitPurchaseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMUnitPurchaseAgreementMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FirstYearEarnoutMember" xlink:label="loc_STRMFirstYearEarnoutMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_STRMFirstYearEarnoutMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecondYearEarnoutMember" xlink:label="loc_STRMSecondYearEarnoutMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_STRMSecondYearEarnoutMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_RenewalContingentConsiderationMember" xlink:label="loc_STRMRenewalContingentConsiderationMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_STRMRenewalContingentConsiderationMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_BusinessAcquisitionEquityInterestIssuedFairValue" xlink:label="loc_STRMBusinessAcquisitionEquityInterestIssuedFairValue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMBusinessAcquisitionEquityInterestIssuedFairValue_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsDescription_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsDescription_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PaymentsToAcquireBusinessesSellerExpenses" xlink:label="loc_STRMPaymentsToAcquireBusinessesSellerExpenses_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMPaymentsToAcquireBusinessesSellerExpenses_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment" xlink:label="loc_STRMPaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMPaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PaymentOfSaasContingentConsiderationInCashPercentage" xlink:label="loc_STRMPaymentOfSaasContingentConsiderationInCashPercentage_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMPaymentOfSaasContingentConsiderationInCashPercentage_160" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PaymentOfSaasContingentConsiderationInSharesPercentage" xlink:label="loc_STRMPaymentOfSaasContingentConsiderationInSharesPercentage_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMPaymentOfSaasContingentConsiderationInSharesPercentage_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FirstYearPaymentOfSaasContingentConsiderationDescription" xlink:label="loc_STRMFirstYearPaymentOfSaasContingentConsiderationDescription_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMFirstYearPaymentOfSaasContingentConsiderationDescription_160" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecondYearPaymentOfSaasContingentConsiderationDescription" xlink:label="loc_STRMSecondYearPaymentOfSaasContingentConsiderationDescription_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMSecondYearPaymentOfSaasContingentConsiderationDescription_160" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ForecastedRevenueDescription" xlink:label="loc_STRMForecastedRevenueDescription_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMForecastedRevenueDescription_160" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_RenewalContingentConsiderationDescription" xlink:label="loc_STRMRenewalContingentConsiderationDescription_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMRenewalContingentConsiderationDescription_160" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_160" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_160" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_160" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross_160" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_160" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative" xlink:title="00000042 - Disclosure - OPERATING LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AlpharettaOfficeLeaseMember" xlink:label="loc_STRMAlpharettaOfficeLeaseMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMAlpharettaOfficeLeaseMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SubleaseAgreementMember" xlink:label="loc_STRMSubleaseAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSubleaseAgreementMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SuwaneeOfficeLeaseMember" xlink:label="loc_STRMSuwaneeOfficeLeaseMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSuwaneeOfficeLeaseMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RentalProperties" xlink:label="loc_us-gaapRentalProperties_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRentalProperties_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseCost_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SubleaseTerm" xlink:label="loc_STRMSubleaseTerm_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_STRMSubleaseTerm_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaapSubleaseIncome_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSubleaseIncome_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOtherIncome_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsForRent_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_130" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ARR RATIO (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OctoberThirtyOneTwoThousandAndTwentyTwoMember" xlink:label="loc_STRMOctoberThirtyOneTwoThousandAndTwentyTwoMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMOctoberThirtyOneTwoThousandAndTwentyTwoMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandTwentyThreeMember" xlink:label="loc_STRMJanuaryThirtyOneTwoThousandTwentyThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJanuaryThirtyOneTwoThousandTwentyThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AprilThirtyTwoThousandTwentyThreeMember" xlink:label="loc_STRMAprilThirtyTwoThousandTwentyThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMAprilThirtyTwoThousandTwentyThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JulyThirtyOneTwoThousandTwentyThreeMember" xlink:label="loc_STRMJulyThirtyOneTwoThousandTwentyThreeMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJulyThirtyOneTwoThousandTwentyThreeMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OctoberThirtyOneTwoThousandTwentyThreeMember" xlink:label="loc_STRMOctoberThirtyOneTwoThousandTwentyThreeMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMOctoberThirtyOneTwoThousandTwentyThreeMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandTwentyFourMember" xlink:label="loc_STRMJanuaryThirtyOneTwoThousandTwentyFourMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJanuaryThirtyOneTwoThousandTwentyFourMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MaximumDebtToArrRatio" xlink:label="loc_STRMMaximumDebtToArrRatio_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_STRMMaximumDebtToArrRatio_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AprilThirtyTwoThousandTwentyFourMember" xlink:label="loc_STRMAprilThirtyTwoThousandTwentyFourMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMAprilThirtyTwoThousandTwentyFourMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember" xlink:label="loc_STRMJulyThirtyOneTwoThousandTwentyFourAndThereafterMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJulyThirtyOneTwoThousandTwentyFourAndThereafterMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MaximumDebtToAdjustedEbitdaRatio" xlink:label="loc_STRMMaximumDebtToAdjustedEbitdaRatio_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_STRMMaximumDebtToAdjustedEbitdaRatio_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/DebtDetailsNarrative" xlink:title="00000046 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_LoanAgreementMember" xlink:label="loc_STRMLoanAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMLoanAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecurityAgreementMember" xlink:label="loc_STRMSecurityAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSecurityAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecondModificationAgreementMember" xlink:label="loc_STRMSecondModificationAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSecondModificationAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecondAmendedAndRestatedLoanAgreementMember" xlink:label="loc_STRMSecondAmendedAndRestatedLoanAgreementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSecondAmendedAndRestatedLoanAgreementMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_WesternAllianceBankMember" xlink:label="loc_STRMWesternAllianceBankMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_STRMWesternAllianceBankMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_BridgeBankMember" xlink:label="loc_STRMBridgeBankMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_STRMBridgeBankMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaapBaseRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapBaseRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaapAccretionExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAccretionExpense_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLineOfCredit" xlink:label="loc_us-gaapLongTermLineOfCredit_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermLineOfCredit_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="loc_us-gaapDebtInstrumentCovenantDescription_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCovenantDescription_150" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FixedChargeCoverageRatio" xlink:label="loc_STRMFixedChargeCoverageRatio_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_STRMFixedChargeCoverageRatio_150" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfCarryingAmountOfGoodwillDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF CARRYING AMOUNT OF GOODWILL (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ClientRelationshipsMember" xlink:label="loc_STRMClientRelationshipsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_STRMClientRelationshipsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_InternallyDevelopedSoftwareMember" xlink:label="loc_STRMInternallyDevelopedSoftwareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_STRMInternallyDevelopedSoftwareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaapTrademarksAndTradeNamesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksAndTradeNamesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative" xlink:title="00000050 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AbandonedAssetWroteOff" xlink:label="loc_STRMAbandonedAssetWroteOff_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_STRMAbandonedAssetWroteOff_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000053 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfGrossUnrecognizedTaxBenefitsDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative" xlink:title="00000055 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ThroughFiscalTwoThousandThirtyEightMember" xlink:label="loc_STRMThroughFiscalTwoThousandThirtyEightMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_STRMThroughFiscalTwoThousandThirtyEightMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_TaxCutsAndJobsActMember" xlink:label="loc_STRMTaxCutsAndJobsActMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_STRMTaxCutsAndJobsActMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_StateMember" xlink:label="loc_STRMStateMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_STRMStateMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FederalRDMember" xlink:label="loc_STRMFederalRDMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_STRMFederalRDMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_GeorgiaRDMember" xlink:label="loc_STRMGeorgiaRDMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_STRMGeorgiaRDMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_IncreaseInValuationAllowance" xlink:label="loc_STRMIncreaseInValuationAllowance_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_STRMIncreaseInValuationAllowance_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_100" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/EquityDetailsNarrative" xlink:title="00000056 - Disclosure - EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PurchaseAgreementMember" xlink:label="loc_STRMPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_TwoThousandTwentyTwoOfferingMember" xlink:label="loc_STRMTwoThousandTwentyTwoOfferingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_STRMTwoThousandTwentyTwoOfferingMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" xlink:label="loc_STRMThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_STRMThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OneHundredEightyConsultingLLCMember" xlink:label="loc_STRMOneHundredEightyConsultingLLCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_STRMOneHundredEightyConsultingLLCMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_130" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/MajorClientsDetailsNarrative" xlink:title="00000057 - Disclosure - MAJOR CLIENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OneCustomerMember" xlink:label="loc_STRMOneCustomerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_STRMOneCustomerMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_TwoCustomerMember" xlink:label="loc_STRMTwoCustomerMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_STRMTwoCustomerMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CustomerOneMember" xlink:label="loc_STRMCustomerOneMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_STRMCustomerOneMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CustomerTwoMember" xlink:label="loc_STRMCustomerTwoMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_STRMCustomerTwoMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CustomerThreeMember" xlink:label="loc_STRMCustomerThreeMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_STRMCustomerThreeMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CustomerFourMember" xlink:label="loc_STRMCustomerFourMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_STRMCustomerFourMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCustomer" xlink:label="loc_us-gaapConcentrationRiskCustomer_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskCustomer_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_140" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/EmployeeRetirementPlanDetailsNarrative" xlink:title="00000058 - Disclosure - EMPLOYEE RETIREMENT PLAN (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000061 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_TwoThousandThirteenIncentiveCompensationPlanMember" xlink:label="loc_STRMTwoThousandThirteenIncentiveCompensationPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMTwoThousandThirteenIncentiveCompensationPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_StockOptionsMember" xlink:label="loc_STRMStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_STRMStockOptionsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MrGreenMember" xlink:label="loc_STRMMrGreenMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_STRMMrGreenMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MrStilwillMember" xlink:label="loc_STRMMrStilwillMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_STRMMrStilwillMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_NumberOfOptionsToPurchaseCommonStock" xlink:label="loc_STRMNumberOfOptionsToPurchaseCommonStock_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_STRMNumberOfOptionsToPurchaseCommonStock_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_InvestmentOwnershipPercentage" xlink:label="loc_STRMInvestmentOwnershipPercentage_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_STRMInvestmentOwnershipPercentage_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_130" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MasterServicesAgreementMember" xlink:label="loc_STRMMasterServicesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMMasterServicesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SOWMember" xlink:label="loc_STRMSOWMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSOWMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OneHundredEightyConsultingLLCMember" xlink:label="loc_STRMOneHundredEightyConsultingLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_STRMOneHundredEightyConsultingLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProfessionalFees_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_NonEmployeeStockCompensation" xlink:label="loc_STRMNonEmployeeStockCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_STRMNonEmployeeStockCompensation_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails" xlink:title="00000064 - Disclosure - SCHEDULE OF MAXIMUM ARR NET LEVERAGE RATIO (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AprilThirtyTwoThousandAndTwentyFourMember" xlink:label="loc_STRMAprilThirtyTwoThousandAndTwentyFourMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMAprilThirtyTwoThousandAndTwentyFourMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JulyThirtyOneTwoThousandAndTwentyFourMember" xlink:label="loc_STRMJulyThirtyOneTwoThousandAndTwentyFourMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJulyThirtyOneTwoThousandAndTwentyFourMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember" xlink:label="loc_STRMOctoberThirtyOneTwoThousandAndTwentyFourMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMOctoberThirtyOneTwoThousandAndTwentyFourMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember" xlink:label="loc_STRMJanuaryThirtyOneTwoThousandAndTwentyFiveMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJanuaryThirtyOneTwoThousandAndTwentyFiveMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MaximumArrNetLeverageRatio" xlink:label="loc_STRMMaximumArrNetLeverageRatio_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMMaximumArrNetLeverageRatio_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails" xlink:title="00000065 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AprilThirtyTwoThousandTwentyFiveMember" xlink:label="loc_STRMAprilThirtyTwoThousandTwentyFiveMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMAprilThirtyTwoThousandTwentyFiveMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JulyThirtyOneTwoThousandTwentyFiveMember" xlink:label="loc_STRMJulyThirtyOneTwoThousandTwentyFiveMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJulyThirtyOneTwoThousandTwentyFiveMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OctoberThirtyOneTwoThousandTwentyFiveMember" xlink:label="loc_STRMOctoberThirtyOneTwoThousandTwentyFiveMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMOctoberThirtyOneTwoThousandTwentyFiveMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember" xlink:label="loc_STRMJanuaryThirtyOneTwoThousandTwentySixAndThereafterMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJanuaryThirtyOneTwoThousandTwentySixAndThereafterMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MaximumDebtToAdjustedEbitdaRatio" xlink:label="loc_STRMMaximumDebtToAdjustedEbitdaRatio_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMMaximumDebtToAdjustedEbitdaRatio_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails" xlink:title="00000066 - Disclosure - SCHEDULE OF MINIMUM ADJUSTED EBITDA (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember" xlink:label="loc_STRMJanuaryThirtyOneTwoThousandAndTwentyFourMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJanuaryThirtyOneTwoThousandAndTwentyFourMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AprilThirtyTwoThousandAndTwentyFourMember" xlink:label="loc_STRMAprilThirtyTwoThousandAndTwentyFourMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMAprilThirtyTwoThousandAndTwentyFourMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JulyThirtyOneTwoThousandAndTwentyFourMember" xlink:label="loc_STRMJulyThirtyOneTwoThousandAndTwentyFourMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJulyThirtyOneTwoThousandAndTwentyFourMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember" xlink:label="loc_STRMOctoberThirtyOneTwoThousandAndTwentyFourMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMOctoberThirtyOneTwoThousandAndTwentyFourMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember" xlink:label="loc_STRMJanuaryThirtyOneTwoThousandAndTwentyFiveMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJanuaryThirtyOneTwoThousandAndTwentyFiveMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MinimumAdjustedEbitda" xlink:label="loc_STRMMinimumAdjustedEbitda_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMMinimumAdjustedEbitda_60" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative" xlink:title="00000067 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecuritiesPurchaseAgreementMember" xlink:label="loc_STRMSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ThirdModificationLoanAgreementMember" xlink:label="loc_STRMThirdModificationLoanAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMThirdModificationLoanAgreementMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_NotesMember" xlink:label="loc_STRMNotesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_STRMNotesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ExceptDirectorsAndOfficersMember" xlink:label="loc_STRMExceptDirectorsAndOfficersMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_STRMExceptDirectorsAndOfficersMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AffiliatesEffectivePercentage" xlink:label="loc_STRMAffiliatesEffectivePercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMAffiliatesEffectivePercentage_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FixedChargeCoverageRatio" xlink:label="loc_STRMFixedChargeCoverageRatio_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMFixedChargeCoverageRatio_100" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReservesDetails" xlink:title="00000068 - Disclosure - Valuation and Qualifying Accounts and Reserves (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>strm-20240131_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SoftwareasAsAServiceMember" xlink:label="STRM_SoftwareasAsAServiceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SoftwareasAsAServiceMember" xlink:to="STRM_SoftwareasAsAServiceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_SoftwareasAsAServiceMember_lbl" xml:lang="en-US">Softwareas As A Service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MaintenanceAndSupportMember" xlink:label="STRM_MaintenanceAndSupportMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_MaintenanceAndSupportMember" xlink:to="STRM_MaintenanceAndSupportMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_MaintenanceAndSupportMember_lbl" xml:lang="en-US">Maintenance And Support [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ProfessionalFeesAndLicensesMember" xlink:label="STRM_ProfessionalFeesAndLicensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ProfessionalFeesAndLicensesMember" xlink:to="STRM_ProfessionalFeesAndLicensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ProfessionalFeesAndLicensesMember_lbl" xml:lang="en-US">Professional Fees And Licenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SoftwareMember" xlink:label="STRM_SoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SoftwareMember" xlink:to="STRM_SoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_SoftwareMember_lbl" xml:lang="en-US">Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_InternalUseSoftwareMember" xlink:label="STRM_InternalUseSoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_InternalUseSoftwareMember" xlink:to="STRM_InternalUseSoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_InternalUseSoftwareMember_lbl" xml:lang="en-US">Internal-Use Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecurityAgreementMember" xlink:label="STRM_SecurityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SecurityAgreementMember" xlink:to="STRM_SecurityAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_SecurityAgreementMember_lbl" xml:lang="en-US">Security Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecondAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="STRM_SecondAmendedAndRestatedLoanAndSecurityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SecondAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:to="STRM_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xml:lang="en-US">Second Amended and Restated Loan and Security Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DebtAgreementMember" xlink:label="STRM_DebtAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_DebtAgreementMember" xlink:to="STRM_DebtAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_DebtAgreementMember_lbl" xml:lang="en-US">Debt Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_EquityAwardMember" xlink:label="STRM_EquityAwardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_EquityAwardMember" xlink:to="STRM_EquityAwardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_EquityAwardMember_lbl" xml:lang="en-US">Equity Award [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OfficersAndDirectorsMember" xlink:label="STRM_OfficersAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_OfficersAndDirectorsMember" xlink:to="STRM_OfficersAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_OfficersAndDirectorsMember_lbl" xml:lang="en-US">Officers and Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ComputerEquipmentAndSoftwareMember" xlink:label="STRM_ComputerEquipmentAndSoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ComputerEquipmentAndSoftwareMember" xlink:to="STRM_ComputerEquipmentAndSoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OfficeFurnitureAndFixturesMember" xlink:label="STRM_OfficeFurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_OfficeFurnitureAndFixturesMember" xlink:to="STRM_OfficeFurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_OfficeFurnitureAndFixturesMember_lbl" xml:lang="en-US">Office Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfSoftwareAsASeviceMember" xlink:label="STRM_CostOfSoftwareAsASeviceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CostOfSoftwareAsASeviceMember" xlink:to="STRM_CostOfSoftwareAsASeviceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_CostOfSoftwareAsASeviceMember_lbl" xml:lang="en-US">Cost Of Software As A Sevice [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfProfessionalFeesAndLicensesMember" xlink:label="STRM_CostOfProfessionalFeesAndLicensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CostOfProfessionalFeesAndLicensesMember" xlink:to="STRM_CostOfProfessionalFeesAndLicensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_CostOfProfessionalFeesAndLicensesMember_lbl" xml:lang="en-US">Cost Of Professional Fees And Licenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceAxis_lbl" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember" xlink:label="us-gaap_TransferredOverTimeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransferredOverTimeMember" xlink:to="us-gaap_TransferredOverTimeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransferredOverTimeMember_lbl" xml:lang="en-US">Transferred over Time [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredAtPointInTimeMember" xlink:label="us-gaap_TransferredAtPointInTimeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransferredAtPointInTimeMember" xlink:to="us-gaap_TransferredAtPointInTimeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransferredAtPointInTimeMember_lbl" xml:lang="en-US">Transferred at Point in Time [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_UnvestedRestrictedStockMember" xlink:label="STRM_UnvestedRestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_UnvestedRestrictedStockMember" xlink:to="STRM_UnvestedRestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_UnvestedRestrictedStockMember_lbl" xml:lang="en-US">Unvested Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_UnvestedRestrictedSharesMember" xlink:label="STRM_UnvestedRestrictedSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_UnvestedRestrictedSharesMember" xlink:to="STRM_UnvestedRestrictedSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_UnvestedRestrictedSharesMember_lbl" xml:lang="en-US">Unvested Restricted Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SeveranceExpensesMember" xlink:label="STRM_SeveranceExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SeveranceExpensesMember" xlink:to="STRM_SeveranceExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_SeveranceExpensesMember_lbl" xml:lang="en-US">Severance Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ProfessionalFeesMember" xlink:label="STRM_ProfessionalFeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ProfessionalFeesMember" xlink:to="STRM_ProfessionalFeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ProfessionalFeesMember_lbl" xml:lang="en-US">Professional Fees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AccruedExpensesMember" xlink:label="STRM_AccruedExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AccruedExpensesMember" xlink:to="STRM_AccruedExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AccruedExpensesMember_lbl" xml:lang="en-US">Accrued Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AveleadConsultingLLCMember" xlink:label="STRM_AveleadConsultingLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AveleadConsultingLLCMember" xlink:to="STRM_AveleadConsultingLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AveleadConsultingLLCMember_lbl" xml:lang="en-US">Avelead Consulting LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AcquisitionRestrictedCommonStockMember" xlink:label="STRM_AcquisitionRestrictedCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AcquisitionRestrictedCommonStockMember" xlink:to="STRM_AcquisitionRestrictedCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AcquisitionRestrictedCommonStockMember_lbl" xml:lang="en-US">Acquisition Restricted Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_UnitPurchaseAgreementMember" xlink:label="STRM_UnitPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_UnitPurchaseAgreementMember" xlink:to="STRM_UnitPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_UnitPurchaseAgreementMember_lbl" xml:lang="en-US">Unit Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FirstYearEarnoutMember" xlink:label="STRM_FirstYearEarnoutMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_FirstYearEarnoutMember" xlink:to="STRM_FirstYearEarnoutMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_FirstYearEarnoutMember_lbl" xml:lang="en-US">First Year Earnout [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_RenewalContingentConsiderationMember" xlink:label="STRM_RenewalContingentConsiderationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_RenewalContingentConsiderationMember" xlink:to="STRM_RenewalContingentConsiderationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_RenewalContingentConsiderationMember_lbl" xml:lang="en-US">Renewal Contingent Consideration [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecondYearEarnoutMember" xlink:label="STRM_SecondYearEarnoutMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SecondYearEarnoutMember" xlink:to="STRM_SecondYearEarnoutMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_SecondYearEarnoutMember_lbl" xml:lang="en-US">Second Year Earnout [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AlpharettaOfficeLeaseMember" xlink:label="STRM_AlpharettaOfficeLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AlpharettaOfficeLeaseMember" xlink:to="STRM_AlpharettaOfficeLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AlpharettaOfficeLeaseMember_lbl" xml:lang="en-US">Alpharetta Office Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SubleaseAgreementMember" xlink:label="STRM_SubleaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SubleaseAgreementMember" xlink:to="STRM_SubleaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_SubleaseAgreementMember_lbl" xml:lang="en-US">Sublease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SuwaneeOfficeLeaseMember" xlink:label="STRM_SuwaneeOfficeLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SuwaneeOfficeLeaseMember" xlink:to="STRM_SuwaneeOfficeLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_SuwaneeOfficeLeaseMember_lbl" xml:lang="en-US">Suwanee Office Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_LoanAgreementMember" xlink:label="STRM_LoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_LoanAgreementMember" xlink:to="STRM_LoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_LoanAgreementMember_lbl" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US">Lender Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_WesternAllianceBankMember" xlink:label="STRM_WesternAllianceBankMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_WesternAllianceBankMember" xlink:to="STRM_WesternAllianceBankMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_WesternAllianceBankMember_lbl" xml:lang="en-US">Western Alliance Bank [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US">Prime Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BaseRateMember" xlink:to="us-gaap_BaseRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BaseRateMember_lbl" xml:lang="en-US">Base Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_BridgeBankMember" xlink:label="STRM_BridgeBankMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_BridgeBankMember" xlink:to="STRM_BridgeBankMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_BridgeBankMember_lbl" xml:lang="en-US">Bridge Bank [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecondModificationAgreementMember" xlink:label="STRM_SecondModificationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SecondModificationAgreementMember" xlink:to="STRM_SecondModificationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_SecondModificationAgreementMember_lbl" xml:lang="en-US">Second Modification Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecondAmendedAndRestatedLoanAgreementMember" xlink:label="STRM_SecondAmendedAndRestatedLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SecondAmendedAndRestatedLoanAgreementMember" xlink:to="STRM_SecondAmendedAndRestatedLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_SecondAmendedAndRestatedLoanAgreementMember_lbl" xml:lang="en-US">Second Amended And Restated Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OctoberThirtyOneTwoThousandAndTwentyTwoMember" xlink:label="STRM_OctoberThirtyOneTwoThousandAndTwentyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_OctoberThirtyOneTwoThousandAndTwentyTwoMember" xlink:to="STRM_OctoberThirtyOneTwoThousandAndTwentyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_OctoberThirtyOneTwoThousandAndTwentyTwoMember_lbl" xml:lang="en-US">October 31, 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandTwentyThreeMember" xlink:label="STRM_JanuaryThirtyOneTwoThousandTwentyThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JanuaryThirtyOneTwoThousandTwentyThreeMember" xlink:to="STRM_JanuaryThirtyOneTwoThousandTwentyThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_JanuaryThirtyOneTwoThousandTwentyThreeMember_lbl" xml:lang="en-US">January 31, 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AprilThirtyTwoThousandTwentyThreeMember" xlink:label="STRM_AprilThirtyTwoThousandTwentyThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AprilThirtyTwoThousandTwentyThreeMember" xlink:to="STRM_AprilThirtyTwoThousandTwentyThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AprilThirtyTwoThousandTwentyThreeMember_lbl" xml:lang="en-US">April 30, 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JulyThirtyOneTwoThousandTwentyThreeMember" xlink:label="STRM_JulyThirtyOneTwoThousandTwentyThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JulyThirtyOneTwoThousandTwentyThreeMember" xlink:to="STRM_JulyThirtyOneTwoThousandTwentyThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_JulyThirtyOneTwoThousandTwentyThreeMember_lbl" xml:lang="en-US">July 31, 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OctoberThirtyOneTwoThousandTwentyThreeMember" xlink:label="STRM_OctoberThirtyOneTwoThousandTwentyThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_OctoberThirtyOneTwoThousandTwentyThreeMember" xlink:to="STRM_OctoberThirtyOneTwoThousandTwentyThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_OctoberThirtyOneTwoThousandTwentyThreeMember_lbl" xml:lang="en-US">October 31, 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandTwentyFourMember" xlink:label="STRM_JanuaryThirtyOneTwoThousandTwentyFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JanuaryThirtyOneTwoThousandTwentyFourMember" xlink:to="STRM_JanuaryThirtyOneTwoThousandTwentyFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_JanuaryThirtyOneTwoThousandTwentyFourMember_lbl" xml:lang="en-US">January 31, 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AprilThirtyTwoThousandTwentyFourMember" xlink:label="STRM_AprilThirtyTwoThousandTwentyFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AprilThirtyTwoThousandTwentyFourMember" xlink:to="STRM_AprilThirtyTwoThousandTwentyFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AprilThirtyTwoThousandTwentyFourMember_lbl" xml:lang="en-US">April 30, 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember" xlink:label="STRM_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember" xlink:to="STRM_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember_lbl" xml:lang="en-US">July 31, 2024 and Thereafter [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer Relationships [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ClientRelationshipsMember" xlink:label="STRM_ClientRelationshipsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ClientRelationshipsMember" xlink:to="STRM_ClientRelationshipsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ClientRelationshipsMember_lbl" xml:lang="en-US">Client Relationships [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_InternallyDevelopedSoftwareMember" xlink:label="STRM_InternallyDevelopedSoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_InternallyDevelopedSoftwareMember" xlink:to="STRM_InternallyDevelopedSoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_InternallyDevelopedSoftwareMember_lbl" xml:lang="en-US">Internally Developed Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="us-gaap_TrademarksAndTradeNamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksAndTradeNamesMember" xlink:to="us-gaap_TrademarksAndTradeNamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TrademarksAndTradeNamesMember_lbl" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ThroughFiscalTwoThousandThirtyEightMember" xlink:label="STRM_ThroughFiscalTwoThousandThirtyEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ThroughFiscalTwoThousandThirtyEightMember" xlink:to="STRM_ThroughFiscalTwoThousandThirtyEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ThroughFiscalTwoThousandThirtyEightMember_lbl" xml:lang="en-US">Through Fiscal Two Thousand Thirty Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_TaxCutsAndJobsActMember" xlink:label="STRM_TaxCutsAndJobsActMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_TaxCutsAndJobsActMember" xlink:to="STRM_TaxCutsAndJobsActMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_TaxCutsAndJobsActMember_lbl" xml:lang="en-US">Tax Cuts and Jobs Act [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_StateMember" xlink:label="STRM_StateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_StateMember" xlink:to="STRM_StateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_StateMember_lbl" xml:lang="en-US">State [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FederalRDMember" xlink:label="STRM_FederalRDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_FederalRDMember" xlink:to="STRM_FederalRDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_FederalRDMember_lbl" xml:lang="en-US">Federal RD [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_GeorgiaRDMember" xlink:label="STRM_GeorgiaRDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_GeorgiaRDMember" xlink:to="STRM_GeorgiaRDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_GeorgiaRDMember_lbl" xml:lang="en-US">Georgia RD [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PurchaseAgreementMember" xlink:label="STRM_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PurchaseAgreementMember" xlink:to="STRM_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_TwoThousandTwentyTwoOfferingMember" xlink:label="STRM_TwoThousandTwentyTwoOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_TwoThousandTwentyTwoOfferingMember" xlink:to="STRM_TwoThousandTwentyTwoOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_TwoThousandTwentyTwoOfferingMember_lbl" xml:lang="en-US">2022 Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OneHundredEightyConsultingLLCMember" xlink:label="STRM_OneHundredEightyConsultingLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_OneHundredEightyConsultingLLCMember" xlink:to="STRM_OneHundredEightyConsultingLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_OneHundredEightyConsultingLLCMember_lbl" xml:lang="en-US">180 Consulting LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" xlink:label="STRM_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" xlink:to="STRM_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_lbl" xml:lang="en-US">Third Amended And Restated 2013 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OneCustomerMember" xlink:label="STRM_OneCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_OneCustomerMember" xlink:to="STRM_OneCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_OneCustomerMember_lbl" xml:lang="en-US">One Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_TwoCustomerMember" xlink:label="STRM_TwoCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_TwoCustomerMember" xlink:to="STRM_TwoCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_TwoCustomerMember_lbl" xml:lang="en-US">Two Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CustomerOneMember" xlink:label="STRM_CustomerOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CustomerOneMember" xlink:to="STRM_CustomerOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_CustomerOneMember_lbl" xml:lang="en-US">Customer One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CustomerTwoMember" xlink:label="STRM_CustomerTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CustomerTwoMember" xlink:to="STRM_CustomerTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_CustomerTwoMember_lbl" xml:lang="en-US">Customer Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CustomerThreeMember" xlink:label="STRM_CustomerThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CustomerThreeMember" xlink:to="STRM_CustomerThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_CustomerThreeMember_lbl" xml:lang="en-US">Customer Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CustomerFourMember" xlink:label="STRM_CustomerFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CustomerFourMember" xlink:to="STRM_CustomerFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_CustomerFourMember_lbl" xml:lang="en-US">Customer Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_TwoThousandThirteenIncentiveCompensationPlanMember" xlink:label="STRM_TwoThousandThirteenIncentiveCompensationPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_TwoThousandThirteenIncentiveCompensationPlanMember" xlink:to="STRM_TwoThousandThirteenIncentiveCompensationPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_TwoThousandThirteenIncentiveCompensationPlanMember_lbl" xml:lang="en-US">2013 Incentive Compensation Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_StockOptionsMember" xlink:label="STRM_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_StockOptionsMember" xlink:to="STRM_StockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MrGreenMember" xlink:label="STRM_MrGreenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_MrGreenMember" xlink:to="STRM_MrGreenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_MrGreenMember_lbl" xml:lang="en-US">Mr Green [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MrStilwillMember" xlink:label="STRM_MrStilwillMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_MrStilwillMember" xlink:to="STRM_MrStilwillMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_MrStilwillMember_lbl" xml:lang="en-US">Mr Stil will [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MasterServicesAgreementMember" xlink:label="STRM_MasterServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_MasterServicesAgreementMember" xlink:to="STRM_MasterServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_MasterServicesAgreementMember_lbl" xml:lang="en-US">Master services agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SOWMember" xlink:label="STRM_SOWMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SOWMember" xlink:to="STRM_SOWMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_SOWMember_lbl" xml:lang="en-US">SOW [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecuritiesPurchaseAgreementMember" xlink:label="STRM_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SecuritiesPurchaseAgreementMember" xlink:to="STRM_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_NotesMember" xlink:label="STRM_NotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_NotesMember" xlink:to="STRM_NotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_NotesMember_lbl" xml:lang="en-US">Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ExceptDirectorsAndOfficersMember" xlink:label="STRM_ExceptDirectorsAndOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ExceptDirectorsAndOfficersMember" xlink:to="STRM_ExceptDirectorsAndOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ExceptDirectorsAndOfficersMember_lbl" xml:lang="en-US">Except Directors And Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ThirdModificationLoanAgreementMember" xlink:label="STRM_ThirdModificationLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ThirdModificationLoanAgreementMember" xlink:to="STRM_ThirdModificationLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ThirdModificationLoanAgreementMember_lbl" xml:lang="en-US">Third Modification Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AprilThirtyTwoThousandAndTwentyFourMember" xlink:label="STRM_AprilThirtyTwoThousandAndTwentyFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AprilThirtyTwoThousandAndTwentyFourMember" xlink:to="STRM_AprilThirtyTwoThousandAndTwentyFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="STRM_AprilThirtyTwoThousandAndTwentyFourMember_lbl" xml:lang="en-US">April 30, 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JulyThirtyOneTwoThousandAndTwentyFourMember" xlink:label="STRM_JulyThirtyOneTwoThousandAndTwentyFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JulyThirtyOneTwoThousandAndTwentyFourMember" xlink:to="STRM_JulyThirtyOneTwoThousandAndTwentyFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_JulyThirtyOneTwoThousandAndTwentyFourMember_lbl" xml:lang="en-US">July 31, 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember" xlink:label="STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember" xlink:to="STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember_lbl" xml:lang="en-US">October 31, 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember" xlink:label="STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember" xlink:to="STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember_lbl" xml:lang="en-US">January 31, 2025 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AprilThirtyTwoThousandTwentyFiveMember" xlink:label="STRM_AprilThirtyTwoThousandTwentyFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AprilThirtyTwoThousandTwentyFiveMember" xlink:to="STRM_AprilThirtyTwoThousandTwentyFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AprilThirtyTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">April 30, 2025 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JulyThirtyOneTwoThousandTwentyFiveMember" xlink:label="STRM_JulyThirtyOneTwoThousandTwentyFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JulyThirtyOneTwoThousandTwentyFiveMember" xlink:to="STRM_JulyThirtyOneTwoThousandTwentyFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_JulyThirtyOneTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">July 31, 2025 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OctoberThirtyOneTwoThousandTwentyFiveMember" xlink:label="STRM_OctoberThirtyOneTwoThousandTwentyFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_OctoberThirtyOneTwoThousandTwentyFiveMember" xlink:to="STRM_OctoberThirtyOneTwoThousandTwentyFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_OctoberThirtyOneTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">October 31, 2025 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember" xlink:label="STRM_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember" xlink:to="STRM_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember_lbl" xml:lang="en-US">January 31, 2026 And Thereafter [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember" xlink:label="STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember" xlink:to="STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember_lbl" xml:lang="en-US">January 31, 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents incorporated by reference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of allowance for credit losses of $86,000 and $132,000, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated amortization of $291,000 and $246,000 respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of use asset for operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="us-gaap_CapitalizedComputerSoftwareNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareNet" xlink:to="us-gaap_CapitalizedComputerSoftwareNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareNet_lbl" xml:lang="en-US">Capitalized software development costs, net of accumulated amortization of $7,960,000 and $6,224,000, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net of accumulated amortization of $4,019,000 and $2,627,000, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Current portion of term loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US">Acquisition earnout liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US">Term loan, net of deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLineOfCredit" xlink:label="us-gaap_LongTermLineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLineOfCredit" xlink:to="us-gaap_LongTermLineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLineOfCredit_lbl" xml:lang="en-US">Line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenues, less current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies &#8211; Note 12</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.01 par value per share, 85,000,000 shares authorized; 58,945,498 and 57,567,210 shares issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated amortization, property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:label="us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:to="us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_lbl" xml:lang="en-US">Capitalized Computer Software, Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization, intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfSoftwareAsService" xlink:label="STRM_CostOfSoftwareAsService" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CostOfSoftwareAsService" xlink:to="STRM_CostOfSoftwareAsService_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_CostOfSoftwareAsService_lbl" xml:lang="en-US">Cost of software as a service</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfMaintenanceAndSupport" xlink:label="STRM_CostOfMaintenanceAndSupport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CostOfMaintenanceAndSupport" xlink:to="STRM_CostOfMaintenanceAndSupport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_CostOfMaintenanceAndSupport_lbl" xml:lang="en-US">Cost of maintenance and support</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfProfessionalFeesAndLicenses" xlink:label="STRM_CostOfProfessionalFeesAndLicenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CostOfProfessionalFeesAndLicenses" xlink:to="STRM_CostOfProfessionalFeesAndLicenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_CostOfProfessionalFeesAndLicenses_lbl" xml:lang="en-US">Cost of professional fees and licenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Impairment of goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AcquisitionEarnoutValuationAdjustments" xlink:label="STRM_AcquisitionEarnoutValuationAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AcquisitionEarnoutValuationAdjustments" xlink:to="STRM_AcquisitionEarnoutValuationAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AcquisitionEarnoutValuationAdjustments_lbl" xml:lang="en-US">Acquisition earnout valuation adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of common shares - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of common shares - diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of Stock Options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted stock issued, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Common Stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xml:lang="en-US">Restricted stock forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">Restricted stock forfeited, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_StockIssuedDuringPeriodValueSurrenderOfShares" xlink:label="STRM_StockIssuedDuringPeriodValueSurrenderOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_StockIssuedDuringPeriodValueSurrenderOfShares" xlink:to="STRM_StockIssuedDuringPeriodValueSurrenderOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_StockIssuedDuringPeriodValueSurrenderOfShares_lbl" xml:lang="en-US">Surrender of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_StockIssuedDuringPeriodSharesSurrenderOfShares" xlink:label="STRM_StockIssuedDuringPeriodSharesSurrenderOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_StockIssuedDuringPeriodSharesSurrenderOfShares" xlink:to="STRM_StockIssuedDuringPeriodSharesSurrenderOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="STRM_StockIssuedDuringPeriodSharesSurrenderOfShares_lbl" xml:lang="en-US">Surrender of stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther" xlink:label="us-gaap_StockholdersEquityOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityOther" xlink:to="us-gaap_StockholdersEquityOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityOther_lbl" xml:lang="en-US">Adoption of ASU 2016-13</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AcquisitionEarnoutValuationAdjustments" xlink:to="STRM_AcquisitionEarnoutValuationAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="STRM_AcquisitionEarnoutValuationAdjustments_2_lbl" xml:lang="en-US">Acquisition earnout valuation adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ProvisionForDeferredIncomeTaxes" xlink:label="STRM_ProvisionForDeferredIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ProvisionForDeferredIncomeTaxes" xlink:to="STRM_ProvisionForDeferredIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ProvisionForDeferredIncomeTaxes_lbl" xml:lang="en-US">Provision for deferred income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US">Accounts and contract receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToDevelopSoftware" xlink:label="us-gaap_PaymentsToDevelopSoftware" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToDevelopSoftware" xlink:to="us-gaap_PaymentsToDevelopSoftware_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToDevelopSoftware_lbl" xml:lang="en-US">Capitalization of software development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl" xml:lang="en-US">Payment of acquisition earnout liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments for costs directly attributable to the issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Repayment of bank term loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Payments related to settlement of employee shared-based awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payment of deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid, net of amounts capitalized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS COMBINATION</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DisclosureOperatingLeasesAbstract" xlink:label="STRM_DisclosureOperatingLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_DisclosureOperatingLeasesAbstract" xlink:to="STRM_DisclosureOperatingLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_DisclosureOperatingLeasesAbstract_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">OPERATING LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">GOODWILL AND INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">MAJOR CLIENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">EMPLOYEE RETIREMENT PLAN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DisclosureSubsequentEventsAbstract" xlink:label="STRM_DisclosureSubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_DisclosureSubsequentEventsAbstract" xlink:to="STRM_DisclosureSubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_DisclosureSubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DisclosureValuationAndQualifyingAccountsAndReservesAbstract" xlink:label="STRM_DisclosureValuationAndQualifyingAccountsAndReservesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_DisclosureValuationAndQualifyingAccountsAndReservesAbstract" xlink:to="STRM_DisclosureValuationAndQualifyingAccountsAndReservesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_DisclosureValuationAndQualifyingAccountsAndReservesAbstract_lbl" xml:lang="en-US">Valuation And Qualifying Accounts And Reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xml:lang="en-US">Valuation and Qualifying Accounts and Reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_GoingConcernPolicyTextBlock" xlink:label="STRM_GoingConcernPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_GoingConcernPolicyTextBlock" xlink:to="STRM_GoingConcernPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_GoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AllowanceForCreditLossesPolicyTextBlock" xlink:label="STRM_AllowanceForCreditLossesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AllowanceForCreditLossesPolicyTextBlock" xlink:to="STRM_AllowanceForCreditLossesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AllowanceForCreditLossesPolicyTextBlock_lbl" xml:lang="en-US">Allowance for Credit Losses</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AccruedExpensesPolicyTextBlock" xlink:label="STRM_AccruedExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AccruedExpensesPolicyTextBlock" xlink:to="STRM_AccruedExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AccruedExpensesPolicyTextBlock_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ConcessionsAccrualPolicyTextBlock" xlink:label="STRM_ConcessionsAccrualPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ConcessionsAccrualPolicyTextBlock" xlink:to="STRM_ConcessionsAccrualPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ConcessionsAccrualPolicyTextBlock_lbl" xml:lang="en-US">Concessions Accrual</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsIncurredPolicy" xlink:label="us-gaap_CostsIncurredPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsIncurredPolicy" xlink:to="us-gaap_CostsIncurredPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsIncurredPolicy_lbl" xml:lang="en-US">Debt Issuance Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xml:lang="en-US">Capitalized Software Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_EquityAwardPolicyTextBlock" xlink:label="STRM_EquityAwardPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_EquityAwardPolicyTextBlock" xlink:to="STRM_EquityAwardPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_EquityAwardPolicyTextBlock_lbl" xml:lang="en-US">Equity Awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Earnings (Loss) Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Loss Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_lbl" xml:lang="en-US">Restructuring</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Accounting Pronouncements Recently Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="STRM_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="STRM_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock" xlink:label="STRM_ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock" xlink:to="STRM_ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESERVE RESULTS IN FUTURE PERIODS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCRUED EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PropertyPlantAndEquipmentTableTextBlock" xlink:label="STRM_PropertyPlantAndEquipmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PropertyPlantAndEquipmentTableTextBlock" xlink:to="STRM_PropertyPlantAndEquipmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_PropertyPlantAndEquipmentTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock" xlink:label="STRM_ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock" xlink:to="STRM_ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DISAGGREGATON OF REVENUE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATION OF THE RESTRUCTURING LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ScheduleOfMaximumDebtToARRRatioTableTextBlock" xlink:label="STRM_ScheduleOfMaximumDebtToARRRatioTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ScheduleOfMaximumDebtToARRRatioTableTextBlock" xlink:to="STRM_ScheduleOfMaximumDebtToARRRatioTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ScheduleOfMaximumDebtToARRRatioTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF MAXIMUM DEBT TO ARR RATIO</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock" xlink:label="STRM_ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock" xlink:to="STRM_ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CARRYING AMOUNT OF GOODWILL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ScheduleOfMaximumARRNetLeverageTableTextBlock" xlink:label="STRM_ScheduleOfMaximumARRNetLeverageTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ScheduleOfMaximumARRNetLeverageTableTextBlock" xlink:to="STRM_ScheduleOfMaximumARRNetLeverageTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ScheduleOfMaximumARRNetLeverageTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF MAXIMUM ARR NET LEVERAGE RATIO</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock" xlink:label="STRM_ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock" xlink:to="STRM_ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ScheduleOfMinimumAdjustedEBITDATableTextBlock" xlink:label="STRM_ScheduleOfMinimumAdjustedEBITDATableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ScheduleOfMinimumAdjustedEBITDATableTextBlock" xlink:to="STRM_ScheduleOfMinimumAdjustedEBITDATableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ScheduleOfMinimumAdjustedEBITDATableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF MINIMUM ADJUSTED EBITDA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Payment of acquisition earnout liabilities in restricted common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CapitalizedSoftwarePurchasedWithStock" xlink:label="STRM_CapitalizedSoftwarePurchasedWithStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CapitalizedSoftwarePurchasedWithStock" xlink:to="STRM_CapitalizedSoftwarePurchasedWithStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_CapitalizedSoftwarePurchasedWithStock_lbl" xml:lang="en-US">Capitalized software purchased with stock (See Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DeferredFinancingCosts" xlink:label="STRM_DeferredFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_DeferredFinancingCosts" xlink:to="STRM_DeferredFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_DeferredFinancingCosts_lbl" xml:lang="en-US">Deferred financing costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_2_lbl" xml:lang="en-US">Allowance for credit losses, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AllowanceForDoubtfulAccountsReceivableCECLAdoption" xlink:label="STRM_AllowanceForDoubtfulAccountsReceivableCECLAdoption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AllowanceForDoubtfulAccountsReceivableCECLAdoption" xlink:to="STRM_AllowanceForDoubtfulAccountsReceivableCECLAdoption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AllowanceForDoubtfulAccountsReceivableCECLAdoption_lbl" xml:lang="en-US">Allowance for credit losses, CECL Adoption</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_2_lbl" xml:lang="en-US">Allowance for credit losses, Provision adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xml:lang="en-US">Allowance for credit losses, Write-offs &amp; Recoveries</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_3_lbl" xml:lang="en-US">Allowance for credit losses, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Employee benefits and related compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent" xlink:label="us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent" xlink:to="us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent_lbl" xml:lang="en-US">Professional fees and services</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ThirdPartylicense" xlink:label="STRM_ThirdPartylicense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ThirdPartylicense" xlink:to="STRM_ThirdPartylicense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ThirdPartylicense_lbl" xml:lang="en-US">Third party licenses</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ConcessionAccrualAmount" xlink:label="STRM_ConcessionAccrualAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ConcessionAccrualAmount" xlink:to="STRM_ConcessionAccrualAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ConcessionAccrualAmount_lbl" xml:lang="en-US">Customer concessions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent_lbl" xml:lang="en-US">State income and sales taxes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest, primarily on term loan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property and equipment, useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="us-gaap_CapitalizedComputerSoftwareAmortization1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1_lbl" xml:lang="en-US">Total amortization expense on internally-developed software</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AcquisitionEarnoutLiabilityFairValue" xlink:label="STRM_AcquisitionEarnoutLiabilityFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AcquisitionEarnoutLiabilityFairValue" xlink:to="STRM_AcquisitionEarnoutLiabilityFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AcquisitionEarnoutLiabilityFairValue_lbl" xml:lang="en-US">Acquisition earn out liability fair value, observable inputs</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AcquisitionEarnoutLiabilityChangeInValuation" xlink:label="STRM_AcquisitionEarnoutLiabilityChangeInValuation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AcquisitionEarnoutLiabilityChangeInValuation" xlink:to="STRM_AcquisitionEarnoutLiabilityChangeInValuation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AcquisitionEarnoutLiabilityChangeInValuation_lbl" xml:lang="en-US">Acquisition earnout liability, change in valuation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Total revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Loss, net of tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Basic net loss per share of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:to="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_lbl" xml:lang="en-US">Loss available to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">Diluted net loss per share of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average shares outstanding &#8211; Basic (1)</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks" xlink:label="STRM_EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks" xlink:to="STRM_EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks_lbl" xml:lang="en-US">Effect of dilutive securities - Stock options and Restricted stock (2)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted average shares outstanding &#8211; Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Basic and diluted net loss per share of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Diluted earnings per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_3_lbl" xml:lang="en-US">Accrued Balance as of January 31, 2023</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">2023 Expenses to Date</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AccruedCashPayments" xlink:label="STRM_AccruedCashPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AccruedCashPayments" xlink:to="STRM_AccruedCashPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AccruedCashPayments_lbl" xml:lang="en-US">2023 Cash Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_4_lbl" xml:lang="en-US">Accrued Balance as of October 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AccruedCostsIncurred" xlink:label="STRM_AccruedCostsIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AccruedCostsIncurred" xlink:to="STRM_AccruedCostsIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AccruedCostsIncurred_lbl" xml:lang="en-US">Total Costs Incurred to Date</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AccruedExpectedCosts" xlink:label="STRM_AccruedExpectedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AccruedExpectedCosts" xlink:to="STRM_AccruedExpectedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AccruedExpectedCosts_lbl" xml:lang="en-US">Total Expected Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US">Acquisition related costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ConcessionAccrualAmount" xlink:to="STRM_ConcessionAccrualAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="STRM_ConcessionAccrualAmount_2_lbl" xml:lang="en-US">Concession accrual amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:to="us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_2_lbl" xml:lang="en-US">Capitalized software development costs, net of accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="us-gaap_CapitalizedComputerSoftwareAmortization1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1_2_lbl" xml:lang="en-US">Capitalized Computer Software, Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Asset Impairment Charges</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AmortizedAndAbandonedAssets" xlink:label="STRM_AmortizedAndAbandonedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AmortizedAndAbandonedAssets" xlink:to="STRM_AmortizedAndAbandonedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AmortizedAndAbandonedAssets_lbl" xml:lang="en-US">Amortized and abandoned assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PrimeInterestRatePercentage" xlink:label="STRM_PrimeInterestRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PrimeInterestRatePercentage" xlink:to="STRM_PrimeInterestRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_PrimeInterestRatePercentage_lbl" xml:lang="en-US">Prime interest rate percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Debt instrument carrying amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Term loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US">Revenue remaining performance obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_lbl" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, explanation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" xml:lang="en-US">Deferred costs, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedAmortizationOfOtherDeferredCosts" xlink:label="us-gaap_AccumulatedAmortizationOfOtherDeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedAmortizationOfOtherDeferredCosts" xlink:to="us-gaap_AccumulatedAmortizationOfOtherDeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedAmortizationOfOtherDeferredCosts_lbl" xml:lang="en-US">Accumulated amortization of deferred costs</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DeferredCostsAmortizationExpenses" xlink:label="STRM_DeferredCostsAmortizationExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_DeferredCostsAmortizationExpenses" xlink:to="STRM_DeferredCostsAmortizationExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_DeferredCostsAmortizationExpenses_lbl" xml:lang="en-US">Deferred costs, amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAmortizationOfDeferredCharges" xlink:label="us-gaap_OtherAmortizationOfDeferredCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAmortizationOfDeferredCharges" xlink:to="us-gaap_OtherAmortizationOfDeferredCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAmortizationOfDeferredCharges_lbl" xml:lang="en-US">Amortized contracts</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DeferredCommissionsCostsPaidAndPayable" xlink:label="STRM_DeferredCommissionsCostsPaidAndPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_DeferredCommissionsCostsPaidAndPayable" xlink:to="STRM_DeferredCommissionsCostsPaidAndPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_DeferredCommissionsCostsPaidAndPayable_lbl" xml:lang="en-US">Deferred commissions costs paid and payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDeferredSalesCommissions" xlink:label="us-gaap_AmortizationOfDeferredSalesCommissions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDeferredSalesCommissions" xlink:to="us-gaap_AmortizationOfDeferredSalesCommissions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDeferredSalesCommissions_lbl" xml:lang="en-US">Amortization expense with deferred sales commissions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostImpairmentLoss" xlink:label="us-gaap_CapitalizedContractCostImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostImpairmentLoss" xlink:to="us-gaap_CapitalizedContractCostImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostImpairmentLoss_lbl" xml:lang="en-US">Impairment loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Finite-lived intangible assets amortized period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Compensation expense related to stock-based award</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SurrenderOfStockSharesDuringPeriod" xlink:label="STRM_SurrenderOfStockSharesDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SurrenderOfStockSharesDuringPeriod" xlink:to="STRM_SurrenderOfStockSharesDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_SurrenderOfStockSharesDuringPeriod_lbl" xml:lang="en-US">Surrender of stock, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xml:lang="en-US">Cost of shares for tax withholding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Number shares of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_NumberOfEmployeesTerminated" xlink:label="STRM_NumberOfEmployeesTerminated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_NumberOfEmployeesTerminated" xlink:to="STRM_NumberOfEmployeesTerminated_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_NumberOfEmployeesTerminated_lbl" xml:lang="en-US">Number of employees terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PercentageOfWorkforceTerminated" xlink:label="STRM_PercentageOfWorkforceTerminated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PercentageOfWorkforceTerminated" xlink:to="STRM_PercentageOfWorkforceTerminated_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_PercentageOfWorkforceTerminated_lbl" xml:lang="en-US">Percentage of workforce terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCosts" xlink:to="us-gaap_RestructuringCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCosts_lbl" xml:lang="en-US">Restructuring costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Business combination, cash payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_lbl" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US">Business acquisition, equity interest issued or issuable, number of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_BusinessAcquisitionEquityInterestIssuedFairValue" xlink:label="STRM_BusinessAcquisitionEquityInterestIssuedFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_BusinessAcquisitionEquityInterestIssuedFairValue" xlink:to="STRM_BusinessAcquisitionEquityInterestIssuedFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_BusinessAcquisitionEquityInterestIssuedFairValue_lbl" xml:lang="en-US">Business acquisition equity fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl" xml:lang="en-US">Business combination description</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PaymentsToAcquireBusinessesSellerExpenses" xlink:label="STRM_PaymentsToAcquireBusinessesSellerExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PaymentsToAcquireBusinessesSellerExpenses" xlink:to="STRM_PaymentsToAcquireBusinessesSellerExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_PaymentsToAcquireBusinessesSellerExpenses_lbl" xml:lang="en-US">[custom:PaymentsToAcquireBusinessesSellerExpenses]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment" xlink:label="STRM_PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment" xlink:to="STRM_PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment_lbl" xml:lang="en-US">[custom:PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PaymentOfSaasContingentConsiderationInCashPercentage" xlink:label="STRM_PaymentOfSaasContingentConsiderationInCashPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PaymentOfSaasContingentConsiderationInCashPercentage" xlink:to="STRM_PaymentOfSaasContingentConsiderationInCashPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_PaymentOfSaasContingentConsiderationInCashPercentage_lbl" xml:lang="en-US">Payment of SaaS contingent consideration in cash, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PaymentOfSaasContingentConsiderationInSharesPercentage" xlink:label="STRM_PaymentOfSaasContingentConsiderationInSharesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PaymentOfSaasContingentConsiderationInSharesPercentage" xlink:to="STRM_PaymentOfSaasContingentConsiderationInSharesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="STRM_PaymentOfSaasContingentConsiderationInSharesPercentage_lbl" xml:lang="en-US">Payment of SaaS contingent consideration in cash, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FirstYearPaymentOfSaasContingentConsiderationDescription" xlink:label="STRM_FirstYearPaymentOfSaasContingentConsiderationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_FirstYearPaymentOfSaasContingentConsiderationDescription" xlink:to="STRM_FirstYearPaymentOfSaasContingentConsiderationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_FirstYearPaymentOfSaasContingentConsiderationDescription_lbl" xml:lang="en-US">First year payment of SaaS contingent consideration, description</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecondYearPaymentOfSaasContingentConsiderationDescription" xlink:label="STRM_SecondYearPaymentOfSaasContingentConsiderationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SecondYearPaymentOfSaasContingentConsiderationDescription" xlink:to="STRM_SecondYearPaymentOfSaasContingentConsiderationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_SecondYearPaymentOfSaasContingentConsiderationDescription_lbl" xml:lang="en-US">Second year payment of SaaS contingent consideration, description</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ForecastedRevenueDescription" xlink:label="STRM_ForecastedRevenueDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ForecastedRevenueDescription" xlink:to="STRM_ForecastedRevenueDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_ForecastedRevenueDescription_lbl" xml:lang="en-US">Forecasted revenue description</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_RenewalContingentConsiderationDescription" xlink:label="STRM_RenewalContingentConsiderationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_RenewalContingentConsiderationDescription" xlink:to="STRM_RenewalContingentConsiderationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_RenewalContingentConsiderationDescription_lbl" xml:lang="en-US">Renewal contingent consideration, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock par or stated value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock number of shares issued in transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RentalProperties" xlink:label="us-gaap_RentalProperties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RentalProperties" xlink:to="us-gaap_RentalProperties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RentalProperties_lbl" xml:lang="en-US">Related to space rental</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease, payments</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SubleaseTerm" xlink:label="STRM_SubleaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SubleaseTerm" xlink:to="STRM_SubleaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_SubleaseTerm_lbl" xml:lang="en-US">Sublease, term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Sublease income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income related to sublease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Payments for rent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_2_lbl" xml:lang="en-US">Term loan</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FinancingCostPayable" xlink:label="STRM_FinancingCostPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_FinancingCostPayable" xlink:to="STRM_FinancingCostPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_FinancingCostPayable_lbl" xml:lang="en-US">Financing cost payable</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DeferredFinancingCost" xlink:label="STRM_DeferredFinancingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_DeferredFinancingCost" xlink:to="STRM_DeferredFinancingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="STRM_DeferredFinancingCost_lbl" xml:lang="en-US">Less: Deferred financing cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LongTermDebtCurrent_2_lbl" xml:lang="en-US">Less: Current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Non-current portion of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MaximumDebtToArrRatio" xlink:label="STRM_MaximumDebtToArrRatio" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_MaximumDebtToArrRatio" xlink:to="STRM_MaximumDebtToArrRatio_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_MaximumDebtToArrRatio_lbl" xml:lang="en-US">Maximum Debt to ARR Ratio</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MaximumDebtToAdjustedEbitdaRatio" xlink:label="STRM_MaximumDebtToAdjustedEbitdaRatio" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_MaximumDebtToAdjustedEbitdaRatio" xlink:to="STRM_MaximumDebtToAdjustedEbitdaRatio_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_MaximumDebtToAdjustedEbitdaRatio_lbl" xml:lang="en-US">Maximum Debt to Adjusted EBITDA Ratio</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">Long term debt, maturity, year two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">Long term debt, maturity, year three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US">Long term debt, maturity, year four</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xml:lang="en-US">Long term debt, maturity, year five</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="us-gaap_AccretionExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionExpense_lbl" xml:lang="en-US">Accretion expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Line of credit facility, matures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="us-gaap_DebtInstrumentCovenantDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCovenantDescription" xlink:to="us-gaap_DebtInstrumentCovenantDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCovenantDescription_lbl" xml:lang="en-US">Debt financial covenants, description</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FixedChargeCoverageRatio" xlink:label="STRM_FixedChargeCoverageRatio" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_FixedChargeCoverageRatio" xlink:to="STRM_FixedChargeCoverageRatio_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_FixedChargeCoverageRatio_lbl" xml:lang="en-US">Fixed charge coverage ratio</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Goodwill_2_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_2_lbl" xml:lang="en-US">Impairment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Goodwill_3_lbl" xml:lang="en-US">Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Estimated Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_3_lbl" xml:lang="en-US">Iimpairment of goodwill</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2_lbl" xml:lang="en-US">Impairment of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense on intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AbandonedAssetWroteOff" xlink:label="STRM_AbandonedAssetWroteOff" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AbandonedAssetWroteOff" xlink:to="STRM_AbandonedAssetWroteOff_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AbandonedAssetWroteOff_lbl" xml:lang="en-US">Abandoned asset wrote off</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Current tax expense:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current tax benefit (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Deferred tax expense:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred tax benefit (expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income tax benefit (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal tax benefit at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State and local tax expense, net of federal</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_IncreaseInValuationAllowance" xlink:label="STRM_IncreaseInValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_IncreaseInValuationAllowance" xlink:to="STRM_IncreaseInValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_IncreaseInValuationAllowance_lbl" xml:lang="en-US">Increase in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xml:lang="en-US">Reserve for uncertain tax position</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Federal research and development (R&amp;D) tax credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Allowance for credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent" xlink:label="STRM_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent" xlink:to="STRM_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Finite-lived intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">R&amp;D tax credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Finite-lived intangible liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Net deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Beginning of fiscal year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Additions for tax positions for the current year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">Additions for tax positions of prior years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xml:lang="en-US">Subtractions for tax positions of prior years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_2_lbl" xml:lang="en-US">End of fiscal year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income tax rates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carry forwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_IncreaseInValuationAllowance" xlink:to="STRM_IncreaseInValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="STRM_IncreaseInValuationAllowance_2_lbl" xml:lang="en-US">Increase in the valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_3_lbl" xml:lang="en-US">Uncertain tax positions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_3_lbl" xml:lang="en-US">Common stock par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock issued for resale</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Number of additional shares authorized to issue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized to issue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCustomer" xlink:label="us-gaap_ConcentrationRiskCustomer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCustomer" xlink:to="us-gaap_ConcentrationRiskCustomer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCustomer_lbl" xml:lang="en-US">Concentration Risk, Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration Risk, Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Defined contribution plan, cost recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Remaining Life in Years, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average exercise price, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of options, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Remaining Life in Years, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of options, Vested or expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Vested or expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Remaining Life in Years, Vested or expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Vested or expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of RSUs, Non vested, Outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of RSUs, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, RSUs granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of RSUs, vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, RSUs vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number RSUs, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, RSUs forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of RSUs, Non vested, Outstanding, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Stock options plan, description</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_NumberOfOptionsToPurchaseCommonStock" xlink:label="STRM_NumberOfOptionsToPurchaseCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_NumberOfOptionsToPurchaseCommonStock" xlink:to="STRM_NumberOfOptionsToPurchaseCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_NumberOfOptionsToPurchaseCommonStock_lbl" xml:lang="en-US">Number of options to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized Compensation cost, stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock option expense</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_InvestmentOwnershipPercentage" xlink:label="STRM_InvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_InvestmentOwnershipPercentage" xlink:to="STRM_InvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_InvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership Percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Number of restricted stocks awarded, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Cost expected remaining period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_NonEmployeeStockCompensation" xlink:label="STRM_NonEmployeeStockCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_NonEmployeeStockCompensation" xlink:to="STRM_NonEmployeeStockCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_NonEmployeeStockCompensation_lbl" xml:lang="en-US">[custom:NonEmployeeStockCompensation]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForRent_2_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MaximumArrNetLeverageRatio" xlink:label="STRM_MaximumArrNetLeverageRatio" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_MaximumArrNetLeverageRatio" xlink:to="STRM_MaximumArrNetLeverageRatio_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_MaximumArrNetLeverageRatio_lbl" xml:lang="en-US">Maximum ARR net leverage ratio</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MinimumAdjustedEbitda" xlink:label="STRM_MinimumAdjustedEbitda" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_MinimumAdjustedEbitda" xlink:to="STRM_MinimumAdjustedEbitda_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_MinimumAdjustedEbitda_lbl" xml:lang="en-US">Minimum Adjusted EBITDA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Debt principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of shares purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_2_lbl" xml:lang="en-US">Notes bear interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_2_lbl" xml:lang="en-US">Notes maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AffiliatesEffectivePercentage" xlink:label="STRM_AffiliatesEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AffiliatesEffectivePercentage" xlink:to="STRM_AffiliatesEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AffiliatesEffectivePercentage_lbl" xml:lang="en-US">Affiliates effective percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Purchase price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xml:lang="en-US">Aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_lbl" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CostOfSoftwareAsService" xlink:to="STRM_CostOfSoftwareAsService_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_CostOfSoftwareAsService_doc" xml:lang="en-US">Cost of software as a service.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CostOfMaintenanceAndSupport" xlink:to="STRM_CostOfMaintenanceAndSupport_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_CostOfMaintenanceAndSupport_doc" xml:lang="en-US">Cost of maintenance and support.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CostOfProfessionalFeesAndLicenses" xlink:to="STRM_CostOfProfessionalFeesAndLicenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_CostOfProfessionalFeesAndLicenses_doc" xml:lang="en-US">Cost of professional fees and licenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AcquisitionEarnoutValuationAdjustments" xlink:to="STRM_AcquisitionEarnoutValuationAdjustments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AcquisitionEarnoutValuationAdjustments_doc" xml:lang="en-US">Acquisition earnout valuation adjustments.</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SurrenderOfStockDuringPeriodValue" xlink:label="STRM_SurrenderOfStockDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SurrenderOfStockDuringPeriodValue" xlink:to="STRM_SurrenderOfStockDuringPeriodValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_SurrenderOfStockDuringPeriodValue_doc" xml:lang="en-US">Surrender of stock during period value.</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensation" xlink:label="STRM_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensation" xlink:to="STRM_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensation_doc" xml:lang="en-US">Adjustment to additional paid in capital  income tax effect from share based compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SurrenderOfStockSharesDuringPeriod" xlink:to="STRM_SurrenderOfStockSharesDuringPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_SurrenderOfStockSharesDuringPeriod_doc" xml:lang="en-US">Surrender of stock shares during period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ProvisionForDeferredIncomeTaxes" xlink:to="STRM_ProvisionForDeferredIncomeTaxes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ProvisionForDeferredIncomeTaxes_doc" xml:lang="en-US">Provision for deferred income taxes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_GoingConcernPolicyTextBlock" xlink:to="STRM_GoingConcernPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_GoingConcernPolicyTextBlock_doc" xml:lang="en-US">Going Concern [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock" xlink:to="STRM_ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock_doc" xml:lang="en-US">Schedule of non-cash items related to condensed consolidated statements of cash flow [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CapitalizedSoftwarePurchasedWithStock" xlink:to="STRM_CapitalizedSoftwarePurchasedWithStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_CapitalizedSoftwarePurchasedWithStock_doc" xml:lang="en-US">Capitalized software purchased with stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AllowanceForDoubtfulAccountsPolicyTextBlock" xlink:label="STRM_AllowanceForDoubtfulAccountsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AllowanceForDoubtfulAccountsPolicyTextBlock" xlink:to="STRM_AllowanceForDoubtfulAccountsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AllowanceForDoubtfulAccountsPolicyTextBlock_doc" xml:lang="en-US">Allowance for Doubtful Accounts [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AllowanceForDoubtfulAccountsReceivableCECLAdoption" xlink:to="STRM_AllowanceForDoubtfulAccountsReceivableCECLAdoption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AllowanceForDoubtfulAccountsReceivableCECLAdoption_doc" xml:lang="en-US">Allowance for credit losses, CECL adoption.</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AllowanceForDoubtfulAccountsReceivableProvisionadjustments" xlink:label="STRM_AllowanceForDoubtfulAccountsReceivableProvisionadjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AllowanceForDoubtfulAccountsReceivableProvisionadjustments" xlink:to="STRM_AllowanceForDoubtfulAccountsReceivableProvisionadjustments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AllowanceForDoubtfulAccountsReceivableProvisionadjustments_doc" xml:lang="en-US">Allowance for credit losses, Provision adjustments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AccruedExpensesPolicyTextBlock" xlink:to="STRM_AccruedExpensesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AccruedExpensesPolicyTextBlock_doc" xml:lang="en-US">Accrued Expenses [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ThirdPartylicense" xlink:to="STRM_ThirdPartylicense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ThirdPartylicense_doc" xml:lang="en-US">Third party license.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ConcessionAccrualAmount" xlink:to="STRM_ConcessionAccrualAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ConcessionAccrualAmount_doc" xml:lang="en-US">Concession accrual amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ConcessionsAccrualPolicyTextBlock" xlink:to="STRM_ConcessionsAccrualPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ConcessionsAccrualPolicyTextBlock_doc" xml:lang="en-US">Concessions Accrual [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ComputerEquipmentAndSoftwareMember" xlink:to="STRM_ComputerEquipmentAndSoftwareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ComputerEquipmentAndSoftwareMember_doc" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_OfficeFurnitureAndFixturesMember" xlink:to="STRM_OfficeFurnitureAndFixturesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_OfficeFurnitureAndFixturesMember_doc" xml:lang="en-US">Office Furniture and Fixtures [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SoftwareMember" xlink:to="STRM_SoftwareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_SoftwareMember_doc" xml:lang="en-US">Software [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_InternalUseSoftwareMember" xlink:to="STRM_InternalUseSoftwareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_InternalUseSoftwareMember_doc" xml:lang="en-US">Internal-Use Software [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AmortizedAndAbandonedAssets" xlink:to="STRM_AmortizedAndAbandonedAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AmortizedAndAbandonedAssets_doc" xml:lang="en-US">Amortized and abandoned assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock" xlink:to="STRM_ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock_doc" xml:lang="en-US">Schedule of amortization expense for internally developed software table [Text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AcquisitionEarnoutLiabilityFairValue" xlink:to="STRM_AcquisitionEarnoutLiabilityFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AcquisitionEarnoutLiabilityFairValue_doc" xml:lang="en-US">Acquisition earnout liability, fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AcquisitionEarnoutLiabilityChangeInValuation" xlink:to="STRM_AcquisitionEarnoutLiabilityChangeInValuation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AcquisitionEarnoutLiabilityChangeInValuation_doc" xml:lang="en-US">Acquisition earnout liability, change in valuation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SecurityAgreementMember" xlink:to="STRM_SecurityAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_SecurityAgreementMember_doc" xml:lang="en-US">Security Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PrimeInterestRatePercentage" xlink:to="STRM_PrimeInterestRatePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_PrimeInterestRatePercentage_doc" xml:lang="en-US">Prime interest rate percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SecondAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:to="STRM_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_doc" xml:lang="en-US">Second Amended And Restated Loan And Security Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_DebtAgreementMember" xlink:to="STRM_DebtAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_DebtAgreementMember_doc" xml:lang="en-US">Debt Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_DeferredCostsAmortizationExpenses" xlink:to="STRM_DeferredCostsAmortizationExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_DeferredCostsAmortizationExpenses_doc" xml:lang="en-US">Deferred costs, amortization expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_DeferredCommissionsCostsPaidAndPayable" xlink:to="STRM_DeferredCommissionsCostsPaidAndPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_DeferredCommissionsCostsPaidAndPayable_doc" xml:lang="en-US">Deferred commissions costs paid and payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_EquityAwardPolicyTextBlock" xlink:to="STRM_EquityAwardPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_EquityAwardPolicyTextBlock_doc" xml:lang="en-US">Equity Award [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_EquityAwardMember" xlink:to="STRM_EquityAwardMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_EquityAwardMember_doc" xml:lang="en-US">Equity Award [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_OfficersAndDirectorsMember" xlink:to="STRM_OfficersAndDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_OfficersAndDirectorsMember_doc" xml:lang="en-US">Officers and Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks" xlink:to="STRM_EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks_doc" xml:lang="en-US">Effect of dilutive securities - Stock options and Restricted stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_NumberOfEmployeesTerminated" xlink:to="STRM_NumberOfEmployeesTerminated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_NumberOfEmployeesTerminated_doc" xml:lang="en-US">Number of employees terminated.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PercentageOfWorkforceTerminated" xlink:to="STRM_PercentageOfWorkforceTerminated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_PercentageOfWorkforceTerminated_doc" xml:lang="en-US">Percentage of workforce terminated.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SeveranceExpensesMember" xlink:to="STRM_SeveranceExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_SeveranceExpensesMember_doc" xml:lang="en-US">Severance Expenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ProfessionalFeesMember" xlink:to="STRM_ProfessionalFeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ProfessionalFeesMember_doc" xml:lang="en-US">Professional Fees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AccruedExpensesMember" xlink:to="STRM_AccruedExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AccruedExpensesMember_doc" xml:lang="en-US">Accrued Expenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AccruedCashPayments" xlink:to="STRM_AccruedCashPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AccruedCashPayments_doc" xml:lang="en-US">Accrued cash payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AccruedExpectedCosts" xlink:to="STRM_AccruedExpectedCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AccruedExpectedCosts_doc" xml:lang="en-US">Accrued expected costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="STRM_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_doc" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AccruedCostsIncurred" xlink:to="STRM_AccruedCostsIncurred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AccruedCostsIncurred_doc" xml:lang="en-US">Accrued costs incurred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PropertyPlantAndEquipmentTableTextBlock" xlink:to="STRM_PropertyPlantAndEquipmentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_PropertyPlantAndEquipmentTableTextBlock_doc" xml:lang="en-US">Property Plant and Equipment [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AveleadConsultingLLCMember" xlink:to="STRM_AveleadConsultingLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AveleadConsultingLLCMember_doc" xml:lang="en-US">Avelead Consulting LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_BusinessAcquisitionEquityInterestIssuedFairValue" xlink:to="STRM_BusinessAcquisitionEquityInterestIssuedFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_BusinessAcquisitionEquityInterestIssuedFairValue_doc" xml:lang="en-US">Business acquisition equity fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AcquisitionRestrictedCommonStockMember" xlink:to="STRM_AcquisitionRestrictedCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AcquisitionRestrictedCommonStockMember_doc" xml:lang="en-US">Acquisition Restricted Common Stock [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_UnitPurchaseAgreementMember" xlink:to="STRM_UnitPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_UnitPurchaseAgreementMember_doc" xml:lang="en-US">Unit Purchase Agreement [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PaymentsToAcquireBusinessesSellerExpenses" xlink:to="STRM_PaymentsToAcquireBusinessesSellerExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_PaymentsToAcquireBusinessesSellerExpenses_doc" xml:lang="en-US">Payments to acquire business seller, expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment" xlink:to="STRM_PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment_doc" xml:lang="en-US">Payment for estimated working capital adjustment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PaymentOfSaasContingentConsiderationInCashPercentage" xlink:to="STRM_PaymentOfSaasContingentConsiderationInCashPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_PaymentOfSaasContingentConsiderationInCashPercentage_doc" xml:lang="en-US">Payment of SaaS contingent consideration in cash, percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PaymentOfSaasContingentConsiderationInSharesPercentage" xlink:to="STRM_PaymentOfSaasContingentConsiderationInSharesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_PaymentOfSaasContingentConsiderationInSharesPercentage_doc" xml:lang="en-US">Payment of saas contingent consideration in shares percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_RenewalContingentConsiderationDescription" xlink:to="STRM_RenewalContingentConsiderationDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_RenewalContingentConsiderationDescription_doc" xml:lang="en-US">Renewal contingent consideration, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ForecastedRevenueDescription" xlink:to="STRM_ForecastedRevenueDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ForecastedRevenueDescription_doc" xml:lang="en-US">Forecasted revenue description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SecondYearPaymentOfSaasContingentConsiderationDescription" xlink:to="STRM_SecondYearPaymentOfSaasContingentConsiderationDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_SecondYearPaymentOfSaasContingentConsiderationDescription_doc" xml:lang="en-US">Second year payment of SaaS contingent consideration, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_FirstYearPaymentOfSaasContingentConsiderationDescription" xlink:to="STRM_FirstYearPaymentOfSaasContingentConsiderationDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_FirstYearPaymentOfSaasContingentConsiderationDescription_doc" xml:lang="en-US">First year payment of SaaS contingent consideration, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_RenewalContingentConsiderationMember" xlink:to="STRM_RenewalContingentConsiderationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_RenewalContingentConsiderationMember_doc" xml:lang="en-US">Renewal Contingent Consideration [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_FirstYearEarnoutMember" xlink:to="STRM_FirstYearEarnoutMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_FirstYearEarnoutMember_doc" xml:lang="en-US">First Year Earnout [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AveleadMember" xlink:label="STRM_AveleadMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AveleadMember" xlink:to="STRM_AveleadMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AveleadMember_doc" xml:lang="en-US">Avelead [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_BusinessCombinationEarnoutRestrictedShares" xlink:label="STRM_BusinessCombinationEarnoutRestrictedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_BusinessCombinationEarnoutRestrictedShares" xlink:to="STRM_BusinessCombinationEarnoutRestrictedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_BusinessCombinationEarnoutRestrictedShares_doc" xml:lang="en-US">Business combination earnout restricted shares.</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedUnbilledRevenue" xlink:label="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedUnbilledRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedUnbilledRevenue" xlink:to="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedUnbilledRevenue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedUnbilledRevenue_doc" xml:lang="en-US">Revenue.</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_doc" xml:lang="en-US">Accrued expenses.</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationshipsSaaS" xlink:label="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationshipsSaaS" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationshipsSaaS" xlink:to="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationshipsSaaS_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationshipsSaaS_doc" xml:lang="en-US">Customer Relationships (SaaS).</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationshipsConsulting" xlink:label="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationshipsConsulting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationshipsConsulting" xlink:to="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationshipsConsulting_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationshipsConsulting_doc" xml:lang="en-US">Customer Relationships (Consulting).</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInternallyDevelopedSoftware" xlink:label="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInternallyDevelopedSoftware" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInternallyDevelopedSoftware" xlink:to="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInternallyDevelopedSoftware_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInternallyDevelopedSoftware_doc" xml:lang="en-US">Internally Developed Software.</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademarksAndTradenames" xlink:label="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademarksAndTradenames" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademarksAndTradenames" xlink:to="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademarksAndTradenames_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademarksAndTradenames_doc" xml:lang="en-US">Trademarks and tradenames.</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ScheduleOfIntangibleAssetsAndGoodwillEstimatedUsefulLivesTableTextBlock" xlink:label="STRM_ScheduleOfIntangibleAssetsAndGoodwillEstimatedUsefulLivesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ScheduleOfIntangibleAssetsAndGoodwillEstimatedUsefulLivesTableTextBlock" xlink:to="STRM_ScheduleOfIntangibleAssetsAndGoodwillEstimatedUsefulLivesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ScheduleOfIntangibleAssetsAndGoodwillEstimatedUsefulLivesTableTextBlock_doc" xml:lang="en-US">Schedule Of Intangible Assets And Goodwill Estimated Useful Lives Table [TextBlock]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLifeDescription" xlink:label="STRM_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLifeDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLifeDescription" xlink:to="STRM_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLifeDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLifeDescription_doc" xml:lang="en-US">Estimated useful lives.</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CustomerRelationshipsConsultingMember" xlink:label="STRM_CustomerRelationshipsConsultingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CustomerRelationshipsConsultingMember" xlink:to="STRM_CustomerRelationshipsConsultingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_CustomerRelationshipsConsultingMember_doc" xml:lang="en-US">Customer Relationships Consulting [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SubleaseTerm" xlink:to="STRM_SubleaseTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_SubleaseTerm_doc" xml:lang="en-US">Sublease term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SubleaseAgreementMember" xlink:to="STRM_SubleaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_SubleaseAgreementMember_doc" xml:lang="en-US">Sublease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AlpharettaOfficeLeaseMember" xlink:to="STRM_AlpharettaOfficeLeaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AlpharettaOfficeLeaseMember_doc" xml:lang="en-US">Alpharetta Office Lease [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SuwaneeOfficeLeaseMember" xlink:to="STRM_SuwaneeOfficeLeaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_SuwaneeOfficeLeaseMember_doc" xml:lang="en-US">Suwanee Office Lease [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SecondYearEarnoutMember" xlink:to="STRM_SecondYearEarnoutMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_SecondYearEarnoutMember_doc" xml:lang="en-US">Second Year Earnout [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_BridgeBankMember" xlink:to="STRM_BridgeBankMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_BridgeBankMember_doc" xml:lang="en-US">Bridge Bank [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_LoanAndSecurityAgreementMember" xlink:label="STRM_LoanAndSecurityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_LoanAndSecurityAgreementMember" xlink:to="STRM_LoanAndSecurityAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_LoanAndSecurityAgreementMember_doc" xml:lang="en-US">Loan and Security Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SecondModificationAgreementMember" xlink:to="STRM_SecondModificationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_SecondModificationAgreementMember_doc" xml:lang="en-US">Second Modification Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ScheduleOfMaximumDebtToARRRatioTableTextBlock" xlink:to="STRM_ScheduleOfMaximumDebtToARRRatioTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ScheduleOfMaximumDebtToARRRatioTableTextBlock_doc" xml:lang="en-US">Schedule Of Maximum Debt To ARR Ratio [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_MaximumDebtToArrRatio" xlink:to="STRM_MaximumDebtToArrRatio_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_MaximumDebtToArrRatio_doc" xml:lang="en-US">Maximum Debt to ARR Ratio.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_OctoberThirtyOneTwoThousandAndTwentyTwoMember" xlink:to="STRM_OctoberThirtyOneTwoThousandAndTwentyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_OctoberThirtyOneTwoThousandAndTwentyTwoMember_doc" xml:lang="en-US">October 31, 2022 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JanuaryThirtyOneTwoThousandTwentyThreeMember" xlink:to="STRM_JanuaryThirtyOneTwoThousandTwentyThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_JanuaryThirtyOneTwoThousandTwentyThreeMember_doc" xml:lang="en-US">January 31, 2023 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AprilThirtyTwoThousandTwentyThreeMember" xlink:to="STRM_AprilThirtyTwoThousandTwentyThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AprilThirtyTwoThousandTwentyThreeMember_doc" xml:lang="en-US">April 30, 2023 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JulyThirtyOneTwoThousandTwentyThreeMember" xlink:to="STRM_JulyThirtyOneTwoThousandTwentyThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_JulyThirtyOneTwoThousandTwentyThreeMember_doc" xml:lang="en-US">July 31, 2023 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_OctoberThirtyOneTwoThousandTwentyThreeMember" xlink:to="STRM_OctoberThirtyOneTwoThousandTwentyThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_OctoberThirtyOneTwoThousandTwentyThreeMember_doc" xml:lang="en-US">October 31, 2023 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JanuaryThirtyOneTwoThousandTwentyFourMember" xlink:to="STRM_JanuaryThirtyOneTwoThousandTwentyFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_JanuaryThirtyOneTwoThousandTwentyFourMember_doc" xml:lang="en-US">January 31, 2024 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock" xlink:to="STRM_ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock_doc" xml:lang="en-US">Schedule Of Maximum Debt To Adjusted EBITDA Ratio [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_MaximumDebtToAdjustedEbitdaRatio" xlink:to="STRM_MaximumDebtToAdjustedEbitdaRatio_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_MaximumDebtToAdjustedEbitdaRatio_doc" xml:lang="en-US">Maximum Debt to Adjusted EBITDA Ratio.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AprilThirtyTwoThousandTwentyFourMember" xlink:to="STRM_AprilThirtyTwoThousandTwentyFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AprilThirtyTwoThousandTwentyFourMember_doc" xml:lang="en-US">April 30, 2024 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember" xlink:to="STRM_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember_doc" xml:lang="en-US">July 31, 2024 and Thereafter [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_FixedChargeCoverageRatio" xlink:to="STRM_FixedChargeCoverageRatio_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_FixedChargeCoverageRatio_doc" xml:lang="en-US">Fixed charge coverage ratio.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SecondAmendedAndRestatedLoanAgreementMember" xlink:to="STRM_SecondAmendedAndRestatedLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_SecondAmendedAndRestatedLoanAgreementMember_doc" xml:lang="en-US">Second Amended And Restated Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_LoanAgreementMember" xlink:to="STRM_LoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_LoanAgreementMember_doc" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_WesternAllianceBankMember" xlink:to="STRM_WesternAllianceBankMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_WesternAllianceBankMember_doc" xml:lang="en-US">Western Alliance Bank [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ClientRelationshipsMember" xlink:to="STRM_ClientRelationshipsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ClientRelationshipsMember_doc" xml:lang="en-US">Client Relationships [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_InternallyDevelopedSoftwareMember" xlink:to="STRM_InternallyDevelopedSoftwareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_InternallyDevelopedSoftwareMember_doc" xml:lang="en-US">Internally Developed Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FiniteLivedIntangibleAssetsAmortizationExpenseCurrentYear" xlink:label="STRM_FiniteLivedIntangibleAssetsAmortizationExpenseCurrentYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_FiniteLivedIntangibleAssetsAmortizationExpenseCurrentYear" xlink:to="STRM_FiniteLivedIntangibleAssetsAmortizationExpenseCurrentYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_FiniteLivedIntangibleAssetsAmortizationExpenseCurrentYear_doc" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Current Year.</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AmortizationOfIntangibleAssetsWroteOffFully" xlink:label="STRM_AmortizationOfIntangibleAssetsWroteOffFully" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AmortizationOfIntangibleAssetsWroteOffFully" xlink:to="STRM_AmortizationOfIntangibleAssetsWroteOffFully_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AmortizationOfIntangibleAssetsWroteOffFully_doc" xml:lang="en-US">Amortization of intangible assets wrote off fully.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_IncreaseInValuationAllowance" xlink:to="STRM_IncreaseInValuationAllowance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_IncreaseInValuationAllowance_doc" xml:lang="en-US">Increase in valuation allowance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent" xlink:to="STRM_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent_doc" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities, Current.</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ThroughFiscal2038Member" xlink:label="STRM_ThroughFiscal2038Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ThroughFiscal2038Member" xlink:to="STRM_ThroughFiscal2038Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ThroughFiscal2038Member_doc" xml:lang="en-US">Through Fiscal 2038 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_TaxCutsAndJobsActMember" xlink:to="STRM_TaxCutsAndJobsActMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_TaxCutsAndJobsActMember_doc" xml:lang="en-US">Tax Cuts and Jobs Act [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ThroughFiscalTwoThousandThirtyEightMember" xlink:to="STRM_ThroughFiscalTwoThousandThirtyEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ThroughFiscalTwoThousandThirtyEightMember_doc" xml:lang="en-US">Through Fiscal Two Thousand Thirty Eight [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_StateMember" xlink:to="STRM_StateMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_StateMember_doc" xml:lang="en-US">State [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_FederalRDMember" xlink:to="STRM_FederalRDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_FederalRDMember_doc" xml:lang="en-US">Federal RD [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_GeorgiaRDMember" xlink:to="STRM_GeorgiaRDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_GeorgiaRDMember_doc" xml:lang="en-US">Georgia RD [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PurchaseAgreementMember" xlink:to="STRM_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_TwoThousandTwentyTwoOfferingMember" xlink:to="STRM_TwoThousandTwentyTwoOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_TwoThousandTwentyTwoOfferingMember_doc" xml:lang="en-US">2022 Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_OneHundredEightyConsultingLLCMember" xlink:to="STRM_OneHundredEightyConsultingLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_OneHundredEightyConsultingLLCMember_doc" xml:lang="en-US">180 Consulting LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" xlink:to="STRM_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_doc" xml:lang="en-US">Third Amended And Restated 2013 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_TwoCustomerMember" xlink:to="STRM_TwoCustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_TwoCustomerMember_doc" xml:lang="en-US">Two Customer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_OneCustomerMember" xlink:to="STRM_OneCustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_OneCustomerMember_doc" xml:lang="en-US">One Customer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CustomerOneMember" xlink:to="STRM_CustomerOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_CustomerOneMember_doc" xml:lang="en-US">Customer One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CustomerTwoMember" xlink:to="STRM_CustomerTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_CustomerTwoMember_doc" xml:lang="en-US">Customer Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CustomerThreeMember" xlink:to="STRM_CustomerThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_CustomerThreeMember_doc" xml:lang="en-US">Customer Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_CustomerFourMember" xlink:to="STRM_CustomerFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_CustomerFourMember_doc" xml:lang="en-US">Customer Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_StockOptionsPlanDescription" xlink:label="STRM_StockOptionsPlanDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_StockOptionsPlanDescription" xlink:to="STRM_StockOptionsPlanDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_StockOptionsPlanDescription_doc" xml:lang="en-US">Stock options plan, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_TwoThousandThirteenIncentiveCompensationPlanMember" xlink:to="STRM_TwoThousandThirteenIncentiveCompensationPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_TwoThousandThirteenIncentiveCompensationPlanMember_doc" xml:lang="en-US">2013 Incentive Compensation Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_StockOptionsMember" xlink:to="STRM_StockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_StockOptionsMember_doc" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_NumberOfOptionsToPurchaseCommonStock" xlink:to="STRM_NumberOfOptionsToPurchaseCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_NumberOfOptionsToPurchaseCommonStock_doc" xml:lang="en-US">Number of options to purchase common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_InvestmentOwnershipPercentage" xlink:to="STRM_InvestmentOwnershipPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_InvestmentOwnershipPercentage_doc" xml:lang="en-US">Investment ownership percentage.</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_VestInFourQuarterlyInstallmentsMember" xlink:label="STRM_VestInFourQuarterlyInstallmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_VestInFourQuarterlyInstallmentsMember" xlink:to="STRM_VestInFourQuarterlyInstallmentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_VestInFourQuarterlyInstallmentsMember_doc" xml:lang="en-US">Vest in Four Equal Quarterly Installments [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_MrGreenMember" xlink:to="STRM_MrGreenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_MrGreenMember_doc" xml:lang="en-US">Mr Green [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_MrStilwillMember" xlink:to="STRM_MrStilwillMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_MrStilwillMember_doc" xml:lang="en-US">Mr Stil will [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_MasterServicesAgreementMember" xlink:to="STRM_MasterServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_MasterServicesAgreementMember_doc" xml:lang="en-US">Master services agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SOWMember" xlink:to="STRM_SOWMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_SOWMember_doc" xml:lang="en-US">SOW [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AprilThirtyTwoThousandAndTwentyFourMember" xlink:to="STRM_AprilThirtyTwoThousandAndTwentyFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AprilThirtyTwoThousandAndTwentyFourMember_doc" xml:lang="en-US">April Thirty Two Thousand And Twenty Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JulyThirtyOneTwoThousandAndTwentyFourMember" xlink:to="STRM_JulyThirtyOneTwoThousandAndTwentyFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_JulyThirtyOneTwoThousandAndTwentyFourMember_doc" xml:lang="en-US">July Thirty One Two Thousand And Twenty Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember" xlink:to="STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember_doc" xml:lang="en-US">October Thirty One Two Thousand And Twenty Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember" xlink:to="STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember_doc" xml:lang="en-US">January 31, 2024 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember" xlink:to="STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember_doc" xml:lang="en-US">January Thirty One Two Thousand And Twenty Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AprilThirtyTwoThousandTwentyFiveMember" xlink:to="STRM_AprilThirtyTwoThousandTwentyFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AprilThirtyTwoThousandTwentyFiveMember_doc" xml:lang="en-US">April 30, 2025 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JulyThirtyOneTwoThousandTwentyFiveMember" xlink:to="STRM_JulyThirtyOneTwoThousandTwentyFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_JulyThirtyOneTwoThousandTwentyFiveMember_doc" xml:lang="en-US">July 31, 2025 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_OctoberThirtyOneTwoThousandTwentyFiveMember" xlink:to="STRM_OctoberThirtyOneTwoThousandTwentyFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_OctoberThirtyOneTwoThousandTwentyFiveMember_doc" xml:lang="en-US">October 31, 2025 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember" xlink:to="STRM_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember_doc" xml:lang="en-US">January 31, 2026  And Thereafter [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecondModificationDebtAgreementMember" xlink:label="STRM_SecondModificationDebtAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SecondModificationDebtAgreementMember" xlink:to="STRM_SecondModificationDebtAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_SecondModificationDebtAgreementMember_doc" xml:lang="en-US">Second Modification Debt Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ThirdModificationDebtAgreementMember" xlink:label="STRM_ThirdModificationDebtAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ThirdModificationDebtAgreementMember" xlink:to="STRM_ThirdModificationDebtAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ThirdModificationDebtAgreementMember_doc" xml:lang="en-US">Third Modification Debt Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ThirdModificationLoanAgreementMember" xlink:to="STRM_ThirdModificationLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ThirdModificationLoanAgreementMember_doc" xml:lang="en-US">Third Modification Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_MaximumArrNetLeverageRatio" xlink:to="STRM_MaximumArrNetLeverageRatio_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_MaximumArrNetLeverageRatio_doc" xml:lang="en-US">Maximum arr net leverage ratio.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ScheduleOfMaximumARRNetLeverageTableTextBlock" xlink:to="STRM_ScheduleOfMaximumARRNetLeverageTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ScheduleOfMaximumARRNetLeverageTableTextBlock_doc" xml:lang="en-US">Schedule Of Maximum ARR Net Leverage Table [TextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock" xlink:to="STRM_ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock_doc" xml:lang="en-US">Schedule Of Maximum Debt To Adjustments EBITDA RatioTable [TextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ScheduleOfMinimumAdjustedEBITDATableTextBlock" xlink:to="STRM_ScheduleOfMinimumAdjustedEBITDATableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ScheduleOfMinimumAdjustedEBITDATableTextBlock_doc" xml:lang="en-US">Schedule Of Minimum Adjusted EBITDA Table [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_MinimumAdjustedEbitda" xlink:to="STRM_MinimumAdjustedEbitda_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_MinimumAdjustedEbitda_doc" xml:lang="en-US">Minimum Adjusted Ebitda.</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ImpairmentOfFinitelivedAssets" xlink:label="STRM_ImpairmentOfFinitelivedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ImpairmentOfFinitelivedAssets" xlink:to="STRM_ImpairmentOfFinitelivedAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ImpairmentOfFinitelivedAssets_doc" xml:lang="en-US">Impairment of finite lived assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_SecuritiesPurchaseAgreementMember" xlink:to="STRM_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_ExceptDirectorsAndOfficersMember" xlink:to="STRM_ExceptDirectorsAndOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_ExceptDirectorsAndOfficersMember_doc" xml:lang="en-US">Except Directors And Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AffiliatesEffectivePercentage" xlink:to="STRM_AffiliatesEffectivePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AffiliatesEffectivePercentage_doc" xml:lang="en-US">Affiliates effective percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_NotesMember" xlink:to="STRM_NotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_NotesMember_doc" xml:lang="en-US">Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_StockIssuedDuringPeriodValueSurrenderOfShares" xlink:to="STRM_StockIssuedDuringPeriodValueSurrenderOfShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_StockIssuedDuringPeriodValueSurrenderOfShares_doc" xml:lang="en-US">Surrender of stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_StockIssuedDuringPeriodSharesSurrenderOfShares" xlink:to="STRM_StockIssuedDuringPeriodSharesSurrenderOfShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_StockIssuedDuringPeriodSharesSurrenderOfShares_doc" xml:lang="en-US">Surrender of stock, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_UnvestedRestrictedStockMember" xlink:to="STRM_UnvestedRestrictedStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_UnvestedRestrictedStockMember_doc" xml:lang="en-US">Unvested Restricted Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_UnvestedRestrictedSharesMember" xlink:to="STRM_UnvestedRestrictedSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_UnvestedRestrictedSharesMember_doc" xml:lang="en-US">Unvested Restricted Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:label="STRM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:to="STRM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_doc" xml:lang="en-US">Finite-lived intangible assets amortization expense after year four.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AbandonedAssetWroteOff" xlink:to="STRM_AbandonedAssetWroteOff_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="STRM_AbandonedAssetWroteOff_doc" xml:lang="en-US">Abandoned asset wrote off.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_AprilThirtyTwoThousandAndTwentyFourMember" xlink:to="STRM_AprilThirtyTwoThousandAndTwentyFourMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_AprilThirtyTwoThousandAndTwentyFourMember_3_lbl" xml:lang="en-US">April 30, 2024 [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember" xlink:to="STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember_3_lbl" xml:lang="en-US">January 31, 2024 [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_2_lbl" xml:lang="en-US">Costs and Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_StockIssuedDuringPeriodSharesSurrenderOfShares" xlink:to="STRM_StockIssuedDuringPeriodSharesSurrenderOfShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_StockIssuedDuringPeriodSharesSurrenderOfShares_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodSharesSurrenderOfShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToDevelopSoftware" xlink:to="us-gaap_PaymentsToDevelopSoftware_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToDevelopSoftware_2_lbl" xml:lang="en-US">Payments to Develop Software</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_2_lbl" xml:lang="en-US">Payments of Merger Related Costs, Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_2_lbl" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2_lbl" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2_lbl" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_PaymentOfSaasContingentConsiderationInSharesPercentage" xlink:to="STRM_PaymentOfSaasContingentConsiderationInSharesPercentage_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_PaymentOfSaasContingentConsiderationInSharesPercentage_3_lbl" xml:lang="en-US">PaymentOfSaasContingentConsiderationInSharesPercentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="STRM_DeferredFinancingCost" xlink:to="STRM_DeferredFinancingCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="STRM_DeferredFinancingCost_2_lbl" xml:lang="en-US">DeferredFinancingCost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_2_lbl" xml:lang="en-US">Long-Term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_2_lbl" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_2_lbl" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_2_lbl" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Goodwill and Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_2_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>strm-20240131_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://streamlinehealth.net/role/Cover" xlink:href="strm-20240131.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/BalanceSheets" xlink:href="strm-20240131.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/BalanceSheetsParenthetical" xlink:href="strm-20240131.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/StatementsOfOperations" xlink:href="strm-20240131.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity" xlink:href="strm-20240131.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/StatementsOfCashFlows" xlink:href="strm-20240131.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/OrganizationAndDescriptionOfBusiness" xlink:href="strm-20240131.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SignificantAccountingPolicies" xlink:href="strm-20240131.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/BusinessCombination" xlink:href="strm-20240131.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/OperatingLeases" xlink:href="strm-20240131.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/Debt" xlink:href="strm-20240131.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/GoodwillAndIntangibleAssets" xlink:href="strm-20240131.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/IncomeTaxes" xlink:href="strm-20240131.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/Equity" xlink:href="strm-20240131.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/MajorClients" xlink:href="strm-20240131.xsd#MajorClients" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/EmployeeRetirementPlan" xlink:href="strm-20240131.xsd#EmployeeRetirementPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/Stock-basedCompensation" xlink:href="strm-20240131.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/CommitmentsAndContingencies" xlink:href="strm-20240131.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/RelatedPartyTransactions" xlink:href="strm-20240131.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SubsequentEvents" xlink:href="strm-20240131.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReserves" xlink:href="strm-20240131.xsd#ValuationAndQualifyingAccountsAndReserves" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies" xlink:href="strm-20240131.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SignificantAccountingPoliciesTables" xlink:href="strm-20240131.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/DebtTables" xlink:href="strm-20240131.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsTables" xlink:href="strm-20240131.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/IncomeTaxesTables" xlink:href="strm-20240131.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/Stock-basedCompensationTables" xlink:href="strm-20240131.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SubsequentEventsTables" xlink:href="strm-20240131.xsd#SubsequentEventsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfNon-cashItemsRelatedToCondensedConsolidatedStatementsOfCashFlowsDetails" xlink:href="strm-20240131.xsd#ScheduleOfNon-cashItemsRelatedToCondensedConsolidatedStatementsOfCashFlowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfReserveResultsInFuturePeriodsDetails" xlink:href="strm-20240131.xsd#ScheduleOfReserveResultsInFuturePeriodsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfAccruedExpensesDetails" xlink:href="strm-20240131.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails" xlink:href="strm-20240131.xsd#ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails" xlink:href="strm-20240131.xsd#ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="strm-20240131.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical" xlink:href="strm-20240131.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfDisaggregatonOfRevenueDetails" xlink:href="strm-20240131.xsd#ScheduleOfDisaggregatonOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:href="strm-20240131.xsd#ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical" xlink:href="strm-20240131.xsd#ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails" xlink:href="strm-20240131.xsd#ScheduleOfReconciliationOfRestructuringLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="strm-20240131.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative" xlink:href="strm-20240131.xsd#BusinessCombinationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative" xlink:href="strm-20240131.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails" xlink:href="strm-20240131.xsd#ScheduleOfOutstandingPrincipalBalancesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails" xlink:href="strm-20240131.xsd#ScheduleOfMaximumDebtToArrRatioDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails" xlink:href="strm-20240131.xsd#ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/DebtDetailsNarrative" xlink:href="strm-20240131.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfCarryingAmountOfGoodwillDetails" xlink:href="strm-20240131.xsd#ScheduleOfCarryingAmountOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails" xlink:href="strm-20240131.xsd#ScheduleOfFinite-livedIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:href="strm-20240131.xsd#ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative" xlink:href="strm-20240131.xsd#GoodwillAndIntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails" xlink:href="strm-20240131.xsd#ScheduleOfIncomeTaxesForContinuingOperationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="strm-20240131.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="strm-20240131.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfGrossUnrecognizedTaxBenefitsDetails" xlink:href="strm-20240131.xsd#ScheduleOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative" xlink:href="strm-20240131.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/EquityDetailsNarrative" xlink:href="strm-20240131.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/MajorClientsDetailsNarrative" xlink:href="strm-20240131.xsd#MajorClientsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/EmployeeRetirementPlanDetailsNarrative" xlink:href="strm-20240131.xsd#EmployeeRetirementPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails" xlink:href="strm-20240131.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails" xlink:href="strm-20240131.xsd#ScheduleOfRestrictedStockAwardActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative" xlink:href="strm-20240131.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="strm-20240131.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="strm-20240131.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails" xlink:href="strm-20240131.xsd#ScheduleOfMaximumArrNetLeverageRatioDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails" xlink:href="strm-20240131.xsd#ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails" xlink:href="strm-20240131.xsd#ScheduleOfMinimumAdjustedEbitdaDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative" xlink:href="strm-20240131.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReservesDetails" xlink:href="strm-20240131.xsd#ValuationAndQualifyingAccountsAndReservesDetails" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaapContractWithCustomerAssetNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaapCapitalizedComputerSoftwareNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapCapitalizedComputerSoftwareNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaapAssetAcquisitionContingentConsiderationLiabilityCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLineOfCredit" xlink:label="loc_us-gaapLongTermLineOfCredit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLongTermLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:label="loc_us-gaapCapitalizedComputerSoftwareAccumulatedAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCapitalizedComputerSoftwareAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SoftwareasAsAServiceMember" xlink:label="loc_STRMSoftwareasAsAServiceMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_STRMSoftwareasAsAServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MaintenanceAndSupportMember" xlink:label="loc_STRMMaintenanceAndSupportMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_STRMMaintenanceAndSupportMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ProfessionalFeesAndLicensesMember" xlink:label="loc_STRMProfessionalFeesAndLicensesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_STRMProfessionalFeesAndLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfSoftwareAsService" xlink:label="loc_STRMCostOfSoftwareAsService" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_STRMCostOfSoftwareAsService" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfMaintenanceAndSupport" xlink:label="loc_STRMCostOfMaintenanceAndSupport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_STRMCostOfMaintenanceAndSupport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfProfessionalFeesAndLicenses" xlink:label="loc_STRMCostOfProfessionalFeesAndLicenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_STRMCostOfProfessionalFeesAndLicenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AcquisitionEarnoutValuationAdjustments" xlink:label="loc_STRMAcquisitionEarnoutValuationAdjustments" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_STRMAcquisitionEarnoutValuationAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_StockIssuedDuringPeriodValueSurrenderOfShares" xlink:label="loc_STRMStockIssuedDuringPeriodValueSurrenderOfShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMStockIssuedDuringPeriodValueSurrenderOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_StockIssuedDuringPeriodSharesSurrenderOfShares" xlink:label="loc_STRMStockIssuedDuringPeriodSharesSurrenderOfShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMStockIssuedDuringPeriodSharesSurrenderOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaapStockholdersEquityOther" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AcquisitionEarnoutValuationAdjustments" xlink:label="loc_STRMAcquisitionEarnoutValuationAdjustments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_STRMAcquisitionEarnoutValuationAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ProvisionForDeferredIncomeTaxes" xlink:label="loc_STRMProvisionForDeferredIncomeTaxes" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_STRMProvisionForDeferredIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToDevelopSoftware" xlink:label="loc_us-gaapPaymentsToDevelopSoftware" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToDevelopSoftware" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="loc_us-gaapPaymentsOfMergerRelatedCostsFinancingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfMergerRelatedCostsFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfLongTermDebt" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaapProceedsFromPaymentsForOtherFinancingActivities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/OrganizationAndDescriptionOfBusiness" xlink:title="00000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/BusinessCombination" xlink:title="00000009 - Disclosure - BUSINESS COMBINATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/OperatingLeases" xlink:title="00000010 - Disclosure - OPERATING LEASES">
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DisclosureOperatingLeasesAbstract" xlink:label="loc_STRMDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_STRMDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Debt" xlink:title="00000011 - Disclosure - DEBT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/GoodwillAndIntangibleAssets" xlink:title="00000012 - Disclosure - GOODWILL AND INTANGIBLE ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/IncomeTaxes" xlink:title="00000013 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Equity" xlink:title="00000014 - Disclosure - EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/MajorClients" xlink:title="00000015 - Disclosure - MAJOR CLIENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/EmployeeRetirementPlan" xlink:title="00000016 - Disclosure - EMPLOYEE RETIREMENT PLAN">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Stock-basedCompensation" xlink:title="00000017 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/RelatedPartyTransactions" xlink:title="00000019 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SubsequentEvents" xlink:title="00000020 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DisclosureSubsequentEventsAbstract" xlink:label="loc_STRMDisclosureSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_STRMDisclosureSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReserves" xlink:title="00000021 - Disclosure - Valuation and Qualifying Accounts and Reserves">
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DisclosureValuationAndQualifyingAccountsAndReservesAbstract" xlink:label="loc_STRMDisclosureValuationAndQualifyingAccountsAndReservesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_srtScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_STRMDisclosureValuationAndQualifyingAccountsAndReservesAbstract" xlink:to="loc_srtScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_GoingConcernPolicyTextBlock" xlink:label="loc_STRMGoingConcernPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_STRMGoingConcernPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AllowanceForCreditLossesPolicyTextBlock" xlink:label="loc_STRMAllowanceForCreditLossesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_STRMAllowanceForCreditLossesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AccruedExpensesPolicyTextBlock" xlink:label="loc_STRMAccruedExpensesPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_STRMAccruedExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ConcessionsAccrualPolicyTextBlock" xlink:label="loc_STRMConcessionsAccrualPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_STRMConcessionsAccrualPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsIncurredPolicy" xlink:label="loc_us-gaapCostsIncurredPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCostsIncurredPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwarePolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_EquityAwardPolicyTextBlock" xlink:label="loc_STRMEquityAwardPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_STRMEquityAwardPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:label="loc_us-gaapCostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_STRMRecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_STRMRecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SignificantAccountingPoliciesTables" xlink:title="00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock" xlink:label="loc_STRMScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_STRMScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaapScheduleOfRestructuringReserveByTypeOfCostTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_STRMPropertyPlantAndEquipmentTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_STRMPropertyPlantAndEquipmentTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock" xlink:label="loc_STRMScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_STRMScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/DebtTables" xlink:title="00000024 - Disclosure - DEBT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ScheduleOfMaximumDebtToARRRatioTableTextBlock" xlink:label="loc_STRMScheduleOfMaximumDebtToARRRatioTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_STRMScheduleOfMaximumDebtToARRRatioTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock" xlink:label="loc_STRMScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_STRMScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsTables" xlink:title="00000025 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaapScheduleOfGoodwillTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfGoodwillTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/IncomeTaxesTables" xlink:title="00000026 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Stock-basedCompensationTables" xlink:title="00000027 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SubsequentEventsTables" xlink:title="00000028 - Disclosure - SUBSEQUENT EVENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DisclosureSubsequentEventsAbstract" xlink:label="loc_STRMDisclosureSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ScheduleOfMaximumARRNetLeverageTableTextBlock" xlink:label="loc_STRMScheduleOfMaximumARRNetLeverageTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_STRMDisclosureSubsequentEventsAbstract" xlink:to="loc_STRMScheduleOfMaximumARRNetLeverageTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock" xlink:label="loc_STRMScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_STRMDisclosureSubsequentEventsAbstract" xlink:to="loc_STRMScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ScheduleOfMinimumAdjustedEBITDATableTextBlock" xlink:label="loc_STRMScheduleOfMinimumAdjustedEBITDATableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_STRMDisclosureSubsequentEventsAbstract" xlink:to="loc_STRMScheduleOfMinimumAdjustedEBITDATableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfNon-cashItemsRelatedToCondensedConsolidatedStatementsOfCashFlowsDetails" xlink:title="00000029 - Disclosure - SCHEDULE OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CapitalizedSoftwarePurchasedWithStock" xlink:label="loc_STRMCapitalizedSoftwarePurchasedWithStock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_STRMCapitalizedSoftwarePurchasedWithStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DeferredFinancingCosts" xlink:label="loc_STRMDeferredFinancingCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_STRMDeferredFinancingCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfReserveResultsInFuturePeriodsDetails" xlink:title="00000030 - Disclosure - SCHEDULE OF RESERVE RESULTS IN FUTURE PERIODS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AllowanceForDoubtfulAccountsReceivableCECLAdoption" xlink:label="loc_STRMAllowanceForDoubtfulAccountsReceivableCECLAdoption" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_STRMAllowanceForDoubtfulAccountsReceivableCECLAdoption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedExchangeFeeRebateCurrentAndNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAccruedExchangeFeeRebateCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ThirdPartylicense" xlink:label="loc_STRMThirdPartylicense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_STRMThirdPartylicense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ConcessionAccrualAmount" xlink:label="loc_STRMConcessionAccrualAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_STRMConcessionAccrualAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaapSalesAndExciseTaxPayableCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSalesAndExciseTaxPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ComputerEquipmentAndSoftwareMember" xlink:label="loc_STRMComputerEquipmentAndSoftwareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_STRMComputerEquipmentAndSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OfficeFurnitureAndFixturesMember" xlink:label="loc_STRMOfficeFurnitureAndFixturesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_STRMOfficeFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfSoftwareAsASeviceMember" xlink:label="loc_STRMCostOfSoftwareAsASeviceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_STRMCostOfSoftwareAsASeviceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CostOfProfessionalFeesAndLicensesMember" xlink:label="loc_STRMCostOfProfessionalFeesAndLicensesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_STRMCostOfProfessionalFeesAndLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="loc_us-gaapCapitalizedComputerSoftwareAmortization1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCapitalizedComputerSoftwareAmortization1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AcquisitionEarnoutLiabilityFairValue" xlink:label="loc_STRMAcquisitionEarnoutLiabilityFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_STRMAcquisitionEarnoutLiabilityFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical" xlink:title="00000035 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AcquisitionEarnoutLiabilityChangeInValuation" xlink:label="loc_STRMAcquisitionEarnoutLiabilityChangeInValuation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_STRMAcquisitionEarnoutLiabilityChangeInValuation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfDisaggregatonOfRevenueDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF DISAGGREGATON OF REVENUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaapTimingOfTransferOfGoodOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTimingOfTransferOfGoodOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaapTimingOfTransferOfGoodOrServiceDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTimingOfTransferOfGoodOrServiceAxis" xlink:to="loc_us-gaapTimingOfTransferOfGoodOrServiceDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaapTransferredOverTimeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTimingOfTransferOfGoodOrServiceDomain" xlink:to="loc_us-gaapTransferredOverTimeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredAtPointInTimeMember" xlink:label="loc_us-gaapTransferredAtPointInTimeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTimingOfTransferOfGoodOrServiceDomain" xlink:to="loc_us-gaapTransferredAtPointInTimeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaapIncomeLossFromContinuingOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerDilutedShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks" xlink:label="loc_STRMEffectOfDilutiveSecuritiesStockOptionsRestrictedStocks" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_STRMEffectOfDilutiveSecuritiesStockOptionsRestrictedStocks" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical" xlink:title="00000038 - Disclosure - SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_UnvestedRestrictedStockMember" xlink:label="loc_STRMUnvestedRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_STRMUnvestedRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_UnvestedRestrictedSharesMember" xlink:label="loc_STRMUnvestedRestrictedSharesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_STRMUnvestedRestrictedSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF RECONCILIATION OF THE RESTRUCTURING LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SeveranceExpensesMember" xlink:label="loc_STRMSeveranceExpensesMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_STRMSeveranceExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ProfessionalFeesMember" xlink:label="loc_STRMProfessionalFeesMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_STRMProfessionalFeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AccruedExpensesMember" xlink:label="loc_STRMAccruedExpensesMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_STRMAccruedExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AccruedCashPayments" xlink:label="loc_STRMAccruedCashPayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMAccruedCashPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AccruedCostsIncurred" xlink:label="loc_STRMAccruedCostsIncurred" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMAccruedCostsIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AccruedExpectedCosts" xlink:label="loc_STRMAccruedExpectedCosts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMAccruedExpectedCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000040 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SoftwareMember" xlink:label="loc_STRMSoftwareMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_STRMSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_InternalUseSoftwareMember" xlink:label="loc_STRMInternalUseSoftwareMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_STRMInternalUseSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecurityAgreementMember" xlink:label="loc_STRMSecurityAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSecurityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecondAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="loc_STRMSecondAmendedAndRestatedLoanAndSecurityAgreementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSecondAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DebtAgreementMember" xlink:label="loc_STRMDebtAgreementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMDebtAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaapOtherNoncurrentAssetsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_us-gaapOtherNoncurrentAssetsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_EquityAwardMember" xlink:label="loc_STRMEquityAwardMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_STRMEquityAwardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapGranteeStatusAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtTitleOfIndividualAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OfficersAndDirectorsMember" xlink:label="loc_STRMOfficersAndDirectorsMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_STRMOfficersAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ConcessionAccrualAmount" xlink:label="loc_STRMConcessionAccrualAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_STRMConcessionAccrualAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:label="loc_us-gaapCapitalizedComputerSoftwareAccumulatedAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCapitalizedComputerSoftwareAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="loc_us-gaapCapitalizedComputerSoftwareAmortization1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCapitalizedComputerSoftwareAmortization1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AmortizedAndAbandonedAssets" xlink:label="loc_STRMAmortizedAndAbandonedAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_STRMAmortizedAndAbandonedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PrimeInterestRatePercentage" xlink:label="loc_STRMPrimeInterestRatePercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_STRMPrimeInterestRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaapRevenueRemainingPerformanceObligation" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRevenueRemainingPerformanceObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:label="loc_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="loc_us-gaapDeferredCostsCurrentAndNoncurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredCostsCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedAmortizationOfOtherDeferredCosts" xlink:label="loc_us-gaapAccumulatedAmortizationOfOtherDeferredCosts" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedAmortizationOfOtherDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DeferredCostsAmortizationExpenses" xlink:label="loc_STRMDeferredCostsAmortizationExpenses" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_STRMDeferredCostsAmortizationExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAmortizationOfDeferredCharges" xlink:label="loc_us-gaapOtherAmortizationOfDeferredCharges" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOtherAmortizationOfDeferredCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DeferredCommissionsCostsPaidAndPayable" xlink:label="loc_STRMDeferredCommissionsCostsPaidAndPayable" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_STRMDeferredCommissionsCostsPaidAndPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDeferredSalesCommissions" xlink:label="loc_us-gaapAmortizationOfDeferredSalesCommissions" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAmortizationOfDeferredSalesCommissions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostImpairmentLoss" xlink:label="loc_us-gaapCapitalizedContractCostImpairmentLoss" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCapitalizedContractCostImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SurrenderOfStockSharesDuringPeriod" xlink:label="loc_STRMSurrenderOfStockSharesDuringPeriod" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_STRMSurrenderOfStockSharesDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_NumberOfEmployeesTerminated" xlink:label="loc_STRMNumberOfEmployeesTerminated" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_STRMNumberOfEmployeesTerminated" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PercentageOfWorkforceTerminated" xlink:label="loc_STRMPercentageOfWorkforceTerminated" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_STRMPercentageOfWorkforceTerminated" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaapRestructuringCosts" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRestructuringCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative" xlink:title="00000041 - Disclosure - BUSINESS COMBINATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AveleadConsultingLLCMember" xlink:label="loc_STRMAveleadConsultingLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_STRMAveleadConsultingLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AcquisitionRestrictedCommonStockMember" xlink:label="loc_STRMAcquisitionRestrictedCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_STRMAcquisitionRestrictedCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_UnitPurchaseAgreementMember" xlink:label="loc_STRMUnitPurchaseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMUnitPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapAwardDateAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FirstYearEarnoutMember" xlink:label="loc_STRMFirstYearEarnoutMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_STRMFirstYearEarnoutMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecondYearEarnoutMember" xlink:label="loc_STRMSecondYearEarnoutMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_STRMSecondYearEarnoutMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_RenewalContingentConsiderationMember" xlink:label="loc_STRMRenewalContingentConsiderationMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_STRMRenewalContingentConsiderationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_BusinessAcquisitionEquityInterestIssuedFairValue" xlink:label="loc_STRMBusinessAcquisitionEquityInterestIssuedFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMBusinessAcquisitionEquityInterestIssuedFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsDescription" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PaymentsToAcquireBusinessesSellerExpenses" xlink:label="loc_STRMPaymentsToAcquireBusinessesSellerExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMPaymentsToAcquireBusinessesSellerExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment" xlink:label="loc_STRMPaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMPaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PaymentOfSaasContingentConsiderationInCashPercentage" xlink:label="loc_STRMPaymentOfSaasContingentConsiderationInCashPercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMPaymentOfSaasContingentConsiderationInCashPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PaymentOfSaasContingentConsiderationInSharesPercentage" xlink:label="loc_STRMPaymentOfSaasContingentConsiderationInSharesPercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMPaymentOfSaasContingentConsiderationInSharesPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FirstYearPaymentOfSaasContingentConsiderationDescription" xlink:label="loc_STRMFirstYearPaymentOfSaasContingentConsiderationDescription" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMFirstYearPaymentOfSaasContingentConsiderationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecondYearPaymentOfSaasContingentConsiderationDescription" xlink:label="loc_STRMSecondYearPaymentOfSaasContingentConsiderationDescription" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMSecondYearPaymentOfSaasContingentConsiderationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ForecastedRevenueDescription" xlink:label="loc_STRMForecastedRevenueDescription" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMForecastedRevenueDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_RenewalContingentConsiderationDescription" xlink:label="loc_STRMRenewalContingentConsiderationDescription" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_STRMRenewalContingentConsiderationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative" xlink:title="00000042 - Disclosure - OPERATING LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DisclosureOperatingLeasesAbstract" xlink:label="loc_STRMDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_STRMDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AlpharettaOfficeLeaseMember" xlink:label="loc_STRMAlpharettaOfficeLeaseMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMAlpharettaOfficeLeaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SubleaseAgreementMember" xlink:label="loc_STRMSubleaseAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSubleaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SuwaneeOfficeLeaseMember" xlink:label="loc_STRMSuwaneeOfficeLeaseMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSuwaneeOfficeLeaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RentalProperties" xlink:label="loc_us-gaapRentalProperties" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRentalProperties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SubleaseTerm" xlink:label="loc_STRMSubleaseTerm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_STRMSubleaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaapSubleaseIncome" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSubleaseIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FinancingCostPayable" xlink:label="loc_STRMFinancingCostPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_STRMFinancingCostPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DeferredFinancingCost" xlink:label="loc_STRMDeferredFinancingCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_STRMDeferredFinancingCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ARR RATIO (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OctoberThirtyOneTwoThousandAndTwentyTwoMember" xlink:label="loc_STRMOctoberThirtyOneTwoThousandAndTwentyTwoMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMOctoberThirtyOneTwoThousandAndTwentyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandTwentyThreeMember" xlink:label="loc_STRMJanuaryThirtyOneTwoThousandTwentyThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJanuaryThirtyOneTwoThousandTwentyThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AprilThirtyTwoThousandTwentyThreeMember" xlink:label="loc_STRMAprilThirtyTwoThousandTwentyThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMAprilThirtyTwoThousandTwentyThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JulyThirtyOneTwoThousandTwentyThreeMember" xlink:label="loc_STRMJulyThirtyOneTwoThousandTwentyThreeMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJulyThirtyOneTwoThousandTwentyThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OctoberThirtyOneTwoThousandTwentyThreeMember" xlink:label="loc_STRMOctoberThirtyOneTwoThousandTwentyThreeMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMOctoberThirtyOneTwoThousandTwentyThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandTwentyFourMember" xlink:label="loc_STRMJanuaryThirtyOneTwoThousandTwentyFourMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJanuaryThirtyOneTwoThousandTwentyFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MaximumDebtToArrRatio" xlink:label="loc_STRMMaximumDebtToArrRatio" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_STRMMaximumDebtToArrRatio" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AprilThirtyTwoThousandTwentyFourMember" xlink:label="loc_STRMAprilThirtyTwoThousandTwentyFourMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMAprilThirtyTwoThousandTwentyFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember" xlink:label="loc_STRMJulyThirtyOneTwoThousandTwentyFourAndThereafterMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJulyThirtyOneTwoThousandTwentyFourAndThereafterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MaximumDebtToAdjustedEbitdaRatio" xlink:label="loc_STRMMaximumDebtToAdjustedEbitdaRatio" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_STRMMaximumDebtToAdjustedEbitdaRatio" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/DebtDetailsNarrative" xlink:title="00000046 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_LoanAgreementMember" xlink:label="loc_STRMLoanAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecurityAgreementMember" xlink:label="loc_STRMSecurityAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSecurityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecondModificationAgreementMember" xlink:label="loc_STRMSecondModificationAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSecondModificationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecondAmendedAndRestatedLoanAgreementMember" xlink:label="loc_STRMSecondAmendedAndRestatedLoanAgreementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSecondAmendedAndRestatedLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_WesternAllianceBankMember" xlink:label="loc_STRMWesternAllianceBankMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_STRMWesternAllianceBankMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_BridgeBankMember" xlink:label="loc_STRMBridgeBankMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_STRMBridgeBankMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaapBaseRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapBaseRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaapAccretionExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAccretionExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLineOfCredit" xlink:label="loc_us-gaapLongTermLineOfCredit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="loc_us-gaapDebtInstrumentCovenantDescription" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCovenantDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FixedChargeCoverageRatio" xlink:label="loc_STRMFixedChargeCoverageRatio" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_STRMFixedChargeCoverageRatio" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfCarryingAmountOfGoodwillDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF CARRYING AMOUNT OF GOODWILL (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwill_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ClientRelationshipsMember" xlink:label="loc_STRMClientRelationshipsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_STRMClientRelationshipsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_InternallyDevelopedSoftwareMember" xlink:label="loc_STRMInternallyDevelopedSoftwareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_STRMInternallyDevelopedSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaapTrademarksAndTradeNamesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksAndTradeNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative" xlink:title="00000050 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AbandonedAssetWroteOff" xlink:label="loc_STRMAbandonedAssetWroteOff" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_STRMAbandonedAssetWroteOff" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_IncreaseInValuationAllowance" xlink:label="loc_STRMIncreaseInValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_STRMIncreaseInValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxContingencies" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000053 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaapDeferredTaxAssetsDeferredIncome" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsDeferredIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent" xlink:label="loc_STRMDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_STRMDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfGrossUnrecognizedTaxBenefitsDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative" xlink:title="00000055 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapAwardDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ThroughFiscalTwoThousandThirtyEightMember" xlink:label="loc_STRMThroughFiscalTwoThousandThirtyEightMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_STRMThroughFiscalTwoThousandThirtyEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_TaxCutsAndJobsActMember" xlink:label="loc_STRMTaxCutsAndJobsActMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_STRMTaxCutsAndJobsActMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_StateMember" xlink:label="loc_STRMStateMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_STRMStateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FederalRDMember" xlink:label="loc_STRMFederalRDMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_STRMFederalRDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_GeorgiaRDMember" xlink:label="loc_STRMGeorgiaRDMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_STRMGeorgiaRDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_IncreaseInValuationAllowance" xlink:label="loc_STRMIncreaseInValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_STRMIncreaseInValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/EquityDetailsNarrative" xlink:title="00000056 - Disclosure - EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_PurchaseAgreementMember" xlink:label="loc_STRMPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_TwoThousandTwentyTwoOfferingMember" xlink:label="loc_STRMTwoThousandTwentyTwoOfferingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_STRMTwoThousandTwentyTwoOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" xlink:label="loc_STRMThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_STRMThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OneHundredEightyConsultingLLCMember" xlink:label="loc_STRMOneHundredEightyConsultingLLCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_STRMOneHundredEightyConsultingLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/MajorClientsDetailsNarrative" xlink:title="00000057 - Disclosure - MAJOR CLIENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OneCustomerMember" xlink:label="loc_STRMOneCustomerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_STRMOneCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_TwoCustomerMember" xlink:label="loc_STRMTwoCustomerMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_STRMTwoCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CustomerOneMember" xlink:label="loc_STRMCustomerOneMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_STRMCustomerOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CustomerTwoMember" xlink:label="loc_STRMCustomerTwoMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_STRMCustomerTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CustomerThreeMember" xlink:label="loc_STRMCustomerThreeMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_STRMCustomerThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_CustomerFourMember" xlink:label="loc_STRMCustomerFourMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_STRMCustomerFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCustomer" xlink:label="loc_us-gaapConcentrationRiskCustomer" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskCustomer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/EmployeeRetirementPlanDetailsNarrative" xlink:title="00000058 - Disclosure - EMPLOYEE RETIREMENT PLAN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaapDefinedContributionPlanCostRecognized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanCostRecognized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000061 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_TwoThousandThirteenIncentiveCompensationPlanMember" xlink:label="loc_STRMTwoThousandThirteenIncentiveCompensationPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMTwoThousandThirteenIncentiveCompensationPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_StockOptionsMember" xlink:label="loc_STRMStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_STRMStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MrGreenMember" xlink:label="loc_STRMMrGreenMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_STRMMrGreenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MrStilwillMember" xlink:label="loc_STRMMrStilwillMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_STRMMrStilwillMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_NumberOfOptionsToPurchaseCommonStock" xlink:label="loc_STRMNumberOfOptionsToPurchaseCommonStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_STRMNumberOfOptionsToPurchaseCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_InvestmentOwnershipPercentage" xlink:label="loc_STRMInvestmentOwnershipPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_STRMInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MasterServicesAgreementMember" xlink:label="loc_STRMMasterServicesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMMasterServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SOWMember" xlink:label="loc_STRMSOWMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSOWMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OneHundredEightyConsultingLLCMember" xlink:label="loc_STRMOneHundredEightyConsultingLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_STRMOneHundredEightyConsultingLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_NonEmployeeStockCompensation" xlink:label="loc_STRMNonEmployeeStockCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_STRMNonEmployeeStockCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails" xlink:title="00000064 - Disclosure - SCHEDULE OF MAXIMUM ARR NET LEVERAGE RATIO (Details)">
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DisclosureSubsequentEventsAbstract" xlink:label="loc_STRMDisclosureSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_STRMDisclosureSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AprilThirtyTwoThousandAndTwentyFourMember" xlink:label="loc_STRMAprilThirtyTwoThousandAndTwentyFourMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMAprilThirtyTwoThousandAndTwentyFourMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JulyThirtyOneTwoThousandAndTwentyFourMember" xlink:label="loc_STRMJulyThirtyOneTwoThousandAndTwentyFourMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJulyThirtyOneTwoThousandAndTwentyFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember" xlink:label="loc_STRMOctoberThirtyOneTwoThousandAndTwentyFourMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMOctoberThirtyOneTwoThousandAndTwentyFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember" xlink:label="loc_STRMJanuaryThirtyOneTwoThousandAndTwentyFiveMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJanuaryThirtyOneTwoThousandAndTwentyFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MaximumArrNetLeverageRatio" xlink:label="loc_STRMMaximumArrNetLeverageRatio" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMMaximumArrNetLeverageRatio" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails" xlink:title="00000065 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO (Details)">
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DisclosureSubsequentEventsAbstract" xlink:label="loc_STRMDisclosureSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_STRMDisclosureSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AprilThirtyTwoThousandTwentyFiveMember" xlink:label="loc_STRMAprilThirtyTwoThousandTwentyFiveMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMAprilThirtyTwoThousandTwentyFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JulyThirtyOneTwoThousandTwentyFiveMember" xlink:label="loc_STRMJulyThirtyOneTwoThousandTwentyFiveMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJulyThirtyOneTwoThousandTwentyFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OctoberThirtyOneTwoThousandTwentyFiveMember" xlink:label="loc_STRMOctoberThirtyOneTwoThousandTwentyFiveMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMOctoberThirtyOneTwoThousandTwentyFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember" xlink:label="loc_STRMJanuaryThirtyOneTwoThousandTwentySixAndThereafterMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJanuaryThirtyOneTwoThousandTwentySixAndThereafterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MaximumDebtToAdjustedEbitdaRatio" xlink:label="loc_STRMMaximumDebtToAdjustedEbitdaRatio" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMMaximumDebtToAdjustedEbitdaRatio" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails" xlink:title="00000066 - Disclosure - SCHEDULE OF MINIMUM ADJUSTED EBITDA (Details)">
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DisclosureSubsequentEventsAbstract" xlink:label="loc_STRMDisclosureSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_STRMDisclosureSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember" xlink:label="loc_STRMJanuaryThirtyOneTwoThousandAndTwentyFourMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJanuaryThirtyOneTwoThousandAndTwentyFourMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AprilThirtyTwoThousandAndTwentyFourMember" xlink:label="loc_STRMAprilThirtyTwoThousandAndTwentyFourMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMAprilThirtyTwoThousandAndTwentyFourMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JulyThirtyOneTwoThousandAndTwentyFourMember" xlink:label="loc_STRMJulyThirtyOneTwoThousandAndTwentyFourMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJulyThirtyOneTwoThousandAndTwentyFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember" xlink:label="loc_STRMOctoberThirtyOneTwoThousandAndTwentyFourMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMOctoberThirtyOneTwoThousandAndTwentyFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember" xlink:label="loc_STRMJanuaryThirtyOneTwoThousandAndTwentyFiveMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_STRMJanuaryThirtyOneTwoThousandAndTwentyFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_MinimumAdjustedEbitda" xlink:label="loc_STRMMinimumAdjustedEbitda" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMMinimumAdjustedEbitda" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative" xlink:title="00000067 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DisclosureSubsequentEventsAbstract" xlink:label="loc_STRMDisclosureSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_STRMDisclosureSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_SecuritiesPurchaseAgreementMember" xlink:label="loc_STRMSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ThirdModificationLoanAgreementMember" xlink:label="loc_STRMThirdModificationLoanAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_STRMThirdModificationLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_NotesMember" xlink:label="loc_STRMNotesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_STRMNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_ExceptDirectorsAndOfficersMember" xlink:label="loc_STRMExceptDirectorsAndOfficersMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_STRMExceptDirectorsAndOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_AffiliatesEffectivePercentage" xlink:label="loc_STRMAffiliatesEffectivePercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMAffiliatesEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_FixedChargeCoverageRatio" xlink:label="loc_STRMFixedChargeCoverageRatio" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_STRMFixedChargeCoverageRatio" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReservesDetails" xlink:title="00000068 - Disclosure - Valuation and Qualifying Accounts and Reserves (Details)">
      <link:loc xlink:type="locator" xlink:href="strm-20240131.xsd#STRM_DisclosureValuationAndQualifyingAccountsAndReservesAbstract" xlink:label="loc_STRMDisclosureValuationAndQualifyingAccountsAndReservesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_STRMDisclosureValuationAndQualifyingAccountsAndReservesAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="loc_us-gaapValuationAllowancesAndReservesChargedToCostAndExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_STRMDisclosureValuationAndQualifyingAccountsAndReservesAbstract" xlink:to="loc_us-gaapValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="loc_us-gaapValuationAllowancesAndReservesChargedToOtherAccounts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_STRMDisclosureValuationAndQualifyingAccountsAndReservesAbstract" xlink:to="loc_us-gaapValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaapValuationAllowancesAndReservesDeductions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_STRMDisclosureValuationAndQualifyingAccountsAndReservesAbstract" xlink:to="loc_us-gaapValuationAllowancesAndReservesDeductions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_STRMDisclosureValuationAndQualifyingAccountsAndReservesAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961601827376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--01-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-28132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">STREAMLINE
HEALTH SOLUTIONS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001008586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-1455414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2400
Old Milton Pkwy.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Box 1353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alpharetta<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">GA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">30009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(888)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">997-8732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.01 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">STRM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,165,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,362,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents incorporated by reference</a></td>
<td class="text">Information
required by Part III is incorporated by reference from the Registrant&#8217;s Proxy Statement for its 2024 annual meeting of stockholders
or an amendment to this Annual Report on Form 10-K, which will be filed with the Securities and Exchange Commission within 120 days after
the end of its fiscal year ended January 31, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">FORVIS, LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Atlanta,
Georgia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961599791088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,190,000<span></span>
</td>
<td class="nump">$ 6,598,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for credit losses of $86,000 and $132,000, respectively</a></td>
<td class="nump">4,237,000<span></span>
</td>
<td class="nump">7,719,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract receivables</a></td>
<td class="nump">780,000<span></span>
</td>
<td class="nump">960,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">629,000<span></span>
</td>
<td class="nump">710,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,836,000<span></span>
</td>
<td class="nump">15,987,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated amortization of $291,000 and $246,000 respectively</a></td>
<td class="nump">88,000<span></span>
</td>
<td class="nump">79,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of use asset for operating lease</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Capitalized software development costs, net of accumulated amortization of $7,960,000 and $6,224,000, respectively</a></td>
<td class="nump">5,798,000<span></span>
</td>
<td class="nump">5,846,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $4,019,000 and $2,627,000, respectively</a></td>
<td class="nump">12,071,000<span></span>
</td>
<td class="nump">14,793,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,276,000<span></span>
</td>
<td class="nump">23,089,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other</a></td>
<td class="nump">1,666,000<span></span>
</td>
<td class="nump">1,695,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">32,899,000<span></span>
</td>
<td class="nump">45,534,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">41,735,000<span></span>
</td>
<td class="nump">61,521,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,253,000<span></span>
</td>
<td class="nump">626,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,023,000<span></span>
</td>
<td class="nump">3,265,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of term loan</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
<td class="nump">7,112,000<span></span>
</td>
<td class="nump">8,361,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Acquisition earnout liability</a></td>
<td class="nump">1,794,000<span></span>
</td>
<td class="nump">3,738,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,682,000<span></span>
</td>
<td class="nump">16,775,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Term loan, net of deferred financing costs</a></td>
<td class="nump">7,566,000<span></span>
</td>
<td class="nump">8,964,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Line of credit</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues, less current portion</a></td>
<td class="nump">173,000<span></span>
</td>
<td class="nump">167,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">104,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">9,239,000<span></span>
</td>
<td class="nump">9,235,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">22,921,000<span></span>
</td>
<td class="nump">26,010,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies &#8211; Note 12</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value per share, 85,000,000 shares authorized; 58,945,498 and 57,567,210 shares issued and outstanding, respectively</a></td>
<td class="nump">590,000<span></span>
</td>
<td class="nump">576,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">133,923,000<span></span>
</td>
<td class="nump">131,973,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(115,699,000)<span></span>
</td>
<td class="num">(97,038,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">18,814,000<span></span>
</td>
<td class="nump">35,511,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 41,735,000<span></span>
</td>
<td class="nump">$ 61,521,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961599607472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="nump">$ 132,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated amortization, property and equipment</a></td>
<td class="nump">291,000<span></span>
</td>
<td class="nump">246,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization', window );">Capitalized Computer Software, Accumulated Amortization</a></td>
<td class="nump">7,960,000<span></span>
</td>
<td class="nump">6,224,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization, intangible assets</a></td>
<td class="nump">$ 4,019,000<span></span>
</td>
<td class="nump">$ 2,627,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">85,000,000<span></span>
</td>
<td class="nump">85,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">58,945,498<span></span>
</td>
<td class="nump">57,567,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">58,945,498<span></span>
</td>
<td class="nump">57,567,210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961599340304">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 22,596,000<span></span>
</td>
<td class="nump">$ 24,889,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_CostOfSoftwareAsService', window );">Cost of software as a service</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,573,000<span></span>
</td>
<td class="nump">6,358,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_CostOfMaintenanceAndSupport', window );">Cost of maintenance and support</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">315,000<span></span>
</td>
<td class="nump">427,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_CostOfProfessionalFeesAndLicenses', window );">Cost of professional fees and licenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,165,000<span></span>
</td>
<td class="nump">6,610,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,710,000<span></span>
</td>
<td class="nump">16,283,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,704,000<span></span>
</td>
<td class="nump">6,042,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,813,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">963,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,243,000<span></span>
</td>
<td class="nump">35,720,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(19,647,000)<span></span>
</td>
<td class="num">(10,831,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,071,000)<span></span>
</td>
<td class="num">(749,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AcquisitionEarnoutValuationAdjustments', window );">Acquisition earnout valuation adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,944,000<span></span>
</td>
<td class="nump">71,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,000<span></span>
</td>
<td class="nump">201,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,743,000)<span></span>
</td>
<td class="num">(11,308,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46,000<span></span>
</td>
<td class="num">(71,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (18,697,000)<span></span>
</td>
<td class="num">$ (11,379,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Earnings Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted Earnings Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares - basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">56,510,419<span></span>
</td>
<td class="nump">49,324,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares - diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56,510,419<span></span>
</td>
<td class="nump">49,324,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=STRM_SoftwareasAsAServiceMember', window );">Softwareas As A Service [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 14,075,000<span></span>
</td>
<td class="nump">$ 12,326,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=STRM_MaintenanceAndSupportMember', window );">Maintenance And Support [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,318,000<span></span>
</td>
<td class="nump">4,483,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=STRM_ProfessionalFeesAndLicensesMember', window );">Professional Fees And Licenses [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,203,000<span></span>
</td>
<td class="nump">$ 8,080,000<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Excludes
    the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of January 31, 2024
    and 2023, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zOkiNJqczEvk" title="Diluted earnings per share">1,970,521</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z2lI0oNs2rt9" title="Diluted earnings per share">1,848,031</span> unvested restricted shares of common stock, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_AcquisitionEarnoutValuationAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition earnout valuation adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_AcquisitionEarnoutValuationAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_CostOfMaintenanceAndSupport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance and support.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_CostOfMaintenanceAndSupport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_CostOfProfessionalFeesAndLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of professional fees and licenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_CostOfProfessionalFeesAndLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_CostOfSoftwareAsService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of software as a service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_CostOfSoftwareAsService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=STRM_SoftwareasAsAServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=STRM_SoftwareasAsAServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=STRM_MaintenanceAndSupportMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=STRM_MaintenanceAndSupportMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=STRM_ProfessionalFeesAndLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=STRM_ProfessionalFeesAndLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961597389792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jan. 31, 2022</a></td>
<td class="nump">$ 478,000<span></span>
</td>
<td class="nump">$ 119,225,000<span></span>
</td>
<td class="num">$ (85,659,000)<span></span>
</td>
<td class="nump">$ 34,044,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jan. 31, 2022</a></td>
<td class="nump">47,840,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of Stock Options, shares</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock issued</a></td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="num">(19,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock issued, shares</a></td>
<td class="nump">1,876,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 82,000<span></span>
</td>
<td class="nump">11,246,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,328,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock, shares</a></td>
<td class="nump">8,171,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Offering expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Restricted stock forfeited</a></td>
<td class="num">$ (2,000)<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Restricted stock forfeited, shares</a></td>
<td class="num">(199,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_StockIssuedDuringPeriodValueSurrenderOfShares', window );">Surrender of stock</a></td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="num">(196,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(197,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_StockIssuedDuringPeriodSharesSurrenderOfShares', window );">Surrender of stock, shares</a></td>
<td class="num">(127,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,761,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,761,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,379,000)<span></span>
</td>
<td class="num">(11,379,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jan. 31, 2023</a></td>
<td class="nump">$ 576,000<span></span>
</td>
<td class="nump">131,973,000<span></span>
</td>
<td class="num">(97,038,000)<span></span>
</td>
<td class="nump">$ 35,511,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jan. 31, 2023</a></td>
<td class="nump">57,567,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of Stock Options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock issued</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock issued, shares</a></td>
<td class="nump">1,947,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Restricted stock forfeited</a></td>
<td class="num">$ (4,000)<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Restricted stock forfeited, shares</a></td>
<td class="num">(378,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_StockIssuedDuringPeriodValueSurrenderOfShares', window );">Surrender of stock</a></td>
<td class="num">$ (2,000)<span></span>
</td>
<td class="num">(278,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(280,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_StockIssuedDuringPeriodSharesSurrenderOfShares', window );">Surrender of stock, shares</a></td>
<td class="num">(190,950)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,244,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,244,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,697,000)<span></span>
</td>
<td class="num">(18,697,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Adoption of ASU 2016-13</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jan. 31, 2024</a></td>
<td class="nump">$ 590,000<span></span>
</td>
<td class="nump">$ 133,923,000<span></span>
</td>
<td class="num">$ (115,699,000)<span></span>
</td>
<td class="nump">$ 18,814,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jan. 31, 2024</a></td>
<td class="nump">58,945,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_StockIssuedDuringPeriodSharesSurrenderOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Surrender of stock, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_StockIssuedDuringPeriodSharesSurrenderOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_StockIssuedDuringPeriodValueSurrenderOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Surrender of stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_StockIssuedDuringPeriodValueSurrenderOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961599640128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,697,000)<span></span>
</td>
<td class="num">$ (11,379,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,331,000<span></span>
</td>
<td class="nump">4,313,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AcquisitionEarnoutValuationAdjustments', window );">Acquisition earnout valuation adjustments</a></td>
<td class="num">(1,944,000)<span></span>
</td>
<td class="num">(71,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_ProvisionForDeferredIncomeTaxes', window );">Provision for deferred income taxes</a></td>
<td class="num">(104,000)<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">2,102,000<span></span>
</td>
<td class="nump">1,680,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">9,813,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">963,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for credit losses</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">189,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Accounts and contract receivables</a></td>
<td class="nump">3,708,000<span></span>
</td>
<td class="num">(4,202,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(401,000)<span></span>
</td>
<td class="num">(1,197,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">544,000<span></span>
</td>
<td class="num">(152,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(1,277,000)<span></span>
</td>
<td class="nump">1,069,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenues</a></td>
<td class="num">(1,243,000)<span></span>
</td>
<td class="nump">2,598,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,215,000)<span></span>
</td>
<td class="num">(7,143,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(54,000)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToDevelopSoftware', window );">Capitalization of software development costs</a></td>
<td class="num">(1,567,000)<span></span>
</td>
<td class="num">(1,925,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,621,000)<span></span>
</td>
<td class="num">(1,935,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,316,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities', window );">Payment of acquisition earnout liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,012,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for costs directly attributable to the issuance of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of bank term loan</a></td>
<td class="num">(750,000)<span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from line of credit</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to settlement of employee shared-based awards</a></td>
<td class="num">(280,000)<span></span>
</td>
<td class="num">(197,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of deferred financing costs</a></td>
<td class="num">(44,000)<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">428,000<span></span>
</td>
<td class="nump">5,791,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(3,408,000)<span></span>
</td>
<td class="num">(3,287,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">6,598,000<span></span>
</td>
<td class="nump">9,885,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">3,190,000<span></span>
</td>
<td class="nump">6,598,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid, net of amounts capitalized</a></td>
<td class="nump">989,000<span></span>
</td>
<td class="nump">651,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_AcquisitionEarnoutValuationAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition earnout valuation adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_AcquisitionEarnoutValuationAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_ProvisionForDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision for deferred income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_ProvisionForDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for financing costs associated with business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToDevelopSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToDevelopSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961595657168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zA2UWp7zlpaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
1 &#8212; <span id="xdx_828_zms7fanVITki">ORGANIZATION AND DESCRIPTION OF BUSINESS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Streamline
Health Solutions, Inc. and each of its wholly-owned subsidiaries, Streamline Health, LLC, Avelead Consulting, LLC, Streamline
Consulting Solutions, LLC and Streamline Pay &amp; Benefits, LLC, (collectively, unless the context requires otherwise, &#8220;we&#8221;,
&#8220;us&#8221;, &#8220;our&#8221;, &#8220;Streamline&#8221;, or the &#8220;Company&#8221;) operates in one segment as a provider
of healthcare information technology solutions and associated services. The Company provides these capabilities through the
licensing of its Coding &amp; CDI, eValuator coding analysis platform, RevID, and other workflow software applications and the use
of such applications by software as a service (&#8220;SaaS&#8221;). The Company also provides audit services to help clients
optimize their internal clinical documentation and coding functions, as well as implementation and consulting services to complement
its software solutions. The Company&#8217;s software and services enable hospitals and integrated healthcare delivery systems in the
United States and Canada to capture, store, manage, route, retrieve and process patient clinical, financial and other healthcare
provider information related to the patient revenue cycle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fiscal
Year</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references to a fiscal year refer to the fiscal year commencing February 1 in that calendar year and ending on January 31 of the following
calendar year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961596701552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zuoJOMT1riek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
2 &#8212; <span id="xdx_82D_zKMZYRenVXTh">SIGNIFICANT ACCOUNTING POLICIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zBSu67ZrIzqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zMxyAnKWevrd">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of Streamline Health Solutions, Inc. and its wholly-owned subsidiaries, Streamline
Health, LLC, Avelead Consulting, LLC, Streamline Consulting Solutions, LLC and Streamline Pay &amp; Benefits, LLC. All significant intercompany
transactions and balances are eliminated in consolidation. All amounts in the consolidated financial statements, notes and tables have
been rounded to the nearest thousand dollars, except share and per share amounts, unless otherwise indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has determined it has only one operating segment based on the guidance of <i>ASC 280-10-50 </i>paragraphs 1 through 8, The Company
has a sole chief operating decision maker who reviews a single set of financials, information, has accountability for the performance
of the organization, and allocates resources to drive success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal 2022, the Company had two reporting units for evaluation of goodwill: Streamline Solutions and Avelead Solutions. The Company
determined that, effective January 1, 2023, it has one reporting unit for purposes of evaluation of goodwill, which was used for evaluation
of goodwill for fiscal 2023. At the end of fiscal 2022, the Company consolidated and combined its operations for Streamline Solutions
and Avelead Solutions. For total assets at January 31, 2024 and 2023 and total revenue and net loss for the fiscal years ended January
31, 2024 and 2023, see our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary
Data&#8221; herein.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_ecustom--GoingConcernPolicyTextBlock_z04TyckKPcLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zcBCCKzLHlv8">Going
Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of obligations in the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the Company&#8217;s Quarterly Report on Form 10-Q for the period ended October 31, 2023, the Company raised substantial doubt about
its ability to continue as a going concern. It cited the &#8220;ability to achieve cash from operations and raise additional debt or
equity capital to fund its ongoing operations&#8221; as requirements to mitigate the substantial doubt. As of this filing, the
Company has been able to successfully implement a cost reduction plan, obtain additional capital, and restructure the covenants for
its existing credit facility. Collectively, these initiatives alleviated the substantial doubt about the Company&#8217;s ability to continue as a going concern. Refer to the
&#8220;Restructuring&#8221; subtopic of this Note 1 (Organization and Description of Business) and Note 14 &#8211; Subsequent Events
to our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; for
additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zT18YACMCUE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zLdYdGtUBpJ7">Reclassification</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
amounts for fiscal 2022 were reclassified to conform to the current period classification. The Company incurred certain acquisition-related
costs related to the acquisition of Avelead totaling $<span id="xdx_90C_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20230201__20240131_zLSxskQwCZpi" title="Acquisition related costs">149,000</span> consisting primarily of professional service fees. The aforementioned acquisition-related
costs for fiscal 2022 were previously presented in a separate, single caption and are now included in selling, general, and administrative
expense in the accompanying condensed consolidated statements of operations, which is consistent with the presentation for the current
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--UseOfEstimates_zYRzg40CSL39" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_z7lvcZppkJTa">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management
to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing
basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, stock-based compensation,
capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration and income
taxes. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQN5GPYeb917" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zpKSz8Ifca33">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash demand deposits. Cash deposits
are placed in Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured financial institutions. Cash deposits may exceed FDIC
insured levels from time to time. For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company
considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Non-Cash
Items</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_ecustom--ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock_z1maRBLwUz69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following items that were non-cash items related to the consolidated statements of cash flows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zNqLG3nkHJTj" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230201__20240131_zurqW0nQ9sbh" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220201__20230131_zEEvneV5twwa" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Fiscal Year</b></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr id="xdx_40A_eus-gaap--RestrictedStockExpense_zog1qLL5VDyc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Payment of acquisition earnout liabilities in restricted common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">3,012,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--CapitalizedSoftwarePurchasedWithStock_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized software purchased with stock (<i>See Note 12</i>)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DeferredFinancingCosts_z5B0BQA42Im8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zY1Afzd2Ab5g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--TradeAndOtherAccountsReceivablePolicy_ztpdyWecksi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zFjauAPTw4g3">Receivables</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
and contract receivables are comprised of amounts owed to the Company for licensed software, professional services, including coding
audit services, consulting services, maintenance services, and software as a service and are presented net of the allowance for credit losses. The timing of revenue recognition may not coincide with the billing terms of the client contract, resulting in unbilled receivables
or deferred revenues; therefore, certain contract receivables represent revenues recognized prior to client billings. Individual contract
terms with clients or resellers determine when receivables are due. Accounts receivable represent amounts that the entity has an unconditional
right to consideration. For billings where the criteria for revenue recognition have not been met, deferred revenue is recorded until
the Company satisfies the respective performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--AllowanceForCreditLossesPolicyTextBlock_ze7ToCazvDBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zZjdgKK0Ieh1">Allowance
for Credit Losses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adjusts accounts receivable down to net realizable value. Effective February 1, 2023, the Company implemented ASC 326-10,
Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;CECL&#8221;).
CECL provides the framework for the Company to evaluate its allowance for credit losses. In determining the
allowance for credit losses, the Company established a historical credit loss rate adjusted for a premium, addressing any
prospective changes to the risk of credit loss, that is applied against current sales. The Company evaluates individual receivables
based upon the most recent information available and the status of any open or unresolved issues with the client preventing the
payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables.
During these periodic reviews, significant judgement is required for the Company to determine the appropriate allowances for
doubtful accounts for estimated losses resulting from the unwillingness of its clients or resellers to make required payments. The
Company believes its reserve is adequate, however, results may differ in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the changes to the allowance account with the adoption of CECL:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_891_eus-gaap--ScheduleOfRestructuringReserveByTypeOfCostTextBlock_zfqA1D3oTMu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zu0obzYOwHKb" style="display: none">SCHEDULE
OF RESERVE RESULTS IN FUTURE PERIODS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CECL Adoption</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="text-align: center">&#160;</td><td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Provision adjustments</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Write-offs &amp; Recoveries</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 39%; text-align: left; padding-bottom: 1.5pt">Allowance for credit losses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20230201__20240131_z5AgnJ7s7tPl" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Balance">132,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--AllowanceForDoubtfulAccountsReceivableCECLAdoption_c20230201__20240131_zeIXWjucoLQ4" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, CECL Adoption">(36,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="width: 1%">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 1%">$</td>
    <td id="xdx_987_eus-gaap--ProvisionForDoubtfulAccounts_c20230201__20240131_zUzIajVrro0k" style="border-bottom: Black 1.5pt solid; text-align: right; width: 9%; vertical-align: bottom" title="Allowance for credit losses, Provision adjustments">(10,000</td>
    <td style="padding-bottom: 1.5pt; width: 1%">)&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 2%; text-align: left">$</td><td id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20230201__20240131_zZhmkzIUbMp2" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Write-offs &amp; Recoveries"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20230201__20240131_zZ33ZyhBjhP5" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Balance">86,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zkt8sf5GfK1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_ecustom--AccruedExpensesPolicyTextBlock_zAS3WcLE6cMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zEPilTYadTI9">Accrued
Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p><p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zssA1ZOPLkr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zjVvaM2jJJZh" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF ACCRUED EXPENSES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49F_20240131_zudJCphoE676" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_491_20230131_zZ3PQl6Hw3c3" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">January 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="text-align: center">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedSalariesCurrent_iI_zqBBCbxfpXD5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Employee benefits and related compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"> 1,071,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,079,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedExchangeFeeRebateCurrentAndNoncurrent_iI_zw3eVdmgVRr7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Professional fees and services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">389,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">294,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ThirdPartylicense_iI_zLPCmN1DR3Ol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Third party licenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">285,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ConcessionAccrualAmount_iI_zg0nP7105bSd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Customer concessions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">233,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">226,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_zvCIgbXYJ7Ra" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">State income and sales taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">226,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">331,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestPayableCurrent_iI_z4i3QH3r3wQ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Interest, primarily on term loan</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_iTI_zNtAGpNP6L76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Total accrued expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"> 2,023,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,265,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_ziQEqkTWZ7Nk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p id="xdx_844_ecustom--ConcessionsAccrualPolicyTextBlock_zVUnlXdpFBWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zlO4ItNiqHx7">Concessions
Accrual</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company offers certain service level agreements within its client contracts such as uptime, support hours, and levels of support. Our
contracts may include, and we may offer, credits to clients when these service line agreements are not met. The service level agreements
are accounted for as variable consideration using a portfolio approach. As a result, we record an estimate of these concessions against
our recorded revenue. In determining the concessions accrual, the Company evaluates historical concessions granted relative to revenue
as well as future potential risk that these service level agreements will not be met. The Company records a provision, reducing revenue,
for the estimated amount of concessions incurred on the revenue recorded. The Company evaluates the amount of the concession accrual
each period for adequacy. Historically, concessions have not been significant. The concession accrual included in accrued expenses on
the Company&#8217;s consolidated balance sheet was $<span id="xdx_90F_ecustom--ConcessionAccrualAmount_iI_c20240131_zAOFCrXEIub6" title="Concession accrual amount">233,000</span> and $<span id="xdx_905_ecustom--ConcessionAccrualAmount_iI_c20230131_zWGrpYfO73Rl" title="Concession accrual amount">226,000</span> as of January 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zutAhpeflC7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zd2A8EaYq0yl">Property
and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_ecustom--PropertyPlantAndEquipmentTableTextBlock_zC7KvXeAvWKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related
assets. Estimated useful lives are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z81ryXv2b0Dk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    equipment and software</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember__srt--RangeAxis__srt--MinimumMember_z0N5TyjreMg1" title="Property and equipment, useful lives">3</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember__srt--RangeAxis__srt--MaximumMember_z7GCMwRYZIdk" title="Property and equipment, useful lives">4</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDDJAkGpKx3" title="Property and equipment, useful lives">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    furniture and fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zNnHLxZxDsNd" title="Property and equipment, useful lives">5</span>-<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z8hTCuXJU7Ic" title="Property and equipment, useful lives">7</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zH8BRKAElZcc" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0599">Term
    of lease or estimated useful life, whichever is shorter</span></span></span></td></tr>
  </table>
<p id="xdx_8A8_zyNmEEv8K9y2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for property and equipment in fiscal 2023 and 2022 was $<span id="xdx_90D_eus-gaap--Depreciation_pp0p0_c20230201__20240131_zQ9oaRDYoXqc" title="Depreciation expense">45,000</span> and $<span id="xdx_904_eus-gaap--Depreciation_pp0p0_c20220201__20230131_zq7fFQ6ABi41" title="Depreciation expense">54,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Normal
repairs and maintenance are expensed as incurred. Replacements are capitalized and the property and equipment accounts are relieved of
the items being replaced or disposed of, if no longer of value. The related cost and accumulated depreciation of the disposed assets
are eliminated and any gain or loss on disposition is included in the results of operations in the year of disposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zaelwKPvQTk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zAB09QPfEXra">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine whether an arrangement is a lease at inception. Right-of-use assets represent our right to use an underlying asset for the
lease term, and lease liabilities represent our obligation to make lease payments arising from the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected
lease term. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our
obligation to make lease payments arising from the lease. Since our lease arrangements do not provide an implicit rate, we use our estimated
incremental borrowing rate for the expected remaining lease term at commencement date in determining the present value of future lease
payments. We recognize operating lease cost on a straight-line basis by aggregating any rent abatement with the total expected rental
payments and amortizing the expense ratably over the term of the lease. Sublease income is recognized as other income over the period
of the lease, as the sublease is outside of the Company&#8217;s normal business operations. See Note 4 &#8211; Operating Leases for further
details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--CostsIncurredPolicy_zkpabqXMLj52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zbj0NRIwpPY4">Debt
Issuance Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
related to the Second Amended and Restated Loan and Security Agreement (as amended and modified, the &#8220;Loan Agreement&#8221;)
with Western Alliance Bank (&#8220;WAB&#8221;) was capitalized and amortized to interest expense on a straight-line basis, which is not materially different
from the effective interest method, over the term of the related debt, and presented on the Company&#8217;s consolidated balance sheets
as a direct deduction from the carrying amount of the non-current portion of our term loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zX8DXegzCyW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zs8Gtbk0U2t3">Impairment
of Long-Lived Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews the carrying value of long-lived assets for impairment whenever facts and circumstances exist that would suggest that
assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation
are changes in market position and profitability. If facts and circumstances are present which may indicate that the carrying amount
of the assets may not be recoverable, the Company will prepare a projection of the undiscounted cash flows of the specific asset or asset
group and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment
will be made to reduce the carrying amount of these assets to their fair values. For fiscal 2023, an impairment of long-lived assets
in the amount of $963,000 was recorded. Refer to Note 6 &#8211; Goodwill and Intangible Assets to our consolidated financial statements
included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_zF7a44pacboh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zwXJ9NUbrFKi">Capitalized
Software Development Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software
development costs for software to be sold, leased, or marketed are accounted for in accordance with ASC 985-20, <i>Software &#8212; Costs
of Software to be Sold, Leased or Marketed</i>. Costs associated with the planning and design phase of software development are classified
as research and development costs and are expensed as incurred. Once technological feasibility has been established, a portion of the
costs incurred in development, including coding, testing and quality assurance, are capitalized until available for general release to
clients, and subsequently reported at the lower of unamortized cost or net realizable value. Amortization is calculated on a solution-by-solution
basis and is included in cost of professional fees and licenses on the consolidated statements of operations. Annual amortization is
measured at the greater of (i) the ratio of the software product&#8217;s current gross revenues to the total of current and expected
gross revenues or (ii) straight-line over the remaining economic life of the software (typically two years). Unamortized capitalized
costs determined to be in excess of the net realizable value of a solution are expensed at the date of such determination. Capitalized
software development costs for software to be sold, leased, or marketed, net of accumulated amortization, totaled $<span id="xdx_902_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SoftwareMember_z8hB6KTQk9M5" title="Capitalized software development costs, net of accumulated amortization">287,000</span> and $<span id="xdx_907_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20230131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SoftwareMember_zAXpZNJbSf9l" title="Capitalized software development costs, net of accumulated amortization">522,000</span>
as of January 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal-use
software development costs are accounted for in accordance with ASC 350-40, <i>Internal-Use Software</i>. The costs incurred in the preliminary
stages of development are expensed as research and development costs as incurred. Once an application has reached the development stage,
internal and external costs incurred to develop internal-use software are capitalized and amortized on a straight-line basis over the
estimated useful life of the software (typically three to four years). Maintenance and enhancement costs, including those costs in the
post-implementation stages, are typically expensed as incurred, unless such costs relate to substantial upgrades and enhancements to
the software that result in added functionality, in which case the costs are capitalized and amortized on a straight-line basis over
the estimated useful life of the software. The Company reviews the carrying value for impairment whenever facts and circumstances exist
that would suggest that assets might be impaired or that the useful lives should be modified. Amortization expense related to capitalized
internal-use software development costs is included in Cost of software as a service on the consolidated statements of operations. Capitalized
software development costs for internal-use software, net of accumulated amortization, totaled $<span id="xdx_90E_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zOXhpu5ZLb8l" title="Capitalized software development costs, net of accumulated amortization">5,511,000</span> and $<span id="xdx_909_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20230131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zH2TNWGlNF9d" title="Capitalized software development costs, net of accumulated amortization">5,324,000</span> as of January
31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated useful lives of software (including software to be sold and internal-use software) are reviewed frequently and adjusted as
appropriate to reflect upcoming development activities that may include significant upgrades and/or enhancements to the existing functionality.
The Company reviews, on an on-going basis, the carrying value of its capitalized software development expenditures, net of accumulated
amortization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense on all capitalized software development was $<span id="xdx_900_eus-gaap--CapitalizedComputerSoftwareAmortization1_pp0p0_c20230201__20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zc4Hyffjbrol">2,463,000</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_905_eus-gaap--CapitalizedComputerSoftwareAmortization1_pp0p0_c20220201__20230131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zOk89cFM1Ls9">2,423,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
fiscal 2023 and 2022, respectively. Further, the Company recognized an impairment of approximately $<span id="xdx_907_eus-gaap--AssetImpairmentCharges_pp0p0_c20230201__20240131_zslU6fQnpVz9">18,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_90E_eus-gaap--AssetImpairmentCharges_pp0p0_c20220201__20230131_zw3eAPJdspS2">0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
fiscal 2023 and fiscal 2022, respectively, related to cancelled or abandoned enhancement projects during fiscal 2023 and fiscal 2022
that have been recognized within amortization expense. Additionally, in fiscal 2023, entries of approximately $<span id="xdx_906_ecustom--AmortizedAndAbandonedAssets_pp0p0_c20230201__20240131_zfwYJdf0m7B7">18,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
fully amortized and abandoned assets were offset from their corresponding capitalization and
accumulated amortization balance sheet accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the &#8220;carry-over&#8221; method for amortizing capitalized software development costs. Under the &#8220;carry-over&#8221;
method, the costs of the enhancements are added to the unamortized costs of the previous version of the product and the combined amount
is amortized over the remaining useful life of the product. Including unamortized cost of the original product with the cost of the enhancement
for purposes of applying the net realizable value test and amortization provisions is consistent with accounting guidance for software
companies that improve their software and discontinue selling or marketing the older versions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"></p><p id="xdx_898_ecustom--ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock_zyTJHWMBeMT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zhrv1Qznrut">SCHEDULE
OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230201__20240131_zQfxTl39hMgl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220201__20230131_zz7OEADW8UZj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Amortization expense on internally-developed software included in:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CapitalizedComputerSoftwareAmortization1_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfSoftwareAsASeviceMember_zcyQJUA5T4Pa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: justify">Cost of software as a service</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,229,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,068,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareAmortization1_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfSoftwareAsASeviceMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfProfessionalFeesAndLicensesMember_zQTBEgFtBCWl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Cost of professional fees and licenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">234,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">355,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CapitalizedComputerSoftwareAmortization1_zRiRX6M6htrb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total amortization expense on internally-developed software</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,463,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,423,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zzFc3kastks3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interest capitalized to software development cost reduces the Company&#8217;s interest expense recognized in the consolidated statements
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expense was $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230201__20240131_zssQTQhnUnt1" title="Research and development expense">5,704,000</span> and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220201__20230131_z9G8p4mA0aH9" title="Research and development expense">6,042,000</span> in fiscal 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z7tG6fNFobLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zbQxjSCMpnXj">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB&#8217;s authoritative guidance on fair value measurements establishes a framework for measuring fair value and expands
disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to
develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine
fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the
following three categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Quoted market prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs that are not corroborated by market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based
on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. For fiscal 2023 and 2022,
there were no transfers of assets or liabilities between Levels 1, 2, or 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zxOrPn2IPCe5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below provides information on our liabilities that are measured at fair value on a recurring basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zTMLbE3nRxHe" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total Fair</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quoted Prices in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Active Markets</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Observable Inputs</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unobservable Inputs</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>At January 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F46_zvAP6QeUHmKf" style="padding-left: 10pt; width: 36%; text-align: left">Acquisition earnout liability (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131_fKDEp_z6YHvUHgJQGh" style="width: 12%; text-align: right" title="Acquisition earnout liability, Fair Value">1,794,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zqleoxHBOC68" style="width: 12%; text-align: right" title="Acquisition earnout liability fair value">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0647">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEp_zYR5RNQPDAd6" style="width: 12%; text-align: right" title="Acquisition earn out liability"><span style="-sec-ix-hidden: xdx2ixbrl0649">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fKDEp_zj6kL5TBNcA9" style="width: 12%; text-align: right" title="Acquisition earn out liability fair value, observable inputs">1,794,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>At January 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F4F_z7qG32tUQ7Ui" style="padding-left: 10pt; text-align: left">Acquisition earnout liability (1)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131_fKDEp_z7lGordx0Joa" style="text-align: right" title="Acquisition earnout liability, Fair Value">3,738,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zlmP8WJ3vUs4" style="text-align: right" title="Acquisition earnout liability fair value"><span style="-sec-ix-hidden: xdx2ixbrl0655">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEp_zcRF96jDYkij" style="text-align: right" title="Acquisition earn out liability"><span style="-sec-ix-hidden: xdx2ixbrl0657">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fKDEp_zKFbiSF0PWr6" style="text-align: right" title="Acquisition earn out liability fair value, observable inputs">3,738,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td id="xdx_F0D_zJGjjfpxLUhd" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zzAhJ0nNsIgj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fair value of the acquisition earnout liability is based upon a probability-weighted discounted cash flow that was completed at the
    date of acquisition and updated as of January 31, 2024. The change in the fair value of the acquisition earnout liability decreased
    $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUgQVNTRVRTIEFORCBMSUFCSUxJVElFUyBNRUFTVVJFRCBPTiBSRUNVUlJJTkcgQkFTSVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--AcquisitionEarnoutLiabilityChangeInValuation_c20230201__20240131_z0jICDkaYQXh" title="Acquisition earnout liability, change in valuation">1,944,000</span> for the year ended January 31, 2024, which is entirely recognized in &#8220;Acquisition earnout valuation adjustments&#8221;
    in the accompanying consolidated statement of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    probability-weighted discounted cash flow is calculated using a Monte Carlo valuation method. The valuation model provides numerous
    outcomes. The outcomes are averaged and discounted to present value, which provides the current value point estimate. The significant
    inputs include our forecast of Avelead SaaS revenue, the probabilities associated with each of (i) a change in control or (ii) a
    certain client termination, as well as other normal and customary inputs to financial models, including but not limited to, risk
    factors and interest rates.</span></td></tr>
  </table>
<p id="xdx_8A8_zApULSgz9ali" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s term loan under its Loan Agreement was determined through an analysis of the interest rate spread from
the date of closing the loan (August 2021) to the date of the most recent balance sheets, January 31, 2024 and January 31, 2023. The
term loan bears interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zAsaxSKShrR2" title="Prime interest rate">1.5</span>%, with a Prime
&#8220;floor&#8221; rate of <span id="xdx_90D_ecustom--PrimeInterestRatePercentage_pid_dp_uPure_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_z5xOTtlqE5H3" title="Prime interest rate percentage">3.25</span>%. The prime rate is variable and, thus accommodates changes in the market interest rate. However, the
interest rate spread (the <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131_zwxH5JQDtpE">1.5</span>% added to the Prime Rate) is fixed. We estimated the impact of the changes in the interest rate spread
by analogizing the effect of the change in the Corporate bond rates, reduced for any changes in the market interest rate. This provided
us with an estimated change to the interest rate spread of approximately <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--TypeOfArrangementAxis__custom--SecondAmendedAndRestatedLoanAndSecurityAgreementMember_zizgfI88JDdc" title="Interest rate">0.5</span>% from the date we entered the debt agreement to January
31, 2024 and January 31, 2023. The fair value of the debt as of January 31, 2024 and January 31, 2023 was estimated to be $<span id="xdx_90F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_zGvO65KA1klc" title="Debt instrument carrying amount">8,807,000</span>
and $<span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_zFSdnLsbmjmb" title="Debt instrument carrying amount">9,550,000</span>, respectively, or a discount to book value of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_z4wysqInh0nb" title="Term loan">193,000</span> and $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_zPpmQzcVJBDd" title="Term loan">200,000</span>, respectively. The fair value of the line of credit
as of January 31, 2024 was estimated to be $<span id="xdx_90B_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFjJDCqM5xMa" title="Debt instrument carrying amount">1,463,000</span>, or a discount to book value of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z5ECMMfpfUK6" title="Term loan">37,000</span>. The fair value of long-term debt was estimated using Level 2 inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z0La9yYYwfQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zwV0UXDf5CDf">Revenue
Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
derive revenue from the sale of internally-developed software, either by licensing for local installation or by a SaaS delivery model,
through our direct sales force or through third-party resellers. Licensed, locally-installed clients on a perpetual model utilize our
support and maintenance services for a separate fee, whereas term-based locally installed license fees and SaaS fees include support
and maintenance. We also derive revenue from professional services that support the implementation, configuration, training and optimization
of the applications, as well as audit services and consulting services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize revenue in accordance with Accounting Standards Codification (ASC) 606, <i>Revenue from Contracts with Clients</i> (&#8220;ASC
606&#8221;), under the core principle of recognizing revenue to depict the transfer of promised goods or services to clients in an amount
that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
commence revenue recognition (Step 5 below) in accordance with that core principle after applying the following steps:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    1: Identify the contract(s) with a client</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    2: Identify the performance obligations in the contract</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    3: Determine the transaction price</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    4: Allocate the transaction price to the performance obligations in the contract</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    5: Recognize revenue when (or as) the entity satisfies a performance obligation</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Often
contracts contain more than one performance obligation. Performance obligations are the unit of accounting for revenue recognition and
generally represent the distinct goods or services that are promised to the client. Revenue is recognized net of any taxes collected
from clients and subsequently remitted to governmental authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we determine that we have not satisfied a performance obligation, we defer recognition of the revenue until the performance obligation
is satisfied. Maintenance and support and SaaS agreements are generally non-cancellable or contain significant penalties for early cancellation,
although clients typically have the right to terminate their contracts for cause if we fail to perform material obligations. However,
if non-standard acceptance periods, non-standard performance criteria, or cancellation or right of refund terms are required, revenue
is recognized upon the satisfaction of such criteria.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price is determined by summing all the consideration the Company expects to receive from the client under the contract. At
times, a contract may have variable attributes (i.e., performance guarantees, service level agreements, optional terms) that the Company
must consider when establishing the transaction price to mitigate significant revenue reversals for the contract. The determined transaction
price is allocated based on the standalone selling price (&#8220;SSP&#8221;) of the performance obligations in contract. Significant
judgment is required to determine the SSP for each performance obligation, inclusion of variable consideration, the amount allocated
to each performance obligation and whether it depicts the amount that the Company expects to receive in exchange for the related product
and/or service. The Company recognizes revenue for implementation of its eValuator SaaS solution over the contract term, as it has been
determined that those implementation services are not a distinct performance obligation. Services for other SaaS and Software solutions
such as CDI, RevID and Compare, have been determined as a distinct performance obligation. For these agreements, the Company estimates
SSP of its software licenses using the residual approach when the software license is sold with other services and observable SSPs exist
for the other services. The Company estimates the SSP for maintenance, professional services, software as a service and audit services
based on observable standalone sales.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract
Combination</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may execute more than one contract or agreement with a single client. The Company evaluates whether the agreements were negotiated
as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance
of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions
reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related
to those arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has utilized the portfolio approach as the practical expedient. We have applied the revenue model to a portfolio of contracts
with similar characteristics where we expected that the financial statements would not differ materially from applying it to the individual
contracts within that portfolio.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Software
Licenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s software license arrangements provide the client with the right to use functional intellectual property. Implementation,
support, and other services are typically considered distinct performance obligations when sold with a software license unless these
services are determined to significantly modify the software. Revenue is recognized at a point in time. Typically, this is upon shipment
of components or electronic download of software.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Maintenance
and Support Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
maintenance and support obligations include multiple discrete performance obligations, with the two largest being unspecified product
upgrades or enhancements, and technical support, which can be offered at various points during a contract period. We believe that the
multiple discrete performance obligations within our overall maintenance and support obligations can be viewed as a single performance
obligation since both the unspecified upgrades and technical support are activities to fulfill the maintenance performance obligation
and are rendered concurrently. Maintenance and support agreements entitle clients to technology support, version upgrades, bug fixes
and service packs. We recognize maintenance and support revenue over the contract term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Software-Based
Solution Professional Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides various professional services to clients with software licenses. These include project management, software implementation
and software modification services. Revenues from arrangements to provide professional services are generally distinct from the other
promises in the contract and are recognized as the related services are performed. Consideration payable under these arrangements is
either fixed fee or on a time-and-materials basis and is recognized over time as the services are performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Software
as a Service</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SaaS-based
contracts include a right to use of the Company&#8217;s platform and support which represent a single promise to provide continuous access
to its software solutions. Implementation services for the Company&#8217;s eValuator product are included as part of the single promise
for its respective contracts. The Company recognizes revenue for implementation of the eValuator product over the contract term as it
is determined that the implementation on eValuator is not a distinct performance obligation. Implementation services for other SaaS products
are deemed to be separate performance obligations that are recognized over time as the services are performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides technology-enabled coding audit services to help clients review and optimize their internal clinical documentation and
coding functions across the applicable segment of the client&#8217;s enterprise. Audit services are a separate performance obligation.
We recognize revenue over time as the services are performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disaggregation
of Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_z0jY4a01NTw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information about disaggregated revenue by type and nature of revenue stream:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zlMowoknXAu9" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF DISAGGREGATON OF REVENUE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230201__20240131_zXglfbiAOxt4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220201__20230131_zjOgp3IivuTh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zQhbKUjvP4Ig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Over time revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">22,358,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">23,670,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zYqnLNCuvL5i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Point in time revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">238,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,219,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zNl6JRI2goeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,596,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,889,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z571tbGvK3ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company includes revenue categories of (i) over time and (ii) point in time revenue. The Company includes revenue categories of (i) SaaS,
(ii) maintenance and support, (iii) professional services, and (iv) audit services as over time revenue. For point in time revenue, the
performance obligation is recognized as the point in time when the obligation is fully satisfied. The Company includes software licenses
as point in time revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract
Assets and Deferred Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company receives payments from clients based upon contractual billing schedules. Contract receivables include amounts related to the
Company&#8217;s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenues include
payments received in advance of performance under the contract. Our contract receivables and deferred revenue are reported on an individual
contract basis at the end of each reporting period. Contract receivables are classified as current or noncurrent based on the timing
of when we expect to bill the client. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to
recognize revenue. In the year ended January 31, 2024, we recognized approximately $<span id="xdx_904_eus-gaap--DeferredRevenue_iI_pp0p0_c20230131_zjvxR3hWRfE3" title="Deferred revenue">7,642,000</span> in revenue from deferred revenues outstanding
as of January 31, 2023. Revenue allocated to remaining performance obligations was $<span id="xdx_903_eus-gaap--RevenueRemainingPerformanceObligation_iI_pp0p0_c20240131_zzJQFtl5lLgi" title="Revenue remaining performance obligation">31,414,000</span> &#160;&#160;as of January 31, 2024, of
which <span id="xdx_90E_eus-gaap--RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_c20230201__20240131_zMKGqlhUohX1" title="Revenue, remaining performance obligation, expected timing of satisfaction, explanation">the Company expects to recognize approximately 46% over the next 12 months and the remainder thereafter.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deferred
costs (costs to fulfill a contract and contract acquisition costs)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
defer the direct costs, which include salaries and benefits, for professional services related to SaaS contracts as a cost to fulfill
a contract. These deferred costs will be amortized on a straight-line basis over the contractual term. As of January 31, 2024, and 2023,
we had deferred costs of $<span id="xdx_907_eus-gaap--DeferredCostsCurrentAndNoncurrent_iI_pp0p0_c20240131_zVdxuFx5yI48" title="Deferred costs, net">77,000</span> and $<span id="xdx_90E_eus-gaap--DeferredCostsCurrentAndNoncurrent_iI_pp0p0_c20230131_zfIOvjbI3BN" title="Deferred costs, net">94,000</span>, respectively, net of accumulated amortization of $<span id="xdx_905_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_pp0p0_c20240131_zXk7UyCFT7qd" title="Accumulated amortization of deferred costs">102,000</span> and $<span id="xdx_909_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_pp0p0_c20230131_zfuai8uwzf78" title="Accumulated amortization of deferred costs">176,000</span>, respectively. Amortization
expense of these costs was $<span id="xdx_90A_ecustom--DeferredCostsAmortizationExpenses_pp0p0_c20230201__20240131_z8JxABz7wmd9" title="Deferred costs, amortization expense">82,000</span> and $<span id="xdx_901_ecustom--DeferredCostsAmortizationExpenses_pp0p0_c20220201__20230131_zM3D3eB7wswd" title="Deferred costs, amortization expense">83,000</span> in fiscal 2023 and 2022, respectively. There were no impairment losses for these capitalized
costs for the fiscal 2023 and 2022. Additionally, in fiscal 2023, approximately $<span id="xdx_905_eus-gaap--OtherAmortizationOfDeferredCharges_pp0p0_c20230201__20240131_z0ccSphI8kFj" title="Amortized contracts">155,000</span> of fully amortized contracts were cleared
from their corresponding capitalization and accumulated amortization balance sheet accounts, while no such adjustments were made in fiscal
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
acquisition costs, which consist of sales commissions paid or payable, is considered incremental and recoverable costs of obtaining a
contract with a client. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis
over the contract term. As a practical expedient, we expense sales commissions as incurred when the amortization period of related deferred
commission costs would have been one year or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
commissions costs paid and payable, which are included on the consolidated balance sheets within other non-current assets totaled $<span id="xdx_90E_ecustom--DeferredCommissionsCostsPaidAndPayable_iI_pp0p0_c20240131__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherNoncurrentAssetsMember_z6mG0uzfKR5b" title="Deferred commissions costs paid and payable">1,461,000</span>
and $<span id="xdx_907_ecustom--DeferredCommissionsCostsPaidAndPayable_iI_pp0p0_c20230131__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherNoncurrentAssetsMember_zp6gUZHH6ZN2" title="Deferred commissions costs paid and payable">1,534,000</span>, respectively, as of January 31, 2024 and 2023. In fiscal 2023 and 2022, amortization expense associated with deferred
sales commissions was $<span id="xdx_905_eus-gaap--AmortizationOfDeferredSalesCommissions_pp0p0_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zgWVS2cRmPA3" title="Amortization expense with deferred sales commissions">588,000</span> and $<span id="xdx_90D_eus-gaap--AmortizationOfDeferredSalesCommissions_pp0p0_c20220201__20230131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zC5wRguPWwcf" title="Amortization expense with deferred sales commissions">411,000</span>, respectively, and was included in selling, general and administrative expenses on the consolidated
statements of operations. There were $<span id="xdx_909_eus-gaap--CapitalizedContractCostImpairmentLoss_pp0p0_c20230201__20240131_zq6Lz5yN6ife" title="Impairment loss">35,000</span> and <span id="xdx_901_eus-gaap--CapitalizedContractCostImpairmentLoss_pp0p0_do_c20220201__20230131_zbNQzc4gtAk9" title="Impairment loss">no</span> impairment losses for these capitalized costs that was included with the amortization
expense for fiscal 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zL8F4xbnR08b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zXy7zlnS4U5c">Concentrations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments, which potentially expose the Company to concentrations of credit risk, consist primarily of accounts receivable. The Company&#8217;s
accounts receivables are concentrated in the healthcare industry. However, the Company&#8217;s clients typically are well-established
hospitals, medical facilities or major health information systems companies with good credit histories that resell the Company&#8217;s
solutions. Payments from clients have been received within normal time frames for the industry. However, some hospitals and medical facilities
have experienced significant operating losses as a result of limits on third-party reimbursements from insurance companies and governmental
entities and extended payment of receivables from these entities is not uncommon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has relied on a limited number of clients and remarketing partners for a substantial portion of its total revenues.
The Company expects that a significant portion of its future revenues will continue to be generated by a limited number of clients and
its remarketing partners.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zeAj1BAjGsyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zR3ftPEEQhza">Goodwill
and Intangible Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
and other intangible assets were recognized in conjunction with the Avelead acquisition, and certain other acquisitions from fiscal
2013 and prior (prior to divestiture of such assets). Identifiable intangible assets include purchased intangible assets with finite
lives, which primarily consist of internally-developed software and client relationships. Finite-lived purchased intangible assets
are amortized over their expected period of benefit, which generally ranges from <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dxL_c20240131__srt--RangeAxis__srt--MinimumMember_zA4bGYLesFfg" title="Finite-lived intangible assets amortized period::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl0732">one</span></span>
to <span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20240131__srt--RangeAxis__srt--MaximumMember_zBVML3cJc0Db" title="Finite-lived intangible assets amortized period">15</span>
years, using the straight-line method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses the useful lives and possible impairment of intangible assets when an event occurs that may trigger such a review. Factors
considered important which could trigger a review include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    underperformance relative to historical or projected future operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    changes in the manner of use of the acquired assets or the strategy for the overall business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification
    of other impaired assets within a reporting unit;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disposition
    of a significant portion of an operating segment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    negative industry or economic trends;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    decline in the Company&#8217;s stock price for a sustained period; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decline in the market capitalization relative to the net book value.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining
whether a triggering event has occurred involves significant judgment by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses goodwill annually (as of November 1), or more frequently when events and circumstances, such as the ones mentioned above,
occur indicating that the recorded goodwill may be impaired. In assessing qualitative factors to determine whether it is more likely
than not that the fair value of a reporting unit is less than its carrying amount, the Company assesses relevant events and circumstances
that may impact the fair value and the carrying amount of a reporting unit. The identification of relevant events and circumstances and
how these may impact a reporting unit&#8217;s fair value or carrying amount involve significant judgments by management. These judgments
include the consideration of macroeconomic conditions, industry and market considerations, cost factors, overall financial performance,
events which are specific to the Company and trends in the market price of the Company&#8217;s common stock. Each factor is assessed
to determine whether it impacts the impairment test positively or negatively, and the magnitude of any such impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended January 31, 2023, the Company did not note any of the above qualitative factors, which would be considered a triggering
event for goodwill impairment. During the year ended January 31, 2024, the Company identified one or more factors that triggered goodwill
impairment as of October 31, 2023, as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the third quarter of fiscal 2023, the Company received a notice from a significant SaaS client of its intent not to renew its contract
following the expiration of the current term on December 31, 2023. At that time, the Company elected to accelerate the execution of the
2023 Restructuring that was designed to reduce costs while maintaining the Company&#8217;s ability to expand its SaaS business. Both
the client termination and the execution of the Strategic Restructuring were announced on October 16, 2023. Following these announcements,
the Company&#8217;s share price declined significantly. Based on these events (collectively, the &#8220;Triggering Events&#8221;), the
Company identified indicators of possible impairment and initiated testing using a valuation date of October 31, 2023. The impairment
tests were conducted under guidance of ASC Topic 360, Impairment and Disposal of Long-Lived Assets (&#8220;ASC 360&#8221;) for certain
long-lived assets, including capitalized contract costs, developed technology, client relationships and trade names, and in accordance
with ASC Topic 350, Intangibles &#8211; Goodwill and Other (&#8220;ASC 350&#8221;) with respect to the reporting unit&#8217;s goodwill.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reporting
units are determined based on the organizational structure the entity has in place at the date of the impairment test. A reporting unit
is an operating segment or component business unit with the following characteristics: (a) it has discrete financial information, (b)
segment management regularly reviews its operating results (generally an operating segment has a segment manager who is directly accountable
to and maintains regular contact with the chief operating decision maker to discuss operating activities, financial results, forecasts
or plans for the segment), and (c) its economic characteristics are dissimilar from other units (this contemplates the nature of the
products and services, the nature of the production process, the type or class of client for the products and services and the methods
used to distribute the products and services). The Company determined that for fiscal 2023 it has one operating segment and one reporting
unit, while for fiscal 2022 it had one operating segment and two reporting units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of its reporting unit using a combination of the market approach and income approach, via
discounted cash flow valuation models which include, but are not limited to, assumptions such as a &#8220;risk-free&#8221; rate of
return on an investment, the weighted average cost of capital of a market participant and future revenue, operating margin, working
capital and capital expenditure trends. Determining the fair value of reporting units and goodwill includes significant judgment by
management, and different judgments could yield different results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performed its annual goodwill assessment for fiscal 2023 as of October 31, 2023 using the approaches described above. The
assessment identified a goodwill impairment of $9,813,000 that was recorded. Based on the analysis performed for fiscal 2022, the fair
value of the reporting units exceeded the carrying amount of the reporting unit, including goodwill, and, therefore, a goodwill impairment
loss was not recognized. &#160; Refer to Note 6 &#8211; Goodwill and Intangible Assets to our consolidated financial statements included
in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84C_ecustom--EquityAwardPolicyTextBlock_zKl6DDIRUcyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_za30GXIH31Ah">Equity
Awards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as
expense over the requisite service period. For awards to non-employees, the Company recognizes compensation expense in the same
manner as if the entity had paid cash for the goods or services. The Company incurred total annual compensation expense related to
stock-based awards of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230201__20240131__us-gaap--AwardTypeAxis__custom--EquityAwardMember_zH1uJNztuAL8" title="Compensation expense related to stock-based award">2,102,000</span>
in fiscal 2023, net of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20230201__20240131__us-gaap--AwardTypeAxis__custom--EquityAwardMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zw4aTB8Ufp58" title="Compensation expense related to stock-based award">140,000</span>
of capitalized non-employee stock compensation, and $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20220201__20230131__us-gaap--AwardTypeAxis__custom--EquityAwardMember_z74WRKZ8A4ye" title="Compensation expense related to stock-based award">1,680,000</span>
net of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20220201__20230131__us-gaap--AwardTypeAxis__custom--EquityAwardMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMZp75ifhVhj" title="Compensation expense related to stock-based award">81,000</span> of capitalized non-employee stock compensation, in fiscal 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the stock options granted are estimated at the date of grant using a Black-Scholes option pricing model. Option pricing
model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. The Company
recognizes forfeitures as they occur. These assumptions are subjective and are generally derived from external (such as, risk-free rate
of interest) and historical data (such as, volatility factor, expected term and forfeiture rates). Future grants of equity awards accounted
for as stock-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period
of future awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market
close price per share on the grant date. The Company expenses the compensation cost of these awards as the restriction period
lapses, which is typically a one- to four-year service period to the Company. In fiscal 2023 and 2022, <span id="xdx_903_ecustom--SurrenderOfStockSharesDuringPeriod_c20230201__20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztKBLwWQQkS" title="Surrender of stock, shares">190,950</span>
and <span id="xdx_90E_ecustom--SurrenderOfStockSharesDuringPeriod_c20220201__20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCzvG3cob019" title="Surrender of stock, shares">127,429</span>
shares of common stock were surrendered to the Company to satisfy tax withholding obligations totaling $<span id="xdx_901_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z9vP8EYbfCl1" title="Cost of shares for tax withholding">280,000</span>
and $<span id="xdx_908_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHWOF4tLnhYd" title="Cost of shares for tax withholding">197,000</span>,
respectively, in connection with the vesting of restricted stock awards. Shares surrendered by the restricted stock award recipients
in accordance with the applicable plan are deemed cancelled, and therefore are not available to be reissued. The Company awarded <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230201__20240131__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zn293hzastO8" title="Number shares of restricted stock">1,203,621</span>
and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220201__20230131__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zz1WS8q7RpXb" title="Number shares of restricted stock">890,731</span>
shares of restricted stock to its executive officers and directors of the Company in fiscal 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_z2Bp32guHuX7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zuOU4Xaz3zHi">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net
deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be
realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets
will not be realized. Refer to Note 7 &#8211; Income Taxes to our consolidated financial statements included in Part II, Item 8, &#8220;Financial
Statements and Supplementary Data&#8221; for further details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether
certain tax positions are more likely than not to be sustained upon examination by tax authorities. At January 31, 2024, the Company
believes it has appropriately accounted for any uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zdkEWKyw49A8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zOl7MFqG7GD1">Net
Earnings (Loss) Per Common Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company presents basic and diluted earnings per share (&#8220;EPS&#8221;) data for our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
unvested restricted stock awards are considered non-participating securities because holders are not entitled to non-forfeitable rights
to dividends or dividend equivalents during the vesting term. In accordance with ASC 260, securities are deemed not to be participating
in losses if there is no obligation to fund such losses. Diluted EPS for our common stock is computed using the treasury stock method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zSKoGeFheh9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is the calculation of the basic and diluted net loss per share of common stock:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zm55lTHK41lc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230201__20240131_zT16hi7c2tZe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220201__20230131_zYEzhQSz4uQ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Basic earnings (loss) per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperations_i01_zBDKZfLAlsh" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Loss, net of tax</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(18,697,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(11,379,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_i01_zcADVlyaHmAd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic net loss per share of common stock </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.33</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.23</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Diluted earnings (loss) per share (1):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_i01_zrjqeeC06QW2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss available to common stockholders </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,697,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,379,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_i01_zHSqEJzPzmPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Diluted net loss per share of common stock </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.33</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.23</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_zcStVat5IQg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,697,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,379,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zGLtOkhm5wdg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average shares outstanding &#8211; Basic (1)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F45_zYg8GXeSOw63" style="display: none">(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,510,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,324,858</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks_pid_z9VIeZG2nNmb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of dilutive securities - Stock options and Restricted stock (2)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F4E_z505HyUzBWob" style="display: none">(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0783">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zDqQ2pJbNI0e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average shares outstanding &#8211; Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">56,510,419</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">49,324,858</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareBasic_pid_zMA0HSp97Zkj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net loss per share of common stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zUrF65h71AU9"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zomVu3fzr7o6">(0.33</span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zaQNiVQiGZue"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zRmiwnEX7gW2">(0.23</span></span></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_F0E_zl3tpEFjuksg" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_zbOLVzSiI5j4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excludes
    the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of January 31, 2024
    and 2023, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zOkiNJqczEvk" title="Diluted earnings per share">1,970,521</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z2lI0oNs2rt9" title="Diluted earnings per share">1,848,031</span> unvested restricted shares of common stock, respectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_F01_zJ3XaglWt9Ta" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zqD6zjckRZpk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
    net loss per share excludes the effect of shares that are anti-dilutive. As of January 31, 2024, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6ObtBNkGuq3" title="Diluted earnings per share">67,500</span> outstanding stock
    options and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedSharesMember_z7x8lmNjloWl" title="Diluted earnings per share">1,970,521</span> unvested restricted shares of common stock. As of January 31, 2023, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zg2cyB4sQ6Wk" title="Diluted earnings per share">628,598</span> outstanding stock options
    and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zKuhWu16S4uk" title="Diluted earnings per share">1,848,031</span> unvested restricted shares of common stock.</span></td></tr>
  </table>
<p id="xdx_8AF_z8jXXPKpkPg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_846_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zvZi28wtxQN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zumJhOzXsvw9">Loss
Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the possibility of various loss contingencies arising in the normal course of business. We consider the likelihood of
the loss or impairment of an asset or the incurrence of a liability as well as our ability to reasonably estimate the amount of loss
in determining loss contingencies. An estimated loss contingency is accrued when it is probable that a liability has been incurred or
an asset has been impaired, and the amount of loss can be reasonably estimated. We regularly evaluate current information available to
us to determine whether to accrue for a loss contingency and adjust any previous accrual.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_zQ0wKmvymZw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zugotMys2zFf">Restructuring</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 16, 2023, the Company announced it was executing a Strategic Restructuring designed to reduce expenses while maintaining the
Company&#8217;s ability to expand its SaaS business. The Strategic Restructuring initiatives included a reduction in force, resulting
in the termination of <span id="xdx_908_ecustom--NumberOfEmployeesTerminated_iI_uInteger_c20231016_ztRLXFZsGe6k" title="Number of employees terminated">26</span> employees, or approximately <span id="xdx_90C_ecustom--PercentageOfWorkforceTerminated_iI_dp_uPure_c20231016_zCIaWNVmFlOl" title="Percentage of workforce terminated">24</span>% of the Company&#8217;s workforce. To execute the Strategic Restructuring, the
Company incurred one-time restructuring costs associated with the workforce reduction of approximately $<span id="xdx_905_eus-gaap--RestructuringCosts_c20231016__20231016_zOntCOm1uCwk" title="Restructuring costs">759,000</span>, and the Company has
recognized all expenses associated with the Strategic Restructuring as of the end of fiscal 2023. The costs pertain to severance and
other employee termination-related costs and various professional fees the Company required to assist with execution of the Strategic
Restructuring. The following is a reconciliation of the Strategic Restructuring liability reflected on the Company&#8217;s condensed
consolidated balance sheet under &#8220;Accrued expenses&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p id="xdx_89B_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_zcPd5Sclhq91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_zVUN80vYpDjh" style="display: none">SCHEDULE OF RECONCILIATION OF THE
RESTRUCTURING LIABILITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="22" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Accrued</b></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Accrued</b></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of January 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance as of January 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 Expenses to Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 Cash Payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance as of January 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Costs Incurred to Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Expected Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Severance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 34%">Cost of sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zK31whEsQUl" style="width: 8%; text-align: right" title="Accrued Balance as of January 31, 2023">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0821">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zsRfRkAAqw71" style="width: 8%; text-align: right" title="2023 Expenses to Date">154</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zcnAbrwMJzQa" style="width: 8%; text-align: right" title="2023 Cash Payments">154</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z1XWbK9im3gh" style="width: 8%; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zb2xjwlXrNb4" style="width: 8%; text-align: right" title="Total Costs Incurred to Date">154</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zFGeb8oZh734" style="width: 8%; text-align: right" title="Total Expected Costs">154</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling, general, and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zgF3AlYQNYUi" style="text-align: right" title="Accrued Balance as of January 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0833">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zFKeiNiACPD5" style="text-align: right" title="2023 Expenses to Date">350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zlGv358wxWZ9" style="text-align: right" title="2023 Cash Payments">276</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zwjns1Y39W3j" style="text-align: right" title="Accrued Balance as of October 31, 2023">74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zqiRzO1j4id2" style="text-align: right" title="Total Costs Incurred to Date">350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zm3HYOaSlDqi" style="text-align: right" title="Total Expected Costs">350</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zy3QuKboUiOk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Balance as of January 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0845">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUNiTrqAejec" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Expenses to Date">227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4NPCwihCzLj" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Cash Payments">227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zuMRQ6AL6PJf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgrKQdtRzK87" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Costs Incurred to Date">227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z7In9BvhxtD8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Expected Costs">227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total severance expense</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zcGYDLCzhqB2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of January 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zFdNqBp0GSDf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Expenses to Date">731</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zbwd77jepsYj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Cash Payments">657</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zwEck8mknhDi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023">74</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_980_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zFr7ZMv4ErYc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Costs Incurred to Date">731</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zqrWNVOuH3bk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Expected Costs">731</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Professional fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zdCAEngK0Gh6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Balance as of January 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0869">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zSWcGLNkZwgd" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Expenses to Date">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zUTCupmUPFGg" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Cash Payments">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zbnlHH6m9rwd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0875">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zsWSpXRo7Mkg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Costs Incurred to Date">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zlKYj9LQchU5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Expected Costs">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_z5PZIGP8Azf2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of January 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0881">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zyRdI1Qbma37" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Expenses to Date">759</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98A_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zMmuGj9t21Bk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Cash Payments">685</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zhqpQ87SlXH6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023">74</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zeQHXKBypUL1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Costs Incurred to Date">759</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zKbmG4cP32U4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Expected Costs">759</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zRFfSpqmEYml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z1THQ0hFrhN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zikcQEMVG2X">Accounting
Pronouncements Recently Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2019, the FASB issued ASU 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which improves guidance around accounting for financial losses on accounts receivable. For smaller reporting entities, ASU
2016-13 is effective for annual periods beginning after December 15, 2022, including interim periods within those fiscal years. The Company&#8217;s
adoption of ASU 2016-13 was effective February 1, 2023. An analysis of contract receivables, including credit losses, was conducted during
the first quarter of fiscal 2024. The adoption of this ASU did not have a material impact on our consolidated financial statements
or disclosures.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zbwSureRh1pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zZlBtIO4H9M6">Recent
Accounting Pronouncements Not Yet Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves
guidance around the disclosures about a public entity&#8217;s reportable segments and additional details about a reportable segment&#8217;s
expenses. ASU 2023-07 is effective for all public entities for annual periods beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. The Company&#8217;s adoption of ASU 2023-07 will be effective in the annual report
for the fiscal year ending January 31, 2025. The adoption of this ASU is not expected to have a material impact on our consolidated financial
statements or disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhance the transparency
and decision usefulness of income tax disclosures. For public entities, ASU 2023-09 is effective for annual periods beginning after December
15, 2024. The adoption of this ASU is not expected to have a material impact on our consolidated financial statements or disclosures.</span></p>

<p id="xdx_859_zOFzDldd3uXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961595472096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS COMBINATION</a></td>
<td class="text"><p id="xdx_808_eus-gaap--BusinessCombinationDisclosureTextBlock_z0GiYrjXb3kk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
3 &#8212; <span id="xdx_821_zTDtu1VIstu2">BUSINESS COMBINATION </span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Avelead
Acquisition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acquired all of the equity interests of Avelead as part of the Company&#8217;s strategic expansion into the revenue cycle management,
acute-care healthcare space (the &#8220;Transaction&#8221;). The Transaction was completed on August 16, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate consideration for the purchase of Avelead was approximately $<span id="xdx_903_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zljhiLyQsGWi">29.7</span> million (at fair value) consisting of (i) $<span id="xdx_90D_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn5n6_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zFrLiyTqrCN3">12.5</span> million in
cash, net of cash acquired, (ii) $<span id="xdx_907_eus-gaap--BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_iI_pn5n6_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zBuvZghmG4Pl">6.5</span> million in common stock, and (iii) approximately $<span id="xdx_90A_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn5n6_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_z9jKYmQFYSdc">10.7</span> million in contingent consideration (see
below). The Company issued <span id="xdx_90D_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardTypeAxis__custom--AcquisitionRestrictedCommonStockMember_zJlIzxzGJ0si">5,021,972</span> shares of its restricted common stock (the &#8220;Acquisition Restricted Common Stock&#8221;). The
Acquisition Restricted Common Stock had a fair value as of the closing date of the acquisition of $<span id="xdx_90A_ecustom--BusinessAcquisitionEquityInterestIssuedFairValue_iI_pn5n6_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardTypeAxis__custom--AcquisitionRestrictedCommonStockMember_zDCi3oV8pN2c">6.5</span> million. <span id="xdx_908_eus-gaap--BusinessCombinationContingentConsiderationArrangementsDescription_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardTypeAxis__custom--AcquisitionRestrictedCommonStockMember_ztVzzWeVUgTj" title="Business combination description">Additionally, the Transaction
included two types of contingent consideration; the first is referred to herein as &#8220;SaaS Contingent Consideration&#8221; and the
second is referred to herein as &#8220;Renewal Contingent Consideration.&#8221; The SaaS Contingent Consideration and Renewal Contingent
Consideration had an aggregate value of approximately $10.7 million as of the date of closing.</span> The owners of Avelead are also referred
to herein as &#8220;Sellers&#8221; and are enumerated in the UPA (as defined below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Unit Purchase Agreement (hereafter referred to as the &#8220;UPA&#8221;), stated that the purchase price for Avelead at closing included
a cash payment of $<span id="xdx_905_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn5n6_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zuopL5akMCN6">11.9
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. Additionally, the Company paid $<span id="xdx_90D_ecustom--PaymentsToAcquireBusinessesSellerExpenses_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zmRCUNKv4She">285,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the Sellers&#8217; closing costs, $<span id="xdx_90F_ecustom--PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_z6dF7hfxdaDi">285,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">related to the working capital adjustment as
defined in the UPA. Finally, at closing, the Company issued the Acquisition Restricted Common Stock with a fair value of approximately
$<span id="xdx_90A_ecustom--BusinessAcquisitionEquityInterestIssuedFairValue_iI_pn5n6_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardTypeAxis__custom--AcquisitionRestrictedCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zbQyiyN8LFj1">6.5
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, based on a 30-day average of the closing
price of the Company&#8217;s common stock prior to the closing date. The SaaS Contingent Consideration and the Renewal Contingent Consideration
described in more detail below were included in the UPA as potential future consideration for the Transaction. These are reflected on
the Company&#8217;s consolidated balance sheet as &#8220;Acquisition earnout liability.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
contingent consideration is comprised of &#8220;SaaS Contingent Consideration&#8221; and &#8220;Renewal Contingent Consideration&#8221;
which are described in more detail as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    SaaS Contingent Consideration is calculated based upon Avelead&#8217;s recurring SaaS revenue recognized during the first and second
    year following the closing of the Transaction. The Company will pay the SaaS Contingent Consideration as follows: (i) <span id="xdx_90A_ecustom--PaymentOfSaasContingentConsiderationInCashPercentage_iI_pid_dp_uPure_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zMOz2yXFDH6k" title="Payment of SaaS contingent consideration in cash, percentage">50</span>% in cash
    and (ii) <span id="xdx_90C_ecustom--PaymentOfSaasContingentConsiderationInSharesPercentage_iI_pid_dp_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_z3Wg896PKv6h" title="Payment of SaaS contingent consideration in cash, percentage">50</span>% in shares of Company common stock valued at the time the earnout is paid subject to a collar, as described below.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 74.2pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--FirstYearPaymentOfSaasContingentConsiderationDescription_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_z3WMjwobknx" title="First year payment of SaaS contingent consideration, description">The
    first year SaaS Contingent Consideration was calculated as 75% of Avelead&#8217;s recognized SaaS revenue from September 1, 2021
    to August 31, 2022. The first-year payment was subject to a deduction of $665,000 spread equally between the cash and common stock
    portion of the earnout consideration. Assuming that Avelead was within 80% of its forecasted SaaS revenue in the first year earnout,
    the Company agreed to a floor and ceiling on the value of the Company&#8217;s restricted common stock issued as consideration for
    the earnout. That collar had a floor of $3.50 per share and a ceiling of $5.50 per share for the first year earnout. The first year
    SaaS Contingent Consideration was paid on November 21, 2022, as discussed in more detail below.</span> </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--SecondYearPaymentOfSaasContingentConsiderationDescription_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zYuX1Amlmfv3" title="Second year payment of SaaS contingent consideration, description">The
    second year SaaS Contingent Consideration was calculated as 40% of Avelead&#8217;s recognized SaaS revenue from September 1, 2022
    to August 31, 2023. Assuming that Avelead was within 80% of its forecasted SaaS revenue in the second year earnout, the Company agreed
    to a floor and ceiling on the Company&#8217;s restricted common stock issued as consideration for the earnout. That collar had a
    floor of $4.50 per share and a ceiling of $6.50 per share for the second year earnout. The second year SaaS Contingent Consideration
    remained outstanding as of January 31, 2024, as the Company and the Sellers work towards a resolution regarding the payment of the
    second year SaaS Contingent Consideration. </span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_90A_ecustom--ForecastedRevenueDescription_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zPpBj5hYLXzf" title="Forecasted revenue description">If
    Avelead does not achieve 80% of its forecasted revenue, the price per share will revert back to the Company&#8217;s market price
    based upon a 30-day average.</span></i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 74.2pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
    &#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--RenewalContingentConsiderationDescription_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_z9OYtmiVY2qe" title="Renewal contingent consideration, description">The
    Renewal Contingent Consideration was tied directly to a successful renewal of a specific client of Avelead. To meet the definition
    of a renewal, Avelead was required to achieve a minimum threshold of contracted revenue in an updated, annual, renewed contract with
    the specified client. The renewal occurred on or about June 1, 2022 and June 1, 2023. The Renewal Contingent Consideration was payable
    in shares of Company restricted common stock valued as of the date of closing. The Renewal Contingent Consideration is either earned
    or not earned based upon the renewal of the specified client at the minimum amount of contracted revenue. There is no pro-ration
    of the underlying Renewal Contingent Consideration. On November 21, 2022, the Company issued 627,746 shares of restricted common
    stock to the Sellers in connection with the first year Renewal Contingent Consideration. The second year Renewal Contingent Consideration
    remained outstanding as of January 31, 2024, as the Company and the Sellers work towards a resolution regarding the payment of the
    second year Renewal Contingent Consideration.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2022, the Company made the first year earnout payments and issued shares of restricted common stock to the Sellers in accordance
with the UPA. In connection with the first year earnout payment, the Company made an aggregate cash payment of $<span id="xdx_909_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_c20221120__20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardDateAxis__custom--FirstYearEarnoutMember_z49niAWMqlBg" title="Business combination, cash payments">2,012,000</span> and issued
<span id="xdx_908_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20221120__20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardDateAxis__custom--FirstYearEarnoutMember_zzRDn1IGFC2f" title="Business acquisition, equity interest issued or issuable, number of shares">1,243,292</span> unregistered securities in the form of restricted common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--AwardDateAxis__custom--FirstYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_z1a40Gt4ZmPi" title="Common stock par or stated value per share">0.01</span> per share (&#8220;restricted common stock&#8221;),
for the SaaS Contingent Consideration and issued <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20221120__20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--RenewalContingentConsiderationMember__us-gaap--AwardDateAxis__custom--FirstYearEarnoutMember_zNYU9YI7nPt7" title="Sale of stock number of shares issued in transaction">627,746</span> shares of restricted common stock for the Renewal Contingent Consideration.
The estimated aggregate value of the first year earnout payment was $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20221120__20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--AwardDateAxis__custom--FirstYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zn6xY44bmVrg" title="Sale of stock consideration">4,000,000</span> with respect to the SaaS Contingent Consideration and
$<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20221120__20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--RenewalContingentConsiderationMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zRvUhSxrupE5" title="Sale of stock">1,000,000</span> with respect to the Renewal Contingent Consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 31, 2024, the Company has not made the second year earnout payments to the Sellers or issued shares of common stock in connection
therewith. In connection with the second year earnout payment, the Company has estimated cash payments of $<span id="xdx_901_eus-gaap--PaymentsToAcquireBusinessesGross_c20230201__20240131__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zrG109Fkx30a">1,214,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and will issue <span id="xdx_90B_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20230201__20240131__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_z1Xaz1O44iii">961,640
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of restricted common stock for the SaaS
Contingent Consideration and <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230201__20240131__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zP9G4OCg78r9">627,746
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of restricted common stock for the Renewal
Contingent Consideration. The estimated aggregate value of the second year earnout payment is $<span id="xdx_907_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_c20240131__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_za2lbhNYsX3g">1,550,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the SaaS Contingent Consideration and $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230201__20240131__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember_zs5shzbs4PK8">244,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the Renewal Contingent Consideration. The
Company and the Sellers reached an agreement to defer the cash portion of the SaaS Contingent Consideration and Renewal Contingent Consideration
payments over time through October 31, 2024. On March 27, 2024, the Company issued <span id="xdx_900_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240326__20240327__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zOJJ8hYvl6qa">961,640
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of restricted common stock to the Sellers
for the SaaS Contingent Consideration and <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240326__20240327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zzXxlfFPzjM3">627,746
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of restricted common stock for the Renewal
Contingent Consideration. These liabilities are reflected at the fair value of the future commitment on the Company&#8217;s consolidated
balance sheet, as Acquisition Earnout Liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement and a separation agreement with each of the two Sellers. Acquisition-related costs
include the cost of a two-year separation agreement with one of the Sellers. The separation agreement was expensed at the closing of
the transaction as there were no material future obligations of the Seller to the Company within acquisition-related costs. The
employment agreement with the other Seller had a two-year term and entitled the Seller to six-months separation pay in the event of
termination without cause. The expense for the employment agreement is recognized ratably over the service period customary with
other employment agreements within selling, general, and administrative expense. On September 1, 2023, the Company terminated
the employment agreement. In exchange for a general release from the Seller, the Company agreed to accelerate the vesting of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230901__20230901__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zTzrifl80XDi">150,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">outstanding
and unvested shares of restricted common stock of the Company previously granted to the Seller, subject to such Seller&#8217;s
non-revocation of a general release of claims against the Company.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961595628880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--LesseeOperatingLeasesTextBlock_zZ6L7M7dB6D5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
4 &#8212; <span id="xdx_829_zORiPJxz1Ht5">OPERATING LEASES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine whether an arrangement is a lease at inception. Right-of-use assets represent our right to use an underlying asset for the
lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use
assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term.
Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate for the expected remaining lease
term at commencement date for new and existing leases in determining the present value of future lease payments. Operating lease expense
is recognized on a straight-line basis over the lease term. The Company has moved to a virtual office model and does not have a physical
office space. Membership agreements and daily space rentals are leveraged by the Company when groups need to meet in person with the
costs expensed as incurred. As of January 31, 2024, the Company recorded $<span id="xdx_90D_eus-gaap--RentalProperties_iI_c20240131_z2mmkkD3VD8g" title="Related to space rental">30,000</span> related to such space
rentals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Alpharetta
Office Lease</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The Company entered into a lease
for office space in Alpharetta, Georgia, on March 1, 2020. The lease expired on March 31, 2023. At inception, the Company recorded a right-of
use asset of $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20211031_zuP0bsIHz5Kc">540,000</span>, and related current and long-term operating lease obligation in the accompanying consolidated balance sheet. As
of January 31, 2023, operating lease right-of use assets totaled $<span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20230131_zMQCNrdm2jBk">32,000</span>, and the associated lease liability of $<span id="xdx_903_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20230131_z1GAL0ABNyY8">35,000</span> is included in
current liabilities. The Company used a discount rate of <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20230131_zeDFLRWvNKX6">6.5</span>% to determine the lease liability. As of January 31, 2024 and 2023, the Company
had lease operating costs of approximately $<span id="xdx_90C_eus-gaap--OperatingLeaseCost_c20230201__20240131_zXRatNaUCtw2">32,000</span> and $<span id="xdx_908_eus-gaap--OperatingLeaseCost_c20220201__20230131_zLKYqNB83osg">194,000</span>, respectively. The Company paid cash of approximately $<span id="xdx_908_eus-gaap--OperatingLeasePayments_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--AlpharettaOfficeLeaseMember_zQK5b0xMCyhk">36,000</span> and $<span id="xdx_901_eus-gaap--OperatingLeasePayments_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--AlpharettaOfficeLeaseMember_z6126frP7vGg">210,000</span>
for the lease in fiscal 2023 and fiscal 2022, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2021, the Company entered into an agreement with a third-party to sublease its office space in Alpharetta, Georgia, (the
&#8220;Sublease Agreement&#8221;). The sublease term is for <span id="xdx_901_ecustom--SubleaseTerm_dtM_c20210929__20211002__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember_z3Hdl6GBoTVc" title="Sublease, term">18</span>
months which coincides with the Company&#8217;s underlying lease (see below). The Company received $<span id="xdx_90E_eus-gaap--SubleaseIncome_c20210929__20211002__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember_zp86tu3avmI2" title="Sublease income">292,000</span>
from the sublessee over the term of the sublease. The sublease did not relieve the Company of its original obligation under the
lease, and therefore the Company did not adjust the operating lease right-of-use asset and related liability. The Company incurred
an amount of fees and expenses to enter into the Sublease Agreement that were recorded as &#8220;acquisition-related costs&#8221;
for fiscal 2021. As of January 31, 2024, the Company recorded $<span id="xdx_90D_eus-gaap--OtherIncome_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember_z2p1ft3suaAh" title="Other income related to sublease">33,000</span>
as other income related to the sublease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Suwanee
Office Lease</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
acquiring Avelead on August 16, 2021 (refer to Note 3 &#8211; Business Combination), the Company assumed an operating
lease agreement for the corporate office space of Avelead. The 36-month term lease commenced March 1, 2019, and initially expired on
<span id="xdx_905_eus-gaap--LeaseExpirationDate1_dd_c20210814__20210816__us-gaap--TypeOfArrangementAxis__custom--SuwaneeOfficeLeaseMember_zHbO3yR6pZM3" title="Lease expiration date">February 28, 2022</span>. As of January 31, 2024, the Company recorded $<span id="xdx_90B_eus-gaap--PaymentsForRent_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SuwaneeOfficeLeaseMember_z71DgwKydOKh" title="Payments for rent">6,000</span> in rent expense. The lessor is an entity controlled by one of
the Sellers that was employed by the Company until August 2023. In February 2022, the Company renewed the lease for twelve months. The
Company made monthly lease payments of $<span id="xdx_90D_eus-gaap--OperatingLeasePayments_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SuwaneeOfficeLeaseMember_zhqUe2Q07mXj" title="Operating lease, payments">5,999</span> for a total of $<span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_c20230228__us-gaap--TypeOfArrangementAxis__custom--SuwaneeOfficeLeaseMember_zXDQKxe118l" title="Operating lease">71,984</span> over the term of the lease. The lease expired on February 28, 2023,
and was not renewed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961598198528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zsxCJkOLdqxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
5 &#8212; <span id="xdx_829_zYHz7clzYlC3">DEBT</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfDebtTableTextBlock_zZTqivM7mC6l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
principal balances on debt consisted of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zIytIO7PNH0l" style="display: none">SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240131_zacxl86TTnN4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230131_zRpV9I2nBiVh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzuRq_zw3eOnhiWl2h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Term loan</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">9,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">9,750,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinancingCostPayable_iI_maLTDzuRq_z5rOfXEcrXl2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><p style="margin: 0">Financing cost payable</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">135,000</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredFinancingCost_iNI_di_msLTDzuRq_zd3Zcy02MIQ6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Deferred financing cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(69,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(105,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--LongTermDebt_iTI_mtLTDzuRq_z56OAhOzgq42" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,066,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,714,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LongTermDebtCurrent_iNI_di_zWlNIc4uEZT1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: Current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(750,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iTI_zvHBV6E31KO2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Non-current portion of debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,566,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,964,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zlautnZKsq8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Term
Loan Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 26, 2021, the Company and its subsidiaries entered into the Loan Agreement with WAB. Pursuant
to the Loan Agreement, WAB agreed to provide the Company and its subsidiaries with a term loan facility in the maximum principal amount
of $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--WesternAllianceBankMember_zolzc6KMxtG3" title="Line of credit facility, maximum borrowing capacity">10,000,000</span>. Amounts outstanding under the term loan portion of the Loan Agreement bear interest at a per annum rate equal to the
Prime Rate (as published in The Wall Street Journal) plus <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20210826__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zvnjpTPQ0A9e" title="Debt instrument, interest rate, effective percentage">1.5</span>%, with a Prime &#8220;floor&#8221; rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210826__us-gaap--VariableRateAxis__us-gaap--BaseRateMember_zmoy6yfsNuyj" title="Debt instrument, interest rate, stated percentage">3.25</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement has a five-year term, and the maximum principal amount was advanced in a single-cash advance on or about the closing date.
Interest accrued under the Loan Agreement is due monthly, and the Company is required to make monthly interest-only payments through
the one-year anniversary of the closing date. From the first anniversary of the closing date through the maturity date, the Company is
required to make monthly payments of principal and interest that increase over the term of the agreement. The Loan Agreement requires
principal repayments on the anniversary date of the closing of the debt agreement of $<span id="xdx_906_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--WesternAllianceBankMember_zMv6ZNbCxWF2" title="Long term debt, maturity, year two">500,000</span> in the second year, $<span id="xdx_902_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--WesternAllianceBankMember_zWlDZJVGh1af" title="Long term debt, maturity, year three">1,000,000</span> in the third
year, $<span id="xdx_90D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--WesternAllianceBankMember_zG9kAWnzotu2" title="Long term debt, maturity, year four">2,000,000</span> in the fourth year, and $<span id="xdx_90A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--BridgeBankMember_zQPu2yxZHzmh" title="Long term debt, maturity, year five">3,000,000</span> in the fifth year, respectively, with the remaining outstanding principal balance
and all accrued but unpaid interest due in full on the maturity date. The Loan Agreement may also require early repayments if certain
conditions are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded $<span id="xdx_908_eus-gaap--DeferredOfferingCosts_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zfFHRTnmpuu" title="Deferred offering costs">130,000</span> in deferred financing costs related to the Loan Agreement. These deferred financing costs are being amortized
over the term of the loan. The Company will also incur $<span id="xdx_90A_eus-gaap--AmortizationOfFinancingCosts_c20210825__20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zVZ9UOeEzA46" title="Amortization of debt issuance costs">200,000</span> in financing costs at the earlier of the term date of the loan, or pre-payment.
These costs are being accreted, through interest expense, to the full value of the $<span id="xdx_902_eus-gaap--AccretionExpense_c20210825__20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z8xJYZF8FsI5" title="Accretion expense">200,000</span> over the term of the loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Debt
Modification and Revolving Line of Credit</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 29, 2022, the Company executed the Second Modification (the &#8220;Second Modification&#8221;) to the Second Amended and Restated
Loan and Security Agreement (as amended and modified, the &#8220;Loan Agreement&#8221;). The Second Modification expanded the Company&#8217;s
total borrowing to include a $<span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zbZxdumpgfDb" title="Line of credit facility, maximum borrowing capacity">2,000,000</span> revolving line of credit. The revolving line of credit is co-terminus with the term loan and
matures on <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zzY8SicthUyk" title="Line of credit facility, matures">August 26, 2026</span>. There are no requirements to draw on the line of credit. Amounts outstanding under the line of credit portion
of the Loan Agreement bear interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20221129__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_z1sKUFS2jD6h" title="Debt instrument, interest rate, effective percentage">1.5</span>%,
with a Prime &#8220;floor&#8221; rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20221129__us-gaap--VariableRateAxis__us-gaap--BaseRateMember__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zTdGrQuN08lk" title="Debt instrument, interest rate, effective percentage">3.25</span>%. The Second Modification also amended the covenants of the Company under the Loan Agreement.
At January 31, 2024, there was a $<span id="xdx_90C_eus-gaap--LongTermLineOfCredit_iI_c20240131_zVOo7cyBolKa" title="Line of credit">1,500,000</span> balance outstanding on the revolving line of credit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Second Modification includes customary financial covenants as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Minimum
    Cash. </b><span id="xdx_902_eus-gaap--DebtInstrumentCovenantDescription_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zAi2y4nfay61" title="Debt financial covenants, description">Borrowers shall, at all times, maintain unrestricted cash in an amount not less than Two Million Dollars ($2,000,000).</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
    Debt to ARR Ratio. </b>Borrowers&#8217; Maximum Debt to ARR Ratio, measured on a quarterly basis as of the last day of each fiscal
    quarter, shall not be greater than the amount set forth under the heading &#8220;Maximum Debt to ARR Ratio&#8221; as of, and for
    each of the dates appearing adjacent to such &#8220;Maximum Debt to ARR Ratio&#8221;.</span></td></tr>
  </table>
<p id="xdx_89C_ecustom--ScheduleOfMaximumDebtToARRRatioTableTextBlock_zFsyON9BqLI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z3IDq1bf3Ssi" style="display: none">SCHEDULE OF MAXIMUM DEBT TO ARR RATIO</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 82%; font-weight: bold">Quarter Ending</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum Debt to</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARR Ratio</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>October 31, 2022</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyTwoMember__srt--RangeAxis__srt--MinimumMember_zkYZyp1qcArk" title="Maximum Debt to ARR Ratio">0.80</span> to <span id="xdx_90A_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyTwoMember__srt--RangeAxis__srt--MaximumMember_zS6lLRAspk34" title="Maximum Debt to ARR Ratio">1.00</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>January 31, 2023</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_z0nfek6Cs6Mk" title="Maximum Debt to ARR Ratio">0.70</span> to <span id="xdx_90B_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_zGxFFbwbwcJf" title="Maximum Debt to ARR Ratio">1.00</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>April 30, 2023</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_zjdTm3Km4f02" title="Maximum Debt to ARR Ratio">0.65</span> to <span id="xdx_90B_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_z5yhyJiREnbi" title="Maximum Debt to ARR Ratio">1.00</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>July 31, 2023</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_zlDVmHjdrCC9" title="Maximum Debt to ARR Ratio">0.60</span> to <span id="xdx_908_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_zIU2Q1CZLso3" title="Maximum Debt to ARR Ratio">1.00</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>October 31, 2023</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_z2V2Wox2jlPh" title="Maximum Debt to ARR Ratio">0.55</span> to <span id="xdx_90B_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_zjZmiRMW8Ztd" title="Maximum Debt to ARR Ratio">1.00</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>January 31, 2024</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyFourMember__srt--RangeAxis__srt--MinimumMember_zBWwJwWdAdPd" title="Maximum Debt to ARR Ratio">0.50</span> to <span id="xdx_90A_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyFourMember__srt--RangeAxis__srt--MaximumMember_zMtLsRQmtJC4" title="Maximum Debt to ARR Ratio">1.00</span></td></tr>
  </table>

<p id="xdx_8AA_zHzogOIpf796" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
    Debt to Adjusted EBITDA Ratio. </b>Commencing with the quarter ending April 30, 2024, Borrowers&#8217; Maximum Debt to Adjusted EBITDA
    Ratio, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4) quarter period then ended,
    shall not be greater than the amount set forth under the heading &#8220;Maximum Debt to Adjusted EBITDA Ratio&#8221; as of, and for
    each of the dates appearing adjacent to such &#8220;Maximum Debt to Adjusted EBITDA Ratio&#8221;.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p id="xdx_897_ecustom--ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock_z2gxz2BthnRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z751i3gbxyBb" style="display: none">SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 82%; font-weight: bold">Quarter Ending</td><td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center">Maximum Debt to <br/> Adjusted EBITDA <br/> Ratio</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>April 30, 2024</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFourMember__srt--RangeAxis__srt--MaximumMember_zkR455tskqui" title="Maximum Debt to Adjusted EBITDA Ratio">3.50</span> to <span id="xdx_906_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFourMember__srt--RangeAxis__srt--MinimumMember_zoRTWmnmgy78" title="Maximum Debt to Adjusted EBITDA Ratio">1.00</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">July 31, 2024 and on the last day of each quarter, thereafter</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFourAndThereafterMember__srt--RangeAxis__srt--MaximumMember_zNn7v3KAhd88" title="Maximum Debt to Adjusted EBITDA Ratio">2.00</span> to <span id="xdx_908_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFourAndThereafterMember__srt--RangeAxis__srt--MinimumMember_zVr7Scg6blh1" title="Maximum Debt to Adjusted EBITDA Ratio">1.00</span></td></tr>
  </table>

<p id="xdx_8AE_ziSMZYVA39b1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed
    Charge Coverage Ratio</b>. Commencing with the quarter ending April 30, 2024, Borrowers shall maintain a Fixed Charge Coverage Ratio
    of not less than <span id="xdx_90E_ecustom--FixedChargeCoverageRatio_iI_pid_dp_uPure_c20240131__us-gaap--TypeOfArrangementAxis__custom--SecondAmendedAndRestatedLoanAgreementMember__srt--RangeAxis__srt--MaximumMember_zstQE2rV7Vya" title="Fixed charge coverage ratio">1.20</span> to <span id="xdx_90B_ecustom--FixedChargeCoverageRatio_iI_pid_dp_uPure_c20240131__us-gaap--TypeOfArrangementAxis__custom--SecondAmendedAndRestatedLoanAgreementMember__srt--RangeAxis__srt--MinimumMember_ze42ulTljAX2" title="Fixed charge coverage ratio">1.00</span>, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4)
    quarter period then ended.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement also includes customary negative covenants, subject to exceptions, which limit transfers, capital expenditures, indebtedness,
certain liens, investments, acquisitions, dispositions of assets, restricted payments, and the business activities of the Company, as
well as customary representations and warranties, affirmative covenants and events of default, including cross defaults and a change
of control default. The line of credit also is subject to customary prepayment requirements. For the period ended January 31, 2024, the
Company was not in compliance with the Maximum Debt to ARR Ratio covenant pursuant to the Second Modification; however, on February 7,
2024, the Company was provided a waiver exception for being non-compliant. (Refer to Note 14 &#8211; Subsequent to our consolidated financial
statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; for additional information.). Substantially
all the assets of the Company are collateralized by the Loan Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded $<span id="xdx_903_eus-gaap--DeferredOfferingCosts_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_ztfOiIrVBthh" title="Deferred offering costs">20,000</span> in deferred financing costs related to the Second Modification. These deferred financing costs are being amortized
over the remaining term of the loan. The Company also incurred $<span id="xdx_90F_eus-gaap--AmortizationOfFinancingCosts_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zdXe0A0VdW5k" title="Amortization of debt issuance costs">50,000</span> in financing costs at the earlier of the term date of the loan,
or pre-payment. These costs are being accreted, through interest expense, to the full value of the $<span id="xdx_902_eus-gaap--AccretionExpense_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zYaSLtehLtff" title="Accretion expense">250,000</span> over the remaining term of
the loan. The full value of $<span id="xdx_903_eus-gaap--AccretionExpense_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zeeRIhZKuXXh" title="Accretion expense">250,000</span> includes the $<span id="xdx_906_eus-gaap--AmortizationOfFinancingCosts_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zvowiqlzqXJ4" title="Amortization of debt issuance costs">200,000</span> costs incurred in connection with the Loan Agreement (see below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 7, 2024, the Company executed the Third Modification and Waiver (the &#8220;Third Modification&#8221;) to the Loan Agreement.
Refer to Note 14 &#8211; Subsequent Events to our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements
and Supplementary Data&#8221; for additional information regarding the Third Modification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961595562464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_803_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zwOGYfPl1Qci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
6 &#8212; <span id="xdx_82D_zUp5YMYXKat6">GOODWILL AND INTANGIBLE ASSETS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Goodwill</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zZardVLaIU58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
changes in the carrying amount of goodwill were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zxZmo1Gj5IRe" style="display: none">SCHEDULE OF CARRYING AMOUNT OF GOODWILL</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; font-weight: bold">Balance as of January 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Goodwill_iS_c20230201__20240131_zlxNipDbwq9l" style="width: 18%; text-align: right" title="Beginning Balance">23,089,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--GoodwillImpairmentLoss_iN_di_c20230201__20240131_zyFcjkFtMFB7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment">(9,813,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance as of January 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--Goodwill_iE_c20230201__20240131_zsZz6nlQnf98" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">13,276,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_z27e2JlM9LW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, the Company was notified by a legacy client of its intent to not renew its contract as of its expiration on December 31,
2023. At that time, the Company elected to accelerate the execution of a planned strategic restructuring that was designed to reduce
costs while maintaining the Company&#8217;s ability to expand its SaaS business. Both the client termination and the execution of the
strategic restructuring were announced on October 16, 2023. Following these announcements, the Company&#8217;s share price declined significantly.
Based on these events (collectively, the &#8220;Triggering Events&#8221;), the Company identified indicators of possible impairment and
initiated testing using a valuation date of October 31, 2023. The impairment tests were conducted under guidance of ASC Topic 360, Impairment
and Disposal of Long-Lived Assets (&#8220;ASC 360&#8221;) for certain long-lived assets, including capitalized contract costs, developed
technology, client relationships and trade names, and in accordance with ASC Topic 350, Intangibles &#8211; Goodwill and Other (&#8220;ASC
350&#8221;) with respect to the reporting unit&#8217;s goodwill.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that, effective January 31, 2023, it had one reporting unit for purposes of evaluation of goodwill. Based on the Triggering
Events and in conjunction with the preparation of the Company&#8217;s financial statements for the three and nine months ended October
31, 2023, the Company tested the reporting unit&#8217;s goodwill for possible impairment as of October 31, 2023. The testing for impairment
was performed under the guidance of ASC 350. The testing utilized a discounted debt-free net cash flow (&#8220;DCF&#8221;) method under
the income approach and the market capitalization method (&#8220;MCM&#8221;) under the market approach. The sum of the weighted values
of each method was used to derive the fair value of the Company&#8217;s equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MCM calculates the aggregate market value of the Company based on the total number of shares outstanding and the current market price
of the shares as of the valuation date. Data on similar mergers and acquisitions within the healthcare technology sector are observed
to determine control premium that represents a stock premium percentage offered by an acquirer to a public company. The control premium
applied to the aggregate market value represents MCM calculated fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DCF incorporates the use of projected financial information and a discount rate using a weighted average cost of capital with cost of
equity estimated based on the capital asset pricing model. The cash-flow projections are based on financial forecasts developed by management
that include forecasts of future operating results based on internal budgets and strategic plans to invest in working capital to support
anticipated revenue growth. External factors and business conditions are considered by management when setting the long-term growth rates.
The selected discount rate considers the risk and nature of the reporting unit&#8217;s cash flows and the rates of return market participants
would require to invest their capital in the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company concluded that its goodwill was impaired based on the weighted combination of the DCF and MCM value estimates which resulted
in a calculated fair value lower than the equity carrying value. The Company recorded an impairment of goodwill in the amount of $<span id="xdx_902_eus-gaap--GoodwillImpairmentLoss_c20230201__20240131_zr3YIcIRhfe6" title="Iimpairment of goodwill">9,813,000</span>
reported as &#8220;Goodwill Impairment&#8221; on its condensed consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z0tKhaXfP2ba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zCWJo3lKiO31" style="display: none">SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Estimated</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Useful Life</p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gross</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Assets</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Accumulated</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Amortization</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finite-lived assets:</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 32%; text-align: left">Client relationships</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zrAtJp1Pwu99">10
</span>years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zPJhIoUfjtKd" style="width: 14%; text-align: right">8,370,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zw0aySaIuQo2" style="width: 14%; text-align: right">2,058,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zbvzIg2SW02k" style="width: 14%; text-align: right">6,312,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Internally developed software</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zj9hTXL9sRC9" title="Estimated Useful Life">9</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zuZLW7E0x7p1" style="text-align: right">6,380,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zWvK68GGiqZ1" style="text-align: right">1,742,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zbgqaPz0jdNk" style="text-align: right">4,638,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Trademarks and tradenames</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zolfD7Xprw4j" title="Estimated Useful Life">15</span> years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zhhRANoQzo49" style="border-bottom: Black 1.5pt solid; text-align: right">1,340,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zgxDtPUtCJSj" style="border-bottom: Black 1.5pt solid; text-align: right">219,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zMOvLqsAVzh5" style="border-bottom: Black 1.5pt solid; text-align: right">1,121,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131_z1OkRfogUgF1" style="border-bottom: Black 2.5pt double; text-align: right">16,090,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131_zLFdb3M5fFda" style="border-bottom: Black 2.5pt double; text-align: right">4,019,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131_zcTyDDCzHyGg" style="border-bottom: Black 2.5pt double; text-align: right">12,071,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2023</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Estimated</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Gross</b></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finite-lived assets:</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 42%; text-align: left">Client relationships</td><td style="width: 2%">&#160;</td>
    <td style="width: 11%; text-align: right"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zV1i0JE3VEpk" title="Estimated Useful Life">8</span>-<span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember__srt--RangeAxis__srt--MaximumMember_z8hVTU3RojKg" title="Estimated Useful Life">10</span> years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zzoDVtEV274l" style="width: 11%; text-align: right" title="Gross Assets">9,700,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zCK2Hn9NRNKd" style="width: 11%; text-align: right" title="Accumulated Amortization">1,463,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zBouebbLJZMb" style="width: 11%; text-align: right" title="Net Assets">8,237,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Internally Developed Software</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zeeptGzkGeei" title="Estimated Useful Life">9</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_z0VNmctoNHRb" style="text-align: right" title="Gross Assets">6,380,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zQoRviMMpna8" style="text-align: right" title="Accumulated Amortization">1,034,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zFptHsuDx831" style="text-align: right" title="Net Assets">5,346,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Trademarks and Tradenames</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zXxhFr1tiWyg" title="Estimated Useful Life">15</span> years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zeu2D5Iz8Rm1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Assets">1,340,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zJTw8PcWAA04" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Amortization">130,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zXmjGzLczgw6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Assets">1,210,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131_zYwcI85UHPe2" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Assets">17,420,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131_z1I7dKke1HEa" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization">2,627,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131_zKr0y3GhpsI3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Assets">14,793,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zRgg54n2w0Ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
360 defines a multi-step process to test long-lived assets, including intangible assets, for recoverability that if failed would indicate
impairment. First, the Company must consider whether indicators of impairment of long-lived assets are present, which the Company determined
the Triggering Events provided such indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Next,
the Company must review the long-lived assets to define asset group(s) that would reflect the lowest level of assets to which discrete
cash flows are identifiable. In performing this review, the Company identified that the long-lived asset &#8220;client relationships&#8221;
related to Avelead should be classified as abandoned (the &#8220;Abandoned Asset&#8221;) with the Company determining that it no longer
has plans to provide the corresponding consulting service. The Abandoned Asset&#8217;s carrying value would need to be set to its salvage
value which would be zero given no future cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined the lowest level of discrete cash flows is at the reporting unit level, and all remaining long-lived assets (excluding
the Abandoned Asset) and goodwill would represent its only asset group. Recoverability is assessed by comparing that the sum of the discrete
undiscounted cash flows exceeds the carrying value of the asset group. The undiscounted cash flow projections are based on 8-year (representing
the useful life of the primary asset in the asset group) financial forecasts developed by management that include forecasts of future
operating results based on internal budgets and strategic plans to investment in working capital to support anticipated revenue growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undiscounted cash flows for the long-lived assets were above the carrying amounts indicating that the long-lived asset group is recoverable
and no further impairment to long-lived assets exists as of October 31, 2023. In fiscal 2023, the Company recorded $<span id="xdx_900_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_c20230201__20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z4d3XJczvN0k" title="Impairment of intangible assets">963,000</span> as &#8220;Impairment
of long-lived assets&#8221; on its condensed consolidated statement of operations to adjust the Abandoned Asset to its salvage value
of zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized amortization expense on intangible assets of $<span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230201__20240131_zeHV6Fia2Wl1" title="Amortization expense on intangible assets">1,760,000</span> and $<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220201__20230131_z6qmN26wFBeb" title="Amortization expense on intangible assets">1,971,000</span> for fiscal 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z3WsMyjAmgHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
over the next five fiscal years for intangible assets is estimated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zheQPGRews7k" style="display: none">SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20240131_z3oLC4PSdK9f" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Annual</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Amortization Expense</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_pp0p0_maFLIANzAN0_zTk48zW7E1g2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 24%; text-align: right">1,635,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_maFLIANzAN0_zzQpMrORtxil" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,635,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_maFLIANzAN0_zwCQrZv3s3Y5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,635,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_maFLIANzAN0_zaXNcPo0IcJ" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,635,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_maFLIANzAN0_zDyuNEpyY9lj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,635,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_maFLIANzAN0_zveLcOWCT879" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,896,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzAN0_zi4Bbf2nuCsl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,071,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8A3_zdySMZfatYue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company wrote-off the Abandoned Asset during fiscal 2023 with a gross asset value of $<span id="xdx_902_ecustom--AbandonedAssetWroteOff_c20230201__20240131_zn6JKjcl5iYd" title="Abandoned asset wrote off">1,330,000</span>.
There was no impact to the consolidated statements of operations as this eliminated the asset and accumulated amortization of the
fully amortized intangible assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961595619024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_z0QsTAEQDhKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
7 &#8212; <span id="xdx_825_zUoyWeLKFENi">INCOME TAXES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z1Qrk4Y3zRCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal 2023 and 2022, income taxes  consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zA0vPqReRg71" style="display: none">SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230201__20240131_zK9Z94Chs8Aj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220201__20230131_ztYIg4MFNvs7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zHdWE5OHgBu4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current tax expense:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pp0p0_maCITEBzxs7_maCITEBzyfy_zln98wYUgcac" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1167">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1168">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_maCITEBzxs7_maCITEBzyfy_z0HCcPDp7gu5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 68%; padding-bottom: 1.5pt">State</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">(58,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">(62,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_mtCITEBzyfy_maITEBzkRn_zI44rvTIDQjh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total current tax benefit (expense)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(58,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(62,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_pp0p0_zVVcGihGw8gi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax expense:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_pp0p0_maDITEBzEci_zX46sTZiTwB9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">86,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_pp0p0_maDITEBzEci_z0sLtM9QTvO5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_mtDITEBzEci_maITEBzkRn_zEsztPFY84Xi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total deferred tax benefit (expense)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">104,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iNT_pp0p0_di_zAQDDkMGpnl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Income tax benefit (expense)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">46,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(71,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A9_zGMnPHHgPuia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax expense differs from the amount computed using the federal statutory income tax rate of <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230201__20240131_zwyrMnXeSjJf" title="Federal statutory income tax rates"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220201__20230131_zyESb8BACKog" title="Federal statutory income tax rates">21</span></span>% for fiscal 2023 and 2022 as follows:</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zMHzVXyBtkoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zpGmPnL31wr4" style="display: none">SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230201__20240131_zdRPrvbxm4N2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220201__20230131_znHyhoj5jHN1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzHX9_zYnfgoYxevDb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Federal tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,887,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,348,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzHX9_zZ04t8iYdAol" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State and local tax expense, net of federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(28,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(52,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--IncreaseInValuationAllowance_maITEBzHX9_z7as09OTZl36" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Increase in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,994,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,128,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Permanent items:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzHX9_zrEiOYLMxBih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationTaxContingencies_maITEBzHX9_ztJDKeJbtkIi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reserve for uncertain tax position</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzHX9_zFpDOgFQVLdj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Federal research and development (R&amp;D) tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maITEBzHX9_zpOrSEBP7lQc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(289,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzHX9_zEbhWzWLmjt" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">56,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_iN_pp0p0_di_mtITEBzHX9_zQgu6mmP2ozl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax benefit (expense)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">46,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(71,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A1_zgdgYCRdCv9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zv36hcAdw4Jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides deferred income taxes for temporary differences between assets and liabilities recognized for financial reporting and
income tax purposes. The income tax effects of these temporary differences and credits are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zfItXsqgt5ii" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240131_zXO8HXMTiuV8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230131_z8vd3bHHaNpi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_pp0p0_maDTAGz9oc_zRIO7O8FElF" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: left">Allowance for credit losses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">26,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">39,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pp0p0_maDTAGz9oc_zd6lF5OZoxfc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">209,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent_iI_pp0p0_maDTAGz9oc_zeOTs4iteHP8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">232,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGz9oc_zMLinn0EzTNg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net operating loss carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,748,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,242,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGz9oc_zCWnxE8BKypi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">342,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0_maDTAGz9oc_z85X9citugQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Finite-lived intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,739,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,344,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGz9oc_zBnPnRI21A1d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">R&amp;D tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,434,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,407,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGz9oc_zIclNQdpMsZi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz9oc_maDTANzJA3_zkAnyFA288R1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,651,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,730,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzJA3_zDkBBx59OVWl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,646,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,347,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzJA3_msDTLz2p6_zZJc9wZIqx7b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Net deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">383,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iNI_di_msDITLz6FT_z0DOkUahtVz9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_iNI_pp0p0_di_maDITLz6FT_zZM8b7iXr1I7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Finite-lived intangible liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1262">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(482,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pp0p0_di_mtDITLz6FT_maDTLz2p6_zcoJWLgTWOc2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(487,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxLiabilities_iNTI_pp0p0_di_mtDTLz2p6_zQ7nVN5dLW39" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1268">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(104,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A9_z6lYHOtDhRmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
January 31, 2024, the Company had U.S. federal net operating loss carry forwards of $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_c20240131_zGGtBbLB9te8" title="Operating loss carry forwards">65,107,000</span> and
$<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_c20240131__us-gaap--AwardDateAxis__custom--ThroughFiscalTwoThousandThirtyEightMember_z0ISIW5wxln1" title="Operating loss carry forwards">29,083,000</span>
of these net operating losses expire at various dates through fiscal 2038. The remaining $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240131__us-gaap--IncomeTaxAuthorityAxis__custom--TaxCutsAndJobsActMember_zCo0WH0jSV71" title="Operating loss carry forwards">36,024,000</span>
of these net operating losses can be carried forward indefinitely under the provisions of the Tax Cuts and Jobs Act (TCJA). The TCJA
also eliminated the ability to carry back net operating losses. The Company also had state net operating loss carry forwards of
$<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240131__us-gaap--IncomeTaxAuthorityAxis__custom--StateMember_zuICpj29hBA7" title="Operating loss carry forwards">37,650,000</span>
and Federal R&amp;D credit carry forwards of $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240131__us-gaap--IncomeTaxAuthorityAxis__custom--FederalRDMember_zhseEcqZgeGe" title="Operating loss carry forwards">1,699,000</span>
and Georgia R&amp;D credit carry forwards of $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240131__us-gaap--IncomeTaxAuthorityAxis__custom--GeorgiaRDMember_zqlleKFDmiul" title="Operating loss carry forwards">94,000</span>,
all of which expire at various dates through fiscal 2042.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that all or some portion
of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of
future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal
of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The Company established
a valuation allowance of $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20240131_zMVGNVAkXOc7" title="Valuation allowance">19,646,000</span> and $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20230131_zusbfdb8iKXi" title="Valuation allowance">14,347,000</span> at January 31, 2024 and 2023, respectively. The increase in the valuation allowance
of $<span id="xdx_90B_ecustom--IncreaseInValuationAllowance_iN_di_c20230201__20240131_zd3t7kwtsuQ4" title="Increase in the valuation allowance">3,994,000</span> was driven primarily by the Company&#8217;s federal net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and its subsidiaries are subject to U.S. federal income tax as well as income taxes in multiple state and local jurisdictions.
The Company has concluded all U.S. federal tax matters for years through January 31, 2020. All material state and local income tax matters
have been concluded for years through January 31, 2019. The Company is no longer subject to IRS examination for periods prior to the
tax year ended January 31, 2020; however, carry forward losses that were generated prior to the tax year ended January 31, 2020 may still
be adjusted by the IRS if they are used in a future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has recorded a reserve, including interest and penalties, for uncertain tax positions of $<span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefits_iI_c20240131_zuyb7xilvXH1" title="Uncertain tax positions">340,000</span> and $<span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_c20230131_zeHJDZeMPYP" title="Uncertain tax positions">333,000</span> as of January
31, 2024 and 2023, respectively. As of January 31, 2024 and 2023, the Company had no accrued interest and penalties associated with unrecognized
tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zBBYb2k1Qaif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the beginning and ending amounts of gross unrecognized tax benefits (excluding interest and penalties) is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zco6YfUw1Us3" style="display: none">SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230201__20240131_zAFXu7xAOzG5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220201__20230131_zrpjmT2kHiN6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--UnrecognizedTaxBenefits_iS_pp0p0_zcGhxziP7LK6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Beginning of fiscal year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">333,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">315,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zHnr6XOaNOl4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additions for tax positions for the current year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_znxu2MOPPXM7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additions for tax positions of prior years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1301">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_iN_pp0p0_di_zxYg9zzSSCdb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Subtractions for tax positions of prior years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1305">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--UnrecognizedTaxBenefits_iE_pp0p0_zlVG4La0zBuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">End of fiscal year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">340,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">333,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zQr5qCZdR7kg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961595490000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1lTSQwNPUv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
8 &#8212; <span id="xdx_826_zKMNKL0mM8ve">EQUITY</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital
Raise</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 24, 2022, the Company entered into purchase agreements with certain investors pursuant to which the Company agreed to issue and
sell in a registered direct offering (the &#8220;2022 Offering&#8221;) an aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221023__20221024__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoOfferingMember_zFQ3m2idyT17" title="Number of shares issued">6,299,989</span> shares of common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221024__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoOfferingMember_zmlwlvaOToyl" title="Common stock par value">0.01</span>
per share, at a purchase price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20221024__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoOfferingMember_zrsaMwwpvWtc" title="Purchase price">1.32</span> per share. The gross proceeds to the Company from the 2022 Offering were approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20221023__20221024__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoOfferingMember_zeTT1OhRoaZ3" title="Proceeds from issuance of common stock">8,316,000</span>.
The Company used the proceeds of the 2022 Offering for general corporate purposes. The 2022 Offering closed on October 26, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
of Shares Issued to 180 Consulting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2022, the Company filed a Registration Statement on Form S-3 (Registration No. 333-265773) for purposes of registering for resale
<span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220622__us-gaap--RelatedPartyTransactionAxis__custom--OneHundredEightyConsultingLLCMember_zmDdCUaDdny2" title="Common stock issued for resale">272,653</span> shares of common stock issued to 180 Consulting, LLC (&#8220;180 Consulting&#8221;). The Registration Statement was declared
effective by the SEC on July 1, 2022.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 28, 2023, the Company filed a Registration Statement on Form S-3 (Registration No. 333-272993) for purposes of registering for resale
<span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230628__us-gaap--RelatedPartyTransactionAxis__custom--OneHundredEightyConsultingLLCMember_ztJBweR0Qf8k" title="Common stock issued for resale">394,127</span> shares of common stock issued to 180 Consulting, LLC (&#8220;180 Consulting&#8221;). The Registration Statement was declared
effective by the SEC on July 10, 2023.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Authorized
Shares Increase</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the 2022 Annual Meeting, the Company&#8217;s stockholders approved an amendment to the Streamline Health Solutions, Inc. Third Amended
and Restated 2013 Stock Incentive Plan to increase the number of shares of the Company&#8217;s common stock authorized for issuance thereunder
by <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20230201__20240131__us-gaap--PlanNameAxis__custom--ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_z744qi2KtRz4" title="Number of additional shares authorized to issue">2,000,000</span> shares, from <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20220607__us-gaap--PlanNameAxis__custom--ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_zRljjQxsHmD3" title="Number of shares authorized to issue">8,223,246</span> shares to <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240131__us-gaap--PlanNameAxis__custom--ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zWmSjofC3ge8" title="Number of shares authorized to issue">10,223,246</span> shares. The Company&#8217;s stockholders also approved an amendment to the Company&#8217;s
Certificate of Incorporation, as amended, to increase the total number of authorized shares of the Company&#8217;s common stock from
<span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20220607_zRzLxq4Ong2j" title="Common stock, shares authorized">65,000,000</span> shares to <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20240131_zr5QccP3x4X8" title="Common stock, shares authorized">85,000,000</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the 2023 Annual Meeting, the Company&#8217;s stockholders approved an amendment to the 2013 Plan to increase the number of shares of
the Company&#8217;s common stock authorized for issuance thereunder by <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20230615__20230615_zdP2IZQMXGy5" title="Number of additional shares authorized to issue">1,000,000</span> shares, from <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20230615__us-gaap--PlanNameAxis__custom--ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_zXWE8hGqA3J3" title="Number of shares authorized to issue">10,223,246</span> shares to <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20230615__us-gaap--PlanNameAxis__custom--ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zYG2EzryR264" title="Number of shares authorized to issue">11,223,246</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961598675472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CLIENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">MAJOR CLIENTS</a></td>
<td class="text"><p id="xdx_800_eus-gaap--ConcentrationRiskDisclosureTextBlock_z5eB8SJFvElg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
9 &#8212; <span id="xdx_827_zGD4nTjGCSM1">MAJOR CLIENTS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2023, <span id="xdx_907_eus-gaap--ConcentrationRiskCustomer_c20230201__20240131_zUPwj5WXHLgd">one individual client accounted
for 10% or more of our revenue.</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This client accounted
for <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20240131__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zLypvvdd55o7">23</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of total revenue for fiscal 2023. In the third quarter of fiscal 2023, the Company received a notice from this client of its intent not
to renew its contract following the expiration of the current term on December 31, 2023. During fiscal 2022, <span id="xdx_90F_eus-gaap--ConcentrationRiskCustomer_c20220201__20230131_z6P4n6yuGhge">two
individual clients accounted for 10% or more of our revenue.</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
clients accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210201__20220131__srt--MajorCustomersAxis__custom--TwoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z9X1KOGudy7e">20</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210201__20220131__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_z5LRkXkjM4rd">12</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
respectively, of total revenue for fiscal 2022. Four clients represented <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20240131__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z5mnHrJyy0J7">14</span>%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20240131__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z7xKXSAr6sSj">12</span>%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20240131__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zEGnqlVuaWo4">12</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20240131__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zk7bqkzdfSsd">11</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
respectively, of accounts receivable as of January 31, 2024, and four clients represented <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20230131__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zBhFm1wOAXP1">13</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
<span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20230131__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zf18hvwHMAeb">12</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
<span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20230131__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zARBzlAETThi">12</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20230131__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zLM9PZDHfogb">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
respectively, of accounts receivable as of January 31, 2023. Many of our clients are invoiced on an annual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961598196880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE RETIREMENT PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">EMPLOYEE RETIREMENT PLAN</a></td>
<td class="text"><p id="xdx_805_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_z5c6rMuNfTui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
10 &#8212; <span id="xdx_826_zNNifCgVyW4b">EMPLOYEE RETIREMENT PLAN</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has established a 401(k) retirement plan that covers all associates. Company contributions to the plan may be made at the discretion
of the board of directors. The Company&#8217;s matched amount is 50% up to the first 4% of compensation deferred by each associate. The
total compensation expense for this matching contribution was $<span id="xdx_901_eus-gaap--DefinedContributionPlanCostRecognized_pp0p0_c20230201__20240131_zPm2id33qf5" title="Defined contribution plan, cost recognized">242,000</span> and $<span id="xdx_90C_eus-gaap--DefinedContributionPlanCostRecognized_pp0p0_c20220201__20230131_z7D0klclvwO9" title="Defined contribution plan, cost recognized">258,000</span> in fiscal 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961595571200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zR3mSH78pWti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
11 &#8212; <span id="xdx_822_zix3myPlcav8">STOCK-BASED COMPENSATION</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Option Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2013 Plan replaced the Company&#8217;s 2005 Incentive Compensation Plan (the &#8220;2005 Plan&#8221;). The 2005 Plan expired based upon
its terms. Accordingly, all the outstanding awards and any unallocated pool of un-issued options under the 2005 Plan were re-characterized
to the 2013 Plan. <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zRjmMTacv4Z2" title="Stock options plan, description">Under these plans, the Company is authorized to issue equity awards (stock options, stock appreciation rights or &#8220;SARs&#8221;,
and restricted stock) to directors and associates of the Company. Under the 2013 Plan, as amended, the Company is authorized to issue
a number of shares not to exceed <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zYk0QCKfDYrl" title="Number of shares authorized to issue">11,223,246</span>. The options granted under the 2013 Plan have terms of ten years or less, and typically vest
and become fully exercisable ratably over three years of continuous service to the Company from the date of grant</span>. At January 31, 2024
and 2023, options to purchase <span id="xdx_905_ecustom--NumberOfOptionsToPurchaseCommonStock_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z6GtEpRtsUqj" title="Number of options to purchase common stock">67,500</span> and <span id="xdx_903_ecustom--NumberOfOptionsToPurchaseCommonStock_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zI5rslcRw3n3" title="Number of options to purchase common stock">628,958</span> shares of the Company&#8217;s common stock, respectively, had been granted and were
outstanding under these plans. At January 31, 2024, there were no SARs outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXNWPfNbByXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity in fiscal 2023 follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_z6AWhgsLlTTl" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life in <br/> Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">intrinsic <br/> value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding as of January 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230201__20240131_z9rzQnSYOxv8" style="width: 12%; text-align: right" title="Number of options, Outstanding">628,958</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230201__20240131_zBV5DS90SPtf" style="width: 12%; text-align: right" title="Weighted average exercise price, Outstanding">1.95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220201__20230131_zQn7bX5YnDDd" title="Remaining Life in Years, Outstanding">7.31</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230201__20240131_zE19UeU1K4mc" style="width: 12%; text-align: right" title="Aggregate intrinsic value, Outstanding">360,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230201__20240131_zWn0MkN626K1" style="text-align: right" title="Number of options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1381">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230201__20240131_zz3I3PGuVxR1" style="text-align: right" title="Weighted average exercise price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1383">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230201__20240131_z7EX6ISFLaa4" style="text-align: right" title="Number of options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1385">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230201__20240131_zkqgh9ok7CU7" style="text-align: right" title="Weighted average exercise price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1387">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230201__20240131_zZWVO32mGON7" style="text-align: right" title="Number of options, Expired">(39,250</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230201__20240131_zZju4jJge4L1" style="text-align: right" title="Weighted average exercise price, Expired">7.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230201__20240131_zSPzPuqKmLs" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, Forfeited">(522,208</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230201__20240131_z6OxGZcLNs3a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Forfeited">1.55</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding as of January 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230201__20240131_zXz717fImZ23" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Outstanding">67,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230201__20240131_zAtr4ouxiGWg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding">1.73</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230201__20240131_zkDfaZVnkpE" title="Remaining Life in Years, Outstanding">2.37</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230201__20240131_zSuSirRD9zde" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1403">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable as of January 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240131_zA224pL4KPVd" style="text-align: right" title="Number of options, Exercisable">67,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240131_zC5bpjYI2ujg" style="text-align: right" title="Weighted average exercise price, Exercisable">1.73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230201__20240131_zb27FH3wNuqc" title="Remaining Life in Years, Exercisable">2.37</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20240131_zxHUGEW6m4E6" style="text-align: right" title="Aggregate intrinsic value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1411">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested as of January 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20240131_zBrksG5tDsii" style="text-align: right" title="Number of options, Vested or expected to vest">67,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20240131_zKlTMvZVX3ej" style="text-align: right" title="Weighted average exercise price, Vested or expected to vest">1.73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230201__20240131_zwo7CT2xA9lj" title="Remaining Life in Years, Vested or expected to vest">2.37</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pp0p0_c20240131_zYrdbEi8mAVe" style="text-align: right" title="Aggregate intrinsic value, Vested or expected to vest"><span style="-sec-ix-hidden: xdx2ixbrl1419">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zNvMECiwJla5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
options were granted in fiscal 2023 or fiscal 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
January 31, 2024, there was <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_do_c20240131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zHd45qitU1De" title="Unrecognized Compensation cost, stock options">no</span>  unrecognized compensation cost related to non-vested stock-option awards.  The expense associated with stock option awards was $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zzGzYQpHhbQ4" title="Stock option expense">71,000</span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210201__20220131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zpZCOisOlCMk" title="Stock option expense">132,000</span>,
respectively, for fiscal 2023 and 2022. No options were exercised during fiscal 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2013 Plan contains change in control provisions whereby any outstanding equity awards under the plans subject to vesting, which have
not fully vested as of the date of the change in control, shall automatically vest and become immediately exercisable. One of the change
in control provisions is deemed to occur if there is a change in beneficial ownership, or authority to vote, directly or indirectly,
of securities representing <span id="xdx_908_ecustom--InvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240131_zksPPAwG4dsb" title="Ownership Percentage">20</span>% or more of the total of all of the Company&#8217;s then-outstanding voting securities, unless through
a transaction arranged by or consummated with the prior approval of the Board of Directors. Other change in control provisions relate
to mergers and acquisitions or a determination of change in control by the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to grant restricted stock awards to associates and directors under the 2013 Plan. The Company has also issued restricted
stock as inducement grants to certain new employees. The restrictions on the shares granted generally lapse over a one- to four-year
term of continuous employment from the date of grant. On November 1, 2022, our then-serving CEO, Wyche T. Green, III, was awarded <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20221101__20221101__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFXwcPEJqNWd" title="Number of restricted stocks awarded, shares">50,000</span>
shares of restricted common stock that will vest in three substantially equal annual installments commencing on the first anniversary
of the date of grant. On May 20, 2022, Mr. Green was awarded <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220520__20220520__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxLQszwr6Ht9" title="Number of restricted stocks awarded, shares">150,000</span> shares of restricted common stock that will vest in three substantially
equal annual installments commencing on the first anniversary of the date of grant. On April 1, 2023, Mr. Green was awarded <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230401__20230401__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--MrGreenMember_z37kHInn2VAe" title="Number of restricted stocks awarded, shares">200,000</span> shares
of restricted common stock that will vest in three substantially equal annual installments commencing on the first anniversary of the
date of grant. Prior to his appointment as CEO of the Company, Mr. Stilwill was awarded <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230401__20230401__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--MrStilwillMember_z2X04kcHRQv4" title="Number of restricted stocks awarded, shares">170,000</span> shares of restricted common stock on
April 1, 2023, that will vest in three substantially equal annual installments commencing on the first anniversary of the date of grant.
The grant date fair value per share of restricted stock, which is based on the closing price of our common stock on the grant date, is
expensed on a straight-line basis as the restriction period lapses. The shares represented by restricted stock awards are
considered outstanding at the grant date, as the recipients are entitled to voting rights. A summary of restricted stock award activity
for fiscal 2023 and 2022 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zjM3yWYFsDA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zO7G2ebkJoQl" style="display: none">SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Weighted</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Non-vested</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Average</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Number of</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Grant Date</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair Value</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 64%">Non-vested balance at January 31, 2022</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220201__20230131_zYnFhfptDY6l" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Number of RSUs, Non vested, Outstanding, Beginning balance">1,043,350</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220201__20230131_zEuLXWMANKh6" title="Weighted Average Grant Date Fair Value, Beginniing balance">1.57</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zGP6dQdbY7b2" style="text-align: right" title="Number of RSUs, granted">1,505,731</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zmB5td5Fd6fl" title="Weighted Average Grant Date Fair Value, RSUs granted">1.47</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2rQ1F0faCo8" style="text-align: right" title="Number of RSUs, vested">(501,750</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcM3KJZ27nH3" title="Weighted Average Grant Date Fair Value, RSUs vested">1.63</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcWA3EZI1BR2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number RSUs, forfeited">(199,300</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs36HOvacnKh" title="Weighted Average Grant Date Fair Value, RSUs forfeited">1.49</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Non-vested balance at January 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230201__20240131_zBoj4mi8JkQf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs, Non vested, Outstanding, Beginning balance">1,848,031</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230201__20240131_zi6wkponXkb9" title="Weighted Average Grant Date Fair Value, Beginning balance">1.48</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4cAqLD9qWHi" style="text-align: right" title="Number of RSUs, granted">1,488,621</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUoxAxyM8tqb" title="Weighted Average Grant Date Fair Value, RSUs granted">1.57</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztks46YVO2pc" style="text-align: right" title="Number of RSUs, vested">(982,631</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs4ruRfP73dc" title="Weighted Average Grant Date Fair Value, RSUs vested">1.48</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3kMfkbYn4Vd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number RSUs, forfeited">(383,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcCEpa7518V" title="Weighted Average Grant Date Fair Value, RSUs forfeited">1.67</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Non-vested balance at January 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230201__20240131_zJ3GXytTKXPk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs, Non vested, Outstanding, Ending balance">1,970,521</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230201__20240131_zOW8QWyzHUNf" title="Weighted Average Grant Date Fair Value, Ending balance">1.51</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zX3Bw8CpyROg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
January 31, 2024, there was $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztSGfHKRWsE5" title="Unrecognized compensation cost related to restricted stock awards">1,938,000</span> of unrecognized compensation cost related to restricted stock awards. That cost is expected to be recognized
over a remaining period of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_pp0p0_dtY_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOUH2fFwVvP1" title="Cost expected remaining period">1.80</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expense associated with restricted stock awards for associates and directors was $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zH9uUvSujJEk" title="Stock option expense">1,590,000</span> and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210201__20220131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziMLtBvYwohf" title="Stock option expense">983,000</span>,
for fiscal 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961598676896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z3olXSo5JyKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
12&#8212; <span id="xdx_827_zxCT69eXbWf2">COMMITMENTS AND CONTINGENCIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consulting
Agreement with 180 Consulting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 19, 2020, the Company entered into a Master Services Agreement (the &#8220;MSA&#8221;) with 180 Consulting, pursuant to which 180
Consulting has provided and will continue to provide a variety of consulting services in support of eValuator products including product
management, operational consulting, staff augmentation, internal systems platform integration and software engineering services, among
others, through separate executed statements of work (&#8220;SOWs&#8221;). On September 20, 2021, the Company entered into a separate
MSA in support of Avelead products. As of December 2023, all outstanding SOWs under both MSAs were effectively replaced by two new SOWs.
As of the end of fiscal 2023, there were two active SOWs under the eValuator MSA, and no active SOWS under the Avelead MSA. One of the
active SOWs include the ability to earn stock at a conversion rate to be calculated 20 days after the execution of the related SOW. The
MSA includes a termination clause upon a 90-day written notice. While no related party has a direct or indirect material interest in
this MSA or the related SOWs, individuals providing services to us under the MSA, and the related SOWs may share workspace and administrative
costs with 121G Consulting LLC (&#8220;121G&#8221;). 180 Consulting earned <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zMhHLa2jZNJl">564,707
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares for the year ended January 31, 2024 and
has earned an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zyunfUAmg8f1">1,479,911
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares through January 31, 2024. For services
rendered by 180 Consulting, the Company recorded total cash fees of $<span id="xdx_907_eus-gaap--ProfessionalFees_c20230801__20231031__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zPVjOGhQqUA3">2,580,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and non-employee stock compensation of $<span id="xdx_908_eus-gaap--ProfessionalFees_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zs3LLvVHgHHe">582,000
</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for fiscal 2023 as compared to $<span id="xdx_905_ecustom--NonEmployeeStockCompensation_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zBwPgZmRAhM4">1,281,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_ecustom--NonEmployeeStockCompensation_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_z8Z6NjVupbI6">640,000</span>,
respectively, for fiscal 2022</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. In addition, as
of the date of this report, the Company has not issued to 180 Consulting an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231101__20240131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zRSAuzs7dQYa">206,517
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares as compensation for services previously
rendered during the three-months ended January 31, 2024. Such <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231101__20240131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z2oPoPKfdYzd">564,707
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares will be issued in reliance on an exemption
from registration available under Section 4(a)(2) of the Securities Act. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inclusive
of the MSA executed with 180 Consulting are SOWs that provide for the Company to sublicense a software through 180 Consulting that is
owned by 121G. This is a services agreement for access to software that assists the Company in implementing and integrating with our
clients&#8217; technology. The license agreement is designed such that there is no material financial benefit that accrues to 121G. 180
Consulting licenses the software from 121G at cost. The Company paid approximately $<span id="xdx_90D_eus-gaap--ProfessionalFees_pp0p0_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SOWMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zCmpTNOKJGr8" title="Professional fees">563,000</span> and $<span id="xdx_907_eus-gaap--ProfessionalFees_pp0p0_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--SOWMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zXY6VpvP7sgk" title="Professional fees">301,000</span> for the SOWs that include the sublicense
agreement in each of the fiscal years ended January 31, 2024 and 2023, respectively, which are included in the aforementioned totals
above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are, from time to time, a party to various legal proceedings and claims, which arise in the ordinary course of business. We are not aware
of any legal matters that are reasonably possible to have a material adverse effect on the Company&#8217;s consolidated results of operations,
financial position or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961597375648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zoIDIDdfg0Tb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
13 - <span id="xdx_821_zqhEKEEWAwX8">RELATED PARTY TRANSACTIONS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer
to Note 3 &#8211; Business Combination. The Company acquired Avelead on August 16, 2021. We assumed a lease for corporate
office space from one of the selling shareholders of Avelead who was employed by the Company through August 2023. This lease term ended
February 2022 but was renewed for a term of 12 months through February 2023. For the year ended January 31, 2024, the Company recorded
rent expense of $<span id="xdx_90F_eus-gaap--PaymentsForRent_c20230201__20240131_z5zPDi2dKoKd" title="Rent expense">6,000</span>. Refer to Note 4 &#8211; Operating Leases to our consolidated financial statements included in Part II, Item 8,
&#8220;Financial Statements and Supplementary Data&#8221; for more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961599268880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_DisclosureSubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zA3kgVqh9DU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE
14 &#8212; <span id="xdx_824_zRs7xio7EOD4">SUBSEQUENT EVENTS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Debt
Private Placement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 1, 2024, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain
accredited investors, including certain directors and officers of the Company (collectively, the &#8220;Investors&#8221;), pursuant to
which the Company agreed to sell to the Investors unsecured subordinated promissory notes (the &#8220;Notes&#8221;) in the aggregate
principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHXgzuLiZOV4" title="Debt principal amount">4.4</span> million and warrants (the &#8220;Warrants&#8221;) to purchase up to an aggregate of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z9Qs8HhWdpmg" title="Number of shares purchase">4,052,631</span> shares of the
Company&#8217;s common stock (the &#8220;Common Stock&#8221;) in a private placement (the &#8220;Debt Private Placement&#8221;). The
closing of the Debt Private Placement occurred on February 7, 2024 (the &#8220;Closing Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Debt Private Placement, the Investors and each of the Company&#8217;s directors and officers agreed, subject to certain
exceptions set forth in the lock-up agreements, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any
short sale or otherwise dispose of any shares of Common Stock, or any options or warrants to purchase any shares of Common Stock, or
any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock, for a period commencing
on the date of the lock-up agreement and ending 90 days from the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes bear interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20240201__us-gaap--ShortTermDebtTypeAxis__custom--NotesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLMRLP7iySJ8" title="Notes bear interest rate">15</span>% per annum and mature on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20240201__20240201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesMember_zAyPkBibryH8" title="Notes maturity date">August 7, 2026</span> (the &#8220;Maturity Date&#8221;). All accrued and unpaid
interest on the Notes will be capitalized and added to the outstanding principal balance of the Notes and will be payable in cash on
the Maturity Date. The Company may redeem the Notes, in whole or in part, prior to the Maturity Date without any premium or penalty.
In the event the Company prepays any portion of the then outstanding principal balance of the Notes on or before the twelve (12) month
anniversary of the Closing Date, in addition to such prepayment of the principal balance, the Company must pay to the Investors a prepayment
fee (in accordance with the each Investor&#8217;s pro-rata share of the Notes) in an amount equal to the amount of interest that would
have accrued but for the prepayment from the date of such prepayment through such twelve (12) month anniversary of the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights of each Investor to receive payments under the Notes are subordinate to the rights of Western Alliance Bank (&#8220;WAB&#8221;),
pursuant to a subordination agreement which the Investors entered into with WAB concurrently with the Debt Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrants have an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYZJaip5tMMc" title="Warrant exercise price">0.38</span> (except for Warrants issued to the Company&#8217;s directors and officers which have an exercise
price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ExceptDirectorsAndOfficersMember_zXhgZQCv4sW7" title="Warrant exercise price">0.39</span>), are immediately exercisable, and will expire on the fourth anniversary of the Closing Date. The Warrants are subject
to customary adjustments for certain transactions affecting the Company&#8217;s capitalization. The terms of the Warrants preclude a
holder thereof from exercising such holder&#8217;s Warrants, and the Company from giving effect to such exercise, if after giving effect
to the issuance of Common Stock upon such exercise, the holder (together with the holder&#8217;s affiliates and any other persons acting
as a group together with the holder or any of the holder&#8217;s affiliates) would beneficially own in excess of <span id="xdx_902_ecustom--AffiliatesEffectivePercentage_iI_pid_dp_uPure_c20240430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQLorGwk9Su9" title="Affiliates effective percentage">9.99</span>% of the number
of shares of Common Stock outstanding immediately after giving effect to the issuance of Common Stock upon such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes and the Warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended
(the &#8220;Securities Act&#8221;), and/or Regulation D promulgated thereunder and, along with the Common Stock underlying the Warrants,
have not been registered under the Securities Act or applicable state securities laws. Accordingly, the Notes, the Warrants and the Common
Stock underlying the Warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption
from such registration requirements and in accordance with applicable state securities laws. The securities were offered and sold to
&#8220;accredited investors&#8221; as that term is defined in Rule 501(a) under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Private Placement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2024, the Company completed the sale of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240206__20240206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z4ELvf7NvACc" title="Number of shares issued">263,158</span> shares of the Company&#8217;s common stock to an accredited investor at a
purchase price of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_c20240206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zs7wf1kUsyB5" title="Purchase price per share">0.38</span> per share for an aggregate purchase price of $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240206__20240206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zO2Q3YIN7py8" title="Aggregate purchase price">100,000</span> (the &#8220;Common Stock Private Placement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock described above was offered in a private placement under Section 4(a)(2) of the Securities Act and/or Regulation D promulgated
thereunder and has not been registered under the Securities Act or applicable state securities laws. Accordingly, such common stock may
not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements
and in accordance with applicable state securities laws. The Common Stock was offered and sold to an &#8220;accredited investor&#8221;
as that term is defined in Rule 501(a) under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loan
Modification</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 7, 2024, the Company and certain of its subsidiaries entered into a Third Modification and Waiver (the &#8220;Third Modification&#8221;)
to the Loan Agreement with Western Alliance Bank.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Third Modification waived the Company&#8217;s non-compliance with the Maximum Debt to ARR Ratio under the Loan Agreement and amended
certain financial covenants as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
    ARR Net Leverage Ratio. </b>Borrowers&#8217; ARR Net Leverage Ratio, measured on a quarterly basis as of the last day of each fiscal
    quarter, shall not be greater than the amount set forth under the heading &#8220;Maximum ARR Net Leverage Ratio&#8221; as of, and
    for each of the dates appearing adjacent to such &#8220;Maximum ARR Net Leverage Ratio.</span></td></tr>
  </table>
<p id="xdx_898_ecustom--ScheduleOfMaximumARRNetLeverageTableTextBlock_zn3DAkHvDuVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;<span id="xdx_8B2_zl5leknhgzJg" style="display: none">SCHEDULE
OF MAXIMUM ARR NET LEVERAGE RATIO</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 81%; font-weight: bold">Quarter Ending</td>
    <td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum ARR Net Leverage Ratio</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>April 30, 2024</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYL8dbOqU7dj" title="Maximum ARR net leverage ratio">0.50</span> to <span id="xdx_903_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZGaBn88elT7" title="Maximum ARR net leverage ratio">1.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>July 31, 2024</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXDyg1rAAOu" title="Maximum ARR net leverage ratio">0.45</span> to <span id="xdx_901_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4bD19zzJLIi" title="Maximum ARR net leverage ratio">1.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>October 31, 2024</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHNHYJNleNcf" title="Maximum ARR net leverage ratio">0.40</span> to <span id="xdx_90D_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdU4HUWEgNl7" title="Maximum ARR net leverage ratio">1.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>January 31, 2025</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGXzjPhyYRBb" title="Maximum ARR net leverage ratio">0.35</span> to <span id="xdx_908_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zN794vr0cRh" title="Maximum ARR net leverage ratio">1.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zp08xu0aVB09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
    Debt to Adjusted EBITDA Ratio. </b>Commencing with the quarter ending April 30, 2025, Borrowers&#8217; Maximum Debt to Adjusted EBITDA
    Ratio, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4) quarter period then ended,
    shall not be greater than the amount set forth under the heading &#8220;Maximum Debt to Adjusted EBITDA Ratio&#8221; as of, and for
    each of the dates appearing adjacent to such &#8220;Maximum Debt to Adjusted EBITDA Ratio&#8221;.</span></td></tr>
  </table>
<p id="xdx_893_ecustom--ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock_zbRhfhXAR2T4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_z36XCCnXa4R3" style="display: none">SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 81%; font-weight: bold">Quarter Ending</td>
    <td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum Debt to Adjusted EBITDA Ratio</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>April 30, 2025</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z634W75TIPkd" title="Maximum Debt to Adjusted EBITDA Ratio">3.50</span> to <span id="xdx_906_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zW5HjjpfOLK6" title="Maximum Debt to Adjusted EBITDA Ratio">1.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>July 31, 2025</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zndajFfrR7lb" title="Maximum Debt to Adjusted EBITDA Ratio">3.00</span> to <span id="xdx_902_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPNp0gh9xaMj" title="Maximum Debt to Adjusted EBITDA Ratio">1.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>October 31, 2025</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsNDLOgxTSE8" title="Maximum Debt to Adjusted EBITDA Ratio">2.50</span> to <span id="xdx_90B_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKF5mmPQictf" title="Maximum Debt to Adjusted EBITDA Ratio">1.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">January 31, 2026 and on the last day of each quarter thereafter</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQ1edTu7ZW4" title="Maximum Debt to Adjusted EBITDA Ratio">2.00</span> to <span id="xdx_90A_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zieXxiJi69ba" title="Maximum Debt to Adjusted EBITDA Ratio">1.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zgAxWkKvE4b9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed
    Charge Coverage Ratio</b>. Commencing with the quarter ending April 30, 2025, Borrowers shall maintain a Fixed Charge Coverage Ratio
    of not less than <span id="xdx_909_ecustom--FixedChargeCoverageRatio_iI_pid_dp_uPure_c20240207__us-gaap--TypeOfArrangementAxis__custom--ThirdModificationLoanAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIv6ASSMMDf3" title="Fixed charge coverage ratio">1.20</span> to <span id="xdx_90E_ecustom--FixedChargeCoverageRatio_iI_pid_dp_uPure_c20240207__us-gaap--TypeOfArrangementAxis__custom--ThirdModificationLoanAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zM3nVmvbxsm4" title="Fixed charge coverage ratio">1.00</span>, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4)
    quarter period then ended.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>e.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Minimum
    Adjusted EBITDA. </b>Commencing with the quarter ending January 31, 2024, Borrowers shall maintain Adjusted EBITDA, measured on a
    quarterly basis as of the last day of each fiscal quarter, in an amount not less than the amounts (or, in the case of amounts set
    forth in parentheses, no worse than the amounts) set forth under the heading &#8220;Minimum Adjusted EBITDA&#8221; as of, and for
    each of the dates appearing adjacent to such &#8220;Minimum Adjusted EBITDA.</span></td></tr>
  </table>
<p id="xdx_89E_ecustom--ScheduleOfMinimumAdjustedEBITDATableTextBlock_zmyLnqyM4LPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;<span id="xdx_8BC_zGClJf5IisO8" style="display: none">SCHEDULE
OF MINIMUM ADJUSTED EBITDA</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Quarter Ending</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Minimum Adjusted EBITDA</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">January 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAHKv9XnP7Tf" style="width: 16%; text-align: right" title="Minimum Adjusted EBITDA">(5,750,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>April 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztQimNPIzrJa" style="text-align: right" title="Minimum Adjusted EBITDA">(4,560,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>July 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1LyXupcKxgg" style="text-align: right" title="Minimum Adjusted EBITDA">(2,960,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>October 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0Xz7h4bcx13" style="text-align: right" title="Minimum Adjusted EBITDA">(1,500,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>January 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFiveMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3VsY5uHAob2" style="text-align: right" title="Minimum Adjusted EBITDA">430,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zsv2skD6YZbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_DisclosureSubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_DisclosureSubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961698316560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Valuation and Qualifying Accounts and Reserves<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_DisclosureValuationAndQualifyingAccountsAndReservesAbstract', window );"><strong>Valuation And Qualifying Accounts And Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Valuation and Qualifying Accounts and Reserves</a></td>
<td class="text"><p id="xdx_804_esrt--ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_ziJUF1suz0d7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Schedule
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_003"></span><span id="xdx_825_zL7MiJcbFLjh">Valuation
and Qualifying Accounts and Reserves</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Streamline
Health Solutions, Inc and Subsidiaries.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the two years ended January 31, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(in
thousands of dollars)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at Beginning</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Period</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Charged to Costs and</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expenses</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b id="xdx_F5B_zV7DWB6suPWi">(1)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Deductions &#8211; Other Accounts</b></p>

</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F5B_zJuceKht5xe6">(2)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deductions</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>End of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Year ended January 31, 2024:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 32%; text-align: left">Allowance for doubtful accounts</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_98D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_pn3n3_c20230201__20240131_zZLImkf6vnmf" style="width: 10%; text-align: right">132</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_98F_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20230201__20240131_z1k2l5PaLfH3" style="width: 10%; text-align: right">(10</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_986_eus-gaap--ValuationAllowancesAndReservesChargedToOtherAccounts_pn3n3_c20230201__20240131_fKDEp_zh4bBYA0DPNh" style="text-align: right; width: 10%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;(36</td>
    <td style="width: 1%">)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_984_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20230201__20240131_fKDIp_z0Npxkq8WqF7" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1579">&#8212;</span></td><td style="width: 1%; text-align: left"></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_pn3n3_c20230201__20240131_z9TIxgARzxGc" style="width: 10%; text-align: right">86</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Year ended January 31, 2023:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Allowance for doubtful accounts</td><td>&#160;</td>
    <td style="text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_pn3n3_c20220201__20230131_zMH2HRz2Pj17" style="text-align: right">76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20220201__20230131_zj53Qi6VeHek" style="text-align: right">189</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><p class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_98E_eus-gaap--ValuationAllowancesAndReservesChargedToOtherAccounts_pn3n3_c20220201__20230131_fKDEp_zLKF4y0XM5h1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1583">&#8212;</span></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_988_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20220201__20230131_fKDIp_zHOKrlLbtdXd" style="text-align: right">(133</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_98B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_pn3n3_c20220201__20230131_z3ewtJR2qVoi" style="text-align: right">132</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F05_zp3FTL55sJff" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zARjFMaHTQD7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments to retained earnings for adoption of ASC 326-10, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit
Losses on Financial Instruments (Refer to the subtopic of Accounting Pronouncements Recently Adopted in Note 2 &#8211; Significant Accounting
Policies to our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221;
for more information.)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td id="xdx_F05_z4l7xymCPB99" style="font: 10pt Times New Roman, Times, Serif">(2)</td>
    <td id="xdx_F1A_zgnOhMXv45Y2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Uncollectible accounts written off, net of recoveries.</td></tr>
  </table>
<p id="xdx_8A5_zHg4tQmu83L8" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_DisclosureValuationAndQualifyingAccountsAndReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_DisclosureValuationAndQualifyingAccountsAndReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961597970768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zBSu67ZrIzqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zMxyAnKWevrd">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of Streamline Health Solutions, Inc. and its wholly-owned subsidiaries, Streamline
Health, LLC, Avelead Consulting, LLC, Streamline Consulting Solutions, LLC and Streamline Pay &amp; Benefits, LLC. All significant intercompany
transactions and balances are eliminated in consolidation. All amounts in the consolidated financial statements, notes and tables have
been rounded to the nearest thousand dollars, except share and per share amounts, unless otherwise indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has determined it has only one operating segment based on the guidance of <i>ASC 280-10-50 </i>paragraphs 1 through 8, The Company
has a sole chief operating decision maker who reviews a single set of financials, information, has accountability for the performance
of the organization, and allocates resources to drive success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal 2022, the Company had two reporting units for evaluation of goodwill: Streamline Solutions and Avelead Solutions. The Company
determined that, effective January 1, 2023, it has one reporting unit for purposes of evaluation of goodwill, which was used for evaluation
of goodwill for fiscal 2023. At the end of fiscal 2022, the Company consolidated and combined its operations for Streamline Solutions
and Avelead Solutions. For total assets at January 31, 2024 and 2023 and total revenue and net loss for the fiscal years ended January
31, 2024 and 2023, see our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary
Data&#8221; herein.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><p id="xdx_842_ecustom--GoingConcernPolicyTextBlock_z04TyckKPcLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zcBCCKzLHlv8">Going
Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of obligations in the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the Company&#8217;s Quarterly Report on Form 10-Q for the period ended October 31, 2023, the Company raised substantial doubt about
its ability to continue as a going concern. It cited the &#8220;ability to achieve cash from operations and raise additional debt or
equity capital to fund its ongoing operations&#8221; as requirements to mitigate the substantial doubt. As of this filing, the
Company has been able to successfully implement a cost reduction plan, obtain additional capital, and restructure the covenants for
its existing credit facility. Collectively, these initiatives alleviated the substantial doubt about the Company&#8217;s ability to continue as a going concern. Refer to the
&#8220;Restructuring&#8221; subtopic of this Note 1 (Organization and Description of Business) and Note 14 &#8211; Subsequent Events
to our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; for
additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zT18YACMCUE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zLdYdGtUBpJ7">Reclassification</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
amounts for fiscal 2022 were reclassified to conform to the current period classification. The Company incurred certain acquisition-related
costs related to the acquisition of Avelead totaling $<span id="xdx_90C_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20230201__20240131_zLSxskQwCZpi" title="Acquisition related costs">149,000</span> consisting primarily of professional service fees. The aforementioned acquisition-related
costs for fiscal 2022 were previously presented in a separate, single caption and are now included in selling, general, and administrative
expense in the accompanying condensed consolidated statements of operations, which is consistent with the presentation for the current
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_841_eus-gaap--UseOfEstimates_zYRzg40CSL39" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_z7lvcZppkJTa">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management
to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing
basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, stock-based compensation,
capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration and income
taxes. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQN5GPYeb917" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zpKSz8Ifca33">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash demand deposits. Cash deposits
are placed in Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured financial institutions. Cash deposits may exceed FDIC
insured levels from time to time. For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company
considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Non-Cash
Items</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_ecustom--ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock_z1maRBLwUz69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following items that were non-cash items related to the consolidated statements of cash flows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zNqLG3nkHJTj" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230201__20240131_zurqW0nQ9sbh" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220201__20230131_zEEvneV5twwa" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Fiscal Year</b></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr id="xdx_40A_eus-gaap--RestrictedStockExpense_zog1qLL5VDyc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Payment of acquisition earnout liabilities in restricted common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">3,012,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--CapitalizedSoftwarePurchasedWithStock_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized software purchased with stock (<i>See Note 12</i>)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DeferredFinancingCosts_z5B0BQA42Im8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zY1Afzd2Ab5g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Receivables</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--TradeAndOtherAccountsReceivablePolicy_ztpdyWecksi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zFjauAPTw4g3">Receivables</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
and contract receivables are comprised of amounts owed to the Company for licensed software, professional services, including coding
audit services, consulting services, maintenance services, and software as a service and are presented net of the allowance for credit losses. The timing of revenue recognition may not coincide with the billing terms of the client contract, resulting in unbilled receivables
or deferred revenues; therefore, certain contract receivables represent revenues recognized prior to client billings. Individual contract
terms with clients or resellers determine when receivables are due. Accounts receivable represent amounts that the entity has an unconditional
right to consideration. For billings where the criteria for revenue recognition have not been met, deferred revenue is recorded until
the Company satisfies the respective performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AllowanceForCreditLossesPolicyTextBlock', window );">Allowance for Credit Losses</a></td>
<td class="text"><p id="xdx_841_ecustom--AllowanceForCreditLossesPolicyTextBlock_ze7ToCazvDBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zZjdgKK0Ieh1">Allowance
for Credit Losses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adjusts accounts receivable down to net realizable value. Effective February 1, 2023, the Company implemented ASC 326-10,
Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;CECL&#8221;).
CECL provides the framework for the Company to evaluate its allowance for credit losses. In determining the
allowance for credit losses, the Company established a historical credit loss rate adjusted for a premium, addressing any
prospective changes to the risk of credit loss, that is applied against current sales. The Company evaluates individual receivables
based upon the most recent information available and the status of any open or unresolved issues with the client preventing the
payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables.
During these periodic reviews, significant judgement is required for the Company to determine the appropriate allowances for
doubtful accounts for estimated losses resulting from the unwillingness of its clients or resellers to make required payments. The
Company believes its reserve is adequate, however, results may differ in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the changes to the allowance account with the adoption of CECL:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_891_eus-gaap--ScheduleOfRestructuringReserveByTypeOfCostTextBlock_zfqA1D3oTMu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zu0obzYOwHKb" style="display: none">SCHEDULE
OF RESERVE RESULTS IN FUTURE PERIODS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CECL Adoption</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="text-align: center">&#160;</td><td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Provision adjustments</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Write-offs &amp; Recoveries</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 39%; text-align: left; padding-bottom: 1.5pt">Allowance for credit losses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20230201__20240131_z5AgnJ7s7tPl" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Balance">132,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--AllowanceForDoubtfulAccountsReceivableCECLAdoption_c20230201__20240131_zeIXWjucoLQ4" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, CECL Adoption">(36,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="width: 1%">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 1%">$</td>
    <td id="xdx_987_eus-gaap--ProvisionForDoubtfulAccounts_c20230201__20240131_zUzIajVrro0k" style="border-bottom: Black 1.5pt solid; text-align: right; width: 9%; vertical-align: bottom" title="Allowance for credit losses, Provision adjustments">(10,000</td>
    <td style="padding-bottom: 1.5pt; width: 1%">)&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 2%; text-align: left">$</td><td id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20230201__20240131_zZhmkzIUbMp2" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Write-offs &amp; Recoveries"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20230201__20240131_zZ33ZyhBjhP5" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Balance">86,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zkt8sf5GfK1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p id="xdx_843_ecustom--AccruedExpensesPolicyTextBlock_zAS3WcLE6cMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zEPilTYadTI9">Accrued
Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p><p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zssA1ZOPLkr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zjVvaM2jJJZh" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF ACCRUED EXPENSES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49F_20240131_zudJCphoE676" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_491_20230131_zZ3PQl6Hw3c3" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">January 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="text-align: center">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedSalariesCurrent_iI_zqBBCbxfpXD5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Employee benefits and related compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"> 1,071,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,079,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedExchangeFeeRebateCurrentAndNoncurrent_iI_zw3eVdmgVRr7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Professional fees and services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">389,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">294,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ThirdPartylicense_iI_zLPCmN1DR3Ol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Third party licenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">285,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ConcessionAccrualAmount_iI_zg0nP7105bSd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Customer concessions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">233,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">226,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_zvCIgbXYJ7Ra" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">State income and sales taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">226,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">331,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestPayableCurrent_iI_z4i3QH3r3wQ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Interest, primarily on term loan</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_iTI_zNtAGpNP6L76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Total accrued expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"> 2,023,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,265,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_ziQEqkTWZ7Nk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_ConcessionsAccrualPolicyTextBlock', window );">Concessions Accrual</a></td>
<td class="text"><p id="xdx_844_ecustom--ConcessionsAccrualPolicyTextBlock_zVUnlXdpFBWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zlO4ItNiqHx7">Concessions
Accrual</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company offers certain service level agreements within its client contracts such as uptime, support hours, and levels of support. Our
contracts may include, and we may offer, credits to clients when these service line agreements are not met. The service level agreements
are accounted for as variable consideration using a portfolio approach. As a result, we record an estimate of these concessions against
our recorded revenue. In determining the concessions accrual, the Company evaluates historical concessions granted relative to revenue
as well as future potential risk that these service level agreements will not be met. The Company records a provision, reducing revenue,
for the estimated amount of concessions incurred on the revenue recorded. The Company evaluates the amount of the concession accrual
each period for adequacy. Historically, concessions have not been significant. The concession accrual included in accrued expenses on
the Company&#8217;s consolidated balance sheet was $<span id="xdx_90F_ecustom--ConcessionAccrualAmount_iI_c20240131_zAOFCrXEIub6" title="Concession accrual amount">233,000</span> and $<span id="xdx_905_ecustom--ConcessionAccrualAmount_iI_c20230131_zWGrpYfO73Rl" title="Concession accrual amount">226,000</span> as of January 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zutAhpeflC7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zd2A8EaYq0yl">Property
and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_ecustom--PropertyPlantAndEquipmentTableTextBlock_zC7KvXeAvWKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related
assets. Estimated useful lives are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z81ryXv2b0Dk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    equipment and software</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember__srt--RangeAxis__srt--MinimumMember_z0N5TyjreMg1" title="Property and equipment, useful lives">3</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember__srt--RangeAxis__srt--MaximumMember_z7GCMwRYZIdk" title="Property and equipment, useful lives">4</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDDJAkGpKx3" title="Property and equipment, useful lives">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    furniture and fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zNnHLxZxDsNd" title="Property and equipment, useful lives">5</span>-<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z8hTCuXJU7Ic" title="Property and equipment, useful lives">7</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zH8BRKAElZcc" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0599">Term
    of lease or estimated useful life, whichever is shorter</span></span></span></td></tr>
  </table>
<p id="xdx_8A8_zyNmEEv8K9y2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for property and equipment in fiscal 2023 and 2022 was $<span id="xdx_90D_eus-gaap--Depreciation_pp0p0_c20230201__20240131_zQ9oaRDYoXqc" title="Depreciation expense">45,000</span> and $<span id="xdx_904_eus-gaap--Depreciation_pp0p0_c20220201__20230131_zq7fFQ6ABi41" title="Depreciation expense">54,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Normal
repairs and maintenance are expensed as incurred. Replacements are capitalized and the property and equipment accounts are relieved of
the items being replaced or disposed of, if no longer of value. The related cost and accumulated depreciation of the disposed assets
are eliminated and any gain or loss on disposition is included in the results of operations in the year of disposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zaelwKPvQTk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zAB09QPfEXra">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine whether an arrangement is a lease at inception. Right-of-use assets represent our right to use an underlying asset for the
lease term, and lease liabilities represent our obligation to make lease payments arising from the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected
lease term. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our
obligation to make lease payments arising from the lease. Since our lease arrangements do not provide an implicit rate, we use our estimated
incremental borrowing rate for the expected remaining lease term at commencement date in determining the present value of future lease
payments. We recognize operating lease cost on a straight-line basis by aggregating any rent abatement with the total expected rental
payments and amortizing the expense ratably over the term of the lease. Sublease income is recognized as other income over the period
of the lease, as the sublease is outside of the Company&#8217;s normal business operations. See Note 4 &#8211; Operating Leases for further
details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsIncurredPolicy', window );">Debt Issuance Costs</a></td>
<td class="text"><p id="xdx_844_eus-gaap--CostsIncurredPolicy_zkpabqXMLj52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zbj0NRIwpPY4">Debt
Issuance Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
related to the Second Amended and Restated Loan and Security Agreement (as amended and modified, the &#8220;Loan Agreement&#8221;)
with Western Alliance Bank (&#8220;WAB&#8221;) was capitalized and amortized to interest expense on a straight-line basis, which is not materially different
from the effective interest method, over the term of the related debt, and presented on the Company&#8217;s consolidated balance sheets
as a direct deduction from the carrying amount of the non-current portion of our term loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zX8DXegzCyW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zs8Gtbk0U2t3">Impairment
of Long-Lived Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews the carrying value of long-lived assets for impairment whenever facts and circumstances exist that would suggest that
assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation
are changes in market position and profitability. If facts and circumstances are present which may indicate that the carrying amount
of the assets may not be recoverable, the Company will prepare a projection of the undiscounted cash flows of the specific asset or asset
group and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment
will be made to reduce the carrying amount of these assets to their fair values. For fiscal 2023, an impairment of long-lived assets
in the amount of $963,000 was recorded. Refer to Note 6 &#8211; Goodwill and Intangible Assets to our consolidated financial statements
included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Capitalized Software Development Costs</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_zF7a44pacboh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zwXJ9NUbrFKi">Capitalized
Software Development Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software
development costs for software to be sold, leased, or marketed are accounted for in accordance with ASC 985-20, <i>Software &#8212; Costs
of Software to be Sold, Leased or Marketed</i>. Costs associated with the planning and design phase of software development are classified
as research and development costs and are expensed as incurred. Once technological feasibility has been established, a portion of the
costs incurred in development, including coding, testing and quality assurance, are capitalized until available for general release to
clients, and subsequently reported at the lower of unamortized cost or net realizable value. Amortization is calculated on a solution-by-solution
basis and is included in cost of professional fees and licenses on the consolidated statements of operations. Annual amortization is
measured at the greater of (i) the ratio of the software product&#8217;s current gross revenues to the total of current and expected
gross revenues or (ii) straight-line over the remaining economic life of the software (typically two years). Unamortized capitalized
costs determined to be in excess of the net realizable value of a solution are expensed at the date of such determination. Capitalized
software development costs for software to be sold, leased, or marketed, net of accumulated amortization, totaled $<span id="xdx_902_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SoftwareMember_z8hB6KTQk9M5" title="Capitalized software development costs, net of accumulated amortization">287,000</span> and $<span id="xdx_907_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20230131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SoftwareMember_zAXpZNJbSf9l" title="Capitalized software development costs, net of accumulated amortization">522,000</span>
as of January 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal-use
software development costs are accounted for in accordance with ASC 350-40, <i>Internal-Use Software</i>. The costs incurred in the preliminary
stages of development are expensed as research and development costs as incurred. Once an application has reached the development stage,
internal and external costs incurred to develop internal-use software are capitalized and amortized on a straight-line basis over the
estimated useful life of the software (typically three to four years). Maintenance and enhancement costs, including those costs in the
post-implementation stages, are typically expensed as incurred, unless such costs relate to substantial upgrades and enhancements to
the software that result in added functionality, in which case the costs are capitalized and amortized on a straight-line basis over
the estimated useful life of the software. The Company reviews the carrying value for impairment whenever facts and circumstances exist
that would suggest that assets might be impaired or that the useful lives should be modified. Amortization expense related to capitalized
internal-use software development costs is included in Cost of software as a service on the consolidated statements of operations. Capitalized
software development costs for internal-use software, net of accumulated amortization, totaled $<span id="xdx_90E_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zOXhpu5ZLb8l" title="Capitalized software development costs, net of accumulated amortization">5,511,000</span> and $<span id="xdx_909_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20230131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zH2TNWGlNF9d" title="Capitalized software development costs, net of accumulated amortization">5,324,000</span> as of January
31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated useful lives of software (including software to be sold and internal-use software) are reviewed frequently and adjusted as
appropriate to reflect upcoming development activities that may include significant upgrades and/or enhancements to the existing functionality.
The Company reviews, on an on-going basis, the carrying value of its capitalized software development expenditures, net of accumulated
amortization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense on all capitalized software development was $<span id="xdx_900_eus-gaap--CapitalizedComputerSoftwareAmortization1_pp0p0_c20230201__20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zc4Hyffjbrol">2,463,000</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_905_eus-gaap--CapitalizedComputerSoftwareAmortization1_pp0p0_c20220201__20230131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zOk89cFM1Ls9">2,423,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
fiscal 2023 and 2022, respectively. Further, the Company recognized an impairment of approximately $<span id="xdx_907_eus-gaap--AssetImpairmentCharges_pp0p0_c20230201__20240131_zslU6fQnpVz9">18,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_90E_eus-gaap--AssetImpairmentCharges_pp0p0_c20220201__20230131_zw3eAPJdspS2">0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
fiscal 2023 and fiscal 2022, respectively, related to cancelled or abandoned enhancement projects during fiscal 2023 and fiscal 2022
that have been recognized within amortization expense. Additionally, in fiscal 2023, entries of approximately $<span id="xdx_906_ecustom--AmortizedAndAbandonedAssets_pp0p0_c20230201__20240131_zfwYJdf0m7B7">18,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
fully amortized and abandoned assets were offset from their corresponding capitalization and
accumulated amortization balance sheet accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the &#8220;carry-over&#8221; method for amortizing capitalized software development costs. Under the &#8220;carry-over&#8221;
method, the costs of the enhancements are added to the unamortized costs of the previous version of the product and the combined amount
is amortized over the remaining useful life of the product. Including unamortized cost of the original product with the cost of the enhancement
for purposes of applying the net realizable value test and amortization provisions is consistent with accounting guidance for software
companies that improve their software and discontinue selling or marketing the older versions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"></p><p id="xdx_898_ecustom--ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock_zyTJHWMBeMT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zhrv1Qznrut">SCHEDULE
OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230201__20240131_zQfxTl39hMgl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220201__20230131_zz7OEADW8UZj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Amortization expense on internally-developed software included in:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CapitalizedComputerSoftwareAmortization1_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfSoftwareAsASeviceMember_zcyQJUA5T4Pa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: justify">Cost of software as a service</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,229,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,068,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareAmortization1_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfSoftwareAsASeviceMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfProfessionalFeesAndLicensesMember_zQTBEgFtBCWl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Cost of professional fees and licenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">234,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">355,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CapitalizedComputerSoftwareAmortization1_zRiRX6M6htrb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total amortization expense on internally-developed software</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,463,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,423,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zzFc3kastks3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interest capitalized to software development cost reduces the Company&#8217;s interest expense recognized in the consolidated statements
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expense was $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230201__20240131_zssQTQhnUnt1" title="Research and development expense">5,704,000</span> and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220201__20230131_z9G8p4mA0aH9" title="Research and development expense">6,042,000</span> in fiscal 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z7tG6fNFobLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zbQxjSCMpnXj">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB&#8217;s authoritative guidance on fair value measurements establishes a framework for measuring fair value and expands
disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to
develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine
fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the
following three categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Quoted market prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs that are not corroborated by market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based
on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. For fiscal 2023 and 2022,
there were no transfers of assets or liabilities between Levels 1, 2, or 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zxOrPn2IPCe5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below provides information on our liabilities that are measured at fair value on a recurring basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zTMLbE3nRxHe" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total Fair</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quoted Prices in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Active Markets</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Observable Inputs</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unobservable Inputs</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>At January 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F46_zvAP6QeUHmKf" style="padding-left: 10pt; width: 36%; text-align: left">Acquisition earnout liability (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131_fKDEp_z6YHvUHgJQGh" style="width: 12%; text-align: right" title="Acquisition earnout liability, Fair Value">1,794,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zqleoxHBOC68" style="width: 12%; text-align: right" title="Acquisition earnout liability fair value">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0647">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEp_zYR5RNQPDAd6" style="width: 12%; text-align: right" title="Acquisition earn out liability"><span style="-sec-ix-hidden: xdx2ixbrl0649">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fKDEp_zj6kL5TBNcA9" style="width: 12%; text-align: right" title="Acquisition earn out liability fair value, observable inputs">1,794,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>At January 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F4F_z7qG32tUQ7Ui" style="padding-left: 10pt; text-align: left">Acquisition earnout liability (1)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131_fKDEp_z7lGordx0Joa" style="text-align: right" title="Acquisition earnout liability, Fair Value">3,738,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zlmP8WJ3vUs4" style="text-align: right" title="Acquisition earnout liability fair value"><span style="-sec-ix-hidden: xdx2ixbrl0655">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEp_zcRF96jDYkij" style="text-align: right" title="Acquisition earn out liability"><span style="-sec-ix-hidden: xdx2ixbrl0657">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fKDEp_zKFbiSF0PWr6" style="text-align: right" title="Acquisition earn out liability fair value, observable inputs">3,738,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td id="xdx_F0D_zJGjjfpxLUhd" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zzAhJ0nNsIgj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fair value of the acquisition earnout liability is based upon a probability-weighted discounted cash flow that was completed at the
    date of acquisition and updated as of January 31, 2024. The change in the fair value of the acquisition earnout liability decreased
    $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUgQVNTRVRTIEFORCBMSUFCSUxJVElFUyBNRUFTVVJFRCBPTiBSRUNVUlJJTkcgQkFTSVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--AcquisitionEarnoutLiabilityChangeInValuation_c20230201__20240131_z0jICDkaYQXh" title="Acquisition earnout liability, change in valuation">1,944,000</span> for the year ended January 31, 2024, which is entirely recognized in &#8220;Acquisition earnout valuation adjustments&#8221;
    in the accompanying consolidated statement of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    probability-weighted discounted cash flow is calculated using a Monte Carlo valuation method. The valuation model provides numerous
    outcomes. The outcomes are averaged and discounted to present value, which provides the current value point estimate. The significant
    inputs include our forecast of Avelead SaaS revenue, the probabilities associated with each of (i) a change in control or (ii) a
    certain client termination, as well as other normal and customary inputs to financial models, including but not limited to, risk
    factors and interest rates.</span></td></tr>
  </table>
<p id="xdx_8A8_zApULSgz9ali" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s term loan under its Loan Agreement was determined through an analysis of the interest rate spread from
the date of closing the loan (August 2021) to the date of the most recent balance sheets, January 31, 2024 and January 31, 2023. The
term loan bears interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zAsaxSKShrR2" title="Prime interest rate">1.5</span>%, with a Prime
&#8220;floor&#8221; rate of <span id="xdx_90D_ecustom--PrimeInterestRatePercentage_pid_dp_uPure_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_z5xOTtlqE5H3" title="Prime interest rate percentage">3.25</span>%. The prime rate is variable and, thus accommodates changes in the market interest rate. However, the
interest rate spread (the <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131_zwxH5JQDtpE">1.5</span>% added to the Prime Rate) is fixed. We estimated the impact of the changes in the interest rate spread
by analogizing the effect of the change in the Corporate bond rates, reduced for any changes in the market interest rate. This provided
us with an estimated change to the interest rate spread of approximately <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--TypeOfArrangementAxis__custom--SecondAmendedAndRestatedLoanAndSecurityAgreementMember_zizgfI88JDdc" title="Interest rate">0.5</span>% from the date we entered the debt agreement to January
31, 2024 and January 31, 2023. The fair value of the debt as of January 31, 2024 and January 31, 2023 was estimated to be $<span id="xdx_90F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_zGvO65KA1klc" title="Debt instrument carrying amount">8,807,000</span>
and $<span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_zFSdnLsbmjmb" title="Debt instrument carrying amount">9,550,000</span>, respectively, or a discount to book value of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_z4wysqInh0nb" title="Term loan">193,000</span> and $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_zPpmQzcVJBDd" title="Term loan">200,000</span>, respectively. The fair value of the line of credit
as of January 31, 2024 was estimated to be $<span id="xdx_90B_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFjJDCqM5xMa" title="Debt instrument carrying amount">1,463,000</span>, or a discount to book value of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z5ECMMfpfUK6" title="Term loan">37,000</span>. The fair value of long-term debt was estimated using Level 2 inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z0La9yYYwfQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zwV0UXDf5CDf">Revenue
Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
derive revenue from the sale of internally-developed software, either by licensing for local installation or by a SaaS delivery model,
through our direct sales force or through third-party resellers. Licensed, locally-installed clients on a perpetual model utilize our
support and maintenance services for a separate fee, whereas term-based locally installed license fees and SaaS fees include support
and maintenance. We also derive revenue from professional services that support the implementation, configuration, training and optimization
of the applications, as well as audit services and consulting services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize revenue in accordance with Accounting Standards Codification (ASC) 606, <i>Revenue from Contracts with Clients</i> (&#8220;ASC
606&#8221;), under the core principle of recognizing revenue to depict the transfer of promised goods or services to clients in an amount
that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
commence revenue recognition (Step 5 below) in accordance with that core principle after applying the following steps:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    1: Identify the contract(s) with a client</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    2: Identify the performance obligations in the contract</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    3: Determine the transaction price</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    4: Allocate the transaction price to the performance obligations in the contract</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    5: Recognize revenue when (or as) the entity satisfies a performance obligation</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Often
contracts contain more than one performance obligation. Performance obligations are the unit of accounting for revenue recognition and
generally represent the distinct goods or services that are promised to the client. Revenue is recognized net of any taxes collected
from clients and subsequently remitted to governmental authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we determine that we have not satisfied a performance obligation, we defer recognition of the revenue until the performance obligation
is satisfied. Maintenance and support and SaaS agreements are generally non-cancellable or contain significant penalties for early cancellation,
although clients typically have the right to terminate their contracts for cause if we fail to perform material obligations. However,
if non-standard acceptance periods, non-standard performance criteria, or cancellation or right of refund terms are required, revenue
is recognized upon the satisfaction of such criteria.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price is determined by summing all the consideration the Company expects to receive from the client under the contract. At
times, a contract may have variable attributes (i.e., performance guarantees, service level agreements, optional terms) that the Company
must consider when establishing the transaction price to mitigate significant revenue reversals for the contract. The determined transaction
price is allocated based on the standalone selling price (&#8220;SSP&#8221;) of the performance obligations in contract. Significant
judgment is required to determine the SSP for each performance obligation, inclusion of variable consideration, the amount allocated
to each performance obligation and whether it depicts the amount that the Company expects to receive in exchange for the related product
and/or service. The Company recognizes revenue for implementation of its eValuator SaaS solution over the contract term, as it has been
determined that those implementation services are not a distinct performance obligation. Services for other SaaS and Software solutions
such as CDI, RevID and Compare, have been determined as a distinct performance obligation. For these agreements, the Company estimates
SSP of its software licenses using the residual approach when the software license is sold with other services and observable SSPs exist
for the other services. The Company estimates the SSP for maintenance, professional services, software as a service and audit services
based on observable standalone sales.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract
Combination</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may execute more than one contract or agreement with a single client. The Company evaluates whether the agreements were negotiated
as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance
of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions
reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related
to those arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has utilized the portfolio approach as the practical expedient. We have applied the revenue model to a portfolio of contracts
with similar characteristics where we expected that the financial statements would not differ materially from applying it to the individual
contracts within that portfolio.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Software
Licenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s software license arrangements provide the client with the right to use functional intellectual property. Implementation,
support, and other services are typically considered distinct performance obligations when sold with a software license unless these
services are determined to significantly modify the software. Revenue is recognized at a point in time. Typically, this is upon shipment
of components or electronic download of software.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Maintenance
and Support Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
maintenance and support obligations include multiple discrete performance obligations, with the two largest being unspecified product
upgrades or enhancements, and technical support, which can be offered at various points during a contract period. We believe that the
multiple discrete performance obligations within our overall maintenance and support obligations can be viewed as a single performance
obligation since both the unspecified upgrades and technical support are activities to fulfill the maintenance performance obligation
and are rendered concurrently. Maintenance and support agreements entitle clients to technology support, version upgrades, bug fixes
and service packs. We recognize maintenance and support revenue over the contract term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Software-Based
Solution Professional Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides various professional services to clients with software licenses. These include project management, software implementation
and software modification services. Revenues from arrangements to provide professional services are generally distinct from the other
promises in the contract and are recognized as the related services are performed. Consideration payable under these arrangements is
either fixed fee or on a time-and-materials basis and is recognized over time as the services are performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Software
as a Service</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SaaS-based
contracts include a right to use of the Company&#8217;s platform and support which represent a single promise to provide continuous access
to its software solutions. Implementation services for the Company&#8217;s eValuator product are included as part of the single promise
for its respective contracts. The Company recognizes revenue for implementation of the eValuator product over the contract term as it
is determined that the implementation on eValuator is not a distinct performance obligation. Implementation services for other SaaS products
are deemed to be separate performance obligations that are recognized over time as the services are performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides technology-enabled coding audit services to help clients review and optimize their internal clinical documentation and
coding functions across the applicable segment of the client&#8217;s enterprise. Audit services are a separate performance obligation.
We recognize revenue over time as the services are performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disaggregation
of Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_z0jY4a01NTw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information about disaggregated revenue by type and nature of revenue stream:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zlMowoknXAu9" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF DISAGGREGATON OF REVENUE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230201__20240131_zXglfbiAOxt4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220201__20230131_zjOgp3IivuTh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zQhbKUjvP4Ig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Over time revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">22,358,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">23,670,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zYqnLNCuvL5i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Point in time revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">238,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,219,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zNl6JRI2goeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,596,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,889,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z571tbGvK3ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company includes revenue categories of (i) over time and (ii) point in time revenue. The Company includes revenue categories of (i) SaaS,
(ii) maintenance and support, (iii) professional services, and (iv) audit services as over time revenue. For point in time revenue, the
performance obligation is recognized as the point in time when the obligation is fully satisfied. The Company includes software licenses
as point in time revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract
Assets and Deferred Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company receives payments from clients based upon contractual billing schedules. Contract receivables include amounts related to the
Company&#8217;s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenues include
payments received in advance of performance under the contract. Our contract receivables and deferred revenue are reported on an individual
contract basis at the end of each reporting period. Contract receivables are classified as current or noncurrent based on the timing
of when we expect to bill the client. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to
recognize revenue. In the year ended January 31, 2024, we recognized approximately $<span id="xdx_904_eus-gaap--DeferredRevenue_iI_pp0p0_c20230131_zjvxR3hWRfE3" title="Deferred revenue">7,642,000</span> in revenue from deferred revenues outstanding
as of January 31, 2023. Revenue allocated to remaining performance obligations was $<span id="xdx_903_eus-gaap--RevenueRemainingPerformanceObligation_iI_pp0p0_c20240131_zzJQFtl5lLgi" title="Revenue remaining performance obligation">31,414,000</span> &#160;&#160;as of January 31, 2024, of
which <span id="xdx_90E_eus-gaap--RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_c20230201__20240131_zMKGqlhUohX1" title="Revenue, remaining performance obligation, expected timing of satisfaction, explanation">the Company expects to recognize approximately 46% over the next 12 months and the remainder thereafter.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deferred
costs (costs to fulfill a contract and contract acquisition costs)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
defer the direct costs, which include salaries and benefits, for professional services related to SaaS contracts as a cost to fulfill
a contract. These deferred costs will be amortized on a straight-line basis over the contractual term. As of January 31, 2024, and 2023,
we had deferred costs of $<span id="xdx_907_eus-gaap--DeferredCostsCurrentAndNoncurrent_iI_pp0p0_c20240131_zVdxuFx5yI48" title="Deferred costs, net">77,000</span> and $<span id="xdx_90E_eus-gaap--DeferredCostsCurrentAndNoncurrent_iI_pp0p0_c20230131_zfIOvjbI3BN" title="Deferred costs, net">94,000</span>, respectively, net of accumulated amortization of $<span id="xdx_905_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_pp0p0_c20240131_zXk7UyCFT7qd" title="Accumulated amortization of deferred costs">102,000</span> and $<span id="xdx_909_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_pp0p0_c20230131_zfuai8uwzf78" title="Accumulated amortization of deferred costs">176,000</span>, respectively. Amortization
expense of these costs was $<span id="xdx_90A_ecustom--DeferredCostsAmortizationExpenses_pp0p0_c20230201__20240131_z8JxABz7wmd9" title="Deferred costs, amortization expense">82,000</span> and $<span id="xdx_901_ecustom--DeferredCostsAmortizationExpenses_pp0p0_c20220201__20230131_zM3D3eB7wswd" title="Deferred costs, amortization expense">83,000</span> in fiscal 2023 and 2022, respectively. There were no impairment losses for these capitalized
costs for the fiscal 2023 and 2022. Additionally, in fiscal 2023, approximately $<span id="xdx_905_eus-gaap--OtherAmortizationOfDeferredCharges_pp0p0_c20230201__20240131_z0ccSphI8kFj" title="Amortized contracts">155,000</span> of fully amortized contracts were cleared
from their corresponding capitalization and accumulated amortization balance sheet accounts, while no such adjustments were made in fiscal
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
acquisition costs, which consist of sales commissions paid or payable, is considered incremental and recoverable costs of obtaining a
contract with a client. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis
over the contract term. As a practical expedient, we expense sales commissions as incurred when the amortization period of related deferred
commission costs would have been one year or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
commissions costs paid and payable, which are included on the consolidated balance sheets within other non-current assets totaled $<span id="xdx_90E_ecustom--DeferredCommissionsCostsPaidAndPayable_iI_pp0p0_c20240131__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherNoncurrentAssetsMember_z6mG0uzfKR5b" title="Deferred commissions costs paid and payable">1,461,000</span>
and $<span id="xdx_907_ecustom--DeferredCommissionsCostsPaidAndPayable_iI_pp0p0_c20230131__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherNoncurrentAssetsMember_zp6gUZHH6ZN2" title="Deferred commissions costs paid and payable">1,534,000</span>, respectively, as of January 31, 2024 and 2023. In fiscal 2023 and 2022, amortization expense associated with deferred
sales commissions was $<span id="xdx_905_eus-gaap--AmortizationOfDeferredSalesCommissions_pp0p0_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zgWVS2cRmPA3" title="Amortization expense with deferred sales commissions">588,000</span> and $<span id="xdx_90D_eus-gaap--AmortizationOfDeferredSalesCommissions_pp0p0_c20220201__20230131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zC5wRguPWwcf" title="Amortization expense with deferred sales commissions">411,000</span>, respectively, and was included in selling, general and administrative expenses on the consolidated
statements of operations. There were $<span id="xdx_909_eus-gaap--CapitalizedContractCostImpairmentLoss_pp0p0_c20230201__20240131_zq6Lz5yN6ife" title="Impairment loss">35,000</span> and <span id="xdx_901_eus-gaap--CapitalizedContractCostImpairmentLoss_pp0p0_do_c20220201__20230131_zbNQzc4gtAk9" title="Impairment loss">no</span> impairment losses for these capitalized costs that was included with the amortization
expense for fiscal 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zL8F4xbnR08b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zXy7zlnS4U5c">Concentrations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments, which potentially expose the Company to concentrations of credit risk, consist primarily of accounts receivable. The Company&#8217;s
accounts receivables are concentrated in the healthcare industry. However, the Company&#8217;s clients typically are well-established
hospitals, medical facilities or major health information systems companies with good credit histories that resell the Company&#8217;s
solutions. Payments from clients have been received within normal time frames for the industry. However, some hospitals and medical facilities
have experienced significant operating losses as a result of limits on third-party reimbursements from insurance companies and governmental
entities and extended payment of receivables from these entities is not uncommon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has relied on a limited number of clients and remarketing partners for a substantial portion of its total revenues.
The Company expects that a significant portion of its future revenues will continue to be generated by a limited number of clients and
its remarketing partners.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zeAj1BAjGsyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zR3ftPEEQhza">Goodwill
and Intangible Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
and other intangible assets were recognized in conjunction with the Avelead acquisition, and certain other acquisitions from fiscal
2013 and prior (prior to divestiture of such assets). Identifiable intangible assets include purchased intangible assets with finite
lives, which primarily consist of internally-developed software and client relationships. Finite-lived purchased intangible assets
are amortized over their expected period of benefit, which generally ranges from <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dxL_c20240131__srt--RangeAxis__srt--MinimumMember_zA4bGYLesFfg" title="Finite-lived intangible assets amortized period::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl0732">one</span></span>
to <span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20240131__srt--RangeAxis__srt--MaximumMember_zBVML3cJc0Db" title="Finite-lived intangible assets amortized period">15</span>
years, using the straight-line method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses the useful lives and possible impairment of intangible assets when an event occurs that may trigger such a review. Factors
considered important which could trigger a review include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    underperformance relative to historical or projected future operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    changes in the manner of use of the acquired assets or the strategy for the overall business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification
    of other impaired assets within a reporting unit;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disposition
    of a significant portion of an operating segment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    negative industry or economic trends;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    decline in the Company&#8217;s stock price for a sustained period; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decline in the market capitalization relative to the net book value.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining
whether a triggering event has occurred involves significant judgment by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses goodwill annually (as of November 1), or more frequently when events and circumstances, such as the ones mentioned above,
occur indicating that the recorded goodwill may be impaired. In assessing qualitative factors to determine whether it is more likely
than not that the fair value of a reporting unit is less than its carrying amount, the Company assesses relevant events and circumstances
that may impact the fair value and the carrying amount of a reporting unit. The identification of relevant events and circumstances and
how these may impact a reporting unit&#8217;s fair value or carrying amount involve significant judgments by management. These judgments
include the consideration of macroeconomic conditions, industry and market considerations, cost factors, overall financial performance,
events which are specific to the Company and trends in the market price of the Company&#8217;s common stock. Each factor is assessed
to determine whether it impacts the impairment test positively or negatively, and the magnitude of any such impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended January 31, 2023, the Company did not note any of the above qualitative factors, which would be considered a triggering
event for goodwill impairment. During the year ended January 31, 2024, the Company identified one or more factors that triggered goodwill
impairment as of October 31, 2023, as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the third quarter of fiscal 2023, the Company received a notice from a significant SaaS client of its intent not to renew its contract
following the expiration of the current term on December 31, 2023. At that time, the Company elected to accelerate the execution of the
2023 Restructuring that was designed to reduce costs while maintaining the Company&#8217;s ability to expand its SaaS business. Both
the client termination and the execution of the Strategic Restructuring were announced on October 16, 2023. Following these announcements,
the Company&#8217;s share price declined significantly. Based on these events (collectively, the &#8220;Triggering Events&#8221;), the
Company identified indicators of possible impairment and initiated testing using a valuation date of October 31, 2023. The impairment
tests were conducted under guidance of ASC Topic 360, Impairment and Disposal of Long-Lived Assets (&#8220;ASC 360&#8221;) for certain
long-lived assets, including capitalized contract costs, developed technology, client relationships and trade names, and in accordance
with ASC Topic 350, Intangibles &#8211; Goodwill and Other (&#8220;ASC 350&#8221;) with respect to the reporting unit&#8217;s goodwill.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reporting
units are determined based on the organizational structure the entity has in place at the date of the impairment test. A reporting unit
is an operating segment or component business unit with the following characteristics: (a) it has discrete financial information, (b)
segment management regularly reviews its operating results (generally an operating segment has a segment manager who is directly accountable
to and maintains regular contact with the chief operating decision maker to discuss operating activities, financial results, forecasts
or plans for the segment), and (c) its economic characteristics are dissimilar from other units (this contemplates the nature of the
products and services, the nature of the production process, the type or class of client for the products and services and the methods
used to distribute the products and services). The Company determined that for fiscal 2023 it has one operating segment and one reporting
unit, while for fiscal 2022 it had one operating segment and two reporting units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of its reporting unit using a combination of the market approach and income approach, via
discounted cash flow valuation models which include, but are not limited to, assumptions such as a &#8220;risk-free&#8221; rate of
return on an investment, the weighted average cost of capital of a market participant and future revenue, operating margin, working
capital and capital expenditure trends. Determining the fair value of reporting units and goodwill includes significant judgment by
management, and different judgments could yield different results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performed its annual goodwill assessment for fiscal 2023 as of October 31, 2023 using the approaches described above. The
assessment identified a goodwill impairment of $9,813,000 that was recorded. Based on the analysis performed for fiscal 2022, the fair
value of the reporting units exceeded the carrying amount of the reporting unit, including goodwill, and, therefore, a goodwill impairment
loss was not recognized. &#160; Refer to Note 6 &#8211; Goodwill and Intangible Assets to our consolidated financial statements included
in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_EquityAwardPolicyTextBlock', window );">Equity Awards</a></td>
<td class="text"><p id="xdx_84C_ecustom--EquityAwardPolicyTextBlock_zKl6DDIRUcyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_za30GXIH31Ah">Equity
Awards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as
expense over the requisite service period. For awards to non-employees, the Company recognizes compensation expense in the same
manner as if the entity had paid cash for the goods or services. The Company incurred total annual compensation expense related to
stock-based awards of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230201__20240131__us-gaap--AwardTypeAxis__custom--EquityAwardMember_zH1uJNztuAL8" title="Compensation expense related to stock-based award">2,102,000</span>
in fiscal 2023, net of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20230201__20240131__us-gaap--AwardTypeAxis__custom--EquityAwardMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zw4aTB8Ufp58" title="Compensation expense related to stock-based award">140,000</span>
of capitalized non-employee stock compensation, and $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20220201__20230131__us-gaap--AwardTypeAxis__custom--EquityAwardMember_z74WRKZ8A4ye" title="Compensation expense related to stock-based award">1,680,000</span>
net of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20220201__20230131__us-gaap--AwardTypeAxis__custom--EquityAwardMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMZp75ifhVhj" title="Compensation expense related to stock-based award">81,000</span> of capitalized non-employee stock compensation, in fiscal 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the stock options granted are estimated at the date of grant using a Black-Scholes option pricing model. Option pricing
model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. The Company
recognizes forfeitures as they occur. These assumptions are subjective and are generally derived from external (such as, risk-free rate
of interest) and historical data (such as, volatility factor, expected term and forfeiture rates). Future grants of equity awards accounted
for as stock-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period
of future awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market
close price per share on the grant date. The Company expenses the compensation cost of these awards as the restriction period
lapses, which is typically a one- to four-year service period to the Company. In fiscal 2023 and 2022, <span id="xdx_903_ecustom--SurrenderOfStockSharesDuringPeriod_c20230201__20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztKBLwWQQkS" title="Surrender of stock, shares">190,950</span>
and <span id="xdx_90E_ecustom--SurrenderOfStockSharesDuringPeriod_c20220201__20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCzvG3cob019" title="Surrender of stock, shares">127,429</span>
shares of common stock were surrendered to the Company to satisfy tax withholding obligations totaling $<span id="xdx_901_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z9vP8EYbfCl1" title="Cost of shares for tax withholding">280,000</span>
and $<span id="xdx_908_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHWOF4tLnhYd" title="Cost of shares for tax withholding">197,000</span>,
respectively, in connection with the vesting of restricted stock awards. Shares surrendered by the restricted stock award recipients
in accordance with the applicable plan are deemed cancelled, and therefore are not available to be reissued. The Company awarded <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230201__20240131__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zn293hzastO8" title="Number shares of restricted stock">1,203,621</span>
and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220201__20230131__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zz1WS8q7RpXb" title="Number shares of restricted stock">890,731</span>
shares of restricted stock to its executive officers and directors of the Company in fiscal 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_z2Bp32guHuX7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zuOU4Xaz3zHi">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net
deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be
realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets
will not be realized. Refer to Note 7 &#8211; Income Taxes to our consolidated financial statements included in Part II, Item 8, &#8220;Financial
Statements and Supplementary Data&#8221; for further details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether
certain tax positions are more likely than not to be sustained upon examination by tax authorities. At January 31, 2024, the Company
believes it has appropriately accounted for any uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Earnings (Loss) Per Common Share</a></td>
<td class="text"><p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zdkEWKyw49A8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zOl7MFqG7GD1">Net
Earnings (Loss) Per Common Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company presents basic and diluted earnings per share (&#8220;EPS&#8221;) data for our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
unvested restricted stock awards are considered non-participating securities because holders are not entitled to non-forfeitable rights
to dividends or dividend equivalents during the vesting term. In accordance with ASC 260, securities are deemed not to be participating
in losses if there is no obligation to fund such losses. Diluted EPS for our common stock is computed using the treasury stock method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zSKoGeFheh9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is the calculation of the basic and diluted net loss per share of common stock:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zm55lTHK41lc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230201__20240131_zT16hi7c2tZe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220201__20230131_zYEzhQSz4uQ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Basic earnings (loss) per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperations_i01_zBDKZfLAlsh" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Loss, net of tax</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(18,697,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(11,379,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_i01_zcADVlyaHmAd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic net loss per share of common stock </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.33</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.23</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Diluted earnings (loss) per share (1):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_i01_zrjqeeC06QW2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss available to common stockholders </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,697,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,379,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_i01_zHSqEJzPzmPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Diluted net loss per share of common stock </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.33</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.23</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_zcStVat5IQg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,697,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,379,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zGLtOkhm5wdg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average shares outstanding &#8211; Basic (1)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F45_zYg8GXeSOw63" style="display: none">(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,510,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,324,858</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks_pid_z9VIeZG2nNmb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of dilutive securities - Stock options and Restricted stock (2)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F4E_z505HyUzBWob" style="display: none">(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0783">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zDqQ2pJbNI0e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average shares outstanding &#8211; Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">56,510,419</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">49,324,858</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareBasic_pid_zMA0HSp97Zkj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net loss per share of common stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zUrF65h71AU9"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zomVu3fzr7o6">(0.33</span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zaQNiVQiGZue"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zRmiwnEX7gW2">(0.23</span></span></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_F0E_zl3tpEFjuksg" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_zbOLVzSiI5j4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excludes
    the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of January 31, 2024
    and 2023, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zOkiNJqczEvk" title="Diluted earnings per share">1,970,521</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z2lI0oNs2rt9" title="Diluted earnings per share">1,848,031</span> unvested restricted shares of common stock, respectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_F01_zJ3XaglWt9Ta" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zqD6zjckRZpk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
    net loss per share excludes the effect of shares that are anti-dilutive. As of January 31, 2024, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6ObtBNkGuq3" title="Diluted earnings per share">67,500</span> outstanding stock
    options and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedSharesMember_z7x8lmNjloWl" title="Diluted earnings per share">1,970,521</span> unvested restricted shares of common stock. As of January 31, 2023, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zg2cyB4sQ6Wk" title="Diluted earnings per share">628,598</span> outstanding stock options
    and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zKuhWu16S4uk" title="Diluted earnings per share">1,848,031</span> unvested restricted shares of common stock.</span></td></tr>
  </table>
<p id="xdx_8AF_z8jXXPKpkPg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Loss Contingencies</a></td>
<td class="text"><p id="xdx_846_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zvZi28wtxQN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zumJhOzXsvw9">Loss
Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the possibility of various loss contingencies arising in the normal course of business. We consider the likelihood of
the loss or impairment of an asset or the incurrence of a liability as well as our ability to reasonably estimate the amount of loss
in determining loss contingencies. An estimated loss contingency is accrued when it is probable that a liability has been incurred or
an asset has been impaired, and the amount of loss can be reasonably estimated. We regularly evaluate current information available to
us to determine whether to accrue for a loss contingency and adjust any previous accrual.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy', window );">Restructuring</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_zQ0wKmvymZw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zugotMys2zFf">Restructuring</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 16, 2023, the Company announced it was executing a Strategic Restructuring designed to reduce expenses while maintaining the
Company&#8217;s ability to expand its SaaS business. The Strategic Restructuring initiatives included a reduction in force, resulting
in the termination of <span id="xdx_908_ecustom--NumberOfEmployeesTerminated_iI_uInteger_c20231016_ztRLXFZsGe6k" title="Number of employees terminated">26</span> employees, or approximately <span id="xdx_90C_ecustom--PercentageOfWorkforceTerminated_iI_dp_uPure_c20231016_zCIaWNVmFlOl" title="Percentage of workforce terminated">24</span>% of the Company&#8217;s workforce. To execute the Strategic Restructuring, the
Company incurred one-time restructuring costs associated with the workforce reduction of approximately $<span id="xdx_905_eus-gaap--RestructuringCosts_c20231016__20231016_zOntCOm1uCwk" title="Restructuring costs">759,000</span>, and the Company has
recognized all expenses associated with the Strategic Restructuring as of the end of fiscal 2023. The costs pertain to severance and
other employee termination-related costs and various professional fees the Company required to assist with execution of the Strategic
Restructuring. The following is a reconciliation of the Strategic Restructuring liability reflected on the Company&#8217;s condensed
consolidated balance sheet under &#8220;Accrued expenses&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p id="xdx_89B_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_zcPd5Sclhq91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_zVUN80vYpDjh" style="display: none">SCHEDULE OF RECONCILIATION OF THE
RESTRUCTURING LIABILITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="22" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Accrued</b></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Accrued</b></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of January 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance as of January 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 Expenses to Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 Cash Payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance as of January 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Costs Incurred to Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Expected Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Severance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 34%">Cost of sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zK31whEsQUl" style="width: 8%; text-align: right" title="Accrued Balance as of January 31, 2023">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0821">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zsRfRkAAqw71" style="width: 8%; text-align: right" title="2023 Expenses to Date">154</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zcnAbrwMJzQa" style="width: 8%; text-align: right" title="2023 Cash Payments">154</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z1XWbK9im3gh" style="width: 8%; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zb2xjwlXrNb4" style="width: 8%; text-align: right" title="Total Costs Incurred to Date">154</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zFGeb8oZh734" style="width: 8%; text-align: right" title="Total Expected Costs">154</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling, general, and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zgF3AlYQNYUi" style="text-align: right" title="Accrued Balance as of January 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0833">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zFKeiNiACPD5" style="text-align: right" title="2023 Expenses to Date">350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zlGv358wxWZ9" style="text-align: right" title="2023 Cash Payments">276</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zwjns1Y39W3j" style="text-align: right" title="Accrued Balance as of October 31, 2023">74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zqiRzO1j4id2" style="text-align: right" title="Total Costs Incurred to Date">350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zm3HYOaSlDqi" style="text-align: right" title="Total Expected Costs">350</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zy3QuKboUiOk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Balance as of January 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0845">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUNiTrqAejec" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Expenses to Date">227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4NPCwihCzLj" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Cash Payments">227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zuMRQ6AL6PJf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgrKQdtRzK87" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Costs Incurred to Date">227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z7In9BvhxtD8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Expected Costs">227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total severance expense</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zcGYDLCzhqB2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of January 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zFdNqBp0GSDf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Expenses to Date">731</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zbwd77jepsYj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Cash Payments">657</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zwEck8mknhDi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023">74</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_980_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zFr7ZMv4ErYc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Costs Incurred to Date">731</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zqrWNVOuH3bk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Expected Costs">731</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Professional fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zdCAEngK0Gh6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Balance as of January 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0869">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zSWcGLNkZwgd" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Expenses to Date">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zUTCupmUPFGg" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Cash Payments">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zbnlHH6m9rwd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0875">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zsWSpXRo7Mkg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Costs Incurred to Date">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zlKYj9LQchU5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Expected Costs">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_z5PZIGP8Azf2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of January 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0881">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zyRdI1Qbma37" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Expenses to Date">759</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98A_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zMmuGj9t21Bk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Cash Payments">685</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zhqpQ87SlXH6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023">74</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zeQHXKBypUL1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Costs Incurred to Date">759</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zKbmG4cP32U4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Expected Costs">759</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zRFfSpqmEYml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Recently Adopted</a></td>
<td class="text"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z1THQ0hFrhN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zikcQEMVG2X">Accounting
Pronouncements Recently Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2019, the FASB issued ASU 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which improves guidance around accounting for financial losses on accounts receivable. For smaller reporting entities, ASU
2016-13 is effective for annual periods beginning after December 15, 2022, including interim periods within those fiscal years. The Company&#8217;s
adoption of ASU 2016-13 was effective February 1, 2023. An analysis of contract receivables, including credit losses, was conducted during
the first quarter of fiscal 2024. The adoption of this ASU did not have a material impact on our consolidated financial statements
or disclosures.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p id="xdx_84B_ecustom--RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zbwSureRh1pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zZlBtIO4H9M6">Recent
Accounting Pronouncements Not Yet Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves
guidance around the disclosures about a public entity&#8217;s reportable segments and additional details about a reportable segment&#8217;s
expenses. ASU 2023-07 is effective for all public entities for annual periods beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. The Company&#8217;s adoption of ASU 2023-07 will be effective in the annual report
for the fiscal year ending January 31, 2025. The adoption of this ASU is not expected to have a material impact on our consolidated financial
statements or disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhance the transparency
and decision usefulness of income tax disclosures. For public entities, ASU 2023-09 is effective for annual periods beginning after December
15, 2024. The adoption of this ASU is not expected to have a material impact on our consolidated financial statements or disclosures.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_AccruedExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_AccruedExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_AllowanceForCreditLossesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_AllowanceForCreditLossesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_ConcessionsAccrualPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concessions Accrual [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_ConcessionsAccrualPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_EquityAwardPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Award [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_EquityAwardPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going Concern [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recent Accounting Pronouncements Not Yet Adopted [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsIncurredPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for property acquisition, exploration, and development cost incurred in oil- and gas-producing activities and whether cost is capitalized or charged to expense when incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 932<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477215/932-235-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsIncurredPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-40/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/730/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961598519664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock', window );">SCHEDULE OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</a></td>
<td class="text"><p id="xdx_89F_ecustom--ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock_z1maRBLwUz69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following items that were non-cash items related to the consolidated statements of cash flows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zNqLG3nkHJTj" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230201__20240131_zurqW0nQ9sbh" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220201__20230131_zEEvneV5twwa" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Fiscal Year</b></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr id="xdx_40A_eus-gaap--RestrictedStockExpense_zog1qLL5VDyc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Payment of acquisition earnout liabilities in restricted common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">3,012,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--CapitalizedSoftwarePurchasedWithStock_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized software purchased with stock (<i>See Note 12</i>)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DeferredFinancingCosts_z5B0BQA42Im8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">SCHEDULE OF RESERVE RESULTS IN FUTURE PERIODS</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfRestructuringReserveByTypeOfCostTextBlock_zfqA1D3oTMu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zu0obzYOwHKb" style="display: none">SCHEDULE
OF RESERVE RESULTS IN FUTURE PERIODS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CECL Adoption</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="text-align: center">&#160;</td><td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Provision adjustments</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Write-offs &amp; Recoveries</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 39%; text-align: left; padding-bottom: 1.5pt">Allowance for credit losses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20230201__20240131_z5AgnJ7s7tPl" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Balance">132,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--AllowanceForDoubtfulAccountsReceivableCECLAdoption_c20230201__20240131_zeIXWjucoLQ4" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, CECL Adoption">(36,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="width: 1%">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 1%">$</td>
    <td id="xdx_987_eus-gaap--ProvisionForDoubtfulAccounts_c20230201__20240131_zUzIajVrro0k" style="border-bottom: Black 1.5pt solid; text-align: right; width: 9%; vertical-align: bottom" title="Allowance for credit losses, Provision adjustments">(10,000</td>
    <td style="padding-bottom: 1.5pt; width: 1%">)&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 2%; text-align: left">$</td><td id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20230201__20240131_zZhmkzIUbMp2" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Write-offs &amp; Recoveries"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20230201__20240131_zZ33ZyhBjhP5" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Balance">86,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED EXPENSES</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zssA1ZOPLkr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zjVvaM2jJJZh" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF ACCRUED EXPENSES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49F_20240131_zudJCphoE676" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_491_20230131_zZ3PQl6Hw3c3" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">January 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="text-align: center">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedSalariesCurrent_iI_zqBBCbxfpXD5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Employee benefits and related compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"> 1,071,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,079,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedExchangeFeeRebateCurrentAndNoncurrent_iI_zw3eVdmgVRr7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Professional fees and services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">389,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">294,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ThirdPartylicense_iI_zLPCmN1DR3Ol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Third party licenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">285,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ConcessionAccrualAmount_iI_zg0nP7105bSd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Customer concessions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">233,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">226,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_zvCIgbXYJ7Ra" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">State income and sales taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">226,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">331,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestPayableCurrent_iI_z4i3QH3r3wQ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Interest, primarily on term loan</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_iTI_zNtAGpNP6L76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Total accrued expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"> 2,023,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,265,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_PropertyPlantAndEquipmentTableTextBlock', window );">SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_891_ecustom--PropertyPlantAndEquipmentTableTextBlock_zC7KvXeAvWKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related
assets. Estimated useful lives are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z81ryXv2b0Dk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    equipment and software</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember__srt--RangeAxis__srt--MinimumMember_z0N5TyjreMg1" title="Property and equipment, useful lives">3</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember__srt--RangeAxis__srt--MaximumMember_z7GCMwRYZIdk" title="Property and equipment, useful lives">4</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDDJAkGpKx3" title="Property and equipment, useful lives">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    furniture and fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zNnHLxZxDsNd" title="Property and equipment, useful lives">5</span>-<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z8hTCuXJU7Ic" title="Property and equipment, useful lives">7</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zH8BRKAElZcc" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0599">Term
    of lease or estimated useful life, whichever is shorter</span></span></span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock', window );">SCHEDULE OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE</a></td>
<td class="text"><p id="xdx_898_ecustom--ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock_zyTJHWMBeMT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zhrv1Qznrut">SCHEDULE
OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230201__20240131_zQfxTl39hMgl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220201__20230131_zz7OEADW8UZj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Amortization expense on internally-developed software included in:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CapitalizedComputerSoftwareAmortization1_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfSoftwareAsASeviceMember_zcyQJUA5T4Pa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: justify">Cost of software as a service</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,229,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,068,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareAmortization1_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfSoftwareAsASeviceMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfProfessionalFeesAndLicensesMember_zQTBEgFtBCWl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Cost of professional fees and licenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">234,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">355,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CapitalizedComputerSoftwareAmortization1_zRiRX6M6htrb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total amortization expense on internally-developed software</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,463,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,423,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zxOrPn2IPCe5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below provides information on our liabilities that are measured at fair value on a recurring basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zTMLbE3nRxHe" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total Fair</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quoted Prices in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Active Markets</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Observable Inputs</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unobservable Inputs</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>At January 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F46_zvAP6QeUHmKf" style="padding-left: 10pt; width: 36%; text-align: left">Acquisition earnout liability (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131_fKDEp_z6YHvUHgJQGh" style="width: 12%; text-align: right" title="Acquisition earnout liability, Fair Value">1,794,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zqleoxHBOC68" style="width: 12%; text-align: right" title="Acquisition earnout liability fair value">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0647">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEp_zYR5RNQPDAd6" style="width: 12%; text-align: right" title="Acquisition earn out liability"><span style="-sec-ix-hidden: xdx2ixbrl0649">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fKDEp_zj6kL5TBNcA9" style="width: 12%; text-align: right" title="Acquisition earn out liability fair value, observable inputs">1,794,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>At January 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F4F_z7qG32tUQ7Ui" style="padding-left: 10pt; text-align: left">Acquisition earnout liability (1)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131_fKDEp_z7lGordx0Joa" style="text-align: right" title="Acquisition earnout liability, Fair Value">3,738,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zlmP8WJ3vUs4" style="text-align: right" title="Acquisition earnout liability fair value"><span style="-sec-ix-hidden: xdx2ixbrl0655">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEp_zcRF96jDYkij" style="text-align: right" title="Acquisition earn out liability"><span style="-sec-ix-hidden: xdx2ixbrl0657">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fKDEp_zKFbiSF0PWr6" style="text-align: right" title="Acquisition earn out liability fair value, observable inputs">3,738,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td id="xdx_F0D_zJGjjfpxLUhd" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zzAhJ0nNsIgj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fair value of the acquisition earnout liability is based upon a probability-weighted discounted cash flow that was completed at the
    date of acquisition and updated as of January 31, 2024. The change in the fair value of the acquisition earnout liability decreased
    $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUgQVNTRVRTIEFORCBMSUFCSUxJVElFUyBNRUFTVVJFRCBPTiBSRUNVUlJJTkcgQkFTSVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--AcquisitionEarnoutLiabilityChangeInValuation_c20230201__20240131_z0jICDkaYQXh" title="Acquisition earnout liability, change in valuation">1,944,000</span> for the year ended January 31, 2024, which is entirely recognized in &#8220;Acquisition earnout valuation adjustments&#8221;
    in the accompanying consolidated statement of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    probability-weighted discounted cash flow is calculated using a Monte Carlo valuation method. The valuation model provides numerous
    outcomes. The outcomes are averaged and discounted to present value, which provides the current value point estimate. The significant
    inputs include our forecast of Avelead SaaS revenue, the probabilities associated with each of (i) a change in control or (ii) a
    certain client termination, as well as other normal and customary inputs to financial models, including but not limited to, risk
    factors and interest rates.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">SCHEDULE OF DISAGGREGATON OF REVENUE</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_z0jY4a01NTw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information about disaggregated revenue by type and nature of revenue stream:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zlMowoknXAu9" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF DISAGGREGATON OF REVENUE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230201__20240131_zXglfbiAOxt4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220201__20230131_zjOgp3IivuTh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zQhbKUjvP4Ig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Over time revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">22,358,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">23,670,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zYqnLNCuvL5i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Point in time revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">238,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,219,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zNl6JRI2goeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,596,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,889,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zSKoGeFheh9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is the calculation of the basic and diluted net loss per share of common stock:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zm55lTHK41lc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230201__20240131_zT16hi7c2tZe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220201__20230131_zYEzhQSz4uQ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Basic earnings (loss) per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperations_i01_zBDKZfLAlsh" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Loss, net of tax</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(18,697,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(11,379,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_i01_zcADVlyaHmAd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic net loss per share of common stock </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.33</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.23</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Diluted earnings (loss) per share (1):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_i01_zrjqeeC06QW2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss available to common stockholders </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,697,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,379,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_i01_zHSqEJzPzmPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Diluted net loss per share of common stock </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.33</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.23</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_zcStVat5IQg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,697,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,379,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zGLtOkhm5wdg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average shares outstanding &#8211; Basic (1)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F45_zYg8GXeSOw63" style="display: none">(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,510,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,324,858</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks_pid_z9VIeZG2nNmb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of dilutive securities - Stock options and Restricted stock (2)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F4E_z505HyUzBWob" style="display: none">(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0783">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zDqQ2pJbNI0e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average shares outstanding &#8211; Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">56,510,419</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">49,324,858</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareBasic_pid_zMA0HSp97Zkj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net loss per share of common stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zUrF65h71AU9"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zomVu3fzr7o6">(0.33</span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zaQNiVQiGZue"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zRmiwnEX7gW2">(0.23</span></span></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_F0E_zl3tpEFjuksg" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_zbOLVzSiI5j4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excludes
    the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of January 31, 2024
    and 2023, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zOkiNJqczEvk" title="Diluted earnings per share">1,970,521</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z2lI0oNs2rt9" title="Diluted earnings per share">1,848,031</span> unvested restricted shares of common stock, respectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_F01_zJ3XaglWt9Ta" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zqD6zjckRZpk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
    net loss per share excludes the effect of shares that are anti-dilutive. As of January 31, 2024, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6ObtBNkGuq3" title="Diluted earnings per share">67,500</span> outstanding stock
    options and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedSharesMember_z7x8lmNjloWl" title="Diluted earnings per share">1,970,521</span> unvested restricted shares of common stock. As of January 31, 2023, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zg2cyB4sQ6Wk" title="Diluted earnings per share">628,598</span> outstanding stock options
    and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zKuhWu16S4uk" title="Diluted earnings per share">1,848,031</span> unvested restricted shares of common stock.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">SCHEDULE OF RECONCILIATION OF THE RESTRUCTURING LIABILITY</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_zcPd5Sclhq91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_zVUN80vYpDjh" style="display: none">SCHEDULE OF RECONCILIATION OF THE
RESTRUCTURING LIABILITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="22" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Accrued</b></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Accrued</b></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of January 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance as of January 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 Expenses to Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 Cash Payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance as of January 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Costs Incurred to Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Expected Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Severance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 34%">Cost of sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zK31whEsQUl" style="width: 8%; text-align: right" title="Accrued Balance as of January 31, 2023">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0821">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zsRfRkAAqw71" style="width: 8%; text-align: right" title="2023 Expenses to Date">154</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zcnAbrwMJzQa" style="width: 8%; text-align: right" title="2023 Cash Payments">154</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z1XWbK9im3gh" style="width: 8%; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zb2xjwlXrNb4" style="width: 8%; text-align: right" title="Total Costs Incurred to Date">154</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zFGeb8oZh734" style="width: 8%; text-align: right" title="Total Expected Costs">154</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling, general, and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zgF3AlYQNYUi" style="text-align: right" title="Accrued Balance as of January 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0833">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zFKeiNiACPD5" style="text-align: right" title="2023 Expenses to Date">350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zlGv358wxWZ9" style="text-align: right" title="2023 Cash Payments">276</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zwjns1Y39W3j" style="text-align: right" title="Accrued Balance as of October 31, 2023">74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zqiRzO1j4id2" style="text-align: right" title="Total Costs Incurred to Date">350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zm3HYOaSlDqi" style="text-align: right" title="Total Expected Costs">350</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zy3QuKboUiOk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Balance as of January 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0845">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUNiTrqAejec" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Expenses to Date">227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4NPCwihCzLj" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Cash Payments">227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zuMRQ6AL6PJf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgrKQdtRzK87" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Costs Incurred to Date">227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z7In9BvhxtD8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Expected Costs">227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total severance expense</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zcGYDLCzhqB2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of January 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zFdNqBp0GSDf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Expenses to Date">731</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zbwd77jepsYj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Cash Payments">657</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zwEck8mknhDi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023">74</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_980_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zFr7ZMv4ErYc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Costs Incurred to Date">731</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zqrWNVOuH3bk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Expected Costs">731</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Professional fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zdCAEngK0Gh6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Balance as of January 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0869">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zSWcGLNkZwgd" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Expenses to Date">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zUTCupmUPFGg" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Cash Payments">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zbnlHH6m9rwd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0875">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zsWSpXRo7Mkg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Costs Incurred to Date">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zlKYj9LQchU5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Expected Costs">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_z5PZIGP8Azf2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of January 31, 2023"><span style="-sec-ix-hidden: xdx2ixbrl0881">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zyRdI1Qbma37" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Expenses to Date">759</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98A_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zMmuGj9t21Bk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Cash Payments">685</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zhqpQ87SlXH6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023">74</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zeQHXKBypUL1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Costs Incurred to Date">759</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zKbmG4cP32U4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Expected Costs">759</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_PropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property Plant and Equipment [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_PropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of amortization expense for internally developed software table [Text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of non-cash items related to condensed consolidated statements of cash flow [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961694972368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfDebtTableTextBlock_zZTqivM7mC6l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
principal balances on debt consisted of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zIytIO7PNH0l" style="display: none">SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240131_zacxl86TTnN4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230131_zRpV9I2nBiVh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzuRq_zw3eOnhiWl2h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Term loan</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">9,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">9,750,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinancingCostPayable_iI_maLTDzuRq_z5rOfXEcrXl2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><p style="margin: 0">Financing cost payable</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">135,000</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredFinancingCost_iNI_di_msLTDzuRq_zd3Zcy02MIQ6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Deferred financing cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(69,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(105,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--LongTermDebt_iTI_mtLTDzuRq_z56OAhOzgq42" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,066,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,714,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LongTermDebtCurrent_iNI_di_zWlNIc4uEZT1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: Current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(750,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iTI_zvHBV6E31KO2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Non-current portion of debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,566,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,964,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_ScheduleOfMaximumDebtToARRRatioTableTextBlock', window );">SCHEDULE OF MAXIMUM DEBT TO ARR RATIO</a></td>
<td class="text"><p id="xdx_89C_ecustom--ScheduleOfMaximumDebtToARRRatioTableTextBlock_zFsyON9BqLI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z3IDq1bf3Ssi" style="display: none">SCHEDULE OF MAXIMUM DEBT TO ARR RATIO</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 82%; font-weight: bold">Quarter Ending</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum Debt to</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARR Ratio</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>October 31, 2022</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyTwoMember__srt--RangeAxis__srt--MinimumMember_zkYZyp1qcArk" title="Maximum Debt to ARR Ratio">0.80</span> to <span id="xdx_90A_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyTwoMember__srt--RangeAxis__srt--MaximumMember_zS6lLRAspk34" title="Maximum Debt to ARR Ratio">1.00</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>January 31, 2023</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_z0nfek6Cs6Mk" title="Maximum Debt to ARR Ratio">0.70</span> to <span id="xdx_90B_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_zGxFFbwbwcJf" title="Maximum Debt to ARR Ratio">1.00</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>April 30, 2023</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_zjdTm3Km4f02" title="Maximum Debt to ARR Ratio">0.65</span> to <span id="xdx_90B_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_z5yhyJiREnbi" title="Maximum Debt to ARR Ratio">1.00</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>July 31, 2023</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_zlDVmHjdrCC9" title="Maximum Debt to ARR Ratio">0.60</span> to <span id="xdx_908_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_zIU2Q1CZLso3" title="Maximum Debt to ARR Ratio">1.00</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>October 31, 2023</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_z2V2Wox2jlPh" title="Maximum Debt to ARR Ratio">0.55</span> to <span id="xdx_90B_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_zjZmiRMW8Ztd" title="Maximum Debt to ARR Ratio">1.00</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>January 31, 2024</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyFourMember__srt--RangeAxis__srt--MinimumMember_zBWwJwWdAdPd" title="Maximum Debt to ARR Ratio">0.50</span> to <span id="xdx_90A_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyFourMember__srt--RangeAxis__srt--MaximumMember_zMtLsRQmtJC4" title="Maximum Debt to ARR Ratio">1.00</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock', window );">SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO</a></td>
<td class="text"><p id="xdx_897_ecustom--ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock_z2gxz2BthnRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z751i3gbxyBb" style="display: none">SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 82%; font-weight: bold">Quarter Ending</td><td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center">Maximum Debt to <br/> Adjusted EBITDA <br/> Ratio</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>April 30, 2024</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFourMember__srt--RangeAxis__srt--MaximumMember_zkR455tskqui" title="Maximum Debt to Adjusted EBITDA Ratio">3.50</span> to <span id="xdx_906_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFourMember__srt--RangeAxis__srt--MinimumMember_zoRTWmnmgy78" title="Maximum Debt to Adjusted EBITDA Ratio">1.00</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">July 31, 2024 and on the last day of each quarter, thereafter</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFourAndThereafterMember__srt--RangeAxis__srt--MaximumMember_zNn7v3KAhd88" title="Maximum Debt to Adjusted EBITDA Ratio">2.00</span> to <span id="xdx_908_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFourAndThereafterMember__srt--RangeAxis__srt--MinimumMember_zVr7Scg6blh1" title="Maximum Debt to Adjusted EBITDA Ratio">1.00</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_ScheduleOfMaximumDebtToARRRatioTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Maximum Debt To ARR Ratio [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_ScheduleOfMaximumDebtToARRRatioTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Maximum Debt To Adjusted EBITDA Ratio [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961599957744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">SCHEDULE OF CARRYING AMOUNT OF GOODWILL</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zZardVLaIU58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
changes in the carrying amount of goodwill were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zxZmo1Gj5IRe" style="display: none">SCHEDULE OF CARRYING AMOUNT OF GOODWILL</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; font-weight: bold">Balance as of January 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Goodwill_iS_c20230201__20240131_zlxNipDbwq9l" style="width: 18%; text-align: right" title="Beginning Balance">23,089,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--GoodwillImpairmentLoss_iN_di_c20230201__20240131_zyFcjkFtMFB7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment">(9,813,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance as of January 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--Goodwill_iE_c20230201__20240131_zsZz6nlQnf98" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">13,276,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z0tKhaXfP2ba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zCWJo3lKiO31" style="display: none">SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Estimated</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Useful Life</p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gross</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Assets</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Accumulated</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Amortization</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finite-lived assets:</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 32%; text-align: left">Client relationships</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zrAtJp1Pwu99">10
</span>years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zPJhIoUfjtKd" style="width: 14%; text-align: right">8,370,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zw0aySaIuQo2" style="width: 14%; text-align: right">2,058,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zbvzIg2SW02k" style="width: 14%; text-align: right">6,312,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Internally developed software</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zj9hTXL9sRC9" title="Estimated Useful Life">9</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zuZLW7E0x7p1" style="text-align: right">6,380,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zWvK68GGiqZ1" style="text-align: right">1,742,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zbgqaPz0jdNk" style="text-align: right">4,638,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Trademarks and tradenames</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zolfD7Xprw4j" title="Estimated Useful Life">15</span> years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zhhRANoQzo49" style="border-bottom: Black 1.5pt solid; text-align: right">1,340,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zgxDtPUtCJSj" style="border-bottom: Black 1.5pt solid; text-align: right">219,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zMOvLqsAVzh5" style="border-bottom: Black 1.5pt solid; text-align: right">1,121,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131_z1OkRfogUgF1" style="border-bottom: Black 2.5pt double; text-align: right">16,090,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131_zLFdb3M5fFda" style="border-bottom: Black 2.5pt double; text-align: right">4,019,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131_zcTyDDCzHyGg" style="border-bottom: Black 2.5pt double; text-align: right">12,071,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31, 2023</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Estimated</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Gross</b></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finite-lived assets:</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 42%; text-align: left">Client relationships</td><td style="width: 2%">&#160;</td>
    <td style="width: 11%; text-align: right"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zV1i0JE3VEpk" title="Estimated Useful Life">8</span>-<span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember__srt--RangeAxis__srt--MaximumMember_z8hVTU3RojKg" title="Estimated Useful Life">10</span> years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zzoDVtEV274l" style="width: 11%; text-align: right" title="Gross Assets">9,700,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zCK2Hn9NRNKd" style="width: 11%; text-align: right" title="Accumulated Amortization">1,463,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zBouebbLJZMb" style="width: 11%; text-align: right" title="Net Assets">8,237,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Internally Developed Software</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zeeptGzkGeei" title="Estimated Useful Life">9</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_z0VNmctoNHRb" style="text-align: right" title="Gross Assets">6,380,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zQoRviMMpna8" style="text-align: right" title="Accumulated Amortization">1,034,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zFptHsuDx831" style="text-align: right" title="Net Assets">5,346,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Trademarks and Tradenames</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zXxhFr1tiWyg" title="Estimated Useful Life">15</span> years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zeu2D5Iz8Rm1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Assets">1,340,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zJTw8PcWAA04" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Amortization">130,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zXmjGzLczgw6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Assets">1,210,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131_zYwcI85UHPe2" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Assets">17,420,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131_z1I7dKke1HEa" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization">2,627,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131_zKr0y3GhpsI3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Assets">14,793,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z3WsMyjAmgHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
over the next five fiscal years for intangible assets is estimated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zheQPGRews7k" style="display: none">SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20240131_z3oLC4PSdK9f" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Annual</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Amortization Expense</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_pp0p0_maFLIANzAN0_zTk48zW7E1g2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 24%; text-align: right">1,635,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_maFLIANzAN0_zzQpMrORtxil" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,635,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_maFLIANzAN0_zwCQrZv3s3Y5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,635,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_maFLIANzAN0_zaXNcPo0IcJ" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,635,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_maFLIANzAN0_zDyuNEpyY9lj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,635,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_maFLIANzAN0_zveLcOWCT879" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,896,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzAN0_zi4Bbf2nuCsl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,071,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961597260000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z1Qrk4Y3zRCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal 2023 and 2022, income taxes  consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zA0vPqReRg71" style="display: none">SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230201__20240131_zK9Z94Chs8Aj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220201__20230131_ztYIg4MFNvs7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zHdWE5OHgBu4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current tax expense:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pp0p0_maCITEBzxs7_maCITEBzyfy_zln98wYUgcac" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1167">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1168">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_maCITEBzxs7_maCITEBzyfy_z0HCcPDp7gu5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 68%; padding-bottom: 1.5pt">State</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">(58,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">(62,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_mtCITEBzyfy_maITEBzkRn_zI44rvTIDQjh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total current tax benefit (expense)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(58,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(62,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_pp0p0_zVVcGihGw8gi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax expense:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_pp0p0_maDITEBzEci_zX46sTZiTwB9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">86,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_pp0p0_maDITEBzEci_z0sLtM9QTvO5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_mtDITEBzEci_maITEBzkRn_zEsztPFY84Xi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total deferred tax benefit (expense)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">104,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iNT_pp0p0_di_zAQDDkMGpnl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Income tax benefit (expense)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">46,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(71,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zMHzVXyBtkoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zpGmPnL31wr4" style="display: none">SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230201__20240131_zdRPrvbxm4N2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220201__20230131_znHyhoj5jHN1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzHX9_zYnfgoYxevDb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Federal tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,887,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,348,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzHX9_zZ04t8iYdAol" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State and local tax expense, net of federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(28,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(52,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--IncreaseInValuationAllowance_maITEBzHX9_z7as09OTZl36" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Increase in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,994,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,128,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Permanent items:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzHX9_zrEiOYLMxBih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationTaxContingencies_maITEBzHX9_ztJDKeJbtkIi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reserve for uncertain tax position</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzHX9_zFpDOgFQVLdj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Federal research and development (R&amp;D) tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maITEBzHX9_zpOrSEBP7lQc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(289,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzHX9_zEbhWzWLmjt" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">56,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_iN_pp0p0_di_mtITEBzHX9_zQgu6mmP2ozl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax benefit (expense)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">46,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(71,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zv36hcAdw4Jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides deferred income taxes for temporary differences between assets and liabilities recognized for financial reporting and
income tax purposes. The income tax effects of these temporary differences and credits are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zfItXsqgt5ii" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240131_zXO8HXMTiuV8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230131_z8vd3bHHaNpi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_pp0p0_maDTAGz9oc_zRIO7O8FElF" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: left">Allowance for credit losses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">26,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">39,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pp0p0_maDTAGz9oc_zd6lF5OZoxfc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">209,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent_iI_pp0p0_maDTAGz9oc_zeOTs4iteHP8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">232,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGz9oc_zMLinn0EzTNg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net operating loss carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,748,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,242,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGz9oc_zCWnxE8BKypi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">342,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0_maDTAGz9oc_z85X9citugQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Finite-lived intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,739,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,344,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGz9oc_zBnPnRI21A1d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">R&amp;D tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,434,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,407,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGz9oc_zIclNQdpMsZi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz9oc_maDTANzJA3_zkAnyFA288R1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,651,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,730,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzJA3_zDkBBx59OVWl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,646,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,347,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzJA3_msDTLz2p6_zZJc9wZIqx7b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Net deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">383,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iNI_di_msDITLz6FT_z0DOkUahtVz9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_iNI_pp0p0_di_maDITLz6FT_zZM8b7iXr1I7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Finite-lived intangible liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1262">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(482,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pp0p0_di_mtDITLz6FT_maDTLz2p6_zcoJWLgTWOc2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(487,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxLiabilities_iNTI_pp0p0_di_mtDTLz2p6_zQ7nVN5dLW39" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1268">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(104,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zBBYb2k1Qaif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the beginning and ending amounts of gross unrecognized tax benefits (excluding interest and penalties) is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zco6YfUw1Us3" style="display: none">SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230201__20240131_zAFXu7xAOzG5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220201__20230131_zrpjmT2kHiN6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--UnrecognizedTaxBenefits_iS_pp0p0_zcGhxziP7LK6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Beginning of fiscal year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">333,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">315,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zHnr6XOaNOl4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additions for tax positions for the current year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_znxu2MOPPXM7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additions for tax positions of prior years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1301">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_iN_pp0p0_di_zxYg9zzSSCdb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Subtractions for tax positions of prior years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1305">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--UnrecognizedTaxBenefits_iE_pp0p0_zlVG4La0zBuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">End of fiscal year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">340,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">333,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961595619024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION ACTIVITY</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXNWPfNbByXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity in fiscal 2023 follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_z6AWhgsLlTTl" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life in <br/> Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">intrinsic <br/> value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding as of January 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230201__20240131_z9rzQnSYOxv8" style="width: 12%; text-align: right" title="Number of options, Outstanding">628,958</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230201__20240131_zBV5DS90SPtf" style="width: 12%; text-align: right" title="Weighted average exercise price, Outstanding">1.95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220201__20230131_zQn7bX5YnDDd" title="Remaining Life in Years, Outstanding">7.31</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230201__20240131_zE19UeU1K4mc" style="width: 12%; text-align: right" title="Aggregate intrinsic value, Outstanding">360,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230201__20240131_zWn0MkN626K1" style="text-align: right" title="Number of options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1381">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230201__20240131_zz3I3PGuVxR1" style="text-align: right" title="Weighted average exercise price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1383">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230201__20240131_z7EX6ISFLaa4" style="text-align: right" title="Number of options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1385">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230201__20240131_zkqgh9ok7CU7" style="text-align: right" title="Weighted average exercise price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1387">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230201__20240131_zZWVO32mGON7" style="text-align: right" title="Number of options, Expired">(39,250</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230201__20240131_zZju4jJge4L1" style="text-align: right" title="Weighted average exercise price, Expired">7.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230201__20240131_zSPzPuqKmLs" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, Forfeited">(522,208</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230201__20240131_z6OxGZcLNs3a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Forfeited">1.55</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding as of January 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230201__20240131_zXz717fImZ23" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Outstanding">67,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230201__20240131_zAtr4ouxiGWg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding">1.73</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230201__20240131_zkDfaZVnkpE" title="Remaining Life in Years, Outstanding">2.37</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230201__20240131_zSuSirRD9zde" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1403">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable as of January 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240131_zA224pL4KPVd" style="text-align: right" title="Number of options, Exercisable">67,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240131_zC5bpjYI2ujg" style="text-align: right" title="Weighted average exercise price, Exercisable">1.73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230201__20240131_zb27FH3wNuqc" title="Remaining Life in Years, Exercisable">2.37</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20240131_zxHUGEW6m4E6" style="text-align: right" title="Aggregate intrinsic value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1411">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested as of January 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20240131_zBrksG5tDsii" style="text-align: right" title="Number of options, Vested or expected to vest">67,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20240131_zKlTMvZVX3ej" style="text-align: right" title="Weighted average exercise price, Vested or expected to vest">1.73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230201__20240131_zwo7CT2xA9lj" title="Remaining Life in Years, Vested or expected to vest">2.37</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pp0p0_c20240131_zYrdbEi8mAVe" style="text-align: right" title="Aggregate intrinsic value, Vested or expected to vest"><span style="-sec-ix-hidden: xdx2ixbrl1419">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zjM3yWYFsDA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zO7G2ebkJoQl" style="display: none">SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Weighted</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Non-vested</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Average</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Number of</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Grant Date</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair Value</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 64%">Non-vested balance at January 31, 2022</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220201__20230131_zYnFhfptDY6l" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Number of RSUs, Non vested, Outstanding, Beginning balance">1,043,350</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220201__20230131_zEuLXWMANKh6" title="Weighted Average Grant Date Fair Value, Beginniing balance">1.57</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zGP6dQdbY7b2" style="text-align: right" title="Number of RSUs, granted">1,505,731</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zmB5td5Fd6fl" title="Weighted Average Grant Date Fair Value, RSUs granted">1.47</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2rQ1F0faCo8" style="text-align: right" title="Number of RSUs, vested">(501,750</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcM3KJZ27nH3" title="Weighted Average Grant Date Fair Value, RSUs vested">1.63</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcWA3EZI1BR2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number RSUs, forfeited">(199,300</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs36HOvacnKh" title="Weighted Average Grant Date Fair Value, RSUs forfeited">1.49</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Non-vested balance at January 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230201__20240131_zBoj4mi8JkQf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs, Non vested, Outstanding, Beginning balance">1,848,031</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230201__20240131_zi6wkponXkb9" title="Weighted Average Grant Date Fair Value, Beginning balance">1.48</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4cAqLD9qWHi" style="text-align: right" title="Number of RSUs, granted">1,488,621</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUoxAxyM8tqb" title="Weighted Average Grant Date Fair Value, RSUs granted">1.57</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztks46YVO2pc" style="text-align: right" title="Number of RSUs, vested">(982,631</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs4ruRfP73dc" title="Weighted Average Grant Date Fair Value, RSUs vested">1.48</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3kMfkbYn4Vd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number RSUs, forfeited">(383,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcCEpa7518V" title="Weighted Average Grant Date Fair Value, RSUs forfeited">1.67</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Non-vested balance at January 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230201__20240131_zJ3GXytTKXPk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs, Non vested, Outstanding, Ending balance">1,970,521</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230201__20240131_zOW8QWyzHUNf" title="Weighted Average Grant Date Fair Value, Ending balance">1.51</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961680786352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_DisclosureSubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_ScheduleOfMaximumARRNetLeverageTableTextBlock', window );">SCHEDULE OF MAXIMUM ARR NET LEVERAGE RATIO</a></td>
<td class="text"><p id="xdx_898_ecustom--ScheduleOfMaximumARRNetLeverageTableTextBlock_zn3DAkHvDuVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;<span id="xdx_8B2_zl5leknhgzJg" style="display: none">SCHEDULE
OF MAXIMUM ARR NET LEVERAGE RATIO</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 81%; font-weight: bold">Quarter Ending</td>
    <td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum ARR Net Leverage Ratio</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>April 30, 2024</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYL8dbOqU7dj" title="Maximum ARR net leverage ratio">0.50</span> to <span id="xdx_903_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZGaBn88elT7" title="Maximum ARR net leverage ratio">1.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>July 31, 2024</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXDyg1rAAOu" title="Maximum ARR net leverage ratio">0.45</span> to <span id="xdx_901_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4bD19zzJLIi" title="Maximum ARR net leverage ratio">1.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>October 31, 2024</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHNHYJNleNcf" title="Maximum ARR net leverage ratio">0.40</span> to <span id="xdx_90D_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdU4HUWEgNl7" title="Maximum ARR net leverage ratio">1.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>January 31, 2025</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGXzjPhyYRBb" title="Maximum ARR net leverage ratio">0.35</span> to <span id="xdx_908_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zN794vr0cRh" title="Maximum ARR net leverage ratio">1.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock', window );">SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock_zbRhfhXAR2T4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_z36XCCnXa4R3" style="display: none">SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 81%; font-weight: bold">Quarter Ending</td>
    <td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum Debt to Adjusted EBITDA Ratio</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>April 30, 2025</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z634W75TIPkd" title="Maximum Debt to Adjusted EBITDA Ratio">3.50</span> to <span id="xdx_906_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zW5HjjpfOLK6" title="Maximum Debt to Adjusted EBITDA Ratio">1.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>July 31, 2025</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zndajFfrR7lb" title="Maximum Debt to Adjusted EBITDA Ratio">3.00</span> to <span id="xdx_902_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPNp0gh9xaMj" title="Maximum Debt to Adjusted EBITDA Ratio">1.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>October 31, 2025</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsNDLOgxTSE8" title="Maximum Debt to Adjusted EBITDA Ratio">2.50</span> to <span id="xdx_90B_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKF5mmPQictf" title="Maximum Debt to Adjusted EBITDA Ratio">1.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">January 31, 2026 and on the last day of each quarter thereafter</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQ1edTu7ZW4" title="Maximum Debt to Adjusted EBITDA Ratio">2.00</span> to <span id="xdx_90A_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zieXxiJi69ba" title="Maximum Debt to Adjusted EBITDA Ratio">1.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_ScheduleOfMinimumAdjustedEBITDATableTextBlock', window );">SCHEDULE OF MINIMUM ADJUSTED EBITDA</a></td>
<td class="text"><p id="xdx_89E_ecustom--ScheduleOfMinimumAdjustedEBITDATableTextBlock_zmyLnqyM4LPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;<span id="xdx_8BC_zGClJf5IisO8" style="display: none">SCHEDULE
OF MINIMUM ADJUSTED EBITDA</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Quarter Ending</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Minimum Adjusted EBITDA</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">January 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAHKv9XnP7Tf" style="width: 16%; text-align: right" title="Minimum Adjusted EBITDA">(5,750,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>April 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztQimNPIzrJa" style="text-align: right" title="Minimum Adjusted EBITDA">(4,560,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>July 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1LyXupcKxgg" style="text-align: right" title="Minimum Adjusted EBITDA">(2,960,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>October 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0Xz7h4bcx13" style="text-align: right" title="Minimum Adjusted EBITDA">(1,500,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>January 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFiveMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3VsY5uHAob2" style="text-align: right" title="Minimum Adjusted EBITDA">430,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_DisclosureSubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_DisclosureSubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_ScheduleOfMaximumARRNetLeverageTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Maximum ARR Net Leverage Table [TextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_ScheduleOfMaximumARRNetLeverageTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Maximum Debt To Adjustments EBITDA RatioTable [TextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_ScheduleOfMinimumAdjustedEBITDATableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Minimum Adjusted EBITDA Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_ScheduleOfMinimumAdjustedEBITDATableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961599288032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Payment of acquisition earnout liabilities in restricted common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,012,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_CapitalizedSoftwarePurchasedWithStock', window );">Capitalized software purchased with stock (See Note 12)</a></td>
<td class="nump">140,000<span></span>
</td>
<td class="nump">81,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_DeferredFinancingCosts', window );">Deferred financing costs</a></td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_CapitalizedSoftwarePurchasedWithStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized software purchased with stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_CapitalizedSoftwarePurchasedWithStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_DeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_DeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961599910576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESERVE RESULTS IN FUTURE PERIODS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit losses, Balance</a></td>
<td class="nump">$ 132,000<span></span>
</td>
<td class="nump">$ 76,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AllowanceForDoubtfulAccountsReceivableCECLAdoption', window );">Allowance for credit losses, CECL Adoption</a></td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Allowance for credit losses, Provision adjustments</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">189,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Allowance for credit losses, Write-offs &amp; Recoveries</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit losses, Balance</a></td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="nump">$ 132,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_AllowanceForDoubtfulAccountsReceivableCECLAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for credit losses, CECL adoption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_AllowanceForDoubtfulAccountsReceivableCECLAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961599392480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Employee benefits and related compensation</a></td>
<td class="nump">$ 1,071,000<span></span>
</td>
<td class="nump">$ 2,079,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent', window );">Professional fees and services</a></td>
<td class="nump">389,000<span></span>
</td>
<td class="nump">294,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_ThirdPartylicense', window );">Third party licenses</a></td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">285,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_ConcessionAccrualAmount', window );">Customer concessions</a></td>
<td class="nump">233,000<span></span>
</td>
<td class="nump">226,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">State income and sales taxes payable</a></td>
<td class="nump">226,000<span></span>
</td>
<td class="nump">331,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest, primarily on term loan</a></td>
<td class="nump">61,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 2,023,000<span></span>
</td>
<td class="nump">$ 3,265,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_ConcessionAccrualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concession accrual amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_ConcessionAccrualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_ThirdPartylicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Third party license.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_ThirdPartylicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for rebates of an exchange fee some mutual funds impose on shareholders if they exchange (transfer) to another fund within the same fund group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961718126096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT (Details)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_OfficeFurnitureAndFixturesMember', window );">Office Furniture and Fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_OfficeFurnitureAndFixturesMember', window );">Office Furniture and Fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_OfficeFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_OfficeFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961690876288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Total amortization expense on internally-developed software</a></td>
<td class="nump">$ 2,463,000<span></span>
</td>
<td class="nump">$ 2,423,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_CostOfSoftwareAsASeviceMember', window );">Cost Of Software As A Sevice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Total amortization expense on internally-developed software</a></td>
<td class="nump">2,229,000<span></span>
</td>
<td class="nump">2,068,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_CostOfProfessionalFeesAndLicensesMember', window );">Cost Of Professional Fees And Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Total amortization expense on internally-developed software</a></td>
<td class="nump">$ 234,000<span></span>
</td>
<td class="nump">$ 355,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_CostOfSoftwareAsASeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_CostOfSoftwareAsASeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_CostOfProfessionalFeesAndLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_CostOfProfessionalFeesAndLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961597971888">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AcquisitionEarnoutLiabilityFairValue', window );">Acquisition earn out liability fair value, observable inputs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,794,000<span></span>
</td>
<td class="nump">$ 3,738,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AcquisitionEarnoutLiabilityFairValue', window );">Acquisition earn out liability fair value, observable inputs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AcquisitionEarnoutLiabilityFairValue', window );">Acquisition earn out liability fair value, observable inputs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AcquisitionEarnoutLiabilityFairValue', window );">Acquisition earn out liability fair value, observable inputs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,794,000<span></span>
</td>
<td class="nump">$ 3,738,000<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
    fair value of the acquisition earnout liability is based upon a probability-weighted discounted cash flow that was completed at the
    date of acquisition and updated as of January 31, 2024. The change in the fair value of the acquisition earnout liability decreased
    $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUgQVNTRVRTIEFORCBMSUFCSUxJVElFUyBNRUFTVVJFRCBPTiBSRUNVUlJJTkcgQkFTSVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--AcquisitionEarnoutLiabilityChangeInValuation_c20230201__20240131_z0jICDkaYQXh" title="Acquisition earnout liability, change in valuation">1,944,000</span> for the year ended January 31, 2024, which is entirely recognized in &#8220;Acquisition earnout valuation adjustments&#8221;
    in the accompanying consolidated statement of operations.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_AcquisitionEarnoutLiabilityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition earnout liability, fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_AcquisitionEarnoutLiabilityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section FF<br> -Paragraph Question 2<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961694017712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AcquisitionEarnoutLiabilityChangeInValuation', window );">Acquisition earnout liability, change in valuation</a></td>
<td class="nump">$ 1,944,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_AcquisitionEarnoutLiabilityChangeInValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition earnout liability, change in valuation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_AcquisitionEarnoutLiabilityChangeInValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961711351296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DISAGGREGATON OF REVENUE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 22,596,000<span></span>
</td>
<td class="nump">$ 24,889,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">Transferred over Time [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">22,358,000<span></span>
</td>
<td class="nump">23,670,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Transferred at Point in Time [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 238,000<span></span>
</td>
<td class="nump">$ 1,219,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961599476048">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (18,697,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,379,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net loss per share of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted', window );">Loss available to common stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (18,697,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,379,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net loss per share of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (18,697,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,379,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding &#8211; Basic (1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">56,510,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,324,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks', window );">Effect of dilutive securities - Stock options and Restricted stock (2)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding &#8211; Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56,510,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,324,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per share of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Excludes
    the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of January 31, 2024
    and 2023, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zOkiNJqczEvk" title="Diluted earnings per share">1,970,521</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z2lI0oNs2rt9" title="Diluted earnings per share">1,848,031</span> unvested restricted shares of common stock, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Diluted
    net loss per share excludes the effect of shares that are anti-dilutive. As of January 31, 2024, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6ObtBNkGuq3" title="Diluted earnings per share">67,500</span> outstanding stock
    options and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedSharesMember_z7x8lmNjloWl" title="Diluted earnings per share">1,970,521</span> unvested restricted shares of common stock. As of January 31, 2023, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zg2cyB4sQ6Wk" title="Diluted earnings per share">628,598</span> outstanding stock options
    and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zKuhWu16S4uk" title="Diluted earnings per share">1,848,031</span> unvested restricted shares of common stock.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of dilutive securities - Stock options and Restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) from continuing operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961597774640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details) (Parenthetical) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=STRM_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Diluted earnings per share</a></td>
<td class="nump">1,970,521<span></span>
</td>
<td class="nump">1,848,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Diluted earnings per share</a></td>
<td class="nump">67,500<span></span>
</td>
<td class="nump">628,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=STRM_UnvestedRestrictedSharesMember', window );">Unvested Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Diluted earnings per share</a></td>
<td class="nump">1,970,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=STRM_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=STRM_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=STRM_UnvestedRestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=STRM_UnvestedRestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961598448144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION OF THE RESTRUCTURING LIABILITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Balance as of January 31, 2023</a></td>
<td class="nump">$ 3,265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">2023 Expenses to Date</a></td>
<td class="num">(1,277,000)<span></span>
</td>
<td class="nump">$ 1,069,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Balance as of October 31, 2023</a></td>
<td class="nump">2,023,000<span></span>
</td>
<td class="nump">3,265,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Balance as of January 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">2023 Expenses to Date</a></td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedCashPayments', window );">2023 Cash Payments</a></td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Balance as of October 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedCostsIncurred', window );">Total Costs Incurred to Date</a></td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedExpectedCosts', window );">Total Expected Costs</a></td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Balance as of January 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">2023 Expenses to Date</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedCashPayments', window );">2023 Cash Payments</a></td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Balance as of October 31, 2023</a></td>
<td class="nump">74,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedCostsIncurred', window );">Total Costs Incurred to Date</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedExpectedCosts', window );">Total Expected Costs</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Balance as of January 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">2023 Expenses to Date</a></td>
<td class="nump">227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedCashPayments', window );">2023 Cash Payments</a></td>
<td class="nump">227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Balance as of October 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedCostsIncurred', window );">Total Costs Incurred to Date</a></td>
<td class="nump">227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedExpectedCosts', window );">Total Expected Costs</a></td>
<td class="nump">227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=STRM_SeveranceExpensesMember', window );">Severance Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Balance as of January 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">2023 Expenses to Date</a></td>
<td class="nump">731,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedCashPayments', window );">2023 Cash Payments</a></td>
<td class="nump">657,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Balance as of October 31, 2023</a></td>
<td class="nump">74,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedCostsIncurred', window );">Total Costs Incurred to Date</a></td>
<td class="nump">731,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedExpectedCosts', window );">Total Expected Costs</a></td>
<td class="nump">731,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=STRM_ProfessionalFeesMember', window );">Professional Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Balance as of January 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">2023 Expenses to Date</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedCashPayments', window );">2023 Cash Payments</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Balance as of October 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedCostsIncurred', window );">Total Costs Incurred to Date</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedExpectedCosts', window );">Total Expected Costs</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=STRM_AccruedExpensesMember', window );">Accrued Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Balance as of January 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">2023 Expenses to Date</a></td>
<td class="nump">759,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedCashPayments', window );">2023 Cash Payments</a></td>
<td class="nump">685,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Balance as of October 31, 2023</a></td>
<td class="nump">74,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedCostsIncurred', window );">Total Costs Incurred to Date</a></td>
<td class="nump">759,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AccruedExpectedCosts', window );">Total Expected Costs</a></td>
<td class="nump">$ 759,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_AccruedCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_AccruedCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_AccruedCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_AccruedCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_AccruedExpectedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expected costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_AccruedExpectedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=STRM_SeveranceExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=STRM_SeveranceExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=STRM_ProfessionalFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=STRM_ProfessionalFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=STRM_AccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=STRM_AccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961591464640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 16, 2023 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_ConcessionAccrualAmount', window );">Concession accrual amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,000<span></span>
</td>
<td class="nump">$ 226,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization', window );">Capitalized software development costs, net of accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,960,000<span></span>
</td>
<td class="nump">6,224,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Capitalized Computer Software, Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,463,000<span></span>
</td>
<td class="nump">2,423,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AmortizedAndAbandonedAssets', window );">Amortized and abandoned assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,704,000<span></span>
</td>
<td class="nump">6,042,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="nump">9,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,642,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation', window );">Revenue, remaining performance obligation, expected timing of satisfaction, explanation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company expects to recognize approximately 46% over the next 12 months and the remainder thereafter.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrentAndNoncurrent', window );">Deferred costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,000<span></span>
</td>
<td class="nump">94,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedAmortizationOfOtherDeferredCosts', window );">Accumulated amortization of deferred costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="nump">176,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_DeferredCostsAmortizationExpenses', window );">Deferred costs, amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAmortizationOfDeferredCharges', window );">Amortized contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostImpairmentLoss', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation expense related to stock-based award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,102,000<span></span>
</td>
<td class="nump">1,680,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Cost of shares for tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,000<span></span>
</td>
<td class="nump">$ 197,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_NumberOfEmployeesTerminated', window );">Number of employees terminated | Integer</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_PercentageOfWorkforceTerminated', window );">Percentage of workforce terminated</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">$ 759,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=STRM_OfficersAndDirectorsMember', window );">Officers and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number shares of restricted stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,203,621<span></span>
</td>
<td class="nump">890,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_SurrenderOfStockSharesDuringPeriod', window );">Surrender of stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,950<span></span>
</td>
<td class="nump">127,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number shares of restricted stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,947,738<span></span>
</td>
<td class="nump">1,876,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=STRM_EquityAwardMember', window );">Equity Award [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation expense related to stock-based award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,102,000<span></span>
</td>
<td class="nump">$ 1,680,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=STRM_EquityAwardMember', window );">Equity Award [Member] | Share-Based Payment Arrangement, Nonemployee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation expense related to stock-based award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="nump">81,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Cost of shares for tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,000<span></span>
</td>
<td class="nump">197,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-lived intangible assets amortized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-lived intangible assets amortized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredSalesCommissions', window );">Amortization expense with deferred sales commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 588,000<span></span>
</td>
<td class="nump">411,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_DeferredCommissionsCostsPaidAndPayable', window );">Deferred commissions costs paid and payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,461,000<span></span>
</td>
<td class="nump">1,534,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_SecurityAgreementMember', window );">Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_PrimeInterestRatePercentage', window );">Prime interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_SecondAmendedAndRestatedLoanAndSecurityAgreementMember', window );">Second Amended and Restated Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_DebtAgreementMember', window );">Debt Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,807,000<span></span>
</td>
<td class="nump">9,550,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_DebtAgreementMember', window );">Debt Agreement [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,463,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_SoftwareMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization', window );">Capitalized software development costs, net of accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,000<span></span>
</td>
<td class="nump">522,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_InternalUseSoftwareMember', window );">Internal-Use Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization', window );">Capitalized software development costs, net of accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,511,000<span></span>
</td>
<td class="nump">5,324,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software and Software Development Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Capitalized Computer Software, Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,463,000<span></span>
</td>
<td class="nump">$ 2,423,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_AmortizedAndAbandonedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized and abandoned assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_AmortizedAndAbandonedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_ConcessionAccrualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concession accrual amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_ConcessionAccrualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_DeferredCommissionsCostsPaidAndPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred commissions costs paid and payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_DeferredCommissionsCostsPaidAndPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_DeferredCostsAmortizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred costs, amortization expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_DeferredCostsAmortizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_NumberOfEmployeesTerminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of employees terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_NumberOfEmployeesTerminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_PercentageOfWorkforceTerminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of workforce terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_PercentageOfWorkforceTerminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_PrimeInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prime interest rate percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_PrimeInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_SurrenderOfStockSharesDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Surrender of stock shares during period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_SurrenderOfStockSharesDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedAmortizationOfOtherDeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amortization of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs, deferred acquisition costs of insurance companies, or deferred leasing costs for real estate operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedAmortizationOfOtherDeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDeferredSalesCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period for the periodic realization of capitalized fees that were paid to salespeople, distributors, brokers, and agents at the time of the conclusion of the sale. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDeferredSalesCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAmortizationOfDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of other deferred costs recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAmortizationOfDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of when remaining performance obligation is expected to be recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=STRM_OfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=STRM_OfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=STRM_EquityAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=STRM_EquityAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_SecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_SecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_SecondAmendedAndRestatedLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_SecondAmendedAndRestatedLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_DebtAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_DebtAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_SoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_SoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_InternalUseSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=STRM_InternalUseSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961600119264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th"><div>Sep. 01, 2023</div></th>
<th class="th"><div>Nov. 21, 2022</div></th>
<th class="th"><div>Aug. 16, 2021</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_UnitPurchaseAgreementMember', window );">Unit Purchase Agreement [Member] | First Year Earnout [Member] | Renewal Contingent Consideration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=STRM_AveleadConsultingLLCMember', window );">Avelead Consulting LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business combination, cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=STRM_AveleadConsultingLLCMember', window );">Avelead Consulting LLC [Member] | Second Year Earnout [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business acquisition, equity interest issued or issuable, number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">961,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 244,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=STRM_AveleadConsultingLLCMember', window );">Avelead Consulting LLC [Member] | Second Year Earnout [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business acquisition, equity interest issued or issuable, number of shares</a></td>
<td class="nump">961,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in transaction</a></td>
<td class="nump">627,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=STRM_AveleadConsultingLLCMember', window );">Avelead Consulting LLC [Member] | Unit Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business combination, cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_PaymentsToAcquireBusinessesSellerExpenses', window );">[custom:PaymentsToAcquireBusinessesSellerExpenses]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment', window );">[custom:PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_PaymentOfSaasContingentConsiderationInCashPercentage', window );">Payment of SaaS contingent consideration in cash, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_PaymentOfSaasContingentConsiderationInSharesPercentage', window );">Payment of SaaS contingent consideration in cash, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_FirstYearPaymentOfSaasContingentConsiderationDescription', window );">First year payment of SaaS contingent consideration, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
    first year SaaS Contingent Consideration was calculated as 75% of Avelead&#8217;s recognized SaaS revenue from September 1, 2021
    to August 31, 2022. The first-year payment was subject to a deduction of $665,000 spread equally between the cash and common stock
    portion of the earnout consideration. Assuming that Avelead was within 80% of its forecasted SaaS revenue in the first year earnout,
    the Company agreed to a floor and ceiling on the value of the Company&#8217;s restricted common stock issued as consideration for
    the earnout. That collar had a floor of $3.50 per share and a ceiling of $5.50 per share for the first year earnout. The first year
    SaaS Contingent Consideration was paid on November 21, 2022, as discussed in more detail below.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_SecondYearPaymentOfSaasContingentConsiderationDescription', window );">Second year payment of SaaS contingent consideration, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
    second year SaaS Contingent Consideration was calculated as 40% of Avelead&#8217;s recognized SaaS revenue from September 1, 2022
    to August 31, 2023. Assuming that Avelead was within 80% of its forecasted SaaS revenue in the second year earnout, the Company agreed
    to a floor and ceiling on the Company&#8217;s restricted common stock issued as consideration for the earnout. That collar had a
    floor of $4.50 per share and a ceiling of $6.50 per share for the second year earnout. The second year SaaS Contingent Consideration
    remained outstanding as of January 31, 2024, as the Company and the Sellers work towards a resolution regarding the payment of the
    second year SaaS Contingent Consideration.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_ForecastedRevenueDescription', window );">Forecasted revenue description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">If
    Avelead does not achieve 80% of its forecasted revenue, the price per share will revert back to the Company&#8217;s market price
    based upon a 30-day average.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_RenewalContingentConsiderationDescription', window );">Renewal contingent consideration, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
    Renewal Contingent Consideration was tied directly to a successful renewal of a specific client of Avelead. To meet the definition
    of a renewal, Avelead was required to achieve a minimum threshold of contracted revenue in an updated, annual, renewed contract with
    the specified client. The renewal occurred on or about June 1, 2022 and June 1, 2023. The Renewal Contingent Consideration was payable
    in shares of Company restricted common stock valued as of the date of closing. The Renewal Contingent Consideration is either earned
    or not earned based upon the renewal of the specified client at the minimum amount of contracted revenue. There is no pro-ration
    of the underlying Renewal Contingent Consideration. On November 21, 2022, the Company issued 627,746 shares of restricted common
    stock to the Sellers in connection with the first year Renewal Contingent Consideration. The second year Renewal Contingent Consideration
    remained outstanding as of January 31, 2024, as the Company and the Sellers work towards a resolution regarding the payment of the
    second year Renewal Contingent Consideration.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=STRM_AveleadConsultingLLCMember', window );">Avelead Consulting LLC [Member] | Unit Purchase Agreement [Member] | Renewal Contingent Consideration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=STRM_AveleadConsultingLLCMember', window );">Avelead Consulting LLC [Member] | Unit Purchase Agreement [Member] | First Year Earnout [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business combination, cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business acquisition, equity interest issued or issuable, number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,243,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=STRM_AveleadConsultingLLCMember', window );">Avelead Consulting LLC [Member] | Acquisition Restricted Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business acquisition, equity interest issued or issuable, number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,021,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_BusinessAcquisitionEquityInterestIssuedFairValue', window );">Business acquisition equity fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription', window );">Business combination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Additionally, the Transaction
included two types of contingent consideration; the first is referred to herein as &#8220;SaaS Contingent Consideration&#8221; and the
second is referred to herein as &#8220;Renewal Contingent Consideration.&#8221; The SaaS Contingent Consideration and Renewal Contingent
Consideration had an aggregate value of approximately $10.7 million as of the date of closing.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=STRM_AveleadConsultingLLCMember', window );">Avelead Consulting LLC [Member] | Acquisition Restricted Common Stock [Member] | Unit Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_BusinessAcquisitionEquityInterestIssuedFairValue', window );">Business acquisition equity fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_BusinessAcquisitionEquityInterestIssuedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition equity fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_BusinessAcquisitionEquityInterestIssuedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_FirstYearPaymentOfSaasContingentConsiderationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>First year payment of SaaS contingent consideration, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_FirstYearPaymentOfSaasContingentConsiderationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_ForecastedRevenueDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forecasted revenue description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_ForecastedRevenueDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_PaymentOfSaasContingentConsiderationInCashPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of SaaS contingent consideration in cash, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_PaymentOfSaasContingentConsiderationInCashPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_PaymentOfSaasContingentConsiderationInSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of saas contingent consideration in shares percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_PaymentOfSaasContingentConsiderationInSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for estimated working capital adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_PaymentsToAcquireBusinessesSellerExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to acquire business seller, expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_PaymentsToAcquireBusinessesSellerExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_RenewalContingentConsiderationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Renewal contingent consideration, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_RenewalContingentConsiderationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_SecondYearPaymentOfSaasContingentConsiderationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Second year payment of SaaS contingent consideration, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_SecondYearPaymentOfSaasContingentConsiderationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_UnitPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_UnitPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=STRM_FirstYearEarnoutMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=STRM_FirstYearEarnoutMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=STRM_RenewalContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=STRM_RenewalContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=STRM_AveleadConsultingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=STRM_AveleadConsultingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=STRM_SecondYearEarnoutMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=STRM_SecondYearEarnoutMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=STRM_AcquisitionRestrictedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=STRM_AcquisitionRestrictedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961597138768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2021</div></th>
<th class="th"><div>Aug. 16, 2021</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RentalProperties', window );">Related to space rental</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, Operating Lease, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">$ 194,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_AlpharettaOfficeLeaseMember', window );">Alpharetta Office Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_SubleaseAgreementMember', window );">Sublease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_SubleaseTerm', window );">Sublease, term</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income related to sublease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_SuwaneeOfficeLeaseMember', window );">Suwanee Office Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 28,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_SubleaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_SubleaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RentalProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of income producing properties held for rental.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RentalProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_AlpharettaOfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_AlpharettaOfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_SubleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_SubleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_SuwaneeOfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_SuwaneeOfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961594730848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="nump">$ 9,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_FinancingCostPayable', window );">Financing cost payable</a></td>
<td class="nump">135,000<span></span>
</td>
<td class="nump">69,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_DeferredFinancingCost', window );">Less: Deferred financing cost</a></td>
<td class="num">(69,000)<span></span>
</td>
<td class="num">(105,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">9,066,000<span></span>
</td>
<td class="nump">9,714,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion</a></td>
<td class="num">(1,500,000)<span></span>
</td>
<td class="num">(750,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of debt</a></td>
<td class="nump">$ 7,566,000<span></span>
</td>
<td class="nump">$ 8,964,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_DeferredFinancingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_DeferredFinancingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_FinancingCostPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_FinancingCostPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961696666224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF MAXIMUM DEBT TO ARR RATIO (Details)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandAndTwentyTwoMember', window );">October 31, 2022 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToArrRatio', window );">Maximum Debt to ARR Ratio</a></td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandAndTwentyTwoMember', window );">October 31, 2022 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToArrRatio', window );">Maximum Debt to ARR Ratio</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandTwentyThreeMember', window );">January 31, 2023 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToArrRatio', window );">Maximum Debt to ARR Ratio</a></td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandTwentyThreeMember', window );">January 31, 2023 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToArrRatio', window );">Maximum Debt to ARR Ratio</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandTwentyThreeMember', window );">April 30, 2023 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToArrRatio', window );">Maximum Debt to ARR Ratio</a></td>
<td class="nump">0.65%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandTwentyThreeMember', window );">April 30, 2023 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToArrRatio', window );">Maximum Debt to ARR Ratio</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandTwentyThreeMember', window );">July 31, 2023 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToArrRatio', window );">Maximum Debt to ARR Ratio</a></td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandTwentyThreeMember', window );">July 31, 2023 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToArrRatio', window );">Maximum Debt to ARR Ratio</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandTwentyThreeMember', window );">October 31, 2023 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToArrRatio', window );">Maximum Debt to ARR Ratio</a></td>
<td class="nump">0.55%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandTwentyThreeMember', window );">October 31, 2023 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToArrRatio', window );">Maximum Debt to ARR Ratio</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandTwentyFourMember', window );">January 31, 2024 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToArrRatio', window );">Maximum Debt to ARR Ratio</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandTwentyFourMember', window );">January 31, 2024 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToArrRatio', window );">Maximum Debt to ARR Ratio</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_MaximumDebtToArrRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Debt to ARR Ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_MaximumDebtToArrRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandAndTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandAndTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961599253536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO (Details)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandTwentyFourMember', window );">April 30, 2024 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToAdjustedEbitdaRatio', window );">Maximum Debt to Adjusted EBITDA Ratio</a></td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandTwentyFourMember', window );">April 30, 2024 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToAdjustedEbitdaRatio', window );">Maximum Debt to Adjusted EBITDA Ratio</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember', window );">July 31, 2024 and Thereafter [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToAdjustedEbitdaRatio', window );">Maximum Debt to Adjusted EBITDA Ratio</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember', window );">July 31, 2024 and Thereafter [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToAdjustedEbitdaRatio', window );">Maximum Debt to Adjusted EBITDA Ratio</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_MaximumDebtToAdjustedEbitdaRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Debt to Adjusted EBITDA Ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_MaximumDebtToAdjustedEbitdaRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961591447296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Nov. 29, 2022</div></th>
<th class="th"><div>Aug. 26, 2021</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember', window );">Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_LoanAgreementMember', window );">Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion expense</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_LoanAgreementMember', window );">Loan Agreement [Member] | Western Alliance Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">Long term debt, maturity, year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">Long term debt, maturity, year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">Long term debt, maturity, year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_SecurityAgreementMember', window );">Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_SecurityAgreementMember', window );">Security Agreement [Member] | Bridge Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">Long term debt, maturity, year five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_SecondModificationAgreementMember', window );">Second Modification Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion expense</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Line of credit facility, matures</a></td>
<td class="text">Aug. 26,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantDescription', window );">Debt financial covenants, description</a></td>
<td class="text">Borrowers shall, at all times, maintain unrestricted cash in an amount not less than Two Million Dollars ($2,000,000).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_SecondModificationAgreementMember', window );">Second Modification Agreement [Member] | Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_SecondModificationAgreementMember', window );">Second Modification Agreement [Member] | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_SecondAmendedAndRestatedLoanAgreementMember', window );">Second Amended And Restated Loan Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_FixedChargeCoverageRatio', window );">Fixed charge coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_SecondAmendedAndRestatedLoanAgreementMember', window );">Second Amended And Restated Loan Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_FixedChargeCoverageRatio', window );">Fixed charge coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_FixedChargeCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed charge coverage ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_FixedChargeCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481639/420-10-35-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=STRM_WesternAllianceBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=STRM_WesternAllianceBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_SecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_SecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=STRM_BridgeBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=STRM_BridgeBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_SecondModificationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_SecondModificationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_SecondAmendedAndRestatedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_SecondAmendedAndRestatedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961599987120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CARRYING AMOUNT OF GOODWILL (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning Balance</a></td>
<td class="nump">$ 23,089,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="num">(9,813,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending Balance</a></td>
<td class="nump">$ 13,276,000<span></span>
</td>
<td class="nump">$ 23,089,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961598086864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Assets</a></td>
<td class="nump">$ 16,090,000<span></span>
</td>
<td class="nump">$ 17,420,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">4,019,000<span></span>
</td>
<td class="nump">2,627,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Assets</a></td>
<td class="nump">$ 12,071,000<span></span>
</td>
<td class="nump">14,793,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=STRM_ClientRelationshipsMember', window );">Client Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Assets</a></td>
<td class="nump">$ 8,370,000<span></span>
</td>
<td class="nump">9,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">2,058,000<span></span>
</td>
<td class="nump">1,463,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Assets</a></td>
<td class="nump">$ 6,312,000<span></span>
</td>
<td class="nump">$ 8,237,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=STRM_ClientRelationshipsMember', window );">Client Relationships [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=STRM_ClientRelationshipsMember', window );">Client Relationships [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=STRM_InternallyDevelopedSoftwareMember', window );">Internally Developed Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Assets</a></td>
<td class="nump">$ 6,380,000<span></span>
</td>
<td class="nump">$ 6,380,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,742,000<span></span>
</td>
<td class="nump">1,034,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Assets</a></td>
<td class="nump">$ 4,638,000<span></span>
</td>
<td class="nump">$ 5,346,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Assets</a></td>
<td class="nump">$ 1,340,000<span></span>
</td>
<td class="nump">$ 1,340,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">219,000<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Assets</a></td>
<td class="nump">$ 1,121,000<span></span>
</td>
<td class="nump">$ 1,210,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=STRM_ClientRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=STRM_ClientRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=STRM_InternallyDevelopedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=STRM_InternallyDevelopedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961598508176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,635,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">1,635,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">1,635,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">1,635,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">1,635,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,896,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 12,071,000<span></span>
</td>
<td class="nump">$ 14,793,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961600055216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Iimpairment of goodwill</a></td>
<td class="nump">$ 9,813,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of intangible assets</a></td>
<td class="nump">963,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense on intangible assets</a></td>
<td class="nump">1,760,000<span></span>
</td>
<td class="nump">$ 1,971,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AbandonedAssetWroteOff', window );">Abandoned asset wrote off</a></td>
<td class="nump">1,330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 963,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_AbandonedAssetWroteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Abandoned asset wrote off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_AbandonedAssetWroteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961782081024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(58,000)<span></span>
</td>
<td class="num">(62,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax benefit (expense)</a></td>
<td class="num">(58,000)<span></span>
</td>
<td class="num">(62,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">86,000<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax benefit (expense)</a></td>
<td class="nump">104,000<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="num">$ (71,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961711574160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit at statutory rate</a></td>
<td class="nump">$ 3,887,000<span></span>
</td>
<td class="nump">$ 2,348,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local tax expense, net of federal</a></td>
<td class="num">(28,000)<span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_IncreaseInValuationAllowance', window );">Increase in valuation allowance</a></td>
<td class="num">(3,994,000)<span></span>
</td>
<td class="num">(2,128,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="num">(36,000)<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Reserve for uncertain tax position</a></td>
<td class="num">(7,000)<span></span>
</td>
<td class="num">(18,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Federal research and development (R&amp;D) tax credit</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Stock-based compensation</a></td>
<td class="nump">135,000<span></span>
</td>
<td class="num">(289,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">56,000<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="num">$ (71,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_IncreaseInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_IncreaseInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961597456080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for credit losses</a></td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">209,000<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent', window );">Accruals</a></td>
<td class="nump">67,000<span></span>
</td>
<td class="nump">232,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">15,748,000<span></span>
</td>
<td class="nump">11,242,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">427,000<span></span>
</td>
<td class="nump">342,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Finite-lived intangible assets</a></td>
<td class="nump">1,739,000<span></span>
</td>
<td class="nump">1,344,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D tax credit</a></td>
<td class="nump">1,434,000<span></span>
</td>
<td class="nump">1,407,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">19,651,000<span></span>
</td>
<td class="nump">14,730,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(19,646,000)<span></span>
</td>
<td class="num">(14,347,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">383,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Finite-lived intangible liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(482,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(487,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (104,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities, Current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961598914832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning of fiscal year</a></td>
<td class="nump">$ 333,000<span></span>
</td>
<td class="nump">$ 315,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions for the current year</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Subtractions for tax positions of prior years</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">End of fiscal year</a></td>
<td class="nump">$ 340,000<span></span>
</td>
<td class="nump">$ 333,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961601851584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rates</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">$ 65,107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">19,646,000<span></span>
</td>
<td class="nump">$ 14,347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_IncreaseInValuationAllowance', window );">Increase in the valuation allowance</a></td>
<td class="nump">3,994,000<span></span>
</td>
<td class="nump">2,128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">340,000<span></span>
</td>
<td class="nump">$ 333,000<span></span>
</td>
<td class="nump">$ 315,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=STRM_TaxCutsAndJobsActMember', window );">Tax Cuts and Jobs Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">36,024,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=STRM_StateMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">37,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=STRM_FederalRDMember', window );">Federal RD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">1,699,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=STRM_GeorgiaRDMember', window );">Georgia RD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=STRM_ThroughFiscalTwoThousandThirtyEightMember', window );">Through Fiscal Two Thousand Thirty Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">$ 29,083,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_IncreaseInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_IncreaseInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=STRM_TaxCutsAndJobsActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=STRM_TaxCutsAndJobsActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=STRM_StateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=STRM_StateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=STRM_FederalRDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=STRM_FederalRDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=STRM_GeorgiaRDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=STRM_GeorgiaRDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=STRM_ThroughFiscalTwoThousandThirtyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=STRM_ThroughFiscalTwoThousandThirtyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961680896880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 15, 2023</div></th>
<th class="th"><div>Oct. 24, 2022</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jun. 28, 2023</div></th>
<th class="th"><div>Jun. 22, 2022</div></th>
<th class="th"><div>Jun. 07, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,316,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized to issue</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000,000<span></span>
</td>
<td class="nump">85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=STRM_OneHundredEightyConsultingLLCMember', window );">180 Consulting LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock issued for resale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,127<span></span>
</td>
<td class="nump">272,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=STRM_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember', window );">Third Amended And Restated 2013 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized to issue</a></td>
<td class="nump">10,223,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,223,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=STRM_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember', window );">Third Amended And Restated 2013 Stock Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized to issue</a></td>
<td class="nump">11,223,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,223,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_PurchaseAgreementMember', window );">Purchase Agreement [Member] | 2022 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,299,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,316,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=STRM_OneHundredEightyConsultingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=STRM_OneHundredEightyConsultingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=STRM_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=STRM_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=STRM_TwoThousandTwentyTwoOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=STRM_TwoThousandTwentyTwoOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961599402448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CLIENTS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCustomer', window );">Concentration Risk, Customer</a></td>
<td class="text">one individual client accounted
for 10% or more of our revenue.<span></span>
</td>
<td class="text">two
individual clients accounted for 10% or more of our revenue.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=STRM_OneCustomerMember', window );">One Customer [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=STRM_TwoCustomerMember', window );">Two Customer [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=STRM_CustomerOneMember', window );">Customer One [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=STRM_CustomerTwoMember', window );">Customer Two [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=STRM_CustomerThreeMember', window );">Customer Three [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=STRM_CustomerFourMember', window );">Customer Four [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes "Information about Major Customers" that may be disclosed elsewhere (for instance, segment disclosures).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=STRM_OneCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=STRM_OneCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=STRM_TwoCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=STRM_TwoCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=STRM_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=STRM_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=STRM_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=STRM_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=STRM_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=STRM_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=STRM_CustomerFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=STRM_CustomerFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961697935424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE RETIREMENT PLAN (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, cost recognized</a></td>
<td class="nump">$ 242,000<span></span>
</td>
<td class="nump">$ 258,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961599737040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding</a></td>
<td class="nump">628,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding</a></td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Life in Years, Outstanding</a></td>
<td class="text">2 years 4 months 13 days<span></span>
</td>
<td class="text">7 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average exercise price, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of options, Expired</a></td>
<td class="num">(39,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired</a></td>
<td class="nump">$ 7.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited</a></td>
<td class="num">(522,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding</a></td>
<td class="nump">67,500<span></span>
</td>
<td class="nump">628,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding</a></td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 360,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Exercisable</a></td>
<td class="nump">67,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Remaining Life in Years, Exercisable</a></td>
<td class="text">2 years 4 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of options, Vested or expected to vest</a></td>
<td class="nump">67,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested or expected to vest</a></td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Remaining Life in Years, Vested or expected to vest</a></td>
<td class="text">2 years 4 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested or expected to vest</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961600052352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Non vested, Outstanding, Beginning balance</a></td>
<td class="nump">1,848,031<span></span>
</td>
<td class="nump">1,043,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning balance</a></td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="nump">$ 1.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Non vested, Outstanding, Ending balance</a></td>
<td class="nump">1,970,521<span></span>
</td>
<td class="nump">1,848,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending balance</a></td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="nump">$ 1.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs, granted</a></td>
<td class="nump">1,488,621<span></span>
</td>
<td class="nump">1,505,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, RSUs granted</a></td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSUs, vested</a></td>
<td class="num">(982,631)<span></span>
</td>
<td class="num">(501,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, RSUs vested</a></td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="nump">$ 1.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number RSUs, forfeited</a></td>
<td class="num">(383,500)<span></span>
</td>
<td class="num">(199,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, RSUs forfeited</a></td>
<td class="nump">$ 1.67<span></span>
</td>
<td class="nump">$ 1.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961597990112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>May 20, 2022</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_InvestmentOwnershipPercentage', window );">Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,938,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted stocks awarded, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,488,621<span></span>
</td>
<td class="nump">1,505,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Cost expected remaining period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_TwoThousandThirteenIncentiveCompensationPlanMember', window );">2013 Incentive Compensation Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options plan, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under these plans, the Company is authorized to issue equity awards (stock options, stock appreciation rights or &#8220;SARs&#8221;,
and restricted stock) to directors and associates of the Company. Under the 2013 Plan, as amended, the Company is authorized to issue
a number of shares not to exceed 11,223,246. The options granted under the 2013 Plan have terms of ten years or less, and typically vest
and become fully exercisable ratably over three years of continuous service to the Company from the date of grant<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,223,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_NumberOfOptionsToPurchaseCommonStock', window );">Number of options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
<td class="nump">628,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized Compensation cost, stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,000<span></span>
</td>
<td class="nump">$ 132,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_TwoThousandThirteenIncentiveCompensationPlanMember', window );">2013 Incentive Compensation Plan [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,590,000<span></span>
</td>
<td class="nump">$ 983,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted stocks awarded, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_TwoThousandThirteenIncentiveCompensationPlanMember', window );">2013 Incentive Compensation Plan [Member] | Restricted Stock [Member] | Mr Green [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted stocks awarded, shares</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_TwoThousandThirteenIncentiveCompensationPlanMember', window );">2013 Incentive Compensation Plan [Member] | Restricted Stock [Member] | Mr Stil will [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted stocks awarded, shares</a></td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_InvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_InvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_NumberOfOptionsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_NumberOfOptionsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_TwoThousandThirteenIncentiveCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_TwoThousandThirteenIncentiveCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=STRM_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=STRM_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=STRM_MrGreenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=STRM_MrGreenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=STRM_MrStilwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=STRM_MrStilwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961591646880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - 180 Consulting LLC [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_MasterServicesAgreementMember', window );">Master services agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="nump">1,479,911<span></span>
</td>
<td class="nump">206,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 582,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_NonEmployeeStockCompensation', window );">[custom:NonEmployeeStockCompensation]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,281,000<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_MasterServicesAgreementMember', window );">Master services agreement [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=STRM_SOWMember', window );">SOW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 563,000<span></span>
</td>
<td class="nump">$ 301,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_NonEmployeeStockCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_NonEmployeeStockCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_MasterServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_MasterServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=STRM_OneHundredEightyConsultingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=STRM_OneHundredEightyConsultingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_SOWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_SOWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961595769600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961594103472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF MAXIMUM ARR NET LEVERAGE RATIO (Details) - Subsequent Event [Member]<br></strong></div></th>
<th class="th"><div>Feb. 07, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandAndTwentyFourMember', window );">April 30, 2024 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumArrNetLeverageRatio', window );">Maximum ARR net leverage ratio</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandAndTwentyFourMember', window );">April 30, 2024 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumArrNetLeverageRatio', window );">Maximum ARR net leverage ratio</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandAndTwentyFourMember', window );">July 31, 2024 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumArrNetLeverageRatio', window );">Maximum ARR net leverage ratio</a></td>
<td class="nump">0.45%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandAndTwentyFourMember', window );">July 31, 2024 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumArrNetLeverageRatio', window );">Maximum ARR net leverage ratio</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember', window );">October 31, 2024 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumArrNetLeverageRatio', window );">Maximum ARR net leverage ratio</a></td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember', window );">October 31, 2024 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumArrNetLeverageRatio', window );">Maximum ARR net leverage ratio</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember', window );">January 31, 2025 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumArrNetLeverageRatio', window );">Maximum ARR net leverage ratio</a></td>
<td class="nump">0.35%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember', window );">January 31, 2025 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumArrNetLeverageRatio', window );">Maximum ARR net leverage ratio</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_MaximumArrNetLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum arr net leverage ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_MaximumArrNetLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandAndTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandAndTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandAndTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandAndTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961691029984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO (Details) - Subsequent Event [Member]<br></strong></div></th>
<th class="th"><div>Feb. 07, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandTwentyFiveMember', window );">April 30, 2025 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToAdjustedEbitdaRatio', window );">Maximum Debt to Adjusted EBITDA Ratio</a></td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandTwentyFiveMember', window );">April 30, 2025 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToAdjustedEbitdaRatio', window );">Maximum Debt to Adjusted EBITDA Ratio</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandTwentyFiveMember', window );">July 31, 2025 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToAdjustedEbitdaRatio', window );">Maximum Debt to Adjusted EBITDA Ratio</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandTwentyFiveMember', window );">July 31, 2025 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToAdjustedEbitdaRatio', window );">Maximum Debt to Adjusted EBITDA Ratio</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandTwentyFiveMember', window );">October 31, 2025 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToAdjustedEbitdaRatio', window );">Maximum Debt to Adjusted EBITDA Ratio</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandTwentyFiveMember', window );">October 31, 2025 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToAdjustedEbitdaRatio', window );">Maximum Debt to Adjusted EBITDA Ratio</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember', window );">January 31, 2026 And Thereafter [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToAdjustedEbitdaRatio', window );">Maximum Debt to Adjusted EBITDA Ratio</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember', window );">January 31, 2026 And Thereafter [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MaximumDebtToAdjustedEbitdaRatio', window );">Maximum Debt to Adjusted EBITDA Ratio</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_MaximumDebtToAdjustedEbitdaRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Debt to Adjusted EBITDA Ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_MaximumDebtToAdjustedEbitdaRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961597469552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF MINIMUM ADJUSTED EBITDA (Details) - Subsequent Event [Member]<br></strong></div></th>
<th class="th">
<div>Feb. 07, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember', window );">January 31, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MinimumAdjustedEbitda', window );">Minimum Adjusted EBITDA</a></td>
<td class="num">$ (5,750,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandAndTwentyFourMember', window );">April 30, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MinimumAdjustedEbitda', window );">Minimum Adjusted EBITDA</a></td>
<td class="num">(4,560,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandAndTwentyFourMember', window );">July 31, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MinimumAdjustedEbitda', window );">Minimum Adjusted EBITDA</a></td>
<td class="num">(2,960,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember', window );">October 31, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MinimumAdjustedEbitda', window );">Minimum Adjusted EBITDA</a></td>
<td class="num">(1,500,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember', window );">January 31, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_MinimumAdjustedEbitda', window );">Minimum Adjusted EBITDA</a></td>
<td class="nump">$ 430,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_MinimumAdjustedEbitda">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Adjusted Ebitda.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_MinimumAdjustedEbitda</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandAndTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_AprilThirtyTwoThousandAndTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandAndTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_JulyThirtyOneTwoThousandAndTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961597652736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Feb. 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_AffiliatesEffectivePercentage', window );">Affiliates effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="nump">263,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share</a></td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate purchase price</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Except Directors And Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Notes bear interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Notes maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  07,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,052,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Third Modification Loan Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_FixedChargeCoverageRatio', window );">Fixed charge coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Third Modification Loan Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_FixedChargeCoverageRatio', window );">Fixed charge coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_AffiliatesEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Affiliates effective percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_AffiliatesEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_FixedChargeCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed charge coverage ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_FixedChargeCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=STRM_ExceptDirectorsAndOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=STRM_ExceptDirectorsAndOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=STRM_NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=STRM_NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=STRM_ThirdModificationLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=STRM_ThirdModificationLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139961597878864">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Valuation and Qualifying Accounts and Reserves (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_STRM_DisclosureValuationAndQualifyingAccountsAndReservesAbstract', window );"><strong>Valuation And Qualifying Accounts And Reserves</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit losses, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 132,000<span></span>
</td>
<td class="nump">$ 76,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">189,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(36,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(133,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit losses, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="nump">$ 132,000<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Adjustments to retained earnings for adoption of ASC 326-10, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit
Losses on Financial Instruments (Refer to the subtopic of Accounting Pronouncements Recently Adopted in Note 2 &#8211; Significant Accounting
Policies to our consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221;
for more information.)</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Uncollectible accounts written off, net of recoveries.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_STRM_DisclosureValuationAndQualifyingAccountsAndReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">STRM_DisclosureValuationAndQualifyingAccountsAndReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>STRM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>85
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M,D=1/!Q4O)%\D3\N,^52\CA_.6<4IGQU 'P_XUQNWJ@3;!_1NOP74$L#!!0
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M0*;>T[.,)SY*/X["9$][<69;G%FP"GU0]6EQN!)EKUF)7BG9'M]\RS<_,)'
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M(&6T\R;8OH;_2S0/9:W!R\R@:7260HZF?;/=WABU="^'[Y4Q:N$NYU(  1L
MW\\4J,#FQKYOWOY_P>0_4$L#!!0    ( $&+GEBRX.ES30,  ",*   8
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M@/V^J2KZ>L%?TNM?^US\#U!+ P04    " !!BYY8$+)2&T,'   U(0  &
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M#W.+235W],T7(VM_S;V1QLC2/^XYR[ER!O;WK93F],5U</Y/B=5?4$L#!!0
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MU#](7*-;KTOZCG"@A*8G#MXI."R%AK/]6PT[#V<$2+NIPO-"O/CU.S,,%9Y
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M#G>D=,DUEBQLNZ#CJ&!#3D[F,QR8M8 6G23+0"A$L@+9 P@J !096E[P7N'
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M'0WK?,PY'=3(]0*@LX85+-"M6#!M6QX9^W+NK> TH-$ W\0MB[TA'8M0A<L
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MQ+*)HGMHRF=+T%N6_ BK)\B99A(-\*8@Y^@$*T,$)'X#*E)0FE;_EX7?LFB
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M$I G3 OH)4I%98 I @^@Q-@X910&FQ<<7.([6LQ1W>4<59=>#?J9E#ZE/#6
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M.W!RTWBPL" KE%24W4,USQ(I\8 #QRBJW/B,?,$KGO6 /A-2]7AOW<,DO4,
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M"\>V@.?D)9U<(0^R63@*$$A<NZU9+ 2WQ-.P=3.Y@$(:9A8WI+0QXL-]E-Q
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MB(EO=Q%Q^5=N^>VU5BNF<3=0PP\D*IT&YF2)1GFP&IY*.&=O[[X]W']\]_#
MWG[Z<'?_<?KU_M/'ZU,+E/'Y:>*IW#DJ\1XJHYA]4*7-#'M7IB+M$C@%EAJ^
MXL#777R0XGM>#MC9J,_B83P^0.^LD?.,Z)WMD[,VL&(,>ZN*F2PY0J+/IL8
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M"527GBI^AZH=LUM5V)EA5T4JTDT&3:A0Z1$O];B,/^3X!R\:[*!=9W$K[GS
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M=+)E1O0SX;WR9?EAE-G_(<K1_QIE!&#*M4.)W?YJL%W?$IIK7W9R ?"G[U=
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M>VI%&$&''ZV0\S1+W2/MAEF4?V3AK92W8EY:8-+:77&JW<JCQKO,*8.ZYSU
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M: &>+S0,#Q=T0/W)_N2?4$L#!!0    ( $&+GE@KLLF/30@  * 4   9
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MPPLGTUM36'06.+K?C/B1'O]B/T&0.RY !5\QV8S@>#J#Y8["@=@F#.56P-W
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MI+T/LS^TV)@[J(706A3F<<TH]"$D@/^70NCJ!RJH+R5O_@)02P,$%     @
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M+W=O<FMS:&5E=',O<VAE970Q-RYX;6R=5UMOVS84?M>O(-QA2 '%UL7RI;D
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ML<#^(0T3X#S7VO4OK&#X)\'5_P!02P,$%     @ 08N>6.5KUJT' P  B08
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MV0G,";8;U__R*VZX@;'\O^:8-N28N&W!9N<E6YFD(6WAHB>.BYYLY:*WV;0
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M34K1D])GW3,)&D'0-U.R\[X2[UQ -WQ"+$J4&(.I0R7*M8XUN,%YWOD-73+
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M]P%2H&FJ*=>[(-N$T'#P_DZ^B]4YW#82EK,JD&OMY/B=<=E@#!AE$<ZIWC9
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M[V?[2;26#Z#%8A(3-K,I#2FQG*.*VBJNYJZ'%6E-'7("Z@R9'T;.S(V,V-5
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MZ8?@8_WD3/O3:$Q0)235T&&&BP6IR*LH_!)Q.DI,BQ1A:BT7ZZ5;\/#4<IO
MD0B"8K8[$3M7O,URAGWAQ<F6[TMA481GON^@JKKPI+4W U$<LC_>!F+(CBOX
M">M@7_9XAH/5(T(61>:9G*OTB2R!1Q P(Q.L,[/*&W@>.:5?$DIQQ0OD[U'!
MQW0M9%FTE&1RX4I0Z7^L-!U6X@J'Y^S(%)>3Q!$A(J+CQ$Y'UO+$_*#8#V?X
MDF.V1'5EY0,&454.LB)S?[#HM(D7ANOIEB":IBP*?/[K2#DF76 3^80+ 0A6
M%- OR,J1CA DZ_OA^!W6-Z[;Z4KW+]4,89PEMR-5.<5Q]9@7 I])??WN[JG2
MO'?$<%)%&%H!6BS5<O;M6U!F3 #_"Q*NW1'I#AK3<E%[@N,?CYQ,$Q"BP/BF
M;*(J60Q.=-7>APO?^,?9Z]-[8TGSR/E6N/VB9\QB_![,(ZZ+*@QK1[*LY,QC
MXY+Q<.>5BDMZ5O,?DC#0%!X/D=(5E^3HT\DY93QG0#+Q'ZXVQB V7P) \["[
M9T:$EB\OC$V(P8?LO26BXI"2+QXTIWJ2<BGD"9:4C$?T3NY?Z*V)[#) J";E
MR8'+ J&P&1N*9JU<:W3S;5""RCEYQ>OM#3(/44AZ[3$1'%B"MDP7&HF-LCN-
MJYTI<SWF\IEB S7]M6"Y-$@TRV,_2VI2P"W^"OI>*:^LCVX%X0<,/K"&+8WB
M557]D):B_A(\F ^+, -_.RS,E&X!T0A>F*K?D6G >#ICI()W/4:#E= GH4Y]
MM7G2X9R;P#/"#N#Y#6C!NYI+XC"5X57HSLV8V)W[7:.]>H4&QOG0%I23IX6P
MR>G6->_LCK>4>R?R*'D,80>(I:\H"XUB6?@J.VO1]8#*@DO,QFNR="B<1!A5
M[7O,LWG0)W 8OI80[WT0AT<S;9MPW!Z;F00K(K-)7,D,NOT8]K7TWDZ9PZY
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MW^RI4^5@1_<\!;%^B9,W:P-["VJ3?VEWS>,6 UUB_ -0!<\72U!Q /Z_9W$
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MBD*LV10:3B4(_!*3IR> H 2\,Z-%OG_63%.+"M25U 15:H(?3\W@R\MB.1S
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MF%1?@P&X$/\=](TJ!0+T ?F!XW:ZCNNZUB3;8BJA76CTL>MTO,"<HD_G,9J
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MEL5 5VRTV.9#U(/0,)+ERPW,P$0: ?@_%4)7&W-!/54/_@%02P,$%     @
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MW:ZN F=0L%G;W^V=5L?_R?%>R?'>JSD^]6?^:N5/%;_&Z[6_6:/Q8HJ 7G?
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MT'7UNP/W-!7R1(7$0^N>R4B+9T4N\B./3.OIEIVTZ%9G@E8MB>)FT/0&IQ>
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M'A.W1"SPD("<SM'5K<<H)5%=T%5'\96Y%*=<X15KFDM\TU"A#7!^SKG:=72
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M&]/%@[0;S/-("'V<V,8R_U^@^P]02P,$%     @ 08N>6$F45SE3 P  N L
M !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULO59MC]HX$/XKH]SIU$KM
M)B20?3F(Q$)0J=@% =M>6]T'+QD@:F*GMH'=_OK:3C8EW8!:B?8+\<O,,_,\
M'IMI[QC_+-:($A[2A(J.M98RN[)ML5AC2L09RY"JG27C*9%JRE>VR#B2R#BE
MB>TZCF^G)*96T#9K$QZTV48F,<4)![%)4\(?KS%ANX[5L)X6IO%J+?6"';0S
MLL(9RKMLPM7,+E&B.$4J8D:!X[)C=1M7O8:C'8S%NQAW8F\,FLH]8Y_U9!AU
M+$=GA DNI(8@ZK/%'B:)1E)Y?"E K3*F=MP?/Z$/#'E%YIX([+'D?1S)=<>Z
ML"#")=DD<LIV;[ @U-)X"Y8(\PN[PM:Q8+$1DJ6%L\H@C6G^)0^%$'L.#?^
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MI&KU9IFH80Q<.ZCS&6-RL]$!RO$>_@%02P,$%     @ 08N>6!9W6^,#!0
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M&^(#-R[I0>J+.;;W#+C^YME #+40EV4<]VP@=7BQ#C^X6M\[MO7#$0POKME
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MH;*8%1L]BP/)5_E>R7LN)5_F'Q>,SEBF+U#?SSF7SP>Z@G*[[?A_4$L#!!0
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M=^2GF N6I!6Y867)U#OZ^6(H9,$J^W"V+63:%$(["G$I^5SD8E61]_F<STV
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M1X1*%+,?;]34OXP<TH+/K6R@2NTMFF&GK1'"DM -1]T:DFH=36$=/961H1[
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M'BSO[S;2Z=:3,DK-JB9Z]M)OH3X*H_9FU*+3Q\XX.%2RMG0T\NFXHXON[>B
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M+:@A#*6Y4)H'I?E06H"BZ<II;&'+[ MC!T50=QA*<Z$T#TKS:]I8"],=<3I
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M]7(I B7+Y07B^WF6\<T;F8'<&JF*=_$_4$L#!!0    ( $&+GEB"?B-S\@4
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M8<,CXL#J<9]0UW;YJF-H^ -1K8G#)H@##7*@E1(E(\<ERAL:E$ [2\9;[@<
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M\Q$$=?Y0&D71[&OYC/,/!]#2%D+[\U!:!*51%,T6QJP#A&WK )C25@_3=@7
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M.?><Z_BZM>;B22X %'K.*)-M9Z%4?N&Z,EE AN4)SX'I+S,N,JST5,Q=F0O
MJ05EU T\+W(S3)@3MVSL0<0MOE24,'@02"ZS#(N?7:!\W79\9QL8D?E"F8 ;
MMW(\AS&H2?X@],PM65*2 9.$,R1@UG8Z_D4O,NOM@B\$UG)GC(R3*>=/9C)(
MVXYG! &%1!D&K%\KZ &EADC+^+'A=,J4!K@[WK)?6>_:RQ1+Z''Z2%*U:#MG
M#DIAAI=4C?CZ!C9^FH8OX53:)UH7:R//0<E2*IYMP%I!1ECQQL^;.NP _.@
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M;"]W;W)K<VAE971S+W-H965T-#@N>&ULM5E=<^(V%/TK&K?3V9UI8DLV!J?
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MWA!827D[5]X^YF)O-UF'AL!*=>CD=>AH9\"8"S],5M(])XMU "[]!5$IUL-
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MH*0G@JZ2EQ /5 @:)H=+(IL:BP/D]06EXNTD?J^1O\?J_P!02P,$%     @
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M7$<#S(YO!-9B8XRTE0EC]WHRB-J6HQ5!#%.I*;!ZK* '<:R9E(Z?.:E5Q-3
MS?$C^YDQK\Q,L( >B^]()!=MZ]A"$<SP,I;7;/T%<D-US3=EL3"_:)WM#53$
MZ5)(EN1@-4\(S9[X(4_$!L -=@"\'. ]!]1V /P<X!NCF3)CJX\E#EN<K1'7
MNQ6;'IC<&+1R0Z@^QK'DZBU1.!F>7U[V[P;#(>J,^F@PNNF,S@?=X2GJC,>G
M-V-TT >)22S0"'..=<8_HD-T.^ZC@_<?6[94"C2//<VC=;-HWHYHKH<N&)4+
M@4YI!-$V@:VD%_J]1_U=KY+Q*Z9'R'<_(<_Q:B6">J^'^Q5R_"*=ON'S=_"=
M$4HD' Y5HB(TH!+3.9G$@#I"@!3H^U#M1P,)B?A1EKV,O%9.KF_TB4CQ%-J6
MNK("^ JL\,,[-W ^ESG?$]E6'FI%'FI5[.& )"DF7-UWB=@,S1F+UB2.RSQG
M1'5#I(O.*FP>N[[C."U[M6FG,F"Y'53AI%XXJ5<[V3)"GHX4FR,M<Y01!IN.
M@A)#E7'?;B@H# 65ACH)XY+\QJ:*PH/Z'@A :O@J:\$+:VXC<%YZ"UX<JMML
MN)O[MK0W"NV-:NT33"-&U=TR$M&:,ZG$SV9E6ALOM?I^B=;*D/]X3XX+0\>5
MAGJFP@-'UQ";$Q$+DJHZ<0')!'AIC:@D?&N-V!/9EO=FX;WY/VME<Y]YV!/9
M5AY<Y^D;[.R[QN2,];\5F>K(;W5F;S0:ZE\[-_V70%.VI#+[9A>K18_7,9W-
ML_6N[OU, _-$DS6.%YC/"14HAIFB=(X:RB+/>K%L(EEJVID)D^KJF.%"]:_
M]0;U?L943<@G.D#1$8=_ %!+ P04    " !!BYY8"(\K\A<#  "Q"@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6RM5MF.VC 4_14KK:JI5"8+$)9"
M)-8.50<02]M70RX031)3VRS]^]I.R(0AI'0Z+XGMW'-\CNT;W\:!T">V >#H
M&/@A:VH;SK=U76?+#028W9,MA.++BM  <]&E:YUM*6!7@0)?MPS#U@/LA9K3
M4&-CZC3(COM>"&.*V"X(,/W=!I\<FIJIG08FWGK#Y8#N-+9X#5/@\^V8BIZ>
ML+A> "'S2(@HK)I:RZQW3 50$=\].+!4&TDK"T*>9&?@-C5#*@(?EEQ28/':
M0P=\7S()';]B4BV94P+3[1-[7YD79A:808?X/SR7;YI:54,NK/#.YQ-R>(#8
M4%GR+8G/U!,=HMB*H:'ECG$2Q&"A(/#"Z(V/\4*D *9]!6#% .LEH'0%4(P!
M164T4J9L=3''3H.2 Z(R6K#)AEH;A19NO%!NXY13\=43..Y,.P^][OQ;#XWZ
M:##LC!Y[:-;ZV9NB_FB".J/A;#"<#X9?T&C<F[1F@]$0W76!8\]G'U$!S:==
M=/?^8T/G0HHDU)?QM.UH6NO*M*:%'DG(-PSU0A?<<P)=>$B,6"<C;2N7\2L.
M[U'1_(0LPRIE".K<#B_FR"DFZUI4?,4K?)T=I1!RQ/$1P5$D'8-ZUC)%+*5L
M%IG#=;;%2VAJ(DD9T#UHSH=WIFU\SK+X1F1GADN)X5(>N],'%RCVLSSF K-E
MH2Q[_\]SYJR<."OG.IMRS"'+5P2S%4S^+O=.H5PU#*.A[].R,\)L*QUVILI.
M5-FYJF:$8U_\(9Z/V0)"6'D<W<7G+3,M[=LT9X3E:*XDFBNY2=&%%0B][E^S
MHO*66?%&9&>.JXGCZFNSHGJQQ%7[<B,NHPKVU7VH):IJKSO1M8O9S(S#<1E5
M*%[59!K/-Y%QPXEVTV?DIB,=TYZI-DJ7LC/B"K7KNE,WJ)FK>Q N20#_H#>B
M*Z=TE#)V/B.L4#$O]>JIRS\ NE8U$4-+L@MY='TFHTG=U5+5QHOQMJS'5%'Q
M3!,5<X^8KKV0(1]6@M*XKPA1-*J/H@XG6U5B+ @7!8MJ;D1-"50&B.\K0OBI
M(R=(JE3G#U!+ P04    " !!BYY8ODL.M;<#  !""P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970U,BYX;6RMEFUOXC@0Q[_**'=:M=+2//'8!23*@Y;3ME1
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M#BI]W*LF%[DV4.^WC,G7@5Z@:)N'_P)02P,$%     @ 08N>6.<DCYD'!
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MMR0IEO?/?")HIEO0C K9T/1P*7\Y@"D'N3ZG5.PF*D'Q$^/_!5!+ P04
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M-M-"<3L''H.T'<S[F1!Z\V 'J(^.)_\"4$L#!!0    ( $&+GEB4UM;#=@(
M +X%   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;*U4;6_3,!#^*U9
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M>S*C+#UU2"\$C9,/]S,J! V3Y@K(')CJ()\O*!7/%\I ?O8S_@]02P,$%
M  @ 08N>6(82*,'Q P  V0X  !D   !X;"]W;W)K<VAE971S+W-H965T-C N
M>&ULQ5=M;^(X$/XK5NYTNI/:)DY"$GJ !)3><KO=5D!;G5;WP20#1$UBUC:P
M_?=K.S2\);E60KHOB>W,V_,XX_&T-I2]\ 6 0#_2).-M8R'$\MHT>;B E/ K
MNH1,?IE1EA(AIVQN\B4#$FFE-#%MR_+,E,29T6GIM0?6:=&52.(,'ACBJS0E
M[+4'"=VT#6R\+8SB^4*H!;/36I(YC$$\+A^8G)F%E2A.(>,QS1"#6=OHXNL^
M;B@%+?$4PX;OC9&",J7T14V&4=NP5$200"B4"2)?:^A#DBA+,H[O6Z-&X5,I
M[H_?K-]J\!+,E'#HT^0YCL2B;00&BF!&5HD8T<TGV +2 88TX?J)-KFLWS10
MN.*"IEME&4$:9_F;_-@2L:> O0H%>ZM@'RNX%0K.5L'10//(-*P;(DBGQ>@&
M,24MK:F!YD9K2S1QIK9Q+)C\&DL]T1GW/PUN'K\,T/TM&@W&D]&P/QG<H/'D
MOO\9=9^[HQO4[4^&3\/)/^CW&Q D3O@?Z!+]BDS$%X0!;YE"QJ&LF>'69R_W
M:5?XQ#:ZHYE8<#3((H@.#9@20('"?D/1LVLM_DVR*^3@"V1;MEL24/_]ZDY-
M.$Y!JJ/M.56D*F(N>_+OBE"?IC+E.-$_;9<QDLU!IH% TU>T+_= 7O5R=T-8
MA+Y]D2;14$#*_RTC./?OEOM7J7_-ER2$MB%SFP-;@]'Y[1?L67^6D7,F8P=4
MN055;IWUSM=5.@6&Z R-QH_\ GV5+*V!"X@NT/U*<$&R*,[F%Z@'\SC+Y%!F
M;4*R$,IHR7UYVI<ZP-8='+B!Y>"6N=Y'7")GN8[3L JY S"- DRC%LRS/C3D
M9G;7P.0AB/Z2VRV03$Q MR1FZ(DD*W@GEMR5OQ_CE1L< 2D3:OCE*+P"A7>>
M+1GH=QT&[Y3GIF\U[./]*)$[VK<#)'Z!Q#_+?OPW$+^,YV,494)[.W8 (2@@
M!+401I)X%H<*Q%C0\ 5]NP.U/:6G0JVICYX*9S)V@+I9H&[^SP=H\YQ4G<G8
M 578VE5PZT/Y.E<_^7%9W=9EZS31W"#P3A*R3+!A-?RJC,1[]PU\EIQ46&JA
MX/JC;XNC3,JM.""QO0-A?XCR_'@L#=,^(?*R&=C>24DJ$VQ8V*^J27AW&<&U
M!?QCC-<@<=Y3D$JE/*<"P^Z6@-]U3<C9ELW+#.*J,$]K^Z43R-)N'4=:(HB;
M3<>J(GQW"\#GN09HPNO!E-5W[^0G+[TJ-(]@F'M-0@ILKGLGCD*ZRD1^TRY6
MB_ZLJ[N2H_6>ZMMT\[$SDS=]=X3)BPU'"<RD2>O*EX&QO(_*)X(N=2LRI4(V
M-GJXD+TG,"4@O\\H%6\3Y:#H9CL_ 5!+ P04    " !!BYY8O# ,Y(P'  !'
M/   &0   'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6S%FUMOVS84Q]_[*0AO
M&%H@C27ZFC8QD$2795LNJ-OMH=@#(]&V4$ET23J)AWWXD92BBZ-P\7: O"26
MS/,CJ?,7>?0W='S/^#>QHE2BARS-Q4EO)>7Z0[\OHA7-B#AD:YJK;Q:,9T2J
M0[[LBS6G)#9!6=K'CC/N9R3)>[-C<^Z&SX[91J9)3F\X$ILL(WQ[1E-V?])S
M>X\G/B7+E=0G^K/C-5G2.95?UC=<'?4K2IQD-!<)RQ&GBY/>J?LAQ&,=8%K\
MGM![T?B,]%1N&?NF#R[BDYZC1T13&DF-(.K?'3VG::I):AS?2VBOZE,'-C\_
MT@,S>3696R+H.4O_2&*Y.NE->RBF"[))Y2=V_S,M)S32O(BEPOQ%]V5;IX>B
MC9 L*X/5"+(D+_Z3A_)"- +<X3,!N S +PT8E &#W8#!,P'#,F"X$_#L'$9E
MP&@G #\WI'$9,'[I'"9EP,0DJ[BZ)C4>D61VS-D]XKJUHND/)K\F6F4DR;44
MYY*K;Q,5)V?SS]?GO[X_.YW['CJ_OKSQK^:GGR^NK]!;CTJ2I )=$<Z)ULL[
M]!Y]F7OH[8_OCOM2]:T)_:CLQR_ZP<_TXV)TR7*Y$LC/8QJW 7TUZ&KD^''D
M9]A*/%WS0^2X!P@[>- QH'-[^!6[J\)Q1[AG#[\D6Q7Y;+1OC_Z%Y(=H4'0^
M[ @/7A[>-?7PY>'8DHE!I:&!X0V>T]"*</K^3"T(,3IGF5HE!3'KS*E23KZD
M:N62Z':+FNUNR-:</KTG/$9??U-(="%I)O[LF,]9T?^PNW^]6G\0:Q+1DYY:
MC@7E=[0W^^D'=^Q\[-(%),R#A/F0L  2%@+!6O(:5O(:VNBSZ_N<<K%*UNB&
M\DB)1FV172*Q4O85"23,@X3Y!>S(P'2A<3=S#M5=?-?,/62'(1"LE?M1E?N1
M-?>?J) \B:1:,>:21=_0UTN:W5+>N4I84?L* !+F0<)\2%@ "0N!8"VEC"NE
MC%]Y$QI#R@L2YD'"?$A8  D+@6 M>4TJ>4VL"U&Q^K"UD11]T/+JW(2LE'U%
M @GS(&$^)"PH8*/&CN8>#::.X[1WM1"HTU;^IU7^I];\7VWTMH/80CU_5UN2
MT*(0B.CE@\8'2.BU173)P@K?5Q:0, \2YA>P<3.3P^ETC-V=^J2CW<@9308[
M[4*@P;4R?E1E_,B:\7,FI+G33:HYU;Y.DB_1FO*$Q5U)MO+V33(DS(.$^9"P
MP)X#%VTIX>@(985WX$Y13+9==U@(-*J65%RG=E$<ZT"QXP[01:Z?3I([VBY
M;E*25W4K^KLL9*_-5B*L!:V]TWT5!4KS0&D^*"T I850M+:T&@:=^\J%;3D
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M[G5HV0Q&8Z"H;#-N!.K6MMM<OR4@C8.^WPJ!)\,$Z%ZG^"]02P,$%     @
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M :8FR/$EI>+%4/6QOMZ$?P!02P,$%     @ 08N>6/ QD*G3!   2Q\  !D
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MCZ409P%N_TI MPSH7@9<R] K WJW9NB7 ?U; P9E0'[K=G'ON7 >E70V$?Q
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M#T[CAB9$_B6/],BB+#+W)4P3ND"E>:@T'XM6K]S)(KMFC_S CK F:G*(+9"
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MTIC5N>_K=(D%T\=RA8)FYE(5S%!7+7R]4L@RYU3D?A0$/;]@7'BC@1N;JM%
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 08N>6&>??"'B!0  _RP   \
M  !X;"]W;W)K8F]O:RYX;6S%FDMSFT@0@/_*E$[90U;FF4?%J1K!2!X'@<*
M$N>RA24444'@ F1O\NMW!L6;QG9Z]S+XY( 4Z5//X^ONX=U=W7R[KNMOY.]#
M6;7GDWW7W;R=3MO-/C]D[9_U35[)5W9U<\@Z>=E\G;8W39YMVWV>=X=R:IZ=
MN=-#5E23]^_N/VO53.%%W>6;KJ@K>5/=6!?Y7?OK=75);HNVN"[*HOM^/NG_
M7>83<BBJXE#\R+?GD[,):??UW47=%#_JJLM*L6GJLCR?&*<7UGG3%9M'MX6"
M3++KMK_39==Q)D'.)^Z9_,!=T;1=_X[^\S/)>)O+-Y^NCET]+\HN;_RLRQ=-
M?;PIJJ_J8^2OF(*?T<?A_N\IB&^;_Q/&>K<K-KE?;XZ'O.I.<6SR4@%6[;ZX
M:2>DR@[Y^<2K;_-&_1[Y!7Q[^FV=A *1:MX6\H6&;WL\G2A56Y?%5G[[ELRR
M,JLV.>E#V ) $P$TGPV0O%AE -)"(*T1(86"4/^A)?6.1#>#H;812/O9(+U]
M5@%(!X%TG@\R:_< TD4@7;V04;R@(?]"$QZ%A(8^\9GP8K[JKZ,Y@'R%0+[2
M"RGX(N1S[M$P(=3SHC1,>+@@JRC@'F<"0+Y&(%_KA9RE@H=,".)%RQD/^X@"
MLC<(V1O-8[QB,>TC%C J!O$RSK#]^DPOE\]F"61!W:%9'HLH\C_Q(.C7  \3
M&B[X+&"$"L&20<0P@1B:#<)#.;D82>CGX2ABOC T"X-]3'ER!6DP,1B:S;"D
MEU%,O("S<#ALF @,S29@RU4073%&8I;PF"TE&UD%%&X/!N8 0[,$1!)Y'U[.
MY-[@J]UKQ4+Q</LRL.W?T+S_2Z8E3U381+\^O:@7  L?[/X&MOT;FO?_F 4T
MD0%<T3BY(DE,91 ]%<4!(:8!0[,'1#H3<K6JV<?6#]:'B8G U"R"=58>^[LD
MJ[;DXS$KB]UW6=$0NMG41YC.F9@C3,V.0-.0OTR(B589FB6!8UH0$_.&J=D;
MRO[DA2QIR[S] T)A^C UZP-/ PC$Q(1B:A8*S .>C"%F$_.9;/(3%&)B4C%U
M%Q4/=\,G XD9Q=1L%.%=,#^5LR^:DS *7WI47!">L*4@2C80$].*J5LK #-F
M@L5KE>B(-) AY2%<,Q8F&4NS9""FW!;C5$Y/]EG-3K6&?(B)2<;2+1F R43"
MEWU2D0HV3P,2<(B)2<;2+1D8S644)_<]A%-((2;:S-(L&8@YISPF:QJD_V[G
M< E9F'8LS=I!,0>9A85IQ]*L'8CI<T$7BY@M:-)WBN22AYB8@"S= @*84D/<
M.S6V>)"JI02K&@L3D*5;0!CF<- Q"UDC6BAFLO3R>,#IS_X@@0T<"[.0I=M"
M:-9KP[XU9B%;LX6>ZA)*^^1=5I3M8&[:F(5LS19ZV#($B%G3P*,*&[.0/:*%
MHC01,E_W^U&/98;,5Q 3LY ]HH66]#-?IDO2ES])1&@<0TST4&5$"SW"]"\A
M)F8A6[.%3H7C8#ZJPU&8MMN8?NP1]>/)X;U2,U+F2')'4K<@)J8?>T3]S'DH
MZXJ7 5^S^[(78F+ZL4?4SSQ-TI@-\DV(B>G'UJP?M'$PD+F#Z<<9L0@:-!'F
MJFL>04Q,/\Z81=!\SKQ$SLQ?P! 3TX\SHGY\-F=Q+)>/C.?C4R,'TX\SHGX6
M<223CS14F9Q,F+Y(8(B)Z<?1K)]A4^O1_@XQT5-]W8<Y_7G7?PC(P03D:!;0
MX SL,2C$Q 3D:!;0[T[%?A)#3$Q SH@"ZEN;)#H]':%.=]:P(>-@ G+&[<(E
M,?=4M7LBII_@TR:8@%S= OIM<_CAH+N8@%S=SY)A)X[D!<3$!.1J%M#OSQS[
M>$),3$#N,]0_,C$F(4MD?;F&F)B W.>L?P8YG(L)R!VQ"[>4B7L?3?\R%6HF
ML!G$1!\LTUT&/3Y?@2:"F)B%7,T60L^>AX..6<CM+33MW]R^?[?-=T65;T/Y
M%:V\O\G*S:HAZL_I&2+;44\"[(YEZ<E[4174V?;^^=W[9X_?_P-02P,$%
M  @ 08N>6!;=:Q0F @  8R@  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<\W:2T[C0!2%X:U$7@"5NJ] BS#J"5/$!JQ0>8@DCEQN ;OO* R28_6@
M)\AG9)4M7_^C3U;9CR]EWPZ[[EBWNU.=?1[VQ[ILML-P^I5276W+H:UWW:D<
MSU?677]HA_.RWZ13NWIO-R7)?!ZIOYW1/#W>SIR]?IW*_TSLUNO=JOSN5G\.
MY3C\8W#ZZ/KWNBUE:&:O;;\IP[))G_OKZ9HNAWQWGMS,GM^63?_\EILT=9!
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M:OY3UGOGUG\</S[+SC;]6SX;_YJW> %02P$"% ,4    " !!BYY8!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( $&+GEA!I..4[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $&+GEB97)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M08N>6$?L(\R7"   KC4  !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $&+GE@D\QI/% <  &L@   8
M          " @=H0  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " !!BYY8LN#I<TT#   C"@  &               @($D&   >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 08N>6$SGRQ.Q!@  2QX
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M965T."YX;6Q02P$"% ,4    " !!BYY88M(0=.T*  !"(@  &
M    @($J8P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M08N>6-^E[C0M!0  TPL  !D              ("!36X  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " !!BYY8@*1M!D@(  !$%   &0
M            @(&Q<P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( $&+GEBXTI0$/0P  +X?   9              " @3!\  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ 08N>6"NRR8]-"
MH!0  !D              ("!I(@  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " !!BYY8+7"9,OD#  !<"0  &0              @($H
MD0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( $&+GE@E
M_/YP4 ,  -<'   9              " @5B5  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ 08N>6##G2T_B @  1 8  !D
M     ("!WY@  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M" !!BYY88"O@>, &  "4#P  &0              @('XFP  >&PO=V]R:W-H
M965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( $&+GE@K0GW?0P<  # 0   9
M              " @>^B  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L!
M A0#%     @ 08N>6.5KUJT' P  B08  !D              ("!::H  'AL
M+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !!BYY8P/8+>NH'
M   P%0  &0              @(&GK0  >&PO=V]R:W-H965T<R]S:&5E=#(P
M+GAM;%!+ 0(4 Q0    ( $&+GECYJ$!?\ ,  / (   9              "
M@<BU  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ 08N>
M6!@BL_=,.P  ,[\  !D              ("![[D  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " !!BYY8_<C?I( +  "5'P  &0
M        @(%R]0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( $&+GEB02"=ZJP,  $<)   9              " @2D! 0!X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 08N>6-AAU3A\!   80L
M !D              ("!"P4! 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " !!BYY8E2B3&3,&  !Y$   &0              @(&^"0$
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( $&+GEA5/C?#
MS0,  #$)   9              " @2@0 0!X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ 08N>6/L#/!=% P  R @  !D
M ("!+!0! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !!
MBYY8W9X:=A(#  "^!P  &0              @(&H%P$ >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( $&+GEBO1Y-; @,  "H)   9
M          " @?$: 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#
M%     @ 08N>6),AAJ4D P  &@D  !D              ("!*AX! 'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !!BYY8EE9;XXP#   C
M$   &0              @(&%(0$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;%!+ 0(4 Q0    ( $&+GEA)E%<Y4P,  +@+   9              " @4@E
M 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ 08N>6.[1
M(.(%!   8!$  !D              ("!TB@! 'AL+W=O<FMS:&5E=',O<VAE
M970S-"YX;6Q02P$"% ,4    " !!BYY8YZ!9N'L"    !0  &0
M    @($.+0$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M $&+GE@$REG(L (  .H'   9              " @< O 0!X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ 08N>6!9W6^,#!0  J!4  !D
M             ("!IS(! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " !!BYY8*SY)1FL#   &#0  &0              @('A-P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( $&+GE@WT^V8&P8
M 'HK   9              " @8,[ 0!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ 08N>6%-OUZ <#   O5\  !D              ("!
MU4$! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !!BYY8
M0Q?R%M,.  !&A0  &0              @($H3@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( $&+GEB"?B-S\@4   8R   9
M      " @3)= 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ 08N>6. BWK38 @  0@@  !D              ("!6V,! 'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !!BYY8HH,8M_,#   K&@
M&0              @(%J9@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( $&+GEAUJA(SU0(  .X*   9              " @91J 0!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ 08N>6&@''Q'Z
M!P  S4L  !D              ("!H&T! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    " !!BYY8*T#QR[D"  !)!P  &0
M@('1=0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( $&+
MGECQE8!"R@0  -,:   9              " @<%X 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ 08N>6"0/ZJ[. @  EPD  !D
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M=#4S+GAM;%!+ 0(4 Q0    ( $&+GEAR%J\W^P(  - (   9
M  " @:J/ 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
M08N>6.&J@&'/!   TQT  !D              ("!W)(! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    " !!BYY8]#0]-4 &  ";.0  &0
M            @('BEP$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( $&+GE@\(807:P0  $8>   9              " @5F> 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ 08N>6)36UL-V @
MO@4  !D              ("!^Z(! 'AL+W=O<FMS:&5E=',O<VAE970U."YX
M;6Q02P$"% ,4    " !!BYY8BN+F9+D$   '&@  &0              @(&H
MI0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( $&+GEB&
M$BC!\0,  -D.   9              " @9BJ 0!X;"]W;W)K<VAE971S+W-H
M965T-C N>&UL4$L! A0#%     @ 08N>6+PP#.2,!P  1SP  !D
M     ("!P*X! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $&+GECNC&CLJ0(  .H(   9              "
M@1W$ 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ 08N>
M6/ QD*G3!   2Q\  !D              ("!_<8! 'AL+W=O<FMS:&5E=',O
M<VAE970V-RYX;6Q02P$"% ,4    " !!BYY8]IUI7T4$  ",#   &0
M        @($'S $ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0
M   ( $&+GE@,!0*6' ,  $@1   -              "  8/0 0!X;"]S='EL
M97,N>&UL4$L! A0#%     @ 08N>6)>*NQS     $P(   L
M ( !RM,! %]R96QS+RYR96QS4$L! A0#%     @ 08N>6&>??"'B!0  _RP
M  \              ( !L]0! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M $&+GE@6W6L4)@(  &,H   :              "  <+: 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( $&+GECA[%X1] $  *(G   3
M              "  2#= 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !,
- $P RQ0  $7? 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>236</ContextCount>
  <ElementCount>395</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>107</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - BUSINESS COMBINATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/BusinessCombination</Role>
      <ShortName>BUSINESS COMBINATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - OPERATING LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/OperatingLeases</Role>
      <ShortName>OPERATING LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/GoodwillAndIntangibleAssets</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/Equity</Role>
      <ShortName>EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - MAJOR CLIENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/MajorClients</Role>
      <ShortName>MAJOR CLIENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - EMPLOYEE RETIREMENT PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/EmployeeRetirementPlan</Role>
      <ShortName>EMPLOYEE RETIREMENT PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Valuation and Qualifying Accounts and Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReserves</Role>
      <ShortName>Valuation and Qualifying Accounts and Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/DebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/Debt</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsTables</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/GoodwillAndIntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/Stock-basedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SUBSEQUENT EVENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/SubsequentEventsTables</Role>
      <ShortName>SUBSEQUENT EVENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/SubsequentEvents</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - SCHEDULE OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfNon-cashItemsRelatedToCondensedConsolidatedStatementsOfCashFlowsDetails</Role>
      <ShortName>SCHEDULE OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - SCHEDULE OF RESERVE RESULTS IN FUTURE PERIODS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfReserveResultsInFuturePeriodsDetails</Role>
      <ShortName>SCHEDULE OF RESERVE RESULTS IN FUTURE PERIODS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfAccruedExpensesDetails</Role>
      <ShortName>SCHEDULE OF ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails</Role>
      <ShortName>SCHEDULE OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical</Role>
      <ShortName>SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - SCHEDULE OF DISAGGREGATON OF REVENUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfDisaggregatonOfRevenueDetails</Role>
      <ShortName>SCHEDULE OF DISAGGREGATON OF REVENUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails</Role>
      <ShortName>SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical</Role>
      <ShortName>SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - SCHEDULE OF RECONCILIATION OF THE RESTRUCTURING LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATION OF THE RESTRUCTURING LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - BUSINESS COMBINATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative</Role>
      <ShortName>BUSINESS COMBINATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/BusinessCombination</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - OPERATING LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative</Role>
      <ShortName>OPERATING LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/OperatingLeases</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails</Role>
      <ShortName>SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ARR RATIO (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails</Role>
      <ShortName>SCHEDULE OF MAXIMUM DEBT TO ARR RATIO (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails</Role>
      <ShortName>SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - DEBT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/DebtDetailsNarrative</Role>
      <ShortName>DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/DebtTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - SCHEDULE OF CARRYING AMOUNT OF GOODWILL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfCarryingAmountOfGoodwillDetails</Role>
      <ShortName>SCHEDULE OF CARRYING AMOUNT OF GOODWILL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails</Role>
      <ShortName>SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/IncomeTaxesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/EquityDetailsNarrative</Role>
      <ShortName>EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/Equity</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - MAJOR CLIENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/MajorClientsDetailsNarrative</Role>
      <ShortName>MAJOR CLIENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/MajorClients</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - EMPLOYEE RETIREMENT PLAN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/EmployeeRetirementPlanDetailsNarrative</Role>
      <ShortName>EMPLOYEE RETIREMENT PLAN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/EmployeeRetirementPlan</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails</Role>
      <ShortName>SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/Stock-basedCompensationTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/CommitmentsAndContingencies</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/RelatedPartyTransactions</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - SCHEDULE OF MAXIMUM ARR NET LEVERAGE RATIO (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails</Role>
      <ShortName>SCHEDULE OF MAXIMUM ARR NET LEVERAGE RATIO (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails</Role>
      <ShortName>SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - SCHEDULE OF MINIMUM ADJUSTED EBITDA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails</Role>
      <ShortName>SCHEDULE OF MINIMUM ADJUSTED EBITDA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/SubsequentEventsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - Valuation and Qualifying Accounts and Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReservesDetails</Role>
      <ShortName>Valuation and Qualifying Accounts and Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReserves</ParentRole>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 -  form10-k.htm 72</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>strm-20240131.xsd</File>
    <File>strm-20240131_cal.xml</File>
    <File>strm-20240131_def.xml</File>
    <File>strm-20240131_lab.xml</File>
    <File>strm-20240131_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="728">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>92
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "STRM",
   "nsuri": "http://streamlinehealth.net/20240131",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "strm-20240131.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "strm-20240131_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "strm-20240131_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "strm-20240131_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "strm-20240131_pre.xml"
     ]
    }
   },
   "keyStandard": 332,
   "keyCustom": 63,
   "axisStandard": 30,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 77,
   "hidden": {
    "total": 76,
    "http://fasb.org/us-gaap/2024": 64,
    "http://streamlinehealth.net/20240131": 9,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 236,
   "entityCount": 1,
   "segmentCount": 107,
   "elementCount": 644,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 728,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://streamlinehealth.net/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://streamlinehealth.net/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://streamlinehealth.net/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://streamlinehealth.net/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "STRM:CostOfSoftwareAsService",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-01-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-01-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://streamlinehealth.net/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://streamlinehealth.net/role/OrganizationAndDescriptionOfBusiness",
     "longName": "00000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://streamlinehealth.net/role/SignificantAccountingPolicies",
     "longName": "00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://streamlinehealth.net/role/BusinessCombination",
     "longName": "00000009 - Disclosure - BUSINESS COMBINATION",
     "shortName": "BUSINESS COMBINATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://streamlinehealth.net/role/OperatingLeases",
     "longName": "00000010 - Disclosure - OPERATING LEASES",
     "shortName": "OPERATING LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://streamlinehealth.net/role/Debt",
     "longName": "00000011 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://streamlinehealth.net/role/GoodwillAndIntangibleAssets",
     "longName": "00000012 - Disclosure - GOODWILL AND INTANGIBLE ASSETS",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://streamlinehealth.net/role/IncomeTaxes",
     "longName": "00000013 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://streamlinehealth.net/role/Equity",
     "longName": "00000014 - Disclosure - EQUITY",
     "shortName": "EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://streamlinehealth.net/role/MajorClients",
     "longName": "00000015 - Disclosure - MAJOR CLIENTS",
     "shortName": "MAJOR CLIENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://streamlinehealth.net/role/EmployeeRetirementPlan",
     "longName": "00000016 - Disclosure - EMPLOYEE RETIREMENT PLAN",
     "shortName": "EMPLOYEE RETIREMENT PLAN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://streamlinehealth.net/role/Stock-basedCompensation",
     "longName": "00000017 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://streamlinehealth.net/role/CommitmentsAndContingencies",
     "longName": "00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://streamlinehealth.net/role/RelatedPartyTransactions",
     "longName": "00000019 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://streamlinehealth.net/role/SubsequentEvents",
     "longName": "00000020 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReserves",
     "longName": "00000021 - Disclosure - Valuation and Qualifying Accounts and Reserves",
     "shortName": "Valuation and Qualifying Accounts and Reserves",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies",
     "longName": "00000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://streamlinehealth.net/role/SignificantAccountingPoliciesTables",
     "longName": "00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "STRM:ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "STRM:ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://streamlinehealth.net/role/DebtTables",
     "longName": "00000024 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsTables",
     "longName": "00000025 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://streamlinehealth.net/role/IncomeTaxesTables",
     "longName": "00000026 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://streamlinehealth.net/role/Stock-basedCompensationTables",
     "longName": "00000027 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://streamlinehealth.net/role/SubsequentEventsTables",
     "longName": "00000028 - Disclosure - SUBSEQUENT EVENTS (Tables)",
     "shortName": "SUBSEQUENT EVENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "STRM:ScheduleOfMaximumARRNetLeverageTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "STRM:ScheduleOfMaximumARRNetLeverageTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://streamlinehealth.net/role/ScheduleOfNon-cashItemsRelatedToCondensedConsolidatedStatementsOfCashFlowsDetails",
     "longName": "00000029 - Disclosure - SCHEDULE OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Details)",
     "shortName": "SCHEDULE OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2022-02-012023-01-31",
      "name": "us-gaap:RestrictedStockExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "STRM:ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-02-012023-01-31",
      "name": "us-gaap:RestrictedStockExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "STRM:ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://streamlinehealth.net/role/ScheduleOfReserveResultsInFuturePeriodsDetails",
     "longName": "00000030 - Disclosure - SCHEDULE OF RESERVE RESULTS IN FUTURE PERIODS (Details)",
     "shortName": "SCHEDULE OF RESERVE RESULTS IN FUTURE PERIODS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2023-01-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "STRM:AllowanceForDoubtfulAccountsReceivableCECLAdoption",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "STRM:AllowanceForCreditLossesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://streamlinehealth.net/role/ScheduleOfAccruedExpensesDetails",
     "longName": "00000031 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details)",
     "shortName": "SCHEDULE OF ACCRUED EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "STRM:AccruedExpensesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "STRM:AccruedExpensesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails",
     "longName": "00000032 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT (Details)",
     "shortName": "SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31_custom_ComputerEquipmentAndSoftwareMember_srt_MinimumMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "STRM:PropertyPlantAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-01-31_custom_ComputerEquipmentAndSoftwareMember_srt_MinimumMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "STRM:PropertyPlantAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://streamlinehealth.net/role/ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails",
     "longName": "00000033 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE (Details)",
     "shortName": "SCHEDULE OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:CapitalizedComputerSoftwareAmortization1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "STRM:ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-012024-01-31_custom_CostOfSoftwareAsASeviceMember",
      "name": "us-gaap:CapitalizedComputerSoftwareAmortization1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "STRM:ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
     "longName": "00000034 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "STRM:AcquisitionEarnoutLiabilityFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "STRM:AcquisitionEarnoutLiabilityFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical",
     "longName": "00000035 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical)",
     "shortName": "SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "STRM:AcquisitionEarnoutLiabilityChangeInValuation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "STRM:AcquisitionEarnoutLiabilityChangeInValuation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://streamlinehealth.net/role/ScheduleOfDisaggregatonOfRevenueDetails",
     "longName": "00000036 - Disclosure - SCHEDULE OF DISAGGREGATON OF REVENUE (Details)",
     "shortName": "SCHEDULE OF DISAGGREGATON OF REVENUE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-012024-01-31_us-gaap_TransferredOverTimeMember",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails",
     "longName": "00000037 - Disclosure - SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details)",
     "shortName": "SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical",
     "longName": "00000038 - Disclosure - SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details) (Parenthetical)",
     "shortName": "SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2023-02-012024-01-31_custom_UnvestedRestrictedStockMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-012024-01-31_custom_UnvestedRestrictedStockMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails",
     "longName": "00000039 - Disclosure - SCHEDULE OF RECONCILIATION OF THE RESTRUCTURING LIABILITY (Details)",
     "shortName": "SCHEDULE OF RECONCILIATION OF THE RESTRUCTURING LIABILITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2023-01-31",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-012024-01-31_us-gaap_CostOfSalesMember",
      "name": "us-gaap:IncreaseDecreaseInAccruedLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000040 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PriorPeriodReclassificationAdjustmentDescription",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PriorPeriodReclassificationAdjustmentDescription",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative",
     "longName": "00000041 - Disclosure - BUSINESS COMBINATION (Details Narrative)",
     "shortName": "BUSINESS COMBINATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_RenewalContingentConsiderationMember_custom_FirstYearEarnoutMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative",
     "longName": "00000042 - Disclosure - OPERATING LEASES (Details Narrative)",
     "shortName": "OPERATING LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:RentalProperties",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:RentalProperties",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails",
     "longName": "00000043 - Disclosure - SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES (Details)",
     "shortName": "SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "STRM:FinancingCostPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails",
     "longName": "00000044 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ARR RATIO (Details)",
     "shortName": "SCHEDULE OF MAXIMUM DEBT TO ARR RATIO (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandAndTwentyTwoMember_srt_MinimumMember",
      "name": "STRM:MaximumDebtToArrRatio",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "STRM:ScheduleOfMaximumDebtToARRRatioTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandAndTwentyTwoMember_srt_MinimumMember",
      "name": "STRM:MaximumDebtToArrRatio",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "STRM:ScheduleOfMaximumDebtToARRRatioTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails",
     "longName": "00000045 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO (Details)",
     "shortName": "SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyFourMember_srt_MaximumMember",
      "name": "STRM:MaximumDebtToAdjustedEbitdaRatio",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "STRM:ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyFourMember_srt_MaximumMember",
      "name": "STRM:MaximumDebtToAdjustedEbitdaRatio",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "STRM:ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://streamlinehealth.net/role/DebtDetailsNarrative",
     "longName": "00000046 - Disclosure - DEBT (Details Narrative)",
     "shortName": "DEBT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-08-26_us-gaap_PrimeRateMember",
      "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://streamlinehealth.net/role/ScheduleOfCarryingAmountOfGoodwillDetails",
     "longName": "00000047 - Disclosure - SCHEDULE OF CARRYING AMOUNT OF GOODWILL (Details)",
     "shortName": "SCHEDULE OF CARRYING AMOUNT OF GOODWILL (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2023-01-31",
      "name": "us-gaap:Goodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails",
     "longName": "00000048 - Disclosure - SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS (Details)",
     "shortName": "SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails",
     "longName": "00000049 - Disclosure - SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details)",
     "shortName": "SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative",
     "longName": "00000050 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details Narrative)",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails",
     "longName": "00000051 - Disclosure - SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION (Details)",
     "shortName": "SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "00000052 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)",
     "shortName": "SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "00000053 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://streamlinehealth.net/role/ScheduleOfGrossUnrecognizedTaxBenefitsDetails",
     "longName": "00000054 - Disclosure - SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS (Details)",
     "shortName": "SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2023-01-31",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative",
     "longName": "00000055 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://streamlinehealth.net/role/EquityDetailsNarrative",
     "longName": "00000056 - Disclosure - EQUITY (Details Narrative)",
     "shortName": "EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-06-152023-06-15",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://streamlinehealth.net/role/MajorClientsDetailsNarrative",
     "longName": "00000057 - Disclosure - MAJOR CLIENTS (Details Narrative)",
     "shortName": "MAJOR CLIENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:ConcentrationRiskCustomer",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:ConcentrationRiskCustomer",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://streamlinehealth.net/role/EmployeeRetirementPlanDetailsNarrative",
     "longName": "00000058 - Disclosure - EMPLOYEE RETIREMENT PLAN (Details Narrative)",
     "shortName": "EMPLOYEE RETIREMENT PLAN (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails",
     "longName": "00000059 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2023-01-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails",
     "longName": "00000060 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details)",
     "shortName": "SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2023-01-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-01-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative",
     "longName": "00000061 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)",
     "shortName": "STOCK-BASED COMPENSATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "STRM:InvestmentOwnershipPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "STRM:InvestmentOwnershipPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://streamlinehealth.net/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "00000063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:PaymentsForRent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R64": {
     "role": "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails",
     "longName": "00000064 - Disclosure - SCHEDULE OF MAXIMUM ARR NET LEVERAGE RATIO (Details)",
     "shortName": "SCHEDULE OF MAXIMUM ARR NET LEVERAGE RATIO (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-07_custom_AprilThirtyTwoThousandAndTwentyFourMember_srt_MinimumMember_us-gaap_SubsequentEventMember",
      "name": "STRM:MaximumArrNetLeverageRatio",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "STRM:ScheduleOfMaximumARRNetLeverageTableTextBlock",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-07_custom_AprilThirtyTwoThousandAndTwentyFourMember_srt_MinimumMember_us-gaap_SubsequentEventMember",
      "name": "STRM:MaximumArrNetLeverageRatio",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "STRM:ScheduleOfMaximumARRNetLeverageTableTextBlock",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails",
     "longName": "00000065 - Disclosure - SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO (Details)",
     "shortName": "SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-07_custom_AprilThirtyTwoThousandTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember",
      "name": "STRM:MaximumDebtToAdjustedEbitdaRatio",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "STRM:ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-07_custom_AprilThirtyTwoThousandTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember",
      "name": "STRM:MaximumDebtToAdjustedEbitdaRatio",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "STRM:ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails",
     "longName": "00000066 - Disclosure - SCHEDULE OF MINIMUM ADJUSTED EBITDA (Details)",
     "shortName": "SCHEDULE OF MINIMUM ADJUSTED EBITDA (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember",
      "name": "STRM:MinimumAdjustedEbitda",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "STRM:ScheduleOfMinimumAdjustedEBITDATableTextBlock",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember",
      "name": "STRM:MinimumAdjustedEbitda",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "STRM:ScheduleOfMinimumAdjustedEBITDATableTextBlock",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative",
     "longName": "00000067 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "AsOf2024-04-30_us-gaap_SubsequentEventMember",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-04-30_us-gaap_SubsequentEventMember",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReservesDetails",
     "longName": "00000068 - Disclosure - Valuation and Qualifying Accounts and Reserves (Details)",
     "shortName": "Valuation and Qualifying Accounts and Reserves (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "AsOf2023-01-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-01to2024-01-31",
      "name": "us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "STRM_AbandonedAssetWroteOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AbandonedAssetWroteOff",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Abandoned asset wrote off",
        "documentation": "Abandoned asset wrote off."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r697"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net of allowance for credit losses of $86,000 and $132,000, respectively",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_AccretionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionExpense",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion expense",
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r805"
     ]
    },
    "STRM_AccruedCashPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AccruedCashPayments",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Cash Payments",
        "documentation": "Accrued cash payments."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_AccruedCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AccruedCostsIncurred",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Costs Incurred to Date",
        "documentation": "Accrued costs incurred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedExchangeFeeRebateCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional fees and services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for rebates of an exchange fee some mutual funds impose on shareholders if they exchange (transfer) to another fund within the same fund group."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "STRM_AccruedExpectedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AccruedExpectedCosts",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Expected Costs",
        "documentation": "Accrued expected costs."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_AccruedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AccruedExpensesMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses [Member]",
        "documentation": "Accrued Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_AccruedExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AccruedExpensesPolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses",
        "documentation": "Accrued Expenses [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets",
      "http://streamlinehealth.net/role/ScheduleOfAccruedExpensesDetails",
      "http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "periodStartLabel": "Accrued Balance as of January 31, 2023",
        "periodEndLabel": "Accrued Balance as of October 31, 2023",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee benefits and related compensation",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r657"
     ]
    },
    "us-gaap_AccumulatedAmortizationOfOtherDeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedAmortizationOfOtherDeferredCosts",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization of deferred costs",
        "documentation": "Accumulated amortization of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs, deferred acquisition costs of insurance companies, or deferred leasing costs for real estate operations."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization, property and equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r166",
      "r540"
     ]
    },
    "STRM_AcquisitionEarnoutLiabilityChangeInValuation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AcquisitionEarnoutLiabilityChangeInValuation",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition earnout liability, change in valuation",
        "documentation": "Acquisition earnout liability, change in valuation."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_AcquisitionEarnoutLiabilityFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AcquisitionEarnoutLiabilityFairValue",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition earn out liability fair value, observable inputs",
        "documentation": "Acquisition earnout liability, fair value."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_AcquisitionEarnoutValuationAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AcquisitionEarnoutValuationAdjustments",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      },
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows",
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition earnout valuation adjustments",
        "negatedLabel": "Acquisition earnout valuation adjustments",
        "documentation": "Acquisition earnout valuation adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_AcquisitionRestrictedCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AcquisitionRestrictedCommonStockMember",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition Restricted Common Stock [Member]",
        "documentation": "Acquisition Restricted Common Stock [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r755",
      "r756",
      "r757",
      "r759",
      "r853",
      "r915"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering expenses",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_AffiliatesEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AffiliatesEffectivePercentage",
     "presentation": [
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliates effective percentage",
        "documentation": "Affiliates effective percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r411"
     ]
    },
    "STRM_AllowanceForCreditLossesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AllowanceForCreditLossesPolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for Credit Losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheetsParenthetical",
      "http://streamlinehealth.net/role/ScheduleOfReserveResultsInFuturePeriodsDetails",
      "http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for doubtful accounts",
        "periodStartLabel": "Allowance for credit losses, Balance",
        "periodEndLabel": "Allowance for credit losses, Balance",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r244",
      "r248",
      "r249",
      "r252",
      "r878"
     ]
    },
    "STRM_AllowanceForDoubtfulAccountsReceivableCECLAdoption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AllowanceForDoubtfulAccountsReceivableCECLAdoption",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfReserveResultsInFuturePeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for credit losses, CECL Adoption",
        "documentation": "Allowance for credit losses, CECL adoption."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfReserveResultsInFuturePeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Allowance for credit losses, Write-offs &amp; Recoveries",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "STRM_AlpharettaOfficeLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AlpharettaOfficeLeaseMember",
     "presentation": [
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alpharetta Office Lease [Member]",
        "documentation": "Alpharetta Office Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDeferredSalesCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDeferredSalesCommissions",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense with deferred sales commissions",
        "documentation": "The amount of expense recognized in the current period for the periodic realization of capitalized fees that were paid to salespeople, distributors, brokers, and agents at the time of the conclusion of the sale. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r82"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt issuance costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r321",
      "r751",
      "r861"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense on intangible assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r260",
      "r267",
      "r665"
     ]
    },
    "STRM_AmortizedAndAbandonedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AmortizedAndAbandonedAssets",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortized and abandoned assets",
        "documentation": "Amortized and abandoned assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted earnings per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "STRM_AprilThirtyTwoThousandAndTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AprilThirtyTwoThousandAndTwentyFourMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "April 30, 2024 [Member]",
        "documentation": "April Thirty Two Thousand And Twenty Four [Member]",
        "label": "April 30, 2024 [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_AprilThirtyTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AprilThirtyTwoThousandTwentyFiveMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 30, 2025 [Member]",
        "documentation": "April 30, 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_AprilThirtyTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AprilThirtyTwoThousandTwentyFourMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 30, 2024 [Member]",
        "documentation": "April 30, 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_AprilThirtyTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AprilThirtyTwoThousandTwentyThreeMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 30, 2023 [Member]",
        "documentation": "April 30, 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative",
      "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://streamlinehealth.net/role/DebtDetailsNarrative",
      "http://streamlinehealth.net/role/EquityDetailsNarrative",
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition earnout liability",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r31"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r128",
      "r170",
      "r194",
      "r229",
      "r231",
      "r238",
      "r239",
      "r245",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r464",
      "r466",
      "r489",
      "r534",
      "r599",
      "r661",
      "r662",
      "r697",
      "r715",
      "r811",
      "r812",
      "r865"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r175",
      "r194",
      "r245",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r464",
      "r466",
      "r489",
      "r697",
      "r811",
      "r812",
      "r865"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r245",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r464",
      "r466",
      "r489",
      "r811",
      "r812",
      "r865"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r729",
      "r730"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r729",
      "r730"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r729",
      "r730"
     ]
    },
    "STRM_AveleadConsultingLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "AveleadConsultingLLCMember",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Avelead Consulting LLC [Member]",
        "documentation": "Avelead Consulting LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative",
      "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative",
      "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r881",
      "r882"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r280",
      "r881",
      "r882"
     ]
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BaseRateMember",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_BridgeBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "BridgeBankMember",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bridge Bank [Member]",
        "documentation": "Bridge Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r457",
      "r679",
      "r680"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r457",
      "r679",
      "r680"
     ]
    },
    "STRM_BusinessAcquisitionEquityInterestIssuedFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "BusinessAcquisitionEquityInterestIssuedFairValue",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business acquisition equity fair value",
        "documentation": "Business acquisition equity fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned",
        "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business acquisition, equity interest issued or issuable, number of shares",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition related costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r11"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationArrangementsDescription",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combination description",
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r112",
      "r460",
      "r480",
      "r481",
      "r482"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombination"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BUSINESS COMBINATION",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r458"
     ]
    },
    "us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedComputerSoftwareAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheetsParenthetical",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Computer Software, Accumulated Amortization",
        "verboseLabel": "Capitalized software development costs, net of accumulated amortization",
        "documentation": "For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r652"
     ]
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total amortization expense on internally-developed software",
        "verboseLabel": "Capitalized Computer Software, Amortization",
        "documentation": "Amount of expense for amortization of capitalized computer software costs."
       }
      }
     },
     "auth_ref": [
      "r651",
      "r652"
     ]
    },
    "us-gaap_CapitalizedComputerSoftwareNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedComputerSoftwareNet",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized software development costs, net of accumulated amortization of $7,960,000 and $6,224,000, respectively",
        "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_CapitalizedContractCostImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedContractCostImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss",
        "documentation": "Amount of impairment loss for asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "STRM_CapitalizedSoftwarePurchasedWithStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "CapitalizedSoftwarePurchasedWithStock",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfNon-cashItemsRelatedToCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized software purchased with stock (See Note 12)",
        "documentation": "Capitalized software purchased with stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r165",
      "r656"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r89",
      "r190"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r89"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow disclosures:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares purchase",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "STRM_ClientRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ClientRelationshipsMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Client Relationships [Member]",
        "documentation": "Client Relationships [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://streamlinehealth.net/role/EquityDetailsNarrative",
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies \u2013 Note 12",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r120",
      "r535",
      "r586"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r282",
      "r283",
      "r646",
      "r800",
      "r806"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r647"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://streamlinehealth.net/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for resale",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r706",
      "r707",
      "r709",
      "r710",
      "r711",
      "r712",
      "r755",
      "r756",
      "r759",
      "r853",
      "r912",
      "r915"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheetsParenthetical",
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative",
      "http://streamlinehealth.net/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common stock par or stated value per share",
        "terseLabel": "Common stock par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheetsParenthetical",
      "http://streamlinehealth.net/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r587"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r73",
      "r587",
      "r605",
      "r915",
      "r916"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.01 par value per share, 85,000,000 shares authorized; 58,945,498 and 57,567,210 shares issued and outstanding, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r536",
      "r697"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment and Software [Member]",
        "documentation": "Computer Equipment and Software [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r54",
      "r55",
      "r242",
      "r645"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r54",
      "r55",
      "r242",
      "r565",
      "r645"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r54",
      "r55",
      "r242",
      "r645",
      "r742"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r135"
     ]
    },
    "us-gaap_ConcentrationRiskCustomer": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCustomer",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Customer",
        "documentation": "Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes \"Information about Major Customers\" that may be disclosed elsewhere (for instance, segment disclosures)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r26",
      "r95"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClients"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MAJOR CLIENTS",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r54",
      "r55",
      "r242"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r27",
      "r54",
      "r115",
      "r645"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r54",
      "r55",
      "r242",
      "r645"
     ]
    },
    "STRM_ConcessionAccrualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ConcessionAccrualAmount",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfAccruedExpensesDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer concessions",
        "verboseLabel": "Concession accrual amount",
        "documentation": "Concession accrual amount."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_ConcessionsAccrualPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ConcessionsAccrualPolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concessions Accrual",
        "documentation": "Concessions Accrual [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract receivables",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r356"
     ]
    },
    "STRM_CostOfMaintenanceAndSupport": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "CostOfMaintenanceAndSupport",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of maintenance and support",
        "documentation": "Cost of maintenance and support."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_CostOfProfessionalFeesAndLicenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "CostOfProfessionalFeesAndLicenses",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of professional fees and licenses",
        "documentation": "Cost of professional fees and licenses."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_CostOfProfessionalFeesAndLicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "CostOfProfessionalFeesAndLicensesMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost Of Professional Fees And Licenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_CostOfSoftwareAsASeviceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "CostOfSoftwareAsASeviceMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost Of Software As A Sevice [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_CostOfSoftwareAsService": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "CostOfSoftwareAsService",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of software as a service",
        "documentation": "Cost of software as a service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring",
        "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101"
     ]
    },
    "us-gaap_CostsIncurredPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsIncurredPolicy",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs",
        "documentation": "Disclosure of accounting policy for property acquisition, exploration, and development cost incurred in oil- and gas-producing activities and whether cost is capitalized or charged to expense when incurred."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax expense:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r754",
      "r851"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current tax benefit (expense)",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r754"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r754",
      "r851"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r242"
     ]
    },
    "STRM_CustomerFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "CustomerFourMember",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Four [Member]",
        "documentation": "Customer Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer One [Member]",
        "documentation": "Customer One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r786",
      "r787",
      "r788",
      "r789",
      "r791",
      "r793",
      "r796",
      "r797"
     ]
    },
    "STRM_CustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "CustomerThreeMember",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Three [Member]",
        "documentation": "Customer Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Two [Member]",
        "documentation": "Customer Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_DebtAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "DebtAgreementMember",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Agreement [Member]",
        "documentation": "Debt Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r192",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r288",
      "r289",
      "r299",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r315",
      "r322",
      "r323",
      "r325",
      "r498"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument carrying amount",
        "verboseLabel": "Term loan",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r119",
      "r326"
     ]
    },
    "us-gaap_DebtInstrumentCovenantDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCovenantDescription",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt financial covenants, description",
        "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r57"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan",
        "verboseLabel": "Debt principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r498",
      "r499",
      "r668",
      "r669",
      "r694"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument, interest rate, effective percentage",
        "verboseLabel": "Notes bear interest rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r328",
      "r498",
      "r499",
      "r694"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "verboseLabel": "Debt instrument, interest rate, stated percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r301"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r694",
      "r752",
      "r860",
      "r862"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of credit facility, matures",
        "verboseLabel": "Notes maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r667",
      "r856",
      "r857"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r39",
      "r40",
      "r56",
      "r106",
      "r107",
      "r196",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r694",
      "r752",
      "r860",
      "r862"
     ]
    },
    "STRM_DeferredCommissionsCostsPaidAndPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "DeferredCommissionsCostsPaidAndPayable",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred commissions costs paid and payable",
        "documentation": "Deferred commissions costs paid and payable."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_DeferredCostsAmortizationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "DeferredCostsAmortizationExpenses",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred costs, amortization expense",
        "documentation": "Deferred costs, amortization expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCurrentAndNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred costs, net",
        "documentation": "The carrying amount of deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r850",
      "r851"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax expense:"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_DeferredFinancingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "DeferredFinancingCost",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Deferred financing cost",
        "label": "DeferredFinancingCost"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_DeferredFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "DeferredFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfNon-cashItemsRelatedToCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax benefit (expense)",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r141",
      "r754"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r117",
      "r434"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenues",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenues, less current portion",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r850",
      "r851"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-lived intangible assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R&amp;D tax credit",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property and equipment",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "STRM_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accruals",
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities, Current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for credit losses",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finite-lived intangible liabilities",
        "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/EmployeeRetirementPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined contribution plan, cost recognized",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r32"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r32"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DISAGGREGATON OF REVENUE",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r380",
      "r408",
      "r409",
      "r410",
      "r682"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_DisclosureOperatingLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "DisclosureOperatingLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_DisclosureSubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "DisclosureSubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_DisclosureValuationAndQualifyingAccountsAndReservesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "DisclosureValuationAndQualifyingAccountsAndReservesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation And Qualifying Accounts And Reserves"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r729",
      "r730"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r729",
      "r730",
      "r732"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents incorporated by reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails",
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic Earnings Per Share",
        "verboseLabel": "Basic and diluted net loss per share of common stock",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r216",
      "r218",
      "r223",
      "r224",
      "r225",
      "r228",
      "r455",
      "r462",
      "r476",
      "r477",
      "r531",
      "r545",
      "r658"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails",
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted Earnings Per Share",
        "verboseLabel": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r218",
      "r223",
      "r224",
      "r225",
      "r228",
      "r455",
      "r462",
      "r476",
      "r477",
      "r531",
      "r545",
      "r658"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Earnings (Loss) Per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r227"
     ]
    },
    "STRM_EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of dilutive securities - Stock options and Restricted stock (2)",
        "documentation": "Effect of dilutive securities - Stock options and Restricted stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal statutory income tax rates",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r419",
      "r446",
      "r685"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r685"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r843",
      "r844"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r685"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Compensation cost, stock options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_EquityAwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "EquityAwardMember",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Award [Member]",
        "documentation": "Equity Award [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_EquityAwardPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "EquityAwardPolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards",
        "documentation": "Equity Award [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r161",
      "r179",
      "r180",
      "r181",
      "r201",
      "r202",
      "r203",
      "r205",
      "r210",
      "r212",
      "r214",
      "r230",
      "r246",
      "r247",
      "r272",
      "r342",
      "r444",
      "r445",
      "r452",
      "r453",
      "r454",
      "r456",
      "r461",
      "r462",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r500",
      "r502",
      "r511",
      "r544",
      "r559",
      "r560",
      "r561",
      "r575",
      "r628"
     ]
    },
    "STRM_ExceptDirectorsAndOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ExceptDirectorsAndOfficersMember",
     "presentation": [
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Except Directors And Officers [Member]",
        "documentation": "Except Directors And Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r854",
      "r855",
      "r858"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r485",
      "r486",
      "r488",
      "r521",
      "r522",
      "r523",
      "r668",
      "r669",
      "r676",
      "r677",
      "r678",
      "r686",
      "r690"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r360",
      "r365",
      "r479",
      "r486",
      "r521",
      "r676",
      "r677",
      "r678",
      "r686"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r360",
      "r365",
      "r479",
      "r480",
      "r486",
      "r522",
      "r668",
      "r669",
      "r676",
      "r677",
      "r678",
      "r686"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r479",
      "r480",
      "r481",
      "r482",
      "r486",
      "r523",
      "r668",
      "r669",
      "r676",
      "r677",
      "r678",
      "r686",
      "r690"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r485",
      "r486",
      "r488",
      "r521",
      "r522",
      "r523",
      "r668",
      "r669",
      "r676",
      "r677",
      "r678",
      "r686",
      "r690"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "STRM_FederalRDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "FederalRDMember",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal RD [Member]",
        "documentation": "Federal RD [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_FinancingCostPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "FinancingCostPayable",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing cost payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheetsParenthetical",
      "http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization, intangible assets",
        "verboseLabel": "Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r254",
      "r266",
      "r665"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r794",
      "r918"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r652",
      "r665"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r652",
      "r665"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r652",
      "r665"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r652",
      "r665"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r269",
      "r270",
      "r528",
      "r529",
      "r652"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Assets",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r266",
      "r529",
      "r665"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r266",
      "r269",
      "r270",
      "r271",
      "r528",
      "r652",
      "r665"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r269",
      "r270",
      "r652"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails",
      "http://streamlinehealth.net/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Assets",
        "totalLabel": "Total",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r793"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-lived intangible assets amortized period",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "STRM_FirstYearEarnoutMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "FirstYearEarnoutMember",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Year Earnout [Member]",
        "documentation": "First Year Earnout [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_FirstYearPaymentOfSaasContingentConsiderationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "FirstYearPaymentOfSaasContingentConsiderationDescription",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First year payment of SaaS contingent consideration, description",
        "documentation": "First year payment of SaaS contingent consideration, description."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_FixedChargeCoverageRatio": {
     "xbrltype": "percentItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "FixedChargeCoverageRatio",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed charge coverage ratio",
        "documentation": "Fixed charge coverage ratio."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_ForecastedRevenueDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ForecastedRevenueDescription",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecasted revenue description",
        "documentation": "Forecasted revenue description."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_GeorgiaRDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "GeorgiaRDMember",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Georgia RD [Member]",
        "documentation": "Georgia RD [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_GoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "GoingConcernPolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern",
        "documentation": "Going Concern [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets",
      "http://streamlinehealth.net/role/ScheduleOfCarryingAmountOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r255",
      "r530",
      "r662",
      "r664",
      "r688",
      "r697",
      "r775",
      "r782"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/GoodwillAndIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GOODWILL AND INTANGIBLE ASSETS",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r785"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r785"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 6.0
      },
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfCarryingAmountOfGoodwillDetails",
      "http://streamlinehealth.net/role/StatementsOfCashFlows",
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of goodwill",
        "negatedLabel": "Impairment",
        "verboseLabel": "Iimpairment of goodwill",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r256",
      "r257",
      "r258",
      "r664",
      "r688"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r729",
      "r730"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 7.0
      },
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative",
      "http://streamlinehealth.net/role/StatementsOfCashFlows",
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets",
        "verboseLabel": "Impairment of intangible assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r31",
      "r98",
      "r687"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r99"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss, net of tax",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r80",
      "r91",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r222",
      "r225",
      "r462"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r122",
      "r127",
      "r532",
      "r542",
      "r660",
      "r661",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic net loss per share of common stock",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r123",
      "r182",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r218",
      "r223",
      "r224",
      "r455",
      "r462",
      "r477",
      "r531",
      "r879"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted net loss per share of common stock",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r182",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r218",
      "r223",
      "r224",
      "r225",
      "r462",
      "r477",
      "r531",
      "r879"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r280",
      "r281",
      "r483",
      "r484",
      "r487",
      "r556",
      "r558",
      "r613",
      "r652",
      "r689",
      "r883"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r483",
      "r484",
      "r487",
      "r556",
      "r558",
      "r613",
      "r652",
      "r689",
      "r883"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r419",
      "r420",
      "r427",
      "r440",
      "r685",
      "r847"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r419",
      "r420",
      "r427",
      "r440",
      "r685",
      "r847"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r414",
      "r419",
      "r424",
      "r425",
      "r426",
      "r432",
      "r438",
      "r447",
      "r449",
      "r450",
      "r451",
      "r571",
      "r685"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://streamlinehealth.net/role/ScheduleOfIncomeTaxesForContinuingOperationDetails",
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefit (expense)",
        "negatedTotalLabel": "Income tax benefit (expense)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r142",
      "r213",
      "r214",
      "r229",
      "r235",
      "r239",
      "r418",
      "r419",
      "r448",
      "r547",
      "r685"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r416",
      "r417",
      "r432",
      "r433",
      "r437",
      "r442",
      "r567"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal tax benefit at statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r685"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r843",
      "r845"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r843",
      "r844"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and local tax expense, net of federal",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r685",
      "r843"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve for uncertain tax position",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r685",
      "r843"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal research and development (R&amp;D) tax credit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r843",
      "r845"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes paid",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r189",
      "r439",
      "r440"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts and contract receivables",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails",
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other liabilities",
        "verboseLabel": "2023 Expenses to Date",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenues",
        "label": "Increase (Decrease) in Deferred Revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "STRM_IncreaseInValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "IncreaseInValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in valuation allowance",
        "negatedLabel": "Increase in the valuation allowance",
        "documentation": "Increase in valuation allowance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net of accumulated amortization of $4,019,000 and $2,627,000, respectively",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r793",
      "r795"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r231",
      "r234",
      "r236",
      "r239",
      "r497",
      "r661",
      "r662"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest paid, net of amounts capitalized",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r187",
      "r188"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest, primarily on term loan",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "STRM_InternalUseSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "InternalUseSoftwareMember",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internal-Use Software [Member]",
        "documentation": "Internal-Use Software [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_InternallyDevelopedSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "InternallyDevelopedSoftwareMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internally Developed Software [Member]",
        "documentation": "Internally Developed Software [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_InvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "InvestmentOwnershipPercentage",
     "presentation": [
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership Percentage",
        "documentation": "Investment ownership percentage."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_JanuaryThirtyOneTwoThousandAndTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "JanuaryThirtyOneTwoThousandAndTwentyFiveMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 31, 2025 [Member]",
        "documentation": "January Thirty One Two Thousand And Twenty Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_JanuaryThirtyOneTwoThousandAndTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "JanuaryThirtyOneTwoThousandAndTwentyFourMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "January 31, 2024 [Member]",
        "documentation": "January 31, 2024 [Member]",
        "label": "January 31, 2024 [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_JanuaryThirtyOneTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "JanuaryThirtyOneTwoThousandTwentyFourMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 31, 2024 [Member]",
        "documentation": "January 31, 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 31, 2026 And Thereafter [Member]",
        "documentation": "January 31, 2026  And Thereafter [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_JanuaryThirtyOneTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "JanuaryThirtyOneTwoThousandTwentyThreeMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 31, 2023 [Member]",
        "documentation": "January 31, 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_JulyThirtyOneTwoThousandAndTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "JulyThirtyOneTwoThousandAndTwentyFourMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 31, 2024 [Member]",
        "documentation": "July Thirty One Two Thousand And Twenty Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_JulyThirtyOneTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "JulyThirtyOneTwoThousandTwentyFiveMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 31, 2025 [Member]",
        "documentation": "July 31, 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "JulyThirtyOneTwoThousandTwentyFourAndThereafterMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 31, 2024 and Thereafter [Member]",
        "documentation": "July 31, 2024 and Thereafter [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_JulyThirtyOneTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "JulyThirtyOneTwoThousandTwentyThreeMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 31, 2023 [Member]",
        "documentation": "July 31, 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease expiration date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r510"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/OperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r61",
      "r62",
      "r63",
      "r66",
      "r67",
      "r68",
      "r71",
      "r194",
      "r245",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r465",
      "r466",
      "r467",
      "r489",
      "r585",
      "r659",
      "r715",
      "r811",
      "r865",
      "r866"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r121",
      "r538",
      "r697",
      "r753",
      "r771",
      "r859"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r164",
      "r194",
      "r245",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r465",
      "r466",
      "r467",
      "r489",
      "r697",
      "r811",
      "r865",
      "r866"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r66",
      "r67",
      "r68",
      "r71",
      "r194",
      "r245",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r465",
      "r466",
      "r467",
      "r489",
      "r811",
      "r865",
      "r866"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r65",
      "r752",
      "r809",
      "r810"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r65",
      "r752",
      "r809"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of credit facility, maximum borrowing capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r65"
     ]
    },
    "STRM_LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "LoanAgreementMember",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreement [Member]",
        "documentation": "Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r119",
      "r312",
      "r327",
      "r668",
      "r669",
      "r694",
      "r877"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets",
      "http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of term loan",
        "negatedLabel": "Less: Current portion",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long term debt, maturity, year five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r196",
      "r317"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long term debt, maturity, year four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r196",
      "r317"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long term debt, maturity, year three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r196",
      "r317"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long term debt, maturity, year two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r196",
      "r317"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfOutstandingPrincipalBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Non-current portion of debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_LongTermLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermLineOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets",
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of credit",
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r37",
      "r38"
     ]
    },
    "us-gaap_LongTermLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermLoansPayable",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan, net of deferred financing costs",
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "STRM_MaintenanceAndSupportMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "MaintenanceAndSupportMember",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maintenance And Support [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r674",
      "r699",
      "r702",
      "r814",
      "r880",
      "r884",
      "r885",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911"
     ]
    },
    "STRM_MasterServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "MasterServicesAgreementMember",
     "presentation": [
      "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Master services agreement [Member]",
        "documentation": "Master services agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_MaximumArrNetLeverageRatio": {
     "xbrltype": "percentItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "MaximumArrNetLeverageRatio",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum ARR net leverage ratio",
        "documentation": "Maximum arr net leverage ratio."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_MaximumDebtToAdjustedEbitdaRatio": {
     "xbrltype": "percentItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "MaximumDebtToAdjustedEbitdaRatio",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Debt to Adjusted EBITDA Ratio",
        "documentation": "Maximum Debt to Adjusted EBITDA Ratio."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_MaximumDebtToArrRatio": {
     "xbrltype": "percentItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "MaximumDebtToArrRatio",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Debt to ARR Ratio",
        "documentation": "Maximum Debt to ARR Ratio."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative",
      "http://streamlinehealth.net/role/EquityDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails",
      "http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r159",
      "r160",
      "r284",
      "r285",
      "r286",
      "r287",
      "r375",
      "r412",
      "r482",
      "r526",
      "r555",
      "r557",
      "r564",
      "r577",
      "r578",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r648",
      "r649",
      "r663",
      "r672",
      "r681",
      "r690",
      "r691",
      "r692",
      "r693",
      "r700",
      "r813",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "STRM_MinimumAdjustedEbitda": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "MinimumAdjustedEbitda",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum Adjusted EBITDA",
        "documentation": "Minimum Adjusted Ebitda."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails",
      "http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r159",
      "r160",
      "r284",
      "r285",
      "r286",
      "r287",
      "r375",
      "r412",
      "r482",
      "r526",
      "r555",
      "r557",
      "r564",
      "r577",
      "r578",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r648",
      "r649",
      "r663",
      "r672",
      "r681",
      "r690",
      "r691",
      "r692",
      "r700",
      "r813",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "STRM_MrGreenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "MrGreenMember",
     "presentation": [
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Green [Member]",
        "documentation": "Mr Green [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_MrStilwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "MrStilwillMember",
     "presentation": [
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Stil will [Member]",
        "documentation": "Mr Stil will [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r674",
      "r699",
      "r702",
      "r814",
      "r880",
      "r884",
      "r885",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://streamlinehealth.net/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails",
      "http://streamlinehealth.net/role/StatementsOfCashFlows",
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity",
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r91",
      "r124",
      "r162",
      "r176",
      "r177",
      "r181",
      "r194",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r213",
      "r214",
      "r222",
      "r245",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r455",
      "r462",
      "r477",
      "r489",
      "r543",
      "r607",
      "r626",
      "r627",
      "r713",
      "r811"
     ]
    },
    "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss available to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) from continuing operations available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r219",
      "r220",
      "r221",
      "r225"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Pronouncements Recently Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_NonEmployeeStockCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "NonEmployeeStockCompensation",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:NonEmployeeStockCompensation]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_NotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "NotesMember",
     "presentation": [
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes [Member]",
        "documentation": "Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_NumberOfEmployeesTerminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "NumberOfEmployeesTerminated",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of employees terminated",
        "documentation": "Number of employees terminated."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_NumberOfOptionsToPurchaseCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "NumberOfOptionsToPurchaseCommonStock",
     "presentation": [
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options to purchase common stock",
        "documentation": "Number of options to purchase common stock."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_OctoberThirtyOneTwoThousandAndTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "OctoberThirtyOneTwoThousandAndTwentyFourMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 31, 2024 [Member]",
        "documentation": "October Thirty One Two Thousand And Twenty Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_OctoberThirtyOneTwoThousandAndTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "OctoberThirtyOneTwoThousandAndTwentyTwoMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 31, 2022 [Member]",
        "documentation": "October 31, 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_OctoberThirtyOneTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "OctoberThirtyOneTwoThousandTwentyFiveMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 31, 2025 [Member]",
        "documentation": "October 31, 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_OctoberThirtyOneTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "OctoberThirtyOneTwoThousandTwentyThreeMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 31, 2023 [Member]",
        "documentation": "October 31, 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_OfficeFurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "OfficeFurnitureAndFixturesMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Furniture and Fixtures [Member]",
        "documentation": "Office Furniture and Fixtures [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_OfficersAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "OfficersAndDirectorsMember",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officers and Directors [Member]",
        "documentation": "Officers and Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_OneCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "OneCustomerMember",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Customer [Member]",
        "documentation": "One Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_OneHundredEightyConsultingLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "OneHundredEightyConsultingLLCMember",
     "presentation": [
      "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://streamlinehealth.net/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "180 Consulting LLC [Member]",
        "documentation": "180 Consulting LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r660",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r696"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets",
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligations",
        "verboseLabel": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease, payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r509"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets",
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of use asset for operating lease",
        "verboseLabel": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carry forwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/OrganizationAndDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r114"
     ]
    },
    "us-gaap_OtherAmortizationOfDeferredCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAmortizationOfDeferredCharges",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortized contracts",
        "documentation": "Amount of amortization of other deferred costs recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r82"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income related to sublease",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r608",
      "r640",
      "r641",
      "r642"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "STRM_PaymentOfSaasContingentConsiderationInCashPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "PaymentOfSaasContingentConsiderationInCashPercentage",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of SaaS contingent consideration in cash, percentage",
        "documentation": "Payment of SaaS contingent consideration in cash, percentage."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_PaymentOfSaasContingentConsiderationInSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "PaymentOfSaasContingentConsiderationInSharesPercentage",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Payment of SaaS contingent consideration in cash, percentage",
        "documentation": "Payment of saas contingent consideration in shares percentage.",
        "label": "PaymentOfSaasContingentConsiderationInSharesPercentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative",
      "http://streamlinehealth.net/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for rent",
        "verboseLabel": "Rent expense",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of deferred financing costs",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfMergerRelatedCostsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of acquisition earnout liabilities",
        "label": "Payments of Merger Related Costs, Financing Activities",
        "documentation": "The cash outflow for financing costs associated with business combinations."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for costs directly attributable to the issuance of common stock",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments related to settlement of employee shared-based awards",
        "label": "Cost of shares for tax withholding",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "STRM_PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment]",
        "documentation": "Payment for estimated working capital adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r459"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combination, cash payments",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "STRM_PaymentsToAcquireBusinessesSellerExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "PaymentsToAcquireBusinessesSellerExpenses",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:PaymentsToAcquireBusinessesSellerExpenses]",
        "documentation": "Payments to acquire business seller, expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_PaymentsToDevelopSoftware": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToDevelopSoftware",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Capitalization of software development costs",
        "label": "Payments to Develop Software",
        "documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/EmployeeRetirementPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EMPLOYEE RETIREMENT PLAN",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r678"
     ]
    },
    "STRM_PercentageOfWorkforceTerminated": {
     "xbrltype": "percentItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "PercentageOfWorkforceTerminated",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of workforce terminated",
        "documentation": "Percentage of workforce terminated."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://streamlinehealth.net/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://streamlinehealth.net/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840"
     ]
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r274"
     ]
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Table]",
        "documentation": "Disclosure of information about crypto-asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r274"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "STRM_PrimeInterestRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "PrimeInterestRatePercentage",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prime interest rate percentage",
        "documentation": "Prime interest rate percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrimeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrimeRateMember",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prime Rate [Member]",
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/EquityDetailsNarrative",
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from line of credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r752"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r750"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r240",
      "r527",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r655",
      "r673",
      "r698",
      "r700",
      "r701",
      "r703",
      "r704",
      "r744",
      "r807",
      "r808",
      "r814",
      "r880",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r240",
      "r527",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r655",
      "r673",
      "r698",
      "r700",
      "r701",
      "r703",
      "r704",
      "r744",
      "r807",
      "r808",
      "r814",
      "r880",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r713",
      "r913",
      "r914"
     ]
    },
    "STRM_ProfessionalFeesAndLicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ProfessionalFeesAndLicensesMember",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Fees And Licenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_ProfessionalFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ProfessionalFeesMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Fees [Member]",
        "documentation": "Professional Fees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails",
      "http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r510"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails",
      "http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net of accumulated amortization of $291,000 and $246,000 respectively",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r510",
      "r533",
      "r541",
      "r697"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r136",
      "r140",
      "r539"
     ]
    },
    "STRM_PropertyPlantAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "PropertyPlantAndEquipmentTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT",
        "documentation": "Property Plant and Equipment [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails",
      "http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r510"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "STRM_ProvisionForDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ProvisionForDeferredIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for deferred income taxes",
        "documentation": "Provision for deferred income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfReserveResultsInFuturePeriodsDetails",
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for credit losses",
        "verboseLabel": "Allowance for credit losses, Provision adjustments",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r250"
     ]
    },
    "STRM_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://streamlinehealth.net/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative",
      "http://streamlinehealth.net/role/EquityDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails",
      "http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r159",
      "r160",
      "r284",
      "r285",
      "r286",
      "r287",
      "r358",
      "r375",
      "r403",
      "r404",
      "r405",
      "r412",
      "r482",
      "r524",
      "r525",
      "r526",
      "r555",
      "r557",
      "r564",
      "r577",
      "r578",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r648",
      "r649",
      "r663",
      "r672",
      "r681",
      "r690",
      "r691",
      "r692",
      "r693",
      "r700",
      "r707",
      "r804",
      "r813",
      "r856",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative",
      "http://streamlinehealth.net/role/EquityDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails",
      "http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r159",
      "r160",
      "r284",
      "r285",
      "r286",
      "r287",
      "r358",
      "r375",
      "r403",
      "r404",
      "r405",
      "r412",
      "r482",
      "r524",
      "r525",
      "r526",
      "r555",
      "r557",
      "r564",
      "r577",
      "r578",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r648",
      "r649",
      "r663",
      "r672",
      "r681",
      "r690",
      "r691",
      "r692",
      "r693",
      "r700",
      "r707",
      "r804",
      "r813",
      "r856",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "STRM_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements Not Yet Adopted",
        "documentation": "Recent Accounting Pronouncements Not Yet Adopted [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://streamlinehealth.net/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r864"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://streamlinehealth.net/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r514",
      "r516",
      "r517",
      "r572",
      "r573",
      "r574",
      "r611",
      "r612",
      "r613",
      "r632",
      "r634"
     ]
    },
    "STRM_RenewalContingentConsiderationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "RenewalContingentConsiderationDescription",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Renewal contingent consideration, description",
        "documentation": "Renewal contingent consideration, description."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_RenewalContingentConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "RenewalContingentConsiderationMember",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Renewal Contingent Consideration [Member]",
        "documentation": "Renewal Contingent Consideration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RentalProperties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RentalProperties",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related to space rental",
        "documentation": "Carrying amount of income producing properties held for rental."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r876"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of bank term loan",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r569"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r652",
      "r661",
      "r873"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Software Development Costs",
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination."
       }
      }
     },
     "auth_ref": [
      "r798",
      "r842",
      "r917"
     ]
    },
    "us-gaap_RestrictedStockExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockExpense",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfNon-cashItemsRelatedToCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of acquisition earnout liabilities in restricted common stock",
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring costs",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r108",
      "r537",
      "r562",
      "r563",
      "r570",
      "r588",
      "r697"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r201",
      "r202",
      "r203",
      "r205",
      "r210",
      "r212",
      "r214",
      "r246",
      "r247",
      "r272",
      "r444",
      "r445",
      "r452",
      "r453",
      "r454",
      "r456",
      "r461",
      "r462",
      "r468",
      "r470",
      "r471",
      "r473",
      "r475",
      "r500",
      "r502",
      "r559",
      "r561",
      "r575",
      "r915"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDisaggregatonOfRevenueDetails",
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total revenues",
        "verboseLabel": "Total revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r229",
      "r232",
      "r233",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r354",
      "r355",
      "r527"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r654"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue remaining performance obligation",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, remaining performance obligation, expected timing of satisfaction, explanation",
        "documentation": "Description of when remaining performance obligation is expected to be recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_SOWMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "SOWMember",
     "presentation": [
      "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SOW [Member]",
        "documentation": "SOW [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock",
        "verboseLabel": "Aggregate purchase price",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock number of shares issued in transaction",
        "verboseLabel": "Number of shares issued",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesAndExciseTaxPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income and sales taxes payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r741"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r215",
      "r376",
      "r737",
      "r758"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ACCRUED EXPENSES",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE",
        "documentation": "Schedule of amortization expense for internally developed software table [Text block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r457"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://streamlinehealth.net/role/EquityDetailsNarrative",
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r685",
      "r843"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r266",
      "r269",
      "r270",
      "r271",
      "r528",
      "r652",
      "r665"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r792"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF CARRYING AMOUNT OF GOODWILL",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784"
     ]
    },
    "STRM_ScheduleOfMaximumARRNetLeverageTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ScheduleOfMaximumARRNetLeverageTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SubsequentEventsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF MAXIMUM ARR NET LEVERAGE RATIO",
        "documentation": "Schedule Of Maximum ARR Net Leverage Table [TextBlock]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_ScheduleOfMaximumDebtToARRRatioTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ScheduleOfMaximumDebtToARRRatioTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF MAXIMUM DEBT TO ARR RATIO",
        "documentation": "Schedule Of Maximum Debt To ARR Ratio [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO",
        "documentation": "Schedule Of Maximum Debt To Adjusted EBITDA Ratio [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SubsequentEventsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO",
        "documentation": "Schedule Of Maximum Debt To Adjustments EBITDA RatioTable [TextBlock]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_ScheduleOfMinimumAdjustedEBITDATableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ScheduleOfMinimumAdjustedEBITDATableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SubsequentEventsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF MINIMUM ADJUSTED EBITDA",
        "documentation": "Schedule Of Minimum Adjusted EBITDA Table [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
        "documentation": "Schedule of non-cash items related to condensed consolidated statements of cash flow [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareDetails",
      "http://streamlinehealth.net/role/ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r510"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RECONCILIATION OF THE RESTRUCTURING LIABILITY",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r100",
      "r101"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RESERVE RESULTS IN FUTURE PERIODS",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r102"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails",
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION ACTIVITY",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r109"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r684"
     ]
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReserves"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation and Qualifying Accounts and Reserves",
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r200"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/GoodwillAndIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r794"
     ]
    },
    "STRM_SecondAmendedAndRestatedLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "SecondAmendedAndRestatedLoanAgreementMember",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Amended And Restated Loan Agreement [Member]",
        "documentation": "Second Amended And Restated Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_SecondAmendedAndRestatedLoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "SecondAmendedAndRestatedLoanAndSecurityAgreementMember",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Amended and Restated Loan and Security Agreement [Member]",
        "documentation": "Second Amended And Restated Loan And Security Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_SecondModificationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "SecondModificationAgreementMember",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Modification Agreement [Member]",
        "documentation": "Second Modification Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_SecondYearEarnoutMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "SecondYearEarnoutMember",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Year Earnout [Member]",
        "documentation": "Second Year Earnout [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_SecondYearPaymentOfSaasContingentConsiderationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "SecondYearPaymentOfSaasContingentConsiderationDescription",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second year payment of SaaS contingent consideration, description",
        "documentation": "Second year payment of SaaS contingent consideration, description."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "STRM_SecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "SecurityAgreementMember",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Agreement [Member]",
        "documentation": "Security Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_SeveranceExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "SeveranceExpensesMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Expenses [Member]",
        "documentation": "Severance Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://streamlinehealth.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expense",
        "label": "Compensation expense related to stock-based award",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost expected remaining period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options plan, description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number RSUs, forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, RSUs forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails",
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of RSUs, granted",
        "verboseLabel": "Number of restricted stocks awarded, shares",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, RSUs granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of RSUs, Non vested, Outstanding, Beginning balance",
        "periodEndLabel": "Number of RSUs, Non vested, Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning balance",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of RSUs, vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, RSUs vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails",
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://streamlinehealth.net/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of additional shares authorized to issue",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://streamlinehealth.net/role/EquityDetailsNarrative",
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares authorized to issue",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Number of options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate intrinsic value, Outstanding",
        "periodEndLabel": "Aggregate intrinsic value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options, Outstanding",
        "periodEndLabel": "Number of options, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Outstanding",
        "periodEndLabel": "Weighted average exercise price, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, Vested or expected to vest",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, Vested or expected to vest",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Vested or expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfRestrictedStockAwardActivityDetails",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining Life in Years, Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining Life in Years, Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining Life in Years, Vested or expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://streamlinehealth.net/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r801",
      "r802",
      "r803"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r801",
      "r802",
      "r803"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r191"
     ]
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_SoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "SoftwareMember",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software [Member]",
        "documentation": "Software [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_SoftwareasAsAServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "SoftwareasAsAServiceMember",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Softwareas As A Service [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "STRM_StateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "StateMember",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State [Member]",
        "documentation": "State [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r73",
      "r76",
      "r77",
      "r161",
      "r179",
      "r180",
      "r181",
      "r201",
      "r202",
      "r203",
      "r205",
      "r210",
      "r212",
      "r214",
      "r230",
      "r246",
      "r247",
      "r272",
      "r342",
      "r444",
      "r445",
      "r452",
      "r453",
      "r454",
      "r456",
      "r461",
      "r462",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r500",
      "r502",
      "r511",
      "r544",
      "r559",
      "r560",
      "r561",
      "r575",
      "r628"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDisaggregatonOfRevenueDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails",
      "http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails",
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity",
      "http://streamlinehealth.net/role/StatementsOfOperations",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r230",
      "r502",
      "r527",
      "r566",
      "r576",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r587",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r606",
      "r609",
      "r610",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r628",
      "r708"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustedEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToArrRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r215",
      "r376",
      "r737",
      "r738",
      "r758"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDisaggregatonOfRevenueDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails",
      "http://streamlinehealth.net/role/ScheduleOfReconciliationOfRestructuringLiabilityDetails",
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity",
      "http://streamlinehealth.net/role/StatementsOfOperations",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r230",
      "r243",
      "r502",
      "r527",
      "r566",
      "r576",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r587",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r606",
      "r609",
      "r610",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r628",
      "r708"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://streamlinehealth.net/role/EquityDetailsNarrative",
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock, shares",
        "verboseLabel": "Number of shares issued",
        "terseLabel": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r72",
      "r73",
      "r108",
      "r568",
      "r628",
      "r643"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted stock forfeited, shares",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r72",
      "r73",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock issued, shares",
        "verboseLabel": "Number shares of restricted stock",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfStockOptionActivityDetails",
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of Stock Options, shares",
        "verboseLabel": "Number of options, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r72",
      "r73",
      "r108",
      "r389"
     ]
    },
    "STRM_StockIssuedDuringPeriodSharesSurrenderOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "StockIssuedDuringPeriodSharesSurrenderOfShares",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Surrender of stock, shares",
        "documentation": "Surrender of stock, shares.",
        "label": "StockIssuedDuringPeriodSharesSurrenderOfShares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r72",
      "r73",
      "r108",
      "r575",
      "r628",
      "r643",
      "r714"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted stock forfeited",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r72",
      "r73",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock issued",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r72",
      "r73",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r73",
      "r76",
      "r77",
      "r108"
     ]
    },
    "STRM_StockIssuedDuringPeriodValueSurrenderOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "StockIssuedDuringPeriodValueSurrenderOfShares",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Surrender of stock",
        "documentation": "Surrender of stock."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]",
        "documentation": "Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://streamlinehealth.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets",
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r76",
      "r77",
      "r96",
      "r589",
      "r605",
      "r629",
      "r630",
      "r697",
      "r715",
      "r753",
      "r771",
      "r859",
      "r915"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://streamlinehealth.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r193",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r474",
      "r631",
      "r633",
      "r644"
     ]
    },
    "us-gaap_StockholdersEquityOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityOther",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption of ASU 2016-13",
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_SubleaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "SubleaseAgreementMember",
     "presentation": [
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublease Agreement [Member]",
        "documentation": "Sublease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublease income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r696"
     ]
    },
    "STRM_SubleaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "SubleaseTerm",
     "presentation": [
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublease, term",
        "documentation": "Sublease term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r519"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r519"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfMaximumArrNetLeverageRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMaximumDebtToAdjustmentsEbitdaRatioDetails",
      "http://streamlinehealth.net/role/ScheduleOfMinimumAdjustedEbitdaDetails",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r519"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://streamlinehealth.net/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r520"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_SurrenderOfStockSharesDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "SurrenderOfStockSharesDuringPeriod",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Surrender of stock, shares",
        "documentation": "Surrender of stock shares during period"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_SuwaneeOfficeLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "SuwaneeOfficeLeaseMember",
     "presentation": [
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Suwanee Office Lease [Member]",
        "documentation": "Suwanee Office Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_TaxCutsAndJobsActMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "TaxCutsAndJobsActMember",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Cuts and Jobs Act [Member]",
        "documentation": "Tax Cuts and Jobs Act [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember",
     "presentation": [
      "http://streamlinehealth.net/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Amended And Restated 2013 Stock Incentive Plan [Member]",
        "documentation": "Third Amended And Restated 2013 Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_ThirdModificationLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ThirdModificationLoanAgreementMember",
     "presentation": [
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Modification Loan Agreement [Member]",
        "documentation": "Third Modification Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_ThirdPartylicense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ThirdPartylicense",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third party licenses",
        "documentation": "Third party license."
       }
      }
     },
     "auth_ref": []
    },
    "STRM_ThroughFiscalTwoThousandThirtyEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "ThroughFiscalTwoThousandThirtyEightMember",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Through Fiscal Two Thousand Thirty Eight [Member]",
        "documentation": "Through Fiscal Two Thousand Thirty Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDisaggregatonOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Timing of Transfer of Good or Service [Axis]",
        "documentation": "Information by timing of transfer of good or service to customer."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r814"
     ]
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDisaggregatonOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r814"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r863"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r768",
      "r769",
      "r770"
     ]
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TrademarksAndTradeNamesMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfFinite-livedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademarks and Trade Names [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r793",
      "r795",
      "r796",
      "r797"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransferredAtPointInTimeMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDisaggregatonOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transferred at Point in Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred at point in time."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_TransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransferredOverTimeMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfDisaggregatonOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transferred over Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred over time."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "STRM_TwoCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "TwoCustomerMember",
     "presentation": [
      "http://streamlinehealth.net/role/MajorClientsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Customer [Member]",
        "documentation": "Two Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_TwoThousandThirteenIncentiveCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "TwoThousandThirteenIncentiveCompensationPlanMember",
     "presentation": [
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2013 Incentive Compensation Plan [Member]",
        "documentation": "2013 Incentive Compensation Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_TwoThousandTwentyTwoOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "TwoThousandTwentyTwoOfferingMember",
     "presentation": [
      "http://streamlinehealth.net/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Offering [Member]",
        "documentation": "2022 Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative",
      "http://streamlinehealth.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://streamlinehealth.net/role/DebtDetailsNarrative",
      "http://streamlinehealth.net/role/EquityDetailsNarrative",
      "http://streamlinehealth.net/role/OperatingLeasesDetailsNarrative",
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://streamlinehealth.net/role/Stock-basedCompensationDetailsNarrative",
      "http://streamlinehealth.net/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "STRM_UnitPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "UnitPurchaseAgreementMember",
     "presentation": [
      "http://streamlinehealth.net/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unit Purchase Agreement [Member]",
        "documentation": "Unit Purchase Agreement [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/IncomeTaxesDetailsNarrative",
      "http://streamlinehealth.net/role/ScheduleOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning of fiscal year",
        "periodEndLabel": "End of fiscal year",
        "label": "Uncertain tax positions",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r428",
      "r684"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions for tax positions for the current year",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r684"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions for tax positions of prior years",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r684"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Subtractions for tax positions of prior years",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "STRM_UnvestedRestrictedSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "UnvestedRestrictedSharesMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Shares [Member]",
        "documentation": "Unvested Restricted Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "STRM_UnvestedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "UnvestedRestrictedStockMember",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Stock [Member]",
        "documentation": "Unvested Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://streamlinehealth.net/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r133",
      "r134",
      "r137",
      "r138"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "crdr": "credit",
     "presentation": [
      "http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://streamlinehealth.net/role/ValuationAndQualifyingAccountsAndReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails",
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common shares - diluted",
        "verboseLabel": "Weighted average shares outstanding \u2013 Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r225"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://streamlinehealth.net/role/ScheduleOfBasicAndDilutedNetLossPerShareOfCommonStockDetails",
      "http://streamlinehealth.net/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common shares - basic",
        "verboseLabel": "Weighted average shares outstanding \u2013 Basic (1)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r225"
     ]
    },
    "STRM_WesternAllianceBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://streamlinehealth.net/20240131",
     "localname": "WesternAllianceBankMember",
     "presentation": [
      "http://streamlinehealth.net/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Western Alliance Bank [Member]",
        "documentation": "Western Alliance Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://streamlinehealth.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-13"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-14"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "FF",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.FF.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481639/420-10-35-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-40/tableOfContent"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/730/tableOfContent"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>93
<FILENAME>0001493152-24-017297-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-017297-xbrl.zip
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M_3^=]=NO+@<OJRP%$>WD+1F;&#.+<6JCFA$;-_2E)>E/?L(K2;/S-1 =P<U
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M-6<C">O--- =(;&-QQI\@RK'-/(=@J0!MZ7*&ZHE"GI84<,=Z[@D"+[_5A3
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MJV:R#X=>)BEK/8R7BG&HI\'>!\ZA\9 UO0B/1M@P@ 9%L <[[8,:$+2I#VS
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MZ;FQ3B"3"C<N45,L,(3#**BO&;+C][*LX\[5$S<2%PQWN;8><!Y6AG"8U*0
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M]8-8?Z_'1W>T\$+J?=R*@[V:&CT^NF/B[\T0:)(-_W/&V_@C'9@W'9_])M8
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MB3W>34<4R>]F#*C?.TX+?#D>/.N^L[OF1K'0VX9!N2@IM3<O@2@D("TS3/K
M52YCTEYL(LB.C:69[ZI@6IYZ<0H/HZNG#.:H4MD![/+H9(867\2.2EVT7SX\
M&25?H##*@SC-JZ]@U"E=:+Q2HX36TIRO=4X@;J.*E$[;Z;2=&ZL//V^7MG-X
M<OP.M)WC\6CPD0D=';\[.?M$V1242#$^&QP-O?/AX=FPRZ9XF%I0S1JEE "6
M2V4>)92H,)68/3'FJO:RBM8@9\WT7(,8 1Z?EY'D!<ZY7C-R>"80!.R8U!@[
M%(B 6!6< 9FZV@FE;\"3U8\XW%^B(:KRG-,<@C0D*6,)AJ?C%; !H#&(HP3Y
M0?69Y/T5>L8Y#Y=I]F4:IY=>OH+1%KDO\A6$^1(4DGP)JD,,GR[GJQQ4"Q!8
MLRPME[F3LL[3#+#\U-4K8"47E&#B:;3.(YT$1NA:4BDPEE--4I"E.1OAU0K(
M@LQ)MDCR1(%J"JD_)>XJ6/Z:@D/*F\;Z:T0QC0!.3KH .E#IN52DKJ5+4,E@
MVSEYI%J7T)M&";P I5M#5>#,2S.Y?J^F-=6R"64^79'K@[G5[S#.2NI)F2U1
MG5G+W?&K/*5V!4=VD[7NA5:L3E]FF--$@:8R,?]PKSBKS'2G)9,7'H47@WX5
M&N;2C$>: ^3M6*[BDY*6EH47P[GEZ*W?^F.C+/K5=8(_%;(.^,/<ZWX/0[M+
MX2*@N@L;"W4.^P)_\ QX%& .BP41@>H@W.$LTL3R+MB6P;_Y<B_X+98MR8]Q
M8%4H[XM>DO/-?$]T)' R--U:']5?K;)@CH1<Z#@5 M5R&9N$-M^YH<Y"^[55
M!V4;[(B:[BP,(RP##E.[+\# =X8Y!8T!;0!>Y\AW\1'\)^Q@G *_@ ,65A_[
MP@#;Z:AX&Z8FQ"I9(P(S'4*-">>P'[B*\&_@2_!;..$EL5TLCWP"=F'396EK
M.)G5X<(B4Y,M+W'UL-C?,NF<57Y,I*[I_60G 'USE?=[1J&GD&Z::$>F5.?2
MXV2U:L9J@H<4?\B7J%@UB+4'U=+*AKI+I+E(YI%^#Y/XI(9)/L,5S9?(_NF[
M74K]7J?$/BZY#')"86V37)G<=!1['L4DZ<"#>,(=D_"_+]N%+*3R,VQB$[X3
MR+;+"BR&#+KJ%W(:X5VZ0, 'FK5)0YSI1&<J!D,:;3;<='(7R-;!K+ F;+TF
MG'\_ ZV#EA06,"0#=F:2).W#E?6'7I7P O$?P"S$FXU2+T=Q#8<#BP;(OY#B
MP66[LK;$AJO2D76+>R,WHQ,^Q3IA;9Q%3HXCIVXF>"F-D]P>LG\N0I7/7\D=
MBD7YN@3%BK6&%9]?-G9K+)?J1>AB<2:0"FCK0U]L_,9XM)^TLW10@6)47H 3
M!EDT82Z-!U(8%-#*N:F2-X$*1KI<49@ -0QB\*9NCQ0RYTO#B:W_I7JN^N):
M/]#-))7CG^'KJLW!@G^'<"VR56,S6P07;.2RG,!%@,.H+E04&\IK.VQ8!3T)
MIV:AHL0(K'X/0^>8BK0N<M??Y^ :P"[&ZA+=9RN[@^Q/4AX[24Q:#&B$\#^@
MB,[F'KZA);?(ZO1K;,+.4QA$*#X?X_D(:^@(>$R *E\R;\W"965L=<097J.$
M<JQB;Y*&Y$ZQL2,Y'B7F#R/#05XJ-#2=>+1]T6*A0ZPM8FX NE+=4R/5HPYW
MP]?QT'E*"5YM'" !.B@GK$PDH)5K_04SFUFGQA_P(#9K!J10PH4ZYAF8.S P
M9#6I$:VR'K)X96:=;,Z2[^YYCJ_9*?IG;]X5+B9T8IED0)=[TL90N8\MF,5C
MVL9U'IDR?G7.S],NYZ?+^7G,.3];:(JZW*W?<]D;YUK&P+6-O*ZIC#593;(T
M"PU"BE7WR;H0Q9CB*_(Q,584J1.MDZKJA'ECY?!B7M[,F/Y3JC@WQ51<U $1
MIPZM-97/)D'(R]'R1"'ESG2/8A?M(L )]/ 2N6^Z2.,2I&X&^^*(;Q.B9.6D
M7F?C8WHH&J67F(_!HM1H,5:$<4((+1R5_\@0KJ!FTUR$O+B$N([*?1>L+B^/
M'0]/V5+344.:K=**TJR:P42,#C27:V-4&IC!D5M7PXQBQ+H4>2ZN2'S=2B&X
MC6R@$20DTY**L\UY17=OALI-A=2Q!KOEKR%W'>DI'"=OC*X$K)1'3X(W8.OJ
MZ?[!3][.P2_>Y[WSO<,][Y]@ML'D#WYY]FQGLKMSL+L+YRM![A-&P!Y*N'KY
M7'$6.49S/;"'%E%"AJG$CO'/.")EBX.A4QV2A8$F/:$ PK&C4#L%6FM:H6*'
M!QN/!7&H7X$\A$5$?PQ\L_-U5S@0,8. =#EEWN'S&WSKCG$T;TX!B_ A'9'V
MRN%DIAPGR/_RA>.A-P_D=Y9HV'B\?#NK751S0.NFB+O7\!URM;GX@M /!F=F
M1EY[-$Y*8K]P&R^B-+8,&U;B%3Z^\Y20'VF&%!&GFA&XJD6E:YLJ#6\:Q62!
MPOG  3":4#U%/B7-[L%(# %$(@ JS MX5W(-7+6[\]_ZSE]I]>!%N\KRP1-H
MX-9\V-<(E'PZJGC8R*64(Z=HP;)HIDMZZ662L]S'(RX5KB!.*6!%O@K?*Z)"
MOJ*4"G2 2C&LR7C<1&QWT+[Y0=M1N_W>.)5J&HH:.H=@PQG+" U0Y C#=ZQS
M:>8GXH]'MD_.D *=<G7'A2]E6@Y01UOME\$51&=/RKDRH!)..:1Y#;T:]9N\
M2>%.FEF!LU!?HT6Y0)]FE")VR90SL2J]26%)D@Y;Y[5K XR,"!,1**(1SI:H
MRL4-X[FDF)2B*?KQ61T4"8@<N]]#SZ"($/1Y2EE4;0"C6;:7$:+KQ;K*38Z6
M*+3* 7G!FWME)A2MS,:RQ\LZQDPS6ZB[[]_^OD_^PGTWD$H,\V,-*\HU^"M<
M8 V2!T8S7.#J E")7IF+3_Q [BS=K,O4DTU"W0D+!G/?FD>DP@6J)*H1]L$Q
MG"3G\5*!HK<Y8".)H(3I0&2D4]_X>CD:@C'';.&[>-H(:)2G('B-R].&AM"S
M:L']*"$5.(1O<NJNW)*T[9YB](<K%7R;M,JYEF3LBU)JKSVH\.Z];\G.1>%]
MPZOMII26&0=*!.L0SM?FW>WW;K>]SKZN'R+<T"*+)F51WVSQTLM787V+ZZX5
MV4WQF=">TN+I;!'Q-<%:D\J#/;WBN,A*ITE[_0@IZ^N[:!-=KRPBWVM.OU!?
M2$A55=F8,YNQ)7211BBYC-M!AS6GA4GBG%YYYMPW.ELK[\3%Y2"I@PELS% #
MQ/8SQ<L< @49. *):U)D@>HH YL&[5T3C1?LRDM%$4M%*>=3+HD6_L.OARL$
MY 8<W) +VO#C['7"YT%8-2YOL/BC&)M"^Z&9M$"F,^?@4^3+#77QC_%Z)M:
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MAGP8 $>@%<%'J1/+.OCMI::%3+%ND/)DN3P.USI?,XA@2!B32]T:QX*U(:I
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MGJ+^,*HFNJ]DL0XB)+59KH4HZZH1NI!-GI<SP)1PSO&\!]RD>"1:F\N/&H:
MXQ6_1@#43 C[LQOB]E(_B!KSLUU<?/)S(].*HP7!5R)&:D:MI&G9=L5:=5Y?
M"Y4;@C?S/Q(5G/A@FV+<2NMT7/%&WP3+!GO.V&0*L\>D<^YL\KE7.B)F&MZ?
MDDA4W%8U--WF_[YN> L?O/?=.^%_ZISPG1.^<\(_+ ,IO-9 VHC%OA&'W7CO
MZU;+[2R5FC!W+!"W+=K4*DVY*X,=0M'TV&@ 1)O,DH :95WHW9H#L#Z'AOES
M!85-H[%IS9&CRS2>:[=G0)K;R((11NZT>/2:88-=SUBR5RIJ"'I'4F[V:3EN
MIE<LEEM_+!F0:_V]N"\7.KW8V>U+2ZT:&/LKZ3- >/S&^E6!4<-A<?EOLO0J
M8R=W24%.B(UE19W 36F)N+QJ0+)?[1AS\P$+&+_@ $C3EEW+;91WY+6FKB;O
M@)1HH9+:5^ND^@#5>L[R"V(5+4P-@37OW-=*+O_S%ZRLRPB1I"JZ0R/ /_:Q
MLX,W*Q_0'LCYJ,$[I4E0];B\R9@%]7X/S;Z%U*AM6=@R!YXQNE1Y.=BG2JN_
M0WT7'$NB4JSIR0V:NU/H04Z5#5>^J<-+QDNV(:!G6EW<1,^O75]4K]M=NNV:
M]:#=GWL#U9JU31C9YF52FXPT*4TO=<=7(#YA^059D%-R3^$^OVQN)>_-NBX/
MQ_UZ=?XJE^_.VULI\G4O^U_2Y/^&DW?G<-<R"%R16N^SUH8@U!W+:0C"[[;I
MLK[W"W&\E\YK/+5(2R 3=&#T H%U$'WU$)-LGLLE<IENO[>#)\8<"Z 0;$9-
M?>5I1+;1,SW5M+!H/J+:JJ4[J&\BMB(:SC4VR23BWHJ]4;5L:,GD,H<-(\"F
MX@M6 !=*PE95W1 ZK30OL1/9J[A%B^>1/R%_("P_5EAE^B(-V/3EF! %%^&O
M&9";H>F8:?12$,LD)DEM)K'\+ CTLC!AR:NBB:8BC0;TS'CTHBAW)$1:#YX8
M/DCQ6-JPS?$5&WVI3K-_W252JRR--U^FINQB%0 ;>E2.N\K0E(WS:ML&ZT4:
MT*$H,SR0_AIH'=:.25X=$V1DY)SPK8Y$?*?*5>>@T-IJ49^6N%PLB?,9>FP%
M6H2YX#O/]G?;A,KFI,/-@:L=9.U\?J4J1-C'WQS8MQ-6N4DBJ:=HN'4&EV"[
M8"=:IBE6EY@&CVP^0@^:2#^L]3--G=#'',$EUGB>=@Y>('>"%3$[RM'5G6=9
MN,M,HC&A&QV]O7YO?/7FKNN)IKE50=8#O@JU' H0_TJ]GQR9UJ+X)0EP-VK(
MZC9-Y5S.D(,D.  _YV5",](S=1NQ-B^CZZ CA:F6N!$M0'V)N!+3J6=L/D?*
M:D.D7+5\C8.6!B#%<F!9(1ID.K2N/Q!O&;$2JZ&@OEJCD#ZZ1*_MUR7%LNGB
MV%08M.FHT(/\]:[2@SV:R1ZH?)852;O<Y8JV"S,)U-=H 3L3HO\B,_*&O,;5
M5C I)BE*?=&DPP,QR*)**T85?/?U"8HJ+D;"G LN#/&6L4KD*<H^JO*4#G;4
M[L[!S[MVFWAWS**O1W5K,2A>7S86D7\\<?D'YQF09*GY+MVRKWJM#8:4D*]'
M*)U"VVT(9 ]V%R5W=H/\EP.3>L5*.CZ(WTQA78B/GNE9*6$"^YH]_-V3@YW)
M[LYSGG@.I@^'?U%C /FL8ID5+*"*J*CLYOR;#NT: W=Y,%+&64-1 '_GA8IC
MT10O-._#P8LGS$0DNPCU11#93J7:-,KRHL4[*=()]( Z4UVO,ZLDN'E+)8.8
M:#?_XB;:98M@K)E6%'6H!5$Y<B>MMOP:[Y7<$3B&?V47ZE*TW^,)F7G43J3#
MY(^ %6%O-N_90?4.M*\:W*'.VAN\;2/+DCVY <_BTV<-B)O=);V!K5IU#U/)
MS.4B=G:SV^7=^G)Y=+M>[K*K@.5$390A1P+&_'KT)MK3>WZ_QSE@L-KI$RQJ
MA/T3&8C2C22;$7SX<TO,;I6]F0-G%%63_1AXD&*AJ^$5:_772+Y(D46SF980
M$>;PT?*W! 8>:1A@*QVAFAVAI\IZ(0Y/WIX-O%-@'5&YD,;?M62QM3Z2CA?A
M+_;]1&]#OV>]K*T.BH;KL=5)T>Q'Z P$ZQ"+UU'\0('FGN#&4T) %J3;5I>W
MZ?J9@8VZ])!7!!+\#CD/&(11*0R5;FB3P1R"Z8P1&U)K3A9)-"ES[VT9SG0!
M,\#$O"CFS /I2-COK><YFW1FW*$JR=EH(!L%WLTL B>2C[\%_2B*);XLQH9Q
MZ545R6#7UZ5MQ=Y;0Y9"*4M@&8-_[S+@*[UO:!U;]YL;L%\_-,3"V<_'.^NF
M^) YCJ>Q4OQLNT]3C-L(<YIAC.I$8PM#K@PGLUN.#Z]*=#9#[+9U];PD5Q1&
MUZ(E4U\72RVICVO^I(;!Z!B\?*\/A8!Z%\L@K?9C*3>_RC>P\S:+,DFS1#?3
M:^&<?$7W1//FT8^L^VK-Q+&OF\ M6%".-U@)5#G.)X-T)?2G2YO/.DFH5]7]
M355?TV@**BG)[XDN+K7X,"M;@??/O-]XC(VF5'!>O,F'(N0;TJ0H-=7Q[NVU
M7"P9A)SU]==46B%[+&45[95P9N[<Y.J1-@M9KM!FXZ.>(^(J2J*^\EEM\4'*
MG U7I<V8:Q73^PS+,_RR'M\JVJ^ON$KM0H!!&5)>B)IARG=;Q**Z/WR(J_O,
M?@O09<H,]XL_<!+WUB^A W_4<+'*%E7*HS,MQ]32NRX;H5.KF[Y:%BUKZT1\
M2F$Z?4[I 87IJXL=BMO$3>5WK963K%%:3Q^:@Q[HQ.P<)O+(-*ZK$R]^[A(O
MNL2+QYQXT:%>W"?JQ=/M0KT8'/TV.APRB>,3[_3LY/QT>#@>_3;TAI]./Y[\
M,3P[[^ P'J(-/IJZ^3:YUE\HKQO#KJ3 NFYP5!>K!)+ 5+:!:DB(4%@NAK86
M:SW-6H6LI@ZM^3]!QZ;^\>CB$O KW\VZ-54)H R2,H[4&OUE/=V#U.DJ144[
MX)*1:V]:I"7,4%!&>\QA'8I^;XH]5)PTI1R$.O[N91O^4SUG":LGXU0,#K#1
M9B5R_@KHJ1H*0U=2>%'_%7M/R=1;?UV'H-3)DAO+DF?;)4L./PR.WXLL&1V#
MT74\/COYV$F/AR@]"$RI6<RKO,,YL#QRCV J6);&F^ <7!<.9TYB\*A(P=YA
MT(C<=R0#?\.I1/@@RR%,%2A6_1YVV0O12:H2+O1H2X&B%ZY1QV5ICKOK MZ)
M#TS+./8Y;PT1#22YXF43*M&9,6>_P:#U$L(;IM[=,M5N0_US6D,3N$6:74OI
M],[772YDJ>6>M.?;K5>RH&/A[Y6RW$7N&SGE[J2*Y>_EOE4 X$TWY;WEOA67
M.K[0]?2W.N#7G::_K5^M*Q+BX,KBNJQL3B!O;\U3W+SL-^(-+E_PKF(+'#K<
M=/$9I:WF\6Z&+,2]C)H:1C>S &]AK*OXA;<Y?.$D-?%\C.)+L4H':87@;AF6
MA/%(.*'+U G^I90K*0*K\[6#IW)04/<U+MX6;OX_R]I<C**-\;EK$XA!4K4D
M$;OG[B9'EX_LIF.*Z$HW%F"W.J1KPHFR5;[%(?5J9[3"S;G[0]H(_#:-5&1N
M9O^!C&OBLQ0&N:[VH!7CUSK?GU$TM#9(XS4M,,RF5*%Q]NZE4D'4$ENCT5:J
MT"P]N,=*A5JLU"U5>&3&ZS:J[1,0ON^N1+3V-XITD]&#6:RY6[CO)*WAC<U_
M?5SQGCLC'W?S)MM^<,>;'L&F#[S [F<@<LZ(CR@35D<J5PA<#OA&/?>P&2*L
MH"#0[ .N2/ +E(-+R!EN*C<GKF4:H].2;BF%:I0>-RKTPOMI1Y-=>![,=5B"
MT#EX3I!\3LX:?@)<=5'&,V+:5;K,\*O,;1 4I)BBO"/(W5HNBD36)0.#$BD0
M?C]= X1!8LUK\XWO:2# N<PTREGWR,O)GV[^ *\!7A07!_X5HGYT5^9A71FZ
M,["5P@S9Q6TX(#HUK&)!J'UYHZ[U&>9&.P#\<'KA$\PCMY4MU5DB\UE_-76L
M>(+$PZU-UB*8")@4WK"$R5N?V6P QQ[CGP6H!:27B<Y<RITZW#.Z:L_")\\V
M''.P"ID]Q"OR+L!ZRS]]DNZ@[F14:MH@S;-H.SBC1<K<(6'SQNF?!(1/B)B+
MM."$X<M*'5W+2R@+DXB,F'7VU7377-,=!M,V0<TFE:93F4N:465LIXX\L"N'
M=V[LG*%<QZ"3D@\@H_05V/R"@8KH0[%4\EP7ZS5=CVU_K\XZ^:7+.NFR3AYS
MULG6<[<+86YHRI>+A=6N%=A3V0R3"$$[S68JB?ZMN*HUL,G;@M>01_!RY6"O
ML?14FS <UC7^2OJ3&MXF9)_N'SQ#K06+: :25(R*S!GWF "-AIQ<(V ["7DZ
M3DDQ,546E5+-SK"E? O*0!D7N2ENIFQ0RI)E1#-4>2[6"H)LT!STJ<DNQHDD
M)E/!6F"9T"/++]Q*QP)B?[8@;J+7:&;B;W0*,?2 ?RBC@S;=#Y'K_"-41@IM
MY#9WV>G"8FQ-//=1B%DK59T4'D-,;%?!'/UF-FMUW=EGL[,K/ ?7O56=U5J0
MDY 9^5J9GJL5EDF_9UNW5;>0!D-M'+$2\0Q7?6&"NHNEH4S#HS+8^BA32>T5
MW:A1<@=TD'JT8>#F6K@59< *?ME_3W?_^<N7+]&=CBDJ5?8O3AI+U#9Y4=W!
M^CT>S*1V<U(Q8U,FWM]:JQTEM"SG&8:WC#G61DZ%^8_D-"/1-CD<SE$9Z% 2
MO6V---P@)#C1>+3@'/N(O4VO3M+6_&TG+3W3M=.Q\7@^-B=IE^%SGQD^S[<K
MPV=P^)_')[]_'!Z]'WX:'H^[S- '*<O'+J!I'8:3RH10_F)":/ E22]C'<XX
M[9+;>BL3'.JB -]^)RE+BXT.Z?=9!:4Y1.VDOE)LVLDZ ;7!XTQ8Z42/,HR*
MR0W.R(6*2]*7C/HEA@OU<6T4T'&ET=^CHY:1ZWN_2"8M^_5]HL^!=8XH(UE(
M(B4/U8>(N]Y@-C';&1R4K_K">WF0+O6]V9_=X;U5K'(]Q9#Q"+FFEQ0J-"/D
MPUH&F)B5UM'\-TX>&<OUHV?SK_#D+=)$%VC8A&JA9CHW%<=L$E-$'?W4BG"+
M/!<?1ETH,.D=:"U7,Z<00]M\^SWYM.IJK$),_2IT=?D01G29Z3_+$-,-ZL-7
MH(*8N4%EB%@YKITL_R;5A!=ITU8,V61N1<75Y,J'#E9G12&!)#F7---49DG[
M9E:S7FC=DJN(C;1<_S_"V"=L+&0ZCO34U$ &:9E5@#VDS2/@?1Z:Y@+2WCJ;
M1!@ 33/"_^EXP3?G!8$(L@*>DTPD0EVP^#>6MS?Y.0(F8,^G-C%BKS#)#CJX
M88218+R0. S#H,"_3'/R=:S-&G,Q2"5RO!Q'1^$(4;J2',>8ZQB=("!)(TJM
M*A.-G;\#33R!&X5QI-&=.(DH=IPY\\;.#\UITV6I#%M^#Z5L.:\Q[Q#[5C%<
M#'VT-N!.SG%-<^%A/2K*\,NJL19?-M,_2N<V$<"*Z 8A;C$-L64Q[-<\0NO7
MN-^KW6/WI6:3&%&HVBI&U]FP\D#JGVF45$G)-K2?4.P>1$@%1$;4F"RMK)0&
M)TX&795?,!%8.,+)R-C10) +&&N1_2;\AQHICO.!BJ\*.J!.HS"=N*\#=FUK
MTS'TZF/VXLJI9W<D(%)AUL0H>N+HM9ERTK?%JP]2Z^A1?4S'P>9^X#%!+&(6
MJ20M9&XF(Z*5DLX+TGE!;NX%>;%=7I#CD_'H<-@Y/QZDIC' S#"3HDNUKHLR
MB01VS[(UYG@$>QNV=(6?@01+W$8[+C!?7F(7R8C!7>3)J=.?AU.-4#N@;E"Y
MU-\6F,>2+E=66B-F#VCB89@A?&C8>5X>TC%RZ^," 56NU;QA9,%N'=M0WVX#
MS;+?[=L.-L;:[W*ESS&LLH@CK$GXP- WYVE<BG4_2H+[B@[_STSO8/^7_7UO
M0""7IRK[XAUEU.)PBZ=T7D98N7'P],563V,0+^=@0Q2% OWZ/>9N1,I[MK^_
M_W*[IU44,/#A'+TF3F].ZGS\R+*4KTZI>]FEU'4I=5U*W<-2JR;K:I7C&&XJ
M58X[B7U "T2<Q.HT="3QDYA_,HU<=XH!OWY<S&[+I) 4Z-ARR3;[R&ENJJ50
M<JX('5$G!@XQ;,+1TJ RVFK/PQH/<Q),Q0 89>2?,TBO;O=FB=MPHA)A#@B!
ME;77.:\ZY]7-G5<_;9OSZOC)Z'@\/'LW/!L>'PX[+]9#E).-3%SR_[>GXM;"
M8HVD10[Y.IT#[3<&V=@1L/5Z<H3SYQ>N#4M>K0WC,H@L14C:>M]4.#?\R\LH
MYPX)&2+6L01?_QEW!?!QZ@@&0<)>]7O PK.9<?(M8Q5)$R6N@2,<E6$%+'"R
MQ,3:,L'H]Z%M!L>QZ&/R#L+S'Q4HZMZ9Z8AN>H/C,R=!4"[-<^=JJ@O*K;(^
MBT&M[)9_<UZ5N'$:EJ3'NN\7<'M>R*G&))S8YP@.?1FG&+F;84P]63!H/*BP
M2; RWDT>J-_;H?"GJEI=FE_ SN'S%?([IN)7?E%9=B1B[3?UC:I QK79_RA!
M3 L#-HP%ALLLQ:99-KAFY"VW96>)V_HNMQ,H@R\0JG<:E-*JQ50H1 DUA.=E
M-FD((L3Y=MCL-YAKL&N!E1%E!^$Z2$]P1JGU4MI &Q8LA+N>3F8&/IP#MW !
MESJ(IBC""&T]+;1,L\I5_MEX#S<>-"I(;CL*5#:"AX'^MV0P_*JZ^;'IN)VJ
M<I^JRL_;I:H,SL]'[X\QT=AG.L\_'QX.S\]/SLZ]P?&1Q]]W<;@'J<&,J<=$
MI8LP&%)",!.LPDAEO">0#M@@(N*Z(]L$CR2.YC;.Q)M)1XDRDY=*W:3TC'I5
M2KFZP@]SOZIC$^@G!6)REN3KG;;YB[JD RF>Y%.4-851/]K+0D1@5$5SR,.G
M4VK*0K!Z!F4#)&.09J""L,39,> 3( US%;-ARQ!3IIJP5CWHVZ=,M;1#KO11
M;)!FL&DG6J:(J;()$H+?X+/<>-H)?Y(ECNM9X+/U9A57]_*1U6U?Q;Q]&=W3
M<?-U].YX&4&;==:1>@W!0;T*7L=!:;#9F$Z/2$KFJ?DT3/I-0=B+K3/$AL?M
M4X3?5QE95JTQ.]J^X.AE<9;<;G#GV.BTA9MK"[]LE[;PZ>1H]&YT.!B/3HX[
ME6 ;5 )'0DFKZ= G*'4R[+&P8P*2.R7!9?RUP.\6:<B-M\0&A5<GR.FECQ39
ME]3E,R/+T4WC$::)MAEGN4];U(R.2W9<\N9<\N5V<<GSX6_#L\';T<?1^(^.
M2SY,+HD]QCBO78!SG=1V =/ETBAVR)4(*=) P*M9 C8/7#&F7N5DLK_*JR(\
MT\^.>6*_1[\NN;=%A#9"7F M?YI)HU:$+F!D4\7E";Z89,TJ!?LRGS5:=/CE
MZ13[<.<&+!Q]G]%B&6L#4:"-*M[63,,;U?DW5@24B4FZYT(F"A>JFO8NMF4U
M=Q.&M))%M5<M(@A<8'H;<^@185?%IC5Y\;0S-]D.!Q16>9<JDE[45,^29K;^
MK;Y3LE&/3$A=G<ESL-^E\G2I/(\YE:?3T>Y11WNZOUTZVN')9PS0GP[..H2-
MAZJCK5NR6!G"YB7AM948U4;%).>F(U7^TT6D0&T(" Q.?'82Q"4L6.Q!-HL*
M"B?F =JV(0W,$,W5, 2+FJ4)1QYW?79S&[-6X-\=*DCM<%4.?!V\"<.1)LK*
M-;/-GX+2I+Z@UI3.R-OJKXV%J+"B./9[N5IHQ_Y^9)I*QZKOE54?;!>K'AZ/
M1V?2\FSP_FQ(L$@=SWZX/-L%V*1X5E)$F78RF-0B-:TNQ:IL=I+G, X#PR]4
M41B\ZSI>'#%23'75V$2$8DK4=(QRAC![2R\PQI/HM,P=#!.? V0F\4O0$!(]
M2XM(24V4"7JA5[/0'+JDK*'6GO=U4CMNW''CFW/C+6MF?#0Z/_T\%G9\-CP_
M^?BYBP8]5'X\I' -XIMN\K4QXH?O&1@[9*)AE"\9'3F+<DKR+RF#A%-2@:\F
M\G.;":HYAP'=CI1INLRTP2L"]DQ)@(QBG%&O8>>S%K8N*7K*_<!D)=J DR37
MXOLNTOA"H$+8^1HUA,M.E?1(RK-Q^PI&3-V):IV_1)4!.9)64R4E,%1%ZA.I
M;I>\&1 +0(OD7U:_Y'P8=RANK5=+V21L*958Z5=KT/Q.$A4'SAB#H+".9"<'
MUWT$.U=P6NPGZH^&GYUB[F@(9HX9'&RL!1P?L(+JP^=Y&D1"_S!B!ZG":GH)
M*9J>TZGSE6+'=P&GLK5WEQ)<6F#:^<I;IH4VO0H8-8#3L!TJ8"$#9/#D,5ZH
M*%YSGO-NH-Q=+"D..</>7U-%1S,U6R*.]3"BMMU)("H'MHF+I@5F:>\<O)"V
M;-35D>%I-O3H,CYQN2@>6I FQBHG0$;'I^0-3V!P"TZDFPO*"==6W0CU0@"$
MZNMA;]SU>X9G;ADK6?C&X2-/?%F4M/9TT^C0.NOZ?6:]#CZ.WA__ZX?#(3J'
M_KI.\PLZIS<ZL>]=VVD^Q?[FOZ#P/'_YC_IV85&@SNYRMT;<AP_3LW 6;D+<
MC74BILI2_?0?ZPO%2U#S@#^R97-RUVZLB'7V2&>/-.V19]MEC[P_^6UX=@R;
MSE1^'/S^RGMW<O;YDW<^_#@\[&R3AVJ;4 Z&DR"P(8B/2%%4*F3*FL+*Q- ;
MVZ/3(^AUC]6EU:+/"REO-D DUIWN/O49."MU<*'6R0YBH*!3U@ 8*WCOO,+W
M%CS%6@-SI\NAJ<VNHZHB:B87(9'B)PH_P2920YAW95RDV&:T3-!RD2FP.DQY
M#=)ME%[#O6ZZ3+N.^=^2^6]9KX3#DR/Q1)TSJ_>>[[\<=/S^(?+[MG+KM<2K
M]?KJ1BWVAG8SQ'#=7CIT$)#Q5B4BR,I7I@K&M@QM*SGR$6F.^]-Z,W@0.3%*
ME*2EVR^_FF&]>4QV2?@-"DWR'>$D4S$UMSKWJ3Z&FC&1!P-!N/WUJ1B_QYJ
MO/(]TO4)\7:;HI+$ Q*PYQUIK&=1,3='M[,(L=(ZFI0%9Q;6_%/U+3)-CJHJ
M&6<R;=N"W8PXI=QS^B$'Z%]KM""BY^WFN7WI*VQ)Z2LOH"4R%X$)7'_[=656
M.^A'K&J(R!&$@G37FRN6L=RTC2N&8"&6Y014!#Q:F0H92T4E'G:"@\_S.:86
M5#7J< N_Z*)>4E1O'T)G5I"935]HU>])-9140F-N@G2_;>M:RX=Z;>J[OJ2T
MKJI]JUT1*JF2XB:"C4YR]AE5 ZYO#;J25&A+#JN94(FA$GQP^@F=AUQG%UA'
M[I0FT.\Y=Z["H3'DY=%7;!X K(-=<^OH!=CHMOT=N)FA5GC-@&]HE<61SG;W
MO/$Z]ZCH-JV"'9V-XI'1UR=$!R:( .U929#G&'64OE1X5NQIKE!VS.I4;PC+
MS#BIG=E5'=7P?FV:DKUMN':M-PY+\]?8!['-5>6\!E90+K#"75H7+E44;B:2
M[LJ<";T9G9(KPVV.%RI*"'/ ]/\*2UWY(7%YV%<:8905I /WOP..H[D;H]/N
ML)F>_$[PB&PU(6OI7$+(W<[LY>%;I0P7U]9K;CN_5?TC^:=5WO(-C YJ=&WN
M:?NJR(LH(G/-96T7=!9==\.O+*8Y-H'<K:/"KPG)?H]>)&.:;G6)X"V T*,@
MA.^F<5/E) APAE2@=:'"R]8NA07W=Y<>X/6!<&K52)P"?YTLJS$J.C:*W-5M
M%:0X/K7!Y$"*:3Z^P<2T4I*ZF#0W]Y9[X^S!^OJW![M,G79AZTBE**":=5)U
M31#5H4U+H"5/)+Q0*V?%?SA8*X2/ N(3^0C78/-%PBB)IB0[S:6[B(125/<@
MCDSN?U4=$2V5&Z9C Y?K?$T'F1 .E#U!1KYQLH5E %7DIC-:.Z/UYD;KED';
M_SX:?_AP\A&W'>G>ZTS5AV:JCMWF?JBF(K>=IZ#4<8NDEGZ[K<@5)/J:>%,,
M-@5<$+5=1,4HU%=TWE4LULIX[ @W81E$/7!<&XR(J+4S>=RH17^9_,VE2VO'
MZ^[#=/_WW&25]WM8$V3 Z_?^W^/:GFMJRPZZVK*NMNPQUY;=%6[PMY)XH):,
MCOL]4$V.A^?GWN\?AF?#DW>HGOA-H3:G_N1@97#2WUKBD &2JGJ1*QM;([_.
M-,KR0CJ-2;[38Q-6]Z_O?\OTHBO;H]2T[\,37(#C?_WP]"_,]IYW#H$:QF?#
MP:>/HV,)(GT8#CZ./W@FI_G<]T;'AVO&1:6C_P];6[+]+QK<=NW'?VN)[6N>
M_>,>[\G]D?W\YWNF^QMM_SUN^5VNU]O5KTRGD'C5AE^GV=U&[M\WLQB]^3'_
MD6?P^RH 43;>\]Z#2$Q>_SAZ"-SA7H_'5IP\VA8F3WSPXRHX)EO5;=,WWZ;#
MN8JP](,I1"?Z=6V4'J=;K%,1MT)%'/[7\!"4P=^NZ.'0:8&=%O@HY$>G!=Y&
M"]1)N/(^ED&4?N\JX%*%F-%GMY V[P%MF[-5WM.#G[NM>KA;]1YK0S')/2NZ
M;7JXVW2HL@Q4R2)-I&O$^X'W;/]@T]UZ-$K[E@8A06XY<4B*NQ2I*\%J!>3&
MTX]B[?L*4S[MPI1=F+(+4SXT_D5F^(?1V]&XWQMXXQ-O^.GTX\D?" -6 8)Y
M.^+ULY^89FS>T6 \Q$Y&WLD[[]WP[=GGP=D?WG/?>[K_],#WW@['OP^'QUX5
M#-H0!Z)^2+\/CX_^Z/<^?CX<G<"I\ Y//IT.C\^I(P(]\'9X/'PW:H!*=EF,
M71;C5>M]L+<EV8N?WYP7*BN8PB-5Z-<_?GZSU])/,L?'.-YOTMH^J2R8>P=\
M[S9D/3[0G;]:6[^[H;=@(>[N,#V]^M _&&,'#OU;JB*A.E,5JVS%IQX_E0_L
M(:<R&JJB@/]+2J#JWSKT,BD\_X^#G_?]_?U]0>=WD:1,I1'_RLOT10044@E-
MB)-BU*L54V$2^VU]5I7-+^4PE.E/+<O<FKE,AV6 &3L:2^,,-;;!IQ1:YE28
M,'4[DYT3PK_DO#)Z%<&.:)L 6RL=VE @DR#H%Y5+H?5HRCMTWBBIW#;>L#W^
M\4?I$_\V6_5L>[C7@%@*D_@V3<J<V=<8.T 5AN%,\ LN:N+/9RE6T5H.I0L7
M9*B%\? X,4-T3%0NE;!8L#2IBNZ8"NQ!>1&%I70P,:GV#BY@.WD[RPQ[]FEN
M+VP+D)"G: 16V[7T/M__1XV%6<7$8=KBNU*YMUA)*5M&';(XS;^ A7T"Q_ )
M_B$8?BXQ-9;OIN8+N+>MDE/<-<6M"&Y92B;&7<]PK1ZN5FR@A(YEC,? $2%5
MQ5VCRHZF*C#J6(1<$F >/8Z#T!Q-7+XQ42H@E??[=M8(!ZERQ,7SL)*4JKD3
MH^@]-VQ]&N58\K#2*G-J1YO?2+DI"\:6$E\DBYHMFD6IT8@MLO-.<&P#1_K.
M!<?S[1$<;P4*@N0%4UKI>(;]:: @$@VPT;W>T>DL_S65KLAP<D]Z$%,[@TT<
MRW:.GYH*4\LJ26IH0U)>XX)8F-\ZI 'S9 H4P7RL#%\$0I+0E0#$;?"_!+1$
M6*-!D)7:NU"!P[<9.13KZ VZ$WU2I 7L$+ UM =FLXSZ_B(%3_?Y@24R<F!D
M"Z\FVI[N4].[[_2*=-QL:[;JQ?9XKMYGH)\QA7 !SS2BVP0,]98&7QJ.++[J
MA/_+Z,&.YC+#@8B/8*%FL4+%$;&!@ /]^MT>A!O<V0=,:[=5#Y36';7+Q WX
MVN&M^_D%>:VRZ@;G<R6 YF!M+D"ID ;UH(]@OTR0UO^QO[=_0-*6GO49G&B5
MEIDWQ^8DY*G.#/81-93'7RMXZ1)L&2Y7$QT(+4&T-PAT7I0)H:!"BP&>D6G-
MK3N503D'?D$F+QDNB&8/GS(@3BJ-*:4ZCG^,=E%>1ZIA5QS3P0M2@]&I5XB'
M#CY0 \QHDV;4IK*=:WP&(<=)-<(?(?=$984) 6WE&7-1;V18H7<:DP^4P=HS
MS4A#[I[1\SP'B_7_R,$0KLD_>/;*.UG25OSJ?51P#+ITA"YRS^3_^/;DZ ^\
M #]^&'_Z^.;_ U!+ P04    " !!BYY886ZB^D(#  !A$0  "@   &5X,C$M
M,2YH=&WM6/]OFD 4_]W$_^%&8K,E(M;59E%*(D(G"P4C=$M_/.74V_!@<-9V
M?_WN!/Q*+>MT29N9*'+<>^_S/N_=O<?)/??&5,HEN:=W-'8%_".[AFOJBBPE
M5_942A_+JJW= <>],_4K81P0V@+G]9 "%\]0#"RT (-@!DDU&:@"!T5X+#!!
M)MK/Y"AZH"+T\82TP @1BJ(VF,%H@HE(@[ %ZJO;84!I,&,C@G)&AG'8EJ7^
MCK*B(#*=3!F;NOJVP2::"$^F-!W"Q$-<=;W6Q$10Y&O;<C>-BF,XP_YCZSFS
MR[DQ_H42E$R3JN@/4SS$M%QJG-?.94EE5'/URM^[ES(8TGT.0[KM;$+],3W+
M8G0D7PZ&ZOCH65P<=Z!W;DS#TLLEEO&FVP..;=ZZAFTY56!8W=I1@_7O'<PB
M]*J=<&Y5Q]",SL#0G7+)O@;KL(&W%[7\1>5V5%,'7=TT^QU-,ZS/5T)=6-X[
M_4XWNT_M#X/(0Y$X"GP?AC'3G/UK@P7VZ)2;JE<2VT4W=%XE!IF!>Q11/()^
MQD*RYPAI/9%=;8N)!>+;+)_E>VV0@LNV*=6'HQ_@O-9D(.+ QYZ@6'"&6"W2
ME,.*0NAYF$Q6FI8ZUORY6B$X><7I>8A?YA&./3RB." @&,OJ0 $&&051&$20
M#QX9?]?F<;:NA(9P=%\JP%X0Y.TBSH67YNNFV2W$[&=0+%D8,H9D$@5SXO%,
M#2)6CB?#]XWZ1;7Q\5.UT6Q^R$FH31=]-*:KC+Z\J B*0R,$9SXF"/00].FT
M"DRSN^M9*M&H'$Z6;*E<5O*7O(9\N(#17JK^H?H=[=RI;4KW12XJ.6V,H+!%
M_91$KI'*$4+V;8HI*A G0>G<(Q]!#W0#$L]]RE)K*S@'N2I"?V$%AQ@NQNII
MJ'Q!]F]E_)I8X 3^G.]"\7^*7YBM&[SVX2,X@[.P#51$T!C3M\RJM&PT3MDQ
M?9_'%(\?3]XR,0?>B2*XQLCW6BR($];]..CG')$1%VP#.UPND18P84R!*&;D
M:\;7#-7.*]4E+X#/%]33-6O;G?'3*X"]%.9M^#F%@:G>+^!9%L@2XR*C98-,
MB;.9,/;JTV0-?P7JZ<.'C2FKAQ(_(DG.3/C1RF]02P,$%     @ 08N>6)Z
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M5%!O9HY.:_-G&. 5M2AE.1&S9=3,%3NGG?#M!T7+G SSHZ(Y4?X+4$L#!!0
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MPOCNX@'[D'.8@-V@>1;9*P;'^^/E5WV\?')V'G2VU) _(\A=,NM@BHJ4%(S
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M%,ZE8.GLSL):^ZOG5RTP:D4L3;4'V*HS)([H9AC"/,$1[2=-5>W%9N7>HL(
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M(C_(DXP% EQ#BRZ!IS*8@SS'+^53F8. ^53 HVQ*30D&D,<IB@P9]4K=HGF
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MEE!%DD@$#P7APT=]J]+@_BS.KL2BJR"W15=IDMM]@VUEJN;S0=SQ6YAGJ=V
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M]I&=UV='OZ,&V'DW?'_ZZC]02P,$%     @ 08N>6'SN[7U\L0( J=<8  P
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M?.TVF_>\O7WP_=LYW/:ITSF%?W!=][]Y<_<[;M7WJBWZKK?H_H_;ZN!-FQN
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MVDN"3\F]$?NAB]E[,J>>X6+&H9TI#H&R0[_,9JLW-S:?"GPG^#,3DO=>Q)T
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MJ@!H,51DV#R%_E#C H:7Q%>,"**:R6_O[:V-H^J0)>GH-/2BM!,%J+,-\1'
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MNUF^0[37M'2'>)<K7*:L41OSQ3U5DU^)RR@%ZL<66&L!CT.,7#T8:X*?>P]
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M(IA/(GC(/IQGEX('W$M&V(;MI$NNGJ(?J/KP:U*\ER/H_.2W6KCH[#F]%PM
M0ROEX)EH%-386V/O_"K[>1$, I7W8@61QO[*8)&'5V-:SSGSLX2GG(D)<Q$7
M&7U+*Q\/Z51NS53UB5LIZ*Z]?TZ\+I:]V%@]DSE*;2LOYVN<,E'2L"M/9J%Q
ML1\GZ05+!@?L,BVET5L;,'5E=@;XOVA8EX=M<IWT_AS2.IR%QK^7YX73(H$9
MAF$>HXO:]\Q$FF\U-S>6F#$N&)/"TYBI:+S[N#5K.KSQV3 ]X GSTS@1G2@X
MZ7:YSY*:7\TR[_.N;5\ZW"P(T)W\TQU8NKS>TGD0I@OGJ%1(\PCQNC-3\5IC
M<HW)#^2S-D[.RCPN#JC^$@=P^CZEO7Z.O:@<Q!J;<;B\"N.MF</WV*NIZ0A/
M&G8X!T0Z2_*8[13NQY$'CVKR>$'RL+>_)H_G(H_.,.$A55&,K+(*L%DNKF$%
M(ZL+XPK0".+A.0['Q5O/?19YL,T6?=Q[LVHB664B66X]:_Z)I%:T7H)(?LG"
MD3SVDXC5LN0N,GG =M729+4)9;7ER3P02BU17H)03OPTOL09 [50N2>M/&S'
M:KFR\N2RVJ)E3LBEEBXOHH9Y4>8E=Z@6_(K5TL5H8@_:L5JZK#RYK+9TF1-R
MJ:7+_+B,:ZER7W]Q+4UJ\JBER,N31RT]YLE%7,N/^_N':PE2DT@M0^:#1&HI
M,F<.X5J0/,@;7,N2FE!J<3)/A%)+E#ES LN3/^<WZ-OLLX1YW935H?G[>(-O
MV[I:TM0$5$N=>22@6@+-&0%5);G45#+[E)8:;Z=:0K)R*/N\!2,UMDXY17WE
M\/6Y$])KC)U^\NO*(>T+I+K6>#O]M+J5P]L72**K\?9=%G&)M-_.#\I8-6">
MR!+V@8MXJ]W:?0>7Z$?IGPK/QV=5/_R\[R5,3'J^VB6ZYI$O -!.JU]";=O&
M6TOAG5^S 4N\-!['FONOO0Q>Q3.M-QZP*![PZ(YWWKD?Y9=6/%;_;"__[FT\
MA5?<?DI#^/C(,SH&[.N-\R[]%&("ZII[O>$]OWF7L)#:EX@^'[K=)!Z<L:[X
MU]J1YZ? T7:VMM?<-%;?Q7$:Q2G#[W<VUM[<\8B;X*;-\87PE-VI/&7OT4_1
MR]EN/?T1F]-8R_94]G7[\?MJEO/D3=W=K7[$[M[6O1_Q=N/1C\BW8_=M>\)3
M]A[TE.H#OL]3Y'):V[MOJQ[1 MW@_H# U96 //0IU:<#3]F]]W+>;MWQB#?T
M# $ZL<\$?$-?])D7H#!__P98Z ?'<=X/79&.0M"ANB!'W[FMC6'J7H R(=RO
M[-H]BP=>U)!?--QS$+_=GUP4MTTOY+WHG8MCBUGRDSOPDAZ/FFD\?.?"(\P7
MEW$*:B)]M_;AO1AZD?V^9M<;\'#T[JXWTK6"_\TD@/"D-_@H^&?X86'7\#__
MW=K9^*FXDO]J-MTCSL+@G7N6A:QYZO68VVQ^> _'I5]ZS8.TCP_9^.=:X8?+
M.('#E?!_##W_A[L%&R'BD ?%U^/:U,5Z;?+ZUOJVOB.'#S%%_=<"[TT!OH4]
MA"<CTCW@-=^%K M/W:A:^%37=&G.[G+9%OA6+?#;U^.+PP/G_*)S<7B^Q.L\
M/]S_=G9\<7QX[G2^'KB'O^__W/GZZ=#=/_GRY?C\_/CDZQ(NOJT6_YL'PB_J
MI7'4< [VW?;&]M;>$BYWHC18^)5I+#XZ.?OBR">BS02:T/>]C</O+&"\V3R(
M_6R@'!3??1PAM-'>:'W_CEZ!C=9FZ_O?0S;<V-S^]/O.[A8\#M28*([().6^
MJ\Q_4(3*T]G2.!^FM28;?4O-%AZZYD8>.HYP+I/]_K4/K8WFKZ0JY>_(\>VY
M4&\U4.W/3*2\.YKFTEY]\9(?SDG$7K_$\F9]2*EW&3) B#"$;WW@C/]: QL-
M_QYZ0:#_?O!*+872Z(5^'(;>4  X^A-Y.-ZGR<.??\62E/M>J,\=ME2Y2]ZG
MP:/!W5C?YM%4U:82?_I8XD^=*,J\\(P-XR2MYE/[V9>_/T>C2!SM/II/=>-D
MX*7_6N,WZ;O+. Z9%Z5)QDH,;*N*@=D (@+M[6[M_#21EZE_TN )1S%C:@;)
MT?GZ]5OG,T%X=GAZ<G;AGGX[.__6^7KA7IRXH!U=@ KDMC;=DS.WM?TJ>.V>
M'+D7/Q^ZN>*4*TV=_0O\N;6WN57@Y; '\)]$FLU$9!^6AB,N,;,_BA,G[3.W
MRP5P%W?$O,1E4< "]RY5XY3B"(=RW$(U+1_\RO9OSO:OKH[Z4Z'E &-$<%\_
M\$8(*8M*)+U=1=(%0,=9U*Y:UWZ6P /3(]J(/^#IMR[-]X_"LU_;G7^+[M27
M-K:L'7M9D^!<^Z#B9"Y.CJQD6(VQ0VV5#C5_ZA%\(ZK7_G]?VN=_'&Y_^O/X
M\2RZL+[=JF,K@;)&$:Z)G/AV!KT<EL!<\:*9N%Q.SE;)-*U5T>=41=ME4SGQ
M(L$Q.G";.MK[=>^7\Z_7?X9B>YKJ:-<+15D??5MI4)>@5#KIUJ+KI!=GG:_G
MQZAXUGKIPLN"&>JEJ<%_5R:N4!C/_9[_7QI;?[S\7M02_T%\8#\>#+C I"OG
MB(,T!'9VR9)W8XJJYMZ'E!J%E\HK)Q@>GSOMX" YV#_:G(Z&NF?SYC(,E"/7
M;+]M;;9?W.M9H^;4'.ZWH^ 9ZW&!W"G]"HA1C8;)T<?^[YL?_4[[\?:OC8;M
MC7$T+,)!&9.'G2^?C[\>.C\?=CY?_.R>GWS^AI+TO.$>?]U?7S$4?<\_O#J\
M@0UT<.?<N.LF9L=<3[ABR'S,90U<#H>="M?O>PG \!KV:2DWI+9$[@!W:^^?
MSR#XRMRE4^ NQY$?)Z#O>ZCY4&[T?IQ%:3+:CX,)S.8_?[WM_?*VUSN[V)N&
MI=(4S,<!K"D;)O$5TD[9+=5NC7.C6^%>^W# 0N_:PSS1NWG0DPP8=93MF9]D
MB9JF ?3+X%^K@'\7WLVQRO*74P!OT[:2G:OK^/>SX=][T]&VVNUQQ)H T-J'
MS5:SM;6]O=6:[!N<8 W. <>9O>@C&B0 X\2-P:)*P%I+N BX3T95W"W(N:EY
M#>:;TF:_[\?K9^OGZP3AX6 8QB-,7>>KBXC<%@P&'Y.>%_&_Z;O7-1[.8-N+
M/), _1JOC^WU?'C(:OOT21)\IR#!.T&0,"'4/Y]YQ%H3I'?[[Y-^_]?MS?;C
M]<:"]-X<E]X5P*Q]   VG),P<+_P, 51=/KC>C3).AV/7-ZUVG;U:G_Y-/JC
MG0T_)7ML.JO=NL]JVVL?/L8W;FMS>W/5S.^[+!VU2_OP\22YB*^CZG-K_;+-
M#\_^\^?/;&<ZY[8]\=QR4-8^=,(A%MNEJ3<),<=2,O>JED=JV$ER"J842,()
M%MSO/Y_Y7C?:.3F<$B7N3%QC"9ZU#Y\Z$Q8X,66@\+S3&$S%\/_X<+)]ZO]?
M'+P=_K'M]::3@-K>G;BZ C1@(L#5>ZM&=Z"#JMUPXJX[3."8^= +77;#_"SE
M5^@* [V B=?N*]@I%[=JI7Q>R[&R6RQYY&.=A'F32?+/KSQF?_SV?QNGCP]N
M%TBR$,*VW[_VX=7;MV]?3R#",1YZH);P.083Y[0?1[=&>[I_'E[\N[OQVQEO
M36<9A6A/&8:U#WM[N\VWNRL7[$&6DD<;_N>_W[9;NS\))V4A&^+VN!'M3\,%
M5A-FZ#5V071Z< 0U9UG E6'A%(B*A*><"4<&35C" G>8)2+#Z$D:P\W2C=1J
MO[I\C<$5C-EW_/3=LA+!$D=/Y*Z.>Y%*5:Z7Y2I7N4L/6M/FSG.XN"]X&BK?
M9]=EGM]W_= 38@91AN?U+\W@0%IOG^5 $@_)@=9S/AI<QF%]%A7QG]E'K> L
M,%N@0!OLQN]C>UL7V/EUG\,W.<^?8@SE*5[J"J?W"^C7VL!7TG'4:E\2IZE6
M3G_C\<W'X:?T2S"=')#-0@Y(&88U2JA2GM[S-/9_--Q_;*QOM-RAE[A77I@Q
MS*-SJ870S*.PDR3,?#KCYP.[=):1XI6235:CUJ>]_F<O&9U=?/US.JA5".@7
M )"=V&J$F4.$V2ZQHT/%QR>GI?WAWUQ\^[4E/O''^\#+F2(H/:J21#;;5>S*
MAG$-1)$(O+\F^0;P>/:](4^]T,7*9);.9WYW;5O.SK;LK81MB5I9'+%E7=Z\
MH+.J5E!?\@A#Y%A_U)YR =)Q%&#<G3F7(]?O,[ + *H?+I>(;&6A<N%Z[C4+
MP^:/*+Z&ES-/ !X$\(/(T*'F"3=@71[))%5L&N5N;6QKDL@I":ECW?T#/J@B
MH3N"-[_!.W_%5YZK-Q[3"ZNEAG?3_?GJY\[1Q\]34F0KXL03  (1$4\*3YD2
M_55!JYJ,)I-1%*?PS5\91UD"(J2+)24)%<Z):MFRB7E(YB\J,LLES>VT=%B@
MI?_$81:EH(YC74@RH7+Z]][O!TEW\.D_%]/)E-RLR#XH 5+33DT[9=JY[C/*
M!"T1T*O6:[</L@:I)G"],#2D8]/4)5,7P#.+9%0@'TLJ:6W? 9+"G[%&TPW@
MUZA'EPX3YC.*%[7:+C5!$.XK>![8&*[(_+XK^C&69.@*P+3OI678KSTQ3OET
MLUK#:Q"C4>"^:K]V<(V78*G [Y=_P@KP>KH4;D(HU'.P_%80$ 2D)U)W;\,-
MO)%8'^,%FP5>H%HTR(I=M*%3+YW43.%Z[WAO\UOW1)Q.2:Q6)+94P[/VX0_L
M(GTK:W"_QJXI.%X5JJFYQ&U< JD'"&? TQ1(C85 0$D<H1\D'+GLBB4C%WMU
M)X"/F&5RX*6>>R3E<(&)Y,^P!3,JMXY2;L]8+Y/]>]WSYL6L.8:$QS ")EZO
MC^4E[)2*=,PR<96*RB94I%ZV#K?BC;VM*56D;E;D=E7#4Y-Y3>:/(',R2D,
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MSBT>K4K_AGE%E,7A.(K#$'P!&TC#*] IMMCG:D@&38U,"P]5S77F[DA6E>N
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MH8K4ZN@VFA)IML/QX<B#!(WSB*5F#]4FP=^RK;/^/@05$12YAHL-#,W3$/K
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M,._6W0Z8@_EZD;!0< F0.^Z(>8G\34M@^P>:_4S]"]PC=IED'DC EH0;H[)
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M[WS?;;_=:+8VFML;%)+'4I9>X@W[PFV9+#'@2640L',CQN#ZG'6ME^IF&L[
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MM>JU-M+!JH"$DT=69XM.,"]KQKVTZS5AI%Q=(;89\C0-607:X* G[!.%1MG
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MR(1V)2D<-#&*Q9Q4A9N#TOZ2>:]DBMF0XE>P9JV4,P=ZO$HMY1216DD1IY"
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MGJ*H_*6X(2!S. @/0_./D^/V/.0WP[_V;Y#_K<%?^[ 0_0=#_Z3]FQ+7!GR
MT^AL^';9C^[_GN^9P*M[COWXZ/1D,T;^34M/)OIPZ:]V8 ;?<PU_GZ:U<HR,
M#VIL+YKYQ\E #V[5RJR['.LOP5U/W(_F98SF<17%$@VM_1H\R=;'64OSK10
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MX6(G7%$!ASN!N9:+0[#5E?15A/M/1*XUE2; Q1?\I$.-I$I"9$IKV%Y! 5.
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M?<_3$MXZPW4D*>>/E@+^/$8V^UZ=G9W*-0[</-DR>V3I -V\S$C!(&_@=<Y
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MEE+PSH97AV).'49\@]5V"PKI$C>T]5-GJ]C&;LW+K?7A$F$;664%PE%1YA?
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M\MY^*'X)B$\<UQH0K2C[9 [)1@GL4XNV%QO@GZ#CPF"CR?.$H.,V(P_78;@
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M"KV*)\Q^&YPVPD<R>F#(P1-3Q\12HF%J.K"7> /,HH/Y19;,*RS40^'<JX=
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MM;\&_GQX ;&" B.]<P#1NUU$N+6<RN3;3^9^1B-Y\6F*^1!=+)OPW8%'& Y
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MZ&=_4P6(U#GTE@4G,L:+BKGQC-1]B_6H:.C.PQ/%&AU-B70#:P!Z!<BB1!C
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MVX9]6ALL,!#9WW,F?TD$JIJZ0K=<E1JM9$9[(9-2'%>\N$E=HUMN2,WFMCL
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M_-^A=Y3#?=V@GR,=36Y*I:IWDH.KRU[GRVG_K"=\ZG5.KSZ)@_/3ZZO^^=E
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MSQ&,3]_E.=R]E%D[I!PPLW=BEFNY,)NUPYJC4#XRSBDWU_MC'?J-,_W32\:
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M'(E_61=A^;O!D,.!#5C9.<0[8KC>VKUF6DAD(7"$K_D!:D'P'F=((#>*2E"
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M:?&:-AQ*$4O?5[]+5""LK/"-:/]!'4\BYYK2!>5N'6J3]GHNZ;%'6(4;F*8
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MQBRTP326!Y;H%-B15X)YN%W5IFJ/2^#5^#*>"U5CO]-",!+-TGD6%'-=.%8
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M+SHJG,:0_K$'B6#,N8I[R$Z*6;C1^]-L\QP5]!;8)&A-L(%9N!HF"M:MKS%
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M4"=F:78$A\;7\(ZI V_U=[@CD;<H?@:,M@#SEY(JG3R:"BPAF='>6VIX,!N
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M\19,6+UMC_-@:"#]Y0"[ KQ*$!8%^,2)&0M&OJR9HMV0T5V+3S2=GL>L62%
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MFW,^S(^?+X7)GUZSD9$W8B:&6 MQM \Z^0^R0V(0STIC9"UQ%W9VZZD4I:B
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M2#GT%]PIA;9EU4#M4=$S4\/$..,>-%*13?.0NW% #_A1W+U-&>FZA)Y+X=_
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MF9=7CI.?N=*6J['?? LO!7=Y)3OF_M^()4%+ K^J).C2+0^FL@V=9<';EPB
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MA:FM3=VZDRVJK"U7A%W%-=8?$S+V.HCAM4?\1-IGC;CV,+]7CZQ&*_>[?%Z
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M)Q2DRJ22DL3U9EXWP$C6D :M3R?HP]0<Q)4QT&ZB33%=\,(4]@NXO!6PY:0
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MD);O3/9,-\T'I?D@*<&T-JOW'Y_JUGG]J&C3FO-V#+X20'K?H]&>=[*!OM1
M5<9#E6O[N<OI$I^-1)0AO&_QJ'YL@^M%$!T"(<2E##"W:I7">M2,7^,D?8ID
M=%0F>1S()&O!A&O>SPN:>JD-RDY6$4GC7>"0,2?X?L892**EM;WZB#Z%8F$M
M&A7":#2(B49+#1$>YD)1%OZHY^6SF_U6XC^?H[^AI5@=3;@TBW V34?S4 A
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M15O<2 0.XJ< ?!4F4P-=(@)]EYV;[/*((5;J8D&<PU]2-/I+"1K=D4?$[[P
M!0PZ-T07CUU@@H&!8COU!&K8XB]H '4?HUT9F12B3KE,REFJF\$!BZ%1\A6$
M3_8AB.V9X<R,,4%XUWDEA7'HL@':H\W18 I^KH;NJG<<)(8(JQ$AFZ$/;DGT
M#T"_' Q@"S39(BV4!TC(V-?^N%JWK_Q8MD8Z_29&8R%6IH]EJ,UFZ)#=PZ0>
M(NHG/!KE;^1TZ.MLY//JN3VRLPSZ*AN2+,&<VOA18N6@B6/HEYEBB45T<-B=
MJ4GD/AH2Z!4C -'N>1& ?AJ!? 5K]L6A=GI%P*$0V2#"4OM3%=<%Q(D(PR&
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M)UVT-\..H@VI*3U-SZ_5QL5%OS&6A;U)WOY\Y6Q8 N:FW3J]0D6Y!S+58'J
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MZ_"/3F53&HXT7= G5LD1#H$Q0":9;Y*D6O.&:%*+"SM&![VCKY+A1+3H015
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M'9>!1(D#)HQQ!T2?#%<NT6D3\ N49FC@^QRUGCD6@"UO$N@!@N&?L8'"#-6
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MV2LA,ST9]SZV4+NJBDNLZ?VJ,]YL)([/))'A'AJ3^XOKPS?K0.$S";0BC^I
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MYBZ,X*UW4G"H3!8GTC:LY9$S(Y2Q%J?>\Q#F[LHRJ=UFZX.F)OSF7>2RH47
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M9-#:G^TJFH&[('GMI+QBK,\>GCSH?C,-BZ2L,#991X G=0'3-8\4697P \C
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MWI4IZDCD>:$C*]:,;4G0[1D+@HDSNC'&H.-T9(;<'_4[P=Z[8^JZXC*,*$S
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MB@2UCR$,)Y\@^)PS=+->,<9'^:](M*8CV6Q>5M&=*Y-")A( 0??VD.2"I'H
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ML<1%\"N,U@5 (D>';3@2LF#%<'Q;M9;#;J+.ASZY*;7?.D]-30&9J5;B&=%
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M*C:2$K_VPMS4<,@MB,D6[&3VZ- !8#SY81$CMY5+*+<5N'!XD T4EX!V!GN
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MCMEMQ@@7L8<7S&ZJ<8S":%?6AYS,"=M&9<V4VYUQY3_H(T.-+F)3?R_^8XS
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M'L%R?<A?6J/WPO6$(&\,V\O=CF#:'5]67[(E/W&:9)Q=/?;BL7RK%;:9OAS
MA T2SA\_U(7Q=:@J- *:(_C&8VUHP;J?&0ML=Z45SR[Z0= ]U@&O,"'8 0BK
M0E_J@A[$:@E!W^@N&VECS6"1+@SRFFB8'O7.J-^2@-*E3T!AU[[[.P?R!OO
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MY_<;^$BLMNS-A^ CD'N SOP)/CH;._1BJ3CG(T_G;G4L)Z',7F>FT+M#JS1
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M]H7Y,#_PCL\J6I6N@X@Q]@VYV'F,SC5']L/)]MI[F!,'HGOE<P"^S"C:<O2
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M"",3M8I[(_86XR& V8Z(_(=8,_C-_P)02P,$%     @ 08N>6%%^0DE#00
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MWA)*Z#<_60_3.,$;%)E/;I#2:$#J]"?_HSYR+D8R@ZF"D85.*8[23+6C"TM
MO8]3W3U XB\ZL(OVJX]-.:@&U'L>#7&<V,N=2F+$^3X.G$) :U6B%I(@%B,?
MU'2;D'>I-L*4>6F/;LD=9@%4OIJ0/4,/82+ Z-<M''B,0&A\4F8W1 $9;K5-
M?TAC3@UO0T1+6:7>TYQYACU1J'\70)1G"-2GU6ES,2*$K+-\8ME35'I6<C%D
M=NL0='P^(,0^JT)L%^QM;>X=/\HT&QPS' [E[3N$$8,!")P?58'S0J.]G&#Z
M-/ !>=OPYU]1X(UQ=,-:5D+=.P2=.#\0DC^I0I(>SO0LWC$+@W;<LD/XE)+.
M\HXIOH=N@]G9^UU)X^[</8]H!J%09A*8XA ?$IO/';YI@-M5>YC$. !!JVHK
M./]4HNE&4,Q7ZXX:J@)$2LZ8RP$(2,W&!,/]5^K'F6A,)PIQFKS$:+[$^0*W
M6K'.74)$DBL0I:IFA_./G62-(I!SQ@G$[-<E",49 M%39J9X.4IWAOBC=Z/Q
M)5KB"!4>R)E/1!"$<#]THN?L("!,4R<_$7.0L;W=7%@;:&,?U?YT;)IW<(HI
M,Y[L.<E70OX6E#<]3CIT!-IRND%8E%E(IB@1N2@<--,>@E-J0<$KLW[0(YZL
MVGTVJ"Q7% Q :7/M@8"I!@%19L0XIC5/VB4.2=ZA<Z 4Z09=M\KL&=^0OUH3
M\HSMB\9I2H5@+S/*XT)")<[ZD1I&>PCEN0&!568= 7C(9^,)*]+00@-U%5PF
M/R"\!3O*W]\=L4H(^;/%1RPB=8X.7K5\$G_5DH\]\,-!<?3_X]SC^#\'^4?Z
M]R[R5/?O75I\[U(%H.W<IFDE<)@E9BA_!'/,;7DW35_$B!$/(J=,HSPD$WRB
ML=/+RINW_$Q&2M98A ']=,HZ@-'R[4S=X#7SD*8&?_,^;S+X\F#OM3UJ>JM&
M^V.OC6-/<PG-VNUNAN=E(G.":\?WK'#HW/N)$_  879K8%'5C@Z? ?T\T3.:
MUB1$WN[JSP.IO'WKS],JH,.@7+\K,'P1*M/<CMO>?M+\(@N0K-U.)F%K.+U]
M:P]"*<7@6E"Z%*PX3I$WR@H%;(L/915 "ED,8_.)W"G\F&67E1Y*?PPK<03J
M;9IAO)VA]8#,&*NK*/-8@F!6%@K"FJUEF3RS3,'5EC,X7%?!%N *PEO=&Q?6
MO*T/<,YX745<A"T(<F7!'*S9.T6/V6\J+NE]]ZX"6L(%A)^RJ _F7*P.X%'_
MKB)8Q@8$H;+XD4)(*$V-6VJ3R&(16:88P2&T!U*.$PA+9:$GLLK &$=+Y-/:
M+#7J385!M<?[7-Y83CZMI@"L'>0L5;XC,<?LZ@009:UV"RV4&XQU<4^CB(94
M[.-V2H#,<F[)C*$O<-58 8&J.9<(^^Y]'E+ ()V$BL4+B)4R@Y.(6K"+2STL
MS5$TM\S0]ET.RG.N;"4QVQ8V2@I1#=4TK!H(T'<J*9 #. V5&<0JQ=CK#NDI
MM:#@U5JF#AQ0G!L1T$%[,%AT@[ 4K$?*0T.=>#T.\".0WOP'B4!0,M(@'ZKI
M#.UVM'+"O#!FEA0E=B/_?EOT>E=NN9RASS2=OQ_30$)R)R'_L&=?C*GUW\;"
MLJ<#8SH:C,SY<&9=9_^VQX/+F[DU->?S%M+.LZI=EW/SXS$W<^O+U!I;0V.Z
M&!C#H7TS75C3+X-K>V(-+;,%)DJ*79>3_M,QZ3M!#X;VU:4US0!I828=%KDN
MI?7B^Y-)<VW.C$RR$].8MR%76HBIG+B+8^)&YN6B>8(8U5S+Z7Q_3.<7VQY]
MLR:3;-59TX4Q_6)=3LR!,9^;BQ9$6GCA64[QAV.*K2F9F^9@8?S>!N2, /V+
MC\>DF?^XL19_-$]4L;)D.6F?CDF[,GZS9X/AQ#*G;<!:7D.RG-8?3L1X=3VQ
M_S#-P<Q<6#/SBI \N)X8+6Q$0*7"<KI/3K'YPA[^U]M+LA>-Z/YY;4[G+6V@
MC,J$Y;2?G%F$WBMK044]S[:"H9T=6N:TG1,+JDA83OW)L34S)\:"2/W:F"W^
M&"QF!I'\D(J^#8WAJ$1<*<GO3TZO^<WEG.P7=&Z;7]M9E,)EX,I9.#GC]N,-
MG- ;O(PXV V9_?QE4*6Z&U.'>W]R+G)TN,'?=N.U40J)Q5?V8@3@ZN3LY'*U
M':T%GK*:E@S23\Y6JE"U2!]#LV*1?7+NLO6K%ADJ*%HL!DX.XZ*ZU2*YP$G,
M(EWX/&Z3C:/#@47_Z3WR^(AHD_!]T=8I#M^Z3KS.###Y.;W 1,?P:'H/KVB,
M*+5I'-<4/>#YY"2?#W\U1S=D@9!;_]2>OAT:\U\'UL*\FN\/^85-M9,103/#
M=3HGN]<H^\U\0?[8ZC"D>]9U/+&_$;GE1+0JN/S@(W^D01);X3BE'MBMU98I
ME0^GRD)!*C-S;LZ^4N5X?C,AG%K3P?AF<3,S!^0^;-DC1=R2DRE*T3X]))._
M$TVBR!\YEV8W!$SS=[I@347LF''B;^B<OHG1,@TF_A)E^;?O$=%0:1I,<B_,
M$@ S&3U5*PJ,FO.%=97-VYNY.;Z9#";6./O%]8R:-H@B2\\,>J>\SJY +W)0
M8DW>,4\O<DE1 A/^RVZ1OHILY'O$01IY;\"%1]#F=;@XE,>&=DEI:?^.'&3C
M\GE!/LM^32[46=V;<EFLL#QS(,K:X4EIYCUT%NJLYCVZ#!J".)Y*1*<WZDT#
MJ?/[]4;!;K4X)+VZI0F*]G30\C%Y$1]FT3Q^1T4/V666$Y;E1[OMU%XN?1?M
MB>:]FRYMKNK9= 6DN&R ^V3-@9-;"L9I%&91NX3ZL?^4Q>\R5PVOVVW9^M83
M"F%VP*U,V:+)G-@T&L7:W$?X86L0X2T=1B=5X3?5%Q"/&0BS3ZV6\I[1G&EP
MT?3"KSNGPQ^2#^Y:K4L;7 4[@G<-6M:R2^6%RTEK25>N49Q:ZKKB(F\S"Q-'
MZE=$9)MTPY+[09.VE51@KF*8.BWVABOGB2O68I/6\R3QY7I"'JC+*\LQ AXA
M+R;N"E?JE\ZWGS734WC63%&>("CU,XZ\$'X0C;M T<:D'I&8>K'-,-WD91;.
MPEOL$Z]Q5DAP+G"E5Q)]_N*WV^ HR:.X<^?=&$=9-8W0"8+GO-8EVILKF ZO
MTXB3HF?ORIXM=E'>N7MO,+9G-"["G$V-R>2/P<C\:D[L:^K,M<>+;\;,[/U>
MO=^K]WOU?J_>[]7[O7J_5^_WJ@AVRWZO.+&7.XW)B(TYHB]V.2XO1I^N>;LX
MK-2]?S)A($PL41QG3Z['"-% ]PFAAD:I"0#"[=TA_Y8L5[6[N\Y/?;Y]+.__
MM0T+IB[5_30K7&0NX#U2=(3.W5NE&!,P::B]EHX=/\H2HVQC[K/YZ=SY ?D<
MG:(.O5YZ=CA#;AI%>:DG=M#IR8N"XM5T;%BSP5=C<K./S*>QEQ/+N+0FUH(^
MC;@RC?G-C-Q+R=UU9@YO9C/Z<N+2F%OS1FZH'),IF1[)$D>;[=-9' VCY_L$
M9\)BW4M)5[&>[1E_&?1 -U V%]K<.H6%?6).%I6)]O?,_3*^?-[_]5>?,!6Y
MZ^<)-2VQKYJB_=N_;<J@A"OQI-TE<T]MOO]F;OU3%GBW%,EAU%P\)4$"$)81
ME$ZW4!5(ZWPS;6\V:%IR:$^N%1+-,LY8ON#%-#$ZJ:IT4VUE G@";('[MOJ-
MNT#Q^RKHO5=[Y6T*O?=:WWG+*/Y0!;T/:J- FT*OR!:X<]9L63+<;2X^ZC1U
MHA"GR>YZ^G)  &8ED:ZM%^FM>%61XN=5VQRNG8A,YS5*?-<)R@T0)[D!&C!
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MJ_J=I8>C[.>D\Y 5Z*SJ9E@%3U%V(!1_J-E:,R=$1$[H\E<:;0ZT;OW]214
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MT8F\$;<$P%$S9=9<>0 PBP_]KAD[^GB6N9.&:LRMY?($9*ZOP;2JV'4V>%:
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M# +\2.O7PB *=.XTFL+\U7T-!?-@N!%R8L*2$$K;-!%PEVYB(\85>'E1M=
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M^TG134Q\61T7?P?9 '?0]M. O?[4:C_HF@NL3ZW6IU;3,[6:; ZPMMTODCG
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M4F%$I-&?]UF4KZ/P_'5JR=/&^X*&W#^G#_DH5$4MF:B[&*4&>XA(8CGOM#
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MXI.*>Z>6.4:^HB[30$P%M73.?+0IP7_:)^L,K]F:V)OA?3A&:NZ28<V=..3
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M-V3@:D[T?P?!!0DH[N!I64J)RJ%2T,N7KW<)DH+>]2QUIR_FE@%BD%T6=&4
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M2C&8K,OVI-$=1AHV[X!3]<X]B3-:^O7T (\LI6 %[*."S2$UUB^G+ BV!I8
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M!_\NAJMRW-KAJJA;A\K:FR@)DO $PU6E(0 L-G#4@,T**]"'JWKHNN'JIK8
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MA/SM;E_@;)ENBI<@PV;L'FC+;>KP$>YVDX@'& )#\&/0\RO!S:5^J-9$+<-
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M57NN#7G:>JGNOKHA_SA.DR(+PH(>A:IWMR>O8;Q?TPM5:)I?SDH4B4;T \S
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MJY.?D#\5;_7QVW*5:9[1_])Q";WVG.XI18^)E,K'&O4\4!CP C1#"0N+8!K
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M(4PMO1%!/U-XE'/SD/ F,B>:*=RXP)FCNC$!:3I8+L1[7^2HBE1]-H@.]H-
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M^X9Z_;VZ1GASH.@UQCY/*$Q 8P(J'^9B>A2N?XKJ[V1A,['L][#:F5OE>#U
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MUHTBV+7K1 T+B];'F3/>V:+X6%X4M\[-&N9<HI/442/RVD-E/BW.1F%A<#L
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M3S@(\XDTX(]R;[!WCBYK-/$PM72RL-VZ4>\/YDVAO6AT,3'$&\$6J\H>O2'
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M>N7R7YV"!V^07).QYYO"3,6*?T[SKTP(."C 6S0KE+KUQ'$U6@<CE^Y =@B
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M5EI+*UVGVN2IHNO;]D/_+*+3)J5S22VHEL[MSQ5U\_W-ROG'O3-;#YR?69A
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M?OT$J'Z$O#90PCNY.#B17[HV\%\1^[_0_WEP$T1^\_\#4$L! A0#%     @
M08N>6!>NA$/K30  ;"$"  H              ( !     &5X,3 M-2YH=&U0
M2P$"% ,4    " !!BYY8>=8_>&9'  #1Z $ "@              @ $33@
M97@Q,"TW+FAT;5!+ 0(4 Q0    ( $&+GEAA;J+Z0@,  &$1   *
M      "  :&5  !E>#(Q+3$N:'1M4$L! A0#%     @ 08N>6)Z 3E(Y P
M6 X   H              ( !"YD  &5X,C,M,2YH=&U02P$"% ,4    " !!
MBYY8KY\+0$ (  !T/P  "@              @ %LG   97@S,2TQ+FAT;5!+
M 0(4 Q0    ( $&+GEAPWF+Q%P@   0_   *              "  =2D  !E
M>#,Q+3(N:'1M4$L! A0#%     @ 08N>6%$3ES?+!   XQT   H
M     ( !$ZT  &5X,S(M,2YH=&U02P$"% ,4    " !!BYY8AA_8R\($   X
M'P  "@              @ $&L@  97@S,BTR+FAT;5!+ 0(4 Q0    ( $&+
MGE@1J-<)XA0  +F<   )              "  ?"V  !E>#0M,BYH=&U02P$"
M% ,4    " !!BYY8?.[M?7RQ @"IUQ@ #               @ 'YRP  9F]R
M;3$P+6LN:'1M4$L! A0#%     @ 08N>6$81I/T&&0  G1D! !$
M     ( !GWT# '-T<FTM,C R-# Q,S$N>'-D4$L! A0#%     @ 08N>6"LS
MV)J)&0  OC,! !4              ( !U)8# '-T<FTM,C R-# Q,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( $&+GEA1?D))0T$  /M!!  5              "
M 9"P P!S=')M+3(P,C0P,3,Q7V1E9BYX;6Q02P$"% ,4    " !!BYY8 <G'
MA?*/   A*0@ %0              @ $&\@, <W1R;2TR,#(T,#$S,5]L86(N
M>&UL4$L! A0#%     @ 08N>6)8EQQHF80  P74& !4              ( !
M*X($ '-T<FTM,C R-# Q,S%?<')E+GAM;%!+!08     #P / 'P#  "$XP0
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:STRM="http://streamlinehealth.net/20240131"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="strm-20240131.xsd" xlink:type="simple"/>
    <context id="From2023-02-01to2024-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-04-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2022-02-012023-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_SoftwareasAsAServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">STRM:SoftwareasAsAServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_SoftwareasAsAServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">STRM:SoftwareasAsAServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_MaintenanceAndSupportMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">STRM:MaintenanceAndSupportMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_MaintenanceAndSupportMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">STRM:MaintenanceAndSupportMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_ProfessionalFeesAndLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">STRM:ProfessionalFeesAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_ProfessionalFeesAndLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">STRM:ProfessionalFeesAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-01-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="AsOf2022-01-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="AsOf2022-01-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="AsOf2022-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_InternalUseSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:InternalUseSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_InternalUseSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:InternalUseSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_SecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_SecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_SecondAmendedAndRestatedLoanAndSecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecondAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_DebtAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:DebtAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_DebtAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:DebtAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_DebtAgreementMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:DebtAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_us-gaap_OtherNoncurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_OtherNoncurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_EquityAwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:EquityAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_EquityAwardMember_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:EquityAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_EquityAwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:EquityAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_EquityAwardMember_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:EquityAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_OfficersAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">STRM:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_OfficersAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">STRM:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
        </entity>
        <period>
            <instant>2023-10-16</instant>
        </period>
    </context>
    <context id="From2023-10-162023-10-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
        </entity>
        <period>
            <startDate>2023-10-16</startDate>
            <endDate>2023-10-16</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_ComputerEquipmentAndSoftwareMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_ComputerEquipmentAndSoftwareMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_OfficeFurnitureAndFixturesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:OfficeFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_OfficeFurnitureAndFixturesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:OfficeFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_CostOfSoftwareAsASeviceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:CostOfSoftwareAsASeviceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_CostOfSoftwareAsASeviceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:CostOfSoftwareAsASeviceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_CostOfProfessionalFeesAndLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:CostOfProfessionalFeesAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_CostOfProfessionalFeesAndLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">STRM:CostOfProfessionalFeesAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_us-gaap_TransferredOverTimeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_us-gaap_TransferredOverTimeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_us-gaap_TransferredAtPointInTimeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_us-gaap_TransferredAtPointInTimeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">STRM:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">STRM:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_UnvestedRestrictedSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">STRM:UnvestedRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_SeveranceExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:SeveranceExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_SeveranceExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:SeveranceExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_SeveranceExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:SeveranceExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_ProfessionalFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:ProfessionalFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_ProfessionalFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:ProfessionalFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_ProfessionalFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:ProfessionalFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_AccruedExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:AccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_AccruedExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:AccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_AccruedExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">STRM:AccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-14</startDate>
            <endDate>2021-08-16</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-16_custom_AveleadConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-16</instant>
        </period>
    </context>
    <context id="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_AcquisitionRestrictedCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:AcquisitionRestrictedCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-14</startDate>
            <endDate>2021-08-16</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-16_custom_AveleadConsultingLLCMember_custom_AcquisitionRestrictedCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:AcquisitionRestrictedCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-16</instant>
        </period>
    </context>
    <context id="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:UnitPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-14</startDate>
            <endDate>2021-08-16</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-16_custom_AveleadConsultingLLCMember_custom_AcquisitionRestrictedCommonStockMember_custom_UnitPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:AcquisitionRestrictedCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:UnitPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-16</instant>
        </period>
    </context>
    <context id="AsOf2021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:UnitPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-16</instant>
        </period>
    </context>
    <context id="From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_AveleadConsultingLLCMember_custom_FirstYearEarnoutMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">STRM:FirstYearEarnoutMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:UnitPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-20</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-21_custom_UnitPurchaseAgreementMember_custom_FirstYearEarnoutMember_custom_AveleadConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">STRM:FirstYearEarnoutMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:UnitPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_RenewalContingentConsiderationMember_custom_FirstYearEarnoutMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">STRM:FirstYearEarnoutMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">STRM:RenewalContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:UnitPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-20</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_RenewalContingentConsiderationMember_custom_AveleadConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">STRM:RenewalContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:UnitPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-20</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_SecondYearEarnoutMember_custom_AveleadConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">STRM:SecondYearEarnoutMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_SecondYearEarnoutMember_custom_AveleadConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">STRM:SecondYearEarnoutMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="From2024-03-262024-03-27_custom_SecondYearEarnoutMember_us-gaap_SubsequentEventMember_custom_AveleadConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">STRM:SecondYearEarnoutMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-27</endDate>
        </period>
    </context>
    <context id="From2023-09-012023-09-01_custom_AveleadConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">STRM:AveleadConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-01</endDate>
        </period>
    </context>
    <context id="AsOf2021-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_AlpharettaOfficeLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:AlpharettaOfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_AlpharettaOfficeLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:AlpharettaOfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2021-09-292021-10-02_custom_SubleaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-29</startDate>
            <endDate>2021-10-02</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_SubleaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2021-08-142021-08-16_custom_SuwaneeOfficeLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SuwaneeOfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-14</startDate>
            <endDate>2021-08-16</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_SuwaneeOfficeLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SuwaneeOfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-28_custom_SuwaneeOfficeLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SuwaneeOfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="AsOf2021-08-26_custom_LoanAgreementMember_custom_WesternAllianceBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">STRM:WesternAllianceBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-26</instant>
        </period>
    </context>
    <context id="AsOf2021-08-26_us-gaap_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-26</instant>
        </period>
    </context>
    <context id="AsOf2021-08-26_us-gaap_BaseRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-26</instant>
        </period>
    </context>
    <context id="AsOf2021-08-26_custom_SecurityAgreementMember_custom_BridgeBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">STRM:BridgeBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-26</instant>
        </period>
    </context>
    <context id="AsOf2021-08-26_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-26</instant>
        </period>
    </context>
    <context id="From2021-08-252021-08-26_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-25</startDate>
            <endDate>2021-08-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-29_custom_SecondModificationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecondModificationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-29</instant>
        </period>
    </context>
    <context id="From2022-11-282022-11-29_custom_SecondModificationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecondModificationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-28</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-29_us-gaap_PrimeRateMember_custom_SecondModificationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecondModificationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-29</instant>
        </period>
    </context>
    <context id="AsOf2022-11-29_us-gaap_BaseRateMember_custom_SecondModificationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecondModificationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-29</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_SecondAmendedAndRestatedLoanAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecondAmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_SecondAmendedAndRestatedLoanAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecondAmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="From2022-11-282022-11-29_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-28</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandAndTwentyTwoMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandAndTwentyTwoMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_JanuaryThirtyOneTwoThousandTwentyThreeMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_JanuaryThirtyOneTwoThousandTwentyThreeMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyThreeMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyThreeMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_JulyThirtyOneTwoThousandTwentyThreeMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_JulyThirtyOneTwoThousandTwentyThreeMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandTwentyThreeMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandTwentyThreeMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_JanuaryThirtyOneTwoThousandTwentyFourMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_JanuaryThirtyOneTwoThousandTwentyFourMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyFourMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyFourMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandTwentyFourAndThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandTwentyFourAndThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_ClientRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">STRM:ClientRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_InternallyDevelopedSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">STRM:InternallyDevelopedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_ClientRelationshipsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">STRM:ClientRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_ClientRelationshipsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">STRM:ClientRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_ClientRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">STRM:ClientRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_InternallyDevelopedSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">STRM:InternallyDevelopedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_ThroughFiscalTwoThousandThirtyEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">STRM:ThroughFiscalTwoThousandThirtyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_TaxCutsAndJobsActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">STRM:TaxCutsAndJobsActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_StateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">STRM:StateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_FederalRDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">STRM:FederalRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_GeorgiaRDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">STRM:GeorgiaRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="From2022-10-232022-10-24_custom_PurchaseAgreementMember_custom_TwoThousandTwentyTwoOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">STRM:TwoThousandTwentyTwoOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-23</startDate>
            <endDate>2022-10-24</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-24_custom_PurchaseAgreementMember_custom_TwoThousandTwentyTwoOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">STRM:TwoThousandTwentyTwoOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-24</instant>
        </period>
    </context>
    <context id="AsOf2022-06-22_custom_OneHundredEightyConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-22</instant>
        </period>
    </context>
    <context id="AsOf2023-06-28_custom_OneHundredEightyConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-28</instant>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">STRM:ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-07_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">STRM:ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-07</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">STRM:ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2022-06-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
        </entity>
        <period>
            <instant>2022-06-07</instant>
        </period>
    </context>
    <context id="From2023-06-152023-06-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-15</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-15_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">STRM:ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-15</instant>
        </period>
    </context>
    <context id="AsOf2023-06-15_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">STRM:ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-15</instant>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_OneCustomerMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2021-02-012022-01-31_custom_TwoCustomerMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:TwoCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="From2021-02-012022-01-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_CustomerOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_CustomerTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_CustomerThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_CustomerFourMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_CustomerOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_CustomerTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_CustomerThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_CustomerFourMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">STRM:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2021-02-012022-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">STRM:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="From2022-11-012022-11-01_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="From2022-05-202022-05-20_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-20</startDate>
            <endDate>2022-05-20</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-04-01_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember_custom_MrGreenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">STRM:MrGreenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-04-01_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember_custom_MrStilwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">STRM:MrStilwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2021-02-012022-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:TwoThousandThirteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2023-08-012023-10-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-11-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2023-11-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012024-01-31_custom_SOWMember_custom_OneHundredEightyConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SOWMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012023-01-31_custom_SOWMember_custom_OneHundredEightyConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SOWMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">STRM:OneHundredEightyConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-01_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="AsOf2024-02-01_custom_NotesMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">STRM:NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="From2024-02-012024-02-01_us-gaap_SubsequentEventMember_custom_NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">STRM:NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-01</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-30_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_us-gaap_SubsequentEventMember_custom_ExceptDirectorsAndOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">STRM:ExceptDirectorsAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="From2024-02-062024-02-06_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-06_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_ThirdModificationLoanAgreementMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:ThirdModificationLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_ThirdModificationLoanAgreementMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">STRM:ThirdModificationLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_AprilThirtyTwoThousandAndTwentyFourMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_AprilThirtyTwoThousandAndTwentyFourMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandAndTwentyFourMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandAndTwentyFourMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandAndTwentyFourMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandAndTwentyFourMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFiveMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_AprilThirtyTwoThousandTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_AprilThirtyTwoThousandTwentyFiveMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandTwentyFiveMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandTwentyFiveMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_AprilThirtyTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:AprilThirtyTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JulyThirtyOneTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:OctoberThirtyOneTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFiveMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001008586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">STRM:JanuaryThirtyOneTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Integer">
        <measure>STRM:Integer</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-02-01to2024-01-31" id="Fact000004">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-02-01to2024-01-31" id="Fact000005">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-02-01to2024-01-31" id="Fact000006">0001008586</dei:EntityCentralIndexKey>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-01-31"
      id="xdx2ixbrl0086"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-01-31"
      id="xdx2ixbrl0131"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermLineOfCredit
      contextRef="AsOf2023-01-31"
      id="xdx2ixbrl0147"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2024-01-31"
      id="xdx2ixbrl0152"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-01-31"
      id="xdx2ixbrl0161"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-02-012023-01-31"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2022-02-012023-01-31"
      id="xdx2ixbrl0235"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-02-012023-01-31"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="From2022-02-012023-01-31"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <STRM:StockIssuedDuringPeriodValueSurrenderOfShares
      contextRef="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-02-012024-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-02-01to2024-01-31"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="From2023-02-012024-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="From2023-02-01to2024-01-31"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <STRM:StockIssuedDuringPeriodValueSurrenderOfShares
      contextRef="From2023-02-012024-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="From2023-02-012024-01-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-02-012024-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-02-012024-01-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-02-012023-01-31"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2022-02-012023-01-31"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-02-01to2024-01-31"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities
      contextRef="From2023-02-01to2024-01-31"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-02-01to2024-01-31"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2022-02-012023-01-31"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RestrictedStockExpense
      contextRef="From2023-02-01to2024-01-31"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <STRM:DeferredFinancingCosts
      contextRef="From2022-02-012023-01-31"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="From2023-02-01to2024-01-31"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="AsOf2024-01-31_us-gaap_LeaseholdImprovementsMember"
      id="xdx2ixbrl0599">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <STRM:AcquisitionEarnoutLiabilityFairValue
      contextRef="AsOf2024-01-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0647"
      unitRef="USD"
      xsi:nil="true"/>
    <STRM:AcquisitionEarnoutLiabilityFairValue
      contextRef="AsOf2024-01-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0649"
      unitRef="USD"
      xsi:nil="true"/>
    <STRM:AcquisitionEarnoutLiabilityFairValue
      contextRef="AsOf2023-01-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0655"
      unitRef="USD"
      xsi:nil="true"/>
    <STRM:AcquisitionEarnoutLiabilityFairValue
      contextRef="AsOf2023-01-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0657"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="AsOf2024-01-31_srt_MinimumMember"
      id="xdx2ixbrl0732">P1Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <STRM:EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks
      contextRef="From2023-02-01to2024-01-31"
      id="xdx2ixbrl0782"
      unitRef="Shares"
      xsi:nil="true"/>
    <STRM:EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks
      contextRef="From2022-02-012023-01-31"
      id="xdx2ixbrl0783"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-01-31_us-gaap_CostOfSalesMember"
      id="xdx2ixbrl0821"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-01-31_us-gaap_CostOfSalesMember"
      id="xdx2ixbrl0827"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      id="xdx2ixbrl0833"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-01-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      id="xdx2ixbrl0845"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-01-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      id="xdx2ixbrl0851"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-01-31_custom_SeveranceExpensesMember"
      id="xdx2ixbrl0857"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-01-31_custom_ProfessionalFeesMember"
      id="xdx2ixbrl0869"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-01-31_custom_ProfessionalFeesMember"
      id="xdx2ixbrl0875"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-01-31_custom_AccruedExpensesMember"
      id="xdx2ixbrl0881"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-02-01to2024-01-31"
      id="xdx2ixbrl1167"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2022-02-012023-01-31"
      id="xdx2ixbrl1168"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="AsOf2024-01-31"
      id="xdx2ixbrl1262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2024-01-31"
      id="xdx2ixbrl1268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="From2023-02-01to2024-01-31"
      id="xdx2ixbrl1301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="From2022-02-012023-01-31"
      id="xdx2ixbrl1305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-02-01to2024-01-31"
      id="xdx2ixbrl1381"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-02-01to2024-01-31"
      id="xdx2ixbrl1383"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-02-01to2024-01-31"
      id="xdx2ixbrl1385"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-02-01to2024-01-31"
      id="xdx2ixbrl1387"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-01-31"
      id="xdx2ixbrl1403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-01-31"
      id="xdx2ixbrl1411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2024-01-31"
      id="xdx2ixbrl1419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="From2023-02-01to2024-01-31"
      id="xdx2ixbrl1579"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="From2022-02-012023-01-31"
      id="xdx2ixbrl1583"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-02-01to2024-01-31" id="Fact000013">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-02-01to2024-01-31" id="Fact000014">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-02-01to2024-01-31" id="Fact000015">2024-01-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-02-01to2024-01-31" id="Fact000016">--01-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-02-01to2024-01-31" id="Fact000017">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-02-01to2024-01-31" id="Fact000018">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-02-01to2024-01-31" id="Fact000019">000-28132</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-02-01to2024-01-31" id="Fact000020">STREAMLINE HEALTH SOLUTIONS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-02-01to2024-01-31" id="Fact000021">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-02-01to2024-01-31" id="Fact000022">31-1455414</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-02-01to2024-01-31" id="Fact000023">2400 Old Milton Pkwy.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-02-01to2024-01-31" id="Fact000024">Box 1353</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-02-01to2024-01-31" id="Fact000025">Alpharetta</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-02-01to2024-01-31" id="Fact000026">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-02-01to2024-01-31" id="Fact000027">30009</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-02-01to2024-01-31" id="Fact000028">(888)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-02-01to2024-01-31" id="Fact000029">997-8732</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-02-01to2024-01-31" id="Fact000030">Common     Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-02-01to2024-01-31" id="Fact000031">STRM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-02-01to2024-01-31" id="Fact000032">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-02-01to2024-01-31" id="Fact000033">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2023-02-01to2024-01-31" id="Fact000034">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2023-02-01to2024-01-31" id="Fact000035">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-02-01to2024-01-31" id="Fact000036">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-02-01to2024-01-31" id="Fact000037">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-02-01to2024-01-31" id="Fact000038">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-02-01to2024-01-31" id="Fact000039">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2023-02-01to2024-01-31" id="Fact000040">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-02-01to2024-01-31" id="Fact000042">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2023-02-01to2024-01-31" id="Fact000043">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2023-07-31"
      decimals="0"
      id="Fact000044"
      unitRef="USD">57165443</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-04-26"
      decimals="INF"
      id="Fact000045"
      unitRef="Shares">65362533</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000047">Information
required by Part III is incorporated by reference from the Registrant&#x2019;s Proxy Statement for its 2024 annual meeting of stockholders
or an amendment to this Annual Report on Form 10-K, which will be filed with the Securities and Exchange Commission within 120 days after
the end of its fiscal year ended January 31, 2024</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName contextRef="From2023-02-01to2024-01-31" id="Fact000048">FORVIS, LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-02-01to2024-01-31" id="Fact000049">Atlanta, Georgia</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000057"
      unitRef="USD">3190000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000058"
      unitRef="USD">6598000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">86000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000065"
      unitRef="USD">132000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000060"
      unitRef="USD">4237000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000061"
      unitRef="USD">7719000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000067"
      unitRef="USD">780000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000068"
      unitRef="USD">960000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000070"
      unitRef="USD">629000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">710000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000073"
      unitRef="USD">8836000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">15987000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000082"
      unitRef="USD">291000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000084"
      unitRef="USD">246000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">88000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">79000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">32000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000091"
      unitRef="USD">7960000</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000092"
      unitRef="USD">6224000</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">5798000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">5846000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">4019000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">2627000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000094"
      unitRef="USD">12071000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000095"
      unitRef="USD">14793000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">13276000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">23089000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">1666000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000105"
      unitRef="USD">1695000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">32899000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">45534000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000110"
      unitRef="USD">41735000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000111"
      unitRef="USD">61521000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000119"
      unitRef="USD">1253000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000120"
      unitRef="USD">626000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000122"
      unitRef="USD">2023000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">3265000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000125"
      unitRef="USD">1500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000126"
      unitRef="USD">750000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000128"
      unitRef="USD">7112000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000129"
      unitRef="USD">8361000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000132"
      unitRef="USD">35000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000134"
      unitRef="USD">1794000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000135"
      unitRef="USD">3738000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000137"
      unitRef="USD">13682000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000138"
      unitRef="USD">16775000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLoansPayable
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000143"
      unitRef="USD">7566000</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermLoansPayable
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000144"
      unitRef="USD">8964000</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermLineOfCredit
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000146"
      unitRef="USD">1500000</us-gaap:LongTermLineOfCredit>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000149"
      unitRef="USD">173000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000150"
      unitRef="USD">167000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000153"
      unitRef="USD">104000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000155"
      unitRef="USD">9239000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000156"
      unitRef="USD">9235000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000158"
      unitRef="USD">22921000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000159"
      unitRef="USD">26010000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="Fact000170"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact000172"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="Fact000174"
      unitRef="Shares">85000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact000176"
      unitRef="Shares">85000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="Fact000178"
      unitRef="Shares">58945498</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="Fact000180"
      unitRef="Shares">58945498</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact000182"
      unitRef="Shares">57567210</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact000184"
      unitRef="Shares">57567210</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000167"
      unitRef="USD">590000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000168"
      unitRef="USD">576000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000186"
      unitRef="USD">133923000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000187"
      unitRef="USD">131973000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000189"
      unitRef="USD">-115699000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000190"
      unitRef="USD">-97038000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">18814000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000193"
      unitRef="USD">35511000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">41735000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000196"
      unitRef="USD">61521000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-02-012024-01-31_custom_SoftwareasAsAServiceMember"
      decimals="0"
      id="Fact000201"
      unitRef="USD">14075000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-02-012023-01-31_custom_SoftwareasAsAServiceMember"
      decimals="0"
      id="Fact000202"
      unitRef="USD">12326000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-02-012024-01-31_custom_MaintenanceAndSupportMember"
      decimals="0"
      id="Fact000204"
      unitRef="USD">4318000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-02-012023-01-31_custom_MaintenanceAndSupportMember"
      decimals="0"
      id="Fact000205"
      unitRef="USD">4483000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-02-012024-01-31_custom_ProfessionalFeesAndLicensesMember"
      decimals="0"
      id="Fact000207"
      unitRef="USD">4203000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-02-012023-01-31_custom_ProfessionalFeesAndLicensesMember"
      decimals="0"
      id="Fact000208"
      unitRef="USD">8080000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000210"
      unitRef="USD">22596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000211"
      unitRef="USD">24889000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <STRM:CostOfSoftwareAsService
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000216"
      unitRef="USD">6573000</STRM:CostOfSoftwareAsService>
    <STRM:CostOfSoftwareAsService
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000217"
      unitRef="USD">6358000</STRM:CostOfSoftwareAsService>
    <STRM:CostOfMaintenanceAndSupport
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000219"
      unitRef="USD">315000</STRM:CostOfMaintenanceAndSupport>
    <STRM:CostOfMaintenanceAndSupport
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000220"
      unitRef="USD">427000</STRM:CostOfMaintenanceAndSupport>
    <STRM:CostOfProfessionalFeesAndLicenses
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000222"
      unitRef="USD">4165000</STRM:CostOfProfessionalFeesAndLicenses>
    <STRM:CostOfProfessionalFeesAndLicenses
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000223"
      unitRef="USD">6610000</STRM:CostOfProfessionalFeesAndLicenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000225"
      unitRef="USD">14710000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000226"
      unitRef="USD">16283000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000228"
      unitRef="USD">5704000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000229"
      unitRef="USD">6042000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000231"
      unitRef="USD">9813000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000234"
      unitRef="USD">963000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000237"
      unitRef="USD">42243000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000238"
      unitRef="USD">35720000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000240"
      unitRef="USD">-19647000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000241"
      unitRef="USD">-10831000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000246"
      unitRef="USD">1071000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000247"
      unitRef="USD">749000</us-gaap:InterestExpense>
    <STRM:AcquisitionEarnoutValuationAdjustments
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000249"
      unitRef="USD">1944000</STRM:AcquisitionEarnoutValuationAdjustments>
    <STRM:AcquisitionEarnoutValuationAdjustments
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000250"
      unitRef="USD">71000</STRM:AcquisitionEarnoutValuationAdjustments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000252"
      unitRef="USD">31000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000253"
      unitRef="USD">201000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000255"
      unitRef="USD">-18743000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000256"
      unitRef="USD">-11308000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000258"
      unitRef="USD">-46000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000259"
      unitRef="USD">71000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000261"
      unitRef="USD">-18697000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000262"
      unitRef="USD">-11379000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-02-01to2024-01-31"
      decimals="INF"
      id="Fact000264"
      unitRef="USDPShares">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-02-01to2024-01-31"
      decimals="INF"
      id="Fact000266"
      unitRef="USDPShares">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-02-012023-01-31"
      decimals="INF"
      id="Fact000268"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-02-012023-01-31"
      decimals="INF"
      id="Fact000270"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-02-01to2024-01-31"
      decimals="INF"
      id="Fact000272"
      unitRef="Shares">56510419</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-02-01to2024-01-31"
      decimals="INF"
      id="Fact000274"
      unitRef="Shares">56510419</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-02-012023-01-31"
      decimals="INF"
      id="Fact000276"
      unitRef="Shares">49324858</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-02-012023-01-31"
      decimals="INF"
      id="Fact000278"
      unitRef="Shares">49324858</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000285"
      unitRef="Shares">47840950</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000280"
      unitRef="USD">478000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000281"
      unitRef="USD">119225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-01-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000282"
      unitRef="USD">-85659000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-01-31"
      decimals="0"
      id="Fact000283"
      unitRef="USD">34044000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000292"
      unitRef="Shares">5000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000288"
      unitRef="USD">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000290"
      unitRef="USD">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000299"
      unitRef="Shares">1876962</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000294"
      unitRef="USD">19000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000295"
      unitRef="USD">-19000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000306"
      unitRef="Shares">8171027</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000301"
      unitRef="USD">82000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000302"
      unitRef="USD">11246000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000304"
      unitRef="USD">11328000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000309"
      unitRef="USD">-52000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000311"
      unitRef="USD">-52000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000318"
      unitRef="Shares">199300</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000313"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000314"
      unitRef="USD">-2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <STRM:StockIssuedDuringPeriodSharesSurrenderOfShares
      contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000325"
      unitRef="Shares">127429</STRM:StockIssuedDuringPeriodSharesSurrenderOfShares>
    <STRM:StockIssuedDuringPeriodValueSurrenderOfShares
      contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000320"
      unitRef="USD">-1000</STRM:StockIssuedDuringPeriodValueSurrenderOfShares>
    <STRM:StockIssuedDuringPeriodValueSurrenderOfShares
      contextRef="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000321"
      unitRef="USD">-196000</STRM:StockIssuedDuringPeriodValueSurrenderOfShares>
    <STRM:StockIssuedDuringPeriodValueSurrenderOfShares
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000323"
      unitRef="USD">-197000</STRM:StockIssuedDuringPeriodValueSurrenderOfShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-02-012023-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000328"
      unitRef="USD">1761000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000330"
      unitRef="USD">1761000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-02-012023-01-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000334"
      unitRef="USD">-11379000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000335"
      unitRef="USD">-11379000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000342"
      unitRef="Shares">57567210</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000337"
      unitRef="USD">576000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000338"
      unitRef="USD">131973000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-01-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">-97038000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000340"
      unitRef="USD">35511000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000349"
      unitRef="Shares">57567210</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000344"
      unitRef="USD">576000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000345"
      unitRef="USD">131973000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-01-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000346"
      unitRef="USD">-97038000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000347"
      unitRef="USD">35511000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000356"
      unitRef="Shares">1947738</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000351"
      unitRef="USD">20000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-02-012024-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000352"
      unitRef="USD">-20000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000363"
      unitRef="Shares">378500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000358"
      unitRef="USD">4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="From2023-02-012024-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000359"
      unitRef="USD">-4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <STRM:StockIssuedDuringPeriodSharesSurrenderOfShares
      contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000370"
      unitRef="Shares">190950</STRM:StockIssuedDuringPeriodSharesSurrenderOfShares>
    <STRM:StockIssuedDuringPeriodValueSurrenderOfShares
      contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000365"
      unitRef="USD">-2000</STRM:StockIssuedDuringPeriodValueSurrenderOfShares>
    <STRM:StockIssuedDuringPeriodValueSurrenderOfShares
      contextRef="From2023-02-012024-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000366"
      unitRef="USD">-278000</STRM:StockIssuedDuringPeriodValueSurrenderOfShares>
    <STRM:StockIssuedDuringPeriodValueSurrenderOfShares
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000368"
      unitRef="USD">-280000</STRM:StockIssuedDuringPeriodValueSurrenderOfShares>
    <us-gaap:StockholdersEquityOther
      contextRef="From2023-02-012024-01-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000374"
      unitRef="USD">36000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000375"
      unitRef="USD">36000</us-gaap:StockholdersEquityOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-02-012024-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000378"
      unitRef="USD">2244000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000380"
      unitRef="USD">2244000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-02-012024-01-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000384"
      unitRef="USD">-18697000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000385"
      unitRef="USD">-18697000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000392"
      unitRef="Shares">58945498</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000387"
      unitRef="USD">590000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000388"
      unitRef="USD">133923000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-01-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000389"
      unitRef="USD">-115699000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000390"
      unitRef="USD">18814000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000399"
      unitRef="Shares">58945498</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000394"
      unitRef="USD">590000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000395"
      unitRef="USD">133923000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-01-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000396"
      unitRef="USD">-115699000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000397"
      unitRef="USD">18814000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000404"
      unitRef="USD">-18697000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000405"
      unitRef="USD">-11379000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000410"
      unitRef="USD">4331000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000411"
      unitRef="USD">4313000</us-gaap:DepreciationAndAmortization>
    <STRM:AcquisitionEarnoutValuationAdjustments
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000413"
      unitRef="USD">1944000</STRM:AcquisitionEarnoutValuationAdjustments>
    <STRM:AcquisitionEarnoutValuationAdjustments
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000414"
      unitRef="USD">71000</STRM:AcquisitionEarnoutValuationAdjustments>
    <STRM:ProvisionForDeferredIncomeTaxes
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000416"
      unitRef="USD">-104000</STRM:ProvisionForDeferredIncomeTaxes>
    <STRM:ProvisionForDeferredIncomeTaxes
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000417"
      unitRef="USD">9000</STRM:ProvisionForDeferredIncomeTaxes>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000419"
      unitRef="USD">2102000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000420"
      unitRef="USD">1680000</us-gaap:ShareBasedCompensation>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000422"
      unitRef="USD">9813000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000425"
      unitRef="USD">963000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000428"
      unitRef="USD">-10000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000429"
      unitRef="USD">189000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000434"
      unitRef="USD">-3708000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000435"
      unitRef="USD">4202000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000437"
      unitRef="USD">401000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000438"
      unitRef="USD">1197000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000440"
      unitRef="USD">544000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000441"
      unitRef="USD">-152000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000443"
      unitRef="USD">-1277000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000444"
      unitRef="USD">1069000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000446"
      unitRef="USD">-1243000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000447"
      unitRef="USD">2598000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000449"
      unitRef="USD">-2215000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000450"
      unitRef="USD">-7143000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000455"
      unitRef="USD">54000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000456"
      unitRef="USD">10000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToDevelopSoftware
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000458"
      unitRef="USD">1567000</us-gaap:PaymentsToDevelopSoftware>
    <us-gaap:PaymentsToDevelopSoftware
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000459"
      unitRef="USD">1925000</us-gaap:PaymentsToDevelopSoftware>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000461"
      unitRef="USD">-1621000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000462"
      unitRef="USD">-1935000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000468"
      unitRef="USD">8316000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000471"
      unitRef="USD">2012000</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000474"
      unitRef="USD">52000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000476"
      unitRef="USD">750000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000477"
      unitRef="USD">250000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000479"
      unitRef="USD">1500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000482"
      unitRef="USD">280000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000483"
      unitRef="USD">197000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000485"
      unitRef="USD">44000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000486"
      unitRef="USD">20000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000488"
      unitRef="USD">2000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000489"
      unitRef="USD">6000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000491"
      unitRef="USD">428000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000492"
      unitRef="USD">5791000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000494"
      unitRef="USD">-3408000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000495"
      unitRef="USD">-3287000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000497"
      unitRef="USD">6598000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-01-31"
      decimals="0"
      id="Fact000498"
      unitRef="USD">9885000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000500"
      unitRef="USD">3190000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000501"
      unitRef="USD">6598000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000506"
      unitRef="USD">989000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000507"
      unitRef="USD">651000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000509"
      unitRef="USD">66000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000510"
      unitRef="USD">23000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000512">&lt;p id="xdx_80A_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zA2UWp7zlpaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
1 &#x2014; &lt;span id="xdx_828_zms7fanVITki"&gt;ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Streamline
Health Solutions, Inc. and each of its wholly-owned subsidiaries, Streamline Health, LLC, Avelead Consulting, LLC, Streamline
Consulting Solutions, LLC and Streamline Pay &amp;amp; Benefits, LLC, (collectively, unless the context requires otherwise, &#x201c;we&#x201d;,
&#x201c;us&#x201d;, &#x201c;our&#x201d;, &#x201c;Streamline&#x201d;, or the &#x201c;Company&#x201d;) operates in one segment as a provider
of healthcare information technology solutions and associated services. The Company provides these capabilities through the
licensing of its Coding &amp;amp; CDI, eValuator coding analysis platform, RevID, and other workflow software applications and the use
of such applications by software as a service (&#x201c;SaaS&#x201d;). The Company also provides audit services to help clients
optimize their internal clinical documentation and coding functions, as well as implementation and consulting services to complement
its software solutions. The Company&#x2019;s software and services enable hospitals and integrated healthcare delivery systems in the
United States and Canada to capture, store, manage, route, retrieve and process patient clinical, financial and other healthcare
provider information related to the patient revenue cycle.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fiscal
Year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
references to a fiscal year refer to the fiscal year commencing February 1 in that calendar year and ending on January 31 of the following
calendar year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000514">&lt;p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zuoJOMT1riek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
2 &#x2014; &lt;span id="xdx_82D_zKMZYRenVXTh"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zBSu67ZrIzqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zMxyAnKWevrd"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of Streamline Health Solutions, Inc. and its wholly-owned subsidiaries, Streamline
Health, LLC, Avelead Consulting, LLC, Streamline Consulting Solutions, LLC and Streamline Pay &amp;amp; Benefits, LLC. All significant intercompany
transactions and balances are eliminated in consolidation. All amounts in the consolidated financial statements, notes and tables have
been rounded to the nearest thousand dollars, except share and per share amounts, unless otherwise indicated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has determined it has only one operating segment based on the guidance of &lt;i&gt;ASC 280-10-50 &lt;/i&gt;paragraphs 1 through 8, The Company
has a sole chief operating decision maker who reviews a single set of financials, information, has accountability for the performance
of the organization, and allocates resources to drive success.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
fiscal 2022, the Company had two reporting units for evaluation of goodwill: Streamline Solutions and Avelead Solutions. The Company
determined that, effective January 1, 2023, it has one reporting unit for purposes of evaluation of goodwill, which was used for evaluation
of goodwill for fiscal 2023. At the end of fiscal 2022, the Company consolidated and combined its operations for Streamline Solutions
and Avelead Solutions. For total assets at January 31, 2024 and 2023 and total revenue and net loss for the fiscal years ended January
31, 2024 and 2023, see our consolidated financial statements included in Part II, Item 8, &#x201c;Financial Statements and Supplementary
Data&#x201d; herein.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--GoingConcernPolicyTextBlock_z04TyckKPcLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zcBCCKzLHlv8"&gt;Going
Concern&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of obligations in the normal course of business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the Company&#x2019;s Quarterly Report on Form 10-Q for the period ended October 31, 2023, the Company raised substantial doubt about
its ability to continue as a going concern. It cited the &#x201c;ability to achieve cash from operations and raise additional debt or
equity capital to fund its ongoing operations&#x201d; as requirements to mitigate the substantial doubt. As of this filing, the
Company has been able to successfully implement a cost reduction plan, obtain additional capital, and restructure the covenants for
its existing credit facility. Collectively, these initiatives alleviated the substantial doubt about the Company&#x2019;s ability to continue as a going concern. Refer to the
&#x201c;Restructuring&#x201d; subtopic of this Note 1 (Organization and Description of Business) and Note 14 &#x2013; Subsequent Events
to our consolidated financial statements included in Part II, Item 8, &#x201c;Financial Statements and Supplementary Data&#x201d; for
additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zT18YACMCUE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zLdYdGtUBpJ7"&gt;Reclassification&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
amounts for fiscal 2022 were reclassified to conform to the current period classification. The Company incurred certain acquisition-related
costs related to the acquisition of Avelead totaling $&lt;span id="xdx_90C_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20230201__20240131_zLSxskQwCZpi" title="Acquisition related costs"&gt;149,000&lt;/span&gt; consisting primarily of professional service fees. The aforementioned acquisition-related
costs for fiscal 2022 were previously presented in a separate, single caption and are now included in selling, general, and administrative
expense in the accompanying condensed consolidated statements of operations, which is consistent with the presentation for the current
period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zYRzg40CSL39" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_z7lvcZppkJTa"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management
to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing
basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, stock-based compensation,
capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration and income
taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQN5GPYeb917" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zpKSz8Ifca33"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash demand deposits. Cash deposits
are placed in Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured financial institutions. Cash deposits may exceed FDIC
insured levels from time to time. For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company
considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Non-Cash
Items&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock_z1maRBLwUz69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had the following items that were non-cash items related to the consolidated statements of cash flows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zNqLG3nkHJTj" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230201__20240131_zurqW0nQ9sbh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220201__20230131_zEEvneV5twwa" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Fiscal Year&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RestrictedStockExpense_zog1qLL5VDyc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Payment of acquisition earnout liabilities in restricted common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0530"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,012,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--CapitalizedSoftwarePurchasedWithStock_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Capitalized software purchased with stock (&lt;i&gt;See Note 12&lt;/i&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredFinancingCosts_z5B0BQA42Im8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred financing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0537"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zY1Afzd2Ab5g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--TradeAndOtherAccountsReceivablePolicy_ztpdyWecksi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zFjauAPTw4g3"&gt;Receivables&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
and contract receivables are comprised of amounts owed to the Company for licensed software, professional services, including coding
audit services, consulting services, maintenance services, and software as a service and are presented net of the allowance for credit losses. The timing of revenue recognition may not coincide with the billing terms of the client contract, resulting in unbilled receivables
or deferred revenues; therefore, certain contract receivables represent revenues recognized prior to client billings. Individual contract
terms with clients or resellers determine when receivables are due. Accounts receivable represent amounts that the entity has an unconditional
right to consideration. For billings where the criteria for revenue recognition have not been met, deferred revenue is recorded until
the Company satisfies the respective performance obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--AllowanceForCreditLossesPolicyTextBlock_ze7ToCazvDBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zZjdgKK0Ieh1"&gt;Allowance
for Credit Losses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adjusts accounts receivable down to net realizable value. Effective February 1, 2023, the Company implemented ASC 326-10,
Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;CECL&#x201d;).
CECL provides the framework for the Company to evaluate its allowance for credit losses. In determining the
allowance for credit losses, the Company established a historical credit loss rate adjusted for a premium, addressing any
prospective changes to the risk of credit loss, that is applied against current sales. The Company evaluates individual receivables
based upon the most recent information available and the status of any open or unresolved issues with the client preventing the
payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables.
During these periodic reviews, significant judgement is required for the Company to determine the appropriate allowances for
doubtful accounts for estimated losses resulting from the unwillingness of its clients or resellers to make required payments. The
Company believes its reserve is adequate, however, results may differ in future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the changes to the allowance account with the adoption of CECL:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfRestructuringReserveByTypeOfCostTextBlock_zfqA1D3oTMu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zu0obzYOwHKb" style="display: none"&gt;SCHEDULE
OF RESERVE RESULTS IN FUTURE PERIODS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;CECL Adoption&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Provision adjustments&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Write-offs &amp;amp; Recoveries&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 31, 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 39%; text-align: left; padding-bottom: 1.5pt"&gt;Allowance for credit losses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20230201__20240131_z5AgnJ7s7tPl" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Balance"&gt;132,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--AllowanceForDoubtfulAccountsReceivableCECLAdoption_c20230201__20240131_zeIXWjucoLQ4" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, CECL Adoption"&gt;(36,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ProvisionForDoubtfulAccounts_c20230201__20240131_zUzIajVrro0k" style="border-bottom: Black 1.5pt solid; text-align: right; width: 9%; vertical-align: bottom" title="Allowance for credit losses, Provision adjustments"&gt;(10,000&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;)&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 2%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20230201__20240131_zZhmkzIUbMp2" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Write-offs &amp;amp; Recoveries"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0551"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20230201__20240131_zZ33ZyhBjhP5" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Balance"&gt;86,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zkt8sf5GfK1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--AccruedExpensesPolicyTextBlock_zAS3WcLE6cMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zEPilTYadTI9"&gt;Accrued
Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;&lt;p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zssA1ZOPLkr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zjVvaM2jJJZh" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF ACCRUED EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240131_zudJCphoE676" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230131_zZ3PQl6Hw3c3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;January 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedSalariesCurrent_iI_zqBBCbxfpXD5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Employee benefits and related compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt; 1,071,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,079,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedExchangeFeeRebateCurrentAndNoncurrent_iI_zw3eVdmgVRr7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Professional fees and services&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;389,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;294,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ThirdPartylicense_iI_zLPCmN1DR3Ol" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Third party licenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;285,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ConcessionAccrualAmount_iI_zg0nP7105bSd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Customer concessions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;233,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;226,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_zvCIgbXYJ7Ra" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;State income and sales taxes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;226,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;331,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InterestPayableCurrent_iI_z4i3QH3r3wQ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Interest, primarily on term loan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;61,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_iTI_zNtAGpNP6L76" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Total accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt; 2,023,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,265,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_ziQEqkTWZ7Nk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--ConcessionsAccrualPolicyTextBlock_zVUnlXdpFBWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zlO4ItNiqHx7"&gt;Concessions
Accrual&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company offers certain service level agreements within its client contracts such as uptime, support hours, and levels of support. Our
contracts may include, and we may offer, credits to clients when these service line agreements are not met. The service level agreements
are accounted for as variable consideration using a portfolio approach. As a result, we record an estimate of these concessions against
our recorded revenue. In determining the concessions accrual, the Company evaluates historical concessions granted relative to revenue
as well as future potential risk that these service level agreements will not be met. The Company records a provision, reducing revenue,
for the estimated amount of concessions incurred on the revenue recorded. The Company evaluates the amount of the concession accrual
each period for adequacy. Historically, concessions have not been significant. The concession accrual included in accrued expenses on
the Company&#x2019;s consolidated balance sheet was $&lt;span id="xdx_90F_ecustom--ConcessionAccrualAmount_iI_c20240131_zAOFCrXEIub6" title="Concession accrual amount"&gt;233,000&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--ConcessionAccrualAmount_iI_c20230131_zWGrpYfO73Rl" title="Concession accrual amount"&gt;226,000&lt;/span&gt; as of January 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zutAhpeflC7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zd2A8EaYq0yl"&gt;Property
and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--PropertyPlantAndEquipmentTableTextBlock_zC7KvXeAvWKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related
assets. Estimated useful lives are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_z81ryXv2b0Dk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    equipment and software&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember__srt--RangeAxis__srt--MinimumMember_z0N5TyjreMg1" title="Property and equipment, useful lives"&gt;3&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember__srt--RangeAxis__srt--MaximumMember_z7GCMwRYZIdk" title="Property and equipment, useful lives"&gt;4&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDDJAkGpKx3" title="Property and equipment, useful lives"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zNnHLxZxDsNd" title="Property and equipment, useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z8hTCuXJU7Ic" title="Property and equipment, useful lives"&gt;7&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zH8BRKAElZcc" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;Term
    of lease or estimated useful life, whichever is shorter&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_zyNmEEv8K9y2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense for property and equipment in fiscal 2023 and 2022 was $&lt;span id="xdx_90D_eus-gaap--Depreciation_pp0p0_c20230201__20240131_zQ9oaRDYoXqc" title="Depreciation expense"&gt;45,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--Depreciation_pp0p0_c20220201__20230131_zq7fFQ6ABi41" title="Depreciation expense"&gt;54,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Normal
repairs and maintenance are expensed as incurred. Replacements are capitalized and the property and equipment accounts are relieved of
the items being replaced or disposed of, if no longer of value. The related cost and accumulated depreciation of the disposed assets
are eliminated and any gain or loss on disposition is included in the results of operations in the year of disposal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zaelwKPvQTk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zAB09QPfEXra"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
determine whether an arrangement is a lease at inception. Right-of-use assets represent our right to use an underlying asset for the
lease term, and lease liabilities represent our obligation to make lease payments arising from the lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected
lease term. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our
obligation to make lease payments arising from the lease. Since our lease arrangements do not provide an implicit rate, we use our estimated
incremental borrowing rate for the expected remaining lease term at commencement date in determining the present value of future lease
payments. We recognize operating lease cost on a straight-line basis by aggregating any rent abatement with the total expected rental
payments and amortizing the expense ratably over the term of the lease. Sublease income is recognized as other income over the period
of the lease, as the sublease is outside of the Company&#x2019;s normal business operations. See Note 4 &#x2013; Operating Leases for further
details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--CostsIncurredPolicy_zkpabqXMLj52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zbj0NRIwpPY4"&gt;Debt
Issuance Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost
related to the Second Amended and Restated Loan and Security Agreement (as amended and modified, the &#x201c;Loan Agreement&#x201d;)
with Western Alliance Bank (&#x201c;WAB&#x201d;) was capitalized and amortized to interest expense on a straight-line basis, which is not materially different
from the effective interest method, over the term of the related debt, and presented on the Company&#x2019;s consolidated balance sheets
as a direct deduction from the carrying amount of the non-current portion of our term loan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zX8DXegzCyW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zs8Gtbk0U2t3"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews the carrying value of long-lived assets for impairment whenever facts and circumstances exist that would suggest that
assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation
are changes in market position and profitability. If facts and circumstances are present which may indicate that the carrying amount
of the assets may not be recoverable, the Company will prepare a projection of the undiscounted cash flows of the specific asset or asset
group and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment
will be made to reduce the carrying amount of these assets to their fair values. For fiscal 2023, an impairment of long-lived assets
in the amount of $963,000 was recorded. Refer to Note 6 &#x2013; Goodwill and Intangible Assets to our consolidated financial statements
included in Part II, Item 8, &#x201c;Financial Statements and Supplementary Data&#x201d; for additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_zF7a44pacboh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zwXJ9NUbrFKi"&gt;Capitalized
Software Development Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Software
development costs for software to be sold, leased, or marketed are accounted for in accordance with ASC 985-20, &lt;i&gt;Software &#x2014; Costs
of Software to be Sold, Leased or Marketed&lt;/i&gt;. Costs associated with the planning and design phase of software development are classified
as research and development costs and are expensed as incurred. Once technological feasibility has been established, a portion of the
costs incurred in development, including coding, testing and quality assurance, are capitalized until available for general release to
clients, and subsequently reported at the lower of unamortized cost or net realizable value. Amortization is calculated on a solution-by-solution
basis and is included in cost of professional fees and licenses on the consolidated statements of operations. Annual amortization is
measured at the greater of (i) the ratio of the software product&#x2019;s current gross revenues to the total of current and expected
gross revenues or (ii) straight-line over the remaining economic life of the software (typically two years). Unamortized capitalized
costs determined to be in excess of the net realizable value of a solution are expensed at the date of such determination. Capitalized
software development costs for software to be sold, leased, or marketed, net of accumulated amortization, totaled $&lt;span id="xdx_902_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SoftwareMember_z8hB6KTQk9M5" title="Capitalized software development costs, net of accumulated amortization"&gt;287,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20230131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SoftwareMember_zAXpZNJbSf9l" title="Capitalized software development costs, net of accumulated amortization"&gt;522,000&lt;/span&gt;
as of January 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Internal-use
software development costs are accounted for in accordance with ASC 350-40, &lt;i&gt;Internal-Use Software&lt;/i&gt;. The costs incurred in the preliminary
stages of development are expensed as research and development costs as incurred. Once an application has reached the development stage,
internal and external costs incurred to develop internal-use software are capitalized and amortized on a straight-line basis over the
estimated useful life of the software (typically three to four years). Maintenance and enhancement costs, including those costs in the
post-implementation stages, are typically expensed as incurred, unless such costs relate to substantial upgrades and enhancements to
the software that result in added functionality, in which case the costs are capitalized and amortized on a straight-line basis over
the estimated useful life of the software. The Company reviews the carrying value for impairment whenever facts and circumstances exist
that would suggest that assets might be impaired or that the useful lives should be modified. Amortization expense related to capitalized
internal-use software development costs is included in Cost of software as a service on the consolidated statements of operations. Capitalized
software development costs for internal-use software, net of accumulated amortization, totaled $&lt;span id="xdx_90E_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zOXhpu5ZLb8l" title="Capitalized software development costs, net of accumulated amortization"&gt;5,511,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20230131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zH2TNWGlNF9d" title="Capitalized software development costs, net of accumulated amortization"&gt;5,324,000&lt;/span&gt; as of January
31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives of software (including software to be sold and internal-use software) are reviewed frequently and adjusted as
appropriate to reflect upcoming development activities that may include significant upgrades and/or enhancements to the existing functionality.
The Company reviews, on an on-going basis, the carrying value of its capitalized software development expenditures, net of accumulated
amortization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense on all capitalized software development was $&lt;span id="xdx_900_eus-gaap--CapitalizedComputerSoftwareAmortization1_pp0p0_c20230201__20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zc4Hyffjbrol"&gt;2,463,000&lt;/span&gt; &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
$&lt;span id="xdx_905_eus-gaap--CapitalizedComputerSoftwareAmortization1_pp0p0_c20220201__20230131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zOk89cFM1Ls9"&gt;2,423,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in
fiscal 2023 and 2022, respectively. Further, the Company recognized an impairment of approximately $&lt;span id="xdx_907_eus-gaap--AssetImpairmentCharges_pp0p0_c20230201__20240131_zslU6fQnpVz9"&gt;18,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
$&lt;span id="xdx_90E_eus-gaap--AssetImpairmentCharges_pp0p0_c20220201__20230131_zw3eAPJdspS2"&gt;0 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in
fiscal 2023 and fiscal 2022, respectively, related to cancelled or abandoned enhancement projects during fiscal 2023 and fiscal 2022
that have been recognized within amortization expense. Additionally, in fiscal 2023, entries of approximately $&lt;span id="xdx_906_ecustom--AmortizedAndAbandonedAssets_pp0p0_c20230201__20240131_zfwYJdf0m7B7"&gt;18,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for
fully amortized and abandoned assets were offset from their corresponding capitalization and
accumulated amortization balance sheet accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses the &#x201c;carry-over&#x201d; method for amortizing capitalized software development costs. Under the &#x201c;carry-over&#x201d;
method, the costs of the enhancements are added to the unamortized costs of the previous version of the product and the combined amount
is amortized over the remaining useful life of the product. Including unamortized cost of the original product with the cost of the enhancement
for purposes of applying the net realizable value test and amortization provisions is consistent with accounting guidance for software
companies that improve their software and discontinue selling or marketing the older versions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"&gt;&lt;/p&gt;&lt;p id="xdx_898_ecustom--ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock_zyTJHWMBeMT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zhrv1Qznrut"&gt;SCHEDULE
OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230201__20240131_zQfxTl39hMgl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220201__20230131_zz7OEADW8UZj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Amortization expense on internally-developed software included in:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CapitalizedComputerSoftwareAmortization1_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfSoftwareAsASeviceMember_zcyQJUA5T4Pa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 68%; text-align: justify"&gt;Cost of software as a service&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,229,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,068,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareAmortization1_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfSoftwareAsASeviceMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfProfessionalFeesAndLicensesMember_zQTBEgFtBCWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Cost of professional fees and licenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;234,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;355,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CapitalizedComputerSoftwareAmortization1_zRiRX6M6htrb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt"&gt;Total amortization expense on internally-developed software&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,463,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,423,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zzFc3kastks3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
interest capitalized to software development cost reduces the Company&#x2019;s interest expense recognized in the consolidated statements
of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expense was $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230201__20240131_zssQTQhnUnt1" title="Research and development expense"&gt;5,704,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220201__20230131_z9G8p4mA0aH9" title="Research and development expense"&gt;6,042,000&lt;/span&gt; in fiscal 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z7tG6fNFobLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zbQxjSCMpnXj"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
FASB&#x2019;s authoritative guidance on fair value measurements establishes a framework for measuring fair value and expands
disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to
develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine
fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the
following three categories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1: Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2: Observable market-based inputs or unobservable inputs that are corroborated by market data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3: Unobservable inputs that are not corroborated by market data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based
on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. For fiscal 2023 and 2022,
there were no transfers of assets or liabilities between Levels 1, 2, or 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zxOrPn2IPCe5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below provides information on our liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zTMLbE3nRxHe" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total Fair&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Quoted Prices in&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Active Markets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Significant Other&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Observable Inputs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unobservable Inputs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;At January 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F46_zvAP6QeUHmKf" style="padding-left: 10pt; width: 36%; text-align: left"&gt;Acquisition earnout liability (1)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131_fKDEp_z6YHvUHgJQGh" style="width: 12%; text-align: right" title="Acquisition earnout liability, Fair Value"&gt;1,794,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zqleoxHBOC68" style="width: 12%; text-align: right" title="Acquisition earnout liability fair value"&gt;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEp_zYR5RNQPDAd6" style="width: 12%; text-align: right" title="Acquisition earn out liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fKDEp_zj6kL5TBNcA9" style="width: 12%; text-align: right" title="Acquisition earn out liability fair value, observable inputs"&gt;1,794,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;At January 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F4F_z7qG32tUQ7Ui" style="padding-left: 10pt; text-align: left"&gt;Acquisition earnout liability (1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131_fKDEp_z7lGordx0Joa" style="text-align: right" title="Acquisition earnout liability, Fair Value"&gt;3,738,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zlmP8WJ3vUs4" style="text-align: right" title="Acquisition earnout liability fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEp_zcRF96jDYkij" style="text-align: right" title="Acquisition earn out liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0657"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fKDEp_zKFbiSF0PWr6" style="text-align: right" title="Acquisition earn out liability fair value, observable inputs"&gt;3,738,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td id="xdx_F0D_zJGjjfpxLUhd" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zzAhJ0nNsIgj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    fair value of the acquisition earnout liability is based upon a probability-weighted discounted cash flow that was completed at the
    date of acquisition and updated as of January 31, 2024. The change in the fair value of the acquisition earnout liability decreased
    $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUgQVNTRVRTIEFORCBMSUFCSUxJVElFUyBNRUFTVVJFRCBPTiBSRUNVUlJJTkcgQkFTSVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--AcquisitionEarnoutLiabilityChangeInValuation_c20230201__20240131_z0jICDkaYQXh" title="Acquisition earnout liability, change in valuation"&gt;1,944,000&lt;/span&gt; for the year ended January 31, 2024, which is entirely recognized in &#x201c;Acquisition earnout valuation adjustments&#x201d;
    in the accompanying consolidated statement of operations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    probability-weighted discounted cash flow is calculated using a Monte Carlo valuation method. The valuation model provides numerous
    outcomes. The outcomes are averaged and discounted to present value, which provides the current value point estimate. The significant
    inputs include our forecast of Avelead SaaS revenue, the probabilities associated with each of (i) a change in control or (ii) a
    certain client termination, as well as other normal and customary inputs to financial models, including but not limited to, risk
    factors and interest rates.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_zApULSgz9ali" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s term loan under its Loan Agreement was determined through an analysis of the interest rate spread from
the date of closing the loan (August 2021) to the date of the most recent balance sheets, January 31, 2024 and January 31, 2023. The
term loan bears interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zAsaxSKShrR2" title="Prime interest rate"&gt;1.5&lt;/span&gt;%, with a Prime
&#x201c;floor&#x201d; rate of &lt;span id="xdx_90D_ecustom--PrimeInterestRatePercentage_pid_dp_uPure_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_z5xOTtlqE5H3" title="Prime interest rate percentage"&gt;3.25&lt;/span&gt;%. The prime rate is variable and, thus accommodates changes in the market interest rate. However, the
interest rate spread (the &lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131_zwxH5JQDtpE"&gt;1.5&lt;/span&gt;% added to the Prime Rate) is fixed. We estimated the impact of the changes in the interest rate spread
by analogizing the effect of the change in the Corporate bond rates, reduced for any changes in the market interest rate. This provided
us with an estimated change to the interest rate spread of approximately &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--TypeOfArrangementAxis__custom--SecondAmendedAndRestatedLoanAndSecurityAgreementMember_zizgfI88JDdc" title="Interest rate"&gt;0.5&lt;/span&gt;% from the date we entered the debt agreement to January
31, 2024 and January 31, 2023. The fair value of the debt as of January 31, 2024 and January 31, 2023 was estimated to be $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_zGvO65KA1klc" title="Debt instrument carrying amount"&gt;8,807,000&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_zFSdnLsbmjmb" title="Debt instrument carrying amount"&gt;9,550,000&lt;/span&gt;, respectively, or a discount to book value of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_z4wysqInh0nb" title="Term loan"&gt;193,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_zPpmQzcVJBDd" title="Term loan"&gt;200,000&lt;/span&gt;, respectively. The fair value of the line of credit
as of January 31, 2024 was estimated to be $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFjJDCqM5xMa" title="Debt instrument carrying amount"&gt;1,463,000&lt;/span&gt;, or a discount to book value of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z5ECMMfpfUK6" title="Term loan"&gt;37,000&lt;/span&gt;. The fair value of long-term debt was estimated using Level 2 inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z0La9yYYwfQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zwV0UXDf5CDf"&gt;Revenue
Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
derive revenue from the sale of internally-developed software, either by licensing for local installation or by a SaaS delivery model,
through our direct sales force or through third-party resellers. Licensed, locally-installed clients on a perpetual model utilize our
support and maintenance services for a separate fee, whereas term-based locally installed license fees and SaaS fees include support
and maintenance. We also derive revenue from professional services that support the implementation, configuration, training and optimization
of the applications, as well as audit services and consulting services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
recognize revenue in accordance with Accounting Standards Codification (ASC) 606, &lt;i&gt;Revenue from Contracts with Clients&lt;/i&gt; (&#x201c;ASC
606&#x201d;), under the core principle of recognizing revenue to depict the transfer of promised goods or services to clients in an amount
that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
commence revenue recognition (Step 5 below) in accordance with that core principle after applying the following steps:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
    1: Identify the contract(s) with a client&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
    2: Identify the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
    3: Determine the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
    4: Allocate the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
    5: Recognize revenue when (or as) the entity satisfies a performance obligation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Often
contracts contain more than one performance obligation. Performance obligations are the unit of accounting for revenue recognition and
generally represent the distinct goods or services that are promised to the client. Revenue is recognized net of any taxes collected
from clients and subsequently remitted to governmental authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
we determine that we have not satisfied a performance obligation, we defer recognition of the revenue until the performance obligation
is satisfied. Maintenance and support and SaaS agreements are generally non-cancellable or contain significant penalties for early cancellation,
although clients typically have the right to terminate their contracts for cause if we fail to perform material obligations. However,
if non-standard acceptance periods, non-standard performance criteria, or cancellation or right of refund terms are required, revenue
is recognized upon the satisfaction of such criteria.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
transaction price is determined by summing all the consideration the Company expects to receive from the client under the contract. At
times, a contract may have variable attributes (i.e., performance guarantees, service level agreements, optional terms) that the Company
must consider when establishing the transaction price to mitigate significant revenue reversals for the contract. The determined transaction
price is allocated based on the standalone selling price (&#x201c;SSP&#x201d;) of the performance obligations in contract. Significant
judgment is required to determine the SSP for each performance obligation, inclusion of variable consideration, the amount allocated
to each performance obligation and whether it depicts the amount that the Company expects to receive in exchange for the related product
and/or service. The Company recognizes revenue for implementation of its eValuator SaaS solution over the contract term, as it has been
determined that those implementation services are not a distinct performance obligation. Services for other SaaS and Software solutions
such as CDI, RevID and Compare, have been determined as a distinct performance obligation. For these agreements, the Company estimates
SSP of its software licenses using the residual approach when the software license is sold with other services and observable SSPs exist
for the other services. The Company estimates the SSP for maintenance, professional services, software as a service and audit services
based on observable standalone sales.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Contract
Combination&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may execute more than one contract or agreement with a single client. The Company evaluates whether the agreements were negotiated
as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance
of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions
reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related
to those arrangements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has utilized the portfolio approach as the practical expedient. We have applied the revenue model to a portfolio of contracts
with similar characteristics where we expected that the financial statements would not differ materially from applying it to the individual
contracts within that portfolio.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Software
Licenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s software license arrangements provide the client with the right to use functional intellectual property. Implementation,
support, and other services are typically considered distinct performance obligations when sold with a software license unless these
services are determined to significantly modify the software. Revenue is recognized at a point in time. Typically, this is upon shipment
of components or electronic download of software.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Maintenance
and Support Services&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
maintenance and support obligations include multiple discrete performance obligations, with the two largest being unspecified product
upgrades or enhancements, and technical support, which can be offered at various points during a contract period. We believe that the
multiple discrete performance obligations within our overall maintenance and support obligations can be viewed as a single performance
obligation since both the unspecified upgrades and technical support are activities to fulfill the maintenance performance obligation
and are rendered concurrently. Maintenance and support agreements entitle clients to technology support, version upgrades, bug fixes
and service packs. We recognize maintenance and support revenue over the contract term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Software-Based
Solution Professional Services&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides various professional services to clients with software licenses. These include project management, software implementation
and software modification services. Revenues from arrangements to provide professional services are generally distinct from the other
promises in the contract and are recognized as the related services are performed. Consideration payable under these arrangements is
either fixed fee or on a time-and-materials basis and is recognized over time as the services are performed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Software
as a Service&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SaaS-based
contracts include a right to use of the Company&#x2019;s platform and support which represent a single promise to provide continuous access
to its software solutions. Implementation services for the Company&#x2019;s eValuator product are included as part of the single promise
for its respective contracts. The Company recognizes revenue for implementation of the eValuator product over the contract term as it
is determined that the implementation on eValuator is not a distinct performance obligation. Implementation services for other SaaS products
are deemed to be separate performance obligations that are recognized over time as the services are performed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Audit
Services&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides technology-enabled coding audit services to help clients review and optimize their internal clinical documentation and
coding functions across the applicable segment of the client&#x2019;s enterprise. Audit services are a separate performance obligation.
We recognize revenue over time as the services are performed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Disaggregation
of Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_z0jY4a01NTw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides information about disaggregated revenue by type and nature of revenue stream:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zlMowoknXAu9" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF DISAGGREGATON OF REVENUE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230201__20240131_zXglfbiAOxt4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220201__20230131_zjOgp3IivuTh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zQhbKUjvP4Ig" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Over time revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;22,358,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;23,670,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zYqnLNCuvL5i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Point in time revenue&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;238,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,219,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zNl6JRI2goeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,596,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;24,889,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z571tbGvK3ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company includes revenue categories of (i) over time and (ii) point in time revenue. The Company includes revenue categories of (i) SaaS,
(ii) maintenance and support, (iii) professional services, and (iv) audit services as over time revenue. For point in time revenue, the
performance obligation is recognized as the point in time when the obligation is fully satisfied. The Company includes software licenses
as point in time revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Contract
Assets and Deferred Revenues&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company receives payments from clients based upon contractual billing schedules. Contract receivables include amounts related to the
Company&#x2019;s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenues include
payments received in advance of performance under the contract. Our contract receivables and deferred revenue are reported on an individual
contract basis at the end of each reporting period. Contract receivables are classified as current or noncurrent based on the timing
of when we expect to bill the client. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to
recognize revenue. In the year ended January 31, 2024, we recognized approximately $&lt;span id="xdx_904_eus-gaap--DeferredRevenue_iI_pp0p0_c20230131_zjvxR3hWRfE3" title="Deferred revenue"&gt;7,642,000&lt;/span&gt; in revenue from deferred revenues outstanding
as of January 31, 2023. Revenue allocated to remaining performance obligations was $&lt;span id="xdx_903_eus-gaap--RevenueRemainingPerformanceObligation_iI_pp0p0_c20240131_zzJQFtl5lLgi" title="Revenue remaining performance obligation"&gt;31,414,000&lt;/span&gt; &#160;&#160;as of January 31, 2024, of
which &lt;span id="xdx_90E_eus-gaap--RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_c20230201__20240131_zMKGqlhUohX1" title="Revenue, remaining performance obligation, expected timing of satisfaction, explanation"&gt;the Company expects to recognize approximately 46% over the next 12 months and the remainder thereafter.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Deferred
costs (costs to fulfill a contract and contract acquisition costs)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
defer the direct costs, which include salaries and benefits, for professional services related to SaaS contracts as a cost to fulfill
a contract. These deferred costs will be amortized on a straight-line basis over the contractual term. As of January 31, 2024, and 2023,
we had deferred costs of $&lt;span id="xdx_907_eus-gaap--DeferredCostsCurrentAndNoncurrent_iI_pp0p0_c20240131_zVdxuFx5yI48" title="Deferred costs, net"&gt;77,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--DeferredCostsCurrentAndNoncurrent_iI_pp0p0_c20230131_zfIOvjbI3BN" title="Deferred costs, net"&gt;94,000&lt;/span&gt;, respectively, net of accumulated amortization of $&lt;span id="xdx_905_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_pp0p0_c20240131_zXk7UyCFT7qd" title="Accumulated amortization of deferred costs"&gt;102,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_pp0p0_c20230131_zfuai8uwzf78" title="Accumulated amortization of deferred costs"&gt;176,000&lt;/span&gt;, respectively. Amortization
expense of these costs was $&lt;span id="xdx_90A_ecustom--DeferredCostsAmortizationExpenses_pp0p0_c20230201__20240131_z8JxABz7wmd9" title="Deferred costs, amortization expense"&gt;82,000&lt;/span&gt; and $&lt;span id="xdx_901_ecustom--DeferredCostsAmortizationExpenses_pp0p0_c20220201__20230131_zM3D3eB7wswd" title="Deferred costs, amortization expense"&gt;83,000&lt;/span&gt; in fiscal 2023 and 2022, respectively. There were no impairment losses for these capitalized
costs for the fiscal 2023 and 2022. Additionally, in fiscal 2023, approximately $&lt;span id="xdx_905_eus-gaap--OtherAmortizationOfDeferredCharges_pp0p0_c20230201__20240131_z0ccSphI8kFj" title="Amortized contracts"&gt;155,000&lt;/span&gt; of fully amortized contracts were cleared
from their corresponding capitalization and accumulated amortization balance sheet accounts, while no such adjustments were made in fiscal
2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contract
acquisition costs, which consist of sales commissions paid or payable, is considered incremental and recoverable costs of obtaining a
contract with a client. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis
over the contract term. As a practical expedient, we expense sales commissions as incurred when the amortization period of related deferred
commission costs would have been one year or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
commissions costs paid and payable, which are included on the consolidated balance sheets within other non-current assets totaled $&lt;span id="xdx_90E_ecustom--DeferredCommissionsCostsPaidAndPayable_iI_pp0p0_c20240131__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherNoncurrentAssetsMember_z6mG0uzfKR5b" title="Deferred commissions costs paid and payable"&gt;1,461,000&lt;/span&gt;
and $&lt;span id="xdx_907_ecustom--DeferredCommissionsCostsPaidAndPayable_iI_pp0p0_c20230131__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherNoncurrentAssetsMember_zp6gUZHH6ZN2" title="Deferred commissions costs paid and payable"&gt;1,534,000&lt;/span&gt;, respectively, as of January 31, 2024 and 2023. In fiscal 2023 and 2022, amortization expense associated with deferred
sales commissions was $&lt;span id="xdx_905_eus-gaap--AmortizationOfDeferredSalesCommissions_pp0p0_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zgWVS2cRmPA3" title="Amortization expense with deferred sales commissions"&gt;588,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--AmortizationOfDeferredSalesCommissions_pp0p0_c20220201__20230131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zC5wRguPWwcf" title="Amortization expense with deferred sales commissions"&gt;411,000&lt;/span&gt;, respectively, and was included in selling, general and administrative expenses on the consolidated
statements of operations. There were $&lt;span id="xdx_909_eus-gaap--CapitalizedContractCostImpairmentLoss_pp0p0_c20230201__20240131_zq6Lz5yN6ife" title="Impairment loss"&gt;35,000&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--CapitalizedContractCostImpairmentLoss_pp0p0_do_c20220201__20230131_zbNQzc4gtAk9" title="Impairment loss"&gt;no&lt;/span&gt; impairment losses for these capitalized costs that was included with the amortization
expense for fiscal 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zL8F4xbnR08b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zXy7zlnS4U5c"&gt;Concentrations&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments, which potentially expose the Company to concentrations of credit risk, consist primarily of accounts receivable. The Company&#x2019;s
accounts receivables are concentrated in the healthcare industry. However, the Company&#x2019;s clients typically are well-established
hospitals, medical facilities or major health information systems companies with good credit histories that resell the Company&#x2019;s
solutions. Payments from clients have been received within normal time frames for the industry. However, some hospitals and medical facilities
have experienced significant operating losses as a result of limits on third-party reimbursements from insurance companies and governmental
entities and extended payment of receivables from these entities is not uncommon.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
date, the Company has relied on a limited number of clients and remarketing partners for a substantial portion of its total revenues.
The Company expects that a significant portion of its future revenues will continue to be generated by a limited number of clients and
its remarketing partners.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zeAj1BAjGsyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zR3ftPEEQhza"&gt;Goodwill
and Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
and other intangible assets were recognized in conjunction with the Avelead acquisition, and certain other acquisitions from fiscal
2013 and prior (prior to divestiture of such assets). Identifiable intangible assets include purchased intangible assets with finite
lives, which primarily consist of internally-developed software and client relationships. Finite-lived purchased intangible assets
are amortized over their expected period of benefit, which generally ranges from &lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dxL_c20240131__srt--RangeAxis__srt--MinimumMember_zA4bGYLesFfg" title="Finite-lived intangible assets amortized period::XDX::P1Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0732"&gt;one&lt;/span&gt;&lt;/span&gt;
to &lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20240131__srt--RangeAxis__srt--MaximumMember_zBVML3cJc0Db" title="Finite-lived intangible assets amortized period"&gt;15&lt;/span&gt;
years, using the straight-line method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses the useful lives and possible impairment of intangible assets when an event occurs that may trigger such a review. Factors
considered important which could trigger a review include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant
    underperformance relative to historical or projected future operating results;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant
    changes in the manner of use of the acquired assets or the strategy for the overall business;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identification
    of other impaired assets within a reporting unit;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;disposition
    of a significant portion of an operating segment;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant
    negative industry or economic trends;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant
    decline in the Company&#x2019;s stock price for a sustained period; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a
    decline in the market capitalization relative to the net book value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determining
whether a triggering event has occurred involves significant judgment by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses goodwill annually (as of November 1), or more frequently when events and circumstances, such as the ones mentioned above,
occur indicating that the recorded goodwill may be impaired. In assessing qualitative factors to determine whether it is more likely
than not that the fair value of a reporting unit is less than its carrying amount, the Company assesses relevant events and circumstances
that may impact the fair value and the carrying amount of a reporting unit. The identification of relevant events and circumstances and
how these may impact a reporting unit&#x2019;s fair value or carrying amount involve significant judgments by management. These judgments
include the consideration of macroeconomic conditions, industry and market considerations, cost factors, overall financial performance,
events which are specific to the Company and trends in the market price of the Company&#x2019;s common stock. Each factor is assessed
to determine whether it impacts the impairment test positively or negatively, and the magnitude of any such impact.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended January 31, 2023, the Company did not note any of the above qualitative factors, which would be considered a triggering
event for goodwill impairment. During the year ended January 31, 2024, the Company identified one or more factors that triggered goodwill
impairment as of October 31, 2023, as described below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the third quarter of fiscal 2023, the Company received a notice from a significant SaaS client of its intent not to renew its contract
following the expiration of the current term on December 31, 2023. At that time, the Company elected to accelerate the execution of the
2023 Restructuring that was designed to reduce costs while maintaining the Company&#x2019;s ability to expand its SaaS business. Both
the client termination and the execution of the Strategic Restructuring were announced on October 16, 2023. Following these announcements,
the Company&#x2019;s share price declined significantly. Based on these events (collectively, the &#x201c;Triggering Events&#x201d;), the
Company identified indicators of possible impairment and initiated testing using a valuation date of October 31, 2023. The impairment
tests were conducted under guidance of ASC Topic 360, Impairment and Disposal of Long-Lived Assets (&#x201c;ASC 360&#x201d;) for certain
long-lived assets, including capitalized contract costs, developed technology, client relationships and trade names, and in accordance
with ASC Topic 350, Intangibles &#x2013; Goodwill and Other (&#x201c;ASC 350&#x201d;) with respect to the reporting unit&#x2019;s goodwill.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reporting
units are determined based on the organizational structure the entity has in place at the date of the impairment test. A reporting unit
is an operating segment or component business unit with the following characteristics: (a) it has discrete financial information, (b)
segment management regularly reviews its operating results (generally an operating segment has a segment manager who is directly accountable
to and maintains regular contact with the chief operating decision maker to discuss operating activities, financial results, forecasts
or plans for the segment), and (c) its economic characteristics are dissimilar from other units (this contemplates the nature of the
products and services, the nature of the production process, the type or class of client for the products and services and the methods
used to distribute the products and services). The Company determined that for fiscal 2023 it has one operating segment and one reporting
unit, while for fiscal 2022 it had one operating segment and two reporting units.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates the fair value of its reporting unit using a combination of the market approach and income approach, via
discounted cash flow valuation models which include, but are not limited to, assumptions such as a &#x201c;risk-free&#x201d; rate of
return on an investment, the weighted average cost of capital of a market participant and future revenue, operating margin, working
capital and capital expenditure trends. Determining the fair value of reporting units and goodwill includes significant judgment by
management, and different judgments could yield different results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company performed its annual goodwill assessment for fiscal 2023 as of October 31, 2023 using the approaches described above. The
assessment identified a goodwill impairment of $9,813,000 that was recorded. Based on the analysis performed for fiscal 2022, the fair
value of the reporting units exceeded the carrying amount of the reporting unit, including goodwill, and, therefore, a goodwill impairment
loss was not recognized. &#160; Refer to Note 6 &#x2013; Goodwill and Intangible Assets to our consolidated financial statements included
in Part II, Item 8, &#x201c;Financial Statements and Supplementary Data&#x201d; for additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--EquityAwardPolicyTextBlock_zKl6DDIRUcyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_za30GXIH31Ah"&gt;Equity
Awards&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as
expense over the requisite service period. For awards to non-employees, the Company recognizes compensation expense in the same
manner as if the entity had paid cash for the goods or services. The Company incurred total annual compensation expense related to
stock-based awards of $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230201__20240131__us-gaap--AwardTypeAxis__custom--EquityAwardMember_zH1uJNztuAL8" title="Compensation expense related to stock-based award"&gt;2,102,000&lt;/span&gt;
in fiscal 2023, net of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_c20230201__20240131__us-gaap--AwardTypeAxis__custom--EquityAwardMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zw4aTB8Ufp58" title="Compensation expense related to stock-based award"&gt;140,000&lt;/span&gt;
of capitalized non-employee stock compensation, and $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20220201__20230131__us-gaap--AwardTypeAxis__custom--EquityAwardMember_z74WRKZ8A4ye" title="Compensation expense related to stock-based award"&gt;1,680,000&lt;/span&gt;
net of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20220201__20230131__us-gaap--AwardTypeAxis__custom--EquityAwardMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMZp75ifhVhj" title="Compensation expense related to stock-based award"&gt;81,000&lt;/span&gt; of capitalized non-employee stock compensation, in fiscal 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the stock options granted are estimated at the date of grant using a Black-Scholes option pricing model. Option pricing
model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. The Company
recognizes forfeitures as they occur. These assumptions are subjective and are generally derived from external (such as, risk-free rate
of interest) and historical data (such as, volatility factor, expected term and forfeiture rates). Future grants of equity awards accounted
for as stock-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period
of future awards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market
close price per share on the grant date. The Company expenses the compensation cost of these awards as the restriction period
lapses, which is typically a one- to four-year service period to the Company. In fiscal 2023 and 2022, &lt;span id="xdx_903_ecustom--SurrenderOfStockSharesDuringPeriod_c20230201__20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztKBLwWQQkS" title="Surrender of stock, shares"&gt;190,950&lt;/span&gt;
and &lt;span id="xdx_90E_ecustom--SurrenderOfStockSharesDuringPeriod_c20220201__20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCzvG3cob019" title="Surrender of stock, shares"&gt;127,429&lt;/span&gt;
shares of common stock were surrendered to the Company to satisfy tax withholding obligations totaling $&lt;span id="xdx_901_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z9vP8EYbfCl1" title="Cost of shares for tax withholding"&gt;280,000&lt;/span&gt;
and $&lt;span id="xdx_908_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHWOF4tLnhYd" title="Cost of shares for tax withholding"&gt;197,000&lt;/span&gt;,
respectively, in connection with the vesting of restricted stock awards. Shares surrendered by the restricted stock award recipients
in accordance with the applicable plan are deemed cancelled, and therefore are not available to be reissued. The Company awarded &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230201__20240131__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zn293hzastO8" title="Number shares of restricted stock"&gt;1,203,621&lt;/span&gt;
and &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220201__20230131__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zz1WS8q7RpXb" title="Number shares of restricted stock"&gt;890,731&lt;/span&gt;
shares of restricted stock to its executive officers and directors of the Company in fiscal 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_z2Bp32guHuX7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zuOU4Xaz3zHi"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net
deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be
realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets
will not be realized. Refer to Note 7 &#x2013; Income Taxes to our consolidated financial statements included in Part II, Item 8, &#x201c;Financial
Statements and Supplementary Data&#x201d; for further details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether
certain tax positions are more likely than not to be sustained upon examination by tax authorities. At January 31, 2024, the Company
believes it has appropriately accounted for any uncertain tax positions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zdkEWKyw49A8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zOl7MFqG7GD1"&gt;Net
Earnings (Loss) Per Common Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company presents basic and diluted earnings per share (&#x201c;EPS&#x201d;) data for our common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
unvested restricted stock awards are considered non-participating securities because holders are not entitled to non-forfeitable rights
to dividends or dividend equivalents during the vesting term. In accordance with ASC 260, securities are deemed not to be participating
in losses if there is no obligation to fund such losses. Diluted EPS for our common stock is computed using the treasury stock method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zSKoGeFheh9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is the calculation of the basic and diluted net loss per share of common stock:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zm55lTHK41lc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230201__20240131_zT16hi7c2tZe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220201__20230131_zYEzhQSz4uQ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Basic earnings (loss) per share:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperations_i01_zBDKZfLAlsh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 2.5pt"&gt;Loss, net of tax&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;(18,697,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;(11,379,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_i01_zcADVlyaHmAd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Basic net loss per share of common stock &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Diluted earnings (loss) per share (1):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_i01_zrjqeeC06QW2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Loss available to common stockholders &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,697,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(11,379,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_i01_zHSqEJzPzmPh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Diluted net loss per share of common stock &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetIncomeLoss_zcStVat5IQg3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,697,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(11,379,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zGLtOkhm5wdg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average shares outstanding &#x2013; Basic (1)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F45_zYg8GXeSOw63" style="display: none"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,510,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,324,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks_pid_z9VIeZG2nNmb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effect of dilutive securities - Stock options and Restricted stock (2)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F4E_z505HyUzBWob" style="display: none"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0783"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zDqQ2pJbNI0e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average shares outstanding &#x2013; Diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;56,510,419&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;49,324,858&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EarningsPerShareBasic_pid_zMA0HSp97Zkj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Basic and diluted net loss per share of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zUrF65h71AU9"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zomVu3fzr7o6"&gt;(0.33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zaQNiVQiGZue"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zRmiwnEX7gW2"&gt;(0.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F0E_zl3tpEFjuksg" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F13_zbOLVzSiI5j4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Excludes
    the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of January 31, 2024
    and 2023, there were &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zOkiNJqczEvk" title="Diluted earnings per share"&gt;1,970,521&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z2lI0oNs2rt9" title="Diluted earnings per share"&gt;1,848,031&lt;/span&gt; unvested restricted shares of common stock, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F01_zJ3XaglWt9Ta" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F18_zqD6zjckRZpk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Diluted
    net loss per share excludes the effect of shares that are anti-dilutive. As of January 31, 2024, there were &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6ObtBNkGuq3" title="Diluted earnings per share"&gt;67,500&lt;/span&gt; outstanding stock
    options and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedSharesMember_z7x8lmNjloWl" title="Diluted earnings per share"&gt;1,970,521&lt;/span&gt; unvested restricted shares of common stock. As of January 31, 2023, there were &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zg2cyB4sQ6Wk" title="Diluted earnings per share"&gt;628,598&lt;/span&gt; outstanding stock options
    and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zKuhWu16S4uk" title="Diluted earnings per share"&gt;1,848,031&lt;/span&gt; unvested restricted shares of common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_z8jXXPKpkPg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zvZi28wtxQN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zumJhOzXsvw9"&gt;Loss
Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
are subject to the possibility of various loss contingencies arising in the normal course of business. We consider the likelihood of
the loss or impairment of an asset or the incurrence of a liability as well as our ability to reasonably estimate the amount of loss
in determining loss contingencies. An estimated loss contingency is accrued when it is probable that a liability has been incurred or
an asset has been impaired, and the amount of loss can be reasonably estimated. We regularly evaluate current information available to
us to determine whether to accrue for a loss contingency and adjust any previous accrual.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_zQ0wKmvymZw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zugotMys2zFf"&gt;Restructuring&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 16, 2023, the Company announced it was executing a Strategic Restructuring designed to reduce expenses while maintaining the
Company&#x2019;s ability to expand its SaaS business. The Strategic Restructuring initiatives included a reduction in force, resulting
in the termination of &lt;span id="xdx_908_ecustom--NumberOfEmployeesTerminated_iI_uInteger_c20231016_ztRLXFZsGe6k" title="Number of employees terminated"&gt;26&lt;/span&gt; employees, or approximately &lt;span id="xdx_90C_ecustom--PercentageOfWorkforceTerminated_iI_dp_uPure_c20231016_zCIaWNVmFlOl" title="Percentage of workforce terminated"&gt;24&lt;/span&gt;% of the Company&#x2019;s workforce. To execute the Strategic Restructuring, the
Company incurred one-time restructuring costs associated with the workforce reduction of approximately $&lt;span id="xdx_905_eus-gaap--RestructuringCosts_c20231016__20231016_zOntCOm1uCwk" title="Restructuring costs"&gt;759,000&lt;/span&gt;, and the Company has
recognized all expenses associated with the Strategic Restructuring as of the end of fiscal 2023. The costs pertain to severance and
other employee termination-related costs and various professional fees the Company required to assist with execution of the Strategic
Restructuring. The following is a reconciliation of the Strategic Restructuring liability reflected on the Company&#x2019;s condensed
consolidated balance sheet under &#x201c;Accrued expenses&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p id="xdx_89B_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_zcPd5Sclhq91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zVUN80vYpDjh" style="display: none"&gt;SCHEDULE OF RECONCILIATION OF THE
RESTRUCTURING LIABILITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of January 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Balance as of January 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 Expenses to Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 Cash Payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Balance as of January 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total Costs Incurred to Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total Expected Costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Severance expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 34%"&gt;Cost of sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zK31whEsQUl" style="width: 8%; text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0821"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zsRfRkAAqw71" style="width: 8%; text-align: right" title="2023 Expenses to Date"&gt;154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zcnAbrwMJzQa" style="width: 8%; text-align: right" title="2023 Cash Payments"&gt;154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z1XWbK9im3gh" style="width: 8%; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zb2xjwlXrNb4" style="width: 8%; text-align: right" title="Total Costs Incurred to Date"&gt;154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zFGeb8oZh734" style="width: 8%; text-align: right" title="Total Expected Costs"&gt;154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Selling, general, and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zgF3AlYQNYUi" style="text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0833"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zFKeiNiACPD5" style="text-align: right" title="2023 Expenses to Date"&gt;350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zlGv358wxWZ9" style="text-align: right" title="2023 Cash Payments"&gt;276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zwjns1Y39W3j" style="text-align: right" title="Accrued Balance as of October 31, 2023"&gt;74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zqiRzO1j4id2" style="text-align: right" title="Total Costs Incurred to Date"&gt;350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zm3HYOaSlDqi" style="text-align: right" title="Total Expected Costs"&gt;350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zy3QuKboUiOk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0845"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUNiTrqAejec" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Expenses to Date"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4NPCwihCzLj" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Cash Payments"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zuMRQ6AL6PJf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0851"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgrKQdtRzK87" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Costs Incurred to Date"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z7In9BvhxtD8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Expected Costs"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total severance expense&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zcGYDLCzhqB2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zFdNqBp0GSDf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Expenses to Date"&gt;731&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zbwd77jepsYj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Cash Payments"&gt;657&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zwEck8mknhDi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"&gt;74&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zFr7ZMv4ErYc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Costs Incurred to Date"&gt;731&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zqrWNVOuH3bk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Expected Costs"&gt;731&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Professional fees&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zdCAEngK0Gh6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0869"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zSWcGLNkZwgd" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Expenses to Date"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zUTCupmUPFGg" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Cash Payments"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zbnlHH6m9rwd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0875"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zsWSpXRo7Mkg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Costs Incurred to Date"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zlKYj9LQchU5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Expected Costs"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_z5PZIGP8Azf2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0881"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zyRdI1Qbma37" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Expenses to Date"&gt;759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zMmuGj9t21Bk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Cash Payments"&gt;685&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zhqpQ87SlXH6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"&gt;74&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zeQHXKBypUL1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Costs Incurred to Date"&gt;759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zKbmG4cP32U4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Expected Costs"&gt;759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zRFfSpqmEYml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z1THQ0hFrhN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zikcQEMVG2X"&gt;Accounting
Pronouncements Recently Adopted&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2019, the FASB issued ASU 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which improves guidance around accounting for financial losses on accounts receivable. For smaller reporting entities, ASU
2016-13 is effective for annual periods beginning after December 15, 2022, including interim periods within those fiscal years. The Company&#x2019;s
adoption of ASU 2016-13 was effective February 1, 2023. An analysis of contract receivables, including credit losses, was conducted during
the first quarter of fiscal 2024. The adoption of this ASU did not have a material impact on our consolidated financial statements
or disclosures.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zbwSureRh1pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zZlBtIO4H9M6"&gt;Recent
Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves
guidance around the disclosures about a public entity&#x2019;s reportable segments and additional details about a reportable segment&#x2019;s
expenses. ASU 2023-07 is effective for all public entities for annual periods beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. The Company&#x2019;s adoption of ASU 2023-07 will be effective in the annual report
for the fiscal year ending January 31, 2025. The adoption of this ASU is not expected to have a material impact on our consolidated financial
statements or disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhance the transparency
and decision usefulness of income tax disclosures. For public entities, ASU 2023-09 is effective for annual periods beginning after December
15, 2024. The adoption of this ASU is not expected to have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_859_zOFzDldd3uXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000516">&lt;p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zBSu67ZrIzqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zMxyAnKWevrd"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of Streamline Health Solutions, Inc. and its wholly-owned subsidiaries, Streamline
Health, LLC, Avelead Consulting, LLC, Streamline Consulting Solutions, LLC and Streamline Pay &amp;amp; Benefits, LLC. All significant intercompany
transactions and balances are eliminated in consolidation. All amounts in the consolidated financial statements, notes and tables have
been rounded to the nearest thousand dollars, except share and per share amounts, unless otherwise indicated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has determined it has only one operating segment based on the guidance of &lt;i&gt;ASC 280-10-50 &lt;/i&gt;paragraphs 1 through 8, The Company
has a sole chief operating decision maker who reviews a single set of financials, information, has accountability for the performance
of the organization, and allocates resources to drive success.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
fiscal 2022, the Company had two reporting units for evaluation of goodwill: Streamline Solutions and Avelead Solutions. The Company
determined that, effective January 1, 2023, it has one reporting unit for purposes of evaluation of goodwill, which was used for evaluation
of goodwill for fiscal 2023. At the end of fiscal 2022, the Company consolidated and combined its operations for Streamline Solutions
and Avelead Solutions. For total assets at January 31, 2024 and 2023 and total revenue and net loss for the fiscal years ended January
31, 2024 and 2023, see our consolidated financial statements included in Part II, Item 8, &#x201c;Financial Statements and Supplementary
Data&#x201d; herein.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <STRM:GoingConcernPolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000518">&lt;p id="xdx_842_ecustom--GoingConcernPolicyTextBlock_z04TyckKPcLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zcBCCKzLHlv8"&gt;Going
Concern&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of obligations in the normal course of business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the Company&#x2019;s Quarterly Report on Form 10-Q for the period ended October 31, 2023, the Company raised substantial doubt about
its ability to continue as a going concern. It cited the &#x201c;ability to achieve cash from operations and raise additional debt or
equity capital to fund its ongoing operations&#x201d; as requirements to mitigate the substantial doubt. As of this filing, the
Company has been able to successfully implement a cost reduction plan, obtain additional capital, and restructure the covenants for
its existing credit facility. Collectively, these initiatives alleviated the substantial doubt about the Company&#x2019;s ability to continue as a going concern. Refer to the
&#x201c;Restructuring&#x201d; subtopic of this Note 1 (Organization and Description of Business) and Note 14 &#x2013; Subsequent Events
to our consolidated financial statements included in Part II, Item 8, &#x201c;Financial Statements and Supplementary Data&#x201d; for
additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</STRM:GoingConcernPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2023-02-01to2024-01-31" id="Fact000520">&lt;p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zT18YACMCUE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zLdYdGtUBpJ7"&gt;Reclassification&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
amounts for fiscal 2022 were reclassified to conform to the current period classification. The Company incurred certain acquisition-related
costs related to the acquisition of Avelead totaling $&lt;span id="xdx_90C_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20230201__20240131_zLSxskQwCZpi" title="Acquisition related costs"&gt;149,000&lt;/span&gt; consisting primarily of professional service fees. The aforementioned acquisition-related
costs for fiscal 2022 were previously presented in a separate, single caption and are now included in selling, general, and administrative
expense in the accompanying condensed consolidated statements of operations, which is consistent with the presentation for the current
period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000522"
      unitRef="USD">149000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:UseOfEstimates contextRef="From2023-02-01to2024-01-31" id="Fact000524">&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zYRzg40CSL39" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_z7lvcZppkJTa"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management
to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing
basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, stock-based compensation,
capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration and income
taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000526">&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQN5GPYeb917" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zpKSz8Ifca33"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash demand deposits. Cash deposits
are placed in Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured financial institutions. Cash deposits may exceed FDIC
insured levels from time to time. For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company
considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Non-Cash
Items&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock_z1maRBLwUz69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had the following items that were non-cash items related to the consolidated statements of cash flows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zNqLG3nkHJTj" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230201__20240131_zurqW0nQ9sbh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220201__20230131_zEEvneV5twwa" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Fiscal Year&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RestrictedStockExpense_zog1qLL5VDyc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Payment of acquisition earnout liabilities in restricted common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0530"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,012,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--CapitalizedSoftwarePurchasedWithStock_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Capitalized software purchased with stock (&lt;i&gt;See Note 12&lt;/i&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredFinancingCosts_z5B0BQA42Im8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred financing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0537"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zY1Afzd2Ab5g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <STRM:ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000528">&lt;p id="xdx_89F_ecustom--ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock_z1maRBLwUz69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had the following items that were non-cash items related to the consolidated statements of cash flows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zNqLG3nkHJTj" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF NON-CASH ITEMS RELATED TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230201__20240131_zurqW0nQ9sbh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220201__20230131_zEEvneV5twwa" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Fiscal Year&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RestrictedStockExpense_zog1qLL5VDyc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Payment of acquisition earnout liabilities in restricted common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0530"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,012,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--CapitalizedSoftwarePurchasedWithStock_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Capitalized software purchased with stock (&lt;i&gt;See Note 12&lt;/i&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredFinancingCosts_z5B0BQA42Im8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred financing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0537"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</STRM:ScheduleOfNoncashItemsRelatedToCashFlowTableTextBlock>
    <us-gaap:RestrictedStockExpense
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000531"
      unitRef="USD">3012000</us-gaap:RestrictedStockExpense>
    <STRM:CapitalizedSoftwarePurchasedWithStock
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000533"
      unitRef="USD">140000</STRM:CapitalizedSoftwarePurchasedWithStock>
    <STRM:CapitalizedSoftwarePurchasedWithStock
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000534"
      unitRef="USD">81000</STRM:CapitalizedSoftwarePurchasedWithStock>
    <STRM:DeferredFinancingCosts
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000536"
      unitRef="USD">83000</STRM:DeferredFinancingCosts>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2023-02-01to2024-01-31" id="Fact000539">&lt;p id="xdx_84B_eus-gaap--TradeAndOtherAccountsReceivablePolicy_ztpdyWecksi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zFjauAPTw4g3"&gt;Receivables&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
and contract receivables are comprised of amounts owed to the Company for licensed software, professional services, including coding
audit services, consulting services, maintenance services, and software as a service and are presented net of the allowance for credit losses. The timing of revenue recognition may not coincide with the billing terms of the client contract, resulting in unbilled receivables
or deferred revenues; therefore, certain contract receivables represent revenues recognized prior to client billings. Individual contract
terms with clients or resellers determine when receivables are due. Accounts receivable represent amounts that the entity has an unconditional
right to consideration. For billings where the criteria for revenue recognition have not been met, deferred revenue is recorded until
the Company satisfies the respective performance obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <STRM:AllowanceForCreditLossesPolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000541">&lt;p id="xdx_841_ecustom--AllowanceForCreditLossesPolicyTextBlock_ze7ToCazvDBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zZjdgKK0Ieh1"&gt;Allowance
for Credit Losses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adjusts accounts receivable down to net realizable value. Effective February 1, 2023, the Company implemented ASC 326-10,
Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;CECL&#x201d;).
CECL provides the framework for the Company to evaluate its allowance for credit losses. In determining the
allowance for credit losses, the Company established a historical credit loss rate adjusted for a premium, addressing any
prospective changes to the risk of credit loss, that is applied against current sales. The Company evaluates individual receivables
based upon the most recent information available and the status of any open or unresolved issues with the client preventing the
payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables.
During these periodic reviews, significant judgement is required for the Company to determine the appropriate allowances for
doubtful accounts for estimated losses resulting from the unwillingness of its clients or resellers to make required payments. The
Company believes its reserve is adequate, however, results may differ in future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the changes to the allowance account with the adoption of CECL:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfRestructuringReserveByTypeOfCostTextBlock_zfqA1D3oTMu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zu0obzYOwHKb" style="display: none"&gt;SCHEDULE
OF RESERVE RESULTS IN FUTURE PERIODS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;CECL Adoption&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Provision adjustments&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Write-offs &amp;amp; Recoveries&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 31, 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 39%; text-align: left; padding-bottom: 1.5pt"&gt;Allowance for credit losses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20230201__20240131_z5AgnJ7s7tPl" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Balance"&gt;132,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--AllowanceForDoubtfulAccountsReceivableCECLAdoption_c20230201__20240131_zeIXWjucoLQ4" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, CECL Adoption"&gt;(36,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ProvisionForDoubtfulAccounts_c20230201__20240131_zUzIajVrro0k" style="border-bottom: Black 1.5pt solid; text-align: right; width: 9%; vertical-align: bottom" title="Allowance for credit losses, Provision adjustments"&gt;(10,000&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;)&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 2%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20230201__20240131_zZhmkzIUbMp2" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Write-offs &amp;amp; Recoveries"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0551"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20230201__20240131_zZ33ZyhBjhP5" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Balance"&gt;86,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zkt8sf5GfK1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</STRM:AllowanceForCreditLossesPolicyTextBlock>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000543">&lt;p id="xdx_891_eus-gaap--ScheduleOfRestructuringReserveByTypeOfCostTextBlock_zfqA1D3oTMu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zu0obzYOwHKb" style="display: none"&gt;SCHEDULE
OF RESERVE RESULTS IN FUTURE PERIODS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;CECL Adoption&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Provision adjustments&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Write-offs &amp;amp; Recoveries&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 31, 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 39%; text-align: left; padding-bottom: 1.5pt"&gt;Allowance for credit losses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20230201__20240131_z5AgnJ7s7tPl" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Balance"&gt;132,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--AllowanceForDoubtfulAccountsReceivableCECLAdoption_c20230201__20240131_zeIXWjucoLQ4" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, CECL Adoption"&gt;(36,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ProvisionForDoubtfulAccounts_c20230201__20240131_zUzIajVrro0k" style="border-bottom: Black 1.5pt solid; text-align: right; width: 9%; vertical-align: bottom" title="Allowance for credit losses, Provision adjustments"&gt;(10,000&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;)&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 2%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20230201__20240131_zZhmkzIUbMp2" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Write-offs &amp;amp; Recoveries"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0551"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20230201__20240131_zZ33ZyhBjhP5" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Allowance for credit losses, Balance"&gt;86,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000545"
      unitRef="USD">132000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <STRM:AllowanceForDoubtfulAccountsReceivableCECLAdoption
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000547"
      unitRef="USD">-36000</STRM:AllowanceForDoubtfulAccountsReceivableCECLAdoption>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">-10000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000553"
      unitRef="USD">86000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <STRM:AccruedExpensesPolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000555">&lt;p id="xdx_843_ecustom--AccruedExpensesPolicyTextBlock_zAS3WcLE6cMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zEPilTYadTI9"&gt;Accrued
Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;&lt;p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zssA1ZOPLkr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zjVvaM2jJJZh" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF ACCRUED EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240131_zudJCphoE676" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230131_zZ3PQl6Hw3c3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;January 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedSalariesCurrent_iI_zqBBCbxfpXD5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Employee benefits and related compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt; 1,071,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,079,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedExchangeFeeRebateCurrentAndNoncurrent_iI_zw3eVdmgVRr7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Professional fees and services&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;389,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;294,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ThirdPartylicense_iI_zLPCmN1DR3Ol" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Third party licenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;285,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ConcessionAccrualAmount_iI_zg0nP7105bSd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Customer concessions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;233,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;226,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_zvCIgbXYJ7Ra" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;State income and sales taxes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;226,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;331,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InterestPayableCurrent_iI_z4i3QH3r3wQ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Interest, primarily on term loan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;61,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_iTI_zNtAGpNP6L76" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Total accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt; 2,023,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,265,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_ziQEqkTWZ7Nk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</STRM:AccruedExpensesPolicyTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000557">&lt;p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zssA1ZOPLkr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zjVvaM2jJJZh" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF ACCRUED EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240131_zudJCphoE676" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230131_zZ3PQl6Hw3c3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;January 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedSalariesCurrent_iI_zqBBCbxfpXD5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Employee benefits and related compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt; 1,071,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,079,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedExchangeFeeRebateCurrentAndNoncurrent_iI_zw3eVdmgVRr7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Professional fees and services&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;389,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;294,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ThirdPartylicense_iI_zLPCmN1DR3Ol" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Third party licenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;285,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ConcessionAccrualAmount_iI_zg0nP7105bSd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Customer concessions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;233,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;226,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_zvCIgbXYJ7Ra" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;State income and sales taxes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;226,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;331,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InterestPayableCurrent_iI_z4i3QH3r3wQ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Interest, primarily on term loan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;61,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_iTI_zNtAGpNP6L76" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Total accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt; 2,023,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,265,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000559"
      unitRef="USD">1071000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000560"
      unitRef="USD">2079000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedExchangeFeeRebateCurrentAndNoncurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000562"
      unitRef="USD">389000</us-gaap:AccruedExchangeFeeRebateCurrentAndNoncurrent>
    <us-gaap:AccruedExchangeFeeRebateCurrentAndNoncurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000563"
      unitRef="USD">294000</us-gaap:AccruedExchangeFeeRebateCurrentAndNoncurrent>
    <STRM:ThirdPartylicense
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000565"
      unitRef="USD">43000</STRM:ThirdPartylicense>
    <STRM:ThirdPartylicense
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000566"
      unitRef="USD">285000</STRM:ThirdPartylicense>
    <STRM:ConcessionAccrualAmount
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000568"
      unitRef="USD">233000</STRM:ConcessionAccrualAmount>
    <STRM:ConcessionAccrualAmount
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000569"
      unitRef="USD">226000</STRM:ConcessionAccrualAmount>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000571"
      unitRef="USD">226000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000572"
      unitRef="USD">331000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000574"
      unitRef="USD">61000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000575"
      unitRef="USD">50000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000577"
      unitRef="USD">2023000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000578"
      unitRef="USD">3265000</us-gaap:AccruedLiabilitiesCurrent>
    <STRM:ConcessionsAccrualPolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000580">&lt;p id="xdx_844_ecustom--ConcessionsAccrualPolicyTextBlock_zVUnlXdpFBWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zlO4ItNiqHx7"&gt;Concessions
Accrual&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company offers certain service level agreements within its client contracts such as uptime, support hours, and levels of support. Our
contracts may include, and we may offer, credits to clients when these service line agreements are not met. The service level agreements
are accounted for as variable consideration using a portfolio approach. As a result, we record an estimate of these concessions against
our recorded revenue. In determining the concessions accrual, the Company evaluates historical concessions granted relative to revenue
as well as future potential risk that these service level agreements will not be met. The Company records a provision, reducing revenue,
for the estimated amount of concessions incurred on the revenue recorded. The Company evaluates the amount of the concession accrual
each period for adequacy. Historically, concessions have not been significant. The concession accrual included in accrued expenses on
the Company&#x2019;s consolidated balance sheet was $&lt;span id="xdx_90F_ecustom--ConcessionAccrualAmount_iI_c20240131_zAOFCrXEIub6" title="Concession accrual amount"&gt;233,000&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--ConcessionAccrualAmount_iI_c20230131_zWGrpYfO73Rl" title="Concession accrual amount"&gt;226,000&lt;/span&gt; as of January 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</STRM:ConcessionsAccrualPolicyTextBlock>
    <STRM:ConcessionAccrualAmount
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000582"
      unitRef="USD">233000</STRM:ConcessionAccrualAmount>
    <STRM:ConcessionAccrualAmount
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000584"
      unitRef="USD">226000</STRM:ConcessionAccrualAmount>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000586">&lt;p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zutAhpeflC7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zd2A8EaYq0yl"&gt;Property
and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--PropertyPlantAndEquipmentTableTextBlock_zC7KvXeAvWKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related
assets. Estimated useful lives are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_z81ryXv2b0Dk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    equipment and software&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember__srt--RangeAxis__srt--MinimumMember_z0N5TyjreMg1" title="Property and equipment, useful lives"&gt;3&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember__srt--RangeAxis__srt--MaximumMember_z7GCMwRYZIdk" title="Property and equipment, useful lives"&gt;4&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDDJAkGpKx3" title="Property and equipment, useful lives"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zNnHLxZxDsNd" title="Property and equipment, useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z8hTCuXJU7Ic" title="Property and equipment, useful lives"&gt;7&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zH8BRKAElZcc" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;Term
    of lease or estimated useful life, whichever is shorter&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_zyNmEEv8K9y2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense for property and equipment in fiscal 2023 and 2022 was $&lt;span id="xdx_90D_eus-gaap--Depreciation_pp0p0_c20230201__20240131_zQ9oaRDYoXqc" title="Depreciation expense"&gt;45,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--Depreciation_pp0p0_c20220201__20230131_zq7fFQ6ABi41" title="Depreciation expense"&gt;54,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Normal
repairs and maintenance are expensed as incurred. Replacements are capitalized and the property and equipment accounts are relieved of
the items being replaced or disposed of, if no longer of value. The related cost and accumulated depreciation of the disposed assets
are eliminated and any gain or loss on disposition is included in the results of operations in the year of disposal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <STRM:PropertyPlantAndEquipmentTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000588">&lt;p id="xdx_891_ecustom--PropertyPlantAndEquipmentTableTextBlock_zC7KvXeAvWKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related
assets. Estimated useful lives are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_z81ryXv2b0Dk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    equipment and software&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember__srt--RangeAxis__srt--MinimumMember_z0N5TyjreMg1" title="Property and equipment, useful lives"&gt;3&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember__srt--RangeAxis__srt--MaximumMember_z7GCMwRYZIdk" title="Property and equipment, useful lives"&gt;4&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDDJAkGpKx3" title="Property and equipment, useful lives"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zNnHLxZxDsNd" title="Property and equipment, useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z8hTCuXJU7Ic" title="Property and equipment, useful lives"&gt;7&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zH8BRKAElZcc" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;Term
    of lease or estimated useful life, whichever is shorter&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</STRM:PropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-01-31_custom_ComputerEquipmentAndSoftwareMember_srt_MinimumMember"
      id="Fact000590">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-01-31_custom_ComputerEquipmentAndSoftwareMember_srt_MaximumMember"
      id="Fact000592">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-01-31_us-gaap_OfficeEquipmentMember"
      id="Fact000594">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-01-31_custom_OfficeFurnitureAndFixturesMember_srt_MinimumMember"
      id="Fact000596">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-01-31_custom_OfficeFurnitureAndFixturesMember_srt_MaximumMember"
      id="Fact000598">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000601"
      unitRef="USD">45000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000603"
      unitRef="USD">54000</us-gaap:Depreciation>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000605">&lt;p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zaelwKPvQTk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zAB09QPfEXra"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
determine whether an arrangement is a lease at inception. Right-of-use assets represent our right to use an underlying asset for the
lease term, and lease liabilities represent our obligation to make lease payments arising from the lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected
lease term. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our
obligation to make lease payments arising from the lease. Since our lease arrangements do not provide an implicit rate, we use our estimated
incremental borrowing rate for the expected remaining lease term at commencement date in determining the present value of future lease
payments. We recognize operating lease cost on a straight-line basis by aggregating any rent abatement with the total expected rental
payments and amortizing the expense ratably over the term of the lease. Sublease income is recognized as other income over the period
of the lease, as the sublease is outside of the Company&#x2019;s normal business operations. See Note 4 &#x2013; Operating Leases for further
details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CostsIncurredPolicy contextRef="From2023-02-01to2024-01-31" id="Fact000607">&lt;p id="xdx_844_eus-gaap--CostsIncurredPolicy_zkpabqXMLj52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zbj0NRIwpPY4"&gt;Debt
Issuance Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost
related to the Second Amended and Restated Loan and Security Agreement (as amended and modified, the &#x201c;Loan Agreement&#x201d;)
with Western Alliance Bank (&#x201c;WAB&#x201d;) was capitalized and amortized to interest expense on a straight-line basis, which is not materially different
from the effective interest method, over the term of the related debt, and presented on the Company&#x2019;s consolidated balance sheets
as a direct deduction from the carrying amount of the non-current portion of our term loan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CostsIncurredPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000609">&lt;p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zX8DXegzCyW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zs8Gtbk0U2t3"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews the carrying value of long-lived assets for impairment whenever facts and circumstances exist that would suggest that
assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation
are changes in market position and profitability. If facts and circumstances are present which may indicate that the carrying amount
of the assets may not be recoverable, the Company will prepare a projection of the undiscounted cash flows of the specific asset or asset
group and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment
will be made to reduce the carrying amount of these assets to their fair values. For fiscal 2023, an impairment of long-lived assets
in the amount of $963,000 was recorded. Refer to Note 6 &#x2013; Goodwill and Intangible Assets to our consolidated financial statements
included in Part II, Item 8, &#x201c;Financial Statements and Supplementary Data&#x201d; for additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000611">&lt;p id="xdx_845_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_zF7a44pacboh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zwXJ9NUbrFKi"&gt;Capitalized
Software Development Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Software
development costs for software to be sold, leased, or marketed are accounted for in accordance with ASC 985-20, &lt;i&gt;Software &#x2014; Costs
of Software to be Sold, Leased or Marketed&lt;/i&gt;. Costs associated with the planning and design phase of software development are classified
as research and development costs and are expensed as incurred. Once technological feasibility has been established, a portion of the
costs incurred in development, including coding, testing and quality assurance, are capitalized until available for general release to
clients, and subsequently reported at the lower of unamortized cost or net realizable value. Amortization is calculated on a solution-by-solution
basis and is included in cost of professional fees and licenses on the consolidated statements of operations. Annual amortization is
measured at the greater of (i) the ratio of the software product&#x2019;s current gross revenues to the total of current and expected
gross revenues or (ii) straight-line over the remaining economic life of the software (typically two years). Unamortized capitalized
costs determined to be in excess of the net realizable value of a solution are expensed at the date of such determination. Capitalized
software development costs for software to be sold, leased, or marketed, net of accumulated amortization, totaled $&lt;span id="xdx_902_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SoftwareMember_z8hB6KTQk9M5" title="Capitalized software development costs, net of accumulated amortization"&gt;287,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20230131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SoftwareMember_zAXpZNJbSf9l" title="Capitalized software development costs, net of accumulated amortization"&gt;522,000&lt;/span&gt;
as of January 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Internal-use
software development costs are accounted for in accordance with ASC 350-40, &lt;i&gt;Internal-Use Software&lt;/i&gt;. The costs incurred in the preliminary
stages of development are expensed as research and development costs as incurred. Once an application has reached the development stage,
internal and external costs incurred to develop internal-use software are capitalized and amortized on a straight-line basis over the
estimated useful life of the software (typically three to four years). Maintenance and enhancement costs, including those costs in the
post-implementation stages, are typically expensed as incurred, unless such costs relate to substantial upgrades and enhancements to
the software that result in added functionality, in which case the costs are capitalized and amortized on a straight-line basis over
the estimated useful life of the software. The Company reviews the carrying value for impairment whenever facts and circumstances exist
that would suggest that assets might be impaired or that the useful lives should be modified. Amortization expense related to capitalized
internal-use software development costs is included in Cost of software as a service on the consolidated statements of operations. Capitalized
software development costs for internal-use software, net of accumulated amortization, totaled $&lt;span id="xdx_90E_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zOXhpu5ZLb8l" title="Capitalized software development costs, net of accumulated amortization"&gt;5,511,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_pp0p0_c20230131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zH2TNWGlNF9d" title="Capitalized software development costs, net of accumulated amortization"&gt;5,324,000&lt;/span&gt; as of January
31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives of software (including software to be sold and internal-use software) are reviewed frequently and adjusted as
appropriate to reflect upcoming development activities that may include significant upgrades and/or enhancements to the existing functionality.
The Company reviews, on an on-going basis, the carrying value of its capitalized software development expenditures, net of accumulated
amortization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense on all capitalized software development was $&lt;span id="xdx_900_eus-gaap--CapitalizedComputerSoftwareAmortization1_pp0p0_c20230201__20240131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zc4Hyffjbrol"&gt;2,463,000&lt;/span&gt; &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
$&lt;span id="xdx_905_eus-gaap--CapitalizedComputerSoftwareAmortization1_pp0p0_c20220201__20230131__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zOk89cFM1Ls9"&gt;2,423,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in
fiscal 2023 and 2022, respectively. Further, the Company recognized an impairment of approximately $&lt;span id="xdx_907_eus-gaap--AssetImpairmentCharges_pp0p0_c20230201__20240131_zslU6fQnpVz9"&gt;18,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
$&lt;span id="xdx_90E_eus-gaap--AssetImpairmentCharges_pp0p0_c20220201__20230131_zw3eAPJdspS2"&gt;0 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in
fiscal 2023 and fiscal 2022, respectively, related to cancelled or abandoned enhancement projects during fiscal 2023 and fiscal 2022
that have been recognized within amortization expense. Additionally, in fiscal 2023, entries of approximately $&lt;span id="xdx_906_ecustom--AmortizedAndAbandonedAssets_pp0p0_c20230201__20240131_zfwYJdf0m7B7"&gt;18,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for
fully amortized and abandoned assets were offset from their corresponding capitalization and
accumulated amortization balance sheet accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses the &#x201c;carry-over&#x201d; method for amortizing capitalized software development costs. Under the &#x201c;carry-over&#x201d;
method, the costs of the enhancements are added to the unamortized costs of the previous version of the product and the combined amount
is amortized over the remaining useful life of the product. Including unamortized cost of the original product with the cost of the enhancement
for purposes of applying the net realizable value test and amortization provisions is consistent with accounting guidance for software
companies that improve their software and discontinue selling or marketing the older versions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"&gt;&lt;/p&gt;&lt;p id="xdx_898_ecustom--ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock_zyTJHWMBeMT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zhrv1Qznrut"&gt;SCHEDULE
OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230201__20240131_zQfxTl39hMgl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220201__20230131_zz7OEADW8UZj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Amortization expense on internally-developed software included in:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CapitalizedComputerSoftwareAmortization1_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfSoftwareAsASeviceMember_zcyQJUA5T4Pa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 68%; text-align: justify"&gt;Cost of software as a service&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,229,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,068,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareAmortization1_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfSoftwareAsASeviceMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfProfessionalFeesAndLicensesMember_zQTBEgFtBCWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Cost of professional fees and licenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;234,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;355,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CapitalizedComputerSoftwareAmortization1_zRiRX6M6htrb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt"&gt;Total amortization expense on internally-developed software&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,463,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,423,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zzFc3kastks3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
interest capitalized to software development cost reduces the Company&#x2019;s interest expense recognized in the consolidated statements
of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expense was $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230201__20240131_zssQTQhnUnt1" title="Research and development expense"&gt;5,704,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220201__20230131_z9G8p4mA0aH9" title="Research and development expense"&gt;6,042,000&lt;/span&gt; in fiscal 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization
      contextRef="AsOf2024-01-31_custom_SoftwareMember"
      decimals="0"
      id="Fact000613"
      unitRef="USD">287000</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization
      contextRef="AsOf2023-01-31_custom_SoftwareMember"
      decimals="0"
      id="Fact000615"
      unitRef="USD">522000</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization
      contextRef="AsOf2024-01-31_custom_InternalUseSoftwareMember"
      decimals="0"
      id="Fact000617"
      unitRef="USD">5511000</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization
      contextRef="AsOf2023-01-31_custom_InternalUseSoftwareMember"
      decimals="0"
      id="Fact000619"
      unitRef="USD">5324000</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="From2023-02-012024-01-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      id="Fact000620"
      unitRef="USD">2463000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="From2022-02-012023-01-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      id="Fact000621"
      unitRef="USD">2423000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000622"
      unitRef="USD">18000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000623"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <STRM:AmortizedAndAbandonedAssets
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000624"
      unitRef="USD">18000</STRM:AmortizedAndAbandonedAssets>
    <STRM:ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000626">&lt;p id="xdx_898_ecustom--ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock_zyTJHWMBeMT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zhrv1Qznrut"&gt;SCHEDULE
OF AMORTIZATION EXPENSE FOR INTERNALLY DEVELOPED SOFTWARE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230201__20240131_zQfxTl39hMgl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220201__20230131_zz7OEADW8UZj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Amortization expense on internally-developed software included in:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CapitalizedComputerSoftwareAmortization1_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfSoftwareAsASeviceMember_zcyQJUA5T4Pa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 68%; text-align: justify"&gt;Cost of software as a service&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,229,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,068,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareAmortization1_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfSoftwareAsASeviceMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--CostOfProfessionalFeesAndLicensesMember_zQTBEgFtBCWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Cost of professional fees and licenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;234,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;355,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CapitalizedComputerSoftwareAmortization1_zRiRX6M6htrb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt"&gt;Total amortization expense on internally-developed software&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,463,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,423,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</STRM:ScheduleOfAmortizationExpenseForInternallyDevelopedSoftwareTableTextBlock>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="From2023-02-012024-01-31_custom_CostOfSoftwareAsASeviceMember"
      decimals="0"
      id="Fact000628"
      unitRef="USD">2229000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="From2022-02-012023-01-31_custom_CostOfSoftwareAsASeviceMember"
      decimals="0"
      id="Fact000629"
      unitRef="USD">2068000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="From2023-02-012024-01-31_custom_CostOfProfessionalFeesAndLicensesMember"
      decimals="0"
      id="Fact000631"
      unitRef="USD">234000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="From2022-02-012023-01-31_custom_CostOfProfessionalFeesAndLicensesMember"
      decimals="0"
      id="Fact000632"
      unitRef="USD">355000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000634"
      unitRef="USD">2463000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000635"
      unitRef="USD">2423000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000637"
      unitRef="USD">5704000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000639"
      unitRef="USD">6042000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-02-01to2024-01-31" id="Fact000641">&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z7tG6fNFobLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zbQxjSCMpnXj"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
FASB&#x2019;s authoritative guidance on fair value measurements establishes a framework for measuring fair value and expands
disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to
develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine
fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the
following three categories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1: Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2: Observable market-based inputs or unobservable inputs that are corroborated by market data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3: Unobservable inputs that are not corroborated by market data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based
on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. For fiscal 2023 and 2022,
there were no transfers of assets or liabilities between Levels 1, 2, or 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zxOrPn2IPCe5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below provides information on our liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zTMLbE3nRxHe" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total Fair&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Quoted Prices in&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Active Markets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Significant Other&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Observable Inputs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unobservable Inputs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;At January 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F46_zvAP6QeUHmKf" style="padding-left: 10pt; width: 36%; text-align: left"&gt;Acquisition earnout liability (1)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131_fKDEp_z6YHvUHgJQGh" style="width: 12%; text-align: right" title="Acquisition earnout liability, Fair Value"&gt;1,794,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zqleoxHBOC68" style="width: 12%; text-align: right" title="Acquisition earnout liability fair value"&gt;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEp_zYR5RNQPDAd6" style="width: 12%; text-align: right" title="Acquisition earn out liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fKDEp_zj6kL5TBNcA9" style="width: 12%; text-align: right" title="Acquisition earn out liability fair value, observable inputs"&gt;1,794,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;At January 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F4F_z7qG32tUQ7Ui" style="padding-left: 10pt; text-align: left"&gt;Acquisition earnout liability (1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131_fKDEp_z7lGordx0Joa" style="text-align: right" title="Acquisition earnout liability, Fair Value"&gt;3,738,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zlmP8WJ3vUs4" style="text-align: right" title="Acquisition earnout liability fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEp_zcRF96jDYkij" style="text-align: right" title="Acquisition earn out liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0657"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fKDEp_zKFbiSF0PWr6" style="text-align: right" title="Acquisition earn out liability fair value, observable inputs"&gt;3,738,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td id="xdx_F0D_zJGjjfpxLUhd" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zzAhJ0nNsIgj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    fair value of the acquisition earnout liability is based upon a probability-weighted discounted cash flow that was completed at the
    date of acquisition and updated as of January 31, 2024. The change in the fair value of the acquisition earnout liability decreased
    $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUgQVNTRVRTIEFORCBMSUFCSUxJVElFUyBNRUFTVVJFRCBPTiBSRUNVUlJJTkcgQkFTSVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--AcquisitionEarnoutLiabilityChangeInValuation_c20230201__20240131_z0jICDkaYQXh" title="Acquisition earnout liability, change in valuation"&gt;1,944,000&lt;/span&gt; for the year ended January 31, 2024, which is entirely recognized in &#x201c;Acquisition earnout valuation adjustments&#x201d;
    in the accompanying consolidated statement of operations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    probability-weighted discounted cash flow is calculated using a Monte Carlo valuation method. The valuation model provides numerous
    outcomes. The outcomes are averaged and discounted to present value, which provides the current value point estimate. The significant
    inputs include our forecast of Avelead SaaS revenue, the probabilities associated with each of (i) a change in control or (ii) a
    certain client termination, as well as other normal and customary inputs to financial models, including but not limited to, risk
    factors and interest rates.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_zApULSgz9ali" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s term loan under its Loan Agreement was determined through an analysis of the interest rate spread from
the date of closing the loan (August 2021) to the date of the most recent balance sheets, January 31, 2024 and January 31, 2023. The
term loan bears interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zAsaxSKShrR2" title="Prime interest rate"&gt;1.5&lt;/span&gt;%, with a Prime
&#x201c;floor&#x201d; rate of &lt;span id="xdx_90D_ecustom--PrimeInterestRatePercentage_pid_dp_uPure_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_z5xOTtlqE5H3" title="Prime interest rate percentage"&gt;3.25&lt;/span&gt;%. The prime rate is variable and, thus accommodates changes in the market interest rate. However, the
interest rate spread (the &lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131_zwxH5JQDtpE"&gt;1.5&lt;/span&gt;% added to the Prime Rate) is fixed. We estimated the impact of the changes in the interest rate spread
by analogizing the effect of the change in the Corporate bond rates, reduced for any changes in the market interest rate. This provided
us with an estimated change to the interest rate spread of approximately &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--TypeOfArrangementAxis__custom--SecondAmendedAndRestatedLoanAndSecurityAgreementMember_zizgfI88JDdc" title="Interest rate"&gt;0.5&lt;/span&gt;% from the date we entered the debt agreement to January
31, 2024 and January 31, 2023. The fair value of the debt as of January 31, 2024 and January 31, 2023 was estimated to be $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_zGvO65KA1klc" title="Debt instrument carrying amount"&gt;8,807,000&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_zFSdnLsbmjmb" title="Debt instrument carrying amount"&gt;9,550,000&lt;/span&gt;, respectively, or a discount to book value of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_z4wysqInh0nb" title="Term loan"&gt;193,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember_zPpmQzcVJBDd" title="Term loan"&gt;200,000&lt;/span&gt;, respectively. The fair value of the line of credit
as of January 31, 2024 was estimated to be $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFjJDCqM5xMa" title="Debt instrument carrying amount"&gt;1,463,000&lt;/span&gt;, or a discount to book value of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtAgreementMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z5ECMMfpfUK6" title="Term loan"&gt;37,000&lt;/span&gt;. The fair value of long-term debt was estimated using Level 2 inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000643">&lt;p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zxOrPn2IPCe5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below provides information on our liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zTMLbE3nRxHe" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total Fair&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Quoted Prices in&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Active Markets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Significant Other&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Observable Inputs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unobservable Inputs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;At January 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F46_zvAP6QeUHmKf" style="padding-left: 10pt; width: 36%; text-align: left"&gt;Acquisition earnout liability (1)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131_fKDEp_z6YHvUHgJQGh" style="width: 12%; text-align: right" title="Acquisition earnout liability, Fair Value"&gt;1,794,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zqleoxHBOC68" style="width: 12%; text-align: right" title="Acquisition earnout liability fair value"&gt;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEp_zYR5RNQPDAd6" style="width: 12%; text-align: right" title="Acquisition earn out liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20240131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fKDEp_zj6kL5TBNcA9" style="width: 12%; text-align: right" title="Acquisition earn out liability fair value, observable inputs"&gt;1,794,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;At January 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F4F_z7qG32tUQ7Ui" style="padding-left: 10pt; text-align: left"&gt;Acquisition earnout liability (1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131_fKDEp_z7lGordx0Joa" style="text-align: right" title="Acquisition earnout liability, Fair Value"&gt;3,738,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zlmP8WJ3vUs4" style="text-align: right" title="Acquisition earnout liability fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEp_zcRF96jDYkij" style="text-align: right" title="Acquisition earn out liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0657"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--AcquisitionEarnoutLiabilityFairValue_iI_c20230131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fKDEp_zKFbiSF0PWr6" style="text-align: right" title="Acquisition earn out liability fair value, observable inputs"&gt;3,738,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td id="xdx_F0D_zJGjjfpxLUhd" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zzAhJ0nNsIgj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    fair value of the acquisition earnout liability is based upon a probability-weighted discounted cash flow that was completed at the
    date of acquisition and updated as of January 31, 2024. The change in the fair value of the acquisition earnout liability decreased
    $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUgQVNTRVRTIEFORCBMSUFCSUxJVElFUyBNRUFTVVJFRCBPTiBSRUNVUlJJTkcgQkFTSVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--AcquisitionEarnoutLiabilityChangeInValuation_c20230201__20240131_z0jICDkaYQXh" title="Acquisition earnout liability, change in valuation"&gt;1,944,000&lt;/span&gt; for the year ended January 31, 2024, which is entirely recognized in &#x201c;Acquisition earnout valuation adjustments&#x201d;
    in the accompanying consolidated statement of operations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    probability-weighted discounted cash flow is calculated using a Monte Carlo valuation method. The valuation model provides numerous
    outcomes. The outcomes are averaged and discounted to present value, which provides the current value point estimate. The significant
    inputs include our forecast of Avelead SaaS revenue, the probabilities associated with each of (i) a change in control or (ii) a
    certain client termination, as well as other normal and customary inputs to financial models, including but not limited to, risk
    factors and interest rates.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <STRM:AcquisitionEarnoutLiabilityFairValue
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000645"
      unitRef="USD">1794000</STRM:AcquisitionEarnoutLiabilityFairValue>
    <STRM:AcquisitionEarnoutLiabilityFairValue
      contextRef="AsOf2024-01-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000651"
      unitRef="USD">1794000</STRM:AcquisitionEarnoutLiabilityFairValue>
    <STRM:AcquisitionEarnoutLiabilityFairValue
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000653"
      unitRef="USD">3738000</STRM:AcquisitionEarnoutLiabilityFairValue>
    <STRM:AcquisitionEarnoutLiabilityFairValue
      contextRef="AsOf2023-01-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000659"
      unitRef="USD">3738000</STRM:AcquisitionEarnoutLiabilityFairValue>
    <STRM:AcquisitionEarnoutLiabilityChangeInValuation
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000662"
      unitRef="USD">1944000</STRM:AcquisitionEarnoutLiabilityChangeInValuation>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-01-31_custom_SecurityAgreementMember"
      decimals="INF"
      id="Fact000664"
      unitRef="Pure">0.015</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <STRM:PrimeInterestRatePercentage
      contextRef="From2023-02-012024-01-31_custom_SecurityAgreementMember"
      decimals="INF"
      id="Fact000666"
      unitRef="Pure">0.0325</STRM:PrimeInterestRatePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="Fact000667"
      unitRef="Pure">0.015</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-01-31_custom_SecondAmendedAndRestatedLoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact000669"
      unitRef="Pure">0.005</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-01-31_custom_DebtAgreementMember"
      decimals="0"
      id="Fact000671"
      unitRef="USD">8807000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-01-31_custom_DebtAgreementMember"
      decimals="0"
      id="Fact000673"
      unitRef="USD">9550000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-01-31_custom_DebtAgreementMember"
      decimals="0"
      id="Fact000675"
      unitRef="USD">193000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-01-31_custom_DebtAgreementMember"
      decimals="0"
      id="Fact000677"
      unitRef="USD">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-01-31_custom_DebtAgreementMember_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact000679"
      unitRef="USD">1463000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-01-31_custom_DebtAgreementMember_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact000681"
      unitRef="USD">37000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000683">&lt;p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z0La9yYYwfQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zwV0UXDf5CDf"&gt;Revenue
Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
derive revenue from the sale of internally-developed software, either by licensing for local installation or by a SaaS delivery model,
through our direct sales force or through third-party resellers. Licensed, locally-installed clients on a perpetual model utilize our
support and maintenance services for a separate fee, whereas term-based locally installed license fees and SaaS fees include support
and maintenance. We also derive revenue from professional services that support the implementation, configuration, training and optimization
of the applications, as well as audit services and consulting services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
recognize revenue in accordance with Accounting Standards Codification (ASC) 606, &lt;i&gt;Revenue from Contracts with Clients&lt;/i&gt; (&#x201c;ASC
606&#x201d;), under the core principle of recognizing revenue to depict the transfer of promised goods or services to clients in an amount
that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
commence revenue recognition (Step 5 below) in accordance with that core principle after applying the following steps:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
    1: Identify the contract(s) with a client&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
    2: Identify the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
    3: Determine the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
    4: Allocate the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
    5: Recognize revenue when (or as) the entity satisfies a performance obligation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Often
contracts contain more than one performance obligation. Performance obligations are the unit of accounting for revenue recognition and
generally represent the distinct goods or services that are promised to the client. Revenue is recognized net of any taxes collected
from clients and subsequently remitted to governmental authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
we determine that we have not satisfied a performance obligation, we defer recognition of the revenue until the performance obligation
is satisfied. Maintenance and support and SaaS agreements are generally non-cancellable or contain significant penalties for early cancellation,
although clients typically have the right to terminate their contracts for cause if we fail to perform material obligations. However,
if non-standard acceptance periods, non-standard performance criteria, or cancellation or right of refund terms are required, revenue
is recognized upon the satisfaction of such criteria.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
transaction price is determined by summing all the consideration the Company expects to receive from the client under the contract. At
times, a contract may have variable attributes (i.e., performance guarantees, service level agreements, optional terms) that the Company
must consider when establishing the transaction price to mitigate significant revenue reversals for the contract. The determined transaction
price is allocated based on the standalone selling price (&#x201c;SSP&#x201d;) of the performance obligations in contract. Significant
judgment is required to determine the SSP for each performance obligation, inclusion of variable consideration, the amount allocated
to each performance obligation and whether it depicts the amount that the Company expects to receive in exchange for the related product
and/or service. The Company recognizes revenue for implementation of its eValuator SaaS solution over the contract term, as it has been
determined that those implementation services are not a distinct performance obligation. Services for other SaaS and Software solutions
such as CDI, RevID and Compare, have been determined as a distinct performance obligation. For these agreements, the Company estimates
SSP of its software licenses using the residual approach when the software license is sold with other services and observable SSPs exist
for the other services. The Company estimates the SSP for maintenance, professional services, software as a service and audit services
based on observable standalone sales.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Contract
Combination&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may execute more than one contract or agreement with a single client. The Company evaluates whether the agreements were negotiated
as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance
of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions
reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related
to those arrangements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has utilized the portfolio approach as the practical expedient. We have applied the revenue model to a portfolio of contracts
with similar characteristics where we expected that the financial statements would not differ materially from applying it to the individual
contracts within that portfolio.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Software
Licenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s software license arrangements provide the client with the right to use functional intellectual property. Implementation,
support, and other services are typically considered distinct performance obligations when sold with a software license unless these
services are determined to significantly modify the software. Revenue is recognized at a point in time. Typically, this is upon shipment
of components or electronic download of software.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Maintenance
and Support Services&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
maintenance and support obligations include multiple discrete performance obligations, with the two largest being unspecified product
upgrades or enhancements, and technical support, which can be offered at various points during a contract period. We believe that the
multiple discrete performance obligations within our overall maintenance and support obligations can be viewed as a single performance
obligation since both the unspecified upgrades and technical support are activities to fulfill the maintenance performance obligation
and are rendered concurrently. Maintenance and support agreements entitle clients to technology support, version upgrades, bug fixes
and service packs. We recognize maintenance and support revenue over the contract term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Software-Based
Solution Professional Services&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides various professional services to clients with software licenses. These include project management, software implementation
and software modification services. Revenues from arrangements to provide professional services are generally distinct from the other
promises in the contract and are recognized as the related services are performed. Consideration payable under these arrangements is
either fixed fee or on a time-and-materials basis and is recognized over time as the services are performed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Software
as a Service&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SaaS-based
contracts include a right to use of the Company&#x2019;s platform and support which represent a single promise to provide continuous access
to its software solutions. Implementation services for the Company&#x2019;s eValuator product are included as part of the single promise
for its respective contracts. The Company recognizes revenue for implementation of the eValuator product over the contract term as it
is determined that the implementation on eValuator is not a distinct performance obligation. Implementation services for other SaaS products
are deemed to be separate performance obligations that are recognized over time as the services are performed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Audit
Services&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides technology-enabled coding audit services to help clients review and optimize their internal clinical documentation and
coding functions across the applicable segment of the client&#x2019;s enterprise. Audit services are a separate performance obligation.
We recognize revenue over time as the services are performed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Disaggregation
of Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_z0jY4a01NTw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides information about disaggregated revenue by type and nature of revenue stream:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zlMowoknXAu9" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF DISAGGREGATON OF REVENUE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230201__20240131_zXglfbiAOxt4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220201__20230131_zjOgp3IivuTh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zQhbKUjvP4Ig" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Over time revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;22,358,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;23,670,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zYqnLNCuvL5i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Point in time revenue&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;238,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,219,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zNl6JRI2goeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,596,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;24,889,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z571tbGvK3ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company includes revenue categories of (i) over time and (ii) point in time revenue. The Company includes revenue categories of (i) SaaS,
(ii) maintenance and support, (iii) professional services, and (iv) audit services as over time revenue. For point in time revenue, the
performance obligation is recognized as the point in time when the obligation is fully satisfied. The Company includes software licenses
as point in time revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Contract
Assets and Deferred Revenues&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company receives payments from clients based upon contractual billing schedules. Contract receivables include amounts related to the
Company&#x2019;s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenues include
payments received in advance of performance under the contract. Our contract receivables and deferred revenue are reported on an individual
contract basis at the end of each reporting period. Contract receivables are classified as current or noncurrent based on the timing
of when we expect to bill the client. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to
recognize revenue. In the year ended January 31, 2024, we recognized approximately $&lt;span id="xdx_904_eus-gaap--DeferredRevenue_iI_pp0p0_c20230131_zjvxR3hWRfE3" title="Deferred revenue"&gt;7,642,000&lt;/span&gt; in revenue from deferred revenues outstanding
as of January 31, 2023. Revenue allocated to remaining performance obligations was $&lt;span id="xdx_903_eus-gaap--RevenueRemainingPerformanceObligation_iI_pp0p0_c20240131_zzJQFtl5lLgi" title="Revenue remaining performance obligation"&gt;31,414,000&lt;/span&gt; &#160;&#160;as of January 31, 2024, of
which &lt;span id="xdx_90E_eus-gaap--RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_c20230201__20240131_zMKGqlhUohX1" title="Revenue, remaining performance obligation, expected timing of satisfaction, explanation"&gt;the Company expects to recognize approximately 46% over the next 12 months and the remainder thereafter.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Deferred
costs (costs to fulfill a contract and contract acquisition costs)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
defer the direct costs, which include salaries and benefits, for professional services related to SaaS contracts as a cost to fulfill
a contract. These deferred costs will be amortized on a straight-line basis over the contractual term. As of January 31, 2024, and 2023,
we had deferred costs of $&lt;span id="xdx_907_eus-gaap--DeferredCostsCurrentAndNoncurrent_iI_pp0p0_c20240131_zVdxuFx5yI48" title="Deferred costs, net"&gt;77,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--DeferredCostsCurrentAndNoncurrent_iI_pp0p0_c20230131_zfIOvjbI3BN" title="Deferred costs, net"&gt;94,000&lt;/span&gt;, respectively, net of accumulated amortization of $&lt;span id="xdx_905_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_pp0p0_c20240131_zXk7UyCFT7qd" title="Accumulated amortization of deferred costs"&gt;102,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_pp0p0_c20230131_zfuai8uwzf78" title="Accumulated amortization of deferred costs"&gt;176,000&lt;/span&gt;, respectively. Amortization
expense of these costs was $&lt;span id="xdx_90A_ecustom--DeferredCostsAmortizationExpenses_pp0p0_c20230201__20240131_z8JxABz7wmd9" title="Deferred costs, amortization expense"&gt;82,000&lt;/span&gt; and $&lt;span id="xdx_901_ecustom--DeferredCostsAmortizationExpenses_pp0p0_c20220201__20230131_zM3D3eB7wswd" title="Deferred costs, amortization expense"&gt;83,000&lt;/span&gt; in fiscal 2023 and 2022, respectively. There were no impairment losses for these capitalized
costs for the fiscal 2023 and 2022. Additionally, in fiscal 2023, approximately $&lt;span id="xdx_905_eus-gaap--OtherAmortizationOfDeferredCharges_pp0p0_c20230201__20240131_z0ccSphI8kFj" title="Amortized contracts"&gt;155,000&lt;/span&gt; of fully amortized contracts were cleared
from their corresponding capitalization and accumulated amortization balance sheet accounts, while no such adjustments were made in fiscal
2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contract
acquisition costs, which consist of sales commissions paid or payable, is considered incremental and recoverable costs of obtaining a
contract with a client. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis
over the contract term. As a practical expedient, we expense sales commissions as incurred when the amortization period of related deferred
commission costs would have been one year or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
commissions costs paid and payable, which are included on the consolidated balance sheets within other non-current assets totaled $&lt;span id="xdx_90E_ecustom--DeferredCommissionsCostsPaidAndPayable_iI_pp0p0_c20240131__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherNoncurrentAssetsMember_z6mG0uzfKR5b" title="Deferred commissions costs paid and payable"&gt;1,461,000&lt;/span&gt;
and $&lt;span id="xdx_907_ecustom--DeferredCommissionsCostsPaidAndPayable_iI_pp0p0_c20230131__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherNoncurrentAssetsMember_zp6gUZHH6ZN2" title="Deferred commissions costs paid and payable"&gt;1,534,000&lt;/span&gt;, respectively, as of January 31, 2024 and 2023. In fiscal 2023 and 2022, amortization expense associated with deferred
sales commissions was $&lt;span id="xdx_905_eus-gaap--AmortizationOfDeferredSalesCommissions_pp0p0_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zgWVS2cRmPA3" title="Amortization expense with deferred sales commissions"&gt;588,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--AmortizationOfDeferredSalesCommissions_pp0p0_c20220201__20230131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zC5wRguPWwcf" title="Amortization expense with deferred sales commissions"&gt;411,000&lt;/span&gt;, respectively, and was included in selling, general and administrative expenses on the consolidated
statements of operations. There were $&lt;span id="xdx_909_eus-gaap--CapitalizedContractCostImpairmentLoss_pp0p0_c20230201__20240131_zq6Lz5yN6ife" title="Impairment loss"&gt;35,000&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--CapitalizedContractCostImpairmentLoss_pp0p0_do_c20220201__20230131_zbNQzc4gtAk9" title="Impairment loss"&gt;no&lt;/span&gt; impairment losses for these capitalized costs that was included with the amortization
expense for fiscal 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000685">&lt;p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_z0jY4a01NTw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides information about disaggregated revenue by type and nature of revenue stream:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zlMowoknXAu9" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF DISAGGREGATON OF REVENUE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230201__20240131_zXglfbiAOxt4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220201__20230131_zjOgp3IivuTh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zQhbKUjvP4Ig" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Over time revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;22,358,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;23,670,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zYqnLNCuvL5i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Point in time revenue&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;238,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,219,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zNl6JRI2goeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,596,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;24,889,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-02-012024-01-31_us-gaap_TransferredOverTimeMember"
      decimals="0"
      id="Fact000687"
      unitRef="USD">22358000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-02-012023-01-31_us-gaap_TransferredOverTimeMember"
      decimals="0"
      id="Fact000688"
      unitRef="USD">23670000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-02-012024-01-31_us-gaap_TransferredAtPointInTimeMember"
      decimals="0"
      id="Fact000690"
      unitRef="USD">238000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-02-012023-01-31_us-gaap_TransferredAtPointInTimeMember"
      decimals="0"
      id="Fact000691"
      unitRef="USD">1219000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000693"
      unitRef="USD">22596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000694"
      unitRef="USD">24889000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000696"
      unitRef="USD">7642000</us-gaap:DeferredRevenue>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000698"
      unitRef="USD">31414000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation contextRef="From2023-02-01to2024-01-31" id="Fact000700">the Company expects to recognize approximately 46% over the next 12 months and the remainder thereafter.</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation>
    <us-gaap:DeferredCostsCurrentAndNoncurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000702"
      unitRef="USD">77000</us-gaap:DeferredCostsCurrentAndNoncurrent>
    <us-gaap:DeferredCostsCurrentAndNoncurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000704"
      unitRef="USD">94000</us-gaap:DeferredCostsCurrentAndNoncurrent>
    <us-gaap:AccumulatedAmortizationOfOtherDeferredCosts
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000706"
      unitRef="USD">102000</us-gaap:AccumulatedAmortizationOfOtherDeferredCosts>
    <us-gaap:AccumulatedAmortizationOfOtherDeferredCosts
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000708"
      unitRef="USD">176000</us-gaap:AccumulatedAmortizationOfOtherDeferredCosts>
    <STRM:DeferredCostsAmortizationExpenses
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000710"
      unitRef="USD">82000</STRM:DeferredCostsAmortizationExpenses>
    <STRM:DeferredCostsAmortizationExpenses
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000712"
      unitRef="USD">83000</STRM:DeferredCostsAmortizationExpenses>
    <us-gaap:OtherAmortizationOfDeferredCharges
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000714"
      unitRef="USD">155000</us-gaap:OtherAmortizationOfDeferredCharges>
    <STRM:DeferredCommissionsCostsPaidAndPayable
      contextRef="AsOf2024-01-31_us-gaap_OtherNoncurrentAssetsMember"
      decimals="0"
      id="Fact000716"
      unitRef="USD">1461000</STRM:DeferredCommissionsCostsPaidAndPayable>
    <STRM:DeferredCommissionsCostsPaidAndPayable
      contextRef="AsOf2023-01-31_us-gaap_OtherNoncurrentAssetsMember"
      decimals="0"
      id="Fact000718"
      unitRef="USD">1534000</STRM:DeferredCommissionsCostsPaidAndPayable>
    <us-gaap:AmortizationOfDeferredSalesCommissions
      contextRef="From2023-02-012024-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      id="Fact000720"
      unitRef="USD">588000</us-gaap:AmortizationOfDeferredSalesCommissions>
    <us-gaap:AmortizationOfDeferredSalesCommissions
      contextRef="From2022-02-012023-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      id="Fact000722"
      unitRef="USD">411000</us-gaap:AmortizationOfDeferredSalesCommissions>
    <us-gaap:CapitalizedContractCostImpairmentLoss
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000724"
      unitRef="USD">35000</us-gaap:CapitalizedContractCostImpairmentLoss>
    <us-gaap:CapitalizedContractCostImpairmentLoss
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000726"
      unitRef="USD">0</us-gaap:CapitalizedContractCostImpairmentLoss>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-02-01to2024-01-31" id="Fact000728">&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zL8F4xbnR08b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zXy7zlnS4U5c"&gt;Concentrations&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments, which potentially expose the Company to concentrations of credit risk, consist primarily of accounts receivable. The Company&#x2019;s
accounts receivables are concentrated in the healthcare industry. However, the Company&#x2019;s clients typically are well-established
hospitals, medical facilities or major health information systems companies with good credit histories that resell the Company&#x2019;s
solutions. Payments from clients have been received within normal time frames for the industry. However, some hospitals and medical facilities
have experienced significant operating losses as a result of limits on third-party reimbursements from insurance companies and governmental
entities and extended payment of receivables from these entities is not uncommon.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
date, the Company has relied on a limited number of clients and remarketing partners for a substantial portion of its total revenues.
The Company expects that a significant portion of its future revenues will continue to be generated by a limited number of clients and
its remarketing partners.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000730">&lt;p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zeAj1BAjGsyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zR3ftPEEQhza"&gt;Goodwill
and Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
and other intangible assets were recognized in conjunction with the Avelead acquisition, and certain other acquisitions from fiscal
2013 and prior (prior to divestiture of such assets). Identifiable intangible assets include purchased intangible assets with finite
lives, which primarily consist of internally-developed software and client relationships. Finite-lived purchased intangible assets
are amortized over their expected period of benefit, which generally ranges from &lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dxL_c20240131__srt--RangeAxis__srt--MinimumMember_zA4bGYLesFfg" title="Finite-lived intangible assets amortized period::XDX::P1Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0732"&gt;one&lt;/span&gt;&lt;/span&gt;
to &lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20240131__srt--RangeAxis__srt--MaximumMember_zBVML3cJc0Db" title="Finite-lived intangible assets amortized period"&gt;15&lt;/span&gt;
years, using the straight-line method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses the useful lives and possible impairment of intangible assets when an event occurs that may trigger such a review. Factors
considered important which could trigger a review include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant
    underperformance relative to historical or projected future operating results;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant
    changes in the manner of use of the acquired assets or the strategy for the overall business;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identification
    of other impaired assets within a reporting unit;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;disposition
    of a significant portion of an operating segment;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant
    negative industry or economic trends;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant
    decline in the Company&#x2019;s stock price for a sustained period; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a
    decline in the market capitalization relative to the net book value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determining
whether a triggering event has occurred involves significant judgment by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses goodwill annually (as of November 1), or more frequently when events and circumstances, such as the ones mentioned above,
occur indicating that the recorded goodwill may be impaired. In assessing qualitative factors to determine whether it is more likely
than not that the fair value of a reporting unit is less than its carrying amount, the Company assesses relevant events and circumstances
that may impact the fair value and the carrying amount of a reporting unit. The identification of relevant events and circumstances and
how these may impact a reporting unit&#x2019;s fair value or carrying amount involve significant judgments by management. These judgments
include the consideration of macroeconomic conditions, industry and market considerations, cost factors, overall financial performance,
events which are specific to the Company and trends in the market price of the Company&#x2019;s common stock. Each factor is assessed
to determine whether it impacts the impairment test positively or negatively, and the magnitude of any such impact.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended January 31, 2023, the Company did not note any of the above qualitative factors, which would be considered a triggering
event for goodwill impairment. During the year ended January 31, 2024, the Company identified one or more factors that triggered goodwill
impairment as of October 31, 2023, as described below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the third quarter of fiscal 2023, the Company received a notice from a significant SaaS client of its intent not to renew its contract
following the expiration of the current term on December 31, 2023. At that time, the Company elected to accelerate the execution of the
2023 Restructuring that was designed to reduce costs while maintaining the Company&#x2019;s ability to expand its SaaS business. Both
the client termination and the execution of the Strategic Restructuring were announced on October 16, 2023. Following these announcements,
the Company&#x2019;s share price declined significantly. Based on these events (collectively, the &#x201c;Triggering Events&#x201d;), the
Company identified indicators of possible impairment and initiated testing using a valuation date of October 31, 2023. The impairment
tests were conducted under guidance of ASC Topic 360, Impairment and Disposal of Long-Lived Assets (&#x201c;ASC 360&#x201d;) for certain
long-lived assets, including capitalized contract costs, developed technology, client relationships and trade names, and in accordance
with ASC Topic 350, Intangibles &#x2013; Goodwill and Other (&#x201c;ASC 350&#x201d;) with respect to the reporting unit&#x2019;s goodwill.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reporting
units are determined based on the organizational structure the entity has in place at the date of the impairment test. A reporting unit
is an operating segment or component business unit with the following characteristics: (a) it has discrete financial information, (b)
segment management regularly reviews its operating results (generally an operating segment has a segment manager who is directly accountable
to and maintains regular contact with the chief operating decision maker to discuss operating activities, financial results, forecasts
or plans for the segment), and (c) its economic characteristics are dissimilar from other units (this contemplates the nature of the
products and services, the nature of the production process, the type or class of client for the products and services and the methods
used to distribute the products and services). The Company determined that for fiscal 2023 it has one operating segment and one reporting
unit, while for fiscal 2022 it had one operating segment and two reporting units.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates the fair value of its reporting unit using a combination of the market approach and income approach, via
discounted cash flow valuation models which include, but are not limited to, assumptions such as a &#x201c;risk-free&#x201d; rate of
return on an investment, the weighted average cost of capital of a market participant and future revenue, operating margin, working
capital and capital expenditure trends. Determining the fair value of reporting units and goodwill includes significant judgment by
management, and different judgments could yield different results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company performed its annual goodwill assessment for fiscal 2023 as of October 31, 2023 using the approaches described above. The
assessment identified a goodwill impairment of $9,813,000 that was recorded. Based on the analysis performed for fiscal 2022, the fair
value of the reporting units exceeded the carrying amount of the reporting unit, including goodwill, and, therefore, a goodwill impairment
loss was not recognized. &#160; Refer to Note 6 &#x2013; Goodwill and Intangible Assets to our consolidated financial statements included
in Part II, Item 8, &#x201c;Financial Statements and Supplementary Data&#x201d; for additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="AsOf2024-01-31_srt_MaximumMember"
      id="Fact000734">P15Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <STRM:EquityAwardPolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000736">&lt;p id="xdx_84C_ecustom--EquityAwardPolicyTextBlock_zKl6DDIRUcyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_za30GXIH31Ah"&gt;Equity
Awards&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as
expense over the requisite service period. For awards to non-employees, the Company recognizes compensation expense in the same
manner as if the entity had paid cash for the goods or services. The Company incurred total annual compensation expense related to
stock-based awards of $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230201__20240131__us-gaap--AwardTypeAxis__custom--EquityAwardMember_zH1uJNztuAL8" title="Compensation expense related to stock-based award"&gt;2,102,000&lt;/span&gt;
in fiscal 2023, net of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_c20230201__20240131__us-gaap--AwardTypeAxis__custom--EquityAwardMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zw4aTB8Ufp58" title="Compensation expense related to stock-based award"&gt;140,000&lt;/span&gt;
of capitalized non-employee stock compensation, and $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20220201__20230131__us-gaap--AwardTypeAxis__custom--EquityAwardMember_z74WRKZ8A4ye" title="Compensation expense related to stock-based award"&gt;1,680,000&lt;/span&gt;
net of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20220201__20230131__us-gaap--AwardTypeAxis__custom--EquityAwardMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMZp75ifhVhj" title="Compensation expense related to stock-based award"&gt;81,000&lt;/span&gt; of capitalized non-employee stock compensation, in fiscal 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the stock options granted are estimated at the date of grant using a Black-Scholes option pricing model. Option pricing
model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. The Company
recognizes forfeitures as they occur. These assumptions are subjective and are generally derived from external (such as, risk-free rate
of interest) and historical data (such as, volatility factor, expected term and forfeiture rates). Future grants of equity awards accounted
for as stock-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period
of future awards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market
close price per share on the grant date. The Company expenses the compensation cost of these awards as the restriction period
lapses, which is typically a one- to four-year service period to the Company. In fiscal 2023 and 2022, &lt;span id="xdx_903_ecustom--SurrenderOfStockSharesDuringPeriod_c20230201__20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztKBLwWQQkS" title="Surrender of stock, shares"&gt;190,950&lt;/span&gt;
and &lt;span id="xdx_90E_ecustom--SurrenderOfStockSharesDuringPeriod_c20220201__20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCzvG3cob019" title="Surrender of stock, shares"&gt;127,429&lt;/span&gt;
shares of common stock were surrendered to the Company to satisfy tax withholding obligations totaling $&lt;span id="xdx_901_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z9vP8EYbfCl1" title="Cost of shares for tax withholding"&gt;280,000&lt;/span&gt;
and $&lt;span id="xdx_908_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHWOF4tLnhYd" title="Cost of shares for tax withholding"&gt;197,000&lt;/span&gt;,
respectively, in connection with the vesting of restricted stock awards. Shares surrendered by the restricted stock award recipients
in accordance with the applicable plan are deemed cancelled, and therefore are not available to be reissued. The Company awarded &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230201__20240131__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zn293hzastO8" title="Number shares of restricted stock"&gt;1,203,621&lt;/span&gt;
and &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220201__20230131__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zz1WS8q7RpXb" title="Number shares of restricted stock"&gt;890,731&lt;/span&gt;
shares of restricted stock to its executive officers and directors of the Company in fiscal 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</STRM:EquityAwardPolicyTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-02-012024-01-31_custom_EquityAwardMember"
      decimals="0"
      id="Fact000738"
      unitRef="USD">2102000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-02-012024-01-31_custom_EquityAwardMember_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="0"
      id="Fact000740"
      unitRef="USD">140000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-02-012023-01-31_custom_EquityAwardMember"
      decimals="0"
      id="Fact000742"
      unitRef="USD">1680000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-02-012023-01-31_custom_EquityAwardMember_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="0"
      id="Fact000744"
      unitRef="USD">81000</us-gaap:ShareBasedCompensation>
    <STRM:SurrenderOfStockSharesDuringPeriod
      contextRef="From2023-02-012024-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000746"
      unitRef="Shares">190950</STRM:SurrenderOfStockSharesDuringPeriod>
    <STRM:SurrenderOfStockSharesDuringPeriod
      contextRef="From2022-02-012023-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000748"
      unitRef="Shares">127429</STRM:SurrenderOfStockSharesDuringPeriod>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2023-02-012024-01-31_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact000750"
      unitRef="USD">280000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact000752"
      unitRef="USD">197000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-02-012024-01-31_custom_OfficersAndDirectorsMember"
      decimals="INF"
      id="Fact000754"
      unitRef="Shares">1203621</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-02-012023-01-31_custom_OfficersAndDirectorsMember"
      decimals="INF"
      id="Fact000756"
      unitRef="Shares">890731</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000758">&lt;p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_z2Bp32guHuX7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zuOU4Xaz3zHi"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net
deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be
realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets
will not be realized. Refer to Note 7 &#x2013; Income Taxes to our consolidated financial statements included in Part II, Item 8, &#x201c;Financial
Statements and Supplementary Data&#x201d; for further details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether
certain tax positions are more likely than not to be sustained upon examination by tax authorities. At January 31, 2024, the Company
believes it has appropriately accounted for any uncertain tax positions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000760">&lt;p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zdkEWKyw49A8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zOl7MFqG7GD1"&gt;Net
Earnings (Loss) Per Common Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company presents basic and diluted earnings per share (&#x201c;EPS&#x201d;) data for our common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
unvested restricted stock awards are considered non-participating securities because holders are not entitled to non-forfeitable rights
to dividends or dividend equivalents during the vesting term. In accordance with ASC 260, securities are deemed not to be participating
in losses if there is no obligation to fund such losses. Diluted EPS for our common stock is computed using the treasury stock method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zSKoGeFheh9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is the calculation of the basic and diluted net loss per share of common stock:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zm55lTHK41lc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230201__20240131_zT16hi7c2tZe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220201__20230131_zYEzhQSz4uQ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Basic earnings (loss) per share:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperations_i01_zBDKZfLAlsh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 2.5pt"&gt;Loss, net of tax&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;(18,697,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;(11,379,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_i01_zcADVlyaHmAd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Basic net loss per share of common stock &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Diluted earnings (loss) per share (1):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_i01_zrjqeeC06QW2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Loss available to common stockholders &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,697,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(11,379,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_i01_zHSqEJzPzmPh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Diluted net loss per share of common stock &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetIncomeLoss_zcStVat5IQg3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,697,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(11,379,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zGLtOkhm5wdg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average shares outstanding &#x2013; Basic (1)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F45_zYg8GXeSOw63" style="display: none"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,510,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,324,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks_pid_z9VIeZG2nNmb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effect of dilutive securities - Stock options and Restricted stock (2)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F4E_z505HyUzBWob" style="display: none"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0783"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zDqQ2pJbNI0e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average shares outstanding &#x2013; Diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;56,510,419&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;49,324,858&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EarningsPerShareBasic_pid_zMA0HSp97Zkj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Basic and diluted net loss per share of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zUrF65h71AU9"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zomVu3fzr7o6"&gt;(0.33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zaQNiVQiGZue"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zRmiwnEX7gW2"&gt;(0.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F0E_zl3tpEFjuksg" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F13_zbOLVzSiI5j4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Excludes
    the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of January 31, 2024
    and 2023, there were &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zOkiNJqczEvk" title="Diluted earnings per share"&gt;1,970,521&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z2lI0oNs2rt9" title="Diluted earnings per share"&gt;1,848,031&lt;/span&gt; unvested restricted shares of common stock, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F01_zJ3XaglWt9Ta" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F18_zqD6zjckRZpk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Diluted
    net loss per share excludes the effect of shares that are anti-dilutive. As of January 31, 2024, there were &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6ObtBNkGuq3" title="Diluted earnings per share"&gt;67,500&lt;/span&gt; outstanding stock
    options and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedSharesMember_z7x8lmNjloWl" title="Diluted earnings per share"&gt;1,970,521&lt;/span&gt; unvested restricted shares of common stock. As of January 31, 2023, there were &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zg2cyB4sQ6Wk" title="Diluted earnings per share"&gt;628,598&lt;/span&gt; outstanding stock options
    and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zKuhWu16S4uk" title="Diluted earnings per share"&gt;1,848,031&lt;/span&gt; unvested restricted shares of common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_z8jXXPKpkPg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000762">&lt;p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zSKoGeFheh9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is the calculation of the basic and diluted net loss per share of common stock:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zm55lTHK41lc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230201__20240131_zT16hi7c2tZe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220201__20230131_zYEzhQSz4uQ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Basic earnings (loss) per share:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperations_i01_zBDKZfLAlsh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 2.5pt"&gt;Loss, net of tax&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;(18,697,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;(11,379,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_i01_zcADVlyaHmAd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Basic net loss per share of common stock &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Diluted earnings (loss) per share (1):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_i01_zrjqeeC06QW2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Loss available to common stockholders &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,697,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(11,379,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_i01_zHSqEJzPzmPh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Diluted net loss per share of common stock &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetIncomeLoss_zcStVat5IQg3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,697,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(11,379,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zGLtOkhm5wdg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average shares outstanding &#x2013; Basic (1)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F45_zYg8GXeSOw63" style="display: none"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,510,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,324,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks_pid_z9VIeZG2nNmb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effect of dilutive securities - Stock options and Restricted stock (2)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F4E_z505HyUzBWob" style="display: none"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0783"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zDqQ2pJbNI0e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average shares outstanding &#x2013; Diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;56,510,419&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;49,324,858&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EarningsPerShareBasic_pid_zMA0HSp97Zkj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Basic and diluted net loss per share of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zUrF65h71AU9"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zomVu3fzr7o6"&gt;(0.33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zaQNiVQiGZue"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zRmiwnEX7gW2"&gt;(0.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F0E_zl3tpEFjuksg" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F13_zbOLVzSiI5j4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Excludes
    the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of January 31, 2024
    and 2023, there were &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zOkiNJqczEvk" title="Diluted earnings per share"&gt;1,970,521&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z2lI0oNs2rt9" title="Diluted earnings per share"&gt;1,848,031&lt;/span&gt; unvested restricted shares of common stock, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F01_zJ3XaglWt9Ta" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F18_zqD6zjckRZpk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Diluted
    net loss per share excludes the effect of shares that are anti-dilutive. As of January 31, 2024, there were &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6ObtBNkGuq3" title="Diluted earnings per share"&gt;67,500&lt;/span&gt; outstanding stock
    options and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedSharesMember_z7x8lmNjloWl" title="Diluted earnings per share"&gt;1,970,521&lt;/span&gt; unvested restricted shares of common stock. As of January 31, 2023, there were &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zg2cyB4sQ6Wk" title="Diluted earnings per share"&gt;628,598&lt;/span&gt; outstanding stock options
    and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zKuhWu16S4uk" title="Diluted earnings per share"&gt;1,848,031&lt;/span&gt; unvested restricted shares of common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000764"
      unitRef="USD">-18697000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000765"
      unitRef="USD">-11379000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2023-02-01to2024-01-31"
      decimals="INF"
      id="Fact000767"
      unitRef="USDPShares">-0.33</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2022-02-012023-01-31"
      decimals="INF"
      id="Fact000768"
      unitRef="USDPShares">-0.23</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000770"
      unitRef="USD">-18697000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000771"
      unitRef="USD">-11379000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="From2023-02-01to2024-01-31"
      decimals="INF"
      id="Fact000773"
      unitRef="USDPShares">-0.33</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="From2022-02-012023-01-31"
      decimals="INF"
      id="Fact000774"
      unitRef="USDPShares">-0.23</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000776"
      unitRef="USD">-18697000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000777"
      unitRef="USD">-11379000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-02-01to2024-01-31"
      decimals="INF"
      id="Fact000779"
      unitRef="Shares">56510419</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-02-012023-01-31"
      decimals="INF"
      id="Fact000780"
      unitRef="Shares">49324858</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-02-01to2024-01-31"
      decimals="INF"
      id="Fact000785"
      unitRef="Shares">56510419</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-02-012023-01-31"
      decimals="INF"
      id="Fact000786"
      unitRef="Shares">49324858</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-02-01to2024-01-31"
      decimals="INF"
      id="Fact000788"
      unitRef="USDPShares">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000790"
      unitRef="USDPShares">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000791"
      unitRef="USDPShares">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-02-012023-01-31"
      decimals="INF"
      id="Fact000789"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000792"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000793"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-02-012024-01-31_custom_UnvestedRestrictedStockMember"
      decimals="INF"
      id="Fact000796"
      unitRef="Shares">1970521</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-02-012023-01-31_custom_UnvestedRestrictedStockMember"
      decimals="INF"
      id="Fact000798"
      unitRef="Shares">1848031</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-02-012024-01-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000801"
      unitRef="Shares">67500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-02-012024-01-31_custom_UnvestedRestrictedSharesMember"
      decimals="INF"
      id="Fact000803"
      unitRef="Shares">1970521</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-02-012023-01-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000805"
      unitRef="Shares">628598</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-02-012023-01-31_custom_UnvestedRestrictedStockMember"
      decimals="INF"
      id="Fact000807"
      unitRef="Shares">1848031</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000809">&lt;p id="xdx_846_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zvZi28wtxQN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zumJhOzXsvw9"&gt;Loss
Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
are subject to the possibility of various loss contingencies arising in the normal course of business. We consider the likelihood of
the loss or impairment of an asset or the incurrence of a liability as well as our ability to reasonably estimate the amount of loss
in determining loss contingencies. An estimated loss contingency is accrued when it is probable that a liability has been incurred or
an asset has been impaired, and the amount of loss can be reasonably estimated. We regularly evaluate current information available to
us to determine whether to accrue for a loss contingency and adjust any previous accrual.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy contextRef="From2023-02-01to2024-01-31" id="Fact000811">&lt;p id="xdx_84A_eus-gaap--CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_zQ0wKmvymZw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zugotMys2zFf"&gt;Restructuring&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 16, 2023, the Company announced it was executing a Strategic Restructuring designed to reduce expenses while maintaining the
Company&#x2019;s ability to expand its SaaS business. The Strategic Restructuring initiatives included a reduction in force, resulting
in the termination of &lt;span id="xdx_908_ecustom--NumberOfEmployeesTerminated_iI_uInteger_c20231016_ztRLXFZsGe6k" title="Number of employees terminated"&gt;26&lt;/span&gt; employees, or approximately &lt;span id="xdx_90C_ecustom--PercentageOfWorkforceTerminated_iI_dp_uPure_c20231016_zCIaWNVmFlOl" title="Percentage of workforce terminated"&gt;24&lt;/span&gt;% of the Company&#x2019;s workforce. To execute the Strategic Restructuring, the
Company incurred one-time restructuring costs associated with the workforce reduction of approximately $&lt;span id="xdx_905_eus-gaap--RestructuringCosts_c20231016__20231016_zOntCOm1uCwk" title="Restructuring costs"&gt;759,000&lt;/span&gt;, and the Company has
recognized all expenses associated with the Strategic Restructuring as of the end of fiscal 2023. The costs pertain to severance and
other employee termination-related costs and various professional fees the Company required to assist with execution of the Strategic
Restructuring. The following is a reconciliation of the Strategic Restructuring liability reflected on the Company&#x2019;s condensed
consolidated balance sheet under &#x201c;Accrued expenses&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p id="xdx_89B_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_zcPd5Sclhq91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zVUN80vYpDjh" style="display: none"&gt;SCHEDULE OF RECONCILIATION OF THE
RESTRUCTURING LIABILITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of January 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Balance as of January 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 Expenses to Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 Cash Payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Balance as of January 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total Costs Incurred to Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total Expected Costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Severance expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 34%"&gt;Cost of sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zK31whEsQUl" style="width: 8%; text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0821"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zsRfRkAAqw71" style="width: 8%; text-align: right" title="2023 Expenses to Date"&gt;154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zcnAbrwMJzQa" style="width: 8%; text-align: right" title="2023 Cash Payments"&gt;154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z1XWbK9im3gh" style="width: 8%; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zb2xjwlXrNb4" style="width: 8%; text-align: right" title="Total Costs Incurred to Date"&gt;154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zFGeb8oZh734" style="width: 8%; text-align: right" title="Total Expected Costs"&gt;154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Selling, general, and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zgF3AlYQNYUi" style="text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0833"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zFKeiNiACPD5" style="text-align: right" title="2023 Expenses to Date"&gt;350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zlGv358wxWZ9" style="text-align: right" title="2023 Cash Payments"&gt;276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zwjns1Y39W3j" style="text-align: right" title="Accrued Balance as of October 31, 2023"&gt;74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zqiRzO1j4id2" style="text-align: right" title="Total Costs Incurred to Date"&gt;350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zm3HYOaSlDqi" style="text-align: right" title="Total Expected Costs"&gt;350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zy3QuKboUiOk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0845"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUNiTrqAejec" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Expenses to Date"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4NPCwihCzLj" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Cash Payments"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zuMRQ6AL6PJf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0851"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgrKQdtRzK87" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Costs Incurred to Date"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z7In9BvhxtD8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Expected Costs"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total severance expense&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zcGYDLCzhqB2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zFdNqBp0GSDf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Expenses to Date"&gt;731&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zbwd77jepsYj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Cash Payments"&gt;657&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zwEck8mknhDi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"&gt;74&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zFr7ZMv4ErYc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Costs Incurred to Date"&gt;731&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zqrWNVOuH3bk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Expected Costs"&gt;731&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Professional fees&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zdCAEngK0Gh6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0869"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zSWcGLNkZwgd" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Expenses to Date"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zUTCupmUPFGg" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Cash Payments"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zbnlHH6m9rwd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0875"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zsWSpXRo7Mkg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Costs Incurred to Date"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zlKYj9LQchU5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Expected Costs"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_z5PZIGP8Azf2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0881"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zyRdI1Qbma37" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Expenses to Date"&gt;759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zMmuGj9t21Bk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Cash Payments"&gt;685&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zhqpQ87SlXH6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"&gt;74&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zeQHXKBypUL1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Costs Incurred to Date"&gt;759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zKbmG4cP32U4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Expected Costs"&gt;759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zRFfSpqmEYml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy>
    <STRM:NumberOfEmployeesTerminated
      contextRef="AsOf2023-10-16"
      decimals="INF"
      id="Fact000813"
      unitRef="Integer">26</STRM:NumberOfEmployeesTerminated>
    <STRM:PercentageOfWorkforceTerminated
      contextRef="AsOf2023-10-16"
      decimals="INF"
      id="Fact000815"
      unitRef="Pure">0.24</STRM:PercentageOfWorkforceTerminated>
    <us-gaap:RestructuringCosts
      contextRef="From2023-10-162023-10-16"
      decimals="0"
      id="Fact000817"
      unitRef="USD">759000</us-gaap:RestructuringCosts>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000819">&lt;p id="xdx_89B_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_zcPd5Sclhq91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zVUN80vYpDjh" style="display: none"&gt;SCHEDULE OF RECONCILIATION OF THE
RESTRUCTURING LIABILITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of January 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Balance as of January 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 Expenses to Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 Cash Payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Balance as of January 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total Costs Incurred to Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total Expected Costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Severance expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 34%"&gt;Cost of sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zK31whEsQUl" style="width: 8%; text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0821"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zsRfRkAAqw71" style="width: 8%; text-align: right" title="2023 Expenses to Date"&gt;154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zcnAbrwMJzQa" style="width: 8%; text-align: right" title="2023 Cash Payments"&gt;154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z1XWbK9im3gh" style="width: 8%; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zb2xjwlXrNb4" style="width: 8%; text-align: right" title="Total Costs Incurred to Date"&gt;154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zFGeb8oZh734" style="width: 8%; text-align: right" title="Total Expected Costs"&gt;154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Selling, general, and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zgF3AlYQNYUi" style="text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0833"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zFKeiNiACPD5" style="text-align: right" title="2023 Expenses to Date"&gt;350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zlGv358wxWZ9" style="text-align: right" title="2023 Cash Payments"&gt;276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zwjns1Y39W3j" style="text-align: right" title="Accrued Balance as of October 31, 2023"&gt;74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zqiRzO1j4id2" style="text-align: right" title="Total Costs Incurred to Date"&gt;350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zm3HYOaSlDqi" style="text-align: right" title="Total Expected Costs"&gt;350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zy3QuKboUiOk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0845"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUNiTrqAejec" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Expenses to Date"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4NPCwihCzLj" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Cash Payments"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zuMRQ6AL6PJf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0851"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgrKQdtRzK87" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Costs Incurred to Date"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z7In9BvhxtD8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Expected Costs"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total severance expense&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zcGYDLCzhqB2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zFdNqBp0GSDf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Expenses to Date"&gt;731&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zbwd77jepsYj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Cash Payments"&gt;657&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zwEck8mknhDi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"&gt;74&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zFr7ZMv4ErYc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Costs Incurred to Date"&gt;731&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--SeveranceExpensesMember_zqrWNVOuH3bk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Expected Costs"&gt;731&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Professional fees&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zdCAEngK0Gh6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0869"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zSWcGLNkZwgd" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Expenses to Date"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zUTCupmUPFGg" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023 Cash Payments"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zbnlHH6m9rwd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0875"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zsWSpXRo7Mkg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Costs Incurred to Date"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeesMember_zlKYj9LQchU5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Expected Costs"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccruedLiabilitiesCurrent_iS_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_z5PZIGP8Azf2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of January 31, 2023"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0881"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IncreaseDecreaseInAccruedLiabilities_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zyRdI1Qbma37" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Expenses to Date"&gt;759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AccruedCashPayments_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zMmuGj9t21Bk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="2023 Cash Payments"&gt;685&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AccruedLiabilitiesCurrent_iE_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zhqpQ87SlXH6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accrued Balance as of October 31, 2023"&gt;74&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AccruedCostsIncurred_pn3n3_c20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zeQHXKBypUL1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Costs Incurred to Date"&gt;759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--AccruedExpectedCosts_pn3n3_c20230201__20240131__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember_zKbmG4cP32U4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Expected Costs"&gt;759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-02-012024-01-31_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="Fact000823"
      unitRef="USD">154000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <STRM:AccruedCashPayments
      contextRef="From2023-02-012024-01-31_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="Fact000825"
      unitRef="USD">154000</STRM:AccruedCashPayments>
    <STRM:AccruedCostsIncurred
      contextRef="AsOf2024-01-31_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="Fact000829"
      unitRef="USD">154000</STRM:AccruedCostsIncurred>
    <STRM:AccruedExpectedCosts
      contextRef="From2023-02-012024-01-31_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="Fact000831"
      unitRef="USD">154000</STRM:AccruedExpectedCosts>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-02-012024-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact000835"
      unitRef="USD">350000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <STRM:AccruedCashPayments
      contextRef="From2023-02-012024-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact000837"
      unitRef="USD">276000</STRM:AccruedCashPayments>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact000839"
      unitRef="USD">74000</us-gaap:AccruedLiabilitiesCurrent>
    <STRM:AccruedCostsIncurred
      contextRef="AsOf2024-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact000841"
      unitRef="USD">350000</STRM:AccruedCostsIncurred>
    <STRM:AccruedExpectedCosts
      contextRef="From2023-02-012024-01-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact000843"
      unitRef="USD">350000</STRM:AccruedExpectedCosts>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-02-012024-01-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000847"
      unitRef="USD">227000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <STRM:AccruedCashPayments
      contextRef="From2023-02-012024-01-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000849"
      unitRef="USD">227000</STRM:AccruedCashPayments>
    <STRM:AccruedCostsIncurred
      contextRef="AsOf2024-01-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000853"
      unitRef="USD">227000</STRM:AccruedCostsIncurred>
    <STRM:AccruedExpectedCosts
      contextRef="From2023-02-012024-01-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000855"
      unitRef="USD">227000</STRM:AccruedExpectedCosts>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-02-012024-01-31_custom_SeveranceExpensesMember"
      decimals="-3"
      id="Fact000859"
      unitRef="USD">731000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <STRM:AccruedCashPayments
      contextRef="From2023-02-012024-01-31_custom_SeveranceExpensesMember"
      decimals="-3"
      id="Fact000861"
      unitRef="USD">657000</STRM:AccruedCashPayments>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-01-31_custom_SeveranceExpensesMember"
      decimals="-3"
      id="Fact000863"
      unitRef="USD">74000</us-gaap:AccruedLiabilitiesCurrent>
    <STRM:AccruedCostsIncurred
      contextRef="AsOf2024-01-31_custom_SeveranceExpensesMember"
      decimals="-3"
      id="Fact000865"
      unitRef="USD">731000</STRM:AccruedCostsIncurred>
    <STRM:AccruedExpectedCosts
      contextRef="From2023-02-012024-01-31_custom_SeveranceExpensesMember"
      decimals="-3"
      id="Fact000867"
      unitRef="USD">731000</STRM:AccruedExpectedCosts>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-02-012024-01-31_custom_ProfessionalFeesMember"
      decimals="-3"
      id="Fact000871"
      unitRef="USD">28000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <STRM:AccruedCashPayments
      contextRef="From2023-02-012024-01-31_custom_ProfessionalFeesMember"
      decimals="-3"
      id="Fact000873"
      unitRef="USD">28000</STRM:AccruedCashPayments>
    <STRM:AccruedCostsIncurred
      contextRef="AsOf2024-01-31_custom_ProfessionalFeesMember"
      decimals="-3"
      id="Fact000877"
      unitRef="USD">28000</STRM:AccruedCostsIncurred>
    <STRM:AccruedExpectedCosts
      contextRef="From2023-02-012024-01-31_custom_ProfessionalFeesMember"
      decimals="-3"
      id="Fact000879"
      unitRef="USD">28000</STRM:AccruedExpectedCosts>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-02-012024-01-31_custom_AccruedExpensesMember"
      decimals="-3"
      id="Fact000883"
      unitRef="USD">759000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <STRM:AccruedCashPayments
      contextRef="From2023-02-012024-01-31_custom_AccruedExpensesMember"
      decimals="-3"
      id="Fact000885"
      unitRef="USD">685000</STRM:AccruedCashPayments>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-01-31_custom_AccruedExpensesMember"
      decimals="-3"
      id="Fact000887"
      unitRef="USD">74000</us-gaap:AccruedLiabilitiesCurrent>
    <STRM:AccruedCostsIncurred
      contextRef="AsOf2024-01-31_custom_AccruedExpensesMember"
      decimals="-3"
      id="Fact000889"
      unitRef="USD">759000</STRM:AccruedCostsIncurred>
    <STRM:AccruedExpectedCosts
      contextRef="From2023-02-012024-01-31_custom_AccruedExpensesMember"
      decimals="-3"
      id="Fact000891"
      unitRef="USD">759000</STRM:AccruedExpectedCosts>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000893">&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z1THQ0hFrhN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zikcQEMVG2X"&gt;Accounting
Pronouncements Recently Adopted&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2019, the FASB issued ASU 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which improves guidance around accounting for financial losses on accounts receivable. For smaller reporting entities, ASU
2016-13 is effective for annual periods beginning after December 15, 2022, including interim periods within those fiscal years. The Company&#x2019;s
adoption of ASU 2016-13 was effective February 1, 2023. An analysis of contract receivables, including credit losses, was conducted during
the first quarter of fiscal 2024. The adoption of this ASU did not have a material impact on our consolidated financial statements
or disclosures.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <STRM:RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000895">&lt;p id="xdx_84B_ecustom--RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zbwSureRh1pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zZlBtIO4H9M6"&gt;Recent
Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves
guidance around the disclosures about a public entity&#x2019;s reportable segments and additional details about a reportable segment&#x2019;s
expenses. ASU 2023-07 is effective for all public entities for annual periods beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. The Company&#x2019;s adoption of ASU 2023-07 will be effective in the annual report
for the fiscal year ending January 31, 2025. The adoption of this ASU is not expected to have a material impact on our consolidated financial
statements or disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhance the transparency
and decision usefulness of income tax disclosures. For public entities, ASU 2023-09 is effective for annual periods beginning after December
15, 2024. The adoption of this ASU is not expected to have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;

</STRM:RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000897">&lt;p id="xdx_808_eus-gaap--BusinessCombinationDisclosureTextBlock_z0GiYrjXb3kk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
3 &#x2014; &lt;span id="xdx_821_zTDtu1VIstu2"&gt;BUSINESS COMBINATION &lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Avelead
Acquisition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company acquired all of the equity interests of Avelead as part of the Company&#x2019;s strategic expansion into the revenue cycle management,
acute-care healthcare space (the &#x201c;Transaction&#x201d;). The Transaction was completed on August 16, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate consideration for the purchase of Avelead was approximately $&lt;span id="xdx_903_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zljhiLyQsGWi"&gt;29.7&lt;/span&gt; million (at fair value) consisting of (i) $&lt;span id="xdx_90D_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn5n6_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zFrLiyTqrCN3"&gt;12.5&lt;/span&gt; million in
cash, net of cash acquired, (ii) $&lt;span id="xdx_907_eus-gaap--BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_iI_pn5n6_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zBuvZghmG4Pl"&gt;6.5&lt;/span&gt; million in common stock, and (iii) approximately $&lt;span id="xdx_90A_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn5n6_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_z9jKYmQFYSdc"&gt;10.7&lt;/span&gt; million in contingent consideration (see
below). The Company issued &lt;span id="xdx_90D_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardTypeAxis__custom--AcquisitionRestrictedCommonStockMember_zJlIzxzGJ0si"&gt;5,021,972&lt;/span&gt; shares of its restricted common stock (the &#x201c;Acquisition Restricted Common Stock&#x201d;). The
Acquisition Restricted Common Stock had a fair value as of the closing date of the acquisition of $&lt;span id="xdx_90A_ecustom--BusinessAcquisitionEquityInterestIssuedFairValue_iI_pn5n6_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardTypeAxis__custom--AcquisitionRestrictedCommonStockMember_zDCi3oV8pN2c"&gt;6.5&lt;/span&gt; million. &lt;span id="xdx_908_eus-gaap--BusinessCombinationContingentConsiderationArrangementsDescription_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardTypeAxis__custom--AcquisitionRestrictedCommonStockMember_ztVzzWeVUgTj" title="Business combination description"&gt;Additionally, the Transaction
included two types of contingent consideration; the first is referred to herein as &#x201c;SaaS Contingent Consideration&#x201d; and the
second is referred to herein as &#x201c;Renewal Contingent Consideration.&#x201d; The SaaS Contingent Consideration and Renewal Contingent
Consideration had an aggregate value of approximately $10.7 million as of the date of closing.&lt;/span&gt; The owners of Avelead are also referred
to herein as &#x201c;Sellers&#x201d; and are enumerated in the UPA (as defined below).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Unit Purchase Agreement (hereafter referred to as the &#x201c;UPA&#x201d;), stated that the purchase price for Avelead at closing included
a cash payment of $&lt;span id="xdx_905_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn5n6_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zuopL5akMCN6"&gt;11.9
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million. Additionally, the Company paid $&lt;span id="xdx_90D_ecustom--PaymentsToAcquireBusinessesSellerExpenses_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zmRCUNKv4She"&gt;285,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of the Sellers&#x2019; closing costs, $&lt;span id="xdx_90F_ecustom--PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_z6dF7hfxdaDi"&gt;285,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;related to the working capital adjustment as
defined in the UPA. Finally, at closing, the Company issued the Acquisition Restricted Common Stock with a fair value of approximately
$&lt;span id="xdx_90A_ecustom--BusinessAcquisitionEquityInterestIssuedFairValue_iI_pn5n6_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardTypeAxis__custom--AcquisitionRestrictedCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zbQyiyN8LFj1"&gt;6.5
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, based on a 30-day average of the closing
price of the Company&#x2019;s common stock prior to the closing date. The SaaS Contingent Consideration and the Renewal Contingent Consideration
described in more detail below were included in the UPA as potential future consideration for the Transaction. These are reflected on
the Company&#x2019;s consolidated balance sheet as &#x201c;Acquisition earnout liability.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
contingent consideration is comprised of &#x201c;SaaS Contingent Consideration&#x201d; and &#x201c;Renewal Contingent Consideration&#x201d;
which are described in more detail as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    SaaS Contingent Consideration is calculated based upon Avelead&#x2019;s recurring SaaS revenue recognized during the first and second
    year following the closing of the Transaction. The Company will pay the SaaS Contingent Consideration as follows: (i) &lt;span id="xdx_90A_ecustom--PaymentOfSaasContingentConsiderationInCashPercentage_iI_pid_dp_uPure_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zMOz2yXFDH6k" title="Payment of SaaS contingent consideration in cash, percentage"&gt;50&lt;/span&gt;% in cash
    and (ii) &lt;span id="xdx_90C_ecustom--PaymentOfSaasContingentConsiderationInSharesPercentage_iI_pid_dp_c20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_z3Wg896PKv6h" title="Payment of SaaS contingent consideration in cash, percentage"&gt;50&lt;/span&gt;% in shares of Company common stock valued at the time the earnout is paid subject to a collar, as described below.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 74.2pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--FirstYearPaymentOfSaasContingentConsiderationDescription_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_z3WMjwobknx" title="First year payment of SaaS contingent consideration, description"&gt;The
    first year SaaS Contingent Consideration was calculated as 75% of Avelead&#x2019;s recognized SaaS revenue from September 1, 2021
    to August 31, 2022. The first-year payment was subject to a deduction of $665,000 spread equally between the cash and common stock
    portion of the earnout consideration. Assuming that Avelead was within 80% of its forecasted SaaS revenue in the first year earnout,
    the Company agreed to a floor and ceiling on the value of the Company&#x2019;s restricted common stock issued as consideration for
    the earnout. That collar had a floor of $3.50 per share and a ceiling of $5.50 per share for the first year earnout. The first year
    SaaS Contingent Consideration was paid on November 21, 2022, as discussed in more detail below.&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--SecondYearPaymentOfSaasContingentConsiderationDescription_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zYuX1Amlmfv3" title="Second year payment of SaaS contingent consideration, description"&gt;The
    second year SaaS Contingent Consideration was calculated as 40% of Avelead&#x2019;s recognized SaaS revenue from September 1, 2022
    to August 31, 2023. Assuming that Avelead was within 80% of its forecasted SaaS revenue in the second year earnout, the Company agreed
    to a floor and ceiling on the Company&#x2019;s restricted common stock issued as consideration for the earnout. That collar had a
    floor of $4.50 per share and a ceiling of $6.50 per share for the second year earnout. The second year SaaS Contingent Consideration
    remained outstanding as of January 31, 2024, as the Company and the Sellers work towards a resolution regarding the payment of the
    second year SaaS Contingent Consideration. &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_90A_ecustom--ForecastedRevenueDescription_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zPpBj5hYLXzf" title="Forecasted revenue description"&gt;If
    Avelead does not achieve 80% of its forecasted revenue, the price per share will revert back to the Company&#x2019;s market price
    based upon a 30-day average.&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 74.2pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;br/&gt;
    &#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--RenewalContingentConsiderationDescription_c20210814__20210816__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_z9OYtmiVY2qe" title="Renewal contingent consideration, description"&gt;The
    Renewal Contingent Consideration was tied directly to a successful renewal of a specific client of Avelead. To meet the definition
    of a renewal, Avelead was required to achieve a minimum threshold of contracted revenue in an updated, annual, renewed contract with
    the specified client. The renewal occurred on or about June 1, 2022 and June 1, 2023. The Renewal Contingent Consideration was payable
    in shares of Company restricted common stock valued as of the date of closing. The Renewal Contingent Consideration is either earned
    or not earned based upon the renewal of the specified client at the minimum amount of contracted revenue. There is no pro-ration
    of the underlying Renewal Contingent Consideration. On November 21, 2022, the Company issued 627,746 shares of restricted common
    stock to the Sellers in connection with the first year Renewal Contingent Consideration. The second year Renewal Contingent Consideration
    remained outstanding as of January 31, 2024, as the Company and the Sellers work towards a resolution regarding the payment of the
    second year Renewal Contingent Consideration.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 21, 2022, the Company made the first year earnout payments and issued shares of restricted common stock to the Sellers in accordance
with the UPA. In connection with the first year earnout payment, the Company made an aggregate cash payment of $&lt;span id="xdx_909_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_c20221120__20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardDateAxis__custom--FirstYearEarnoutMember_z49niAWMqlBg" title="Business combination, cash payments"&gt;2,012,000&lt;/span&gt; and issued
&lt;span id="xdx_908_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20221120__20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardDateAxis__custom--FirstYearEarnoutMember_zzRDn1IGFC2f" title="Business acquisition, equity interest issued or issuable, number of shares"&gt;1,243,292&lt;/span&gt; unregistered securities in the form of restricted common stock, par value $&lt;span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--AwardDateAxis__custom--FirstYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_z1a40Gt4ZmPi" title="Common stock par or stated value per share"&gt;0.01&lt;/span&gt; per share (&#x201c;restricted common stock&#x201d;),
for the SaaS Contingent Consideration and issued &lt;span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20221120__20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--RenewalContingentConsiderationMember__us-gaap--AwardDateAxis__custom--FirstYearEarnoutMember_zNYU9YI7nPt7" title="Sale of stock number of shares issued in transaction"&gt;627,746&lt;/span&gt; shares of restricted common stock for the Renewal Contingent Consideration.
The estimated aggregate value of the first year earnout payment was $&lt;span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20221120__20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--AwardDateAxis__custom--FirstYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zn6xY44bmVrg" title="Sale of stock consideration"&gt;4,000,000&lt;/span&gt; with respect to the SaaS Contingent Consideration and
$&lt;span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20221120__20221121__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--RenewalContingentConsiderationMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zRvUhSxrupE5" title="Sale of stock"&gt;1,000,000&lt;/span&gt; with respect to the Renewal Contingent Consideration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of January 31, 2024, the Company has not made the second year earnout payments to the Sellers or issued shares of common stock in connection
therewith. In connection with the second year earnout payment, the Company has estimated cash payments of $&lt;span id="xdx_901_eus-gaap--PaymentsToAcquireBusinessesGross_c20230201__20240131__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zrG109Fkx30a"&gt;1,214,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and will issue &lt;span id="xdx_90B_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20230201__20240131__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_z1Xaz1O44iii"&gt;961,640
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of restricted common stock for the SaaS
Contingent Consideration and &lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230201__20240131__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zP9G4OCg78r9"&gt;627,746
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of restricted common stock for the Renewal
Contingent Consideration. The estimated aggregate value of the second year earnout payment is $&lt;span id="xdx_907_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_c20240131__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_za2lbhNYsX3g"&gt;1,550,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the SaaS Contingent Consideration and $&lt;span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230201__20240131__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember_zs5shzbs4PK8"&gt;244,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the Renewal Contingent Consideration. The
Company and the Sellers reached an agreement to defer the cash portion of the SaaS Contingent Consideration and Renewal Contingent Consideration
payments over time through October 31, 2024. On March 27, 2024, the Company issued &lt;span id="xdx_900_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240326__20240327__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zOJJ8hYvl6qa"&gt;961,640
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of restricted common stock to the Sellers
for the SaaS Contingent Consideration and &lt;span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240326__20240327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardDateAxis__custom--SecondYearEarnoutMember__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zzXxlfFPzjM3"&gt;627,746
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of restricted common stock for the Renewal
Contingent Consideration. These liabilities are reflected at the fair value of the future commitment on the Company&#x2019;s consolidated
balance sheet, as Acquisition Earnout Liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement and a separation agreement with each of the two Sellers. Acquisition-related costs
include the cost of a two-year separation agreement with one of the Sellers. The separation agreement was expensed at the closing of
the transaction as there were no material future obligations of the Seller to the Company within acquisition-related costs. The
employment agreement with the other Seller had a two-year term and entitled the Seller to six-months separation pay in the event of
termination without cause. The expense for the employment agreement is recognized ratably over the service period customary with
other employment agreements within selling, general, and administrative expense. On September 1, 2023, the Company terminated
the employment agreement. In exchange for a general release from the Seller, the Company agreed to accelerate the vesting of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230901__20230901__us-gaap--BusinessAcquisitionAxis__custom--AveleadConsultingLLCMember_zTzrifl80XDi"&gt;150,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;outstanding
and unvested shares of restricted common stock of the Company previously granted to the Seller, subject to such Seller&#x2019;s
non-revocation of a general release of claims against the Company.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember"
      decimals="-5"
      id="Fact000898"
      unitRef="USD">29700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember"
      decimals="-5"
      id="Fact000899"
      unitRef="USD">12500000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="AsOf2021-08-16_custom_AveleadConsultingLLCMember"
      decimals="-5"
      id="Fact000900"
      unitRef="USD">6500000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2021-08-16_custom_AveleadConsultingLLCMember"
      decimals="-5"
      id="Fact000901"
      unitRef="USD">10700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_AcquisitionRestrictedCommonStockMember"
      decimals="INF"
      id="Fact000902"
      unitRef="Shares">5021972</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <STRM:BusinessAcquisitionEquityInterestIssuedFairValue
      contextRef="AsOf2021-08-16_custom_AveleadConsultingLLCMember_custom_AcquisitionRestrictedCommonStockMember"
      decimals="-5"
      id="Fact000903"
      unitRef="USD">6500000</STRM:BusinessAcquisitionEquityInterestIssuedFairValue>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription
      contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_AcquisitionRestrictedCommonStockMember"
      id="Fact000905">Additionally, the Transaction
included two types of contingent consideration; the first is referred to herein as &#x201c;SaaS Contingent Consideration&#x201d; and the
second is referred to herein as &#x201c;Renewal Contingent Consideration.&#x201d; The SaaS Contingent Consideration and Renewal Contingent
Consideration had an aggregate value of approximately $10.7 million as of the date of closing.</us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember"
      decimals="-5"
      id="Fact000906"
      unitRef="USD">11900000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <STRM:PaymentsToAcquireBusinessesSellerExpenses
      contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember"
      decimals="0"
      id="Fact000907"
      unitRef="USD">285000</STRM:PaymentsToAcquireBusinessesSellerExpenses>
    <STRM:PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment
      contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember"
      decimals="0"
      id="Fact000908"
      unitRef="USD">285000</STRM:PaymentsToAcquireBusinessesEstimatedWorkingCapitalAdjustment>
    <STRM:BusinessAcquisitionEquityInterestIssuedFairValue
      contextRef="AsOf2021-08-16_custom_AveleadConsultingLLCMember_custom_AcquisitionRestrictedCommonStockMember_custom_UnitPurchaseAgreementMember"
      decimals="-5"
      id="Fact000909"
      unitRef="USD">6500000</STRM:BusinessAcquisitionEquityInterestIssuedFairValue>
    <STRM:PaymentOfSaasContingentConsiderationInCashPercentage
      contextRef="AsOf2021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember"
      decimals="INF"
      id="Fact000911"
      unitRef="Pure">0.50</STRM:PaymentOfSaasContingentConsiderationInCashPercentage>
    <STRM:PaymentOfSaasContingentConsiderationInSharesPercentage
      contextRef="AsOf2021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember"
      decimals="INF"
      id="Fact000913"
      unitRef="Pure">0.50</STRM:PaymentOfSaasContingentConsiderationInSharesPercentage>
    <STRM:FirstYearPaymentOfSaasContingentConsiderationDescription
      contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember"
      id="Fact000915">The
    first year SaaS Contingent Consideration was calculated as 75% of Avelead&#x2019;s recognized SaaS revenue from September 1, 2021
    to August 31, 2022. The first-year payment was subject to a deduction of $665,000 spread equally between the cash and common stock
    portion of the earnout consideration. Assuming that Avelead was within 80% of its forecasted SaaS revenue in the first year earnout,
    the Company agreed to a floor and ceiling on the value of the Company&#x2019;s restricted common stock issued as consideration for
    the earnout. That collar had a floor of $3.50 per share and a ceiling of $5.50 per share for the first year earnout. The first year
    SaaS Contingent Consideration was paid on November 21, 2022, as discussed in more detail below.</STRM:FirstYearPaymentOfSaasContingentConsiderationDescription>
    <STRM:SecondYearPaymentOfSaasContingentConsiderationDescription
      contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember"
      id="Fact000917">The
    second year SaaS Contingent Consideration was calculated as 40% of Avelead&#x2019;s recognized SaaS revenue from September 1, 2022
    to August 31, 2023. Assuming that Avelead was within 80% of its forecasted SaaS revenue in the second year earnout, the Company agreed
    to a floor and ceiling on the Company&#x2019;s restricted common stock issued as consideration for the earnout. That collar had a
    floor of $4.50 per share and a ceiling of $6.50 per share for the second year earnout. The second year SaaS Contingent Consideration
    remained outstanding as of January 31, 2024, as the Company and the Sellers work towards a resolution regarding the payment of the
    second year SaaS Contingent Consideration.</STRM:SecondYearPaymentOfSaasContingentConsiderationDescription>
    <STRM:ForecastedRevenueDescription
      contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember"
      id="Fact000919">If
    Avelead does not achieve 80% of its forecasted revenue, the price per share will revert back to the Company&#x2019;s market price
    based upon a 30-day average.</STRM:ForecastedRevenueDescription>
    <STRM:RenewalContingentConsiderationDescription
      contextRef="From2021-08-142021-08-16_custom_AveleadConsultingLLCMember_custom_UnitPurchaseAgreementMember"
      id="Fact000921">The
    Renewal Contingent Consideration was tied directly to a successful renewal of a specific client of Avelead. To meet the definition
    of a renewal, Avelead was required to achieve a minimum threshold of contracted revenue in an updated, annual, renewed contract with
    the specified client. The renewal occurred on or about June 1, 2022 and June 1, 2023. The Renewal Contingent Consideration was payable
    in shares of Company restricted common stock valued as of the date of closing. The Renewal Contingent Consideration is either earned
    or not earned based upon the renewal of the specified client at the minimum amount of contracted revenue. There is no pro-ration
    of the underlying Renewal Contingent Consideration. On November 21, 2022, the Company issued 627,746 shares of restricted common
    stock to the Sellers in connection with the first year Renewal Contingent Consideration. The second year Renewal Contingent Consideration
    remained outstanding as of January 31, 2024, as the Company and the Sellers work towards a resolution regarding the payment of the
    second year Renewal Contingent Consideration.</STRM:RenewalContingentConsiderationDescription>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_AveleadConsultingLLCMember_custom_FirstYearEarnoutMember"
      decimals="0"
      id="Fact000923"
      unitRef="USD">2012000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_AveleadConsultingLLCMember_custom_FirstYearEarnoutMember"
      decimals="INF"
      id="Fact000925"
      unitRef="Shares">1243292</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-11-21_custom_UnitPurchaseAgreementMember_custom_FirstYearEarnoutMember_custom_AveleadConsultingLLCMember"
      decimals="INF"
      id="Fact000927"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_RenewalContingentConsiderationMember_custom_FirstYearEarnoutMember"
      decimals="INF"
      id="Fact000929"
      unitRef="Shares">627746</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_AveleadConsultingLLCMember_custom_FirstYearEarnoutMember"
      decimals="0"
      id="Fact000931"
      unitRef="USD">4000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-11-202022-11-21_custom_UnitPurchaseAgreementMember_custom_RenewalContingentConsiderationMember_custom_AveleadConsultingLLCMember"
      decimals="0"
      id="Fact000933"
      unitRef="USD">1000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2023-02-012024-01-31_custom_SecondYearEarnoutMember_custom_AveleadConsultingLLCMember"
      decimals="0"
      id="Fact000934"
      unitRef="USD">1214000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="From2023-02-012024-01-31_custom_SecondYearEarnoutMember_custom_AveleadConsultingLLCMember"
      decimals="INF"
      id="Fact000935"
      unitRef="Shares">961640</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-02-012024-01-31_custom_SecondYearEarnoutMember_custom_AveleadConsultingLLCMember"
      decimals="INF"
      id="Fact000936"
      unitRef="Shares">627746</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-01-31_custom_SecondYearEarnoutMember_custom_AveleadConsultingLLCMember"
      decimals="0"
      id="Fact000937"
      unitRef="USD">1550000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-02-012024-01-31_custom_SecondYearEarnoutMember_custom_AveleadConsultingLLCMember"
      decimals="0"
      id="Fact000938"
      unitRef="USD">244000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="From2024-03-262024-03-27_custom_SecondYearEarnoutMember_us-gaap_SubsequentEventMember_custom_AveleadConsultingLLCMember"
      decimals="INF"
      id="Fact000939"
      unitRef="Shares">961640</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-03-262024-03-27_custom_SecondYearEarnoutMember_us-gaap_SubsequentEventMember_custom_AveleadConsultingLLCMember"
      decimals="INF"
      id="Fact000940"
      unitRef="Shares">627746</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-09-012023-09-01_custom_AveleadConsultingLLCMember"
      decimals="INF"
      id="Fact000941"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000943">&lt;p id="xdx_801_eus-gaap--LesseeOperatingLeasesTextBlock_zZ6L7M7dB6D5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
4 &#x2014; &lt;span id="xdx_829_zORiPJxz1Ht5"&gt;OPERATING LEASES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
determine whether an arrangement is a lease at inception. Right-of-use assets represent our right to use an underlying asset for the
lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use
assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term.
Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate for the expected remaining lease
term at commencement date for new and existing leases in determining the present value of future lease payments. Operating lease expense
is recognized on a straight-line basis over the lease term. The Company has moved to a virtual office model and does not have a physical
office space. Membership agreements and daily space rentals are leveraged by the Company when groups need to meet in person with the
costs expensed as incurred. As of January 31, 2024, the Company recorded $&lt;span id="xdx_90D_eus-gaap--RentalProperties_iI_c20240131_z2mmkkD3VD8g" title="Related to space rental"&gt;30,000&lt;/span&gt; related to such space
rentals.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Alpharetta
Office Lease&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The Company entered into a lease
for office space in Alpharetta, Georgia, on March 1, 2020. The lease expired on March 31, 2023. At inception, the Company recorded a right-of
use asset of $&lt;span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20211031_zuP0bsIHz5Kc"&gt;540,000&lt;/span&gt;, and related current and long-term operating lease obligation in the accompanying consolidated balance sheet. As
of January 31, 2023, operating lease right-of use assets totaled $&lt;span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20230131_zMQCNrdm2jBk"&gt;32,000&lt;/span&gt;, and the associated lease liability of $&lt;span id="xdx_903_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20230131_z1GAL0ABNyY8"&gt;35,000&lt;/span&gt; is included in
current liabilities. The Company used a discount rate of &lt;span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20230131_zeDFLRWvNKX6"&gt;6.5&lt;/span&gt;% to determine the lease liability. As of January 31, 2024 and 2023, the Company
had lease operating costs of approximately $&lt;span id="xdx_90C_eus-gaap--OperatingLeaseCost_c20230201__20240131_zXRatNaUCtw2"&gt;32,000&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--OperatingLeaseCost_c20220201__20230131_zLKYqNB83osg"&gt;194,000&lt;/span&gt;, respectively. The Company paid cash of approximately $&lt;span id="xdx_908_eus-gaap--OperatingLeasePayments_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--AlpharettaOfficeLeaseMember_zQK5b0xMCyhk"&gt;36,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--OperatingLeasePayments_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--AlpharettaOfficeLeaseMember_z6126frP7vGg"&gt;210,000&lt;/span&gt;
for the lease in fiscal 2023 and fiscal 2022, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 1, 2021, the Company entered into an agreement with a third-party to sublease its office space in Alpharetta, Georgia, (the
&#x201c;Sublease Agreement&#x201d;). The sublease term is for &lt;span id="xdx_901_ecustom--SubleaseTerm_dtM_c20210929__20211002__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember_z3Hdl6GBoTVc" title="Sublease, term"&gt;18&lt;/span&gt;
months which coincides with the Company&#x2019;s underlying lease (see below). The Company received $&lt;span id="xdx_90E_eus-gaap--SubleaseIncome_c20210929__20211002__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember_zp86tu3avmI2" title="Sublease income"&gt;292,000&lt;/span&gt;
from the sublessee over the term of the sublease. The sublease did not relieve the Company of its original obligation under the
lease, and therefore the Company did not adjust the operating lease right-of-use asset and related liability. The Company incurred
an amount of fees and expenses to enter into the Sublease Agreement that were recorded as &#x201c;acquisition-related costs&#x201d;
for fiscal 2021. As of January 31, 2024, the Company recorded $&lt;span id="xdx_90D_eus-gaap--OtherIncome_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember_z2p1ft3suaAh" title="Other income related to sublease"&gt;33,000&lt;/span&gt;
as other income related to the sublease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Suwanee
Office Lease&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
acquiring Avelead on August 16, 2021 (refer to Note 3 &#x2013; Business Combination), the Company assumed an operating
lease agreement for the corporate office space of Avelead. The 36-month term lease commenced March 1, 2019, and initially expired on
&lt;span id="xdx_905_eus-gaap--LeaseExpirationDate1_dd_c20210814__20210816__us-gaap--TypeOfArrangementAxis__custom--SuwaneeOfficeLeaseMember_zHbO3yR6pZM3" title="Lease expiration date"&gt;February 28, 2022&lt;/span&gt;. As of January 31, 2024, the Company recorded $&lt;span id="xdx_90B_eus-gaap--PaymentsForRent_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SuwaneeOfficeLeaseMember_z71DgwKydOKh" title="Payments for rent"&gt;6,000&lt;/span&gt; in rent expense. The lessor is an entity controlled by one of
the Sellers that was employed by the Company until August 2023. In February 2022, the Company renewed the lease for twelve months. The
Company made monthly lease payments of $&lt;span id="xdx_90D_eus-gaap--OperatingLeasePayments_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SuwaneeOfficeLeaseMember_zhqUe2Q07mXj" title="Operating lease, payments"&gt;5,999&lt;/span&gt; for a total of $&lt;span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_c20230228__us-gaap--TypeOfArrangementAxis__custom--SuwaneeOfficeLeaseMember_zXDQKxe118l" title="Operating lease"&gt;71,984&lt;/span&gt; over the term of the lease. The lease expired on February 28, 2023,
and was not renewed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:RentalProperties
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000945"
      unitRef="USD">30000</us-gaap:RentalProperties>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-10-31"
      decimals="0"
      id="Fact000946"
      unitRef="USD">540000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000947"
      unitRef="USD">32000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000948"
      unitRef="USD">35000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact000949"
      unitRef="Pure">0.065</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact000950"
      unitRef="USD">32000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact000951"
      unitRef="USD">194000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-02-012024-01-31_custom_AlpharettaOfficeLeaseMember"
      decimals="0"
      id="Fact000952"
      unitRef="USD">36000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-02-012023-01-31_custom_AlpharettaOfficeLeaseMember"
      decimals="0"
      id="Fact000953"
      unitRef="USD">210000</us-gaap:OperatingLeasePayments>
    <STRM:SubleaseTerm
      contextRef="From2021-09-292021-10-02_custom_SubleaseAgreementMember"
      id="Fact000955">P18M</STRM:SubleaseTerm>
    <us-gaap:SubleaseIncome
      contextRef="From2021-09-292021-10-02_custom_SubleaseAgreementMember"
      decimals="0"
      id="Fact000957"
      unitRef="USD">292000</us-gaap:SubleaseIncome>
    <us-gaap:OtherIncome
      contextRef="From2023-02-012024-01-31_custom_SubleaseAgreementMember"
      decimals="0"
      id="Fact000959"
      unitRef="USD">33000</us-gaap:OtherIncome>
    <us-gaap:LeaseExpirationDate1
      contextRef="From2021-08-142021-08-16_custom_SuwaneeOfficeLeaseMember"
      id="Fact000961">2022-02-28</us-gaap:LeaseExpirationDate1>
    <us-gaap:PaymentsForRent
      contextRef="From2023-02-012024-01-31_custom_SuwaneeOfficeLeaseMember"
      decimals="0"
      id="Fact000963"
      unitRef="USD">6000</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-02-012024-01-31_custom_SuwaneeOfficeLeaseMember"
      decimals="0"
      id="Fact000965"
      unitRef="USD">5999</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-02-28_custom_SuwaneeOfficeLeaseMember"
      decimals="0"
      id="Fact000967"
      unitRef="USD">71984</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000969">&lt;p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zsxCJkOLdqxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
5 &#x2014; &lt;span id="xdx_829_zYHz7clzYlC3"&gt;DEBT&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfDebtTableTextBlock_zZTqivM7mC6l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
principal balances on debt consisted of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zIytIO7PNH0l" style="display: none"&gt;SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240131_zacxl86TTnN4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230131_zRpV9I2nBiVh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzuRq_zw3eOnhiWl2h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Term loan&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;9,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;9,750,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FinancingCostPayable_iI_maLTDzuRq_z5rOfXEcrXl2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;p style="margin: 0"&gt;Financing cost payable&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;135,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DeferredFinancingCost_iNI_di_msLTDzuRq_zd3Zcy02MIQ6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Deferred financing cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(69,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(105,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LongTermDebt_iTI_mtLTDzuRq_z56OAhOzgq42" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,066,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,714,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LongTermDebtCurrent_iNI_di_zWlNIc4uEZT1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Less: Current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(750,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iTI_zvHBV6E31KO2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Non-current portion of debt&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,566,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,964,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zlautnZKsq8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Term
Loan Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 26, 2021, the Company and its subsidiaries entered into the Loan Agreement with WAB. Pursuant
to the Loan Agreement, WAB agreed to provide the Company and its subsidiaries with a term loan facility in the maximum principal amount
of $&lt;span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--WesternAllianceBankMember_zolzc6KMxtG3" title="Line of credit facility, maximum borrowing capacity"&gt;10,000,000&lt;/span&gt;. Amounts outstanding under the term loan portion of the Loan Agreement bear interest at a per annum rate equal to the
Prime Rate (as published in The Wall Street Journal) plus &lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20210826__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zvnjpTPQ0A9e" title="Debt instrument, interest rate, effective percentage"&gt;1.5&lt;/span&gt;%, with a Prime &#x201c;floor&#x201d; rate of &lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210826__us-gaap--VariableRateAxis__us-gaap--BaseRateMember_zmoy6yfsNuyj" title="Debt instrument, interest rate, stated percentage"&gt;3.25&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Loan Agreement has a five-year term, and the maximum principal amount was advanced in a single-cash advance on or about the closing date.
Interest accrued under the Loan Agreement is due monthly, and the Company is required to make monthly interest-only payments through
the one-year anniversary of the closing date. From the first anniversary of the closing date through the maturity date, the Company is
required to make monthly payments of principal and interest that increase over the term of the agreement. The Loan Agreement requires
principal repayments on the anniversary date of the closing of the debt agreement of $&lt;span id="xdx_906_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--WesternAllianceBankMember_zMv6ZNbCxWF2" title="Long term debt, maturity, year two"&gt;500,000&lt;/span&gt; in the second year, $&lt;span id="xdx_902_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--WesternAllianceBankMember_zWlDZJVGh1af" title="Long term debt, maturity, year three"&gt;1,000,000&lt;/span&gt; in the third
year, $&lt;span id="xdx_90D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--WesternAllianceBankMember_zG9kAWnzotu2" title="Long term debt, maturity, year four"&gt;2,000,000&lt;/span&gt; in the fourth year, and $&lt;span id="xdx_90A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--BridgeBankMember_zQPu2yxZHzmh" title="Long term debt, maturity, year five"&gt;3,000,000&lt;/span&gt; in the fifth year, respectively, with the remaining outstanding principal balance
and all accrued but unpaid interest due in full on the maturity date. The Loan Agreement may also require early repayments if certain
conditions are met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded $&lt;span id="xdx_908_eus-gaap--DeferredOfferingCosts_iI_c20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zfFHRTnmpuu" title="Deferred offering costs"&gt;130,000&lt;/span&gt; in deferred financing costs related to the Loan Agreement. These deferred financing costs are being amortized
over the term of the loan. The Company will also incur $&lt;span id="xdx_90A_eus-gaap--AmortizationOfFinancingCosts_c20210825__20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zVZ9UOeEzA46" title="Amortization of debt issuance costs"&gt;200,000&lt;/span&gt; in financing costs at the earlier of the term date of the loan, or pre-payment.
These costs are being accreted, through interest expense, to the full value of the $&lt;span id="xdx_902_eus-gaap--AccretionExpense_c20210825__20210826__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z8xJYZF8FsI5" title="Accretion expense"&gt;200,000&lt;/span&gt; over the term of the loan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Debt
Modification and Revolving Line of Credit&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 29, 2022, the Company executed the Second Modification (the &#x201c;Second Modification&#x201d;) to the Second Amended and Restated
Loan and Security Agreement (as amended and modified, the &#x201c;Loan Agreement&#x201d;). The Second Modification expanded the Company&#x2019;s
total borrowing to include a $&lt;span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zbZxdumpgfDb" title="Line of credit facility, maximum borrowing capacity"&gt;2,000,000&lt;/span&gt; revolving line of credit. The revolving line of credit is co-terminus with the term loan and
matures on &lt;span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zzY8SicthUyk" title="Line of credit facility, matures"&gt;August 26, 2026&lt;/span&gt;. There are no requirements to draw on the line of credit. Amounts outstanding under the line of credit portion
of the Loan Agreement bear interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20221129__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_z1sKUFS2jD6h" title="Debt instrument, interest rate, effective percentage"&gt;1.5&lt;/span&gt;%,
with a Prime &#x201c;floor&#x201d; rate of &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20221129__us-gaap--VariableRateAxis__us-gaap--BaseRateMember__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zTdGrQuN08lk" title="Debt instrument, interest rate, effective percentage"&gt;3.25&lt;/span&gt;%. The Second Modification also amended the covenants of the Company under the Loan Agreement.
At January 31, 2024, there was a $&lt;span id="xdx_90C_eus-gaap--LongTermLineOfCredit_iI_c20240131_zVOo7cyBolKa" title="Line of credit"&gt;1,500,000&lt;/span&gt; balance outstanding on the revolving line of credit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Second Modification includes customary financial covenants as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Minimum
    Cash. &lt;/b&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentCovenantDescription_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zAi2y4nfay61" title="Debt financial covenants, description"&gt;Borrowers shall, at all times, maintain unrestricted cash in an amount not less than Two Million Dollars ($2,000,000).&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Maximum
    Debt to ARR Ratio. &lt;/b&gt;Borrowers&#x2019; Maximum Debt to ARR Ratio, measured on a quarterly basis as of the last day of each fiscal
    quarter, shall not be greater than the amount set forth under the heading &#x201c;Maximum Debt to ARR Ratio&#x201d; as of, and for
    each of the dates appearing adjacent to such &#x201c;Maximum Debt to ARR Ratio&#x201d;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_89C_ecustom--ScheduleOfMaximumDebtToARRRatioTableTextBlock_zFsyON9BqLI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_z3IDq1bf3Ssi" style="display: none"&gt;SCHEDULE OF MAXIMUM DEBT TO ARR RATIO&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 82%; font-weight: bold"&gt;Quarter Ending&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Maximum Debt to&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ARR Ratio&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;October 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_900_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyTwoMember__srt--RangeAxis__srt--MinimumMember_zkYZyp1qcArk" title="Maximum Debt to ARR Ratio"&gt;0.80&lt;/span&gt; to &lt;span id="xdx_90A_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyTwoMember__srt--RangeAxis__srt--MaximumMember_zS6lLRAspk34" title="Maximum Debt to ARR Ratio"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;January 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_z0nfek6Cs6Mk" title="Maximum Debt to ARR Ratio"&gt;0.70&lt;/span&gt; to &lt;span id="xdx_90B_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_zGxFFbwbwcJf" title="Maximum Debt to ARR Ratio"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;April 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_zjdTm3Km4f02" title="Maximum Debt to ARR Ratio"&gt;0.65&lt;/span&gt; to &lt;span id="xdx_90B_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_z5yhyJiREnbi" title="Maximum Debt to ARR Ratio"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;July 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_zlDVmHjdrCC9" title="Maximum Debt to ARR Ratio"&gt;0.60&lt;/span&gt; to &lt;span id="xdx_908_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_zIU2Q1CZLso3" title="Maximum Debt to ARR Ratio"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;October 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_900_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_z2V2Wox2jlPh" title="Maximum Debt to ARR Ratio"&gt;0.55&lt;/span&gt; to &lt;span id="xdx_90B_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_zjZmiRMW8Ztd" title="Maximum Debt to ARR Ratio"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;January 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyFourMember__srt--RangeAxis__srt--MinimumMember_zBWwJwWdAdPd" title="Maximum Debt to ARR Ratio"&gt;0.50&lt;/span&gt; to &lt;span id="xdx_90A_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyFourMember__srt--RangeAxis__srt--MaximumMember_zMtLsRQmtJC4" title="Maximum Debt to ARR Ratio"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zHzogOIpf796" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;c.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Maximum
    Debt to Adjusted EBITDA Ratio. &lt;/b&gt;Commencing with the quarter ending April 30, 2024, Borrowers&#x2019; Maximum Debt to Adjusted EBITDA
    Ratio, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4) quarter period then ended,
    shall not be greater than the amount set forth under the heading &#x201c;Maximum Debt to Adjusted EBITDA Ratio&#x201d; as of, and for
    each of the dates appearing adjacent to such &#x201c;Maximum Debt to Adjusted EBITDA Ratio&#x201d;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p id="xdx_897_ecustom--ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock_z2gxz2BthnRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_z751i3gbxyBb" style="display: none"&gt;SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 82%; font-weight: bold"&gt;Quarter Ending&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center"&gt;Maximum Debt to &lt;br/&gt; Adjusted EBITDA &lt;br/&gt; Ratio&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;April 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFourMember__srt--RangeAxis__srt--MaximumMember_zkR455tskqui" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;3.50&lt;/span&gt; to &lt;span id="xdx_906_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFourMember__srt--RangeAxis__srt--MinimumMember_zoRTWmnmgy78" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;July 31, 2024 and on the last day of each quarter, thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFourAndThereafterMember__srt--RangeAxis__srt--MaximumMember_zNn7v3KAhd88" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;2.00&lt;/span&gt; to &lt;span id="xdx_908_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFourAndThereafterMember__srt--RangeAxis__srt--MinimumMember_zVr7Scg6blh1" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_ziSMZYVA39b1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;d.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fixed
    Charge Coverage Ratio&lt;/b&gt;. Commencing with the quarter ending April 30, 2024, Borrowers shall maintain a Fixed Charge Coverage Ratio
    of not less than &lt;span id="xdx_90E_ecustom--FixedChargeCoverageRatio_iI_pid_dp_uPure_c20240131__us-gaap--TypeOfArrangementAxis__custom--SecondAmendedAndRestatedLoanAgreementMember__srt--RangeAxis__srt--MaximumMember_zstQE2rV7Vya" title="Fixed charge coverage ratio"&gt;1.20&lt;/span&gt; to &lt;span id="xdx_90B_ecustom--FixedChargeCoverageRatio_iI_pid_dp_uPure_c20240131__us-gaap--TypeOfArrangementAxis__custom--SecondAmendedAndRestatedLoanAgreementMember__srt--RangeAxis__srt--MinimumMember_ze42ulTljAX2" title="Fixed charge coverage ratio"&gt;1.00&lt;/span&gt;, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4)
    quarter period then ended.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Loan Agreement also includes customary negative covenants, subject to exceptions, which limit transfers, capital expenditures, indebtedness,
certain liens, investments, acquisitions, dispositions of assets, restricted payments, and the business activities of the Company, as
well as customary representations and warranties, affirmative covenants and events of default, including cross defaults and a change
of control default. The line of credit also is subject to customary prepayment requirements. For the period ended January 31, 2024, the
Company was not in compliance with the Maximum Debt to ARR Ratio covenant pursuant to the Second Modification; however, on February 7,
2024, the Company was provided a waiver exception for being non-compliant. (Refer to Note 14 &#x2013; Subsequent to our consolidated financial
statements included in Part II, Item 8, &#x201c;Financial Statements and Supplementary Data&#x201d; for additional information.). Substantially
all the assets of the Company are collateralized by the Loan Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded $&lt;span id="xdx_903_eus-gaap--DeferredOfferingCosts_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_ztfOiIrVBthh" title="Deferred offering costs"&gt;20,000&lt;/span&gt; in deferred financing costs related to the Second Modification. These deferred financing costs are being amortized
over the remaining term of the loan. The Company also incurred $&lt;span id="xdx_90F_eus-gaap--AmortizationOfFinancingCosts_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zdXe0A0VdW5k" title="Amortization of debt issuance costs"&gt;50,000&lt;/span&gt; in financing costs at the earlier of the term date of the loan,
or pre-payment. These costs are being accreted, through interest expense, to the full value of the $&lt;span id="xdx_902_eus-gaap--AccretionExpense_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--SecondModificationAgreementMember_zYaSLtehLtff" title="Accretion expense"&gt;250,000&lt;/span&gt; over the remaining term of
the loan. The full value of $&lt;span id="xdx_903_eus-gaap--AccretionExpense_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zeeRIhZKuXXh" title="Accretion expense"&gt;250,000&lt;/span&gt; includes the $&lt;span id="xdx_906_eus-gaap--AmortizationOfFinancingCosts_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zvowiqlzqXJ4" title="Amortization of debt issuance costs"&gt;200,000&lt;/span&gt; costs incurred in connection with the Loan Agreement (see below).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 7, 2024, the Company executed the Third Modification and Waiver (the &#x201c;Third Modification&#x201d;) to the Loan Agreement.
Refer to Note 14 &#x2013; Subsequent Events to our consolidated financial statements included in Part II, Item 8, &#x201c;Financial Statements
and Supplementary Data&#x201d; for additional information regarding the Third Modification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact000971">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDebtTableTextBlock_zZTqivM7mC6l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
principal balances on debt consisted of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zIytIO7PNH0l" style="display: none"&gt;SCHEDULE OF OUTSTANDING PRINCIPAL BALANCES&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240131_zacxl86TTnN4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230131_zRpV9I2nBiVh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzuRq_zw3eOnhiWl2h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Term loan&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;9,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;9,750,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FinancingCostPayable_iI_maLTDzuRq_z5rOfXEcrXl2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;p style="margin: 0"&gt;Financing cost payable&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;135,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DeferredFinancingCost_iNI_di_msLTDzuRq_zd3Zcy02MIQ6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Deferred financing cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(69,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(105,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LongTermDebt_iTI_mtLTDzuRq_z56OAhOzgq42" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,066,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,714,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LongTermDebtCurrent_iNI_di_zWlNIc4uEZT1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Less: Current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(750,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iTI_zvHBV6E31KO2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Non-current portion of debt&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,566,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,964,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000973"
      unitRef="USD">9000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000974"
      unitRef="USD">9750000</us-gaap:DebtInstrumentCarryingAmount>
    <STRM:FinancingCostPayable
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000976"
      unitRef="USD">135000</STRM:FinancingCostPayable>
    <STRM:FinancingCostPayable
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000977"
      unitRef="USD">69000</STRM:FinancingCostPayable>
    <STRM:DeferredFinancingCost
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000979"
      unitRef="USD">69000</STRM:DeferredFinancingCost>
    <STRM:DeferredFinancingCost
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000980"
      unitRef="USD">105000</STRM:DeferredFinancingCost>
    <us-gaap:LongTermDebt
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000982"
      unitRef="USD">9066000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000983"
      unitRef="USD">9714000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000985"
      unitRef="USD">1500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000986"
      unitRef="USD">750000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact000988"
      unitRef="USD">7566000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact000989"
      unitRef="USD">8964000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2021-08-26_custom_LoanAgreementMember_custom_WesternAllianceBankMember"
      decimals="0"
      id="Fact000991"
      unitRef="USD">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2021-08-26_us-gaap_PrimeRateMember"
      decimals="INF"
      id="Fact000993"
      unitRef="Pure">0.015</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-08-26_us-gaap_BaseRateMember"
      decimals="INF"
      id="Fact000995"
      unitRef="Pure">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="AsOf2021-08-26_custom_LoanAgreementMember_custom_WesternAllianceBankMember"
      decimals="0"
      id="Fact000997"
      unitRef="USD">500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="AsOf2021-08-26_custom_LoanAgreementMember_custom_WesternAllianceBankMember"
      decimals="0"
      id="Fact000999"
      unitRef="USD">1000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="AsOf2021-08-26_custom_LoanAgreementMember_custom_WesternAllianceBankMember"
      decimals="0"
      id="Fact001001"
      unitRef="USD">2000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="AsOf2021-08-26_custom_SecurityAgreementMember_custom_BridgeBankMember"
      decimals="0"
      id="Fact001003"
      unitRef="USD">3000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2021-08-26_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001005"
      unitRef="USD">130000</us-gaap:DeferredOfferingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2021-08-252021-08-26_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001007"
      unitRef="USD">200000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AccretionExpense
      contextRef="From2021-08-252021-08-26_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001009"
      unitRef="USD">200000</us-gaap:AccretionExpense>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2022-11-29_custom_SecondModificationAgreementMember"
      decimals="0"
      id="Fact001011"
      unitRef="USD">2000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2022-11-282022-11-29_custom_SecondModificationAgreementMember"
      id="Fact001013">2026-08-26</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2022-11-29_us-gaap_PrimeRateMember_custom_SecondModificationAgreementMember"
      decimals="INF"
      id="Fact001015"
      unitRef="Pure">0.015</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2022-11-29_us-gaap_BaseRateMember_custom_SecondModificationAgreementMember"
      decimals="INF"
      id="Fact001017"
      unitRef="Pure">0.0325</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermLineOfCredit
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001019"
      unitRef="USD">1500000</us-gaap:LongTermLineOfCredit>
    <us-gaap:DebtInstrumentCovenantDescription
      contextRef="From2022-11-282022-11-29_custom_SecondModificationAgreementMember"
      id="Fact001021">Borrowers shall, at all times, maintain unrestricted cash in an amount not less than Two Million Dollars ($2,000,000).</us-gaap:DebtInstrumentCovenantDescription>
    <STRM:ScheduleOfMaximumDebtToARRRatioTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001023">&lt;p id="xdx_89C_ecustom--ScheduleOfMaximumDebtToARRRatioTableTextBlock_zFsyON9BqLI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_z3IDq1bf3Ssi" style="display: none"&gt;SCHEDULE OF MAXIMUM DEBT TO ARR RATIO&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 82%; font-weight: bold"&gt;Quarter Ending&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Maximum Debt to&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ARR Ratio&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;October 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_900_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyTwoMember__srt--RangeAxis__srt--MinimumMember_zkYZyp1qcArk" title="Maximum Debt to ARR Ratio"&gt;0.80&lt;/span&gt; to &lt;span id="xdx_90A_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyTwoMember__srt--RangeAxis__srt--MaximumMember_zS6lLRAspk34" title="Maximum Debt to ARR Ratio"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;January 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_z0nfek6Cs6Mk" title="Maximum Debt to ARR Ratio"&gt;0.70&lt;/span&gt; to &lt;span id="xdx_90B_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_zGxFFbwbwcJf" title="Maximum Debt to ARR Ratio"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;April 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_zjdTm3Km4f02" title="Maximum Debt to ARR Ratio"&gt;0.65&lt;/span&gt; to &lt;span id="xdx_90B_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_z5yhyJiREnbi" title="Maximum Debt to ARR Ratio"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;July 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_zlDVmHjdrCC9" title="Maximum Debt to ARR Ratio"&gt;0.60&lt;/span&gt; to &lt;span id="xdx_908_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_zIU2Q1CZLso3" title="Maximum Debt to ARR Ratio"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;October 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_900_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MinimumMember_z2V2Wox2jlPh" title="Maximum Debt to ARR Ratio"&gt;0.55&lt;/span&gt; to &lt;span id="xdx_90B_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyThreeMember__srt--RangeAxis__srt--MaximumMember_zjZmiRMW8Ztd" title="Maximum Debt to ARR Ratio"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;January 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyFourMember__srt--RangeAxis__srt--MinimumMember_zBWwJwWdAdPd" title="Maximum Debt to ARR Ratio"&gt;0.50&lt;/span&gt; to &lt;span id="xdx_90A_ecustom--MaximumDebtToArrRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentyFourMember__srt--RangeAxis__srt--MaximumMember_zMtLsRQmtJC4" title="Maximum Debt to ARR Ratio"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</STRM:ScheduleOfMaximumDebtToARRRatioTableTextBlock>
    <STRM:MaximumDebtToArrRatio
      contextRef="AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandAndTwentyTwoMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001025"
      unitRef="Pure">0.0080</STRM:MaximumDebtToArrRatio>
    <STRM:MaximumDebtToArrRatio
      contextRef="AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandAndTwentyTwoMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001027"
      unitRef="Pure">0.0100</STRM:MaximumDebtToArrRatio>
    <STRM:MaximumDebtToArrRatio
      contextRef="AsOf2024-01-31_custom_JanuaryThirtyOneTwoThousandTwentyThreeMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001029"
      unitRef="Pure">0.0070</STRM:MaximumDebtToArrRatio>
    <STRM:MaximumDebtToArrRatio
      contextRef="AsOf2024-01-31_custom_JanuaryThirtyOneTwoThousandTwentyThreeMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001031"
      unitRef="Pure">0.0100</STRM:MaximumDebtToArrRatio>
    <STRM:MaximumDebtToArrRatio
      contextRef="AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyThreeMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001033"
      unitRef="Pure">0.0065</STRM:MaximumDebtToArrRatio>
    <STRM:MaximumDebtToArrRatio
      contextRef="AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyThreeMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001035"
      unitRef="Pure">0.0100</STRM:MaximumDebtToArrRatio>
    <STRM:MaximumDebtToArrRatio
      contextRef="AsOf2024-01-31_custom_JulyThirtyOneTwoThousandTwentyThreeMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001037"
      unitRef="Pure">0.0060</STRM:MaximumDebtToArrRatio>
    <STRM:MaximumDebtToArrRatio
      contextRef="AsOf2024-01-31_custom_JulyThirtyOneTwoThousandTwentyThreeMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001039"
      unitRef="Pure">0.0100</STRM:MaximumDebtToArrRatio>
    <STRM:MaximumDebtToArrRatio
      contextRef="AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandTwentyThreeMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001041"
      unitRef="Pure">0.0055</STRM:MaximumDebtToArrRatio>
    <STRM:MaximumDebtToArrRatio
      contextRef="AsOf2024-01-31_custom_OctoberThirtyOneTwoThousandTwentyThreeMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001043"
      unitRef="Pure">0.0100</STRM:MaximumDebtToArrRatio>
    <STRM:MaximumDebtToArrRatio
      contextRef="AsOf2024-01-31_custom_JanuaryThirtyOneTwoThousandTwentyFourMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001045"
      unitRef="Pure">0.0050</STRM:MaximumDebtToArrRatio>
    <STRM:MaximumDebtToArrRatio
      contextRef="AsOf2024-01-31_custom_JanuaryThirtyOneTwoThousandTwentyFourMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001047"
      unitRef="Pure">0.0100</STRM:MaximumDebtToArrRatio>
    <STRM:ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001049">&lt;p id="xdx_897_ecustom--ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock_z2gxz2BthnRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_z751i3gbxyBb" style="display: none"&gt;SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 82%; font-weight: bold"&gt;Quarter Ending&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center"&gt;Maximum Debt to &lt;br/&gt; Adjusted EBITDA &lt;br/&gt; Ratio&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;April 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFourMember__srt--RangeAxis__srt--MaximumMember_zkR455tskqui" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;3.50&lt;/span&gt; to &lt;span id="xdx_906_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFourMember__srt--RangeAxis__srt--MinimumMember_zoRTWmnmgy78" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;July 31, 2024 and on the last day of each quarter, thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFourAndThereafterMember__srt--RangeAxis__srt--MaximumMember_zNn7v3KAhd88" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;2.00&lt;/span&gt; to &lt;span id="xdx_908_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240131__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFourAndThereafterMember__srt--RangeAxis__srt--MinimumMember_zVr7Scg6blh1" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</STRM:ScheduleOfMaximumDebtToAdjustedEBITDARatioTableTextBlock>
    <STRM:MaximumDebtToAdjustedEbitdaRatio
      contextRef="AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyFourMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001051"
      unitRef="Pure">0.0350</STRM:MaximumDebtToAdjustedEbitdaRatio>
    <STRM:MaximumDebtToAdjustedEbitdaRatio
      contextRef="AsOf2024-01-31_custom_AprilThirtyTwoThousandTwentyFourMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001053"
      unitRef="Pure">0.0100</STRM:MaximumDebtToAdjustedEbitdaRatio>
    <STRM:MaximumDebtToAdjustedEbitdaRatio
      contextRef="AsOf2024-01-31_custom_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001055"
      unitRef="Pure">0.0200</STRM:MaximumDebtToAdjustedEbitdaRatio>
    <STRM:MaximumDebtToAdjustedEbitdaRatio
      contextRef="AsOf2024-01-31_custom_JulyThirtyOneTwoThousandTwentyFourAndThereafterMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001057"
      unitRef="Pure">0.0100</STRM:MaximumDebtToAdjustedEbitdaRatio>
    <STRM:FixedChargeCoverageRatio
      contextRef="AsOf2024-01-31_custom_SecondAmendedAndRestatedLoanAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001059"
      unitRef="Pure">0.0120</STRM:FixedChargeCoverageRatio>
    <STRM:FixedChargeCoverageRatio
      contextRef="AsOf2024-01-31_custom_SecondAmendedAndRestatedLoanAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001061"
      unitRef="Pure">0.0100</STRM:FixedChargeCoverageRatio>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2022-11-29_custom_SecondModificationAgreementMember"
      decimals="0"
      id="Fact001063"
      unitRef="USD">20000</us-gaap:DeferredOfferingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2022-11-282022-11-29_custom_SecondModificationAgreementMember"
      decimals="0"
      id="Fact001065"
      unitRef="USD">50000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AccretionExpense
      contextRef="From2022-11-282022-11-29_custom_SecondModificationAgreementMember"
      decimals="0"
      id="Fact001067"
      unitRef="USD">250000</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="From2022-11-282022-11-29_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001069"
      unitRef="USD">250000</us-gaap:AccretionExpense>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2022-11-282022-11-29_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001071"
      unitRef="USD">200000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001073">&lt;p id="xdx_803_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zwOGYfPl1Qci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
6 &#x2014; &lt;span id="xdx_82D_zUp5YMYXKat6"&gt;GOODWILL AND INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Goodwill&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zZardVLaIU58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
changes in the carrying amount of goodwill were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zxZmo1Gj5IRe" style="display: none"&gt;SCHEDULE OF CARRYING AMOUNT OF GOODWILL&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Balance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; font-weight: bold"&gt;Balance as of January 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--Goodwill_iS_c20230201__20240131_zlxNipDbwq9l" style="width: 18%; text-align: right" title="Beginning Balance"&gt;23,089,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--GoodwillImpairmentLoss_iN_di_c20230201__20240131_zyFcjkFtMFB7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment"&gt;(9,813,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance as of January 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Goodwill_iE_c20230201__20240131_zsZz6nlQnf98" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;13,276,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z27e2JlM9LW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2023, the Company was notified by a legacy client of its intent to not renew its contract as of its expiration on December 31,
2023. At that time, the Company elected to accelerate the execution of a planned strategic restructuring that was designed to reduce
costs while maintaining the Company&#x2019;s ability to expand its SaaS business. Both the client termination and the execution of the
strategic restructuring were announced on October 16, 2023. Following these announcements, the Company&#x2019;s share price declined significantly.
Based on these events (collectively, the &#x201c;Triggering Events&#x201d;), the Company identified indicators of possible impairment and
initiated testing using a valuation date of October 31, 2023. The impairment tests were conducted under guidance of ASC Topic 360, Impairment
and Disposal of Long-Lived Assets (&#x201c;ASC 360&#x201d;) for certain long-lived assets, including capitalized contract costs, developed
technology, client relationships and trade names, and in accordance with ASC Topic 350, Intangibles &#x2013; Goodwill and Other (&#x201c;ASC
350&#x201d;) with respect to the reporting unit&#x2019;s goodwill.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined that, effective January 31, 2023, it had one reporting unit for purposes of evaluation of goodwill. Based on the Triggering
Events and in conjunction with the preparation of the Company&#x2019;s financial statements for the three and nine months ended October
31, 2023, the Company tested the reporting unit&#x2019;s goodwill for possible impairment as of October 31, 2023. The testing for impairment
was performed under the guidance of ASC 350. The testing utilized a discounted debt-free net cash flow (&#x201c;DCF&#x201d;) method under
the income approach and the market capitalization method (&#x201c;MCM&#x201d;) under the market approach. The sum of the weighted values
of each method was used to derive the fair value of the Company&#x2019;s equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
MCM calculates the aggregate market value of the Company based on the total number of shares outstanding and the current market price
of the shares as of the valuation date. Data on similar mergers and acquisitions within the healthcare technology sector are observed
to determine control premium that represents a stock premium percentage offered by an acquirer to a public company. The control premium
applied to the aggregate market value represents MCM calculated fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
DCF incorporates the use of projected financial information and a discount rate using a weighted average cost of capital with cost of
equity estimated based on the capital asset pricing model. The cash-flow projections are based on financial forecasts developed by management
that include forecasts of future operating results based on internal budgets and strategic plans to invest in working capital to support
anticipated revenue growth. External factors and business conditions are considered by management when setting the long-term growth rates.
The selected discount rate considers the risk and nature of the reporting unit&#x2019;s cash flows and the rates of return market participants
would require to invest their capital in the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company concluded that its goodwill was impaired based on the weighted combination of the DCF and MCM value estimates which resulted
in a calculated fair value lower than the equity carrying value. The Company recorded an impairment of goodwill in the amount of $&lt;span id="xdx_902_eus-gaap--GoodwillImpairmentLoss_c20230201__20240131_zr3YIcIRhfe6" title="Iimpairment of goodwill"&gt;9,813,000&lt;/span&gt;
reported as &#x201c;Goodwill Impairment&#x201d; on its condensed consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z0tKhaXfP2ba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zCWJo3lKiO31" style="display: none"&gt;SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Estimated&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Useful Life&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Gross&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Accumulated&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finite-lived assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 32%; text-align: left"&gt;Client relationships&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zrAtJp1Pwu99"&gt;10
&lt;/span&gt;years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zPJhIoUfjtKd" style="width: 14%; text-align: right"&gt;8,370,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zw0aySaIuQo2" style="width: 14%; text-align: right"&gt;2,058,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zbvzIg2SW02k" style="width: 14%; text-align: right"&gt;6,312,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Internally developed software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zj9hTXL9sRC9" title="Estimated Useful Life"&gt;9&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zuZLW7E0x7p1" style="text-align: right"&gt;6,380,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zWvK68GGiqZ1" style="text-align: right"&gt;1,742,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zbgqaPz0jdNk" style="text-align: right"&gt;4,638,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Trademarks and tradenames&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zolfD7Xprw4j" title="Estimated Useful Life"&gt;15&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zhhRANoQzo49" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,340,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zgxDtPUtCJSj" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;219,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zMOvLqsAVzh5" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,121,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131_z1OkRfogUgF1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,090,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131_zLFdb3M5fFda" style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,019,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131_zcTyDDCzHyGg" style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,071,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 31, 2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Estimated&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Accumulated&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt; Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finite-lived assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 42%; text-align: left"&gt;Client relationships&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zV1i0JE3VEpk" title="Estimated Useful Life"&gt;8&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember__srt--RangeAxis__srt--MaximumMember_z8hVTU3RojKg" title="Estimated Useful Life"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zzoDVtEV274l" style="width: 11%; text-align: right" title="Gross Assets"&gt;9,700,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zCK2Hn9NRNKd" style="width: 11%; text-align: right" title="Accumulated Amortization"&gt;1,463,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zBouebbLJZMb" style="width: 11%; text-align: right" title="Net Assets"&gt;8,237,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Internally Developed Software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zeeptGzkGeei" title="Estimated Useful Life"&gt;9&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_z0VNmctoNHRb" style="text-align: right" title="Gross Assets"&gt;6,380,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zQoRviMMpna8" style="text-align: right" title="Accumulated Amortization"&gt;1,034,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zFptHsuDx831" style="text-align: right" title="Net Assets"&gt;5,346,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Trademarks and Tradenames&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zXxhFr1tiWyg" title="Estimated Useful Life"&gt;15&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zeu2D5Iz8Rm1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Assets"&gt;1,340,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zJTw8PcWAA04" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Amortization"&gt;130,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zXmjGzLczgw6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Assets"&gt;1,210,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131_zYwcI85UHPe2" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Assets"&gt;17,420,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131_z1I7dKke1HEa" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization"&gt;2,627,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131_zKr0y3GhpsI3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Assets"&gt;14,793,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zRgg54n2w0Ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
360 defines a multi-step process to test long-lived assets, including intangible assets, for recoverability that if failed would indicate
impairment. First, the Company must consider whether indicators of impairment of long-lived assets are present, which the Company determined
the Triggering Events provided such indication.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Next,
the Company must review the long-lived assets to define asset group(s) that would reflect the lowest level of assets to which discrete
cash flows are identifiable. In performing this review, the Company identified that the long-lived asset &#x201c;client relationships&#x201d;
related to Avelead should be classified as abandoned (the &#x201c;Abandoned Asset&#x201d;) with the Company determining that it no longer
has plans to provide the corresponding consulting service. The Abandoned Asset&#x2019;s carrying value would need to be set to its salvage
value which would be zero given no future cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined the lowest level of discrete cash flows is at the reporting unit level, and all remaining long-lived assets (excluding
the Abandoned Asset) and goodwill would represent its only asset group. Recoverability is assessed by comparing that the sum of the discrete
undiscounted cash flows exceeds the carrying value of the asset group. The undiscounted cash flow projections are based on 8-year (representing
the useful life of the primary asset in the asset group) financial forecasts developed by management that include forecasts of future
operating results based on internal budgets and strategic plans to investment in working capital to support anticipated revenue growth.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
undiscounted cash flows for the long-lived assets were above the carrying amounts indicating that the long-lived asset group is recoverable
and no further impairment to long-lived assets exists as of October 31, 2023. In fiscal 2023, the Company recorded $&lt;span id="xdx_900_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_c20230201__20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z4d3XJczvN0k" title="Impairment of intangible assets"&gt;963,000&lt;/span&gt; as &#x201c;Impairment
of long-lived assets&#x201d; on its condensed consolidated statement of operations to adjust the Abandoned Asset to its salvage value
of zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized amortization expense on intangible assets of $&lt;span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230201__20240131_zeHV6Fia2Wl1" title="Amortization expense on intangible assets"&gt;1,760,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220201__20230131_z6qmN26wFBeb" title="Amortization expense on intangible assets"&gt;1,971,000&lt;/span&gt; for fiscal 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z3WsMyjAmgHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
over the next five fiscal years for intangible assets is estimated as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zheQPGRews7k" style="display: none"&gt;SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240131_z3oLC4PSdK9f" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Annual&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortization Expense&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_pp0p0_maFLIANzAN0_zTk48zW7E1g2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 72%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 24%; text-align: right"&gt;1,635,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_maFLIANzAN0_zzQpMrORtxil" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,635,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_maFLIANzAN0_zwCQrZv3s3Y5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,635,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_maFLIANzAN0_zaXNcPo0IcJ" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,635,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_maFLIANzAN0_zDyuNEpyY9lj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,635,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_maFLIANzAN0_zveLcOWCT879" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,896,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzAN0_zi4Bbf2nuCsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,071,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A3_zdySMZfatYue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company wrote-off the Abandoned Asset during fiscal 2023 with a gross asset value of $&lt;span id="xdx_902_ecustom--AbandonedAssetWroteOff_c20230201__20240131_zn6JKjcl5iYd" title="Abandoned asset wrote off"&gt;1,330,000&lt;/span&gt;.
There was no impact to the consolidated statements of operations as this eliminated the asset and accumulated amortization of the
fully amortized intangible assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001075">&lt;p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zZardVLaIU58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
changes in the carrying amount of goodwill were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zxZmo1Gj5IRe" style="display: none"&gt;SCHEDULE OF CARRYING AMOUNT OF GOODWILL&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Balance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; font-weight: bold"&gt;Balance as of January 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--Goodwill_iS_c20230201__20240131_zlxNipDbwq9l" style="width: 18%; text-align: right" title="Beginning Balance"&gt;23,089,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--GoodwillImpairmentLoss_iN_di_c20230201__20240131_zyFcjkFtMFB7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment"&gt;(9,813,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance as of January 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Goodwill_iE_c20230201__20240131_zsZz6nlQnf98" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;13,276,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001077"
      unitRef="USD">23089000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001079"
      unitRef="USD">9813000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001081"
      unitRef="USD">13276000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001083"
      unitRef="USD">9813000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001085">&lt;p id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z0tKhaXfP2ba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zCWJo3lKiO31" style="display: none"&gt;SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Estimated&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Useful Life&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Gross&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Accumulated&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finite-lived assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 32%; text-align: left"&gt;Client relationships&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zrAtJp1Pwu99"&gt;10
&lt;/span&gt;years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zPJhIoUfjtKd" style="width: 14%; text-align: right"&gt;8,370,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zw0aySaIuQo2" style="width: 14%; text-align: right"&gt;2,058,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zbvzIg2SW02k" style="width: 14%; text-align: right"&gt;6,312,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Internally developed software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zj9hTXL9sRC9" title="Estimated Useful Life"&gt;9&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zuZLW7E0x7p1" style="text-align: right"&gt;6,380,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zWvK68GGiqZ1" style="text-align: right"&gt;1,742,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zbgqaPz0jdNk" style="text-align: right"&gt;4,638,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Trademarks and tradenames&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zolfD7Xprw4j" title="Estimated Useful Life"&gt;15&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zhhRANoQzo49" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,340,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zgxDtPUtCJSj" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;219,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zMOvLqsAVzh5" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,121,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20240131_z1OkRfogUgF1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,090,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240131_zLFdb3M5fFda" style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,019,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20240131_zcTyDDCzHyGg" style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,071,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 31, 2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Estimated&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Accumulated&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt; Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finite-lived assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 42%; text-align: left"&gt;Client relationships&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zV1i0JE3VEpk" title="Estimated Useful Life"&gt;8&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember__srt--RangeAxis__srt--MaximumMember_z8hVTU3RojKg" title="Estimated Useful Life"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zzoDVtEV274l" style="width: 11%; text-align: right" title="Gross Assets"&gt;9,700,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zCK2Hn9NRNKd" style="width: 11%; text-align: right" title="Accumulated Amortization"&gt;1,463,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClientRelationshipsMember_zBouebbLJZMb" style="width: 11%; text-align: right" title="Net Assets"&gt;8,237,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Internally Developed Software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zeeptGzkGeei" title="Estimated Useful Life"&gt;9&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_z0VNmctoNHRb" style="text-align: right" title="Gross Assets"&gt;6,380,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zQoRviMMpna8" style="text-align: right" title="Accumulated Amortization"&gt;1,034,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zFptHsuDx831" style="text-align: right" title="Net Assets"&gt;5,346,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Trademarks and Tradenames&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zXxhFr1tiWyg" title="Estimated Useful Life"&gt;15&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zeu2D5Iz8Rm1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Assets"&gt;1,340,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zJTw8PcWAA04" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Amortization"&gt;130,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zXmjGzLczgw6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Assets"&gt;1,210,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230131_zYwcI85UHPe2" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Assets"&gt;17,420,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230131_z1I7dKke1HEa" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization"&gt;2,627,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230131_zKr0y3GhpsI3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Assets"&gt;14,793,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-01-31_custom_ClientRelationshipsMember"
      id="Fact001086">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-01-31_custom_ClientRelationshipsMember"
      decimals="0"
      id="Fact001087"
      unitRef="USD">8370000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-01-31_custom_ClientRelationshipsMember"
      decimals="0"
      id="Fact001088"
      unitRef="USD">2058000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-01-31_custom_ClientRelationshipsMember"
      decimals="0"
      id="Fact001089"
      unitRef="USD">6312000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-01-31_custom_InternallyDevelopedSoftwareMember"
      id="Fact001091">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-01-31_custom_InternallyDevelopedSoftwareMember"
      decimals="0"
      id="Fact001092"
      unitRef="USD">6380000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-01-31_custom_InternallyDevelopedSoftwareMember"
      decimals="0"
      id="Fact001093"
      unitRef="USD">1742000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-01-31_custom_InternallyDevelopedSoftwareMember"
      decimals="0"
      id="Fact001094"
      unitRef="USD">4638000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-01-31_us-gaap_TrademarksAndTradeNamesMember"
      id="Fact001096">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-01-31_us-gaap_TrademarksAndTradeNamesMember"
      decimals="0"
      id="Fact001097"
      unitRef="USD">1340000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-01-31_us-gaap_TrademarksAndTradeNamesMember"
      decimals="0"
      id="Fact001098"
      unitRef="USD">219000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-01-31_us-gaap_TrademarksAndTradeNamesMember"
      decimals="0"
      id="Fact001099"
      unitRef="USD">1121000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001100"
      unitRef="USD">16090000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001101"
      unitRef="USD">4019000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001102"
      unitRef="USD">12071000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-01-31_custom_ClientRelationshipsMember_srt_MinimumMember"
      id="Fact001104">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-01-31_custom_ClientRelationshipsMember_srt_MaximumMember"
      id="Fact001106">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-01-31_custom_ClientRelationshipsMember"
      decimals="0"
      id="Fact001108"
      unitRef="USD">9700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-01-31_custom_ClientRelationshipsMember"
      decimals="0"
      id="Fact001110"
      unitRef="USD">1463000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-01-31_custom_ClientRelationshipsMember"
      decimals="0"
      id="Fact001112"
      unitRef="USD">8237000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-01-31_custom_InternallyDevelopedSoftwareMember"
      id="Fact001114">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-01-31_custom_InternallyDevelopedSoftwareMember"
      decimals="0"
      id="Fact001116"
      unitRef="USD">6380000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-01-31_custom_InternallyDevelopedSoftwareMember"
      decimals="0"
      id="Fact001118"
      unitRef="USD">1034000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-01-31_custom_InternallyDevelopedSoftwareMember"
      decimals="0"
      id="Fact001120"
      unitRef="USD">5346000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-01-31_us-gaap_TrademarksAndTradeNamesMember"
      id="Fact001122">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-01-31_us-gaap_TrademarksAndTradeNamesMember"
      decimals="0"
      id="Fact001124"
      unitRef="USD">1340000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-01-31_us-gaap_TrademarksAndTradeNamesMember"
      decimals="0"
      id="Fact001126"
      unitRef="USD">130000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-01-31_us-gaap_TrademarksAndTradeNamesMember"
      decimals="0"
      id="Fact001128"
      unitRef="USD">1210000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001130"
      unitRef="USD">17420000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001132"
      unitRef="USD">2627000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001134"
      unitRef="USD">14793000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2023-02-012024-01-31_us-gaap_CustomerRelationshipsMember"
      decimals="0"
      id="Fact001136"
      unitRef="USD">963000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001138"
      unitRef="USD">1760000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001140"
      unitRef="USD">1971000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001142">&lt;p id="xdx_892_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z3WsMyjAmgHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
over the next five fiscal years for intangible assets is estimated as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zheQPGRews7k" style="display: none"&gt;SCHEDULE OF FUTURE AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240131_z3oLC4PSdK9f" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Annual&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortization Expense&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_pp0p0_maFLIANzAN0_zTk48zW7E1g2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 72%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 24%; text-align: right"&gt;1,635,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_maFLIANzAN0_zzQpMrORtxil" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,635,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_maFLIANzAN0_zwCQrZv3s3Y5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,635,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_maFLIANzAN0_zaXNcPo0IcJ" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,635,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_maFLIANzAN0_zDyuNEpyY9lj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,635,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_maFLIANzAN0_zveLcOWCT879" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,896,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzAN0_zi4Bbf2nuCsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,071,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001144"
      unitRef="USD">1635000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001146"
      unitRef="USD">1635000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001148"
      unitRef="USD">1635000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001150"
      unitRef="USD">1635000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001152"
      unitRef="USD">1635000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001154"
      unitRef="USD">3896000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001156"
      unitRef="USD">12071000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <STRM:AbandonedAssetWroteOff
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001158"
      unitRef="USD">1330000</STRM:AbandonedAssetWroteOff>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001160">&lt;p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_z0QsTAEQDhKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
7 &#x2014; &lt;span id="xdx_825_zUoyWeLKFENi"&gt;INCOME TAXES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z1Qrk4Y3zRCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
fiscal 2023 and 2022, income taxes  consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zA0vPqReRg71" style="display: none"&gt;SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230201__20240131_zK9Z94Chs8Aj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220201__20230131_ztYIg4MFNvs7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zHdWE5OHgBu4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current tax expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pp0p0_maCITEBzxs7_maCITEBzyfy_zln98wYUgcac" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1168"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_maCITEBzxs7_maCITEBzyfy_z0HCcPDp7gu5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 68%; padding-bottom: 1.5pt"&gt;State&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right"&gt;(58,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right"&gt;(62,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_mtCITEBzyfy_maITEBzkRn_zI44rvTIDQjh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Total current tax benefit (expense)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(58,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(62,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_pp0p0_zVVcGihGw8gi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_pp0p0_maDITEBzEci_zX46sTZiTwB9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;86,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_pp0p0_maDITEBzEci_z0sLtM9QTvO5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_mtDITEBzEci_maITEBzkRn_zEsztPFY84Xi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Total deferred tax benefit (expense)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;104,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iNT_pp0p0_di_zAQDDkMGpnl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt"&gt;Income tax benefit (expense)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;46,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(71,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zGMnPHHgPuia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
income tax expense differs from the amount computed using the federal statutory income tax rate of &lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230201__20240131_zwyrMnXeSjJf" title="Federal statutory income tax rates"&gt;&lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220201__20230131_zyESb8BACKog" title="Federal statutory income tax rates"&gt;21&lt;/span&gt;&lt;/span&gt;% for fiscal 2023 and 2022 as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zMHzVXyBtkoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zpGmPnL31wr4" style="display: none"&gt;SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230201__20240131_zdRPrvbxm4N2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220201__20230131_znHyhoj5jHN1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzHX9_zYnfgoYxevDb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Federal tax benefit at statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,887,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,348,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzHX9_zZ04t8iYdAol" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State and local tax expense, net of federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(28,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(52,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--IncreaseInValuationAllowance_maITEBzHX9_z7as09OTZl36" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Increase in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,994,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,128,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Permanent items:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzHX9_zrEiOYLMxBih" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(36,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationTaxContingencies_maITEBzHX9_ztJDKeJbtkIi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reserve for uncertain tax position&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzHX9_zFpDOgFQVLdj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Federal research and development (R&amp;amp;D) tax credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maITEBzHX9_zpOrSEBP7lQc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;135,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(289,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzHX9_zEbhWzWLmjt" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;56,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_iN_pp0p0_di_mtITEBzHX9_zQgu6mmP2ozl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income tax benefit (expense)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;46,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(71,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zgdgYCRdCv9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zv36hcAdw4Jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides deferred income taxes for temporary differences between assets and liabilities recognized for financial reporting and
income tax purposes. The income tax effects of these temporary differences and credits are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zfItXsqgt5ii" style="display: none"&gt;SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240131_zXO8HXMTiuV8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230131_z8vd3bHHaNpi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_pp0p0_maDTAGz9oc_zRIO7O8FElF" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 68%; text-align: left"&gt;Allowance for credit losses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;26,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;39,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pp0p0_maDTAGz9oc_zd6lF5OZoxfc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Deferred revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;209,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent_iI_pp0p0_maDTAGz9oc_zeOTs4iteHP8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;232,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGz9oc_zMLinn0EzTNg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,748,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,242,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGz9oc_zCWnxE8BKypi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock-based compensation &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;427,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;342,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0_maDTAGz9oc_z85X9citugQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Finite-lived intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,739,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,344,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGz9oc_zBnPnRI21A1d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;R&amp;amp;D tax credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,434,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,407,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGz9oc_zIclNQdpMsZi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz9oc_maDTANzJA3_zkAnyFA288R1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,651,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,730,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzJA3_zDkBBx59OVWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19,646,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,347,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzJA3_msDTLz2p6_zZJc9wZIqx7b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;383,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iNI_di_msDITLz6FT_z0DOkUahtVz9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_iNI_pp0p0_di_maDITLz6FT_zZM8b7iXr1I7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Finite-lived intangible liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1262"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(482,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pp0p0_di_mtDITLz6FT_maDTLz2p6_zcoJWLgTWOc2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(487,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxLiabilities_iNTI_pp0p0_di_mtDTLz2p6_zQ7nVN5dLW39" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1268"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(104,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_z6lYHOtDhRmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
January 31, 2024, the Company had U.S. federal net operating loss carry forwards of $&lt;span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_c20240131_zGGtBbLB9te8" title="Operating loss carry forwards"&gt;65,107,000&lt;/span&gt; and
$&lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_c20240131__us-gaap--AwardDateAxis__custom--ThroughFiscalTwoThousandThirtyEightMember_z0ISIW5wxln1" title="Operating loss carry forwards"&gt;29,083,000&lt;/span&gt;
of these net operating losses expire at various dates through fiscal 2038. The remaining $&lt;span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240131__us-gaap--IncomeTaxAuthorityAxis__custom--TaxCutsAndJobsActMember_zCo0WH0jSV71" title="Operating loss carry forwards"&gt;36,024,000&lt;/span&gt;
of these net operating losses can be carried forward indefinitely under the provisions of the Tax Cuts and Jobs Act (TCJA). The TCJA
also eliminated the ability to carry back net operating losses. The Company also had state net operating loss carry forwards of
$&lt;span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240131__us-gaap--IncomeTaxAuthorityAxis__custom--StateMember_zuICpj29hBA7" title="Operating loss carry forwards"&gt;37,650,000&lt;/span&gt;
and Federal R&amp;amp;D credit carry forwards of $&lt;span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240131__us-gaap--IncomeTaxAuthorityAxis__custom--FederalRDMember_zhseEcqZgeGe" title="Operating loss carry forwards"&gt;1,699,000&lt;/span&gt;
and Georgia R&amp;amp;D credit carry forwards of $&lt;span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240131__us-gaap--IncomeTaxAuthorityAxis__custom--GeorgiaRDMember_zqlleKFDmiul" title="Operating loss carry forwards"&gt;94,000&lt;/span&gt;,
all of which expire at various dates through fiscal 2042.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that all or some portion
of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of
future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal
of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The Company established
a valuation allowance of $&lt;span id="xdx_90B_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20240131_zMVGNVAkXOc7" title="Valuation allowance"&gt;19,646,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20230131_zusbfdb8iKXi" title="Valuation allowance"&gt;14,347,000&lt;/span&gt; at January 31, 2024 and 2023, respectively. The increase in the valuation allowance
of $&lt;span id="xdx_90B_ecustom--IncreaseInValuationAllowance_iN_di_c20230201__20240131_zd3t7kwtsuQ4" title="Increase in the valuation allowance"&gt;3,994,000&lt;/span&gt; was driven primarily by the Company&#x2019;s federal net operating losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company and its subsidiaries are subject to U.S. federal income tax as well as income taxes in multiple state and local jurisdictions.
The Company has concluded all U.S. federal tax matters for years through January 31, 2020. All material state and local income tax matters
have been concluded for years through January 31, 2019. The Company is no longer subject to IRS examination for periods prior to the
tax year ended January 31, 2020; however, carry forward losses that were generated prior to the tax year ended January 31, 2020 may still
be adjusted by the IRS if they are used in a future period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has recorded a reserve, including interest and penalties, for uncertain tax positions of $&lt;span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefits_iI_c20240131_zuyb7xilvXH1" title="Uncertain tax positions"&gt;340,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_c20230131_zeHJDZeMPYP" title="Uncertain tax positions"&gt;333,000&lt;/span&gt; as of January
31, 2024 and 2023, respectively. As of January 31, 2024 and 2023, the Company had no accrued interest and penalties associated with unrecognized
tax benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zBBYb2k1Qaif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the beginning and ending amounts of gross unrecognized tax benefits (excluding interest and penalties) is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zco6YfUw1Us3" style="display: none"&gt;SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230201__20240131_zAFXu7xAOzG5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220201__20230131_zrpjmT2kHiN6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--UnrecognizedTaxBenefits_iS_pp0p0_zcGhxziP7LK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Beginning of fiscal year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;333,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;315,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zHnr6XOaNOl4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Additions for tax positions for the current year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_znxu2MOPPXM7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Additions for tax positions of prior years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1301"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_iN_pp0p0_di_zxYg9zzSSCdb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Subtractions for tax positions of prior years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1305"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--UnrecognizedTaxBenefits_iE_pp0p0_zlVG4La0zBuf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;End of fiscal year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;340,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;333,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zQr5qCZdR7kg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001162">&lt;p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z1Qrk4Y3zRCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
fiscal 2023 and 2022, income taxes  consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zA0vPqReRg71" style="display: none"&gt;SCHEDULE OF INCOME TAXES FOR CONTINUING OPERATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230201__20240131_zK9Z94Chs8Aj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220201__20230131_ztYIg4MFNvs7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zHdWE5OHgBu4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current tax expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pp0p0_maCITEBzxs7_maCITEBzyfy_zln98wYUgcac" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1168"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_maCITEBzxs7_maCITEBzyfy_z0HCcPDp7gu5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 68%; padding-bottom: 1.5pt"&gt;State&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right"&gt;(58,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right"&gt;(62,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_mtCITEBzyfy_maITEBzkRn_zI44rvTIDQjh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Total current tax benefit (expense)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(58,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(62,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_pp0p0_zVVcGihGw8gi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_pp0p0_maDITEBzEci_zX46sTZiTwB9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;86,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_pp0p0_maDITEBzEci_z0sLtM9QTvO5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_mtDITEBzEci_maITEBzkRn_zEsztPFY84Xi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Total deferred tax benefit (expense)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;104,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iNT_pp0p0_di_zAQDDkMGpnl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt"&gt;Income tax benefit (expense)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;46,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(71,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001170"
      unitRef="USD">-58000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001171"
      unitRef="USD">-62000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001173"
      unitRef="USD">-58000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001174"
      unitRef="USD">-62000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001179"
      unitRef="USD">86000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001180"
      unitRef="USD">-6000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001182"
      unitRef="USD">18000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001183"
      unitRef="USD">-3000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001185"
      unitRef="USD">104000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001186"
      unitRef="USD">-9000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001188"
      unitRef="USD">-46000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001189"
      unitRef="USD">71000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-02-01to2024-01-31"
      decimals="INF"
      id="Fact001191"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-02-012023-01-31"
      decimals="INF"
      id="Fact001193"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001195">&lt;p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zMHzVXyBtkoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zpGmPnL31wr4" style="display: none"&gt;SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230201__20240131_zdRPrvbxm4N2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220201__20230131_znHyhoj5jHN1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzHX9_zYnfgoYxevDb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Federal tax benefit at statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,887,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,348,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzHX9_zZ04t8iYdAol" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State and local tax expense, net of federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(28,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(52,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--IncreaseInValuationAllowance_maITEBzHX9_z7as09OTZl36" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Increase in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,994,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,128,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Permanent items:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzHX9_zrEiOYLMxBih" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(36,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationTaxContingencies_maITEBzHX9_ztJDKeJbtkIi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reserve for uncertain tax position&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzHX9_zFpDOgFQVLdj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Federal research and development (R&amp;amp;D) tax credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maITEBzHX9_zpOrSEBP7lQc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;135,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(289,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzHX9_zEbhWzWLmjt" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;56,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_iN_pp0p0_di_mtITEBzHX9_zQgu6mmP2ozl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income tax benefit (expense)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;46,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(71,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001197"
      unitRef="USD">3887000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001198"
      unitRef="USD">2348000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001200"
      unitRef="USD">-28000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001201"
      unitRef="USD">-52000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <STRM:IncreaseInValuationAllowance
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001203"
      unitRef="USD">-3994000</STRM:IncreaseInValuationAllowance>
    <STRM:IncreaseInValuationAllowance
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001204"
      unitRef="USD">-2128000</STRM:IncreaseInValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001206"
      unitRef="USD">-36000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001207"
      unitRef="USD">-20000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001209"
      unitRef="USD">-7000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001210"
      unitRef="USD">-18000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001212"
      unitRef="USD">-33000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001213"
      unitRef="USD">-91000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001215"
      unitRef="USD">135000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001216"
      unitRef="USD">-289000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001218"
      unitRef="USD">56000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001219"
      unitRef="USD">-3000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001221"
      unitRef="USD">-46000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001222"
      unitRef="USD">71000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001224">&lt;p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zv36hcAdw4Jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides deferred income taxes for temporary differences between assets and liabilities recognized for financial reporting and
income tax purposes. The income tax effects of these temporary differences and credits are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zfItXsqgt5ii" style="display: none"&gt;SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240131_zXO8HXMTiuV8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230131_z8vd3bHHaNpi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_pp0p0_maDTAGz9oc_zRIO7O8FElF" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 68%; text-align: left"&gt;Allowance for credit losses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;26,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;39,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pp0p0_maDTAGz9oc_zd6lF5OZoxfc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Deferred revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;209,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent_iI_pp0p0_maDTAGz9oc_zeOTs4iteHP8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;232,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGz9oc_zMLinn0EzTNg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,748,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,242,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGz9oc_zCWnxE8BKypi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock-based compensation &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;427,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;342,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0_maDTAGz9oc_z85X9citugQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Finite-lived intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,739,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,344,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGz9oc_zBnPnRI21A1d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;R&amp;amp;D tax credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,434,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,407,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGz9oc_zIclNQdpMsZi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz9oc_maDTANzJA3_zkAnyFA288R1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,651,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,730,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzJA3_zDkBBx59OVWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19,646,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,347,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzJA3_msDTLz2p6_zZJc9wZIqx7b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;383,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iNI_di_msDITLz6FT_z0DOkUahtVz9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_iNI_pp0p0_di_maDITLz6FT_zZM8b7iXr1I7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Finite-lived intangible liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1262"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(482,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pp0p0_di_mtDITLz6FT_maDTLz2p6_zcoJWLgTWOc2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(487,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxLiabilities_iNTI_pp0p0_di_mtDTLz2p6_zQ7nVN5dLW39" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1268"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(104,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001226"
      unitRef="USD">26000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001227"
      unitRef="USD">39000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001229"
      unitRef="USD">209000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001230"
      unitRef="USD">122000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <STRM:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001232"
      unitRef="USD">67000</STRM:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent>
    <STRM:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001233"
      unitRef="USD">232000</STRM:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001235"
      unitRef="USD">15748000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001236"
      unitRef="USD">11242000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001238"
      unitRef="USD">427000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001239"
      unitRef="USD">342000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001241"
      unitRef="USD">1739000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001242"
      unitRef="USD">1344000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001244"
      unitRef="USD">1434000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001245"
      unitRef="USD">1407000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001247"
      unitRef="USD">1000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001248"
      unitRef="USD">2000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001250"
      unitRef="USD">19651000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001251"
      unitRef="USD">14730000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001253"
      unitRef="USD">19646000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001254"
      unitRef="USD">14347000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001256"
      unitRef="USD">5000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001257"
      unitRef="USD">383000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001259"
      unitRef="USD">5000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001260"
      unitRef="USD">5000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001263"
      unitRef="USD">482000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001265"
      unitRef="USD">5000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001266"
      unitRef="USD">487000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001269"
      unitRef="USD">104000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001271"
      unitRef="USD">65107000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-01-31_custom_ThroughFiscalTwoThousandThirtyEightMember"
      decimals="0"
      id="Fact001273"
      unitRef="USD">29083000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-01-31_custom_TaxCutsAndJobsActMember"
      decimals="0"
      id="Fact001275"
      unitRef="USD">36024000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-01-31_custom_StateMember"
      decimals="0"
      id="Fact001277"
      unitRef="USD">37650000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-01-31_custom_FederalRDMember"
      decimals="0"
      id="Fact001279"
      unitRef="USD">1699000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-01-31_custom_GeorgiaRDMember"
      decimals="0"
      id="Fact001281"
      unitRef="USD">94000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001283"
      unitRef="USD">19646000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001285"
      unitRef="USD">14347000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <STRM:IncreaseInValuationAllowance
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001287"
      unitRef="USD">-3994000</STRM:IncreaseInValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001289"
      unitRef="USD">340000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001291"
      unitRef="USD">333000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001293">&lt;p id="xdx_89F_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zBBYb2k1Qaif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the beginning and ending amounts of gross unrecognized tax benefits (excluding interest and penalties) is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zco6YfUw1Us3" style="display: none"&gt;SCHEDULE OF GROSS UNRECOGNIZED TAX BENEFITS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230201__20240131_zAFXu7xAOzG5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220201__20230131_zrpjmT2kHiN6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--UnrecognizedTaxBenefits_iS_pp0p0_zcGhxziP7LK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Beginning of fiscal year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;333,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;315,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zHnr6XOaNOl4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Additions for tax positions for the current year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_znxu2MOPPXM7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Additions for tax positions of prior years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1301"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_iN_pp0p0_di_zxYg9zzSSCdb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Subtractions for tax positions of prior years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1305"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--UnrecognizedTaxBenefits_iE_pp0p0_zlVG4La0zBuf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;End of fiscal year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;340,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;333,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001295"
      unitRef="USD">333000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2022-01-31"
      decimals="0"
      id="Fact001296"
      unitRef="USD">315000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001298"
      unitRef="USD">9000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001299"
      unitRef="USD">11000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001302"
      unitRef="USD">7000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001304"
      unitRef="USD">2000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact001307"
      unitRef="USD">340000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001308"
      unitRef="USD">333000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001310">&lt;p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1lTSQwNPUv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
8 &#x2014; &lt;span id="xdx_826_zKMNKL0mM8ve"&gt;EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Capital
Raise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 24, 2022, the Company entered into purchase agreements with certain investors pursuant to which the Company agreed to issue and
sell in a registered direct offering (the &#x201c;2022 Offering&#x201d;) an aggregate of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221023__20221024__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoOfferingMember_zFQ3m2idyT17" title="Number of shares issued"&gt;6,299,989&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221024__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoOfferingMember_zmlwlvaOToyl" title="Common stock par value"&gt;0.01&lt;/span&gt;
per share, at a purchase price of $&lt;span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20221024__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoOfferingMember_zrsaMwwpvWtc" title="Purchase price"&gt;1.32&lt;/span&gt; per share. The gross proceeds to the Company from the 2022 Offering were approximately $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20221023__20221024__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoOfferingMember_zeTT1OhRoaZ3" title="Proceeds from issuance of common stock"&gt;8,316,000&lt;/span&gt;.
The Company used the proceeds of the 2022 Offering for general corporate purposes. The 2022 Offering closed on October 26, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Registration
of Shares Issued to 180 Consulting&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 22, 2022, the Company filed a Registration Statement on Form S-3 (Registration No. 333-265773) for purposes of registering for resale
&lt;span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220622__us-gaap--RelatedPartyTransactionAxis__custom--OneHundredEightyConsultingLLCMember_zmDdCUaDdny2" title="Common stock issued for resale"&gt;272,653&lt;/span&gt; shares of common stock issued to 180 Consulting, LLC (&#x201c;180 Consulting&#x201d;). The Registration Statement was declared
effective by the SEC on July 1, 2022.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 28, 2023, the Company filed a Registration Statement on Form S-3 (Registration No. 333-272993) for purposes of registering for resale
&lt;span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230628__us-gaap--RelatedPartyTransactionAxis__custom--OneHundredEightyConsultingLLCMember_ztJBweR0Qf8k" title="Common stock issued for resale"&gt;394,127&lt;/span&gt; shares of common stock issued to 180 Consulting, LLC (&#x201c;180 Consulting&#x201d;). The Registration Statement was declared
effective by the SEC on July 10, 2023.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Authorized
Shares Increase&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the 2022 Annual Meeting, the Company&#x2019;s stockholders approved an amendment to the Streamline Health Solutions, Inc. Third Amended
and Restated 2013 Stock Incentive Plan to increase the number of shares of the Company&#x2019;s common stock authorized for issuance thereunder
by &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20230201__20240131__us-gaap--PlanNameAxis__custom--ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_z744qi2KtRz4" title="Number of additional shares authorized to issue"&gt;2,000,000&lt;/span&gt; shares, from &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20220607__us-gaap--PlanNameAxis__custom--ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_zRljjQxsHmD3" title="Number of shares authorized to issue"&gt;8,223,246&lt;/span&gt; shares to &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240131__us-gaap--PlanNameAxis__custom--ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zWmSjofC3ge8" title="Number of shares authorized to issue"&gt;10,223,246&lt;/span&gt; shares. The Company&#x2019;s stockholders also approved an amendment to the Company&#x2019;s
Certificate of Incorporation, as amended, to increase the total number of authorized shares of the Company&#x2019;s common stock from
&lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20220607_zRzLxq4Ong2j" title="Common stock, shares authorized"&gt;65,000,000&lt;/span&gt; shares to &lt;span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20240131_zr5QccP3x4X8" title="Common stock, shares authorized"&gt;85,000,000&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the 2023 Annual Meeting, the Company&#x2019;s stockholders approved an amendment to the 2013 Plan to increase the number of shares of
the Company&#x2019;s common stock authorized for issuance thereunder by &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20230615__20230615_zdP2IZQMXGy5" title="Number of additional shares authorized to issue"&gt;1,000,000&lt;/span&gt; shares, from &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20230615__us-gaap--PlanNameAxis__custom--ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_zXWE8hGqA3J3" title="Number of shares authorized to issue"&gt;10,223,246&lt;/span&gt; shares to &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20230615__us-gaap--PlanNameAxis__custom--ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zYG2EzryR264" title="Number of shares authorized to issue"&gt;11,223,246&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-232022-10-24_custom_PurchaseAgreementMember_custom_TwoThousandTwentyTwoOfferingMember"
      decimals="INF"
      id="Fact001312"
      unitRef="Shares">6299989</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-10-24_custom_PurchaseAgreementMember_custom_TwoThousandTwentyTwoOfferingMember"
      decimals="INF"
      id="Fact001314"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-10-24_custom_PurchaseAgreementMember_custom_TwoThousandTwentyTwoOfferingMember"
      decimals="INF"
      id="Fact001316"
      unitRef="USDPShares">1.32</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-10-232022-10-24_custom_PurchaseAgreementMember_custom_TwoThousandTwentyTwoOfferingMember"
      decimals="0"
      id="Fact001318"
      unitRef="USD">8316000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-06-22_custom_OneHundredEightyConsultingLLCMember"
      decimals="INF"
      id="Fact001320"
      unitRef="Shares">272653</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-06-28_custom_OneHundredEightyConsultingLLCMember"
      decimals="INF"
      id="Fact001322"
      unitRef="Shares">394127</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2023-02-012024-01-31_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember"
      decimals="INF"
      id="Fact001324"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2022-06-07_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember"
      decimals="INF"
      id="Fact001326"
      unitRef="Shares">8223246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2024-01-31_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001328"
      unitRef="Shares">10223246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-06-07"
      decimals="INF"
      id="Fact001330"
      unitRef="Shares">65000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="Fact001332"
      unitRef="Shares">85000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2023-06-152023-06-15"
      decimals="INF"
      id="Fact001334"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2023-06-15_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember"
      decimals="INF"
      id="Fact001336"
      unitRef="Shares">10223246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2023-06-15_custom_ThirdAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001338"
      unitRef="Shares">11223246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001340">&lt;p id="xdx_800_eus-gaap--ConcentrationRiskDisclosureTextBlock_z5eB8SJFvElg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
9 &#x2014; &lt;span id="xdx_827_zGD4nTjGCSM1"&gt;MAJOR CLIENTS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
fiscal 2023, &lt;span id="xdx_907_eus-gaap--ConcentrationRiskCustomer_c20230201__20240131_zUPwj5WXHLgd"&gt;one individual client accounted
for 10% or more of our revenue.&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This client accounted
for &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20240131__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zLypvvdd55o7"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of total revenue for fiscal 2023. In the third quarter of fiscal 2023, the Company received a notice from this client of its intent not
to renew its contract following the expiration of the current term on December 31, 2023. During fiscal 2022, &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskCustomer_c20220201__20230131_z6P4n6yuGhge"&gt;two
individual clients accounted for 10% or more of our revenue.&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
clients accounted for &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210201__20220131__srt--MajorCustomersAxis__custom--TwoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z9X1KOGudy7e"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
and &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210201__20220131__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_z5LRkXkjM4rd"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
respectively, of total revenue for fiscal 2022. Four clients represented &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20240131__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z5mnHrJyy0J7"&gt;14&lt;/span&gt;%, &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20240131__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z7xKXSAr6sSj"&gt;12&lt;/span&gt;%, &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20240131__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zEGnqlVuaWo4"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
and &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20240131__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zk7bqkzdfSsd"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
respectively, of accounts receivable as of January 31, 2024, and four clients represented &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20230131__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zBhFm1wOAXP1"&gt;13&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20230131__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zf18hvwHMAeb"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20230131__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zARBzlAETThi"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
and &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20230131__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zLM9PZDHfogb"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
respectively, of accounts receivable as of January 31, 2023. Many of our clients are invoiced on an annual basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskCustomer contextRef="From2023-02-01to2024-01-31" id="Fact001341">one individual client accounted
for 10% or more of our revenue.</us-gaap:ConcentrationRiskCustomer>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-02-012024-01-31_custom_OneCustomerMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      id="Fact001342"
      unitRef="Pure">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskCustomer contextRef="From2022-02-012023-01-31" id="Fact001343">two
individual clients accounted for 10% or more of our revenue.</us-gaap:ConcentrationRiskCustomer>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-02-012022-01-31_custom_TwoCustomerMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      id="Fact001344"
      unitRef="Pure">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-02-012022-01-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneCustomerMember"
      decimals="INF"
      id="Fact001345"
      unitRef="Pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-02-012024-01-31_custom_CustomerOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      id="Fact001346"
      unitRef="Pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-02-012024-01-31_custom_CustomerTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      id="Fact001347"
      unitRef="Pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-02-012024-01-31_custom_CustomerThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      id="Fact001348"
      unitRef="Pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-02-012024-01-31_custom_CustomerFourMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      id="Fact001349"
      unitRef="Pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-02-012023-01-31_custom_CustomerOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      id="Fact001350"
      unitRef="Pure">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-02-012023-01-31_custom_CustomerTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      id="Fact001351"
      unitRef="Pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-02-012023-01-31_custom_CustomerThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      id="Fact001352"
      unitRef="Pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-02-012023-01-31_custom_CustomerFourMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      id="Fact001353"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001355">&lt;p id="xdx_805_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_z5c6rMuNfTui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
10 &#x2014; &lt;span id="xdx_826_zNNifCgVyW4b"&gt;EMPLOYEE RETIREMENT PLAN&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has established a 401(k) retirement plan that covers all associates. Company contributions to the plan may be made at the discretion
of the board of directors. The Company&#x2019;s matched amount is 50% up to the first 4% of compensation deferred by each associate. The
total compensation expense for this matching contribution was $&lt;span id="xdx_901_eus-gaap--DefinedContributionPlanCostRecognized_pp0p0_c20230201__20240131_zPm2id33qf5" title="Defined contribution plan, cost recognized"&gt;242,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--DefinedContributionPlanCostRecognized_pp0p0_c20220201__20230131_z7D0klclvwO9" title="Defined contribution plan, cost recognized"&gt;258,000&lt;/span&gt; in fiscal 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001357"
      unitRef="USD">242000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="From2022-02-012023-01-31"
      decimals="0"
      id="Fact001359"
      unitRef="USD">258000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001361">&lt;p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zR3mSH78pWti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
11 &#x2014; &lt;span id="xdx_822_zix3myPlcav8"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock
Option Plans&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2013 Plan replaced the Company&#x2019;s 2005 Incentive Compensation Plan (the &#x201c;2005 Plan&#x201d;). The 2005 Plan expired based upon
its terms. Accordingly, all the outstanding awards and any unallocated pool of un-issued options under the 2005 Plan were re-characterized
to the 2013 Plan. &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zRjmMTacv4Z2" title="Stock options plan, description"&gt;Under these plans, the Company is authorized to issue equity awards (stock options, stock appreciation rights or &#x201c;SARs&#x201d;,
and restricted stock) to directors and associates of the Company. Under the 2013 Plan, as amended, the Company is authorized to issue
a number of shares not to exceed &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zYk0QCKfDYrl" title="Number of shares authorized to issue"&gt;11,223,246&lt;/span&gt;. The options granted under the 2013 Plan have terms of ten years or less, and typically vest
and become fully exercisable ratably over three years of continuous service to the Company from the date of grant&lt;/span&gt;. At January 31, 2024
and 2023, options to purchase &lt;span id="xdx_905_ecustom--NumberOfOptionsToPurchaseCommonStock_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z6GtEpRtsUqj" title="Number of options to purchase common stock"&gt;67,500&lt;/span&gt; and &lt;span id="xdx_903_ecustom--NumberOfOptionsToPurchaseCommonStock_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zI5rslcRw3n3" title="Number of options to purchase common stock"&gt;628,958&lt;/span&gt; shares of the Company&#x2019;s common stock, respectively, had been granted and were
outstanding under these plans. At January 31, 2024, there were no SARs outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXNWPfNbByXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity in fiscal 2023 follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_z6AWhgsLlTTl" style="display: none"&gt;SCHEDULE OF STOCK OPTION ACTIVITY&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Aggregate&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Life in &lt;br/&gt; Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;intrinsic &lt;br/&gt; value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding as of January 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230201__20240131_z9rzQnSYOxv8" style="width: 12%; text-align: right" title="Number of options, Outstanding"&gt;628,958&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230201__20240131_zBV5DS90SPtf" style="width: 12%; text-align: right" title="Weighted average exercise price, Outstanding"&gt;1.95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220201__20230131_zQn7bX5YnDDd" title="Remaining Life in Years, Outstanding"&gt;7.31&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230201__20240131_zE19UeU1K4mc" style="width: 12%; text-align: right" title="Aggregate intrinsic value, Outstanding"&gt;360,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230201__20240131_zWn0MkN626K1" style="text-align: right" title="Number of options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1381"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230201__20240131_zz3I3PGuVxR1" style="text-align: right" title="Weighted average exercise price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1383"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230201__20240131_z7EX6ISFLaa4" style="text-align: right" title="Number of options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1385"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230201__20240131_zkqgh9ok7CU7" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1387"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230201__20240131_zZWVO32mGON7" style="text-align: right" title="Number of options, Expired"&gt;(39,250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230201__20240131_zZju4jJge4L1" style="text-align: right" title="Weighted average exercise price, Expired"&gt;7.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230201__20240131_zSPzPuqKmLs" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, Forfeited"&gt;(522,208&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230201__20240131_z6OxGZcLNs3a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Forfeited"&gt;1.55&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding as of January 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230201__20240131_zXz717fImZ23" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Outstanding"&gt;67,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230201__20240131_zAtr4ouxiGWg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding"&gt;1.73&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230201__20240131_zkDfaZVnkpE" title="Remaining Life in Years, Outstanding"&gt;2.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230201__20240131_zSuSirRD9zde" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1403"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable as of January 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240131_zA224pL4KPVd" style="text-align: right" title="Number of options, Exercisable"&gt;67,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240131_zC5bpjYI2ujg" style="text-align: right" title="Weighted average exercise price, Exercisable"&gt;1.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230201__20240131_zb27FH3wNuqc" title="Remaining Life in Years, Exercisable"&gt;2.37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20240131_zxHUGEW6m4E6" style="text-align: right" title="Aggregate intrinsic value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1411"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vested as of January 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20240131_zBrksG5tDsii" style="text-align: right" title="Number of options, Vested or expected to vest"&gt;67,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20240131_zKlTMvZVX3ej" style="text-align: right" title="Weighted average exercise price, Vested or expected to vest"&gt;1.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230201__20240131_zwo7CT2xA9lj" title="Remaining Life in Years, Vested or expected to vest"&gt;2.37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pp0p0_c20240131_zYrdbEi8mAVe" style="text-align: right" title="Aggregate intrinsic value, Vested or expected to vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1419"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zNvMECiwJla5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
options were granted in fiscal 2023 or fiscal 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
January 31, 2024, there was &lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_do_c20240131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zHd45qitU1De" title="Unrecognized Compensation cost, stock options"&gt;no&lt;/span&gt;  unrecognized compensation cost related to non-vested stock-option awards.  The expense associated with stock option awards was $&lt;span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zzGzYQpHhbQ4" title="Stock option expense"&gt;71,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210201__20220131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zpZCOisOlCMk" title="Stock option expense"&gt;132,000&lt;/span&gt;,
respectively, for fiscal 2023 and 2022. No options were exercised during fiscal 2023 or 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2013 Plan contains change in control provisions whereby any outstanding equity awards under the plans subject to vesting, which have
not fully vested as of the date of the change in control, shall automatically vest and become immediately exercisable. One of the change
in control provisions is deemed to occur if there is a change in beneficial ownership, or authority to vote, directly or indirectly,
of securities representing &lt;span id="xdx_908_ecustom--InvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240131_zksPPAwG4dsb" title="Ownership Percentage"&gt;20&lt;/span&gt;% or more of the total of all of the Company&#x2019;s then-outstanding voting securities, unless through
a transaction arranged by or consummated with the prior approval of the Board of Directors. Other change in control provisions relate
to mergers and acquisitions or a determination of change in control by the Board of Directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Restricted
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to grant restricted stock awards to associates and directors under the 2013 Plan. The Company has also issued restricted
stock as inducement grants to certain new employees. The restrictions on the shares granted generally lapse over a one- to four-year
term of continuous employment from the date of grant. On November 1, 2022, our then-serving CEO, Wyche T. Green, III, was awarded &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20221101__20221101__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFXwcPEJqNWd" title="Number of restricted stocks awarded, shares"&gt;50,000&lt;/span&gt;
shares of restricted common stock that will vest in three substantially equal annual installments commencing on the first anniversary
of the date of grant. On May 20, 2022, Mr. Green was awarded &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220520__20220520__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxLQszwr6Ht9" title="Number of restricted stocks awarded, shares"&gt;150,000&lt;/span&gt; shares of restricted common stock that will vest in three substantially
equal annual installments commencing on the first anniversary of the date of grant. On April 1, 2023, Mr. Green was awarded &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230401__20230401__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--MrGreenMember_z37kHInn2VAe" title="Number of restricted stocks awarded, shares"&gt;200,000&lt;/span&gt; shares
of restricted common stock that will vest in three substantially equal annual installments commencing on the first anniversary of the
date of grant. Prior to his appointment as CEO of the Company, Mr. Stilwill was awarded &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230401__20230401__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--MrStilwillMember_z2X04kcHRQv4" title="Number of restricted stocks awarded, shares"&gt;170,000&lt;/span&gt; shares of restricted common stock on
April 1, 2023, that will vest in three substantially equal annual installments commencing on the first anniversary of the date of grant.
The grant date fair value per share of restricted stock, which is based on the closing price of our common stock on the grant date, is
expensed on a straight-line basis as the restriction period lapses. The shares represented by restricted stock awards are
considered outstanding at the grant date, as the recipients are entitled to voting rights. A summary of restricted stock award activity
for fiscal 2023 and 2022 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zjM3yWYFsDA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zO7G2ebkJoQl" style="display: none"&gt;SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Weighted&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Non-vested&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Average&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Number of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Grant Date&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 64%"&gt;Non-vested balance at January 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220201__20230131_zYnFhfptDY6l" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Number of RSUs, Non vested, Outstanding, Beginning balance"&gt;1,043,350&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220201__20230131_zEuLXWMANKh6" title="Weighted Average Grant Date Fair Value, Beginniing balance"&gt;1.57&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zGP6dQdbY7b2" style="text-align: right" title="Number of RSUs, granted"&gt;1,505,731&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zmB5td5Fd6fl" title="Weighted Average Grant Date Fair Value, RSUs granted"&gt;1.47&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2rQ1F0faCo8" style="text-align: right" title="Number of RSUs, vested"&gt;(501,750&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcM3KJZ27nH3" title="Weighted Average Grant Date Fair Value, RSUs vested"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcWA3EZI1BR2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number RSUs, forfeited"&gt;(199,300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs36HOvacnKh" title="Weighted Average Grant Date Fair Value, RSUs forfeited"&gt;1.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Non-vested balance at January 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230201__20240131_zBoj4mi8JkQf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs, Non vested, Outstanding, Beginning balance"&gt;1,848,031&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230201__20240131_zi6wkponXkb9" title="Weighted Average Grant Date Fair Value, Beginning balance"&gt;1.48&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4cAqLD9qWHi" style="text-align: right" title="Number of RSUs, granted"&gt;1,488,621&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUoxAxyM8tqb" title="Weighted Average Grant Date Fair Value, RSUs granted"&gt;1.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztks46YVO2pc" style="text-align: right" title="Number of RSUs, vested"&gt;(982,631&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs4ruRfP73dc" title="Weighted Average Grant Date Fair Value, RSUs vested"&gt;1.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3kMfkbYn4Vd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number RSUs, forfeited"&gt;(383,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcCEpa7518V" title="Weighted Average Grant Date Fair Value, RSUs forfeited"&gt;1.67&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Non-vested balance at January 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230201__20240131_zJ3GXytTKXPk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs, Non vested, Outstanding, Ending balance"&gt;1,970,521&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230201__20240131_zOW8QWyzHUNf" title="Weighted Average Grant Date Fair Value, Ending balance"&gt;1.51&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zX3Bw8CpyROg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
January 31, 2024, there was $&lt;span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztSGfHKRWsE5" title="Unrecognized compensation cost related to restricted stock awards"&gt;1,938,000&lt;/span&gt; of unrecognized compensation cost related to restricted stock awards. That cost is expected to be recognized
over a remaining period of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_pp0p0_dtY_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOUH2fFwVvP1" title="Cost expected remaining period"&gt;1.80&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
expense associated with restricted stock awards for associates and directors was $&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zH9uUvSujJEk" title="Stock option expense"&gt;1,590,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210201__20220131__us-gaap--TypeOfArrangementAxis__custom--TwoThousandThirteenIncentiveCompensationPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziMLtBvYwohf" title="Stock option expense"&gt;983,000&lt;/span&gt;,
for fiscal 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="From2023-02-012024-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember"
      id="Fact001363">Under these plans, the Company is authorized to issue equity awards (stock options, stock appreciation rights or &#x201c;SARs&#x201d;,
and restricted stock) to directors and associates of the Company. Under the 2013 Plan, as amended, the Company is authorized to issue
a number of shares not to exceed 11,223,246. The options granted under the 2013 Plan have terms of ten years or less, and typically vest
and become fully exercisable ratably over three years of continuous service to the Company from the date of grant</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2024-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001365"
      unitRef="Shares">11223246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <STRM:NumberOfOptionsToPurchaseCommonStock
      contextRef="From2023-02-012024-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001367"
      unitRef="Shares">67500</STRM:NumberOfOptionsToPurchaseCommonStock>
    <STRM:NumberOfOptionsToPurchaseCommonStock
      contextRef="From2022-02-012023-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001369"
      unitRef="Shares">628958</STRM:NumberOfOptionsToPurchaseCommonStock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001371">&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXNWPfNbByXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity in fiscal 2023 follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_z6AWhgsLlTTl" style="display: none"&gt;SCHEDULE OF STOCK OPTION ACTIVITY&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Aggregate&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Life in &lt;br/&gt; Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;intrinsic &lt;br/&gt; value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding as of January 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230201__20240131_z9rzQnSYOxv8" style="width: 12%; text-align: right" title="Number of options, Outstanding"&gt;628,958&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230201__20240131_zBV5DS90SPtf" style="width: 12%; text-align: right" title="Weighted average exercise price, Outstanding"&gt;1.95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220201__20230131_zQn7bX5YnDDd" title="Remaining Life in Years, Outstanding"&gt;7.31&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230201__20240131_zE19UeU1K4mc" style="width: 12%; text-align: right" title="Aggregate intrinsic value, Outstanding"&gt;360,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230201__20240131_zWn0MkN626K1" style="text-align: right" title="Number of options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1381"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230201__20240131_zz3I3PGuVxR1" style="text-align: right" title="Weighted average exercise price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1383"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230201__20240131_z7EX6ISFLaa4" style="text-align: right" title="Number of options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1385"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230201__20240131_zkqgh9ok7CU7" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1387"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230201__20240131_zZWVO32mGON7" style="text-align: right" title="Number of options, Expired"&gt;(39,250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230201__20240131_zZju4jJge4L1" style="text-align: right" title="Weighted average exercise price, Expired"&gt;7.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230201__20240131_zSPzPuqKmLs" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, Forfeited"&gt;(522,208&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230201__20240131_z6OxGZcLNs3a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Forfeited"&gt;1.55&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding as of January 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230201__20240131_zXz717fImZ23" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Outstanding"&gt;67,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230201__20240131_zAtr4ouxiGWg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding"&gt;1.73&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230201__20240131_zkDfaZVnkpE" title="Remaining Life in Years, Outstanding"&gt;2.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230201__20240131_zSuSirRD9zde" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1403"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable as of January 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240131_zA224pL4KPVd" style="text-align: right" title="Number of options, Exercisable"&gt;67,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240131_zC5bpjYI2ujg" style="text-align: right" title="Weighted average exercise price, Exercisable"&gt;1.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230201__20240131_zb27FH3wNuqc" title="Remaining Life in Years, Exercisable"&gt;2.37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20240131_zxHUGEW6m4E6" style="text-align: right" title="Aggregate intrinsic value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1411"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vested as of January 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20240131_zBrksG5tDsii" style="text-align: right" title="Number of options, Vested or expected to vest"&gt;67,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20240131_zKlTMvZVX3ej" style="text-align: right" title="Weighted average exercise price, Vested or expected to vest"&gt;1.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230201__20240131_zwo7CT2xA9lj" title="Remaining Life in Years, Vested or expected to vest"&gt;2.37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pp0p0_c20240131_zYrdbEi8mAVe" style="text-align: right" title="Aggregate intrinsic value, Vested or expected to vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1419"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact001373"
      unitRef="Shares">628958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact001375"
      unitRef="USDPShares">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-02-012023-01-31" id="Fact001377">P7Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001379"
      unitRef="USD">360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-02-01to2024-01-31"
      decimals="INF"
      id="Fact001389"
      unitRef="Shares">39250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-02-01to2024-01-31"
      decimals="INF"
      id="Fact001391"
      unitRef="USDPShares">7.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-02-01to2024-01-31"
      decimals="INF"
      id="Fact001393"
      unitRef="Shares">522208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-02-01to2024-01-31"
      decimals="INF"
      id="Fact001395"
      unitRef="USDPShares">1.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="Fact001397"
      unitRef="Shares">67500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="Fact001399"
      unitRef="USDPShares">1.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-02-01to2024-01-31" id="Fact001401">P2Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="Fact001405"
      unitRef="Shares">67500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="Fact001407"
      unitRef="USDPShares">1.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-02-01to2024-01-31" id="Fact001409">P2Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="Fact001413"
      unitRef="Shares">67500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="Fact001415"
      unitRef="USDPShares">1.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-02-01to2024-01-31" id="Fact001417">P2Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2024-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember"
      decimals="0"
      id="Fact001421"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-02-012023-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember"
      decimals="0"
      id="Fact001423"
      unitRef="USD">71000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-02-012022-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_custom_StockOptionsMember"
      decimals="0"
      id="Fact001425"
      unitRef="USD">132000</us-gaap:AllocatedShareBasedCompensationExpense>
    <STRM:InvestmentOwnershipPercentage
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="Fact001427"
      unitRef="Pure">0.20</STRM:InvestmentOwnershipPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-11-012022-11-01_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001429"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-05-202022-05-20_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001431"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-04-012023-04-01_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember_custom_MrGreenMember"
      decimals="INF"
      id="Fact001433"
      unitRef="Shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-04-012023-04-01_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember_custom_MrStilwillMember"
      decimals="INF"
      id="Fact001435"
      unitRef="Shares">170000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001437">&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zjM3yWYFsDA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zO7G2ebkJoQl" style="display: none"&gt;SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Weighted&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Non-vested&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Average&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Number of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Grant Date&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 64%"&gt;Non-vested balance at January 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220201__20230131_zYnFhfptDY6l" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Number of RSUs, Non vested, Outstanding, Beginning balance"&gt;1,043,350&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220201__20230131_zEuLXWMANKh6" title="Weighted Average Grant Date Fair Value, Beginniing balance"&gt;1.57&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zGP6dQdbY7b2" style="text-align: right" title="Number of RSUs, granted"&gt;1,505,731&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zmB5td5Fd6fl" title="Weighted Average Grant Date Fair Value, RSUs granted"&gt;1.47&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2rQ1F0faCo8" style="text-align: right" title="Number of RSUs, vested"&gt;(501,750&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcM3KJZ27nH3" title="Weighted Average Grant Date Fair Value, RSUs vested"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcWA3EZI1BR2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number RSUs, forfeited"&gt;(199,300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220201__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs36HOvacnKh" title="Weighted Average Grant Date Fair Value, RSUs forfeited"&gt;1.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Non-vested balance at January 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230201__20240131_zBoj4mi8JkQf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs, Non vested, Outstanding, Beginning balance"&gt;1,848,031&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230201__20240131_zi6wkponXkb9" title="Weighted Average Grant Date Fair Value, Beginning balance"&gt;1.48&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4cAqLD9qWHi" style="text-align: right" title="Number of RSUs, granted"&gt;1,488,621&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUoxAxyM8tqb" title="Weighted Average Grant Date Fair Value, RSUs granted"&gt;1.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztks46YVO2pc" style="text-align: right" title="Number of RSUs, vested"&gt;(982,631&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs4ruRfP73dc" title="Weighted Average Grant Date Fair Value, RSUs vested"&gt;1.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3kMfkbYn4Vd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number RSUs, forfeited"&gt;(383,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230201__20240131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcCEpa7518V" title="Weighted Average Grant Date Fair Value, RSUs forfeited"&gt;1.67&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Non-vested balance at January 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230201__20240131_zJ3GXytTKXPk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs, Non vested, Outstanding, Ending balance"&gt;1,970,521&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230201__20240131_zOW8QWyzHUNf" title="Weighted Average Grant Date Fair Value, Ending balance"&gt;1.51&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-01-31"
      decimals="INF"
      id="Fact001439"
      unitRef="Shares">1043350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-01-31"
      decimals="INF"
      id="Fact001441"
      unitRef="USDPShares">1.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001443"
      unitRef="Shares">1505731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001445"
      unitRef="USDPShares">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001447"
      unitRef="Shares">501750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001449"
      unitRef="USDPShares">1.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001451"
      unitRef="Shares">199300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001453"
      unitRef="USDPShares">1.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact001455"
      unitRef="Shares">1848031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact001457"
      unitRef="USDPShares">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-02-012024-01-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001459"
      unitRef="Shares">1488621</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-02-012024-01-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001461"
      unitRef="USDPShares">1.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-02-012024-01-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001463"
      unitRef="Shares">982631</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-02-012024-01-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001465"
      unitRef="USDPShares">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-02-012024-01-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001467"
      unitRef="Shares">383500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2023-02-012024-01-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001469"
      unitRef="USDPShares">1.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="Fact001471"
      unitRef="Shares">1970521</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="Fact001473"
      unitRef="USDPShares">1.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001475"
      unitRef="USD">1938000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2022-02-012023-01-31_us-gaap_RestrictedStockMember"
      id="Fact001477">P1Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-02-012023-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001479"
      unitRef="USD">1590000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-02-012022-01-31_custom_TwoThousandThirteenIncentiveCompensationPlanMember_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001481"
      unitRef="USD">983000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001483">&lt;p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z3olXSo5JyKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
12&#x2014; &lt;span id="xdx_827_zxCT69eXbWf2"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Consulting
Agreement with 180 Consulting&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 19, 2020, the Company entered into a Master Services Agreement (the &#x201c;MSA&#x201d;) with 180 Consulting, pursuant to which 180
Consulting has provided and will continue to provide a variety of consulting services in support of eValuator products including product
management, operational consulting, staff augmentation, internal systems platform integration and software engineering services, among
others, through separate executed statements of work (&#x201c;SOWs&#x201d;). On September 20, 2021, the Company entered into a separate
MSA in support of Avelead products. As of December 2023, all outstanding SOWs under both MSAs were effectively replaced by two new SOWs.
As of the end of fiscal 2023, there were two active SOWs under the eValuator MSA, and no active SOWS under the Avelead MSA. One of the
active SOWs include the ability to earn stock at a conversion rate to be calculated 20 days after the execution of the related SOW. The
MSA includes a termination clause upon a 90-day written notice. While no related party has a direct or indirect material interest in
this MSA or the related SOWs, individuals providing services to us under the MSA, and the related SOWs may share workspace and administrative
costs with 121G Consulting LLC (&#x201c;121G&#x201d;). 180 Consulting earned &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zMhHLa2jZNJl"&gt;564,707
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares for the year ended January 31, 2024 and
has earned an aggregate of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zyunfUAmg8f1"&gt;1,479,911
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares through January 31, 2024. For services
rendered by 180 Consulting, the Company recorded total cash fees of $&lt;span id="xdx_907_eus-gaap--ProfessionalFees_c20230801__20231031__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zPVjOGhQqUA3"&gt;2,580,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and non-employee stock compensation of $&lt;span id="xdx_908_eus-gaap--ProfessionalFees_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zs3LLvVHgHHe"&gt;582,000
&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for fiscal 2023 as compared to $&lt;span id="xdx_905_ecustom--NonEmployeeStockCompensation_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zBwPgZmRAhM4"&gt;1,281,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90F_ecustom--NonEmployeeStockCompensation_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_z8Z6NjVupbI6"&gt;640,000&lt;/span&gt;,
respectively, for fiscal 2022&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;. In addition, as
of the date of this report, the Company has not issued to 180 Consulting an aggregate of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231101__20240131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zRSAuzs7dQYa"&gt;206,517
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares as compensation for services previously
rendered during the three-months ended January 31, 2024. Such &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231101__20240131__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z2oPoPKfdYzd"&gt;564,707
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares will be issued in reliance on an exemption
from registration available under Section 4(a)(2) of the Securities Act. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inclusive
of the MSA executed with 180 Consulting are SOWs that provide for the Company to sublicense a software through 180 Consulting that is
owned by 121G. This is a services agreement for access to software that assists the Company in implementing and integrating with our
clients&#x2019; technology. The license agreement is designed such that there is no material financial benefit that accrues to 121G. 180
Consulting licenses the software from 121G at cost. The Company paid approximately $&lt;span id="xdx_90D_eus-gaap--ProfessionalFees_pp0p0_c20230201__20240131__us-gaap--TypeOfArrangementAxis__custom--SOWMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zCmpTNOKJGr8" title="Professional fees"&gt;563,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--ProfessionalFees_pp0p0_c20220201__20230131__us-gaap--TypeOfArrangementAxis__custom--SOWMember__dei--LegalEntityAxis__custom--OneHundredEightyConsultingLLCMember_zXY6VpvP7sgk" title="Professional fees"&gt;301,000&lt;/span&gt; for the SOWs that include the sublicense
agreement in each of the fiscal years ended January 31, 2024 and 2023, respectively, which are included in the aforementioned totals
above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Litigation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
are, from time to time, a party to various legal proceedings and claims, which arise in the ordinary course of business. We are not aware
of any legal matters that are reasonably possible to have a material adverse effect on the Company&#x2019;s consolidated results of operations,
financial position or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-02-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember"
      decimals="INF"
      id="Fact001484"
      unitRef="Shares">564707</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember"
      decimals="INF"
      id="Fact001485"
      unitRef="Shares">1479911</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ProfessionalFees
      contextRef="From2023-08-012023-10-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember"
      decimals="0"
      id="Fact001486"
      unitRef="USD">2580000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2022-02-012023-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember"
      decimals="0"
      id="Fact001487"
      unitRef="USD">582000</us-gaap:ProfessionalFees>
    <STRM:NonEmployeeStockCompensation
      contextRef="From2023-02-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember"
      decimals="0"
      id="Fact001488"
      unitRef="USD">1281000</STRM:NonEmployeeStockCompensation>
    <STRM:NonEmployeeStockCompensation
      contextRef="From2022-02-012023-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember"
      decimals="0"
      id="Fact001489"
      unitRef="USD">640000</STRM:NonEmployeeStockCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-11-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember"
      decimals="INF"
      id="Fact001490"
      unitRef="Shares">206517</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-11-012024-01-31_custom_MasterServicesAgreementMember_custom_OneHundredEightyConsultingLLCMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001491"
      unitRef="Shares">564707</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProfessionalFees
      contextRef="From2023-02-012024-01-31_custom_SOWMember_custom_OneHundredEightyConsultingLLCMember"
      decimals="0"
      id="Fact001493"
      unitRef="USD">563000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2022-02-012023-01-31_custom_SOWMember_custom_OneHundredEightyConsultingLLCMember"
      decimals="0"
      id="Fact001495"
      unitRef="USD">301000</us-gaap:ProfessionalFees>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001497">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zoIDIDdfg0Tb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
13 - &lt;span id="xdx_821_zqhEKEEWAwX8"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Refer
to Note 3 &#x2013; Business Combination. The Company acquired Avelead on August 16, 2021. We assumed a lease for corporate
office space from one of the selling shareholders of Avelead who was employed by the Company through August 2023. This lease term ended
February 2022 but was renewed for a term of 12 months through February 2023. For the year ended January 31, 2024, the Company recorded
rent expense of $&lt;span id="xdx_90F_eus-gaap--PaymentsForRent_c20230201__20240131_z5zPDi2dKoKd" title="Rent expense"&gt;6,000&lt;/span&gt;. Refer to Note 4 &#x2013; Operating Leases to our consolidated financial statements included in Part II, Item 8,
&#x201c;Financial Statements and Supplementary Data&#x201d; for more information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PaymentsForRent
      contextRef="From2023-02-01to2024-01-31"
      decimals="0"
      id="Fact001499"
      unitRef="USD">6000</us-gaap:PaymentsForRent>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001501">&lt;p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zA3kgVqh9DU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
14 &#x2014; &lt;span id="xdx_824_zRs7xio7EOD4"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Debt
Private Placement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 1, 2024, the Company entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with certain
accredited investors, including certain directors and officers of the Company (collectively, the &#x201c;Investors&#x201d;), pursuant to
which the Company agreed to sell to the Investors unsecured subordinated promissory notes (the &#x201c;Notes&#x201d;) in the aggregate
principal amount of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHXgzuLiZOV4" title="Debt principal amount"&gt;4.4&lt;/span&gt; million and warrants (the &#x201c;Warrants&#x201d;) to purchase up to an aggregate of &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z9Qs8HhWdpmg" title="Number of shares purchase"&gt;4,052,631&lt;/span&gt; shares of the
Company&#x2019;s common stock (the &#x201c;Common Stock&#x201d;) in a private placement (the &#x201c;Debt Private Placement&#x201d;). The
closing of the Debt Private Placement occurred on February 7, 2024 (the &#x201c;Closing Date&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Debt Private Placement, the Investors and each of the Company&#x2019;s directors and officers agreed, subject to certain
exceptions set forth in the lock-up agreements, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any
short sale or otherwise dispose of any shares of Common Stock, or any options or warrants to purchase any shares of Common Stock, or
any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock, for a period commencing
on the date of the lock-up agreement and ending 90 days from the Closing Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Notes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Notes bear interest at a rate of &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20240201__us-gaap--ShortTermDebtTypeAxis__custom--NotesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLMRLP7iySJ8" title="Notes bear interest rate"&gt;15&lt;/span&gt;% per annum and mature on &lt;span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20240201__20240201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesMember_zAyPkBibryH8" title="Notes maturity date"&gt;August 7, 2026&lt;/span&gt; (the &#x201c;Maturity Date&#x201d;). All accrued and unpaid
interest on the Notes will be capitalized and added to the outstanding principal balance of the Notes and will be payable in cash on
the Maturity Date. The Company may redeem the Notes, in whole or in part, prior to the Maturity Date without any premium or penalty.
In the event the Company prepays any portion of the then outstanding principal balance of the Notes on or before the twelve (12) month
anniversary of the Closing Date, in addition to such prepayment of the principal balance, the Company must pay to the Investors a prepayment
fee (in accordance with the each Investor&#x2019;s pro-rata share of the Notes) in an amount equal to the amount of interest that would
have accrued but for the prepayment from the date of such prepayment through such twelve (12) month anniversary of the Closing Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
rights of each Investor to receive payments under the Notes are subordinate to the rights of Western Alliance Bank (&#x201c;WAB&#x201d;),
pursuant to a subordination agreement which the Investors entered into with WAB concurrently with the Debt Private Placement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Warrants have an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYZJaip5tMMc" title="Warrant exercise price"&gt;0.38&lt;/span&gt; (except for Warrants issued to the Company&#x2019;s directors and officers which have an exercise
price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ExceptDirectorsAndOfficersMember_zXhgZQCv4sW7" title="Warrant exercise price"&gt;0.39&lt;/span&gt;), are immediately exercisable, and will expire on the fourth anniversary of the Closing Date. The Warrants are subject
to customary adjustments for certain transactions affecting the Company&#x2019;s capitalization. The terms of the Warrants preclude a
holder thereof from exercising such holder&#x2019;s Warrants, and the Company from giving effect to such exercise, if after giving effect
to the issuance of Common Stock upon such exercise, the holder (together with the holder&#x2019;s affiliates and any other persons acting
as a group together with the holder or any of the holder&#x2019;s affiliates) would beneficially own in excess of &lt;span id="xdx_902_ecustom--AffiliatesEffectivePercentage_iI_pid_dp_uPure_c20240430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQLorGwk9Su9" title="Affiliates effective percentage"&gt;9.99&lt;/span&gt;% of the number
of shares of Common Stock outstanding immediately after giving effect to the issuance of Common Stock upon such exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Notes and the Warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended
(the &#x201c;Securities Act&#x201d;), and/or Regulation D promulgated thereunder and, along with the Common Stock underlying the Warrants,
have not been registered under the Securities Act or applicable state securities laws. Accordingly, the Notes, the Warrants and the Common
Stock underlying the Warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption
from such registration requirements and in accordance with applicable state securities laws. The securities were offered and sold to
&#x201c;accredited investors&#x201d; as that term is defined in Rule 501(a) under the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock Private Placement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 6, 2024, the Company completed the sale of &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240206__20240206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z4ELvf7NvACc" title="Number of shares issued"&gt;263,158&lt;/span&gt; shares of the Company&#x2019;s common stock to an accredited investor at a
purchase price of $&lt;span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_c20240206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zs7wf1kUsyB5" title="Purchase price per share"&gt;0.38&lt;/span&gt; per share for an aggregate purchase price of $&lt;span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240206__20240206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zO2Q3YIN7py8" title="Aggregate purchase price"&gt;100,000&lt;/span&gt; (the &#x201c;Common Stock Private Placement&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
common stock described above was offered in a private placement under Section 4(a)(2) of the Securities Act and/or Regulation D promulgated
thereunder and has not been registered under the Securities Act or applicable state securities laws. Accordingly, such common stock may
not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements
and in accordance with applicable state securities laws. The Common Stock was offered and sold to an &#x201c;accredited investor&#x201d;
as that term is defined in Rule 501(a) under the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loan
Modification&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 7, 2024, the Company and certain of its subsidiaries entered into a Third Modification and Waiver (the &#x201c;Third Modification&#x201d;)
to the Loan Agreement with Western Alliance Bank.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Third Modification waived the Company&#x2019;s non-compliance with the Maximum Debt to ARR Ratio under the Loan Agreement and amended
certain financial covenants as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Maximum
    ARR Net Leverage Ratio. &lt;/b&gt;Borrowers&#x2019; ARR Net Leverage Ratio, measured on a quarterly basis as of the last day of each fiscal
    quarter, shall not be greater than the amount set forth under the heading &#x201c;Maximum ARR Net Leverage Ratio&#x201d; as of, and
    for each of the dates appearing adjacent to such &#x201c;Maximum ARR Net Leverage Ratio.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_898_ecustom--ScheduleOfMaximumARRNetLeverageTableTextBlock_zn3DAkHvDuVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;span id="xdx_8B2_zl5leknhgzJg" style="display: none"&gt;SCHEDULE
OF MAXIMUM ARR NET LEVERAGE RATIO&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 81%; font-weight: bold"&gt;Quarter Ending&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Maximum ARR Net Leverage Ratio&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;April 30, 2024&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYL8dbOqU7dj" title="Maximum ARR net leverage ratio"&gt;0.50&lt;/span&gt; to &lt;span id="xdx_903_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZGaBn88elT7" title="Maximum ARR net leverage ratio"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;July 31, 2024&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXDyg1rAAOu" title="Maximum ARR net leverage ratio"&gt;0.45&lt;/span&gt; to &lt;span id="xdx_901_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4bD19zzJLIi" title="Maximum ARR net leverage ratio"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;October 31, 2024&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHNHYJNleNcf" title="Maximum ARR net leverage ratio"&gt;0.40&lt;/span&gt; to &lt;span id="xdx_90D_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdU4HUWEgNl7" title="Maximum ARR net leverage ratio"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;January 31, 2025&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGXzjPhyYRBb" title="Maximum ARR net leverage ratio"&gt;0.35&lt;/span&gt; to &lt;span id="xdx_908_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zN794vr0cRh" title="Maximum ARR net leverage ratio"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zp08xu0aVB09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;c.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Maximum
    Debt to Adjusted EBITDA Ratio. &lt;/b&gt;Commencing with the quarter ending April 30, 2025, Borrowers&#x2019; Maximum Debt to Adjusted EBITDA
    Ratio, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4) quarter period then ended,
    shall not be greater than the amount set forth under the heading &#x201c;Maximum Debt to Adjusted EBITDA Ratio&#x201d; as of, and for
    each of the dates appearing adjacent to such &#x201c;Maximum Debt to Adjusted EBITDA Ratio&#x201d;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_893_ecustom--ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock_zbRhfhXAR2T4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_z36XCCnXa4R3" style="display: none"&gt;SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 81%; font-weight: bold"&gt;Quarter Ending&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Maximum Debt to Adjusted EBITDA Ratio&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;April 30, 2025&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z634W75TIPkd" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;3.50&lt;/span&gt; to &lt;span id="xdx_906_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zW5HjjpfOLK6" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;July 31, 2025&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zndajFfrR7lb" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;3.00&lt;/span&gt; to &lt;span id="xdx_902_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPNp0gh9xaMj" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;October 31, 2025&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsNDLOgxTSE8" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;2.50&lt;/span&gt; to &lt;span id="xdx_90B_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKF5mmPQictf" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;January 31, 2026 and on the last day of each quarter thereafter&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQ1edTu7ZW4" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;2.00&lt;/span&gt; to &lt;span id="xdx_90A_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zieXxiJi69ba" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zgAxWkKvE4b9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;d.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fixed
    Charge Coverage Ratio&lt;/b&gt;. Commencing with the quarter ending April 30, 2025, Borrowers shall maintain a Fixed Charge Coverage Ratio
    of not less than &lt;span id="xdx_909_ecustom--FixedChargeCoverageRatio_iI_pid_dp_uPure_c20240207__us-gaap--TypeOfArrangementAxis__custom--ThirdModificationLoanAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIv6ASSMMDf3" title="Fixed charge coverage ratio"&gt;1.20&lt;/span&gt; to &lt;span id="xdx_90E_ecustom--FixedChargeCoverageRatio_iI_pid_dp_uPure_c20240207__us-gaap--TypeOfArrangementAxis__custom--ThirdModificationLoanAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zM3nVmvbxsm4" title="Fixed charge coverage ratio"&gt;1.00&lt;/span&gt;, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4)
    quarter period then ended.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;e.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Minimum
    Adjusted EBITDA. &lt;/b&gt;Commencing with the quarter ending January 31, 2024, Borrowers shall maintain Adjusted EBITDA, measured on a
    quarterly basis as of the last day of each fiscal quarter, in an amount not less than the amounts (or, in the case of amounts set
    forth in parentheses, no worse than the amounts) set forth under the heading &#x201c;Minimum Adjusted EBITDA&#x201d; as of, and for
    each of the dates appearing adjacent to such &#x201c;Minimum Adjusted EBITDA.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_89E_ecustom--ScheduleOfMinimumAdjustedEBITDATableTextBlock_zmyLnqyM4LPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;span id="xdx_8BC_zGClJf5IisO8" style="display: none"&gt;SCHEDULE
OF MINIMUM ADJUSTED EBITDA&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Quarter Ending&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Minimum Adjusted EBITDA&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;January 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAHKv9XnP7Tf" style="width: 16%; text-align: right" title="Minimum Adjusted EBITDA"&gt;(5,750,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;April 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztQimNPIzrJa" style="text-align: right" title="Minimum Adjusted EBITDA"&gt;(4,560,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;July 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1LyXupcKxgg" style="text-align: right" title="Minimum Adjusted EBITDA"&gt;(2,960,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;October 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0Xz7h4bcx13" style="text-align: right" title="Minimum Adjusted EBITDA"&gt;(1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;January 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFiveMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3VsY5uHAob2" style="text-align: right" title="Minimum Adjusted EBITDA"&gt;430,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zsv2skD6YZbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-02-01_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact001503"
      unitRef="USD">4400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-01_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001505"
      unitRef="Shares">4052631</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2024-02-01_custom_NotesMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001507"
      unitRef="Pure">0.15</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-02-012024-02-01_us-gaap_SubsequentEventMember_custom_NotesMember"
      id="Fact001509">2026-08-07</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-04-30_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001511"
      unitRef="USDPShares">0.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-04-30_us-gaap_SubsequentEventMember_custom_ExceptDirectorsAndOfficersMember"
      decimals="INF"
      id="Fact001513"
      unitRef="USDPShares">0.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <STRM:AffiliatesEffectivePercentage
      contextRef="AsOf2024-04-30_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001515"
      unitRef="Pure">0.0999</STRM:AffiliatesEffectivePercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-02-062024-02-06_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001517"
      unitRef="Shares">263158</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-02-06_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001519"
      unitRef="USDPShares">0.38</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-02-062024-02-06_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact001521"
      unitRef="USD">100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <STRM:ScheduleOfMaximumARRNetLeverageTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001523">&lt;p id="xdx_898_ecustom--ScheduleOfMaximumARRNetLeverageTableTextBlock_zn3DAkHvDuVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;span id="xdx_8B2_zl5leknhgzJg" style="display: none"&gt;SCHEDULE
OF MAXIMUM ARR NET LEVERAGE RATIO&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 81%; font-weight: bold"&gt;Quarter Ending&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Maximum ARR Net Leverage Ratio&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;April 30, 2024&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYL8dbOqU7dj" title="Maximum ARR net leverage ratio"&gt;0.50&lt;/span&gt; to &lt;span id="xdx_903_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZGaBn88elT7" title="Maximum ARR net leverage ratio"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;July 31, 2024&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXDyg1rAAOu" title="Maximum ARR net leverage ratio"&gt;0.45&lt;/span&gt; to &lt;span id="xdx_901_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4bD19zzJLIi" title="Maximum ARR net leverage ratio"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;October 31, 2024&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHNHYJNleNcf" title="Maximum ARR net leverage ratio"&gt;0.40&lt;/span&gt; to &lt;span id="xdx_90D_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyFourMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdU4HUWEgNl7" title="Maximum ARR net leverage ratio"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;January 31, 2025&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGXzjPhyYRBb" title="Maximum ARR net leverage ratio"&gt;0.35&lt;/span&gt; to &lt;span id="xdx_908_ecustom--MaximumArrNetLeverageRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zN794vr0cRh" title="Maximum ARR net leverage ratio"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</STRM:ScheduleOfMaximumARRNetLeverageTableTextBlock>
    <STRM:MaximumArrNetLeverageRatio
      contextRef="AsOf2024-02-07_custom_AprilThirtyTwoThousandAndTwentyFourMember_srt_MinimumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001525"
      unitRef="Pure">0.0050</STRM:MaximumArrNetLeverageRatio>
    <STRM:MaximumArrNetLeverageRatio
      contextRef="AsOf2024-02-07_custom_AprilThirtyTwoThousandAndTwentyFourMember_srt_MaximumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001527"
      unitRef="Pure">0.0100</STRM:MaximumArrNetLeverageRatio>
    <STRM:MaximumArrNetLeverageRatio
      contextRef="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandAndTwentyFourMember_srt_MinimumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001529"
      unitRef="Pure">0.0045</STRM:MaximumArrNetLeverageRatio>
    <STRM:MaximumArrNetLeverageRatio
      contextRef="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandAndTwentyFourMember_srt_MaximumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001531"
      unitRef="Pure">0.0100</STRM:MaximumArrNetLeverageRatio>
    <STRM:MaximumArrNetLeverageRatio
      contextRef="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandAndTwentyFourMember_srt_MinimumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001533"
      unitRef="Pure">0.0040</STRM:MaximumArrNetLeverageRatio>
    <STRM:MaximumArrNetLeverageRatio
      contextRef="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandAndTwentyFourMember_srt_MaximumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001535"
      unitRef="Pure">0.0100</STRM:MaximumArrNetLeverageRatio>
    <STRM:MaximumArrNetLeverageRatio
      contextRef="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001537"
      unitRef="Pure">0.0035</STRM:MaximumArrNetLeverageRatio>
    <STRM:MaximumArrNetLeverageRatio
      contextRef="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFiveMember_srt_MaximumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001539"
      unitRef="Pure">0.0100</STRM:MaximumArrNetLeverageRatio>
    <STRM:ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001541">&lt;p id="xdx_893_ecustom--ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock_zbRhfhXAR2T4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_z36XCCnXa4R3" style="display: none"&gt;SCHEDULE OF MAXIMUM DEBT TO ADJUSTMENTS EBITDA RATIO&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 81%; font-weight: bold"&gt;Quarter Ending&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Maximum Debt to Adjusted EBITDA Ratio&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;April 30, 2025&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z634W75TIPkd" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;3.50&lt;/span&gt; to &lt;span id="xdx_906_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zW5HjjpfOLK6" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;July 31, 2025&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zndajFfrR7lb" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;3.00&lt;/span&gt; to &lt;span id="xdx_902_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPNp0gh9xaMj" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;October 31, 2025&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsNDLOgxTSE8" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;2.50&lt;/span&gt; to &lt;span id="xdx_90B_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandTwentyFiveMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKF5mmPQictf" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;January 31, 2026 and on the last day of each quarter thereafter&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQ1edTu7ZW4" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;2.00&lt;/span&gt; to &lt;span id="xdx_90A_ecustom--MaximumDebtToAdjustedEbitdaRatio_iI_pid_dp_uPure_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zieXxiJi69ba" title="Maximum Debt to Adjusted EBITDA Ratio"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</STRM:ScheduleOfMaximumDebtToAdjustmentsEBITDARatioTableTextBlock>
    <STRM:MaximumDebtToAdjustedEbitdaRatio
      contextRef="AsOf2024-02-07_custom_AprilThirtyTwoThousandTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001543"
      unitRef="Pure">0.0350</STRM:MaximumDebtToAdjustedEbitdaRatio>
    <STRM:MaximumDebtToAdjustedEbitdaRatio
      contextRef="AsOf2024-02-07_custom_AprilThirtyTwoThousandTwentyFiveMember_srt_MaximumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001545"
      unitRef="Pure">0.0100</STRM:MaximumDebtToAdjustedEbitdaRatio>
    <STRM:MaximumDebtToAdjustedEbitdaRatio
      contextRef="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001547"
      unitRef="Pure">0.0300</STRM:MaximumDebtToAdjustedEbitdaRatio>
    <STRM:MaximumDebtToAdjustedEbitdaRatio
      contextRef="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandTwentyFiveMember_srt_MaximumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001549"
      unitRef="Pure">0.0100</STRM:MaximumDebtToAdjustedEbitdaRatio>
    <STRM:MaximumDebtToAdjustedEbitdaRatio
      contextRef="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandTwentyFiveMember_srt_MinimumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001551"
      unitRef="Pure">0.0250</STRM:MaximumDebtToAdjustedEbitdaRatio>
    <STRM:MaximumDebtToAdjustedEbitdaRatio
      contextRef="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandTwentyFiveMember_srt_MaximumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001553"
      unitRef="Pure">0.0100</STRM:MaximumDebtToAdjustedEbitdaRatio>
    <STRM:MaximumDebtToAdjustedEbitdaRatio
      contextRef="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember_srt_MinimumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001555"
      unitRef="Pure">0.0200</STRM:MaximumDebtToAdjustedEbitdaRatio>
    <STRM:MaximumDebtToAdjustedEbitdaRatio
      contextRef="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandTwentySixAndThereafterMember_srt_MaximumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001557"
      unitRef="Pure">0.0100</STRM:MaximumDebtToAdjustedEbitdaRatio>
    <STRM:FixedChargeCoverageRatio
      contextRef="AsOf2024-02-07_custom_ThirdModificationLoanAgreementMember_srt_MaximumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001559"
      unitRef="Pure">0.0120</STRM:FixedChargeCoverageRatio>
    <STRM:FixedChargeCoverageRatio
      contextRef="AsOf2024-02-07_custom_ThirdModificationLoanAgreementMember_srt_MinimumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001561"
      unitRef="Pure">0.0100</STRM:FixedChargeCoverageRatio>
    <STRM:ScheduleOfMinimumAdjustedEBITDATableTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001563">&lt;p id="xdx_89E_ecustom--ScheduleOfMinimumAdjustedEBITDATableTextBlock_zmyLnqyM4LPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;span id="xdx_8BC_zGClJf5IisO8" style="display: none"&gt;SCHEDULE
OF MINIMUM ADJUSTED EBITDA&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Quarter Ending&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Minimum Adjusted EBITDA&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;January 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAHKv9XnP7Tf" style="width: 16%; text-align: right" title="Minimum Adjusted EBITDA"&gt;(5,750,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;April 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--AprilThirtyTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztQimNPIzrJa" style="text-align: right" title="Minimum Adjusted EBITDA"&gt;(4,560,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;July 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--JulyThirtyOneTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1LyXupcKxgg" style="text-align: right" title="Minimum Adjusted EBITDA"&gt;(2,960,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;October 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--OctoberThirtyOneTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0Xz7h4bcx13" style="text-align: right" title="Minimum Adjusted EBITDA"&gt;(1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;January 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--MinimumAdjustedEbitda_iI_c20240207__srt--StatementScenarioAxis__custom--JanuaryThirtyOneTwoThousandAndTwentyFiveMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3VsY5uHAob2" style="text-align: right" title="Minimum Adjusted EBITDA"&gt;430,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</STRM:ScheduleOfMinimumAdjustedEBITDATableTextBlock>
    <STRM:MinimumAdjustedEbitda
      contextRef="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001565"
      unitRef="USD">-5750000</STRM:MinimumAdjustedEbitda>
    <STRM:MinimumAdjustedEbitda
      contextRef="AsOf2024-02-07_custom_AprilThirtyTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001567"
      unitRef="USD">-4560000</STRM:MinimumAdjustedEbitda>
    <STRM:MinimumAdjustedEbitda
      contextRef="AsOf2024-02-07_custom_JulyThirtyOneTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001569"
      unitRef="USD">-2960000</STRM:MinimumAdjustedEbitda>
    <STRM:MinimumAdjustedEbitda
      contextRef="AsOf2024-02-07_custom_OctoberThirtyOneTwoThousandAndTwentyFourMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001571"
      unitRef="USD">-1500000</STRM:MinimumAdjustedEbitda>
    <STRM:MinimumAdjustedEbitda
      contextRef="AsOf2024-02-07_custom_JanuaryThirtyOneTwoThousandAndTwentyFiveMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001573"
      unitRef="USD">430000</STRM:MinimumAdjustedEbitda>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="From2023-02-01to2024-01-31" id="Fact001575">&lt;p id="xdx_804_esrt--ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_ziJUF1suz0d7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Schedule
II&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="ak_003"&gt;&lt;/span&gt;&lt;span id="xdx_825_zL7MiJcbFLjh"&gt;Valuation
and Qualifying Accounts and Reserves&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Streamline
Health Solutions, Inc and Subsidiaries.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
the two years ended January 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(in
thousands of dollars)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 1.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance at Beginning&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;of Period&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Charged to Costs and&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Expenses&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;b id="xdx_F5B_zV7DWB6suPWi"&gt;(1)&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Deductions &#x2013; Other Accounts&lt;/b&gt;&lt;/p&gt;

&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b id="xdx_F5B_zJuceKht5xe6"&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Deductions&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance at&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;End of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Period&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Year ended January 31, 2024:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 32%; text-align: left"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_98D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_pn3n3_c20230201__20240131_zZLImkf6vnmf" style="width: 10%; text-align: right"&gt;132&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_98F_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20230201__20240131_z1k2l5PaLfH3" style="width: 10%; text-align: right"&gt;(10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_986_eus-gaap--ValuationAllowancesAndReservesChargedToOtherAccounts_pn3n3_c20230201__20240131_fKDEp_zh4bBYA0DPNh" style="text-align: right; width: 10%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(36&lt;/td&gt;
    &lt;td style="width: 1%"&gt;)&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_984_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20230201__20240131_fKDIp_z0Npxkq8WqF7" style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1579"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_pn3n3_c20230201__20240131_z9TIxgARzxGc" style="width: 10%; text-align: right"&gt;86&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Year ended January 31, 2023:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_pn3n3_c20220201__20230131_zMH2HRz2Pj17" style="text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20220201__20230131_zj53Qi6VeHek" style="text-align: right"&gt;189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_98E_eus-gaap--ValuationAllowancesAndReservesChargedToOtherAccounts_pn3n3_c20220201__20230131_fKDEp_zLKF4y0XM5h1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1583"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_988_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20220201__20230131_fKDIp_zHOKrlLbtdXd" style="text-align: right"&gt;(133&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFZhbHVhdGlvbiBhbmQgUXVhbGlmeWluZyBBY2NvdW50cyBhbmQgUmVzZXJ2ZXMgKERldGFpbHMpAA__" id="xdx_98B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_pn3n3_c20220201__20230131_z3ewtJR2qVoi" style="text-align: right"&gt;132&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F05_zp3FTL55sJff" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F11_zARjFMaHTQD7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustments to retained earnings for adoption of ASC 326-10, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit
Losses on Financial Instruments (Refer to the subtopic of Accounting Pronouncements Recently Adopted in Note 2 &#x2013; Significant Accounting
Policies to our consolidated financial statements included in Part II, Item 8, &#x201c;Financial Statements and Supplementary Data&#x201d;
for more information.)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td id="xdx_F05_z4l7xymCPB99" style="font: 10pt Times New Roman, Times, Serif"&gt;(2)&lt;/td&gt;
    &lt;td id="xdx_F1A_zgnOhMXv45Y2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Uncollectible accounts written off, net of recoveries.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_zHg4tQmu83L8" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2023-01-31"
      decimals="-3"
      id="Fact001576"
      unitRef="USD">132000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="From2023-02-01to2024-01-31"
      decimals="-3"
      id="Fact001577"
      unitRef="USD">-10000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="From2023-02-01to2024-01-31"
      decimals="-3"
      id="Fact001578"
      unitRef="USD">-36000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-01-31"
      decimals="-3"
      id="Fact001580"
      unitRef="USD">86000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2022-01-31"
      decimals="-3"
      id="Fact001581"
      unitRef="USD">76000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="From2022-02-012023-01-31"
      decimals="-3"
      id="Fact001582"
      unitRef="USD">189000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="From2022-02-012023-01-31"
      decimals="-3"
      id="Fact001584"
      unitRef="USD">-133000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2023-01-31"
      decimals="-3"
      id="Fact001585"
      unitRef="USD">132000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <dei:AuditorFirmId contextRef="From2023-02-01to2024-01-31" id="Fact001588">686</dei:AuditorFirmId>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000645"
          xlink:label="Fact000645"
          xlink:type="locator"/>
        <link:footnote id="Footnote000660" xlink:label="Footnote000660" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    fair value of the acquisition earnout liability is based upon a probability-weighted discounted cash flow that was completed at the
    date of acquisition and updated as of January 31, 2024. The change in the fair value of the acquisition earnout liability decreased
    $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUgQVNTRVRTIEFORCBMSUFCSUxJVElFUyBNRUFTVVJFRCBPTiBSRUNVUlJJTkcgQkFTSVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90F_ecustom--AcquisitionEarnoutLiabilityChangeInValuation_c20230201__20240131_z0jICDkaYQXh"
  title="Acquisition earnout liability, change in valuation">1,944,000</xhtml:span> for the year ended January 31, 2024, which is entirely recognized in &#x201c;Acquisition earnout valuation adjustments&#x201d;
    in the accompanying consolidated statement of operations.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000645"
          xlink:to="Footnote000660"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0647"
          xlink:label="xdx2ixbrl0647"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0647"
          xlink:to="Footnote000660"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0649"
          xlink:label="xdx2ixbrl0649"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0649"
          xlink:to="Footnote000660"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000651"
          xlink:label="Fact000651"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000651"
          xlink:to="Footnote000660"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000653"
          xlink:label="Fact000653"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000653"
          xlink:to="Footnote000660"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0655"
          xlink:label="xdx2ixbrl0655"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0655"
          xlink:to="Footnote000660"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0657"
          xlink:label="xdx2ixbrl0657"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0657"
          xlink:to="Footnote000660"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000659"
          xlink:label="Fact000659"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000659"
          xlink:to="Footnote000660"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000779"
          xlink:label="Fact000779"
          xlink:type="locator"/>
        <link:footnote id="Footnote000794" xlink:label="Footnote000794" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Excludes
    the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of January 31, 2024
    and 2023, there were <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zOkiNJqczEvk"
  title="Diluted earnings per share">1,970,521</xhtml:span> and <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z2lI0oNs2rt9"
  title="Diluted earnings per share">1,848,031</xhtml:span> unvested restricted shares of common stock, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000779"
          xlink:to="Footnote000794"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000780"
          xlink:label="Fact000780"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000780"
          xlink:to="Footnote000794"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0782"
          xlink:label="xdx2ixbrl0782"
          xlink:type="locator"/>
        <link:footnote id="Footnote000799" xlink:label="Footnote000799" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Diluted
    net loss per share excludes the effect of shares that are anti-dilutive. As of January 31, 2024, there were <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6ObtBNkGuq3"
  title="Diluted earnings per share">67,500</xhtml:span> outstanding stock
    options and <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230201__20240131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedSharesMember_z7x8lmNjloWl"
  title="Diluted earnings per share">1,970,521</xhtml:span> unvested restricted shares of common stock. As of January 31, 2023, there were <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zg2cyB4sQ6Wk"
  title="Diluted earnings per share">628,598</xhtml:span> outstanding stock options
    and <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJBU0lDIEFORCBESUxVVEVEIE5FVCBMT1NTIFBFUiBTSEFSRSBPRiBDT01NT04gU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220201__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zKuhWu16S4uk"
  title="Diluted earnings per share">1,848,031</xhtml:span> unvested restricted shares of common stock.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0782"
          xlink:to="Footnote000799"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0783"
          xlink:label="xdx2ixbrl0783"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0783"
          xlink:to="Footnote000799"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001578"
          xlink:label="Fact001578"
          xlink:type="locator"/>
        <link:footnote id="Footnote001586" xlink:label="Footnote001586" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Adjustments to retained earnings for adoption of ASC 326-10, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit
Losses on Financial Instruments (Refer to the subtopic of Accounting Pronouncements Recently Adopted in Note 2 &#x2013; Significant Accounting
Policies to our consolidated financial statements included in Part II, Item 8, &#x201c;Financial Statements and Supplementary Data&#x201d;
for more information.)</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001578"
          xlink:to="Footnote001586"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1583"
          xlink:label="xdx2ixbrl1583"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1583"
          xlink:to="Footnote001586"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1579"
          xlink:label="xdx2ixbrl1579"
          xlink:type="locator"/>
        <link:footnote id="Footnote001587" xlink:label="Footnote001587" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Uncollectible accounts written off, net of recoveries.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1579"
          xlink:to="Footnote001587"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001584"
          xlink:label="Fact001584"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001584"
          xlink:to="Footnote001587"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
